<SEC-DOCUMENT>0001479290-20-000058.txt : 20200507 <SEC-HEADER>0001479290-20-000058.hdr.sgml : 20200507 <ACCEPTANCE-DATETIME>20200507172318 ACCESSION NUMBER: 0001479290-20-000058 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 61 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200507 DATE AS OF CHANGE: 20200507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 20857720 BUSINESS ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 </SEC-HEADER> <DOCUMENT> <TYPE>10-Q <SEQUENCE>1 <FILENAME>rvncq12010-q.htm <DESCRIPTION>10-Q <TEXT> <XBRL> <?xml version="1.0" encoding="UTF-8"?> <!--XBRL Document Created with Wdesk from Workiva--> <!--p:2d9cf9d78dee4ac6988918f97ee04469,x:4389f0edb1744b5cb16c4801253218bf--> <!-- Document created using Wdesk --> <!-- Copyright 2020 Workiva --> <html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:rvnc="http://www.revance.com/20200331" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt"> <head> <meta http-equiv="Content-Type" content="text/html" /> <title>Document</title> </head> <body><div style="font-family:Times New Roman;font-size:10pt;"> <div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:AmendmentFlag" id="Fact-A53417FA44C8C6B5686B16CE0BB38847-wk-Fact-A53417FA44C8C6B5686B16CE0BB38847" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-08316D5F92A1DFA463359FDD235CF4A4-wk-Fact-08316D5F92A1DFA463359FDD235CF4A4">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-1B640A2E9A2BDF4008FD9D33A166C8E3-wk-Fact-1B640A2E9A2BDF4008FD9D33A166C8E3">Q1</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:DocumentFiscalYearFocus" id="Fact-1CB60E9EA0FEA7A49D1D9FDD235C3BFF-wk-Fact-1CB60E9EA0FEA7A49D1D9FDD235C3BFF">2020</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="dei:EntityCentralIndexKey" id="Fact-97505126AF2BC14F947E16CE0BB3B5C0-wk-Fact-97505126AF2BC14F947E16CE0BB3B5C0">0001479290</ix:nonNumeric><ix:nonNumeric contextRef="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" name="rvnc:CollaborativeAgreementExtendedContractualPeriod" id="Fact-28574750F5613F3F2DDD9ECF56B2F2BF-wk-Fact-28574750F5613F3F2DDD9ECF56B2F2BF">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" name="rvnc:CollaborativeAgreementExtendedContractualPeriod" id="Fact-4A47EE6E6F640052A910BA75277227CD-wk-Fact-4A47EE6E6F640052A910BA75277227CD">P2Y</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q1YTD" name="rvnc:EquityComponentOfConvertibleDebtTransactionCost" id="Fact-D904FB26257B0C90019E9DEE12F69B44-wk-Fact-D904FB26257B0C90019E9DEE12F69B44">3583000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-8A739AACD4617482682016CE0BF16726-wk-Fact-8A739AACD4617482682016CE0BF16726">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-CD074FF215803999F8E016CE0BF1E9DE-wk-Fact-CD074FF215803999F8E016CE0BF1E9DE">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-DF453F91963E45CA2F0F16CE0BF1C945-wk-Fact-DF453F91963E45CA2F0F16CE0BF1C945">95000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesAuthorized" id="Fact-655A4109DE3243A2D5FE16CE0BF1A1ED-wk-Fact-655A4109DE3243A2D5FE16CE0BF1A1ED">95000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-1E10309A8B1B19FCEFDD16CE0C01C953-wk-Fact-1E10309A8B1B19FCEFDD16CE0C01C953">52374735</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:CommonStockSharesIssued" id="Fact-6D3DFB8AFDBCC479673516CE0BF19E21-wk-Fact-6D3DFB8AFDBCC479673516CE0BF19E21">57026154</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-2F93161C58991DB241E616CE0BF10B60-wk-Fact-2F93161C58991DB241E616CE0BF10B60">52374735</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q1YTD_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" id="Fact-5107A64AA961D0D3BBD49E5C3EF49299-wk-Fact-5107A64AA961D0D3BBD49E5C3EF49299">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" id="Fact-FD4B6FB295556D96C368BA2C8F436F92-wk-Fact-FD4B6FB295556D96C368BA2C8F436F92">0.0308804</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q4YTD" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" id="Fact-18948D1B1026E7BDA5A416CE0DB6E260-wk-Fact-18948D1B1026E7BDA5A416CE0DB6E260">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q1QTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember" name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact-E18BFAFA18947CAE6C689DD0A2B03E69-wk-Fact-E18BFAFA18947CAE6C689DD0A2B03E69">521000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2020Q1QTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember" name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact-5896F6541618082022439DD0A2C0D026-wk-Fact-5896F6541618082022439DD0A2C0D026">44000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-C06BA8AFB9A30F8297F316CE0BF14DAC-wk-Fact-C06BA8AFB9A30F8297F316CE0BF14DAC">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2020Q1" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-E1072FD22819E7636A3516CE0BF1AA8B-wk-Fact-E1072FD22819E7636A3516CE0BF1AA8B">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-F08D0DCC0D81FDB193AA16CE0BF1D3E9-wk-Fact-F08D0DCC0D81FDB193AA16CE0BF1D3E9">5000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-9CD3A459603F4CAEF70316CE0BF1C4B6-wk-Fact-9CD3A459603F4CAEF70316CE0BF1C4B6">5000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-76B39EEBE573DF9DADF916CE0BF149C6-wk-Fact-76B39EEBE573DF9DADF916CE0BF149C6">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesIssued" id="Fact-A982CDBC0914CD08510816CE0BF1E131-wk-Fact-A982CDBC0914CD08510816CE0BF1E131">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-DF98AA929C41ED8B010216CE0BF133C6-wk-Fact-DF98AA929C41ED8B010216CE0BF133C6">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2020Q1" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-7F523DC3C19478143D0516CE0BF1F84A-wk-Fact-7F523DC3C19478143D0516CE0BF1F84A">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="rvnc-20200331.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2020Q1YTD"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="I2020Q2Apr24"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1QTD"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q1"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvnc:FollowOnOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1QTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvnc:FollowOnOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2018Q4"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="I2019Q1Jan31_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1YTD_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rvnc:DevelopmentServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rvnc:DevelopmentServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="D2019Q1Jan_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="I2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:MylanIrelandLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-02-28</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:MylanIrelandLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rvnc:DevelopmentServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rvnc:DevelopmentServicesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="D2020Q1Mar31_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="D2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:MylanIrelandLimitedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-02-28</xbrli:startDate> <xbrli:endDate>2018-02-28</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1YTD_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q4YTD"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:TeoxaneAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:TeoxaneAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputEntityCreditRiskMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputEntityCreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputEntityCreditRiskMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputEntityCreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_ValeantPharmaceuticalsInternationalInc.Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:ValeantPharmaceuticalsInternationalInc.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsOneMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="rvnc:DebtInstrumentConvertibleTermsOfConversionAxis">rvnc:DebtConversionTermsOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-14</xbrli:startDate> <xbrli:endDate>2020-02-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-14</xbrli:startDate> <xbrli:endDate>2020-02-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="D2020Q1Feb14"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-14</xbrli:startDate> <xbrli:endDate>2020-02-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsTwoMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="rvnc:DebtInstrumentConvertibleTermsOfConversionAxis">rvnc:DebtConversionTermsTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-14</xbrli:startDate> <xbrli:endDate>2020-02-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="I2020Q1Feb14"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_rvnc_ESPPPurchasesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rvnc:ESPPPurchasesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_rvnc_ESPPPurchasesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rvnc:ESPPPurchasesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenInducementPlanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="I2020Q1Jan1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenInducementPlanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenInducementPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="I2020Q1Jan1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_AttheMarketOfferingMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvnc:AttheMarketOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="I2020Q1Jan31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="D2019Q4Dec-31_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvnc:FollowOnOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="D2020Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvnc:FollowOnOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="D2020Q1Feb29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-02-01</xbrli:startDate> <xbrli:endDate>2020-02-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="I2020Q1Feb29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-01</xbrli:startDate> <xbrli:endDate>2019-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_TypeOfArrangementAxis_rvnc_BioSentinelInc.Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:BioSentinelInc.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FD2020Q1YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_TypeOfArrangementAxis_rvnc_BotulinumToxinResearchAssociatesInc.Member"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:BotulinumToxinResearchAssociatesInc.Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_ListLaboratoriesMember"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001479290</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:ListLaboratoriesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="day"> <xbrli:measure>rvnc:day</xbrli:measure> </xbrli:unit><xbrli:unit id="shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="usdPerShare"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="usd"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="number"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="segment"> <xbrli:measure>rvnc:segment</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div><a id="s5A3EE47D0F570818571416CE0B93E09D"></a></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:5px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:5px;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:18pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:23%;"></td><td style="width:54%;"></td><td style="width:23%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:18pt;"><span style="font-family:inherit;font-size:18pt;font-weight:bold;">Washington, D.C. 20549</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:center;text-indent:0px;font-size:20pt;"><span style="font-family:inherit;font-size:20pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d12615397e582-wk-Fact-0CB8BE635CEC952959A216CE0B938AEB" name="dei:DocumentType" contextRef="FD2020Q1YTD"><span style="font-size:20pt;font-weight:bold;">10-Q</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:20pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:23%;"></td><td style="width:54%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:65%;"></td><td style="width:31%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Mark One)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d12615397e642-wk-Fact-DD065EDC568892E1983F16CE0B93F88A" name="dei:DocumentQuarterlyReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">☒</ix:nonNumeric></span></span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the quarterly period ended </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d12615397e659-wk-Fact-E16F28BDF23C54B4B6029FDFA838E2B2" name="dei:DocumentPeriodEndDate" contextRef="FD2020Q1YTD" format="ixt:datemonthdayyearen">March 31, 2020</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:4%;"></td><td style="width:65%;"></td><td style="width:31%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">or</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d12615397e692-wk-Fact-C8F943EA2B64D53BA3F216CE0BB3466B" name="dei:DocumentTransitionReport" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">☐</ix:nonNumeric></span></span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the transition period from ___ to ___</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commission File No. </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12615397e723-wk-Fact-5029470F944CC0E4C86016CE0B936A68" name="dei:EntityFileNumber" contextRef="FD2020Q1YTD">001-36297</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:22pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:23%;"></td><td style="width:54%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:22pt;"><span style="font-family:inherit;font-size:22pt;font-weight:bold;"><span><ix:nonNumeric id="d12615397e757-wk-Fact-2395072A736FEF6BB37E16CE0BA3E83F" name="dei:EntityRegistrantName" contextRef="FD2020Q1YTD">Revance Therapeutics, Inc.</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:5px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:23%;"></td><td style="width:27%;"></td><td style="width:27%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"><span><ix:nonNumeric id="d12615397e819-wk-Fact-0B8B372C23E2A9A0B3CB16CE0BA399A4" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2020Q1YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;"><span><ix:nonNumeric id="d12615397e824-wk-Fact-7BF7CA93936BD23F865016CE0BA3744C" name="dei:EntityTaxIdentificationNumber" contextRef="FD2020Q1YTD">77-0551645</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of<br/>incorporation or organization)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span><ix:nonNumeric id="d12615397e854-wk-Fact-8309C7B0EBFC78457E6216CE0B930B3F" name="dei:EntityAddressAddressLine1" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">7555 Gateway Boulevard</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d12615397e859-wk-Fact-B215CA117D9971671C4316CE0B9374E1" name="dei:EntityAddressCityOrTown" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">Newark</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d12615397e864-wk-Fact-579FBCB824E448E2E1A216CE0B930FDC" name="dei:EntityAddressStateOrProvince" contextRef="FD2020Q1YTD" format="ixt-sec:stateprovnameen"><span style="font-weight:bold;">California</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d12615397e869-wk-Fact-0828A197264F13BD2D1316CE0B931242" name="dei:EntityAddressPostalZipCode" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">94560</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Address, including zip code, of principal executive offices)</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d12615397e883-wk-Fact-2F8B6A48EAA0E50795B316CE0B936903" name="dei:CityAreaCode" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">510</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d12615397e888-wk-Fact-E93F324BDCC44D37079416CE0B93D091" name="dei:LocalPhoneNumber" contextRef="FD2020Q1YTD"><span style="font-weight:bold;">742-3400</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Registrant’s telephone number, including area code)</span></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Registered Pursuant to Section 12(b) of the Act:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12615397e941-wk-Fact-E3BDD2CE77BB8634132816CE0BB3B564" name="dei:Security12bTitle" contextRef="FD2020Q1YTD">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12615397e946-wk-Fact-82CAE3D4C954F042C16016CE0BB3B71E" name="dei:TradingSymbol" contextRef="FD2020Q1YTD">RVNC</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12615397e951-wk-Fact-2B4708775AF59480B29E16CE0BB3CA47" name="dei:SecurityExchangeName" contextRef="FD2020Q1YTD" format="ixt-sec:exchnameen">Nasdaq Global Market</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:5px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12615397e956-wk-Fact-85956DFCE3583B41D52016CE0B9362D3" name="dei:EntityCurrentReportingStatus" contextRef="FD2020Q1YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">  </span><span style="font-family:Wingdings;font-size:10pt;">ý</span><span style="font-family:inherit;font-size:10pt;">    No  </span><span style="font-family:Wingdings;font-size:10pt;">¨</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:5px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12615397e969-wk-Fact-7EB9F960391E6F1BA3E716CE0B93A70D" name="dei:EntityInteractiveDataCurrent" contextRef="FD2020Q1YTD">Yes</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">  </span><span style="font-family:Wingdings;font-size:10pt;">ý</span><span style="font-family:inherit;font-size:10pt;">    No  </span><span style="font-family:Wingdings;font-size:10pt;">¨</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:5px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:5px;text-align:left;padding-left:24px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96.72131147540983%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:26%;"></td><td style="width:8%;"></td><td style="width:25%;"></td><td style="width:8%;"></td><td style="width:25%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Large accelerated filer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">☐</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12615397e1008-wk-Fact-62A6A37C2BDB836380DDE64CBBFF2BA6" name="dei:EntityFilerCategory" contextRef="FD2020Q1YTD" format="ixt-sec:entityfilercategoryen">Accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">☒</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d12615397e1023-wk-Fact-75AD781A0DA6055D439516CE0BA359E8" name="dei:EntityEmergingGrowthCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">☐</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-accelerated filer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">☐</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Smaller reporting company</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d12615397e1044-wk-Fact-EABFC43E6E66F0C5F9CA16CE0BA31DA4" name="dei:EntitySmallBusiness" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">☒</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:5px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial statement accounting standards provide pursuance to Section 13(a) of the Exchange Act. </span><span style="font-family:Wingdings;font-size:10pt;">¨</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:5px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12615397e1064-wk-Fact-ADA6C4F55671C9D8781F16CE0B936007" name="dei:EntityShellCompany" contextRef="FD2020Q1YTD" format="ixt-sec:boolballotbox">☐</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">    No  </span><span style="font-family:Wingdings;font-size:10pt;">ý</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Number of shares outstanding of the registrant's common stock, par value $0.001 per share, as of </span><span style="font-family:inherit;font-size:10pt;">April 24, 2020</span><span style="font-family:inherit;font-size:10pt;">: </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12615397e1078-wk-Fact-146E47BAB0EC0CBDD8A540B0ECF1A5EA" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q2Apr24" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">57,052,046</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div><br/></div><div><div style="line-height:120%;padding-bottom:16px;padding-top:5px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:5px;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s0FC18E2919F12D522C9A16CE1896DB6D"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:78%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Page</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sE18B49BCF090A3DD527A16CE18C90A88"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</span></a><span style="font-family:inherit;font-size:10pt;font-weight:bold;">. FINANCIAL INFORMATION</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB75C14BAD737261343AC16CE18E999B8"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Financial Statements (Unaudited)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB75C14BAD737261343AC16CE18E999B8">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s928551B6BA26958D21C516CE0BB37758"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s928551B6BA26958D21C516CE0BB37758">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD6237E22BD5364149BB016CE0C010C91"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD6237E22BD5364149BB016CE0C010C91">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s74EC70C27A22F1FC368116CE0C30D887"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Stockholders' Equity</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s74EC70C27A22F1FC368116CE0C30D887">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s80460D6461A5A0320BD116CE0CCCBCF5"><span style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s80460D6461A5A0320BD116CE0CCCBCF5">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6EAD4C6C52AF9B77490916CE1A238486"><span style="font-family:inherit;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6EAD4C6C52AF9B77490916CE1A238486">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sEF5433D763941B8A5CF816CE1C2A3055"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEF5433D763941B8A5CF816CE1C2A3055">20</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 3.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s292F4432DBE1E8575B2916CE1DB1FCAA"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Quantitative and Qualitative Disclosures about Market Risk</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s292F4432DBE1E8575B2916CE1DB1FCAA">35</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 4.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s1E9CE650E01E1A8825B716CE1DD04BC3"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1E9CE650E01E1A8825B716CE1DD04BC3">35</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sABF19B69467538E9C0CE16CE1DFFEFF8"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</span></a><span style="font-family:inherit;font-size:10pt;font-weight:bold;">. OTHER INFORMATION</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s50EA6EE90834D28FB6B516CE1E1E133C"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s50EA6EE90834D28FB6B516CE1E1E133C">36</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 1A.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE19B4D5E2A8A8247555216CE1E5D6046"><span style="font-family:inherit;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE19B4D5E2A8A8247555216CE1E5D6046">36</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s69E8B960283E81AF9C3A16CE1F2168C4"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s69E8B960283E81AF9C3A16CE1F2168C4">83</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 3.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#sC7D8D3321BA6F63EDE7F16CE1F50EDDD"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC7D8D3321BA6F63EDE7F16CE1F50EDDD">83</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 4.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s122343E4B71DFD05E2E416CE1F6F47E8"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s122343E4B71DFD05E2E416CE1F6F47E8">83</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 5.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-decoration:underline;" href="#s8EED0C078312CBFCC17C16CE1F9E5AE5"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other Information</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8EED0C078312CBFCC17C16CE1F9E5AE5">83</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Item 6.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s81E07E2E773A17E0BF0216CE1FCD32BA"><span style="font-family:inherit;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s81E07E2E773A17E0BF0216CE1FCD32BA">84</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s328F12C490B21E66EA5E16CE11751B67"><span style="font-family:inherit;font-size:10pt;">Signatures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s328F12C490B21E66EA5E16CE11751B67">86</a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">“Revance Therapeutics,” the Revance logos and other trademarks or service marks of Revance appearing in this quarterly report on Form 10-Q are the property of Revance. This Form 10-Q contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unless expressly indicated or the context requires otherwise, the terms “Revance,” “company,” “we,” “us,” and “our,” in this document refer to Revance Therapeutics, Inc., a Delaware corporation, and, where appropriate, its wholly owned subsidiaries.</span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sE18B49BCF090A3DD527A16CE18C90A88"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</span></div><div><a id="sB75C14BAD737261343AC16CE18E999B8"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 1. Condensed Consolidated Financial Statements (Unaudited)</span></div><div><a id="s928551B6BA26958D21C516CE0BB37758"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Balance Sheets</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">ASSETS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">CURRENT ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e712-wk-Fact-F0BFBD873E5A635AA49B9D2B33EAC25C" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">286,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e731-wk-Fact-03395A28B48998BFBDDF9D2B36E6C6D6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171,160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e746-wk-Fact-8C004DAC08A497D128769D2B36C13B66" name="us-gaap:ShortTermInvestments" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">224,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e765-wk-Fact-E707AFBED65FADCCA3299D2B36C1339B" name="us-gaap:ShortTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">118,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e785-wk-Fact-87718DF2B0B8CC92D3FD9D2B36D72016" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e804-wk-Fact-E6F41393145D2FA941829D2B33E46CF9" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,487</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e824-wk-Fact-2D209DD505F5058E44EC9D2B365CC54A" name="us-gaap:AssetsCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">518,441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e843-wk-Fact-6EE0CD3BAB5A35580C299D2B35C9A551" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">296,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e863-wk-Fact-8FC74F339FA59B9DB0609D2B340D13E3" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,967</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e882-wk-Fact-DDD476F9DFAD7A91FAF69D2B36F66AB8" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,755</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e902-wk-Fact-8CF38F2A2EB9F02E1FB29D3FB6622310" name="us-gaap:OtherIntangibleAssetsNet" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,334</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e921-wk-Fact-0A337136D9E3A114EE5D9D3FB6BB9F7A" name="us-gaap:OtherIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease right of use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e941-wk-Fact-EC282D7D56FD98CC252E9D2B33FA311B" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,961</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e960-wk-Fact-C8374AFF91F031E4A46F9D3F0C04C690" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e981-wk-Fact-10F7EDB6B5A4E9C5C0499D3EC48D29C3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1000-wk-Fact-84360100EB83F168D4AD9D3EC494D15C" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other non-current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1020-wk-Fact-B7DD73222DD5B4DEA9119D2B3419A9E6" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1039-wk-Fact-09DD457133C11F0977C09D2B36E676D0" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,669</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">TOTAL ASSETS</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1064-wk-Fact-3915A2EF17097CE0DAD89D2B34678C6B" name="us-gaap:Assets" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">592,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1083-wk-Fact-118CE045B5DE2DAFDF0E9D2B3438E014" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">340,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS’ EQUITY</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">CURRENT LIABILITIES</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1185-wk-Fact-5E15E75B7EB2F41FEDF19D2B342881C1" name="us-gaap:AccountsPayableCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1204-wk-Fact-51149614F0FDAB5D3FF09D2B34288473" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,010</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accruals and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1219-wk-Fact-85DE8FDA1017FF99DB159D2B36F64BD2" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1238-wk-Fact-264EC5A453E68C6B5C509D2B33FF8C22" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenue, current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1258-wk-Fact-188C14911E79D442EA2A9D2B340A8568" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1277-wk-Fact-8FF315723A0CA7256BA49D2B36E687D1" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease liabilities, current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1297-wk-Fact-FC2815627D633CDDBF009D2B36B10B6D" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,627</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1316-wk-Fact-09CC574222CD91219CCD9D40952BB5D8" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,470</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Derivative liability</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1336-wk-Fact-55B1CA30FFD6A2F2949A9D2B3500E8C0" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1355-wk-Fact-4DCAB9419E976BC6EC8B9D2B33F40B7A" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1375-wk-Fact-C17490A4AD7CF1735E3A9D2B352F8A0B" name="us-gaap:LiabilitiesCurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,635</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1394-wk-Fact-4EA4D4422A402876079F9D2B366CFF33" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,979</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible senior notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1415-wk-Fact-309679D6B7186C527E1E9D4077E63E88" name="us-gaap:SeniorLongTermNotes" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1434-wk-Fact-B806F8789FB5B580511D9D4077E68B58" name="us-gaap:SeniorLongTermNotes" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenue, net of current portion</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1454-wk-Fact-CA71EB9B90B2A39C8D519D2B3428BE51" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1473-wk-Fact-30E4C02C05AC370F5B4D9D2B36D7C75E" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,948</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease liabilities, net of current portion</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1493-wk-Fact-77F4EC7CB1AA611F169C9D2B34CB18C6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1512-wk-Fact-71AB17EE2B9510AF898D9D4022B7EED5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">TOTAL LIABILITIES</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1532-wk-Fact-130538A3FA052B4C5DAF9D2B365CED3C" name="us-gaap:Liabilities" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">284,552</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1551-wk-Fact-C688EC2AC964411833E19D2B36D75E78" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">114,797</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Commitments and Contingencies (Note 10)</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1571-wk-Fact-1626B4ACE72837D170CC16CE0BD2516A" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2020Q1" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1590-wk-Fact-E07023E26173C77918F316CE0BD2BE8E" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">STOCKHOLDERS’ EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2020 and December 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1651-wk-Fact-5C2FD04C8409BD5CD5F99D2B36D0DBE8" name="us-gaap:PreferredStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1670-wk-Fact-608B6CD177CC44AE837A9D2B3565C3AD" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock, par value $0.001 per share — 95,000,000 shares authorized both as of March 31, 2020 and December 31, 2019; 57,026,154 and 52,374,735 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1690-wk-Fact-33D606C37B12919053659D2B3419FB18" name="us-gaap:CommonStockValue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1709-wk-Fact-D42F11B6D99BF3273C879D2B349C76CB" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1729-wk-Fact-F657BF73F33C2B51FA609D2B365C1FEA" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,213,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1748-wk-Fact-1C3926188E68593D22CD9D2B36C152D4" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,069,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1768-wk-Fact-FE327EE41F215EC583889D2B340D6823" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1787-wk-Fact-B4C7433FD8EFE5AB645A9D2B33EE6B19" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621436e1807-wk-Fact-BCFBD491579B3B8373929D2B3405D82D" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">906,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621436e1827-wk-Fact-F9D453BC9CAB518148E19D2B35F81B70" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">844,204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">TOTAL STOCKHOLDERS’ EQUITY</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1849-wk-Fact-03146407C6278DA3AC389D2B33CFFF9F" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">308,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1868-wk-Fact-AE894A6E1BEAAF3C3DA59D2B3419611C" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">225,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1893-wk-Fact-14D27C8CD13183E9A7109D2B35948EE2" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">592,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621436e1912-wk-Fact-700D877007C1E4F96D469D2B362D5816" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">340,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="sD6237E22BD5364149BB016CE0C010C91"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A371A310FFDE8A7B1E3D647CDFE8649"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e629-wk-Fact-BF4267F6A30305BC40319D2B5F1EF05F" name="us-gaap:Revenues" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e648-wk-Fact-B98B3B37B25769E22CBB9D2B5D64B2A8" name="us-gaap:Revenues" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e704-wk-Fact-EE29D8B1BD64FC3996679D2B5DDD2560" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,794</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e723-wk-Fact-40254D156FFEECD4E0669D2B5DF72CCC" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e743-wk-Fact-85A0E04DAB3A295CCF519D2B5D4C0969" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e762-wk-Fact-0F40F1356DEA7ED438969D2B5E82470A" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e782-wk-Fact-E06FBEEAA4421CADD0BE9D2B5E98FDFB" name="us-gaap:OperatingExpenses" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">61,018</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e801-wk-Fact-3C7D17648A424A988AF39D2B5EA9F4B1" name="us-gaap:OperatingExpenses" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss from operations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e821-wk-Fact-4A778B6E00077BDAD7879D2B5F294512" name="us-gaap:OperatingIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">60,960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e841-wk-Fact-575870A31ACD2DF5F3109D2B5DA30186" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">36,627</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e862-wk-Fact-624FE0EDC18DA1031C389D2B5F232BCE" name="us-gaap:InvestmentIncomeNonoperating" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,491</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e881-wk-Fact-20CCEA0FA6D9D4DB30099D2B5EA43259" name="us-gaap:InvestmentIncomeNonoperating" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,570</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e901-wk-Fact-AB01D538A5914CE6E1309D2B5F0AB7EE" name="us-gaap:InterestExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e921-wk-Fact-526C4B7F0279B99EB1629D2B5E76DFF2" name="us-gaap:InterestExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes in fair value of derivative liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e941-wk-Fact-F3643A11132DF7FB3A3A9D2B5D2FC532" name="rvnc:GainLossonDerivativeInstrumentsContractNetPretax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e961-wk-Fact-AF0428AC684B0CA7E3E19D2B5E9ECF40" name="rvnc:GainLossonDerivativeInstrumentsContractNetPretax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e983-wk-Fact-E54E3FD7518251E668089D2B5DB8D2DC" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1003-wk-Fact-40E174470D6A3AC5FC769D2B5F157A14" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">155</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1024-wk-Fact-0056394CBAD212A742E59D2B5E7CD264" name="us-gaap:IncomeLossAttributableToParent" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1044-wk-Fact-95C8A11864076B86AEB39D2B5E8C7263" name="us-gaap:IncomeLossAttributableToParent" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income tax provision</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1065-wk-Fact-7E68F15A42AE4CF082DA9D49454F576B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e1085-wk-Fact-16C28965C031E0FBC1E89D494575B27B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1105-wk-Fact-BA1FF15B4CA0DDA458E59D498527475E" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1125-wk-Fact-35172A14585C522013BE9D49851DE52E" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized gain and adjustment on securities included in net loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e1146-wk-Fact-51CF807C0D4E9437C4899D2B5D7F01D8" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e1165-wk-Fact-EC44B8822CCFFEDD73069D2B5E3934BF" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprehensive loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1190-wk-Fact-06C4DC4E1DE75E49F0D19D2B5F10AE7E" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,412</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1210-wk-Fact-F2881B65C6C78A14574A9D2B5F05E091" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Basic and diluted net loss</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1231-wk-Fact-CA84447418828AC9EE8B9D2B5E87760B" name="rvnc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1251-wk-Fact-E6974548A83F8A77AD879D2B5E48DC80" name="rvnc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Basic and diluted net loss per share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1272-wk-Fact-77FADF0F687D2F1A9F1A9D2B5F1AB050" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2020Q1YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12617460e1292-wk-Fact-14507C35D0DB80F6F08A9D2B5E2AFC0C" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Basic and diluted weighted-average number of shares used in computing net loss per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e1308-wk-Fact-1F368849E82927FE05C29D2B5E92DCFB" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2020Q1YTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">53,868,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12617460e1327-wk-Fact-E34105B5A73060CB08159D2B5E0B22A1" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q1QTD" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">41,598,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s74EC70C27A22F1FC368116CE0C30D887"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A371A310FFDE8A7B1E3D647CDFE8649"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Stockholders’ Equity</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share amounts)</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited) </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:61%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Convertible Preferred Stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Common Stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance — Beginning of period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e900-wk-Fact-819C488F63892D235CED9D2BAFC918D8" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">52,374,735</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e914-wk-Fact-00CD0AC75AA83751A4A19D2BB0C764A1" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e933-wk-Fact-B6683177EDCAEC3145B69D2BB108236F" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">36,975,203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e948-wk-Fact-19EEA4D2DC1B2DAAD3539D2BB1FE052F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of common stock in connection with the Teoxane Agreement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e968-wk-Fact-7E3F31BB57ECAAB441C89D8838A5A3C4" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e982-wk-Fact-F9E76A4B79840E0F3A669D886B183A19" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of restricted stock awards and performance stock awards, net of cancellation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1036-wk-Fact-49906911C7D7579A99029D5997D8DE8C" name="rvnc:StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,197,054</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1050-wk-Fact-52CBB5A01C4B40B374BE9D59E1AB111E" name="rvnc:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1069-wk-Fact-4BD40254436BD41414049D59ADEE8F07" name="rvnc:StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">323,026</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of common stock in connection with offerings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1104-wk-Fact-AE52ED6B5C60E4BC486C9D5B18C74BEA" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">975,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1118-wk-Fact-C359DE8DF444E95885F99D5B68EDC2E4" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1137-wk-Fact-327AAC536E076D096B279D5B33B581B7" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,764,705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1152-wk-Fact-81CA9E04B4135BBA0DA89D5B7B091EE3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of common stock upon exercise of stock options and warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1172-wk-Fact-99FE77E900F6A44793D49D5C98EFD6DA" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">52,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1205-wk-Fact-1612B4B52B988478F3709D2BB0E308DC" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,824</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net settlement of restricted stock awards for employee taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e1240-wk-Fact-D89EDB46F80448C5597E9D2BAFA52626" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">72,987</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e1274-wk-Fact-D3EE3F165F3F8CCB26969D2BB12C5125" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">61,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance — End of period</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1311-wk-Fact-38B77879F60727C890129D5D60612506" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">57,026,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1325-wk-Fact-F2EB1B14E09E6EA448FF9D5D64D66E65" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1344-wk-Fact-DE386FE13D851E6AD8EA9D5D69B42B8F" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">44,004,658</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1359-wk-Fact-99C8A42A34F8446546779D5D6E9DED79" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Additional Paid-In Capital</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance — Beginning of period</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1465-wk-Fact-FF161EA58A16ABBBA7989D5DF626C72D" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,069,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1499-wk-Fact-669F69D9004BA69157269D5DFE970D8E" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">830,368</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of common stock in connection with the Teoxane Agreement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1533-wk-Fact-83411B6EA935B31DFD2D9D9EB3226A55" name="us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of restricted stock awards and performance stock awards, net of cancellation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e1601-wk-Fact-2EC08157E1F34FB2E2429D6523C15E9C" name="rvnc:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of common stock in connection with offerings, net of issuance costs of $44 and $521, respectively</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1670-wk-Fact-1C09AEDD2585619EE1D39D2BB0858214" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1704-wk-Fact-67BF1BA337255183F8619D2BAFEA014F" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">107,572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of common stock upon exercise of stock options and warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1738-wk-Fact-04BA1278ED0A372284C29D82A15DDD28" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1772-wk-Fact-5CF6D73C1D44EA7BA5BD9D8241E0D5CC" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Equity component of convertible senior notes, net of transaction costs of $3,583</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1806-wk-Fact-2590D96076B1D1059BC09D9C70E303F9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">108,510</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1874-wk-Fact-3F88020CCEE2D30200619D8167555CB7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e1908-wk-Fact-816323F84A6EDD406CDE9D2BB21BCE87" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,159</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Capped call transactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e1942-wk-Fact-3F1D3388467FFFF34F309D2BAF868AA8" name="rvnc:AdjustmentToAdditionalPaidInCapitalCappedCallTransactions" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net settlement of restricted stock awards for employee taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e2011-wk-Fact-14CBD78598BB57EFE1C59D80DCA0E0B0" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e2046-wk-Fact-1220E1F1C7B6D40983B99D2BB0486136" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,049</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance — End of period</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e2082-wk-Fact-BF700E18BDF89A18F5B29D2BB026F234" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,213,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e2116-wk-Fact-619C7DDC250B9097A72C9D2BB258AC1B" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">941,068</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Accumulated Comprehensive Gain (Loss)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance — Beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e2222-wk-Fact-C97500730B161A6BE6679D2BB06759C0" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e2256-wk-Fact-B1D729612F256359CBF99D2BB0A2EE74" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized gain and adjustment on securities included in net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e2291-wk-Fact-60FF3B2A341AEF4C23729D7FC57A4A5B" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e2325-wk-Fact-2ABEB46FAC958FD186499D7FCCF76B74" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance — End of period</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e2359-wk-Fact-8F9CFAD9E347D394D7689D2BAF60FB72" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e2393-wk-Fact-A1594776776493CB3C149D2BB14E3294" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">70</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated Deficit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance — Beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e2499-wk-Fact-4DD963712F30DA7E81EB9D2BB19D3662" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">844,204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e2534-wk-Fact-3D9F12E28EC4FF3650E29D2BB1BC3358" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">684,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e2569-wk-Fact-26BE0C98A5F797A7C50C9D7F6EE58782" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e2604-wk-Fact-A008AAB8FE0A1F65BDF69D7F75EB1465" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance — End of period</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e2639-wk-Fact-B5F1E994D276143C32CA9D2BB0094B44" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">906,137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12632072e2674-wk-Fact-064A0067FEB101B407EC9D2BB17A8511" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">720,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Stockholders’ Equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e2695-wk-Fact-8E7D441A11370C62FB5A16CE0BF1355D" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2020Q1" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">57,026,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e2714-wk-Fact-03146407C6278DA3AC389D2B33CFFF9F" name="us-gaap:StockholdersEquity" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">308,375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e2728-wk-Fact-97DA84E2548A84F96AF59D7EB8CAF2CF" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q1" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">44,004,658</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12632072e2748-wk-Fact-FF74B35BBC8BADA38B919D7EBABEBF0F" name="us-gaap:StockholdersEquity" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">221,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s80460D6461A5A0320BD116CE0CCCBCF5"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A371A310FFDE8A7B1E3D647CDFE8649"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flows</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited) </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e667-wk-Fact-BA1FF15B4CA0DDA458E59D498527475E" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e687-wk-Fact-35172A14585C522013BE9D49851DE52E" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-cash in-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e744-wk-Fact-FB69C1D3CB63DCDD18649DFF8FAFCC14" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e763-wk-Fact-C8F71AADC9C5100F030E9DFF8FAF0087" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e783-wk-Fact-1247425740E361E1AD1E9DFDB3C4BB02" name="us-gaap:ShareBasedCompensation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e802-wk-Fact-001FBFFAFB70666038F89DFDB40990E2" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,159</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of debt discount and issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e822-wk-Fact-49FFCE3E3264DCB1B7C99DFEDE224C62" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e841-wk-Fact-9D795B8A3A616A92585B9DFEDE22C635" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e861-wk-Fact-3B30301072618322BBD99DFD0B0E4A24" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e880-wk-Fact-DEAF29C8252EE6CB45E79DFD0ACE0907" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">628</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Amortization of discount on investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e900-wk-Fact-FF0630A6E9116BE72D3B9D2C55E6D12F" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">513</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e920-wk-Fact-2784E7DA9DF6591C47E89D2C56068253" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other non-cash operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e941-wk-Fact-342617EE8905DDE0F2849D2C537DFC07" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e960-wk-Fact-0C9D7650CE5F328ACC059D2C53786D2D" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">88</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1022-wk-Fact-6E2099CF8F0E0CE2C3019D2C5325F207" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1041-wk-Fact-837DFFAD3BA66B4B6C8B9D2C54550E0A" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">27,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1061-wk-Fact-FABC3AB954F1555C53519D2C531D1941" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1081-wk-Fact-39A4EC1C884C2EFBD3FE9D2C5369013A" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,018</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease right of use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1102-wk-Fact-174DF8453F017C00F41E9D2C543998B1" name="rvnc:IncreaseDecreaseinOperatingLeaseRightofUseAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">570</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1121-wk-Fact-BF278E303F52C4EC802D9D2C54A35AC5" name="rvnc:IncreaseDecreaseinOperatingLeaseRightofUseAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,440</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other non-current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1142-wk-Fact-1570CE961E738E47D8339D2C555DAC96" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1161-wk-Fact-E0E2EEA14339B05463899D2C55823170" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1181-wk-Fact-35F70206B6197415127E9D2C5349E9BF" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1200-wk-Fact-A30D2532045675A533899D2C53AC9A4C" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,736</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accruals and other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1221-wk-Fact-4240FCF86EFF7B2149E19D2C539CFA34" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1241-wk-Fact-BC5BA473BCB2A4C73D769D2C539C2EAC" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1262-wk-Fact-8C1532DD49772E73B49D9D2C537D086F" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1281-wk-Fact-C61386A9C48EAFF31F969D2C552E8B4A" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1302-wk-Fact-B7623A92458D614324C59D2C551196FD" name="rvnc:IncreaseDecreaseinOperatingLeaseLiabilities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">822</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1322-wk-Fact-A0046BF9ABCCB4D532069D2C533ADC0E" name="rvnc:IncreaseDecreaseinOperatingLeaseLiabilities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Net cash used in operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1342-wk-Fact-7BE5A87584B17EC5B5BD9D2C564BD13E" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">43,289</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1362-wk-Fact-E60F2E10E0166C3BECFA9D2C54E84BF3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,414</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchases of investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1425-wk-Fact-B5F279E745F78C44E2809D2C55C1CD61" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,412</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1445-wk-Fact-74D2F20F9999780BFCBA9D2C533A24B8" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">127,357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1466-wk-Fact-757E0EF790E31D396FAF9D2C56347CE4" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">539</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1486-wk-Fact-96D07C9963A8D39FAD9F9D2C53552000" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchase of intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1507-wk-Fact-3A1B0226533A0264D07A9E03AD88083B" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1527-wk-Fact-2B07AF43E61F098C9D099E03AC206615" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from maturities of investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1547-wk-Fact-55490928DF47FDA98B059D2C5362C59E" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1566-wk-Fact-B2CF6EB7F4499FBF71299D2C53BCE26E" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1586-wk-Fact-C51E6823204E10B4BB919D2C532A7FC9" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">105,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1606-wk-Fact-62719852320B910D2A319D2C539C348A" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">103,441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from issuance of convertible senior notes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1668-wk-Fact-0F9BFF570C5C8C4D5DBA9E071C0C8464" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">287,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1687-wk-Fact-D07491695423D50C2FDE9E071C3D8B6C" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from issuance of common stock in connection with offerings, net of commissions and discount</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1707-wk-Fact-84A9847AD26A05E452419E04CD49C3BB" name="rvnc:ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1726-wk-Fact-6A9B75189FBBD4CA8B079E04CD4978DD" name="rvnc:ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">108,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Proceeds from the exercise of stock options and common stock warrants</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1746-wk-Fact-34E7CCDE114691E14C319D2C53ACF570" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">572</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1765-wk-Fact-6D8C9AAB096A85C2CBA99D2C538DA8B3" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Payment of capped call transactions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1785-wk-Fact-745AE0BF7884156D53509E07EDC8AF72" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1805-wk-Fact-A89F160079C1E3D130C59E07EDCF89D8" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Payment of convertible senior notes transaction costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1825-wk-Fact-8DAACCB91C85E935C94A9E08DA1BC749" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1845-wk-Fact-062384438CFB96A63FCA9E08DA21383F" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net settlement of restricted stock awards for employee taxes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1866-wk-Fact-A723554B268E05562C3C9E053E0940D8" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1886-wk-Fact-4306D317BF23E25EBFA79E053E6A3FA4" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,049</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Payment of offering costs</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1907-wk-Fact-F02B15D6ECC22AFCD3D89E0598409B37" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e1927-wk-Fact-BF141A2072AB0A1D3E8A9E059849DA4D" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Net cash provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1948-wk-Fact-D9B4001402FB28E945F59D2C55A13D18" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">264,347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1967-wk-Fact-A09BE4FE2F1AEC27FBF49D2C540A6547" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">106,868</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e1987-wk-Fact-AE28771CC74C74E110029D2C53EAA896" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,489</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d12621112e2006-wk-Fact-CF0D88A88373C02CEF9A9D2C5474B82F" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,987</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2027-wk-Fact-550B619F1133681193EC9D2C564B91C4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2046-wk-Fact-6CF2B65BE87F716702369D2C54C91913" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2071-wk-Fact-FFB1D2C78FFE15CF67F09D2C53713CE4" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">287,379</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2090-wk-Fact-28AFF7248E8DC3F9C9FE9D2C530C7226" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Issuance of common stock in connection with the Teoxane Agreement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2151-wk-Fact-E312EDFE4F85BA4651829E101A1165AB" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,400</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2170-wk-Fact-1AE289961BBB76CF97C19E101A1800D6" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued transaction costs on convertible senior notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2190-wk-Fact-7C8E711B7C835C6E6DCB9E0DE717D11D" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">487</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2209-wk-Fact-A5B0271DBD69CFCE66189E0DE72F0E0B" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property and equipment purchases included in accounts payable and accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2229-wk-Fact-EB56F84DC0CF679932469E0CC175BD7A" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">247</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2248-wk-Fact-3DCC0246EDDD57137BAF9E0CC175F8D6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued offering costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2268-wk-Fact-4449FC3A57D93B915BD39E0D2565FCBF" name="rvnc:NoncashDeferredOfferingCosts" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d12621112e2287-wk-Fact-C91B5BC0D8148484DC889E0D251FB033" name="rvnc:NoncashDeferredOfferingCosts" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s6EAD4C6C52AF9B77490916CE1A238486"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5A371A310FFDE8A7B1E3D647CDFE8649"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited) </span></div><div style="line-height:120%;padding-bottom:0px;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s785C268B6C9FBC30189216CE0CFBA2CB"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">1. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="TextSelection-C298E355549DB8DDAB7116CE0CFB98F3-0-wk-Fact-E8318E4B1671FE32E81216CE0D0AE048" continuedAt="TextSelection-C298E355549DB8DDAB7116CE0CFB98F3-1" escape="true">The Company and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-C298E355549DB8DDAB7116CE0CFB98F3-1" continuedAt="TextSelection-C298E355549DB8DDAB7116CE0CFB98F3-2"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">The Company</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revance Therapeutics, Inc is a biotechnology company, developing new innovations in neuromodulators for aesthetic and therapeutic indications. Our lead product candidate, DaxibotulinumtoxinA for Injection, combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. We have successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines. In </span><span style="font-family:inherit;font-size:10pt;">November 2019</span><span style="font-family:inherit;font-size:10pt;">, we submitted the Biologics License Application (“BLA”) to the United States (the “U.S.”) Food and Drug Administration (the “FDA”) for DaxibotulinumtoxinA for Injection in the treatment of moderate to severe glabellar (frown) lines. The FDA accepted the BLA on </span><span style="font-family:inherit;font-size:10pt;">February 5, 2020</span><span style="font-family:inherit;font-size:10pt;">, and the Prescription Drug User Fee Act (“PDUFA”) target action date is </span><span style="font-family:inherit;font-size:10pt;">November 25, 2020</span><span style="font-family:inherit;font-size:10pt;">. We are also evaluating DaxibotulinumtoxinA for Injection in upper facial lines - glabellar lines, forehead lines and crow’s feet combined -- as well as in three therapeutic indications -- cervical dystonia, adult upper limb spasticity and plantar fasciitis. Beyond DaxibotulinumtoxinA for Injection, we have begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. In </span><span style="font-family:inherit;font-size:10pt;">January 2020</span><span style="font-family:inherit;font-size:10pt;">, we entered into an exclusive distribution agreement (the “Teoxane Agreement”) with Teoxane SA (“Teoxane”), pursuant to which Teoxane granted us with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid® (RHA®) dermal fillers. We are dedicated to making a difference by transforming patient experiences.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since inception, we have devoted substantially all of our efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, the biosimilar to BOTOX®, and preparing the commercial launch of Teoxane’s line of Resilient Hyaluronic Acid® dermal fillers. We have incurred losses and negative cash flows from operations. We have not generated product revenue to date, and will continue to incur significant research and development and other expenses related to our ongoing operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had a net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12621867e550-wk-Fact-BD9BA33525A31E6315269E43D9A21533" name="us-gaap:NetIncomeLoss" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">61.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had a working capital surplus of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12621867e558-wk-Fact-FE89EF67283137E8FCC59E4406B97DC6" name="rvnc:WorkingCapitalSurplus" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">476.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12621867e562-wk-Fact-4A1A01DEDE27C4BEB81D9E442713B91C" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">906.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. In recent years, we have funded our operations primarily through a combination of issuance and sale of common stock and issuance of convertible senior notes. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had capital resources of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12621867e571-wk-Fact-FC8BE53F87E73911CBC29E449030FB43" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">511.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> consisting of cash, cash equivalents, and short-term investments. We believe that our existing capital resources will fund the operating plan through at least the next </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12621867e575-wk-Fact-FCB6907041EAAFB34D5B9E44B5F3BEF1" name="rvnc:CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum" contextRef="FD2020Q1YTD" format="ixt-sec:durmonth">12</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> months following the issuance of this Form 10-Q, and may identify additional capital resources to fund our operations.</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-505A28BB26367AA2FC5516CE0CFB69B5-0-wk-Fact-930468E0F461FB10F87516CE0D0A87A5" escape="true"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated balance sheets for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which was filed with the Securities and Exchange Commission (“SEC”), on </span><span style="font-family:inherit;font-size:10pt;">February 26, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. We operate in </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12621867e611-wk-Fact-93A3E1F412D50F927257BA900572F212" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2020Q1YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> segment.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><ix:continuation id="TextSelection-C298E355549DB8DDAB7116CE0CFB98F3-2"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-B52B571B2F718C993FDA16CE0CFBFD7A-0-wk-Fact-64D1160B755AF36CAF7816CE0D0A7C44" escape="true"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Principles of Consolidation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include our accounts and our wholly-owned subsidiaries. All intercompany transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:UseOfEstimates" id="TextSelection-A0CD9C376DCF4DC758B616CE0CFB738E-0-wk-Fact-D50947ACBBE8F11583F716CE0D0A74B4" escape="true"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, revenue recognition, deferred revenue classification, accruals including clinical trial costs, stock-based compensation, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration of asset acquisitions, and accounting for income taxes. We base these estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances. The worldwide continued spread of COVID-19 has caused a global slowdown of economic activity which has decreased demand for a broad variety of goods and services, including from our potential customers, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. We are unable to predict the future effect resulting from the COVID-19 pandemic on, for instance, paused clinical trials and revised product launch timing. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="TextSelection-66C1497223B77462043D9E3E8A04BE94-0-wk-Fact-B225DAFAD587D2AC63369E40A8DAA46C" escape="true"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intangible Assets</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets acquired in asset acquisition are stated at cost, less accumulated amortization on the condensed consolidated balance sheets, and are amortized on a ratable basis over their useful life. Assets acquired as part of an asset acquisition that are considered to be in-process research and development are immediately expensed unless there is an alternative future use in other research and development projects.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-7F461FF31C464DCE93D316CE0D0AA8D8-0-wk-Fact-850C8E88B088EBFF15B816CE0D0A1810" escape="true"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">. The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. We adopted ASU 2018-15 on January 1, 2020 on a prospective basis.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.</span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s61098877816DFC60349016CE0D0A029F"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">2. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-3047348B0A28FDA0BCDC16CE0D0A5177-0-wk-Fact-7B7BBD5C829620D2BD1916CE0D58622B" continuedAt="TextSelection-3047348B0A28FDA0BCDC16CE0D0A5177-1" escape="true">Revenue</ix:nonNumeric></span><ix:continuation id="TextSelection-3047348B0A28FDA0BCDC16CE0D0A5177-1" continuedAt="TextSelection-3047348B0A28FDA0BCDC16CE0D0A5177-2"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">    </span></ix:continuation></div><ix:continuation id="TextSelection-3047348B0A28FDA0BCDC16CE0D0A5177-2" continuedAt="TextSelection-3047348B0A28FDA0BCDC16CE0D0A5177-3"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Mylan Collaboration and License Agreement</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">    </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Agreement Terms</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into a collaboration agreement with Mylan Ireland Limited, a wholly-owned indirect subsidiary of Mylan N.V. (“Mylan”) in February 2018 (the “Mylan Collaboration”), pursuant to which we agreed to collaborate with Mylan exclusively, on a world-wide basis (excluding Japan), to develop, manufacture, and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®. In August 2019, the Mylan Collaboration was amended to, among other things, revise the period of time for Mylan to decide whether to continue the development and commercialization of the biosimilar beyond the initial development plan (the “Continuation Decision”) to be on or before the later of (i) April 30, 2020 or (ii) 30 calendar days from the date that we provide Mylan with certain deliverables. On May 1, 2020, we announced that we are continuing discussions with Mylan regarding whether or not Mylan plans to move forward with the biosimilar program.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Mylan Collaboration, Mylan has paid us an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e530-wk-Fact-99E1FC9BC965D91FC5AB9E5649A133B2" name="us-gaap:ContractWithCustomerLiability" contextRef="I2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in non-refundable upfront fees, and the agreement provides for additional contingent payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e534-wk-Fact-63343EFA6DFAD637E8AD9E5674F3B5A2" name="rvnc:ContingentLicensingRoyaltyRevenue" contextRef="I2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate, upon the achievement of specified clinical and regulatory (i.e., a biosimilar biological pathway) milestones and of specified, tiered sales milestones of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e538-wk-Fact-327FB26BBED14B1E15549E56A041864C" name="rvnc:RevenueRecognitionMilestoneMethodMaximumRevenue" contextRef="D2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The payments do not represent a financing component for the transfer of goods or services. The contingent payments would be payable after the Continuation Decision and upon meeting certain milestones. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. We estimated the transaction price for the Mylan Collaboration using the most likely amount method. In order to determine the transaction price, we evaluated all of the payments to be received during the duration of the contract, which included milestones and consideration payable by Mylan. Other than the upfront payment, all other milestones and consideration we may earn under the Mylan Collaboration are subject to uncertainties related to development achievements, Mylan’s rights to terminate the agreement, and estimated effort for cost-sharing payments. Components of such estimated effort for cost-sharing payments include both internal and external costs. Consequently, the transaction price does not include any milestones and considerations that, if included, could result in a probable significant reversal of revenue when related uncertainties become resolved. Sales-based milestones and royalties are not included in the transaction price until the sales occur because the underlying value relates to the license and the license is the predominant feature in the Mylan Collaboration. We re-evaluate the transaction price at each reporting period.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to the unfulfilled performance obligations is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e556-wk-Fact-42410B1C4A4BA2954A749E5707CD7CCE" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">106.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue and estimate deferred revenue based on the cost of services incurred over the total estimated cost of services to be provided for the development period. For revenue recognition purposes, the development period is estimated to extend through </span><span style="font-family:inherit;font-size:10pt;">2024</span><span style="font-family:inherit;font-size:10pt;">. It is possible that this period will change and is assessed at each reporting date.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized revenue related to development services of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e578-wk-Fact-6D828E08D1BE8E3B4E8C9E5766999BA3" name="us-gaap:Revenues" contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e582-wk-Fact-E28C1E5136900260ECAC9E5774C15F6B" name="us-gaap:Revenues" contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we estimated short-term deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e595-wk-Fact-6B056765F8066E6CEFA89E57AB42B5DB" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2020Q1_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e599-wk-Fact-1D6B0DAE2D0C963959F69E57AA08437D" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="FI2019Q4_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively; and long-term deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e603-wk-Fact-A1E2C4AC85D049D320D59E57CF543FA0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2020Q1_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e607-wk-Fact-4CBF9F24FC39579489C69E57CE29C1AA" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q4_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><ix:continuation id="TextSelection-3047348B0A28FDA0BCDC16CE0D0A5177-3"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fosun License Agreement </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Agreement Terms</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">December 2018</span><span style="font-family:inherit;font-size:10pt;">, we entered into a license agreement (the “Fosun License Agreement”) with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”), whereby we have granted Fosun the exclusive rights to develop and commercialize our proprietary DaxibotulinumtoxinA for Injection in mainland China, Hong Kong and Macau (the “Fosun Territory”) and certain sublicense rights.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Fosun License Agreement, in </span><span style="font-family:inherit;font-size:10pt;">January 2019</span><span style="font-family:inherit;font-size:10pt;"> we received a non-refundable upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e632-wk-Fact-73E17E0CE6933B029D4E9E589EAF1EAF" name="us-gaap:ContractWithCustomerAssetGross" contextRef="I2019Q1Jan31_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, net of foreign withholding tax of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d12614521e636-wk-Fact-5A1424060256C3DFF77D9E58F7152DF0" name="rvnc:ForeignWithholdingTaxAmount" contextRef="D2019Q1Jan_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. We are also eligible to receive (i) additional contingent payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e640-wk-Fact-1A8D5070A3D63FA75CCF9E592FAB5F56" name="rvnc:ContingentLicensingRoyaltyRevenue" contextRef="I2019Q1Jan31_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">230.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of specified milestones based on (a) the submission and approval of biologics license applications (“BLAs”) for certain aesthetic and therapeutic indications and (b) first calendar year net sales, and (ii) tiered royalty payments in low double digit to high teen percentages on annual net sales. The royalty percentages are subject to reduction in the event that (i) we do not have any valid and unexpired patent claims that cover the product in the Fosun Territory, (ii) biosimilars of the product are sold in the Fosun Territory or (iii) Fosun needs to pay compensation to third parties to either avoid patent infringement or market the product in the Fosun Territory. In </span><span style="font-family:inherit;font-size:10pt;">March 2020</span><span style="font-family:inherit;font-size:10pt;">, we received from Fosun a milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e649-wk-Fact-94C7169D6B95E75129309E59DC4023AE" name="us-gaap:ContractWithCustomerAssetGross" contextRef="FI2020Q1_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, before foreign withholding tax of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e653-wk-Fact-9F0DD46BF769F09186EB9E5A394A55F1" name="rvnc:ForeignWithholdingTaxAmount" contextRef="D2020Q1Mar31_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, for the acceptance of the BLA submission to the FDA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimated the transaction price for the Fosun License Agreement using the most likely amount method. We evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered. We will re-evaluate the transaction price at each reporting period and upon a change in circumstances. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to unfulfilled performance obligation is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12614521e667-wk-Fact-B7AA8AF59A61402640979E5B17569CBC" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">31.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12614521e673-wk-Fact-D812FF950FD9037E09C316CE0D58CF61" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2020Q1YTD_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> revenue has been recognized from the Fosun License Agreement for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Substantially all payments received to date were included in long-term deferred revenue as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><a id="s100DAB74D4B48990496F16CE0D781A78"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">3. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="TextSelection-22A4B373D1FB4888805216CE0D7851A5-0-wk-Fact-D806EA252BC9E0B8196916CE0D78417B" continuedAt="TextSelection-22A4B373D1FB4888805216CE0D7851A5-1" escape="true">Cash Equivalents and Short-Term Investments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-22A4B373D1FB4888805216CE0D7851A5-1" continuedAt="TextSelection-22A4B373D1FB4888805216CE0D7851A5-2"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our cash equivalents and short-term investments consist of money market funds, U.S. treasury securities, U.S. government agency obligations, commercial paper, and overnight repurchase agreements which are classified as available-for-sale securities.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><ix:continuation id="TextSelection-22A4B373D1FB4888805216CE0D7851A5-2"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="TextSelection-EAD93BF74717DB7B608016CE0D78E0FA-0-wk-Fact-AD32E28F2A4ADE9C9B0F16CE0D78090F" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of amortized cost, unrealized gains and losses, and fair value of our cash equivalents and short-term investments: </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in thousands</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1009-wk-Fact-FFB31A55EA10CDE179C69D30CD4B5B9F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">179,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1028-wk-Fact-FD430ABFE92FADD7A9719D30CDAF49C8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1047-wk-Fact-DD365295C87A8795377E9D30CB1025C2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">179,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1067-wk-Fact-3932BB558B4070C6E1069D30CBC9031A" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1086-wk-Fact-0F663FC0F244AA8142349D30CD79D798" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1106-wk-Fact-250EF027CB9912B10D4C9D30CD4B48F5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1125-wk-Fact-54F9F0B3D7F36C750F009D30CC3D978C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1140-wk-Fact-03CA9651B8ECE6BD29B19D30CA74F25E" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1159-wk-Fact-4EA91C5FC5FDC6B2B1B79D30CC1E1EAA" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1178-wk-Fact-F1078035D5D0223C443C9D30CC9289ED" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1198-wk-Fact-EF784C52EAF02D67A5EA9D30CD4BF645" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,349</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1217-wk-Fact-90302ACF4C35CAC011759D30CCB18B64" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1236-wk-Fact-4C94B2BAF862D410AEF19D30CDAF9EF6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1256-wk-Fact-0A3436B45647749A81499D30CD8947B1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1276-wk-Fact-6F715F8533553B3AADAA9D30CD3AE713" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,634</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1295-wk-Fact-879D06353CAE073629FA9D30CD6AEA92" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">342</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1314-wk-Fact-899CCF1AA6CADF7906089D30C9ED30B2" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,976</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1334-wk-Fact-EA18974E3B97E71E7C1C9D30CCB1B91B" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1353-wk-Fact-DD4156458377701D7C9A9D30CD79179D" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12623856e1372-wk-Fact-CAAA7C63C4EE96F4630F9D30CD792947" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1393-wk-Fact-3FCA806ED77454B8C3C99D30CDDE8001" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,990</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1413-wk-Fact-EC435AC05356F7D549CC9D30CD89F579" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1432-wk-Fact-4E73A6F63CCD43B9A0DF9D30CDAF81B1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1451-wk-Fact-C81D91659EDCF91B9E1B9D30CD8987F5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1471-wk-Fact-738B5276F80871782E419D30CD99978E" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1490-wk-Fact-6CD35A362B548F0AB71E9D30CBE8A323" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1509-wk-Fact-0176C9FA0BA9EA38A12A9D30CA4800CC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1529-wk-Fact-4E810B8019B5126551DF9D30CDBF430C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1549-wk-Fact-9179FC695248AC2561A19D30CDA90241" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1568-wk-Fact-08B016E0C7565DD89F249D30CB94B719" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1587-wk-Fact-3F9F723AD4EF61E4330B9D30CB4968A5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1607-wk-Fact-C7CAE9143205EB1A40E39D30CD3D1A0C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1626-wk-Fact-53AD56CF7E944F7649FC9D30CD5AD968" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1645-wk-Fact-EB20E90A961F89894D219D30CA924A82" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1665-wk-Fact-0001BC41D6882527B4B79D30CA1C8BAD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1690-wk-Fact-447F3A920DD607886B409D30CCB1A464" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">509,109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1709-wk-Fact-0183717938DD5382242A9D30CCC0DFD1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1728-wk-Fact-9312ED530FEEC6AD559D9D30CDCE112D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">509,633</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1748-wk-Fact-33086F7A2CC576592D159D30CCC0322C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">282,683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1767-wk-Fact-308D857D5B258F9D44039D30CDBF8021" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12623856e1787-wk-Fact-FC97D6DAD82AF266E6289D30CC6C0DAB" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e1807-wk-Fact-326E9D25EE9237B3C03B9D30CD5A7E0C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">282,686</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Classified as:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e2154-wk-Fact-82671B996D089C9BD16E9D30CAC17CB6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">285,012</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e2235-wk-Fact-008954EC1DB1335B913A9D30CD3D4758" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">163,731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e2290-wk-Fact-F723E23343663F8B48EB9D30CD9907B1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">224,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e2371-wk-Fact-0F36F04FBC808E0B463C9D30CDBF6634" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">118,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e2436-wk-Fact-9312ED530FEEC6AD559D9D30CDCE112D" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">509,633</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e2517-wk-Fact-326E9D25EE9237B3C03B9D30CD5A7E0C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">282,686</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12623856e2548-wk-Fact-E8EACEF8AFD2F1B3626816CE0D785A65" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" contextRef="FD2020Q1YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> other-than-temporary impairments on our available-for-sale securities and the contractual maturities of the available-for-sale securities are less than one-year.</span></div></ix:continuation><div><a id="s89e018506f474bc9b18873233c39430b"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">4. Filler Distribution Agreement</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="TextSelection-6052ADBFACB5707F72639FEE1B9C0D65-0-wk-Fact-EBDE311A0A60695AC98C9FF146E35ACB" continuedAt="TextSelection-6052ADBFACB5707F72639FEE1B9C0D65-1" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, we entered into an exclusive distribution agreement (the “Teoxane Agreement”) with Teoxane SA (“Teoxane”), pursuant to which Teoxane granted us with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid® (“RHA®”) dermal fillers in exchange for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12615753e514-wk-Fact-B032CD16EFBCDE9244219E658E198858" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock and certain other commitments by us. The Teoxane Agreement includes rights to i) RHA® 2, RHA® 3 and RHA® 4 which have been approved by the FDA for the correction of moderate to severe dynamic facial wrinkles and folds, including RHA® 2, RHA® 3 and RHA® 4 in the currently approved indications, ii) RHA® 1, which is currently in clinical trials for the treatment of perioral rhytids , and iii) future hyaluronic acid filler advancements and products by Teoxane (collectively the “</span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">”) in the U.S. and U.S. territories and possessions. The Teoxane Agreement will be effective for a term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12615753e522-wk-Fact-78A21240FB2EF83546569FF22C5D0437" name="rvnc:CollaborativeAgreementContractualPeriod" contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> upon product launch and may be extended for a two-year period upon the mutual agreement of the parties. We are required to meet certain minimum purchase obligations and certain minimum expenditure requirements, which are discussed in </span><a style="font-family:inherit;font-size:10pt;" href="#s432F768E2BFB1A06A47A16CE0E304583"><span style="font-family:inherit;font-size:10pt;">Note 10</span></a><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If Teoxane pursues regulatory approval for RHA® dermal fillers for certain new indications or filler technologies, including innovations with respect to existing products in the U.S., we will be subject to certain specified cost-sharing arrangements for third party expenses incurred in achieving regulatory approval for such products. We will also have a right of first negotiation with respect to any cosmeceutical products that Teoxane wishes to distribute in the U.S, and Teoxane will have a right of first negotiation in connection with the distribution of DaxibotulinumtoxinA for Injection for aesthetic use, outside the U.S. and U.S. territories where Teoxane has an affiliate. </span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><ix:continuation id="TextSelection-6052ADBFACB5707F72639FEE1B9C0D65-1"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Teoxane Agreement is accounted for as an asset acquisition for the distribution rights of various approved and unapproved products and indications. The aggregate purchase consideration for the distribution rights is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12615753e537-wk-Fact-343DECDAD40A7C6A21FDE6343A734581" name="us-gaap:FairValueOfAssetsAcquired" contextRef="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">43.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, consisting of the fair value of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12615753e541-wk-Fact-B032CD16EFBCDE9244219E658E198858" name="us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets" contextRef="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares transferred to Teoxane and transaction costs. The purchase consideration is allocated to the underlying groups of approved and unapproved products based on their relative fair values, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12615753e545-wk-Fact-F855C0214C7681DFAB0FE63050E7F37D" name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is allocated to certain unapproved products and future innovations, or in-process research and development assets, and is recognized as research and development expense on the condensed consolidated statements of operations and comprehensive loss. The remaining purchase consideration is allocated to the currently approved products and indications, and is recognized as an intangible asset on the condensed consolidated balance sheets. The intangible asset will be amortized over approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12615753e549-wk-Fact-5B212957A92B24563871C3EA30898EFC" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" format="ixt-sec:duryear">4</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years commencing upon the first delivery of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> products from Teoxane. </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-24CE1801B0E9033C4831BA7837866DF3-0-wk-Fact-6D386B417D63DB0E205BBA78D50F08BC" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarized the distribution rights:</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Initial Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution rights to approved products and indications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12615753e718-wk-Fact-ACB6702638F0C7994848E62E1D5FC220" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,334</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12615753e737-wk-Fact-D4BF49E05573B7D002D0E62E1D03BC75" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12615753e756-wk-Fact-B980316ACCA2C4FD0580E62E1D08A987" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,334</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s61ED01426F48B867933F16CE0D58CB5C"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">5. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="TextSelection-DBB7AE9B3B5BB192D6629E96C94D1407-0-wk-Fact-3660FD0AD501CD8DB01E9E96ECB667B2" continuedAt="TextSelection-DBB7AE9B3B5BB192D6629E96C94D1407-1" escape="true">Derivative Liability</ix:nonNumeric></span></div><ix:continuation id="TextSelection-DBB7AE9B3B5BB192D6629E96C94D1407-1"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2012, we entered into a settlement agreement in which we are obligated to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624158e522-wk-Fact-090E38245355008D64549E9792716AFF" name="rvnc:AccruedMilestoneObligations" contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_ValeantPharmaceuticalsInternationalInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> upon achieving regulatory approval for DaxibotulinumtoxinA for Injection or DaxibotulinumtoxinA Topical. We determined that such payment was a derivative instrument that requires fair value accounting as a liability and periodic fair value remeasurements until settled. The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the derivative liability was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624158e533-wk-Fact-E7CA653557F6B1486C1F9E97D3A21ED5" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12624158e537-wk-Fact-4777EACBEA7472881A1C9E9849590818" name="rvnc:FairValueMeasurementInputDuration" contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" format="ixt-sec:duryear">0.7</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> based on an expected BLA approval in 2020, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624158e541-wk-Fact-6EE1F7A3AE3F6E8E93949E982A34735E" name="rvnc:FairValueMeasurementInput" contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624158e545-wk-Fact-12C3D16241CB34166DF89E9876FF250C" name="rvnc:FairValueMeasurementInput" contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputEntityCreditRiskMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the derivative liability was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624158e554-wk-Fact-0B3405EC7B57EDA11A5A9E989A2B438E" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12624158e558-wk-Fact-E2027A98E09CAD8F6D299E98BBB29F5F" name="rvnc:FairValueMeasurementInputDuration" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" format="ixt-sec:duryear">0.9</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> based on an expected BLA approval in 2020, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624158e562-wk-Fact-23240068438ECD436E4F9E98DC86BBB5" name="rvnc:FairValueMeasurementInput" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.6</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624158e566-wk-Fact-B30A08C89656696916C19E98FCF972BD" name="rvnc:FairValueMeasurementInput" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputEntityCreditRiskMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><a id="s4A42A27962668B7D14AF16CE0E171FD0"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">6. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-54BF64622D00411197BD16CE0E1A6FC0-0-wk-Fact-9CD3E937AF03654ACE6216CE0E1DCD47" continuedAt="TextSelection-54BF64622D00411197BD16CE0E1A6FC0-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="TextSelection-54BF64622D00411197BD16CE0E1A6FC0-1" continuedAt="TextSelection-54BF64622D00411197BD16CE0E1A6FC0-2"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have non-cancelable operating leases for facilities for research, manufacturing, and administrative functions, and equipment operating leases. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the weighted average remaining lease term is </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12628723e521-wk-Fact-DE284517372B320E72569E9BD4EDF3CC" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2020Q1" format="ixt-sec:duryear">6.8</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. The monthly payments for the facility lease escalate over the facility lease term with the exception of a decrease in payments at the beginning of </span><span style="font-family:inherit;font-size:10pt;">2022</span><span style="font-family:inherit;font-size:10pt;">. We have options to extend the facility operating leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12628723e529-wk-Fact-75C7BDF5B93E00E0C23D9E9BF8CA4C04" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="FI2020Q1" format="ixt-sec:duryear">14.0</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. Our lease contracts do not contain termination options, residual value guarantees or restrictive covenants. </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-1E961174C9F6342BC47616CE0E1A5C12-0-wk-Fact-73DE5DB974D89088AFAD16CE0E1DC92C" continuedAt="TextSelection-1E961174C9F6342BC47616CE0E1A5C12-1" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating lease costs are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span><ix:nonFraction id="d12628723e649-wk-Fact-23299672053195705A3B9D3180737FCF" name="us-gaap:OperatingLeaseCost" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span><ix:nonFraction id="d12628723e668-wk-Fact-512CFAC19744E643217F9E9B2FEF99FC" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,343</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span><ix:nonFraction id="d12628723e685-wk-Fact-9E5394E019F3046DE0399D318093B095" name="us-gaap:VariableLeaseCost" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span><ix:nonFraction id="d12628723e704-wk-Fact-FE02A81E6B511386D1599E9B316B2121" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span><ix:nonFraction id="d12628723e729-wk-Fact-422A34712A518B8ECB859D31803EB564" name="us-gaap:LeaseCost" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,502</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span><ix:nonFraction id="d12628723e748-wk-Fact-EB3217D241219E39E42F9E9B32C24186" name="us-gaap:LeaseCost" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,633</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-1E961174C9F6342BC47616CE0E1A5C12-1" continuedAt="TextSelection-1E961174C9F6342BC47616CE0E1A5C12-2"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-1E961174C9F6342BC47616CE0E1A5C12-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.</span></div></ix:continuation></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><ix:continuation id="TextSelection-54BF64622D00411197BD16CE0E1A6FC0-2"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-48668C1DA0985CBE1F8416CE0E196C78-0-wk-Fact-E48CD374D4FCAB4A7E3A16CE0E1EDE47" continuedAt="TextSelection-48668C1DA0985CBE1F8416CE0E196C78-1" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, maturities of the Company’s operating lease liabilities are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 remaining nine months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e820-wk-Fact-D32A358D6DB835AEF0AE9D318669F354" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,057</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e835-wk-Fact-B504E5622E380FF7E2DF9D31868B41A5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e855-wk-Fact-8FA5371A4CA2A94266AB9D318734F97E" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e875-wk-Fact-228F8F67A22CA4AE5ADA9D3186BDA90C" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,557</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e895-wk-Fact-5E0DB9B5B6E6418A86AD9D31873A59BB" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e915-wk-Fact-D8494842D1DA9AA7873C9D3187129DE0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e935-wk-Fact-E5DCA83B7CE43869A2A79D318606C912" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,979</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12628723e957-wk-Fact-E3D199DA0528E07151829D31863FA9B0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of operating lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e983-wk-Fact-DE6085B67AC6543639279D3186E8BA11" name="us-gaap:OperatingLeaseLiability" contextRef="FI2020Q1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,517</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Our lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d12628723e996-wk-Fact-293A8C95C7B0647F0E3B9E9F8EEA6F9D" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2020Q1" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">12.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:8pt;">, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates. </span></div></td></tr></table></ix:nonNumeric><ix:nonNumeric contextRef="FD2020Q1YTD" name="rvnc:LesseeSupplementalCashFlowInformationTableTextBlock" id="TextSelection-73354E9BDC2F05107A6716CE0E198E13-0-wk-Fact-E68EB0C234B78133D34216CE0E1D9465" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-48668C1DA0985CBE1F8416CE0E196C78-1"></ix:continuation>Supplemental cash flow information related to the operating leases was as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e1119-wk-Fact-1C7591458A98BC8A667B9D318B437982" name="us-gaap:OperatingLeasePayments" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,677</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e1138-wk-Fact-CF56CEF32AF221C1790B9E9E55AD0A22" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e1158-wk-Fact-969EDEAA2E15E5A9547B9D318B4AD8F8" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628723e1177-wk-Fact-04188F6EE348A2C80AD69E9E57F58E88" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><a id="sA7383604AC085C3D768E16CE0E6EDABB"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">7. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:LongTermDebtTextBlock" id="TextSelection-38233C4932C9AD308CDCBA14EA194951-0-wk-Fact-DBCCBDB2F3D9F7B5AA07BA163DCB335F" continuedAt="TextSelection-38233C4932C9AD308CDCBA14EA194951-1" escape="true">Convertible Senior Notes</ix:nonNumeric></span></div><ix:continuation id="TextSelection-38233C4932C9AD308CDCBA14EA194951-1" continuedAt="TextSelection-38233C4932C9AD308CDCBA14EA194951-2"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">February 14, 2020</span><span style="font-family:inherit;font-size:10pt;">, we issued convertible senior notes that are due in 2027 (the “</span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">”) with an aggregate principal balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624780e526-wk-Fact-2054F579CB22BEBF9DEBBA2E353B2C99" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">287.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, pursuant to an indenture, dated </span><span style="font-family:inherit;font-size:10pt;">February 14, 2020</span><span style="font-family:inherit;font-size:10pt;">, between Revance and U.S. Bank National Association, as trustee (the “Indenture”). The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> are senior unsecured obligations and bear interest at a rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e539-wk-Fact-8F338D68EF70E8540CD3BA199F1A0735" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">1.75</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> per year, payable semiannually in arrears on </span><span style="font-family:inherit;font-size:10pt;">February 15</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August 15</span><span style="font-family:inherit;font-size:10pt;"> of each year, beginning on </span><span style="font-family:inherit;font-size:10pt;">August 15, 2020</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> will mature on </span><span style="font-family:inherit;font-size:10pt;">February 15, 2027</span><span style="font-family:inherit;font-size:10pt;">, unless earlier converted, redeemed or repurchased. In connection with issuing the 2027 Notes, we received </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624780e564-wk-Fact-5874B2D3225AB3C5DD53BA1CDD621E3F" name="us-gaap:ProceedsFromConvertibleDebt" contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">278.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in net proceeds, after deducting the initial purchasers’ discount, commissions, and other issuance costs. A portion of the net proceeds from the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> were used to purchase the capped call transactions described below and the remainder will be used to fund expenses associated with commercial launch activities for both the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and, if approved, DaxibotulinumtoxinA for Injection for glabellar lines, research and development, and other corporate activities.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><ix:continuation id="TextSelection-38233C4932C9AD308CDCBA14EA194951-2" continuedAt="TextSelection-38233C4932C9AD308CDCBA14EA194951-3"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> may be converted at any time by the holders prior to the close of business on the business day immediately preceding </span><span style="font-family:inherit;font-size:10pt;">November 15, 2026</span><span style="font-family:inherit;font-size:10pt;"> only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending on </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> (and only during such fiscal quarter), if the last reported sale price of our common stock for at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e591-wk-Fact-2C64C0184720EB7E8861BA1E43DDE6B2" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsOneMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during a period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e595-wk-Fact-D79E08C85224E98E7EC6BA213713522A" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsOneMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e600-wk-Fact-5A77DA62CBDDA53DE74CBA226AB1875E" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsOneMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">130</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day; (2) during the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e604-wk-Fact-67FBB74F8E4F72935C10BA2685A31A95" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsTwoMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> business day period after any </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e608-wk-Fact-A077975A1532668858DABA26E1499306" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsTwoMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> for each trading day of the measurement period was less than </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e620-wk-Fact-8BDEFFB725303FD87FE3BA293F042DE2" name="rvnc:DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsTwoMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">98</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after </span><span style="font-family:inherit;font-size:10pt;">November 15, 2026</span><span style="font-family:inherit;font-size:10pt;"> until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> at any time, regardless of the foregoing circumstances. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The conversion rate will initially be </span><span style="font-family:inherit;font-size:10pt;">30.8804</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock per </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624780e652-wk-Fact-8846D8BE2A4051205A11BA2F117D0D95" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">32.38</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share of our common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or if we deliver a notice of redemption, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> in connection with such a corporate event or notice of redemption, as the case may be.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not redeem the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> prior to </span><span style="font-family:inherit;font-size:10pt;">February 20, 2024</span><span style="font-family:inherit;font-size:10pt;">. We may redeem for cash all or any portion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, at our option, on or after </span><span style="font-family:inherit;font-size:10pt;">February 20, 2024</span><span style="font-family:inherit;font-size:10pt;"> if the last reported sale price of our common stock has been at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e679-wk-Fact-E6B630CD28FD151F71D3BA35D214B991" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">130</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price then in effect for at least </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e684-wk-Fact-E61631C51C63E544CFE4BA3655D29793" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during any </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e688-wk-Fact-8FB0375FFABD94C2E2ADBA36C204325C" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="day" decimals="INF" scale="0" format="ixt:numdotdecimal">30</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e692-wk-Fact-E5E552B40AC6F2FDD390BA33D961F9E3" name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#212529;">If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their 2027 Notes at a fundamental change repurchase price equal to </span><span style="font-family:inherit;font-size:10pt;color:#212529;"><span><ix:nonFraction id="d12624780e707-wk-Fact-E5E552B40AC6F2FDD390BA33D961F9E3" name="us-gaap:DebtInstrumentRedemptionPricePercentage" contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;color:#212529;"> of the principal amount of the 2027 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accounting for the issuance of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, we separated the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> into liability and equity components. The carrying amount of the liability component was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624780e722-wk-Fact-D4ED2390DB618BC7AA5CBA63C8FEB8A8" name="us-gaap:LongTermDebt" contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">175.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which was calculated by using a discount rate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e726-wk-Fact-236A96A9710F5739AB33BA39170F6439" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">9.5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">, which was estimated to be our borrowing rate on the issuance date for a similar debt instrument without the conversion feature. The carrying amount of the equity component was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624780e730-wk-Fact-6E4A101E63A3B20CC465BA3BDA3C2668" name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">112.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which represents the conversion option, and was determined by deducting the fair value of the liability component from the par value of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. The equity component of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> is included in additional paid-in capital in the condensed consolidated balance sheets and will not be subsequently remeasured as long as it continues to meet the conditions for equity classification. The difference between the principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> and the liability component (the “debt discount”) is amortized to interest expense in the condensed consolidated statements of operations and comprehensive loss using the effective interest method over the term of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total transaction costs for the issuance of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624780e758-wk-Fact-913E03E419E2FC98A573BA5097810FB9" name="us-gaap:DeferredFinanceCostsGross" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, consisting of initial purchasers’ discount, commissions, and other issuance costs. We allocated the total transaction costs proportionally to the liability and equity components. The transaction costs attributed to the liability component were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624780e762-wk-Fact-F94A22E67B0EFF7E65FFBA52F68C9EBB" name="rvnc:DebtIssuanceCostsGrossLiabilityComponent" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which were recorded as debt issuance costs (presented as contra debt in our condensed consolidated balance sheets) and are amortized to interest expense in the condensed consolidated statements of operations and comprehensive loss over the term of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. The transaction costs attributed to the equity component were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624780e770-wk-Fact-32E6B43476522BF263A1BA51AAC0D3F2" name="rvnc:DebtIssuanceCostsGrossEquityComponent" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, which were included in additional paid-in capital.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><ix:continuation id="TextSelection-38233C4932C9AD308CDCBA14EA194951-3"><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ConvertibleDebtTableTextBlock" id="TextSelection-10CD32D4A1C413D096C8BA16A631B3AA-0-wk-Fact-C1A84FE2D9DC7BB4BDDDBA17F4347944" escape="true"><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense relating to the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> in the condensed consolidated statements of operations and comprehensive loss are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e849-wk-Fact-DAB602D4D1F77F95AF72BA44984E86B9" name="us-gaap:InterestExpenseDebtExcludingAmortization" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">643</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e866-wk-Fact-D206663CC30C7AF3157ABA44FC826F77" name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e888-wk-Fact-911D64836C8A8561F60ABA458C3F6254" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e913-wk-Fact-EF7AA1571712A04C9989BA45CF7EDBDE" name="us-gaap:InterestExpenseDebt" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate on the liability component of the </span><span style="font-family:inherit;font-size:8pt;">2027 Notes</span><span style="font-family:inherit;font-size:8pt;"> was </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d12624780e930-wk-Fact-236A96A9710F5739AB33BA39170F6439" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">9.5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, which remained unchanged from the issuance date. As of </span><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, the unamortized debt discount was </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d12624780e942-wk-Fact-60370442A8C4F59693D1BA488AC9264E" name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">110.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;">, and will be amortized over </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonNumeric id="d12624780e947-wk-Fact-DDC7240B5D3521B00E69BA49009E98A9" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" contextRef="FD2020Q1YTD_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" format="ixt-sec:duryear">6.9</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:8pt;"> years.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, the unamortized debt issuance cost for the </span><span style="font-family:inherit;font-size:8pt;">2027 Notes</span><span style="font-family:inherit;font-size:8pt;"> was </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d12624780e967-wk-Fact-17D3A37D2214E1581CDBBA4BA929ACAB" name="us-gaap:DeferredFinanceCostsNet" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:8pt;"> on the condensed consolidated balance sheets.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the convertible senior notes on the condensed consolidated balance sheets represented the carrying amount of the liability component of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, net of unamortized debt discounts and debt issuance costs, which are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e1028-wk-Fact-F94308A32E3FCD2549E0BA6148789613" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">287,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Unamortized debt discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d12624780e1043-wk-Fact-B2DC4EB3720FD0690E9CBA620FB231C1" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">116,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying amount of 2027 Notes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e1069-wk-Fact-4285CA903F9441B93208BA625E108F4B" name="us-gaap:LongTermDebt" contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">171,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Capped Call Transactions</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Concurrently with the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, we entered into capped call transactions with one of the initial purchasers and another financial institution (the “option counterparties”) and used </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d12624780e1087-wk-Fact-8E4D51A7214DF2E94587BA67585A391B" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" contextRef="D2020Q1Feb14" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of the net proceeds from the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce the potential dilutive effect upon conversion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">and/or offset any cash payments we are required to make in excess of the principal amount of converted </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, as the case may be, with such reduction and/or offset subject to a price cap of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624780e1106-wk-Fact-03DBB637D9965989A451BA68437135CA" name="rvnc:CappedCallsPriceCap" contextRef="I2020Q1Feb14" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">48.88</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> of our common stock per share, which represents a premium of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12624780e1110-wk-Fact-5C849DCF1FD48E759B52BA6AF530FC91" name="rvnc:CappedCallsPremiumPercentageOverSalePrice" contextRef="D2020Q1Feb14" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> over the last reported sale price of our common stock on </span><span style="font-family:inherit;font-size:10pt;">February 10, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;color:#212529;">The cap</span><span style="font-family:inherit;font-size:10pt;">ped calls have an initial strike price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624780e1122-wk-Fact-8846D8BE2A4051205A11BA2F117D0D95" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">32.38</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, subject to certain adjustments, which corresponds to the conversion option strike </span><span style="font-family:inherit;font-size:10pt;color:#212529;">price</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. The capped call transactions cover, subject to anti-dilution adjustments, approximately </span><span style="font-family:inherit;font-size:10pt;color:#212529;"><span><ix:nonFraction id="d12624780e1135-wk-Fact-6D10316BC8FD2479034EECDD9B8662A5" name="rvnc:CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments" contextRef="FI2020Q1" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The capped call transactions are separate transactions that we entered into with the option counterparties and are not part of the terms of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. As the capped call transactions meet certain accounting criteria, the premium paid of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12624780e1146-wk-Fact-8E4D51A7214DF2E94587BA67585A391B" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" contextRef="D2020Q1Feb14" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as a reduction in additional paid-in capital in the condensed consolidated balance sheets, and will not be remeasured to fair value as long as the accounting criteria continue to be met. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had not purchased any shares under the capped call transactions.</span></div></ix:continuation><div><a id="sAC5F9581FE1EA89FECFF16CE0E30BF63"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;"> 8. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-0A1A73CDFF70B181F3DC16CE0E3F7D3F-0-wk-Fact-14AEC3B96CD306C2FB0A16CE0E5E13D0" continuedAt="TextSelection-0A1A73CDFF70B181F3DC16CE0E3F7D3F-1" escape="true">Stockholders’ Equity and </ix:nonNumeric></span><ix:continuation id="TextSelection-0A1A73CDFF70B181F3DC16CE0E3F7D3F-1" continuedAt="TextSelection-0A1A73CDFF70B181F3DC16CE0E3F7D3F-2"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</span></ix:continuation></div><ix:continuation id="TextSelection-0A1A73CDFF70B181F3DC16CE0E3F7D3F-2" continuedAt="TextSelection-0A1A73CDFF70B181F3DC16CE0E3F7D3F-3"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock Warrants</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e528-wk-Fact-A50FEF8FBF11EEF204B19EE19175B8D1" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,113</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were outstanding at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12625631e532-wk-Fact-5BC2DF8C8AC3E4BFC0039EE1B9BE456C" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="FI2019Q4_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.95</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, which expired in May 2020. In February 2020, warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e536-wk-Fact-B78506B6F2DBB90DFD469EE215D880A1" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="I2020Q1Feb29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">34,113</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were net exercised for </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e540-wk-Fact-DB8031EBF501EEFBECC19EE37E83F005" name="rvnc:StockIssuedDuringPeriodSharesExerciseofWarrants" contextRef="D2020Q1Feb29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,134</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e549-wk-Fact-06B4B5E67431D8D2E1BA9EE3EE5CF570" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> common stock warrants were outstanding. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0A1A73CDFF70B181F3DC16CE0E3F7D3F-3" continuedAt="TextSelection-0A1A73CDFF70B181F3DC16CE0E3F7D3F-4"><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Equity Incentive Plan (the “2014 EIP”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2020, the number of shares of common stock reserved for issuance under the 2014 EIP increased by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e559-wk-Fact-CED36268861999F29AD39EE97508C433" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="I2020Q1Jan1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,094,989</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares. For the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e571-wk-Fact-B41AEE4EE9A5A87781709EE9DFDE5497" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">765,675</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> stock options and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e575-wk-Fact-FAADF015F35CB55C1C9C9EEA566EF951" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,261,225</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock awards, including </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e580-wk-Fact-30A15B7A692DAA369AEF9EEAAA30170A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">215,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> performance stock awards, were granted under the 2014 EIP. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e588-wk-Fact-33A9BED019B99AD197E29EEC798A521B" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2020Q1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">929,364</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 EIP.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Inducement Plan (the “2014 IN”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e606-wk-Fact-476D33932F260AD23C0F16CE0E5EA0F2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenInducementPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> stock options or restricted stock awards were granted under the 2014 IN. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e614-wk-Fact-F23DD481B27255AB6C499F85639E0AFD" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2020Q1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenInducementPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">246,130</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 IN. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Employee Stock Purchase Plan (the “2014 ESPP”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2020, the number of shares of common stock reserved for issuance under the 2014 ESPP increased by </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e625-wk-Fact-2CE766B17412C0265EAD9F85B602B099" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="I2020Q1Jan1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">300,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e633-wk-Fact-9CA16AA4AF045672C9B59F85F9FF38BC" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,704,005</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 ESPP.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Net Loss per Share</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, which includes the vested restricted stock awards. The diluted net loss per share is calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, underlying shares of convertible senior notes, outstanding stock options, outstanding common stock warrants, unvested restricted stock awards and performance stock awards, and shares of common stock expected to be purchased under 2014 ESPP are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive. </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-520D8B997FB4E39C7E5F16CE0E3F0897-0-wk-Fact-2646A453971AE01D937916CE0E5E5641" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible senior notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e740-wk-Fact-B7FABFBC530F61C71C70E6376F987B45" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">8,878,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e754-wk-Fact-E8280BF7EFCE3AA3CE29E63772A0AC49" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" unitRef="shares" decimals="0" scale="0" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e769-wk-Fact-A4388F7F30FB7968B87B9D3248ACB719" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,305,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e783-wk-Fact-69536A5288B0BEFCB3139D32490438D0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">4,372,676</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards and performance stock awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e798-wk-Fact-59382BFA76B094F8F93A9D3248DB36A5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,799,982</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e812-wk-Fact-560061AFA0BD1F2A30F49D324952BF04" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">768,770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock expected to be purchased on June 30 under the 2014 ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e827-wk-Fact-0B9BF3179C6883D51ED89D3249334C5E" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_rvnc_ESPPPurchasesMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">49,861</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e841-wk-Fact-3377C948C49CD82013E59D32498A7703" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_rvnc_ESPPPurchasesMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">35,619</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e856-wk-Fact-FFE77286625F57B3A0469F989603D9BD" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="shares" decimals="0" scale="0" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e870-wk-Fact-51D264796CA5B60225D79F989A95927E" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">34,113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Follow-On Public Offering</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, we completed a follow-on public offering, pursuant to which we issued </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e886-wk-Fact-BEBB392D7B74191563CC9EE68786700A" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q4Dec-31_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,500,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12625631e890-wk-Fact-E0210BDE4DF7091248C59EE6B8FDF70C" name="us-gaap:SharePrice" contextRef="FI2019Q4_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">17.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12625631e894-wk-Fact-F3F4335AF51E610A531A9EE71D40C914" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2019Q4Dec-31_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">103.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after underwriting discounts, commissions and other offering expenses. In January 2020, the underwriters exercised their over-allotment option to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e898-wk-Fact-54BDECF67E64E281A9DA9F8FCC10907A" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2020Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">975,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> additional shares of common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12625631e902-wk-Fact-58F4545A6A997DF94E329F9042E15990" name="us-gaap:SharePrice" contextRef="I2020Q1Jan31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">17.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12625631e907-wk-Fact-5044724150299B3F98A29F901672E5E2" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2020Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after underwriting discounts, commissions and other offering expenses.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><ix:continuation id="TextSelection-0A1A73CDFF70B181F3DC16CE0E3F7D3F-4"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">At-The-Market Offering</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are party to a controlled equity offering sales agreement with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) (the “2018 ATM Agreement”), under which we may offer and sell common stock having aggregate proceeds of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12625631e917-wk-Fact-063E2CD7059B76A90B46C3F996758BD1" name="rvnc:StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum" contextRef="FD2020Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_AttheMarketOfferingMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">125.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> through Cantor Fitzgerald as our sales agent. Under the 2018 ATM Agreement, sales of common stock through Cantor Fitzgerald will be made by means of ordinary brokers’ transactions on the Nasdaq or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by us and Cantor Fitzgerald. From time to time, Cantor Fitzgerald may sell the common stock based upon our instructions, and we will pay a commission to Cantor Fitzgerald of up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e921-wk-Fact-887D9F75662DE9EF5993E657A0C94792" name="rvnc:SaleofStockIssuanceCostsCommissionPercentageMaximum" contextRef="FD2020Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_AttheMarketOfferingMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the gross sales proceeds of any common stock sold through Cantor Fitzgerald. For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e929-wk-Fact-23FA41FE14D609B7FF69C3F9EB10F888" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2020Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_AttheMarketOfferingMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> common stock was sold under the 2018 ATM Agreement. </span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-based Compensation</span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-775E5E9519BFD6242F029F8E2F86A75B-0-wk-Fact-D7B28D3FA3EA57D331A79F8E3B79F869" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was allocated as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e1050-wk-Fact-A1856EB3F20418F217049F94C2BEA08A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,442</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e1069-wk-Fact-9C5AD018D28AE0E5267D9F94C2A73E78" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e1084-wk-Fact-9FDF17C88F4D0E7BE70D9F94C387A713" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e1103-wk-Fact-C03E2BCA576BB86A38139F94C368F6DD" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,080</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e1128-wk-Fact-BDBD159E793E6A64D5C09F94C35607A8" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2020Q1YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12625631e1147-wk-Fact-070C8EB699468EDC24759F94C4C5BE76" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,159</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sDFBD59766894BA530AC716CE0DB6B6DC"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">9. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-F06E84DBB60CD151613516CE0E15446F-0-wk-Fact-869A00B585092826E02E16CE0E173614" continuedAt="TextSelection-F06E84DBB60CD151613516CE0E15446F-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-F3BF669FB8F1DA1F06BB16CE0E142470-0-wk-Fact-2A9D5197AF028F7AE02116CE0E1788DF" continuedAt="TextSelection-F3BF669FB8F1DA1F06BB16CE0E142470-1" escape="true"><ix:continuation id="TextSelection-F06E84DBB60CD151613516CE0E15446F-1" continuedAt="TextSelection-F06E84DBB60CD151613516CE0E15446F-2"><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy:</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e811-wk-Fact-B3E55C352B95ECBC2A239D329E23573D" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">179,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e830-wk-Fact-1EA899450EED107C481C9D32A04332ED" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">179,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e849-wk-Fact-505F801FC838391995DE9D32A0752ADA" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e869-wk-Fact-487B6E07B785B4C1BD9E9D329F7A80CF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e884-wk-Fact-FCD261DAAC73902343CA9D32A10D571A" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e903-wk-Fact-993F2CBBBFDCD36F79689D329EE615BC" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e922-wk-Fact-3D3D14F24C20E4B1C8A79D329D8F655F" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e942-wk-Fact-10E3349F5DADE24F0CD39D329EB53FE4" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e962-wk-Fact-65F27491F769023C26519EAA9B2D28FC" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,976</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e981-wk-Fact-C164791763B9567C77AA9EAAA66CE21F" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1000-wk-Fact-A2B073A34DD92422188B9EAAB6DAC4B3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159,976</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1020-wk-Fact-37F5CEDCAFD483317F099EAAC745B1A4" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1040-wk-Fact-0D782BB2B1F572ACB9539D329DF20A0B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1059-wk-Fact-27CAA8ACFDA11C42B0C39D32A0DC00D0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1078-wk-Fact-C9B2E72F8F75D1365A4B9D329FE2C7AF" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1098-wk-Fact-5935556E56AD927C523B9D329D80A311" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1123-wk-Fact-0365B2A0A701D3426EF49D329D8F8C18" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">509,633</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1142-wk-Fact-2E9A148167783C83B7109D329E543A3A" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">209,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1161-wk-Fact-3A921FC9039190B7DBF69D32A0A6FAAD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">300,296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1181-wk-Fact-457C4C4AAC87C11E8F8F9D329DA9B33C" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1365-wk-Fact-53DE2763F48DB13283129D329E85A9C5" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1384-wk-Fact-D0373815849059CA64B19D329F49E76B" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1403-wk-Fact-0F6D7DD8520C7F5D7FA09D329F1700D9" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1423-wk-Fact-60448ED4C812193ADD0B9D329DB049B4" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1444-wk-Fact-B36ACB1DE02CB04D8D5B9D329DA33C52" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1463-wk-Fact-F4F6DFB0BD409FF798FF9D329FB1E88C" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1482-wk-Fact-AB11131CFD5989B996C49D329D80B3B6" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1502-wk-Fact-BFEA14A8E225E6C20A3B9D32A01327D5" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><ix:continuation id="TextSelection-F06E84DBB60CD151613516CE0E15446F-2"><ix:continuation id="TextSelection-F3BF669FB8F1DA1F06BB16CE0E142470-1" continuedAt="TextSelection-F3BF669FB8F1DA1F06BB16CE0E142470-2"><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1791-wk-Fact-F370D640CA319B7F23039EADCEDCDD71" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1810-wk-Fact-21E8C58BE391C853FBAC9EADDE01BD3D" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1829-wk-Fact-E924BFBD03E27C9058759EADEEA475D3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1849-wk-Fact-C3BF21327F305DC4361F9EADFCCA0F1B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1864-wk-Fact-CCA68120BE48A14A647C9EAE0577ACC4" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1883-wk-Fact-05ED40C5F01C123B3E5B9EAE1346D60B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1902-wk-Fact-DDFC89B64C2459A24E549EAE1D337C5F" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1922-wk-Fact-115BBA0269070AA00DB19EAE2878D736" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1942-wk-Fact-FF90E7D27029AEEBC96D9EAE31B4B7CC" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1961-wk-Fact-F1CBE27BDEFCA02FE7559EAE3FEF46C5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e1980-wk-Fact-B052CD909B34D425F5F29EAE4E16EE89" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2000-wk-Fact-BF9A89C5EB9518467CD49EAE5B026A09" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2020-wk-Fact-068BAAC169BA715761349EAE61DEDB12" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2039-wk-Fact-745422467A091B9343029EAE6E910FC5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2058-wk-Fact-A4B0FA2682E9E55695F99EAE7C375243" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2078-wk-Fact-A53DA0239946F65364BB9EAE8D4CFEA6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2098-wk-Fact-C118DFE4F37E5758BF179EAE93BE2BB9" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,990</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2117-wk-Fact-F018CE2E830B5FB00C5E9EAE9F044EC5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2136-wk-Fact-3DE32DB64E84DF17E4069EAEACFAC50B" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,990</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2156-wk-Fact-F984492161CCC3BD55809EAEBB9EF585" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2181-wk-Fact-BFA3ABB0821702A2D6D39EAEC4B9F44E" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">282,686</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2200-wk-Fact-447035622EDD7C9181149EAED0D03E2C" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">184,613</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2219-wk-Fact-52BD2E13F0A673314B189EAEDE5547F5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">98,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2239-wk-Fact-D708189AEA1CE9EA85DA9EAEF76845F2" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2424-wk-Fact-A5981257C436066BC3D19EACB70B9204" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2443-wk-Fact-3CB3385E0C86D4CB25639EACBEC60481" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2462-wk-Fact-161766EAEB469701AAB29EACCB3578F0" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2482-wk-Fact-84C5F412CA0636A901F69EACD9707963" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2502-wk-Fact-55BDA79B9D0EA0C620A29EACE707526E" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2521-wk-Fact-DF24E809729C38D8F8EF9EACEC0E0E3E" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2540-wk-Fact-339D5FD43A4B04F6B78B9EACF6D5587E" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2560-wk-Fact-23CB5008B9C4461F7C589EACFFF5EED6" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-F3BF669FB8F1DA1F06BB16CE0E142470-2"></ix:continuation>For Level 1 investments, we use quoted prices in active markets for identical assets to determine the fair value. For Level 2 investments, we use quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trade of or quotes on the same or similar securities. We do not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services. </span></div><ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="TextSelection-879DE68AA6A9BF9C888416CE0E15F6EC-0-wk-Fact-6A134F3CE4AF19CA801216CE0E164576" escape="true"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the change in the fair value of our Level 3 financial instrument:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Liability </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2632-wk-Fact-442C7D9D94EFF8D7A8039D32B23E7A08" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2647-wk-Fact-5516A20C33D502FB39679D32B2459111" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="FD2020Q1YTD_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12628440e2672-wk-Fact-231B73495CA6244BCA159D32B24B5820" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment (</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Note 5</span><span style="font-family:inherit;font-size:10pt;">). Generally, increases or decreases in these unobservable inputs would result in a directionally similar impact to the fair value measurement of this derivative instrument. The significant unobservable inputs used in the fair value measurement of the product approval payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Note 7</span><span style="font-family:inherit;font-size:10pt;">) was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy. We carry </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> at face value less unamortized debt discount and issuance costs on our condensed consolidated balance sheets and present the fair value for disclosure purposes only. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12628440e2717-wk-Fact-64F29F1577F423E2182D9EC0800D3C6C" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="FI2020Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">229.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s432F768E2BFB1A06A47A16CE0E304583"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0FC18E2919F12D522C9A16CE1896DB6D"><span style="font-family:inherit;font-size:10pt;">Table of Contents</span></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements — (Continued)</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Unaudited)</span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">10. <ix:nonNumeric contextRef="FD2020Q1YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-79B8AFFAE68E9E8FC1EC16CE0E30CEBE-0-wk-Fact-486453D02CA93F39E79C16CE0E3054FB" continuedAt="TextSelection-79B8AFFAE68E9E8FC1EC16CE0E30CEBE-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-79B8AFFAE68E9E8FC1EC16CE0E30CEBE-1"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Teoxane Agreement </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are parties to the Teoxane Agreement (</span><a style="font-family:inherit;font-size:10pt;" href="#s89e018506f474bc9b18873233c39430b"><span style="font-family:inherit;font-size:10pt;">Note 4</span></a><span style="font-family:inherit;font-size:10pt;">), which will be effective for a term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d12629071e541-wk-Fact-E91EE9BB15B499C2F3469EC596E47DA3" name="rvnc:CollaborativeAgreementContractualPeriod" contextRef="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> upon product launch and may be extended for a two-year period upon the mutual agreement of the parties. We are required to meet certain minimum purchase obligations during each year of the term. We are also required to meet certain minimum expenditure requirements in connection with commercialization efforts. Either party may terminate the Teoxane Agreement in the event of the insolvency of, or a material breach by, the other party, including certain specified breaches that include the right for Teoxane to terminate the Teoxane Agreement for our failure to meet the minimum purchase requirements or commercialization expenditure during specified periods, or for our breach of the exclusivity obligations under the Teoxane Agreement.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Purchase Commitments</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are parties to a Technology Transfer, Validation and Commercial Fill/Finish Services Agreement with Ajinomoto Althea, Inc. dba Ajinomoto Bio-Pharma Services (“Althea”) (the “Althea Services Agreement”), under which Althea provides us a contract development and manufacturing organization, which allows us to have expanded capacity and a second source for drug product manufacturing in order to support a global launch of DaxibotulinumtoxinA for Injection. The initial term of the Althea Services Agreement expires in 2024, unless terminated sooner by either company and we have minimum purchase obligations based on our production forecasts. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Contingencies</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are obligated to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12629071e557-wk-Fact-A08BD32ABB4F6FDD410116CE0E302F2C" name="rvnc:AccruedMilestoneObligations" contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_ListLaboratoriesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment to a developer of botulinum toxin, List Biological Laboratories, Inc. (“List Laboratories”), when a certain regulatory milestone is achieved. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the milestone had not been achieved. We are also obligated to pay royalties to List Laboratories on future sales of botulinum toxin products.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into an asset purchase agreement (the “BTRX Purchase Agreement”) with Botulinum Toxin Research Associates, Inc. (“BTRX”), under which we are obligated to pay up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12629071e568-wk-Fact-E357AC907C94101B662E16CE0E305C0C" name="rvnc:AccruedMilestoneObligations" contextRef="FI2020Q1_us-gaap_TypeOfArrangementAxis_rvnc_BotulinumToxinResearchAssociatesInc.Member" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">16.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to BTRX upon the satisfaction of milestones relating to our product revenue, intellectual property, and clinical and regulatory events. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, a one-time intellectual property development milestone liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12629071e576-wk-Fact-586135969899C84F490E16CE0E30CFF5" name="us-gaap:FairValueOfAssetsAcquired" contextRef="FD2020Q1YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> has been recorded in accruals on our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into an agreement with BioSentinel, Inc. (“BioSentinel”), under which we in-license BioSentinel’s technology and expertise for research, development and manufacturing purposes. We are obligated to pay BioSentinel minimum quarterly use fees and a one-time milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d12629071e583-wk-Fact-588E0FF0DEFC9EF88FE316CE0E305CC0" name="rvnc:AccruedMilestoneObligations" contextRef="FI2020Q1_us-gaap_TypeOfArrangementAxis_rvnc_BioSentinelInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> when regulatory approval is achieved. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the milestone has not been achieved.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Indemnification</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to our technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments we are obligated to pay under these indemnification agreements is not determinable because it involves claims that may be made against us in the future but have not been made. We have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d12629071e613-wk-Fact-C2DF14F796498883188916CE0E300687" name="rvnc:IndemnificationLiabilityRecordedduringPeriod" contextRef="FD2020Q1YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> amounts associated with the indemnification agreements have been recorded.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="sEF5433D763941B8A5CF816CE1C2A3055"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><a id="sCBF9A1FD79ABBB18E82A16CE135525CE"></a></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the accompanying notes appearing elsewhere in this Quarterly Report on this Form 10-Q and in conjunction with our other SEC filings, including our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, filed with the SEC on </span><span style="font-family:inherit;font-size:10pt;">February 26, 2020</span><span style="font-family:inherit;font-size:10pt;">. This Quarterly Report on Form 10-Q and the following discussion and analysis contains forward-looking statements within meaning of </span><span style="font-family:inherit;font-size:10pt;color:#212529;">within the meaning of the Private Securities Litigation Reform Act of 1995, </span><span style="font-family:inherit;font-size:10pt;">Section 27A of the Securities Act of 1933, as amended </span><span style="font-family:inherit;font-size:10pt;color:#212529;">and Section 21E of the Securities Exchange Act of 1934, as amended.</span><span style="font-family:inherit;font-size:10pt;color:#212529;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">The words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These forward-looking statements include, but are not limited to, statements concerning the following: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our expectations regarding the results, timing, costs and completion of our clinical trials and regulatory submissions needed for the approval of DaxibotulinumtoxinA for Injection, including but not limited to, for the treatment of glabellar (frown) lines, forehead lines, lateral canthal lines, upper facial lines (frown lines, forehead lines and lateral canthal lines combined), cervical dystonia, plantar fasciitis, and adult upper limb spasticity in the U.S., Europe and other countries or for the approval of RHA® 1 in the U.S.;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results, or that positive results would assure regulatory approval or commercial success of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our expectations regarding our future development of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates for other indications, including but not limited to, migraine;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to effectively and reliably manufacture supplies of DaxibotulinumtoxinA for Injection, biosimilar or any future product candidates and to develop, validate and maintain a commercially viable manufacturing process, as well as our ability to acquire supplies of RHA® dermal fillers from Teoxane;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our plans to research, develop and commercialize our product candidates, including the potential for commercialization by us of DaxibotulinumtoxinA for Injection, if approved; our expectations regarding the potential market size, opportunity and growth potential for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, if approved for commercial use;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our belief that DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates can expand overall demand for botulinum toxin;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">that we may not obtain the anticipated financial and other benefits of the Teoxane Agreement with Teoxane Teoxane, including our ability to realize anticipated synergies and successfully commercialize Teoxane’s RHA® dermal fillers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the commercial acceptance and potential of Teoxane’s RHA® dermal fillers, including market size and anticipated adoption rates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">status of commercial collaborations, including collaboration agreement with Mylan’s continuation decision with respect to our collaboration agreement and the timing thereof;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to build our own sales and marketing capabilities, or seek collaborative partners including distributors, to commercialize our product candidates, if approved;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to successfully commercialize our product candidates and the timing of commercialization activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to manufacture in our facility and to scale up our manufacturing capabilities and those of future third-party manufacturers if our product candidates are approved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unanticipated costs or delays in research, development and commercialization efforts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">estimates of our expenses, future revenue, and capital requirements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing or likelihood of regulatory filings and approvals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain and maintain regulatory approval of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to advance product candidates into, and successfully complete, clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the implementation of our business model, and strategic plans for our business, product candidates and technology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to achieve market acceptance of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the rate and degree of market acceptance of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the initiation, timing, progress and results of future preclinical studies and clinical trials and our research and development programs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unanticipated costs or delays in research;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to establish collaborations or obtain funding for our operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our financial performance, including future revenue targets; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">developments and projections relating to our competitors and our industry; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the impact of the COVID-19 pandemic on our manufacturing operations, supply chain, business operations, commercialization efforts, end user demand for our products, clinical trials and other aspects of our business.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These forward-looking statements are subject to a number of risks, uncertainties and assumptions described under the section titled </span><a style="font-family:inherit;font-size:10pt;" href="#sE19B4D5E2A8A8247555216CE1E5D6046"><span style="font-family:inherit;font-size:10pt;">“Risk factors”</span></a><span style="font-family:inherit;font-size:10pt;color:#0000ff;"> </span><span style="font-family:inherit;font-size:10pt;">in this Form 10-Q and the documents incorporated by reference herein. We also operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances described in this Form 10-Q and the documents incorporated by reference herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements contained or incorporated by reference in this offering memorandum and the documents incorporated by reference herein.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or occur. These forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable statement. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason to conform these statements to actual results or to changes in our expectations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">You should read this in this Form 10-Q, together with the information incorporated herein by reference, with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></div><div><a id="s88F1C28F213ED328227A16CE1C7EE475"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revance Therapeutics, Inc is a biotechnology company, developing new innovations in neuromodulators for aesthetic and therapeutic indications. Our lead product candidate, DaxibotulinumtoxinA for Injection, combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. We have successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines. In </span><span style="font-family:inherit;font-size:10pt;">November 2019</span><span style="font-family:inherit;font-size:10pt;">, we submitted the BLA to the U.S. FDA for DaxibotulinumtoxinA for Injection in the treatment of moderate to severe glabellar (frown) lines. The FDA accepted the BLA on </span><span style="font-family:inherit;font-size:10pt;">February 5, 2020</span><span style="font-family:inherit;font-size:10pt;">, and the PDUFA target action date is </span><span style="font-family:inherit;font-size:10pt;">November 25, 2020</span><span style="font-family:inherit;font-size:10pt;">. If the BLA is approved on or by the target action date, we plan to initiate commercialization activities for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines before the end of </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">. We are also evaluating DaxibotulinumtoxinA for Injection in upper facial lines - glabellar lines, forehead lines and crow’s feet combined -- as well as in three therapeutic indications -- cervical dystonia, adult upper limb spasticity and plantar fasciitis. Beyond DaxibotulinumtoxinA for Injection, we have begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. In </span><span style="font-family:inherit;font-size:10pt;">January 2020</span><span style="font-family:inherit;font-size:10pt;">, we entered into the Teoxane Agreement with Teoxane, pursuant to which Teoxane granted us with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of RHA® dermal fillers. We are dedicated to making a difference by transforming patient experiences. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Impact of the COVID-19 Pandemic on Our Operations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 11, 2020, the World Health Organization declared COVID-19, the disease caused by the novel coronavirus, a pandemic and recommended containment and mitigation measures worldwide. On March 13, 2020, the U.S. declared a national emergency with respect to the coronavirus pandemic. This pandemic has severely affected global economic activity, and many countries and many states in the U.S. have reacted to the outbreak by instituting quarantines, mandating business and school closures and restricting travel. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The health and safety of the Revance team, their families and our communities remains our top priority. As a response to COVID-19 pandemic, we curtailed employee travel and implemented a corporate work from home policy in March 2020. We continue to monitor the situation and will gradually resume normal operations once it is prudent to do so, and in compliance with all Federal, State, and local laws. In the meantime, we have adopted remote working tools to minimize the disruption to the achievement of our goals and objectives. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The COVID-19 pandemic may negatively affect our supply chain, end user demand for our products, our ability to obtain approval of product candidates from the FDA or other regulatory authorities and our commercialization activities. For instance, the product supply of RHA® dermal fillers was delayed by distribution partner, Teoxane SA, as they temporarily suspended production in Geneva, Switzerland as a precaution surrounding the COVID-19 pandemic. Teoxane resumed manufacturing operations at the end of April 2020 and has projected to deliver the RHA® dermal fillers to us in June 2020. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> As a result, our anticipated product launch of the RHA® 2, 3 and 4 dermal fillers has been delayed by at least one quarter and the hiring time frame for building our sales force has been adjusted to coincide with product availability. In addition, port closures and other restrictions resulting from the COVID-19 pandemic may disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our clinical trials may also be affected by the COVID-19 pandemic. Site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Currently, enrollment in the JUNIPER Phase 2 adult upper limb spasticity trial is paused due to challenges in subject assessments during time of required social distancing. COVID-19 pandemic may delay enrollment in our global clinical trials, and some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ultimate impact of the COVID-19 pandemic is highly uncertain and we do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our supply chains, end user demand for our products, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">healthcare systems or the global economy as a whole. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Neuromodulator Pipeline</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To ensure proper clinical trial coordination and completion, in line with the FDA-issued guidance of March 18, 2020 on the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Conduct of Clinical Trials of Medical Products during the COVID-19 Pandemic</span><span style="font-family:inherit;font-size:10pt;">, we are evaluating and implementing risk-based approaches for remote clinical trial monitoring and activities, including remote patient assessment, for those subjects who cannot physically visit clinic sites, to ensure the full completion of trials.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">DaxibotulinumtoxinA for Injection - Aesthetics</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Glabellar lines.</span><span style="font-family:inherit;font-size:10pt;"> In December 2018, we announced top-line results for the SAKURA 3 open-label, long-term safety study. DaxibotulinumtoxinA for Injection appeared to be generally well-tolerated with no new tolerability or safety concerns reported. We submitted the BLA in </span><span style="font-family:inherit;font-size:10pt;">November 2019</span><span style="font-family:inherit;font-size:10pt;">. The FDA accepted the BLA on </span><span style="font-family:inherit;font-size:10pt;">February 5, 2020</span><span style="font-family:inherit;font-size:10pt;">, and the PDUFA target action date is </span><span style="font-family:inherit;font-size:10pt;">November 25, 2020</span><span style="font-family:inherit;font-size:10pt;">. If the BLA is approved on or by the target action date, we plan to initiate commercialization activities for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines before the end of 2020. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has not informed us of any changes to its PDUFA date and we continue to assist the FDA with its review. As we have a U.S. based manufacturing facility and manufacture our drug substance and drug product in Newark, California, we do not anticipate any supply chain issues related to the production of DaxibotulinumtoxinA for Injection and expect to have drug product on time for commercial launch, subject to product approval.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Forehead lines</span><span style="font-family:inherit;font-size:10pt;">. In January 2019, we initiated a Phase 2 multicenter, open-label, dose-escalation study to evaluate treatment of moderate or severe dynamic forehead lines in conjunction with treatment of the glabellar complex. The objective is to understand the potential dosing and injection patterns of DaxibotulinumtoxinA for Injection in other areas of the upper face in addition to the lead indication in glabellar lines. We completed enrollment for the study in July 2019 and had all subjects dosed and past the primary endpoint at the time the COVID-19 situation escalated in the U.S. We expect to release top-line results in second quarter of 2020.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lateral canthal lines</span><span style="font-family:inherit;font-size:10pt;">. In March 2019, we initiated a Phase 2 multicenter, open-label, dose-escalation study to evaluate the treatment of moderate or severe lateral canthal lines. The objective is to understand the potential dosing of DaxibotulinumtoxinA for Injection in the lateral canthal area. We completed enrollment for the study in August 2019 and had all subjects dosed and past the primary endpoint at the time the COVID-19 situation escalated in the U.S. We expect to release top-line results in second quarter of 2020.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Upper Facial Lines</span><span style="font-family:inherit;font-size:10pt;">. In December 2019, we initiated a new multicenter, open-label Phase 2 trial for treatment of the upper facial lines -- glabellar (frown), lateral canthal (crow’s feet), and forehead lines combined -- to understand the safety and efficacy, including potential dosing and injection patterns, of DaxibotulinumtoxinA for Injection, covering the upper facial lines. This trial is in addition to the existing open-label Phase 2 clinical trials that the company has already fully enrolled in forehead lines and crow’s feet. We completed enrollment this quarter with all subjects dosed. As a result of the COVID-19 pandemic, the timing of the top-line results release, originally expected in fourth quarter, is subject to change.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">DaxibotulinumtoxinA for Injection - Therapeutics</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cervical dystonia (ASPEN)</span><span style="font-family:inherit;font-size:10pt;">. In June 2018, we announced the initiation of patient dosing in our ASPEN Phase 3 clinical program based on the Phase 2 safety and efficacy results and guidance from the FDA and European Medicines Agency (“EMA”). The ASPEN Phase 3 clinical program consists of two trials to evaluate the safety and efficacy of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults including a randomized, double-blind, placebo-controlled, parallel group trial (ASPEN-1), and an open-label, long-term safety trial (ASPEN-OLS). We completed the ASPEN-1 enrollment in October 2019 with all subjects dosed and past the primary endpoint visit, and expect to release topline results in the second half of 2020. The target number for enrollment for ASPEN-OLS has been met and the trial is ongoing.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Adult upper limb spasticity (JUNIPER)</span><span style="font-family:inherit;font-size:10pt;">. In December 2018, we initiated a Phase 2 trial for the treatment of adult upper limb spasticity (JUNIPER). This is a randomized, double-blind, placebo-controlled, parallel group, dose-ranging trial to evaluate the efficacy and safety of DaxibotulinumtoxinA for Injection for the treatment of upper limb spasticity in adults after stroke or traumatic brain injury. Enrollment in the JUNIPER Phase 2 adult upper limb spasticity trial is paused due to challenges in subject assessments during time of required social distancing. We will provide a new date for expected full enrollment after the trial is reopened and an enrollment trajectory is established.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Plantar fasciitis</span><span style="font-family:inherit;font-size:10pt;">. We initiated our current Phase 2 trial in December 2018. The Phase 2 prospective, randomized, double-blind, multi-center, placebo-controlled study was designed to evaluate the safety and efficacy of two doses of administration of our investigational drug candidate DaxibotulinumtoxinA for Injection in reducing the signs and symptoms of plantar fasciitis. We completed Phase 2 trial enrollment in December 2019 with all subjects dosed and past the primary endpoint. We expect to release top-line results in the second half of 2020.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Migraine</span><span style="font-family:inherit;font-size:10pt;">. As part of our 2020 planning process, we decided to adjust the initiation of migraine clinical trials this year and will re-evaluate the timing next year as part of our 2021 planning cycle.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Teoxane’s Resilient Hyaluronic Acid®</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(RHA®) </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Technology and Launch</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, we entered into the Teoxane Agreement with Teoxane, pursuant to which Teoxane granted us with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of RHA dermal fillers in exchange for </span><span style="font-family:inherit;font-size:10pt;">2,500,000</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock and certain other commitments by us. The Teoxane Agreement includes rights to i) RHA® 2, RHA® 3 and RHA® 4 which have been approved by the FDA for the correction of moderate to severe dynamic facial wrinkles and folds, including RHA® 2, RHA® 3 and RHA® 4 in the currently approved indications, ii) RHA® 1, which is currently in clinical trials for the treatment of perioral rhytids and is anticipated to be approved by the FDA in 2021, and iii) future hyaluronic acid filler advancements and products by Teoxane (collectively the “</span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">”) in the U.S. and U.S. territories and possessions. The Teoxane Agreement will be effective for a term of </span><span style="font-family:inherit;font-size:10pt;">ten years</span><span style="font-family:inherit;font-size:10pt;"> upon the mutual agreement of the parties. We are required to meet certain minimum purchase obligations during each year of the term. We are also required to meet certain minimum expenditure requirements in connection with commercialization efforts. Either party may terminate the Teoxane Agreement in the event of the insolvency of, or a material breach by, the other party, including certain specified breaches that include the right for Teoxane to terminate the Teoxane Agreement for our failure to meet the minimum purchase requirements or commercialization expenditure during specified periods, or for our breach of the exclusivity obligations under the Teoxane Agreement.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of mid-March, product supply of RHA® dermal fillers was delayed due to Teoxane’s temporarily suspended production in Geneva, Switzerland as a precaution surrounding the COVID-19 pandemic. Teoxane resumed manufacturing operations at end of April 2020 and has projected to deliver to deliver the RHA® dermal fillers to us in June 2020. We have adjusted our plan accordingly to build out a U.S. commercial organization and to introduce the FDA-approved RHA® dermal fillers in the U.S. in the third quarter of 2020. Our plan to launch RHA® dermal fillers in the U.S. is subject to change based on Teoxane’s ability to resume production with regard to COVID-19 pandemic containment and recovery in France and Switzerland. The term of the Teoxane agreement does not begin until launch. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Mylan and OnabotulinumtoxinA Biosimilar</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2019, the Mylan Collaboration was amended to, among other things, revise the period of time for the Continuation Decision to be on or before the later of (i) April 30, 2020 or (ii) 30 calendar days from the date that we provide Mylan with certain deliverables. On May 1, 2020, we announced that we are continuing discussion with Mylan regarding whether or not Mylan plans to move forward with the biosimilar program. We expect a decision by the end of May 2020. We will issue an update on the path forward for the program once Mylan’s decision has been reached.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Senior Notes</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">February 14, 2020</span><span style="font-family:inherit;font-size:10pt;">, we issued the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> with an aggregate principal balance of </span><span style="font-family:inherit;font-size:10pt;">$287.5 million</span><span style="font-family:inherit;font-size:10pt;">, pursuant to the Indenture. The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> are senior unsecured obligations and bear interest at a rate of </span><span style="font-family:inherit;font-size:10pt;">1.75%</span><span style="font-family:inherit;font-size:10pt;"> per year, payable semiannually in arrears on </span><span style="font-family:inherit;font-size:10pt;">February 15</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August 15</span><span style="font-family:inherit;font-size:10pt;"> of each year, beginning on </span><span style="font-family:inherit;font-size:10pt;">August 15, 2020</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> will </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">mature on </span><span style="font-family:inherit;font-size:10pt;">February 15, 2027</span><span style="font-family:inherit;font-size:10pt;">, unless earlier converted, redeemed or repurchased. The 2027 Notes are convertible into cash, shares of our common stock, or a combination of cash and shares of our common stock, at our election. In connection with issuing the 2027 Notes, we received </span><span style="font-family:inherit;font-size:10pt;">$278.3 million</span><span style="font-family:inherit;font-size:10pt;"> in net proceeds, after deducting the initial purchasers’ discount, commissions, and other issuance costs. We may not redeem the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> prior to </span><span style="font-family:inherit;font-size:10pt;">February 20, 2024</span><span style="font-family:inherit;font-size:10pt;">, and no sinking fund is provided for the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. Refer to Part I, Item 1. “Condensed Consolidated Financial Statements (Unaudited)—Notes to Condensed Consolidated Financial Statements (Unaudited) —</span><a style="font-family:inherit;font-size:10pt;" href="#sA7383604AC085C3D768E16CE0E6EDABB"><span style="font-family:inherit;font-size:10pt;">Note 7</span></a><span style="font-family:inherit;font-size:10pt;">—Convertible Senior Notes” for details of the convertible senior notes. </span></div><div style="line-height:120%;padding-bottom:16px;padding-top:20px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Follow-On Public Offering</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, we completed a follow-on public offering, pursuant to which we issued </span><span style="font-family:inherit;font-size:10pt;">6,500,000</span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at </span><span style="font-family:inherit;font-size:10pt;">$17.00</span><span style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </span><span style="font-family:inherit;font-size:10pt;">$103.6 million</span><span style="font-family:inherit;font-size:10pt;">, after underwriting discounts, commissions and other offering expenses. In January 2020, the underwriters exercised their over-allotment option to purchase </span><span style="font-family:inherit;font-size:10pt;">975,000</span><span style="font-family:inherit;font-size:10pt;"> additional shares of common stock at </span><span style="font-family:inherit;font-size:10pt;">$17.00</span><span style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </span><span style="font-family:inherit;font-size:10pt;">$15.6 million</span><span style="font-family:inherit;font-size:10pt;">, after underwriting discounts, commissions and other offering expenses.</span></div><div><a id="sE2CA8177F0A49E69F56516CE1CBE8A33"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, our total revenue </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">$0.2 million</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">79%</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, due to relative effort and timing of the initial development activities from the Mylan Collaboration.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Operating Expenses</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operating expenses consist of research and development expenses and selling, general and administrative expenses. The largest component of our operating expenses is our personnel costs including stock-based compensation. We expect our operating expenses to increase in the near term as we prepare to commercialize the Teoxane RHA® dermal fillers in the U.S. and, if the BLA is approved on or before the PDUFA target action date, DaxibotulinumtoxinA for Injection for treatment of glabellar lines, initiate and complete additional clinical trials and associated programs related to DaxibotulinumtoxinA for Injection for the treatment cervical of dystonia, plantar fasciitis, adult upper limb spasticity, and any future new indications, and our biosimilar product candidate.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize research and development expenses as they are incurred. Since our inception, we have focused on our clinical development programs and the related research and development. Since 2002, we have been developing one or more of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, and our biosimilar product candidate and have typically shared our employees, consultants and infrastructure resources across all programs. We believe that the strict allocation of costs by product candidate would not be meaningful, therefore, we generally do not track these costs by product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development expenses consist primarily of:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">salaries and related expenses for personnel in research and development functions, including stock-based compensation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expenses related to the initiation and completion of clinical trials and studies for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical and our biosimilar candidate, including expenses related to production of clinical supplies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fees paid to clinical consultants, contract research organizations (“CROs”) and other vendors, including all related fees for investigator grants, patient screening fees, laboratory work and statistical compilation and analysis; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">other consulting fees paid to third parties;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expenses related to establishment and maintenance of our own manufacturing facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expenses related to the manufacture of drug substance and drug product supplies for ongoing and future preclinical and clinical trials and other pre-commercial supplies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expenses to support our product development and establish manufacturing capabilities to support potential future commercialization of any products for which we may obtain regulatory approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expenses related to license fees and milestone payments under in-licensing agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expenses related to compliance with drug development regulatory requirements in the U.S., the European Union and other foreign jurisdictions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">depreciation and other allocated expenses; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">charges from asset acquisition related to in-process research and development.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our research and development expenses are subject to numerous uncertainties primarily related to the timing and cost needed to complete our respective projects. Further, the development timelines, probability of success and development expenses can differ materially from expectations, and the completion of clinical trials may take several years or more depending on the type, complexity, novelty and intended use of a product candidate. Accordingly, the cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development. We expect to maintain our research and development efforts as we continue our clinical development of DaxibotulinumtoxinA for Injection for the treatment of facial wrinkles and other neuroscience indications, such as cervical dystonia, plantar fasciitis, adult upper limb spasticity, and migraine, any future new indications, and our biosimilar product candidate or if the FDA requires us to conduct additional clinical trials for approval.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our research and development expenses fluctuate as projects transition from one development phase to the next. Depending on the stage of completion and level of effort related to each development phase undertaken, we may reflect variations in our research and development expenses. We expense both internal and external research and development expenses as they are incurred. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our research and development expenses are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90503323836657%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical and regulatory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14,688</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,367</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11,184</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/M</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing and quality</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9,387</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7,362</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other research and development expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,093</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,187</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,442</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,079</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total research and development expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39,794</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23,995</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> %</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/M - Not meaningful</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical and regulatory</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical and regulatory expenses include personnel costs, external clinical trial costs for clinical sites, clinical research organizations, central laboratories, data management, contractors and regulatory activities associated with the development of DaxibotulinumtoxinA for Injection. For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, clinical and regulatory costs totaled </span><span style="font-family:inherit;font-size:10pt;">$14.7 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">37%</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$12.4 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">52%</span><span style="font-family:inherit;font-size:10pt;">, respectively, of the total research and development expenses for the respective periods.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, clinical and regulatory expenses </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$2.3 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">19%</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. This increase is primarily due to increased expenses related to hiring additional personnel and outside services to support new and continuing clinical trials. We expect to maintain our clinical and regulatory expenses in the near term as we initiate and complete clinical trials and other associated programs related to DaxibotulinumtoxinA for Injection for </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the treatment forehead lines, lateral canthal lines, cervical dystonia, plantar fasciitis, and adult upper limb spasticity. We expect a temporary decrease in clinical costs in the near future as a result of pausing JUNIPER and other related activities due to our response to the COVID-19 pandemic.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">In-process research and development</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the Teoxane Agreement, </span><span style="font-family:inherit;font-size:10pt;">$11.2 million</span><span style="font-family:inherit;font-size:10pt;"> of the aggregate purchase consideration is recognized as in-process research and development that are related to certain products and indications not approved by the FDA. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Manufacturing and quality</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Manufacturing and quality expenses include personnel and occupancy expenses, external contract manufacturing costs and pre-approval manufacturing of drug product used in our research and development of DaxibotulinumtoxinA for Injection. Manufacturing and quality expenses also include raw materials, lab supplies, and storage and shipment of our product to support quality control and assurance activities. These expenses do not include clinical expenses associated with the development of DaxibotulinumtoxinA for Injection. For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, manufacturing and quality expenses were </span><span style="font-family:inherit;font-size:10pt;">$9.4 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">24%</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$7.4 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">31%</span><span style="font-family:inherit;font-size:10pt;">, respectively, of the total research and development expenses for the respective periods.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, manufacturing and quality expenses </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$2.0 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">28%</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, primarily due to increased expenses related to manufacturing and quality activities, and hiring additional personnel. We expect to increase our manufacturing and quality efforts as we approach commercialization for the potential launch of DaxibotulinumtoxinA for Injection despite certain disruptions related to the COVID-19 pandemic.Certain amounts of the manufacturing and quality expenses, among other costs, are expected to be treated as inventory costs after the potential approval of DaxibotulinumtoxinA for Injection is obtained.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other research and development expenses</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other research and development expenses include expenses for personnel, contract research organizations, consultants, raw materials, and lab supplies used to conduct preclinical research and development of DaxibotulinumtoxinA for Injection and our biosimilar product candidate. For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, other research and development expenses were </span><span style="font-family:inherit;font-size:10pt;">$2.1 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">5%</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$2.2 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">9%</span><span style="font-family:inherit;font-size:10pt;">, respectively, of the total research and development expenses for the respective periods.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, o</span><span style="font-family:inherit;font-size:10pt;font-style:normal;">ther research and development expenses</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">decreased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$0.1 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">4%</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, primarily due to decreased expenses related to the initial development activities from the Mylan Collaboration, which was completed in February 2019. The level of effort related to the biosimilar development program in 2020 may depend on Mylan’s Continuation Decision. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2019, the Mylan Collaboration was amended to, among other things, revise the period of time for the Continuation Decision to be on or before the later of (i) April 30, 2020 or (ii) 30 calendar days from the date that we provide Mylan with certain deliverables. On May 1, 2020, we announced that we are continuing discussions with Mylan regarding whether or not Mylan plans to move forward with the biosimilar program. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, stock-based compensation included in research and development expenses </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$0.4 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">17%</span><span style="font-family:inherit;font-size:10pt;">, compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, primarily due to increased employee headcount.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Selling, general and Administrative Expenses</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses consist primarily the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers pre-commercial sales and marketing activities and compensation costs of our sales force hired to date; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">other RHA® and DaxibotulinumtoxinA for Injection pre-commercial activities including market research and public relations;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">personnel and service costs in our finance, information technology, commercial, investor relations, legal, human resources, and other administrative functions, including stock-based compensation; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">professional fees for accounting and legal services, including legal services associated with obtaining and maintaining patents.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that our selling, general and administrative expenses will increase with the launch of the RHA® dermal fillers and, if approved, the commercialization of DaxibotulinumtoxinA for Injection. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our selling, general and administration expenses are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses before stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17,122</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,830</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4,102</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,080</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">97</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total selling, general and administrative expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21,224</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12,910</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses before stock-based compensation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, selling, general and administrative expenses </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$6.3 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">58%</span><span style="font-family:inherit;font-size:10pt;">, c</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">ompared to the same period in</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">2019</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, primarily due to</span><span style="font-family:inherit;font-size:10pt;"> ramp up in pre-commercial activities, increased personnel in commercial and administrative functions, and costs related to professional services in preparation for the launch of Teoxane’s RHA® dermal fillers and, if approved, DaxibotulinumtoxinA for Injection.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect selling, general and administrative expenses to ramp-up for the planned commercial activities in the near future. With the revised launch plan for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> mentioned above, the planned activities and related costs are shifted by approximately one quarter from the second quarter to the third quarter of 2020, but the expenses are not expected to decrease as a result of the delay.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based compensation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, stock-based compensation included in selling, general and administrative expenses </span><span style="font-family:inherit;font-size:10pt;">increased</span><span style="font-family:inherit;font-size:10pt;"> by </span><span style="font-family:inherit;font-size:10pt;">$2.0 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">97%</span><span style="font-family:inherit;font-size:10pt;">, compared to the same period in </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">2019</span><span style="font-family:inherit;font-size:10pt;">, primarily due to increased employee headcount, and the stock-based compensation expense for the performance stock awards which were granted starting in the fourth quarter of 2019.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Net Non-Operating Income and Expense</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Income</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income primarily consists of interest income earned on our deposit, money market fund, and investment balances. We expect interest income to vary each reporting period depending on our average deposit, money market fund, and investment balances during the period and market interest rates. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense includes cash and non-cash components. The cash component of the interest expense represents the contractual interest charges for our convertible senior notes. The non-cash component of the interest expense represents the amortization of the debt discount issuance costs for our convertible senior notes issued in February 2020. For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, interest expense of </span><span style="font-family:inherit;font-size:10pt;">$2.1 million</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">was from the</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">issued in February 2020.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Change in Fair Value of Derivative Liability</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The derivative liability on our condensed consolidated balance sheets is remeasured to fair value at each balance sheet date with the corresponding gain or loss recorded. We will continue to record adjustments to the fair value of derivative liability until we make the payment.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Expense, net</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net primarily consists of miscellaneous tax and other expense items.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our net non-operating income and expense are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90503323836657%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands, except percentages)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Change</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,491</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,570</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2,148</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/M</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value of derivative liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(90</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(92</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(126</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(155</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(19</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total net non-operating income (expense)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(873</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,323</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(166</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">N/M - Not meaningful</span></div><div><a id="s08B1D0622AD2C886887216CE1336C8A1"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our financial condition </span><span style="font-family:inherit;font-size:10pt;">is summarized</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">as follows:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">511,270</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">290,115</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">221,155</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Working Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">476,806</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">255,623</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">221,183</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stockholders’ Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">308,375</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">225,490</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82,885</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Sources and Uses of Cash</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We hold our cash, cash equivalents, and short-term investments in a variety of non-interest bearing bank accounts and interest-bearing instruments subject to investment guidelines allowing for certain lower-risk holdings such as, but not limited to, money market accounts, U.S. treasury securities, U.S. government and agency securities, overnight purchase agreements, and commercial paper. Our investment portfolio is structured to provide for investment maturities and access to cash to fund our anticipated working capital needs.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents and short-term investments of </span><span style="font-family:inherit;font-size:10pt;">$511.3 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$290.1 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, which represented an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;">$221.2 million</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> was primarily due to the proceeds from issuance of convertible senior notes of </span><span style="font-family:inherit;font-size:10pt;">$287.5 million</span><span style="font-family:inherit;font-size:10pt;">, the issuance of common stock in connection with the offering, net of commissions and discount, of </span><span style="font-family:inherit;font-size:10pt;">$15.6 million</span><span style="font-family:inherit;font-size:10pt;">. These increases were primarily offset by cash used in operating activities of </span><span style="font-family:inherit;font-size:10pt;">$43.3 million</span><span style="font-family:inherit;font-size:10pt;">, payment of capped call transactions of </span><span style="font-family:inherit;font-size:10pt;">$28.9 million</span><span style="font-family:inherit;font-size:10pt;"> and payments of offering costs and convertible senior notes transaction costs of </span><span style="font-family:inherit;font-size:10pt;">$9.0 million</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We derived the following summary of our condensed consolidated cash flows for the periods indicated from Part I, Item 1, “Financial Information—Condensed Consolidated Financial Statements (Unaudited)” in this Form 10-Q:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by (used in):</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(43,289</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(11,414</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(105,569</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(103,441</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">264,347</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">106,868</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows from Operating Activities</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our cash used in operating activities is primarily driven by personnel, manufacturing and facility costs, clinical development, and pre-commercial activities. The changes in net cash used in operating activities are primarily related to our net loss, working capital fluctuations and changes in our non-cash expenses, all which are highly variable. Our cash flows from operating activities will continue to be affected principally by our working capital requirements and the extent to which we increase spending on personnel and research and development activities as our business grows.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, net cash used in operating activities was </span><span style="font-family:inherit;font-size:10pt;">$43.3 million</span><span style="font-family:inherit;font-size:10pt;">, which was primarily due to approximately $15 million of investing in our personnel and talent retention; approximately $12 million in professional services and consulting; approximately $11 million in clinical trials; $4 million in rent, supplies and utilities; and $4 million in legal and other expenditure; offset by $1.5 million in interest income from our cash, cash equivalent and short-term investments, and $0.9 million payment received from Fosun.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, net cash used in operating activities was $11.4 million, which was primarily due to clinical spend of approximately $11 million to advance our clinical programs toward commercialization; investing in our personnel and talent retention, which represents approximately $14 million; professional services and consulting of approximately $9 million; and rent, supplies and utilities of $5 million; offset by the upfront payment, net with withholding tax, received under the Fosun License Agreement of $27 million. The remaining balance of operating activities related primarily to other supplies.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows from Investing Activities</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, net cash used in investing activities was primarily due to fluctuations in the timing purchases and maturities of investments, purchases of property and equipment, and in 2020, the purchase of intangible assets.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash Flows from Financing Activities</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, net cash provided by financing activities was driven by proceeds from issuance of the 2027 Notes (as described below), proceeds from the issuance of common stock in connection with the offering (as described below), net of commissions and discount, and proceeds from the exercise of stock options and common stock warrants. The inflows were offset by payment of capped call transactions, payments of offering costs and convertible senior notes transaction costs, and net settlement of restricted stock awards for employee taxes. For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, net cash provided by financing activities was primarily driven by proceeds from the issuance of common stock in connection with the offering, net of commissions and discount, proceeds from the exercise of stock options, offset by net settlement of restricted stock awards for employee taxes and payment of offering cost.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Follow-On Public Offering</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During December 2019 and January 2020, we completed a follow-on public offering of an aggregate of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">7,475,000</span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17.00</span><span style="font-family:inherit;font-size:10pt;"> per share including the exercise of the underwriters’ over-allotment option to purchase </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">975,000</span><span style="font-family:inherit;font-size:10pt;"> additional shares of common stock, for net proceeds of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">$119.2 million</span><span style="font-family:inherit;font-size:10pt;">, after underwriting discounts, commissions </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">and other offering expenses, of which </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">$103.6 million</span><span style="font-family:inherit;font-size:10pt;"> was received in December 2019 and </span><span style="font-family:inherit;font-size:10pt;">$15.6 million</span><span style="font-family:inherit;font-size:10pt;"> was received in January 2020.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Convertible Senior Notes</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">February 14, 2020</span><span style="font-family:inherit;font-size:10pt;">, we issued the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> with an aggregate principal balance of </span><span style="font-family:inherit;font-size:10pt;">$287.5 million</span><span style="font-family:inherit;font-size:10pt;">, pursuant to the Indenture. The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> are senior unsecured obligations and bear interest at a rate of </span><span style="font-family:inherit;font-size:10pt;">1.75%</span><span style="font-family:inherit;font-size:10pt;"> per year, payable semiannually in arrears on </span><span style="font-family:inherit;font-size:10pt;">February 15</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August 15</span><span style="font-family:inherit;font-size:10pt;"> of each year, beginning on </span><span style="font-family:inherit;font-size:10pt;">August 15, 2020</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> will mature on </span><span style="font-family:inherit;font-size:10pt;">February 15, 2027</span><span style="font-family:inherit;font-size:10pt;">, unless earlier converted, redeemed or repurchased. In connection with issuing the 2027 Notes, we received </span><span style="font-family:inherit;font-size:10pt;">$278.3 million</span><span style="font-family:inherit;font-size:10pt;"> in net proceeds, after deducting the initial purchasers’ discount, commissions, and other issuance costs. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> may be converted by the holders at any time prior to the close of business on the business day immediately preceding </span><span style="font-family:inherit;font-size:10pt;">November 15, 2026</span><span style="font-family:inherit;font-size:10pt;"> only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending on </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> (and only during such fiscal quarter), if the last reported sale price of our common stock for at least </span><span style="font-family:inherit;font-size:10pt;">20</span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during a period of </span><span style="font-family:inherit;font-size:10pt;">30</span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to </span><span style="font-family:inherit;font-size:10pt;">130%</span><span style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day; (2) during the five business day period after any ten consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> for each trading day of the measurement period was less than </span><span style="font-family:inherit;font-size:10pt;">98%</span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after </span><span style="font-family:inherit;font-size:10pt;">November 15, 2026</span><span style="font-family:inherit;font-size:10pt;"> until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> at any time, regardless of the foregoing circumstances. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The conversion rate will initially be </span><span style="font-family:inherit;font-size:10pt;">30.8804</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock per </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;">$32.38</span><span style="font-family:inherit;font-size:10pt;"> per share of our common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or if we deliver a notice of redemption, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> in connection with such a corporate event or notice of redemption, as the case may be.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not redeem the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> prior to </span><span style="font-family:inherit;font-size:10pt;">February 20, 2024</span><span style="font-family:inherit;font-size:10pt;">. We may redeem for cash all or any portion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, at our option, on or after </span><span style="font-family:inherit;font-size:10pt;">February 20, 2024</span><span style="font-family:inherit;font-size:10pt;"> if the last reported sale price of our common stock has been at least </span><span style="font-family:inherit;font-size:10pt;">130%</span><span style="font-family:inherit;font-size:10pt;"> of the conversion price then in effect for at least </span><span style="font-family:inherit;font-size:10pt;">20</span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during any </span><span style="font-family:inherit;font-size:10pt;">30</span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to </span><span style="font-family:inherit;font-size:10pt;">100%</span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their 2027 Notes at a fundamental change repurchase price equal to 100% of the principal amount of the 2027 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We used </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">$28.9 million</span><span style="font-family:inherit;font-size:10pt;"> of the net proceeds from the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce the potential dilutive effect upon conversion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">and/or offset any cash payments we are required to make in excess of the principal amount of converted </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, as the case may be, with such reduction and/or offset subject to a price cap of </span><span style="font-family:inherit;font-size:10pt;">$48.88</span><span style="font-family:inherit;font-size:10pt;"> of our common stock per share, which represents a premium of </span><span style="font-family:inherit;font-size:10pt;">100%</span><span style="font-family:inherit;font-size:10pt;"> over the last reported sale price of our common stock on </span><span style="font-family:inherit;font-size:10pt;">February 10, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;color:#212529;">The cap</span><span style="font-family:inherit;font-size:10pt;">ped calls have an initial strike price of </span><span style="font-family:inherit;font-size:10pt;">$32.38</span><span style="font-family:inherit;font-size:10pt;"> per share, subject to certain adjustments, which corresponds to the conversion option strike price </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">in the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. The capped call transactions cover, subject to anti-dilution adjustments, approximately </span><span style="font-family:inherit;font-size:10pt;color:#212529;">8.9 million</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Common Stock and Common Stock Equivalents</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">April 24, 2020</span><span style="font-family:inherit;font-size:10pt;">, outstanding shares of common stock were </span><span style="font-family:inherit;font-size:10pt;">57,052,046</span><span style="font-family:inherit;font-size:10pt;">, outstanding stock options were </span><span style="font-family:inherit;font-size:10pt;">5,324,029</span><span style="font-family:inherit;font-size:10pt;">, unvested restricted stock awards and performance stock awards were </span><span style="font-family:inherit;font-size:10pt;">2,820,170</span><span style="font-family:inherit;font-size:10pt;">, shares expected to be purchased on June 30, 2020 under the 2014 ESPP were </span><span style="font-family:inherit;font-size:10pt;">49,861</span><span style="font-family:inherit;font-size:10pt;">, and underlying shares convertible from the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> is </span><span style="font-family:inherit;font-size:10pt;">8,878,938</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Operating and Capital Expenditure Requirements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have not achieved profitability on a quarterly or annual basis since our inception and we expect to continue to incur net loss for the foreseeable future. We expect to make additional capital outlays to increase operating expenditures over the next several years to support the completion of the clinical trials and other associated programs relating to DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia, plantar fasciitis, adult upper limb spasticity, migraine, and other indications, our biosimilar candidate, and shared investment in future innovations in RHA® dermal fillers, seek regulatory approval, prepare for and, if approved, proceed to commercialization, as well as efforts to introduce and sell the Teoxane’s RHA® dermal fillers in the U.S. in 2020. We have funded our operations primarily through the sale and issuance of common stock and, in February 2020, the 2027 Notes. We believe that our existing capital resources will be sufficient to fund our operations for at least the next 12 months following the filing of this Form 10-Q. However, we anticipate that we may need to raise substantial additional financing in the future to fund our operations. Our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional capital sooner than planned. In order to meet these additional cash requirements, we may seek to sell additional equity or issue debt, convertible debt or other securities that may result in dilution to our stockholders. If we raise additional funds through the issuance of debt or convertible debt securities, these securities could have rights senior to those of our common stock and could contain covenants that restrict our operations. There can be no assurance that we will be able to obtain additional equity or debt financing on terms acceptable to us, if at all. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring debt, making capital expenditures or declaring dividends. In addition, the continued spread of COVID-19 and uncertain market conditions may limit our ability to access capital. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If adequate funds are not available to us on a timely basis, or at all, we may be required to terminate or delay clinical trials or other development activities for DaxibotulinumtoxinA for Injection, our biosimilar product candidate and DaxibotulinumtoxinA Topical, and any future product candidates, or delay our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates, if we obtain marketing approval. We may elect to raise additional funds even before we need them if the conditions for raising capital are favorable. Our future capital requirements depend on many factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the results of our clinical trials for DaxibotulinumtoxinA for Injection and preclinical trials of DaxibotulinumtoxinA Topical, biosimilar or any future product candidates; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results, or that positive results would assure regulatory approval or commercial success of our product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing of, and the costs involved in, obtaining regulatory approvals for DaxibotulinumtoxinA for Injection, or any future product candidates including DaxibotulinumtoxinA Topical or biosimilar; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:46px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:22px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">if approved for commercialization by the FDA, the commercial acceptance of DaxibotulinumtoxinA for Injection, including market size and anticipated adoption rates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number and characteristics of any additional product candidates we develop or acquire; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope, progress, results and costs of researching and developing and conducting preclinical and clinical trials of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our plans to research, develop and commercialize the RHA® dermal fillers and our other product candidates, including the potential for commercialization by us of DaxibotulinumtoxinA for Injection, if approved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of commercialization activities for the RHA® dermal fillers and, if approved for sale, DaxibotulinumtoxinA for Injection or any future product candidates including DaxibotulinumtoxinA Topical or biosimilar, including marketing, sales and distribution costs; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of manufacturing DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates and any products we successfully commercialize and maintaining our related facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to successfully commercialize the RHA® dermal fillers and our other product candidates and the timing of commercialization activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements, including the Mylan collaboration, and the terms of and timing such arrangements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">that we may not obtain the anticipated financial and other benefits of the Teoxane Agreement, including our ability to realize anticipated synergies and successfully commercialize the RHA® dermal fillers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the commercial acceptance and potential of the RHA® dermal fillers, including market size and anticipated adoption rates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">physician and patient demand for the RHA® dermal fillers, or, if approved for commercialization, DAXI and any future product candidates, which may be influenced by general consumer confidence, general economic and political conditions, including challenges affecting the global economy resulting from the COVID-19 pandemic, as our products are discretionary items, the purchase of which can be reduced before patients adjust their budgets for necessities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the degree and rate of market acceptance of any future approved products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products or treatments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to establish our marketing, sales, and distribution functions if we receive regulatory approval for our product candidates; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to effectively and reliably manufacture supplies of DaxibotulinumtoxinA for Injection, biosimilar or any future product candidates and to develop, validate and maintain a commercially viable manufacturing processes, as well as our ability to acquire supplies of RHA® dermal fillers from Teoxane;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any product liability or other lawsuits related to our products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the expenses needed to attract and retain skilled personnel; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any litigation, including litigation costs and the outcome of such litigation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs associated with being a public company; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:47px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:23px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing, receipt and amount of sales of, or royalties on, future approved products, if any. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Please read Part II, Item 1A. “</span><a style="font-family:inherit;font-size:10pt;" href="#sE19B4D5E2A8A8247555216CE1E5D6046"><span style="font-family:inherit;font-size:10pt;">Risk Factors</span></a><span style="font-family:inherit;font-size:10pt;">” for additional risks associated with our substantial capital requirements.</span></div><div><a id="s19E088C247DE363D335116CE1D1E5640"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Policies and Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there have been no material changes in our critical accounting policies as compared to those disclosed in Item 7 in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, filed with the SEC on </span><span style="font-family:inherit;font-size:10pt;">February 26, 2020</span><span style="font-family:inherit;font-size:10pt;">, except as a result of the convertible senior notes and the Teoxane Agreement described as below. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Convertible Senior Notes</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to Part I, Item 1. “Condensed Consolidated Financial Statements (Unaudited)—Notes to Condensed Consolidated Financial Statements (Unaudited) —</span><a style="font-family:inherit;font-size:10pt;" href="#sA7383604AC085C3D768E16CE0E6EDABB"><span style="font-family:inherit;font-size:10pt;">Note 7</span></a><span style="font-family:inherit;font-size:10pt;">—Convertible Senior Notes” for details of the convertible senior notes.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Intangible Assets</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to Part I, Item 1, “Financial Information—Notes to Condensed Consolidated Financial Statements (Unaudited)—</span><a style="font-family:inherit;font-size:10pt;" href="#s785C268B6C9FBC30189216CE0CFBA2CB"><span style="font-family:inherit;font-size:10pt;">Note 1</span></a><span style="font-family:inherit;font-size:10pt;">—The Company and Summary of Significant Accounting Policies” and Part I, Item 1. “Condensed Consolidated Financial Statements (Unaudited)—Notes to Condensed Consolidated Financial Statements (Unaudited) —</span><a style="font-family:inherit;font-size:10pt;" href="#s89e018506f474bc9b18873233c39430b"><span style="font-family:inherit;font-size:10pt;">Note 4</span></a><span style="font-family:inherit;font-size:10pt;">—Filler Distribution Agreement” for details of the intangible assets in connection with the Teoxane Agreement. </span></div><div><a id="sD089A33607C77C90A28416CE1D24658E"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Except as follows, there were no material changes outside of the ordinary course of business in our contractual obligations as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, from those as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> as reported in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, as filed with the SEC on </span><span style="font-family:inherit;font-size:10pt;">February 26, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Convertible Senior Notes</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">February 14, 2020</span><span style="font-family:inherit;font-size:10pt;">, we issued the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> with an aggregate principal balance of </span><span style="font-family:inherit;font-size:10pt;">$287.5 million</span><span style="font-family:inherit;font-size:10pt;">, pursuant to the Indenture. The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> are senior unsecured obligations and bear interest at a rate of </span><span style="font-family:inherit;font-size:10pt;">1.75%</span><span style="font-family:inherit;font-size:10pt;"> per year, payable semiannually in arrears on </span><span style="font-family:inherit;font-size:10pt;">February 15</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August 15</span><span style="font-family:inherit;font-size:10pt;"> of each year, beginning on </span><span style="font-family:inherit;font-size:10pt;">August 15, 2020</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> will mature on </span><span style="font-family:inherit;font-size:10pt;">February 15, 2027</span><span style="font-family:inherit;font-size:10pt;">, unless earlier converted, redeemed or repurchased earlier. The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> are convertible into cash, shares of our common stock, or a combination of cash and shares of our common stock, at our election. In connection with issuing the 2027 Notes, we received </span><span style="font-family:inherit;font-size:10pt;">$278.3 million</span><span style="font-family:inherit;font-size:10pt;"> in net proceeds, after deducting the initial purchasers’ discount, commissions, and other issuance costs. We may not redeem the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> prior to </span><span style="font-family:inherit;font-size:10pt;">February 20, 2024</span><span style="font-family:inherit;font-size:10pt;">, and no sinking fund is provided for the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. Refer to Part I, Item 1. “Condensed Consolidated Financial Statements (Unaudited)—Notes to Condensed Consolidated Financial Statements (Unaudited) —</span><a style="font-family:inherit;font-size:10pt;" href="#sA7383604AC085C3D768E16CE0E6EDABB"><span style="font-family:inherit;font-size:10pt;">Note 7</span></a><span style="font-family:inherit;font-size:10pt;">—Convertible Senior Notes” for details of the convertible senior notes. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Teoxane Agreement</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, we entered into the Teoxane Agreement. Pursuant to the Teoxane Agreement, if Teoxane pursues regulatory approval for the RHA® dermal fillers for certain new indications or filler technologies, including innovations with respect to existing products in the U.S., we will be subject to certain specified cost-sharing arrangements for third party expenses incurred in achieving regulatory approval for such products. We are required to meet certain minimum purchase obligations during each year of the term. We are also required to meet certain minimum expenditure requirements in connection with commercialization efforts. Refer to Part I, Item 1. “Condensed Consolidated Financial Statements (Unaudited)—Notes to Condensed Consolidated Financial Statements (Unaudited) —</span><a style="font-family:inherit;font-size:10pt;" href="#s89e018506f474bc9b18873233c39430b"><span style="font-family:inherit;font-size:10pt;">Note 4</span></a><span style="font-family:inherit;font-size:10pt;">—Filler Distribution Agreement” for details of the Teoxane Agreement. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="sC28ECD47609F0FF1DDC916CE1D63FC99"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to “Recent Accounting Pronouncements” in Part I, Item 1, “Financial Information—Notes to Condensed Consolidated Financial Statements (Unaudited)—</span><a style="font-family:inherit;font-size:10pt;" href="#s785C268B6C9FBC30189216CE0CFBA2CB"><span style="font-family:inherit;font-size:10pt;">Note 1</span></a><span style="font-family:inherit;font-size:10pt;">—The Company and Summary of Significant Accounting Policies” in this Form 10-Q.</span></div><div><a id="sD353D3088973315AC3D916CE1D82C6A4"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we did not have any off-balance sheet arrangements or any relationships with any entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.</span></div><div><a id="s292F4432DBE1E8575B2916CE1DB1FCAA"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in foreign currency exchange rates and interest rates. We do not hold or issue financial instruments for trading purposes. For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, our exposure to market risk has not changed materially since that disclosed in Item 7A in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, filed with the SEC on </span><span style="font-family:inherit;font-size:10pt;">February 26, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div><a id="s1E9CE650E01E1A8825B716CE1DD04BC3"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Evaluation of Disclosure Controls and Procedures</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. The term “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, there were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="sABF19B69467538E9C0CE16CE1DFFEFF8"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</span></div><div><a id="s50EA6EE90834D28FB6B516CE1E1E133C"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, we may be involved in litigation relating to claims arising out of our operations. We are not currently involved in any material legal proceedings. We may, however, be involved in material legal proceedings in the future. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on our business, results of operations, financial position or cash flows.</span></div><div><a id="sE19B4D5E2A8A8247555216CE1E5D6046"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 1A. RISK FACTORS</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as all other information included in this Form 10-Q, including our condensed consolidated financial statements, the notes thereto and the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before you decide to purchase shares of our common stock. If any of the following risks actually occurs, our business, prospects, financial condition and operating results could be materially harmed. As a result, the trading price of our common stock could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and stock price.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">We have marked with an asterisk (*) those risks described below that reflect substantive changes from, or additions to, the risks described in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div><a id="sAC8400B609D09196EA2316CE1E7C0F0E"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business and Strategy</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We are substantially dependent on the clinical and commercial success of our product candidate DaxibotulinumtoxinA for Injection.</span><span style="font-family:inherit;font-size:10pt;">*</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To date, we have invested substantial efforts and financial resources in the research and development of botulinum toxin-based product candidates. Our success as a company is substantially dependent on the clinical and commercial success of DaxibotulinumtoxinA for Injection.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We completed Phase 3 clinical development for DaxibotulinumtoxinA for Injection in North America for the treatment of glabellar lines. From 2016 to 2018, we conducted and announced results relating to multiple pivotal and safety trials in our SAKURA Phase 3 program. The SAKURA 1 and SAKURA 2 trials were designed to evaluate the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection for the treatment of moderate-to-severe glabellar lines in adults. In addition to the two pivotal trials, the Phase 3 program includes a long-term open-label safety trial (SAKURA 3), which is designed to evaluate the long-term safety and duration of DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines in adults following both single and repeat treatment administration. SAKURA 3 was designed to support a safety database adequate for both domestic and international marketing applications. We submitted our BLA to the U.S. FDA for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines in November 2019. In February 2020, the FDA accepted the BLA filing. If the BLA is approved on or by the PDUFA target action date, we plan to initiate commercialization activities for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines before the end of 2020. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2015, we initiated a Phase 2 dose-escalating, open-label clinical study of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia. The Phase 2 study evaluated the safety, preliminary efficacy, and duration of effect of DaxibotulinumtoxinA for Injection in subjects with moderate to severe isolated cervical dystonia. Based on the Phase 2 safety and efficacy results and subsequent guidance from the FDA and EMA, in June 2018 we announced the initiation of patient dosing in our ASPEN Phase 3 clinical program. The ASPEN Phase 3 clinical program consists of two trials to evaluate the safety and efficacy of DaxibotulinumtoxinA for Injection for the treatment of cervical dystonia in adults including: a randomized, double-blind, placebo-controlled, parallel group trial and an open-label, long-term safety trial. In October 2019, we completed the ASPEN Phase 3 pivotal trial enrollment, and plan to release topline results in the second half of 2020.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2016, we also initiated a Phase 2 prospective, randomized, double-blinded, placebo-controlled trial of DaxibotulinumtoxinA for Injection in the therapeutic indication of plantar fasciitis. This study evaluated the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection in reducing the signs and symptoms of plantar fasciitis. The study’s primary efficacy endpoint is the improvement in the American Orthopedic Foot and Ankle Score. In January 2018, we announced interim 8-week results from this study. We completed the 16-week trial which showed a 58% reduction of pain from baseline along with a strong placebo response, with the difference between the treatment groups not being statistically significant. We initiated another Phase 2, double-blind, placebo-controlled trial utilizing two doses of DaxibotulinumtoxinA for Injection in the fourth quarter of 2018. We completed Phase 2 trial enrollment in December 2019 and expect to release topline results in the second half of 2020.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2018, we announced two new clinical programs for DaxibotulinumtoxinA for Injection, including adult upper limb spasticity and migraine. We initiated the JUNIPER Phase 2 study in adult upper limb spasticity in the fourth quarter of 2018. Enrollment in the JUNIPER Phase 2 adult upper limb spasticity trial is paused due to challenges in subject assessments during time of required social distancing. We will provide a new date for expected full enrollment after the trial is reopened and an enrollment trajectory is established.</span><span style="font-family:inherit;font-size:10pt;color:#ee2724;"> </span><span style="font-family:inherit;font-size:10pt;">In 2021, we may initiate a study with DaxibotulinumtoxinA for Injection for the treatment of migraine.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2019, we completed the enrollment in the Phase 2 clinical study of DaxibotulinumtoxinA for Injection for forehead lines. In August 2019, we completed Phase 2 study enrollment of DaxibotulinumtoxinA for Injection for lateral canthal lines (crow’s feet). Topline results for both studies are expected in the second quarter of 2020. In December 2019, we initiated an additional study of upper facial lines, which includes glabellar (frown), lateral canthal (crow’s feet), and forehead lines combined. This trial is being conducted to understand the safety and efficacy of DaxibotulinumtoxinA for Injection, including potential dosing and injection patterns for covering upper facial lines. The upper facial lines trial is fully enrolled, and all subjects have been dosed. We previously expected to receive topline results for the upper facial lines trial in fourth quarter of 2020; however, the timing of such topline results in now uncertain and may be delayed by the COVID-19 pandemic. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our near-term prospects, including our ability to finance our company and generate revenue, will depend heavily on the successful development, regulatory approval and commercialization of DaxibotulinumtoxinA for Injection. Our longer-term prospects will depend on the successful development, regulatory approval and commercialization of DaxibotulinumtoxinA for Injection, as well as DaxibotulinumtoxinA Topical, biosimilar or any future product candidates. The preclinical, clinical and commercial success of our product candidates will depend on a number of factors, including the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disruptions to our manufacturing operations, supply chains, business operations, end user demand for our products, commercialization efforts and clinical trials resulting from the COVID-19 pandemic, including a delay in the FDA’s approval of the BLA;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">timely completion of, or need to conduct additional, clinical trials, including our clinical trials for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar and any future product candidates, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the number and design of such trials and the accurate and satisfactory performance of third-party contractors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to demonstrate the effectiveness and differentiation of our products on a consistent basis as compared to existing or future therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to demonstrate to the satisfaction of the FDA, the safety and efficacy of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates through clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">whether we are required by the FDA or other similar foreign regulatory agencies to conduct additional clinical trials to support the approval of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our success in educating physicians and patients about the benefits, administration and use of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, if approved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the prevalence and severity of adverse events experienced with our product candidates or future approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability to raise additional capital on acceptable terms and in the time frames necessary to achieve our goals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">achieving and maintaining compliance with all regulatory requirements applicable to DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates or approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative treatments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effectiveness of our own or our current and any future potential strategic collaborators’ marketing, sales and distribution strategy and operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to effectively and reliably manufacture clinical trial supplies of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates and to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices (“cGMP”);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to successfully commercialize DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, if approved for marketing and sale, whether alone or in collaboration with others;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to enforce our intellectual property rights in and to DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to avoid third-party patent interference or intellectual property infringement claims;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acceptance of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, if approved, as safe and effective by patients and the medical community;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the willingness of third-party payors to reimburse physicians or patients for DaxibotulinumtoxinA for Injection and any future products we may commercialize for therapeutic indications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the willingness of patients to pay out of pocket for DaxibotulinumtoxinA for Injection and any future products we may commercialize for aesthetic indications; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the continued acceptable safety profile of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates following approval.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates. Accordingly, we cannot assure you that we will be able to generate sufficient revenue through the sale of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidate to continue our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We are substantially dependent on the clinical and commercial success of the Teoxane Resilient Hyaluronic Acid®(RHA®) dermal fillers.*</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, we entered into the Teoxane Agreement with Teoxane, pursuant to which Teoxane granted us with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of RHA dermal fillers in exchange for </span><span style="font-family:inherit;font-size:10pt;">2,500,000</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock and certain other commitments by us. The Teoxane Agreement includes rights to i) RHA® 2, RHA® 3 and RHA® 4 which have been approved by the FDA for the correction of moderate to severe dynamic facial wrinkles and folds, including RHA® 2, RHA® 3 and RHA® 4 in the currently approved indications, ii) RHA® 1, which is currently in clinical trials for the treatment of perioral rhytids and is anticipated to be approved by the FDA in 2021, and iii) future hyaluronic acid filler advancements and products by Teoxane (collectively the “</span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">”) in the U.S. and U.S. territories and possessions.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success as a company is substantially dependent on our ability to successfully and timely commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, which will depend on many factors including, but not limited to, our ability to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">develop and execute our sales and marketing strategies for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">develop, maintain and manage the necessary sales, marketing and other capabilities and infrastructure that are required to successfully integrate and commercialize the RHA® dermal fillers, including in connection with our marketing and sale of DaxibotulinumtoxinA for Injection;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">achieve, maintain and grow market acceptance of, and demand for, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish or demonstrate in the medical community the safety and efficacy of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and their potential advantages over and side effects compared to existing dermal fillers and products currently in clinical development;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the relative price of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> as compared to alternative options, and our ability to achieve a suitable profit margin on our sales of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">collaborate with Teoxane to obtain necessary approvals from the FDA and similar regulatory authorities for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adapt to additional changes to the label for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, that could place restrictions on how we market and sell the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, including as a result of adverse events observed in these or other studies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain adequate and timely supply of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> under the Teoxane Agreement; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">comply with the terms of the Teoxane Agreement, including our obligations with respect to purchase quantities and marketing efforts; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">comply with applicable legal and regulatory requirements, including medical device compliance as the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> are Class III Premarket Approval (“PMA”) devices under the Food, Drug and Cosmetic Act, as amended (the “FDCA”); </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">register as the initial importer of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> with FDA and obtain necessary state prescription medical device distribution permits and hire and operationalize complaint and medical device vigilance services in support of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">establish agreements with third party logistics providers to distribute the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> to customers.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#ff0000;"></span><span style="font-family:inherit;font-size:10pt;">If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, which may </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">materially impact the success of our business. For example, as a result of the COVID-19 pandemic, product supply of RHA® dermal fillers was delayed by Teoxane SA, as they temporarily suspended production in Geneva, Switzerland, which in turn has delayed our anticipated product launch of the RHA® 2, 3 and 4 dermal fillers. Teoxane resumed manufacturing operations at the end of April 2020 and has projected to deliver the RHA® dermal fillers to us in June 2020. As a result, our anticipated product launch of the RHA® 2, 3 and 4 dermal fillers has been delayed by at least one quarter. Additional delays in the product supply of the RHA® dermal fillers may cause us to further revise our anticipated product launch. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we fail to comply with the terms of the Teoxane Agreement, including by failing to meet certain obligations in connection with purchase and marketing of </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, Teoxane may terminate the Teoxane Agreement, and we would have no further rights to distribute the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">. In addition, the lack of, or limited, complementary products to be offered by sales personnel in marketing the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> may put us at a competitive disadvantage relative to companies with more extensive product lines. Accordingly, we cannot assure you that we will be able to generate sufficient revenue through the sale of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> to continue our business.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">The current COVID-19 pandemic, as well as other actual or threatened epidemics, pandemics, outbreaks, or public health crises, may adversely affect our financial condition and our business.*</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business could be materially and adversely affected by the risks, or the public perception of the risks, related to an epidemic, pandemic, outbreak, or other public health crisis, such as the recent COVID-19 pandemic. The risk of a continued pandemic, or public perception of the risk, could cause customers to continue to avoid public places, including hospitals and physician offices, and has caused temporary, and may cause long-term, disruptions in our supply chain, manufacturing and/or delays in the delivery of our inventory. Further, such risks could also adversely affect our customers' financial condition, resulting in reduced spending for the aesthetic products. Moreover, an epidemic, pandemic, outbreak or other public health crisis,could require or cause employees to avoid our properties, which could adversely affect our ability to adequately staff and manage our businesses. For instance, “shelter-in-place” or other such orders by governmental entities effected as a result of the COVID-19 pandemic have disrupted our operations, as employees who cannot perform their responsibilities from home are not able to report to work and as we have had to put in place a work from home policy. Risks related to an epidemic, pandemic or other health crisis, such as COVID-19 pandemic, could also continue to lead to the complete or partial closure of one or more of our facilities or operations of our sourcing partners. The ultimate extent of the impact of COVID-19 pandemic or any other epidemic, pandemic or other health crisis on our business, financial condition and results of operations will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of such epidemic, pandemic or other health crisis and actions taken to contain or prevent their further spread, among others. These and other potential impacts of an epidemic, pandemic or other health crisis, such as COVID-19 pandemic, could therefore materially and adversely affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our business has been and could continue to be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations. The COVID-19 pandemic has materially affected and may continue to materially affect our operations, including at our headquarters in the San Francisco Bay Area, which is currently subject to a shelter-in-place order, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.*</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business could be adversely affected by health epidemics in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of clinical trial sites or other business operations. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the COVID-19 pandemic, we have had to limit operations or implement limitations, including a work from home policy. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, manufacturing sites, research or clinical trial sites and other important agencies and contractors. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Port closures and other restrictions resulting from the COVID pandemic may continue to disrupt our supply chain or limit our ability to obtain sufficient materials for our drug products. For example, product supply of RHA® dermal fillers was delayed by distribution partner, Teoxane SA, as they temporarily suspended production in Geneva, Switzerland as a precaution surrounding the COVID-19 pandemic. Teoxane resumed manufacturing operations at the end of April 2020 and has projected to deliver the RHA® dermal fillers to us in June 2020. As a result, our anticipated product launch of the RHA® 2, 3 and 4 dermal fillers has been delayed by at least one quarter. Additional delays in the product supply of the RHA® dermal fillers may cause us to further revise our anticipated product launch. </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our clinical trials have been affected by the COVID-19 pandemic. Site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Currently, enrollment in the JUNIPER Phase 2 adult upper limb spasticity trial is paused due to challenges in subject assessments during time of required social distancing. The COVID-19 pandemic may delay enrollment in our global clinical trials, and some patients may not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There is a risk that other countries or regions may be less effective at containing COVID-19, or it may be more difficult to contain if the pandemic reaches a larger population or broader geography, in which case the risks described herein could be elevated significantly. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the COVID-19 pandemic situation closely.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:justify;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our business is affected by worldwide economic and market conditions; an unstable economy, a decline in consumer-spending levels and other adverse developments, including inflation, could adversely affect our business, results of operations and liquidity.*</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many economic and other factors are outside of our control, including general economic and market conditions, consumer and commercial credit availability, inflation, unemployment, consumer debt levels and other challenges affecting the global economy including the recent COVID-19 pandemic. Increases in the rates of unemployment, reduced access to credit and issues related to the domestic and international political situations may adversely affect consumer confidence and disposable income levels. Decreases in number of physicians and physician offices or financial hardships for physicians may also adversely affect distribution channels of our products. Early societal responses to the COVID-19 pandemic have involved business closures and limited social interaction as well as work reductions.  Low consumer confidence and disposable incomes could lead to reduced consumer spending and lower demand for our products, which are discretionary items, the purchase of which can be reduced before customers adjust their budgets for necessities. Even after the COVID-19 pandemic has subsided, we may continue to experience negative impacts to our business and financial results due to the continued perceived risk of infection or concern of a resurgence of the COVID-19 outbreak as well as COVID-19’s global economic impact, including decreases in consumer discretionary spending and any economic slowdown or recession that has occurred or may occur in the future. These factors could have a negative impact on our potential sales and operating results.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Reports of adverse events or safety concerns involving the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> could delay or prevent Teoxane from obtaining or maintaining regulatory approval for, or could negatively impact our sales of, the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">.</span></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reports of adverse events or safety concerns involving the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> could result in the FDA or other regulatory authorities withdrawing approval of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> for any or all indications that have approval, including the use of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> for specified aesthetic indications. We cannot assure you that patients receiving the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> will not experience serious adverse events in the future that require submission of medical device reports to the FDA. Adverse events may also negatively impact the sales of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">. Teoxane may also be required to further update package inserts and patient information brochures of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> based on reports of adverse events or safety concerns, which could adversely affect acceptance of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> in the market, make competition easier or make it more difficult or expensive for us to commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">.  </span></div><div style="line-height:120%;padding-bottom:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:19px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">The Teoxane Agreement requires us to make specified annual minimum purchases of </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> and to meet specified expenditure levels in connection with our marketing of </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> in furtherance of the commercialization of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, regardless of whether our commercialization efforts are successful. Such expenditure requirements may adversely affect our cash flow and our ability to operate our business and our prospects for future growth, or may result in the termination of the Teoxane Agreement.</span></div><div style="line-height:120%;padding-bottom:19px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Teoxane Agreement requires us to make specified annual minimum purchases of </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, and to meet an annual minimum expenditure on marketing and other areas related to the commercialization of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, regardless of whether our commercialization efforts are successful. If we fail to meet the annual minimum purchase amount or the annual minimum marketing spending requirements specified in the Teoxane Agreement, Teoxane has the right to terminate the Teoxane Agreement. </span></div><div style="line-height:120%;padding-bottom:19px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If our commercialization efforts of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> are unsuccessful, there can be no assurance that we will have sufficient cash flow to comply with such minimum purchase and expenditure requirements. Our obligation to Teoxane to meet such requirements could:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">make it more difficult for us to satisfy obligations with respect to our indebtedness, including the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> (as defined in Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations—</span><a style="font-family:inherit;font-size:10pt;" href="#s08B1D0622AD2C886887216CE1336C8A1"><span style="font-family:inherit;font-size:10pt;">Liquidity and Capital Resources</span></a><span style="font-family:inherit;font-size:10pt;">.”) and any failure to comply with the obligations of any of our debt instruments, including financial and other restrictive covenants, could result in an event of default under the agreements governing such indebtedness; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">require us to dedicate a substantial portion of available cash flow to meet the minimum expenditure requirements, which will reduce the funds available for working capital, capital expenditures, acquisitions and other general corporate purposes; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limit flexibility in planning for and reacting to changes in our business and in the industry in which we operate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limit our ability to engage in strategic transactions or implement our business strategies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limit our ability to borrow additional funds; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">place us at a disadvantage compared to our competitors.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:19px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of the factors listed above could materially and adversely affect our business and our results of operations. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may be unable to obtain regulatory approval for DaxibotulinumtoxinA for Injection, Daxibotulinumtoxin A Topical product candidates, biosimilar product candidates or future product candidates, and Teoxane may be unable to do the same for RHA</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> 1 and future hyaluronic acid filler advancements, under applicable regulatory requirements. The denial or delay of any such approval, including as a result of the COVID-19 pandemic, would delay commercialization and have a material adverse effect on our potential to generate revenue, our business prospects, and our results of operations.*</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#00b0f0;"></span><span style="font-family:inherit;font-size:10pt;">To gain approval to market a biologic product, such as DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical or biosimilar, we must provide the FDA and foreign regulatory authorities with data that adequately demonstrate the safety, efficacy and quality of the product for the intended indication applied for in the BLA, or other respective marketing applications. Teoxane must do the same with its PMAs to the FDA for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">. The development of such products is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical trials. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in clinical trials, including in Phase 3 development, even after promising results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, findings made while clinical trials were underway, safety or efficacy observations, including previously unreported adverse events; and the need to conduct further supportive or unanticipated studies, even after initiating Phase 3 trials. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful or that additional supportive studies will not be required, and the results of clinical trials by other parties may not be indicative of the results in trials we may conduct. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For example, we completed DaxibotulinumtoxinA Topical clinical trials for the treatment of “crow’s feet and primary axillary hyperhidrosis but discontinued further clinical development in 2016 following the results from our REALISE 1 Phase 3 clinical trial for crow’s feet. In 2016, we also initiated a Phase 2 trial of DaxibotulinumtoxinA for Injection for the treatment of plantar fasciitis. In January 2018, we announced interim 8-week results from this study and subsequently completed the 16-week trial, which showed a strong placebo response, with the difference between the treatment groups not being statistically significant. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, the completion of our clinical trials may be delayed as a result of the COVID-19 pandemic. For example, enrollment in the JUNIPER Phase 2 adult upper limb spasticity trial is paused due to challenges in subject assessments during time of required social distancing and the timing of topline results for the DaxibotulinumtoxinA for Injection upper facial lines trial, previously expected in fourth quarter of 2020, is now uncertain and may be delayed.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business currently depends substantially on the successful development, regulatory approval and commercialization of our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Currently, the only products for which we have the rights to commercialize and that have been approved for sale by the applicable regulatory authorities are RHA® 2, RHA® 3, and RHA® 4, and product supply of RHA® dermal fillers was delayed by distribution partner, Teoxane SA, as they temporarily suspended production in Geneva, Switzerland as a precaution surrounding the COVID-19 pandemic.  Teoxane resumed manufacturing operations at the end of April 2020 and has projected to deliver the RHA® dermal fillers to us in June 2020. As a result, our anticipated product launch of the RHA® 2, 3 and 4 dermal fillers has been delayed by at least one quarter. Additional delays in the product supply of the RHA® dermal fillers may cause us to further revise our anticipated product launch. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may never obtain regulatory approval to commercialize DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, or future rights to commercialize RHA® 1 or any hyaluronic acid filler products developed pursuant to the Teoxane Agreement. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of drug, biologic and medical device products are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries, and such regulations differ from country to country. We are not permitted to market our biologic product candidates, including DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar product candidate, any hyaluronic acid filler products, such RHA® 1 or future advancements developed by Teoxane, or future product candidates, in the U.S. until we receive approval of a BLA from the FDA. We are also not permitted to market the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> for additional indications for use unless and until Teoxane receives approval of a PMA supplement for such new indication for use. We are also not permitted to market our product candidates in any foreign countries until we receive the requisite approval from the regulatory authorities of such countries.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA or any foreign regulatory body can delay, limit or deny approval of our product candidates for many reasons, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our inability to demonstrate to the satisfaction of the FDA or an applicable foreign regulatory body that DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, RHA® 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidates are safe and effective for the requested indication;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Teoxane’s inability to satisfy FDA approval requirements with respect to the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our inability to demonstrate proof of concept of DaxibotulinumtoxinA Topical, biosimilar, RHA® 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement or other products in future, new indications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA’s or an applicable foreign regulatory agency’s disagreement with the trial protocol or the interpretation of data from preclinical studies or clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our inability to demonstrate that clinical and other benefits of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, RHA® 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement, or any future product candidates outweigh any safety or other perceived risks;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA’s or an applicable foreign regulatory agency’s requirement for additional preclinical or clinical studies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA’s or an applicable foreign regulatory agency’s non-approval of the formulation, labeling or the specifications of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, RHA® 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA’s or an applicable foreign regulatory agency’s failure to approve our manufacturing processes or facilities, or the manufacturing processes or facilities of third-party manufacturers with which we contract; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential for approval policies or regulations of the FDA or an applicable foreign regulatory agency to significantly change in a manner rendering our clinical data insufficient for approval. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, interruption or delays in the operations of the FDA or other applicable local or foreign regulatory agencies caused by the COVID-19 pandemic may affect the review and approval timelines for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, RHA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidates, including the PDUFA target action date for DaxibotulinumtoxinA for Injection in the treatment of glabellar lines.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business currently depends substantially on the successful development, regulatory approval and commercialization of our product candidates. Of the large number of drugs, including biologics, and medical devices in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">Even if we eventually complete clinical testing and receive approval of any regulatory filing for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, RHA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidates, the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional post-approval clinical trials. The FDA or the applicable foreign regulatory agency also may approve DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, RHA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement, or any future product candidates for a more limited indication or a narrower patient population than we originally requested, and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates, and DaxibotulinumtoxinA for Injection in particular, would delay or prevent commercialization of DaxibotulinumtoxinA for Injection and would materially adversely impact our business, results of operations and prospects.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">All of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> and any of our approved products and product candidates in the future will be subject to ongoing FDA and foreign regulatory obligations and continued regulatory review.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and any third-party contract development and manufacturers or suppliers are required to comply with applicable cGMP regulations and other international regulatory requirements. The regulations require that our product candidates be manufactured and records maintained in a prescribed manner with respect to manufacturing, testing and quality control/quality assurance activities. Manufacturers and suppliers of materials must be named in a BLA submitted to the FDA for any product candidate for which we are seeking FDA approval. The </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> are subject to the FDA’s Quality Systems Regulation (“QSR”), for medical devices. Additionally, third party manufacturers and suppliers and any manufacturing facility must undergo a pre-approval inspection before we can obtain marketing authorization for any of our product candidates. Even after a manufacturer has been qualified by the FDA, the manufacturer must continue to expend time, money and effort in the area of production and quality control to ensure full compliance with cGMP and QSR, as applicable. Manufacturers are subject to regular, periodic inspections by the FDA following initial approval. Further, to the extent that we contract with third parties for the manufacture of our products (for example, Teoxane, with respect to the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">), our ability to control third-party compliance with FDA requirements will be limited to contractual remedies and rights of inspection.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If, as a result of the FDA’s inspections, it determines that the equipment, facilities, laboratories or processes do not comply with applicable FDA regulations and conditions of product approval, the FDA may not approve the product or may suspend the manufacturing operations. If the manufacturing operations of any of the suppliers for our product candidates are suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet market demand, which would harm our business. In addition, if delivery of material from our suppliers were interrupted for any reason, we might be unable to ship our approved product for commercial supply or to supply our products in development for clinical trials. Significant and costly delays can occur if the qualification of a new supplier is required.</span></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Failure to comply with regulatory requirements could prevent or delay marketing approval or require the expenditure of money or other resources to correct. Failure to comply with applicable requirements may also result in warning letters, fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, refusal of the government to renew marketing applications and criminal prosecution, any of which could be harmful to our ability to generate revenues and our stock price. As such, any failure of Teoxane to maintain compliance with the applicable regulations and standards for </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> could increase our costs, cause us to lose revenue, prevent the import and/or export of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, cause the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> to be recalled or withdrawn and prevent us from successfully commercializing the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any regulatory approvals that we receive for our product candidates are likely to contain requirements for post-marketing follow-up studies, which may be costly. Product approvals, once granted, may be modified based on data from subsequent studies or commercial use. As a result, limitations on labeling indications or marketing claims, or withdrawal from the market may be required if problems occur after approval and commercialization.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.*</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since our inception, most of our resources have been dedicated to the research and preclinical and clinical development of our botulinum toxin product candidates, DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical or biosimilar. Our clinical programs for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical or biosimilar will require substantial additional funds to complete. In addition, in connection with the Teoxane Agreement, we must make specified annual minimum purchases of </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services in order to successfully commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$906.1 million</span><span style="font-family:inherit;font-size:10pt;"> and a working capital surplus of </span><span style="font-family:inherit;font-size:10pt;">$476.8 million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. Our net loss was </span><span style="font-family:inherit;font-size:10pt;">$61.9 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$35.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have funded our operations primarily through the sale and issuance of common stock and, in February 2020, the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had capital resources consisting of cash, cash equivalents and short-term investments of </span><span style="font-family:inherit;font-size:10pt;">$511.3 million</span><span style="font-family:inherit;font-size:10pt;">. We believe that we will continue to expend substantial resources for the foreseeable future for the commercialization of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> (including the establishment of our sales and marketing function) and the clinical development of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical or biosimilar and development of any other indications and product candidates that we may choose to pursue. These expenditures will include costs associated with research and development, conducting preclinical studies and clinical trials, and manufacturing and supply, and marketing and selling the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and any other products approved for sale. In addition, other unanticipated costs may arise resulting from implementation of remote working arrangements for our people. Because the outcome of any clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and complete the development and commercialization of DaxibotulinumtoxinA for Injection and any future product candidates. In addition, we have formed strategic collaborations, licensing and similar arrangements with third parties, such as the Teoxane Agreement, the Mylan Collaboration (as defined below) and Fosun License Agreement (as defined below), that we believe can complement or augment our product offerings, and may continue to do so in the foreseeable future.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our existing cash, cash equivalents, and short-term investments will allow us to fund our operations for at least 12 months following the filing of this Form 10-Q. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional capital sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. Such financings may result in dilution to stockholders, imposition of debt covenants and repayment obligations or other restrictions that may affect our business. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe that we have sufficient funds for our current or future operating plans.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our future capital requirements depend on many factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disruptions to our manufacturing operations, supply chains, business operations, end user demand for our products, commercialization efforts or clinical trials or to the resulting from the COVID-19 pandemic, including a delay in the FDA’s approval of the BLA;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">disruptions to the business or operations of our manufacturers, CROs or other third parties with whom we conduct business resulting from the COVID-19 pandemic; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">future global financial crises and economic downturns, including those cause by widespread public health crises such as the COVID-19 pandemic;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to successfully commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to establish our marketing, sales, and distribution functions; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the results of our clinical trials for DaxibotulinumtoxinA for Injection and preclinical studies and clinical trials of DaxibotulinumtoxinA Topical, biosimilar, RHA® 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidates; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing of, and the costs involved in, obtaining regulatory approvals for DaxibotulinumtoxinA for Injection, or any future product candidates including DaxibotulinumtoxinA Topical, biosimilar, RHA® 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidates; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number and characteristics of any additional product candidates we develop or acquire; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the scope, progress, results and costs of researching and developing and conducting preclinical and clinical trials of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, RHA® 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of commercialization activities if DaxibotulinumtoxinA for Injection or any future product candidates, including DaxibotulinumtoxinA Topical, biosimilar or any hyaluronic acid filler products developed pursuant to the Teoxane Agreement, are approved for sale, including marketing, sales and distribution costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of manufacturing DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, any hyaluronic acid filler products developed pursuant to the Teoxane Agreement, or any future product candidates and any products we successfully commercialize and maintaining our related facilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements including the Mylan Collaboration, Fosun Licensing Agreement, and the terms of and timing such arrangements; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the degree and rate of market acceptance of any future approved products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products or treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any product liability or other lawsuits related to our products; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the expenses needed to attract and retain skilled personnel; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any litigation, including litigation costs and the outcome of such litigation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs associated with being a public company; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing, receipt and amount of sales of, or royalties on, future approved products, if any.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional capital may not be available when needed, on terms that are acceptable to us or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, research, development, manufacturing, sales, marketing or other commercial activities for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, any hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidate.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted and the terms of any new equity securities may have a preference over our common stock. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">actions, such as incurring additional debt or making capital expenditures or specified financial ratios, any of which could restrict our ability to commercialize our product candidates or operate as a business.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness, including the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control, including global macroeconomic effects of the COVID-19 pandemic. Our business may not continue to generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We may not have the ability to raise the funds necessary to settle conversions of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2027 Notes</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> in cash or to repurchase the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2027 Notes</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2027 Notes</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Holders of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> will have the right to require us to repurchase all or a portion of their </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> upon the occurrence of a fundamental change (as defined in the indenture for the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">) at a fundamental change repurchase price equal to 100% of the principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> to be repurchased, plus accrued and unpaid interest, if any. In addition, upon conversion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to make cash payments in respect of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> being converted. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> surrendered therefor or notes being converted. In addition, our ability to repurchase the 2027 Notes or to pay cash upon conversions of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> may be limited by law, by regulatory authority or by agreements governing our future indebtedness. Our failure to repurchase notes at a time when the repurchase is required by the indenture or to pay any cash payable on future conversions of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our future indebtedness. If the repayment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> or make cash payments upon conversions thereof.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">The conditional conversion feature of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2027 Notes</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">, if triggered, may adversely affect our financial condition and operating results.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the event the conditional conversion feature of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> is triggered, holders of </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> will be entitled to convert the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> at any time during specified periods at their option. If one or more holders elect to convert their </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, unless we elect to satisfy our conversion obligation by delivering solely shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> as a current rather than long-term liability, which would result in a material reduction of our net working capital.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Even if our product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use necessary for commercial success.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The commercial success of DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and any future product candidates including DaxibotulinumtoxinA Topical or biosimilar, if approved, will depend significantly on the broad adoption and use of the resulting product by physicians for approved indications. The degree and rate of physician adoption of DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and any future product candidates, if approved, will depend on a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effectiveness and duration of effect of our product as compared to existing and future therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">physician willingness to adopt a new therapy to treat glabellar lines, cervical dystonia, plantar fasciitis, adult upper limb spasticity, migraine or other aesthetic or therapeutic indications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patient satisfaction with the results and administration of our product and overall treatment experience;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">patient demand for the treatment of glabellar lines, cervical dystonia, plantar fasciitis or other aesthetic or therapeutic indications;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the willingness of third-party payors to reimburse physicians or patients for DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and any future products we may commercialize for therapeutic indications; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the willingness of patients to pay out of pocket for DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and any future products we may commercialize for aesthetic indications; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the revenue and profitability that our product will offer a physician as compared to alternative therapies.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or any future product candidates are approved for use but fail to achieve the broad degree of physician adoption necessary for commercial success, our operating results and financial condition will be adversely affected.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, DaxibotulinumtoxinA for Injection has only been used in clinical trials to date. Therefore, the commercial or real-world experience may yield different outcomes or patient experiences due to variations in injection techniques, dilution approaches and dosing levels employed by different physician and nurse injectors. As a result, these market-based approaches may differ from our clinical trial design and could negatively impact adoption.</span></div><div style="line-height:120%;padding-bottom:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If our competitors develop and market products that are safer, more effective or more convenient or less expensive than DaxibotulinumtoxinA for Injection or the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, our commercial opportunity will be reduced or eliminated.</span></div><div style="line-height:120%;padding-bottom:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our commercial opportunity with respect to DaxibotulinumtoxinA for Injection or the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> will be reduced or eliminated if our competitors develop and market dermal filler products that are more effective, have fewer side effects, are more convenient or are less expensive than DaxibotulinumtoxinA for Injection or the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">. Our competitors include large, fully-integrated pharmaceutical companies and more established biotechnology and medical device companies, including companies offering injectable dose forms of botulinum toxin procedures and companies offering procedures such as laser treatments, face lifts, chemical peels, fat injections and cold therapy, all of which have significant resources and expertise in research and development, manufacturing, testing, obtaining regulatory approvals and marketing. It is possible that competitors will succeed in developing technologies that are safer, more effective, more convenient or with a lower cost of goods and price than those used in the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and in our product candidates or being developed by us, or that would render our technology obsolete or noncompetitive. </span></div><div style="line-height:120%;padding-bottom:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to enter highly competitive pharmaceutical and medical device markets. Successful competitors in the pharmaceutical and medical device markets have the ability to effectively discover therapies, obtain patents, develop, test and obtain regulatory approvals for products, and have the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff. Numerous companies are engaged in the developing, patenting, manufacturing and marketing healthcare products which we expect will compete with those that we are developing. Many of these competitors are large, experienced companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and other regulatory authorities.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon marketing approval, the first expected use of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, or biosimilar will be in aesthetic medicine. Competition in aesthetic products is significant and dynamic, and is characterized by rapid and substantial technological development and product innovations. Numerous competitors have obtained patents protecting what they consider to be their intellectual property. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In aesthetic medicine, our BLA seeks regulatory approval of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines. We anticipate that DaxibotulinumtoxinA for Injection, if approved, will face significant competition from existing injectable botulinum toxins as well as unapproved and off-label treatments. Further, if approved, in the future we may face competition for DaxibotulinumtoxinA for Injection from biosimilar products and products based upon botulinum toxin. To compete successfully, we will have to demonstrate that the treatment of glabellar lines with DaxibotulinumtoxinA for Injection is a worthwhile aesthetic treatment and has advantages over other therapies. Competition could result in reduced profit margins and limited sales, which would harm our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due to less stringent regulatory requirements, there are many more aesthetic products and procedures available for use in a number of foreign countries than are approved for use in the U.S. There are also fewer limitations on the claims that our competitors in certain countries can make about the effectiveness of their products and the manner in which they can market them.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We currently make our DaxibotulinumtoxinA for Injection clinical drug product exclusively in one internal manufacturing facility. We plan to utilize internal and external facilities, including through one or more third-party contractors, in the future to support commercial production if our product candidates are approved. If these or any future facility or our equipment were damaged or destroyed, or if we experience a significant disruption in our operations for any reason, our ability to continue to operate our business would be materially harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently manufacture our own clinical drug product to support DaxibotulinumtoxinA for Injection development in one internal manufacturing facility. In March 2017, we entered into a Technology Transfer, Validation and Commercial Fill/Finish Services Agreement (the “Althea Services Agreement”) with Ajinomoto Althea, Inc. dba Ajinomoto Bio-Pharma Services (“Althea”), a contract development and manufacturing organization. Under the Althea Services Agreement, Althea will provide us commercial fill/finish services and will serve as a second source of manufacturing for DaxibotulinumtoxinA for Injection. We plan to utilize our internal and external Althea facility to support commercial production of DaxibotulinumtoxinA for Injection, if approved. If these or any future facility were to be damaged, destroyed or otherwise unable to operate, whether due to earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages, actual or threatened epidemics, pandemics, outbreaks, or public health crises, or otherwise, or if performance of such manufacturing facilities is disrupted for any other reason, such an event could delay our clinical trials or, if our product candidates are approved, jeopardize our ability to manufacture our products as promptly as our customers expect or possibly at all. As the ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change, we do not yet know the full extent of potential delays or impacts on our manufacturing operations or on Althea’s ability to provide commercial fill/finish services and serve as a second source of manufacturing for DaxibotulinumtoxinA for Injection. If we experience delays in achieving our development objectives, or if we are unable to manufacture an approved product within a timeframe that meets our customers’ expectations, our business, prospects, financial results and reputation could be materially harmed.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We recognize revenue in accordance with complex accounting standards and changes in the interpretation or application of generally accepted accounting principles may materially affect our financial statements.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (the “FASB”) issued an accounting standard for revenue recognition, Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (“ASC 606”). Further, in April 2016, the FASB amended ASC 606 to provide additional guidance on revenue recognition as it pertains to licenses of intellectual property. We adopted ASC 606 and its related amendments on January 1, 2018.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The nature of our business requires the application of complex revenue recognition rules. Significant judgment is required in the interpretation and application of complex accounting guidance such as ASC 606. Our judgments and assumptions are based on the facts and circumstances of the underlying revenue transactions.</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">The SEC, the American Institute of Certified Public Accountants (“AICPA”), the FASB and various other regulatory or accounting bodies may issue new positions, interpretive views or updated accounting standards on the treatment of complex accounting matters such as revenue recognition that may materially affect our financial statements.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Impairment in the carrying value of long-lived assets could negatively affect our operating results.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no indicators of impairment for the quarters ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Under U.S. GAAP, long-lived assets, such as our fill/finish line, are required to be reviewed for impairment whenever adverse events or changes in circumstances indicate a possible impairment. If business conditions or other factors indicate that the carrying value of the asset may not be recoverable, we may be required to record additional non-cash impairment charges. Additionally, if the carrying value of our capital equipment exceeds current fair value as determined based on the discounted future cash flows of the related product, the capital equipment would be considered impaired and would be reduced to fair value by a non-cash charge to earnings, which could negatively affect our operating results. Events and conditions that could result in impairment in the value of our long-lived assets include adverse clinical trial results, changes in operating plans, unfavorable changes in competitive landscape, adverse changes in the regulatory environment, or other factors leading to reduction in expected long-term sales or profitability. We will evaluate the recoverability and fair value of our long-lived assets, including those related to other components of the fill/finish line, each reporting period to determine the extent to which further non-cash charges to earnings are appropriate. Additional impairment in the value of our long-lived assets may materially and negatively impact our operating results.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We have incurred significant losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future. In January 2020, we entered into the Teoxane Agreement pursuant to which we obtained the right to import, market, promote, sell and distribute the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> in the U.S., its territories and possessions. We have not yet had any commercial sales, and aside from our rights to the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, only have one product candidate in clinical trials, which makes it difficult to assess our future viability.*</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. We are not profitable and have incurred losses in each year since we commenced operations in 2002. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biotechnology industry. We have not yet made any sales of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and have not demonstrated the ability to successfully commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">. To date, we have not obtained any regulatory approvals for any of our product candidates or generated any revenue from product sales relating to DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical or biosimilar. We continue to incur significant research and development and other expenses related to our ongoing clinical trials and operations, and expect to incur substantial expenses in building out our sales, marketing and distribution function as we pursue commercialization of DaxibotulinumtoxinA for Injection, if approved, and the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had a working capital surplus of </span><span style="font-family:inherit;font-size:10pt;">$476.8 million</span><span style="font-family:inherit;font-size:10pt;"> and an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;">$906.1 million</span><span style="font-family:inherit;font-size:10pt;">. Our net loss was </span><span style="font-family:inherit;font-size:10pt;">$61.9 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$35.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. We have funded our operations primarily through the sale and issuance of common stock and the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. Our capital requirements to implement our business strategy are substantial, including our capital requirements to commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and to develop and commercialize DaxibotulinumtoxinA for Injection. We believe that our currently available capital is sufficient to fund our operations through at least the next 12 months following the filing of this Form 10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to continue to incur losses for the foreseeable future, and we anticipate that these losses will increase as we continue our development of, seek regulatory approval for and begin to commercialize DaxibotulinumtoxinA for Injection. Our ability to achieve revenue and profitability is dependent on our ability to complete the development of our product candidates, obtain necessary regulatory approvals and manufacture, market and commercialize our products successfully. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Even if DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, any </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> or any future product candidates obtain regulatory approval, they may never achieve market acceptance or commercial success.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we obtain FDA or other regulatory approvals, DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, any hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidates may not achieve market acceptance among physicians and patients, and may not be commercially successful. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The degree and rate of market acceptance of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, any hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidates for which we receive approval depends on a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the safety and efficacy and duration of the product as demonstrated in clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the clinical indications for which the product is approved; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">acceptance by physicians, major operators of clinics and patients of the product as a safe and effective treatment;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the proper training and administration of our products by physicians and medical staff; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential and perceived advantages of our products over alternative treatments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of treatment in relation to alternative treatments and willingness to pay for our products, if approved, on the part of payors and patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the willingness of patients to pay for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, any hyaluronic acid filler products developed pursuant to the Teoxane Agreement and other aesthetic treatments in general, relative to other discretionary items, especially during economically challenging times;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the willingness of third-party payors to reimburse physicians or patients for DaxibotulinumtoxinA for Injection and any future products we may commercialize for therapeutic indications; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the relative convenience and ease of administration; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the prevalence and severity of adverse events; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the effectiveness of our sales and marketing efforts.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any failure by our product candidates that obtain regulatory approval to achieve market acceptance or commercial success would materially adversely affect our results of operations and delay, prevent or limit our ability to generate revenue and continue our business.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.*</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Furthermore, we rely on contract research organizations (“CROs”), and clinical trial sites to ensure the proper and timely conduct of our clinical trials. While we have agreements governing the committed activities of our CROs, we have limited influence over their actual performance. A failure of one or more of our clinical trials can occur at any time during the clinical trial process. The results of preclinical studies and clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Furthermore, final results may differ from interim results. For example, any positive results generated to date in clinical trials for DaxibotulinumtoxinA for Injection do not ensure that later clinical trials, including any DaxibotulinumtoxinA for Injection clinical trials for the treatment of glabellar lines, will demonstrate similar results. Product candidates in later stages of clinical trials may fail to show the desired safety profile and efficacy despite having progressed through preclinical studies and initial clinical trials. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A number of companies in the biotechnology industry have suffered significant setbacks in advanced clinical trials due to a lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier clinical trials. We have suffered similar setbacks with the clinical development of DaxibotulinumtoxinA Topical and we cannot be certain that we will not face other similar setbacks in the future for DaxibotulinumtoxinA for Injection or other clinical development programs. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have in the past and may in the future experience delays in our ongoing clinical trials, and we do not know whether future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of subjects on time or be completed on schedule, if at all. For example, due to the COVID-19 pandemic, enrollment in the JUNIPER Phase 2 adult upper limb spasticity trial is paused due to challenges in subject assessments during time of required social distancing and the timing of topline results for the DaxibotulinumtoxinA for Injection upper facial lines trial, previously expected in fourth quarter of 2020, is now uncertain and may be delayed. Clinical trials can be delayed or aborted for a variety of reasons, including delay or failure to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain regulatory approval to commence a trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">obtain institutional review board approval at each site;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">recruit suitable subjects to participate in a trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">have subjects complete a trial or return for post-treatment follow-up;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ensure clinical sites observe trial protocol or continue to participate in a trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">address any patient safety concerns that arise during the course of a trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">address any conflicts with new or existing laws or regulations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">add a sufficient number of clinical trial sites; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">manufacture sufficient quantities of product candidate for use in clinical trials.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subject enrollment is a significant factor in the timing of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the drug being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the indications we are investigating.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the data safety monitoring board, for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, failure of inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, discovery of unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions, risks related to conducting clinical trials during the COVID-19 pandemic, or lack of adequate funding to continue the clinical trial.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we experience delays in the completion or termination of any clinical trial of our product candidates, the commercial prospects of these product candidates may be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We have no experience manufacturing DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, or any other product candidates at full commercial scale. If any of these product candidates are approved, we will face certain risks associated with scaling up our manufacturing capabilities to support commercial production.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have developed an integrated manufacturing, research and development facility located at our corporate headquarters. We manufacture drug substance and finished dose forms of the drug product at this facility that we use for research and development purposes and clinical trials. We do not have experience in manufacturing DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, or any other product candidates at commercial scale. If any of our product candidates are approved, we may need to expand our manufacturing facilities, add manufacturing personnel and ensure that validated processes are consistently implemented in our facilities and potentially enter into additional relationships with third-party manufacturers. The upgrade and expansion of our facilities will require additional regulatory approvals. In addition, it will be costly and time-consuming to expand our facilities and recruit necessary additional personnel. If we are unable to expand our manufacturing facilities in compliance with regulatory requirements or to hire additional necessary manufacturing personnel, we may encounter delays or additional costs in achieving our research, development and commercialization objectives, including obtaining regulatory approvals of our product candidates, which could materially damage our business and financial position.</span></div><div style="line-height:120%;padding-bottom:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We rely on Teoxane for the manufacture and supply of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> pursuant to the Teoxane Agreement, and our dependence on Teoxane may impair our ability to commercialize of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">.*</span></div><div style="line-height:120%;padding-bottom:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the Teoxane Agreement, we are not entitled to manufacture the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">. Instead, Teoxane is responsible for supplying all of our requirements for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">. If Teoxane were to cease production or otherwise fail to timely supply us with an adequate supply of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, our ability to commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> would be adversely affected. For example, as a result of the COVID-19 pandemic, product supply of RHA® dermal fillers was delayed by Teoxane SA, as they temporarily suspended production in Geneva, Switzerland. Teoxane resumed manufacturing operations at the end of April 2020 and has projected to the RHA® dermal fillers to us in June 2020. As a result, our anticipated product launch of the RHA® 2, 3 and 4 dermal fillers has been delayed by at least one quarter. Additional delays in the product supply of the RHA® dermal fillers may cause us to further revise our anticipated product launch.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Teoxane is required to produce the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> under QSR in order to meet acceptable standards for commercial sale. If such standards change, the ability of Teoxane to produce the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> on the schedule we require to meet commercialization goals may be affected. Teoxane is subject to pre-approval inspections and periodic unannounced inspections by the FDA and corresponding state and foreign authorities to ensure strict compliance with QSR and other applicable government regulations and corresponding foreign standards. We do not have control over Teoxane’s compliance with these regulations and standards. Any difficulties or delays in Teoxane’s manufacturing and supply of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or any failure of Teoxane to maintain compliance with the applicable regulations and standards could increase our costs, cause us to lose revenue, prevent the import and/or export of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, or cause the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> to be the subject of field alerts, recalls or market withdrawals.</span></div><div style="line-height:120%;padding-bottom:0px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We currently contract with third-party manufacturers for certain components and services necessary to produce DaxibotulinumtoxinA for Injection and expect to continue to do so to support further clinical trials and commercial scale production if DaxibotulinumtoxinA for Injection is approved. This increases the risk that we will not have sufficient quantities of DaxibotulinumtoxinA for Injection or be able to obtain such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently rely on third-party manufacturers for certain components such as bulk peptide and services such as fill/finish services, necessary to produce DaxibotulinumtoxinA for Injection for our clinical trials, and we expect to continue to rely on these or other manufacturers to support our commercial requirements if DaxibotulinumtoxinA for Injection is approved. In particular, in March 2017, we entered into the Althea Services Agreement. We plan to utilize our internal and external Althea facility to support commercial production of DaxibotulinumtoxinA for Injection, if approved. Some of our contracts with these manufacturers contain minimum order and pricing provisions and provide for early termination based on regulatory approval milestones.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reliance on third-party manufacturers entails additional risks, including the reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing agreement by the third party, and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third- party manufacturers may not be able to comply with cGMP or QSR, or similar regulatory requirements outside the U.S. Our failure or the failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of DaxibotulinumtoxinA for Injection, or any other product candidates or products that we may develop. Any failure or refusal to supply the components or services for DaxibotulinumtoxinA for Injection or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We depend on single-source suppliers for the raw materials necessary to produce DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, and any other product candidates. The loss of these suppliers, or their failure to supply us with these raw materials, would materially and adversely affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and our manufacturers purchase the materials necessary to produce DaxibotulinumtoxinA for Injection for our clinical trials from single-source third-party suppliers. There are a limited number of suppliers for the raw materials that we use to manufacture our product candidates, and we may need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials and, if approved, ultimately for commercial sale. In particular, we outsource the manufacture of bulk peptide through</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;"> </span><span style="font-family:inherit;font-size:10pt;">our agreement with Bachem Americas, Inc, which provides for the development, manufacture and supply of peptide in accordance with certain specifications.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have any control over the process or timing of the acquisition of raw materials by our manufacturers. Although we generally do not begin a clinical trial unless we believe that we have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of DaxibotulinumtoxinA for Injection or any future product candidates, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party supplier could considerably delay completion of our clinical trials, product testing and potential regulatory approval of DaxibotulinumtoxinA for Injection or any future product candidates. If we or our manufacturers are unable to purchase these </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">raw materials on acceptable terms and at sufficient quality levels or in adequate quantities if at all, the development of DaxibotulinumtoxinA for Injection and any future product candidates, or the commercial launch of any approved products, would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for our product candidates or generate revenues from the sale of any approved products.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, if there is a disruption to our or our third-party suppliers’ relevant operations, including as a result of the COVID-19 pandemic, we will have no other means of producing DaxibotulinumtoxinA for Injection or any future product candidates until they restore the affected facilities or we or they procure alternative facilities. Additionally, any damage to or destruction of our or our third party or suppliers’ facilities or equipment may significantly impair our ability to manufacture our product candidates on a timely basis.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We currently have limited marketing and sales capabilities and no field sales organization. If we are unable to establish sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> or any other future product candidates, if approved, or generate product revenue.*</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We currently have limited marketing and sales capabilities and no field sales organization. To commercialize DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, or any other future product candidates, if approved, in the U.S., Europe and other jurisdictions we seek to enter, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. In connection with the Teoxane Agreement, we will have to build out our marketing and sales capabilities sooner than we initially anticipated. We expect to market DaxibotulinumtoxinA for Injection and the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, as applicable, through our own sales force in North America, and in Europe and other countries through either our own sales force or a combination of our internal sales force and distributors or partners, which may be expensive and time consuming. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As the product supply of RHA® dermal fillers has been delayed by Teoxane due to factors surrounding the COVID-19 pandemic, our anticipated product launch of the RHA® 2, 3 and 4 dermal fillers has been delayed by at least one quarter. As a result, t</span><span style="font-family:inherit;font-size:10pt;color:#002a3a;">he hiring timeframe for building our sales force has been adjusted to coincide with product availability. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have no prior experience in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. For example, we may experience challenges associated with recruiting </span><span style="font-family:inherit;font-size:10pt;color:#002a3a;">field representatives </span><span style="font-family:inherit;font-size:10pt;">virtually through remote, group interviewing platforms and with onboarding new field representatives during such time as “shelter-in-place” or other such orders by governmental entities necessitate our work from home policy. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products, and may result in a breach of our obligations to Teoxane under the Teoxane Agreement. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, DaxibotulinumtoxinA for Injection or any future product candidates. We also have to compete with other pharmaceutical and life sciences companies to recruit, hire, train and retain sales and marketing personnel, and turnover in our sales force and marketing personnel could negatively affect the commercialization of </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and, if it receives regulatory approval, DaxibotulinumtoxinA for Injection. If we are not successful in commercializing the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, DaxibotulinumtoxinA for Injection or any future product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As we evolve from a company primarily involved in research and development to a company involved in the commercialization of products, we will need to increase the size of our organization and we may experience difficulties in managing this growth.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In order to successfully commercialize our products, we need to expand our organization, including adding marketing, managerial, operational and sales capabilities, or contracting with third parties to provide these capabilities for us. If we are successful in advancing DaxibotulinumtoxinA for Injection or any other product candidates through the development stage towards commercialization, we may need to expand such capabilities even further. Our management, personnel, systems and facilities currently in place are not adequate to support the commercialization of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and the potential commercialization of DaxibotulinumtoxinA for Injection and any other product candidates, if they are approved. Effectively executing our growth strategy requires that we:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">identify recruit, train, integrate, incentivize and retain adequate numbers of effective sales and marketing personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">achieve, maintain and grow market, physician, patient and healthcare payor acceptance of, and demand for our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">manage our clinical trials and manufacturing operations effectively;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">manage our internal development efforts effectively while carrying out our contractual obligations to Teoxane under the Teoxane Agreement and to other third parties; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">continue to improve our operational, financial and management controls, reporting systems and procedures.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As our operations expand, we expect that we will also need to manage additional relationships with various collaborative partners, suppliers and other third parties. Future growth will impose significant added responsibilities on our organization, in particular on management. Our future financial performance and our ability to commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and, if approved, DaxibotulinumtoxinA for Injection and to compete effectively will depend, in part, on our ability to manage any future growth effectively. Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives, or disrupt our operations.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our corporate headquarters and other facilities, including our internal manufacturing facility, are located in the San Francisco Bay Area, which has experienced severe earthquakes. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our manufacturing facility, enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. In particular, because we manufacture botulinum toxin in our facilities, we would be required to obtain further clearance and approval by state, federal or other applicable authorities to continue or resume manufacturing activities. The disaster recovery and business continuity plans we have in place currently are limited and may not be adequate in the event of a serious disaster or similar event. We </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, integral parties in our supply chain are geographically concentrated and operating from single sites, thereby increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We currently rely on third parties and consultants to conduct all our preclinical studies and clinical trials. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> or any future product candidates. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have the ability to independently conduct preclinical studies or clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, collaborative partners and other third parties, such as CROs and clinical data management organizations, to conduct clinical trials on our product candidates. The third parties with whom we contract for execution of our clinical trials play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to conduct our preclinical studies and clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol. Moreover, the FDA and foreign regulatory authorities require us to comply with regulations and standards, commonly referred to as good clinical practices (“GCPs”) and good laboratory practices for conducting, monitoring, recording and reporting the results of clinical and preclinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We also rely on consultants to assist in the execution, including data collection and analysis, of our clinical trials.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, the execution of preclinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. Moreover, these third parties may also have relationships with other commercial entities, some of which may compete with us. These third parties may terminate their agreements with us upon as little as 30 days’ prior written notice of a material breach by us that is not cured within 30 days. Many of these agreements may also be terminated by such third parties under certain other circumstances, including our insolvency or our failure to comply with applicable laws. In general, these agreements require such third parties to reasonably cooperate with us at our expense for an orderly winding down of services of such third parties under the agreements. If the third parties or consultants conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated. We may be unable to recover unused funds from these third-parties. If any of the foregoing were to occur, we may not be able to obtain, or may be delayed in obtaining, regulatory approval for, and will not be able to, or may be delayed in our efforts to, successfully commercialize the product candidate being tested in such trials.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If any products we develop are not accepted by the market or if regulatory agencies limit our labeling indications, require labeling content that diminishes market uptake of our products or limits our marketing claims, we may be unable to generate significant revenues, if any.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we obtain regulatory approval for DaxibotulinumtoxinA for Injection,the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, DaxibotulinumtoxinA Topical, biosimilar, or any other product candidates and are able to commercialize them, these products may not gain market acceptance among physicians, patients, healthcare payors and the medical community.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The degree of market acceptance of any of our approved products will depend upon a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the indication for which the product is approved and its approved labeling;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the presence of other competing approved treatments and therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the potential advantages of the product over existing and future treatment products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the relative convenience and ease of administration of the product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the strength of our sales, marketing and distribution support;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the willingness of third-party payors to provide adequate reimbursement for our approved products, and the willingness of payments to pay for our approved products in the absence of third-party reimbursement; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the price and cost-effectiveness of the product.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA or other regulatory agencies could limit the labeling indication for which our product candidates may be marketed or could otherwise limit marketing efforts for our products. If we are unable to achieve approval or successfully market any of our product candidates, or marketing efforts are restricted by regulatory limits, our ability to generate revenues could be significantly impaired.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If we are found to have improperly promoted off-label uses for our products that are approved for marketing, including the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> and, if approved for marketing, DaxibotulinumtoxinA for Injection, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, and sanctions, product liability claims, and our image and reputation within the industry and marketplace could be harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about regulated products, such as the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and, if approved, DaxibotulinumtoxinA for Injection. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product’s approved labeling. If we are found to have promoted such off-label uses, we may receive warning letters and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management’s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. However, physicians may also misuse the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and, if approved, DaxibotulinumtoxinA for Injection or our other products, or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If these products are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management’s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. Furthermore, the use of these products for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of these events could harm our business and results of operations and cause our stock price to decline.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If there is not sufficient physician and patient demand for and acceptance of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, or, if approved for commercialization, DaxibotulinumtoxinA for Injection and any future product candidates, our financial results and future prospects will be harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Use of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, and, if approved for commercialization, DaxibotulinumtoxinA for Injection for aesthetic indications are elective procedures, the cost of which must be borne by the patient, and we do not expect it to be reimbursable through government or private health insurance. The decision by a patient to elect to undergo the treatment of aesthetic indications with the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or, if approved for commercialization, DaxibotulinumtoxinA for Injection may pursue may be influenced by a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success of any sales and marketing programs that we, or any third parties we engage, undertake, and as to which we have limited experience;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which physicians recommend the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or DaxibotulinumtoxinA for Injection to their patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or DaxibotulinumtoxinA for Injection satisfies patient expectations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to properly train physicians in the use of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and DaxibotulinumtoxinA for Injection or such that their patients do not experience excessive discomfort during treatment or adverse side effects;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost, safety and effectiveness of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and DaxibotulinumtoxinA for Injection versus other treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">consumer sentiment about the benefits and risks of aesthetic procedures generally and the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and DaxibotulinumtoxinA for Injection in particular;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the success of any direct-to-consumer marketing efforts we may initiate; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">general consumer, patient and physician confidence and availability of practicing physicians, which may be impacted by general economic and political conditions, including challenges affecting the global economy resulting from the COVID-19 pandemic.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our business, financial results and future prospects will be materially harmed if we cannot generate sufficient demand for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or, if approved for commercialization, DaxibotulinumtoxinA for Injection or for any other future product candidate. </span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We are subject to uncertainty relating to third-party reimbursement policies which, if not favorable for DaxibotulinumtoxinA for Injection or any future product candidates, could hinder or prevent their commercial success.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to commercialize DaxibotulinumtoxinA for Injection or any future product candidates for therapeutic indications such as cervical dystonia, adult upper limb spasticity, plantar fasciitis or migraine will depend in part on the coverage and reimbursement levels set by governmental authorities, private health insurers and other third-party payors. As a threshold for coverage and reimbursement, third-party payors generally require that drug products have been approved for marketing by the FDA. Third-party payors also are increasingly challenging the effectiveness of and prices charged for medical products and services. We may not obtain adequate third-party coverage or reimbursement for DaxibotulinumtoxinA for Injection or any future product candidates for therapeutic indications, or we may be required to sell them at a discount.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect that third-party payors will consider the efficacy, cost effectiveness and safety of DaxibotulinumtoxinA for Injection in determining whether to approve reimbursement for DaxibotulinumtoxinA for Injection for therapeutic indications and at what level. Our business would be materially adversely affected if we do not receive coverage and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adequate reimbursement of DaxibotulinumtoxinA for Injection for therapeutic indications from private insurers on a timely or satisfactory basis. No uniform policy for coverage and reimbursement for products exists among third-party payors in the U.S.; therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, coverage under certain government programs, such as Medicare and Medicaid, may not be available for certain of our product candidates. As a result, the coverage determination process will likely be a time-consuming and costly process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Our business could also be adversely affected if third-party payors limit the indications for which DaxibotulinumtoxinA for Injection will be reimbursed to a smaller patient set than we believe they are effective in treating.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In some foreign countries, particularly Canada and European countries, the pricing of prescription pharmaceuticals is subject to strict governmental control. In these countries, pricing negotiations with governmental authorities can take six to 12 months or longer after the receipt of regulatory approval and product launch. To obtain favorable reimbursement for the indications sought or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our products, including DaxibotulinumtoxinA for Injection, to other available therapies. If reimbursement for our product is unavailable in any country in which reimbursement is sought, limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed. </span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any future products we develop.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We face an inherent risk of product liability lawsuits as a result of commercializing the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and as a result of the clinical testing of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, or any other product candidates. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">decreased demand for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, DaxibotulinumtoxinA for Injection or any future product candidates or products we develop;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">injury to our reputation and significant negative media attention;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants or cancellation of clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">costs to defend the related litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a diversion of management’s time and our resources;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">substantial monetary awards to trial participants or patients;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">loss of revenue;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">an increase in product liability insurance premiums or an inability to maintain product liability insurance coverage; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the inability to commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, DaxibotulinumtoxinA for Injection or any other products we develop.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or any future products we develop. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing DaxibotulinumtoxinA for Injection we intend to expand our insurance coverage to include the sale of DaxibotulinumtoxinA for Injection as applicable; however, we may be unable to obtain this liability insurance on commercially reasonable terms.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We have been, and in the future may be, subject to securities class action and stockholder derivative actions. These, and potential similar or related litigation, could result in substantial damages and may divert management’s time and attention from our business.     </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have been, and may in the future be, the target of securities class actions or stockholder derivative claims. On May 1, 2015, a securities class action complaint was filed on behalf of City of Warren Police and Fire Retirement System against us and certain of our directors and executive officers at the time of our follow-on public offering, and the investment banking firms that acted as the underwriters in our follow-on public offering. The Court granted final approval of the settlement, as set forth in the Stipulation of Settlement, on July 28, 2017. While the litigation has ended, we may be subject to future securities class action and shareholder derivation actions, which may adversely impact our business, results of operations, financial position or cash flows and divert management’s time and attention from the business.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, conduct our clinical trials and commercialize the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">, DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future products we develop.*</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel. We believe that our future success is highly dependent upon the contributions of our senior management, particularly Mark J. Foley, our President and Chief Executive Officer, Abhay Joshi, Ph.D., our Chief Operating Officer, Tobin C. Schilke, our Chief Financial Officer, and Dustin Sjuts, our Chief Commercial Officer, Aesthetics & Therapeutics, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, the completion of our planned clinical trials or the commercialization of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future products we develop.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leadership transitions can be inherently difficult to manage. Resignations of executive officers may cause disruption in our business, strategic and employee relationships, which may significantly delay or prevent the achievement of our business objectives. Leadership changes may also increase the likelihood of turnover in other key officers and employees and may cause declines in the productivity of existing employees. The search for a replacement officer may take many months or more, further exacerbating these factors. Identifying and hiring an experienced and qualified executive officer are typically difficult. Periods of transition in senior management leadership are often difficult as the new executives gain detailed knowledge of our operations and may result in cultural differences and friction due to changes in strategy and style. During the transition periods, there may be uncertainty among investors, employees, creditors and others concerning our future direction and performance.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We could experience problems attracting and retaining qualified employees. Competition for qualified personnel in the biotechnology and pharmaceuticals field is intense and the turnover rate can be high due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire a significant number of additional personnel as we begin building out a U.S. commercial organization for the distribution of </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> in </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the U.S. and, if the BLA is approved on or by the PDUFA target action date, the planned initiation of commercialization activities for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines before the end of 2020. As the product supply of RHA® dermal fillers has been delayed by Teoxane due to factors surrounding the COVID-19 pandemic, our anticipated product launch of the RHA® 2, 3 and 4 dermal fillers has been delayed by at least one quarter from the second quarter of 2020 to the third quarter of 2020. As a result, the hiring timeframe for building our sales force has been adjusted to coincide with product availability. We have no prior experience in building and managing a sales organization, and we may experience challenges associated with recruiting field representatives virtually through remote, group interviewing platforms and with onboarding new field representatives during such time as “shelter-in-place” or other such orders by governmental entities necessitate our work from home policy.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their previous research output.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">If we are not successful in discovering, developing, acquiring and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Although a substantial amount of our effort will focus on the commercialization of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and the continued clinical testing and potential approval of DaxibotulinumtoxinA for Injection, a key element of our strategy is to discover, develop and commercialize a portfolio of botulinum toxin products for both aesthetic and therapeutic indications. We are seeking to do so through our internal research programs and may explore strategic collaborations for the development or acquisition of new products. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we identify an appropriate collaboration or product acquisition, we may not be successful in negotiating the terms of the collaboration or acquisition, or effectively integrating the collaboration or acquired product into our existing business and operations. Moreover, we may not be able to pursue such opportunities if they fall within the non-compete provision of the Teoxane Agreement, which prohibits us from developing, manufacturing, marketing, selling, detailing or promoting any cross-linked hyaluronic acid dermal filler (other than the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">) in the U.S. during the term of the Teoxane Agreement. We have limited experience in successfully acquiring and integrating products and technologies into our business and operations, and even if we are able to consummate an acquisition or other investment, we may not realize the anticipated benefits of such acquisitions or investments. We may face risks, uncertainties and disruptions, including difficulties in the integration of the operations and services of these acquisitions. If we fail to successfully integrate collaborations, assets, products or technologies that we enter into or acquire, or if we fail to successfully exploit acquired product distribution rights and maintain acquired relationships with customers, our business could be harmed. </span><span style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt"> </sub></span><span style="font-family:inherit;font-size:10pt;">Furthermore, we may have to incur debt or issue equity securities in connection with proposed collaborations or to pay for any product acquisitions or investments, the issuance of which could be dilutive to our existing shareholders. Identifying, contemplating, negotiating or completing a collaboration or product acquisition and integrating an acquired product or technology could significantly divert management and employee time and resources.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While DaxibotulinumtoxinA for Injection is in the clinical development stage, DaxibotulinumtoxinA Topical and all of our other potential product candidates remain in the discovery or preclinical stage. Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the research methodology used may not be successful in identifying potential product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">competitors may develop alternatives that render our product candidates obsolete or less attractive;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">product candidates we develop may nevertheless be covered by third parties’ patents or other exclusive rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">intellectual property rights of third parties may potentially block our entry into certain geographies or make such entry economically impracticable.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed and our business will be more vulnerable to problems that we encounter in commercializing the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and in developing and commercializing DaxibotulinumtoxinA for Injection. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">The requirements of being a public company may strain our resources, divert management’s attention and affect our ability to attract and retain qualified members of our board of directors.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or (the “Exchange Act”), the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”), The Nasdaq Stock Market LLC listing rules and other applicable securities rules and regulations. Compliance with these rules and regulations has increased and will continue to increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly, and increase demand on our systems and resources. The Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management’s attention may be diverted from other business concerns, which could harm our business and operating results. Although we have hired additional employees to comply with these requirements, we may need to hire more employees in the future, which will increase our costs and expenses.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a public company that is subject to these rules and regulations we may find it is more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors and qualified executive officers.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We need to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act, and the failure to do so could have a material adverse effect on our business and stock price. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. We are required to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our independent registered public accounting firm is required to attest to the effectiveness of our internal control over financial reporting in connection with the filing of our Annual Report on Form 10-K. If we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our common stock could decline and we could be subject to actions or investigations by the SEC, or other regulatory authorities, which would require additional financial and management resources. </span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We may experience difficulties maintaining our new enterprise resource planning system.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of 2019, we implemented a new enterprise resource planning (“ERP”) system and expect to continue with additional ERP implementations, including those in preparation of potential product launches. ERP implementations are complex and time-consuming, and involve substantial expenditures on system software and implementation activities. The ERP system will be critical to our ability to provide important information to our management, obtain and deliver our products, provide services and customer support, send invoices and track payments, fulfill contractual obligations, accurately maintain books and records, provide accurate, timely and reliable reports on our financial and operating results or otherwise operate our business. ERP implementations also require transformation of business and financial processes in order to reap the benefits of the ERP system; any such transformation involves risks inherent in the conversion to a new computer system, including loss of information and potential disruption to our normal operations. The implementation and maintenance of the new ERP system has required, and will continue to require, the investment of significant financial and human resources. Any disruptions, delays or deficiencies in the design or the ongoing maintenance of the new ERP system could adversely affect our ability to process orders, ship products, provide services and customer support, send invoices and track payments, fulfill contractual obligations, accurately maintain books and records, provide accurate, timely and reliable reports on our financial and operating results, or otherwise operate our business. Additionally, if the system does not operate as intended, the effectiveness of our internal control over financial reporting could be adversely affected or our ability to assess it adequately could be delayed.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental laws and regulations, which can be expensive and restrict how we do business.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our sales, marketing, research and development and manufacturing activities and our third-party manufacturers’ and suppliers’ activities involve the controlled storage, use and disposal of hazardous materials owned by us, including botulinum toxin type A, a key component of our product candidates, and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We are licensed with the Centers for Disease Control and Prevention (“CDC”) and with the California Department of Health, Food and Drug Branch for use of botulinum toxin and to manufacture both the active pharmaceutical ingredient and the finished product in topical and injectable dose forms. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’ facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">We may use third-party collaborators to help us develop, validate or commercialize any new products, and our ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may continue to license or selectively pursue strategic collaborations for the development, validation and commercialization of DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, hyaluronic acid filler products, and any future product candidates. For instance, in February 2018, we and Mylan entered into the Mylan Collaboration, pursuant to which we and Mylan will collaborate exclusively, on a world-wide basis (excluding Japan), to develop, manufacture and commercialize our biosimilar product candidate. In December 2018, we and Fosun entered into the Fosun License Agreement pursuant to which we have granted Fosun the exclusive rights to develop and commercialize DaxibotulinumtoxinA for Injection in the Fosun Territory and certain sublicense rights. In addition, we entered into the Teoxane Agreement in January 2020, pursuant to which Teoxane granted us the exclusive right to import, market, promote, sell and distribute the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> in the U.S., its territories and possessions. In any third-party collaboration, we are dependent upon the success of the collaborators to perform their responsibilities with continued cooperation. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. We cannot control the amount and timing of our collaborators’ resources that will be devoted to performing their responsibilities under our agreements with them. Our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us. The development, validation and commercialization of our product candidates will be delayed if collaborators fail to conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements or if they breach or terminate their collaboration agreements with us. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disputes with our collaborators could also impair our reputation or result in development delays, decreased revenues and litigation expenses. Our collaboration with Mylan is for the development of a biosimilar product, which is subject to risks inherent with the relatively short history of biosimilar product approvals in the U.S. The biosimilar product would be subject to similar commercial risks as our DaxibotulinumtoxinA for Injection and Daxibotulinumtoxin A Topical product candidates. In February 2019, we and Mylan participated in a BIAM with the FDA to discuss the feasibility of a 351(k) biosimilar submission and the necessary development pathway for the biosimilar product candidate. While we believe that such a pathway is viable, the successful development and commercialization of a biosimilar product in any indications of BOTOX® or BOTOX Cosmetic® would be subject to FDA requirements that would need to be assessed by us and Mylan in determining the development of the biosimilar product candidate. In August 2019, we announced an amendment to the Mylan Collaboration pursuant to which, among other things, we agreed to extend the period of time for Mylan to make a decision under the collaboration agreement as to whether to continue the development and commercialization of a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX® beyond the initial development plan to prepare for and conduct the BIAM with the FDA. Such amendment to the Mylan Collaboration and the FDA requirements may also limit our ability to begin development of the biosimilar in 2020, as presently planned or at all. On May 1, 2020, we announced that we are continuing discussions with Mylan regarding whether or not Mylan plans to move forward with the biosimilar program. Even if successfully developed, the biosimilar product would be subject to similar commercial risks as our DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA Topical product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unfavorable global economic conditions or trade relations could adversely affect our business, financial condition or results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Furthermore, the demand for aesthetic or therapeutic medical procedures may be particularly vulnerable to unfavorable economic conditions. We do not expect sales of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> for aesthetic indications or sales of DaxibotulinumtoxinA for Injection for the treatment of glabellar lines to be reimbursed by any government or third-party payor and, as a result, demand for the first indications of each of our product candidates will be tied to discretionary spending levels of our targeted patient population. Future global financial crises and economic downturns, including those cause by widespread public health crises such as the COVID-19 pandemic, may cause extreme volatility and disruptions in capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, if approved, and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, changes in U.S. and foreign trade policies or border closures related to the COVID-19 pandemic could trigger retaliatory actions by affected countries, resulting in “trade wars”, which may reduce customer demand for goods exported out of the U.S. if the parties having to pay those retaliatory tariffs increase their prices, or if trading partners limit their trade with the U.S. If these consequences are realized, the price to the consumer of aesthetic or therapeutic medical procedures from products exported out of the U.S. may increase, resulting in a material reduction in the demand for our future product candidates. Such a reduction may materially and adversely affect our potential sales and our business. In particular, under our Fosun License Agreement, we are responsible for manufacturing DaxibotulinumtoxinA for Injection and supplying it to Fosun, which would then develop commercialize, market and sell it in mainland China, Hong Kong and Macau. If this arrangement is restricted in any way due to the U.S.-China trade relation or the COVD-19 pandemic, the contingent payments we are entitled to receive under the agreement, which are based on product sales, among other things, may be adversely affected. In addition, under the Teoxane Agreement, we are responsible for the commercialization of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> in the U.S., and rely on Teoxane for our entire supply of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, which has been impacted by COVID-19 pandemic.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, travel and import restrictions, including those resulting from the COVID-19 pandemic, have disrupted and may continue to disrupt our supply chain and ability to distribute the RHA® dermal fillers. Any import or export or other cargo restrictions related to our products, including those resulting from the COVID-19 pandemic, would restrict our ability to ship or receive products and harm our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current or future economic climate and financial market conditions could adversely impact our business.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Adverse tax laws or regulations could be enacted or existing laws could be applied to us or our customers, which could increase the costs of our services and adversely impact our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The application of federal, state, local and international tax laws to services provided electronically is evolving. New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time (possibly with retroactive effect), and could be applied solely or disproportionately to services provided over the internet. These enactments could adversely affect our sales activity due to the inherent cost increase the taxes would represent and ultimately result in a negative impact on our operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us (possibly with retroactive effect), which could require us or our customers to pay additional tax amounts, as well as require us or our customers to pay fines or penalties and interest for past amounts. If we are unsuccessful in collecting such taxes from our customers, we could be held liable for such costs, thereby adversely impacting our operating results and cash flows.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, we have undertaken certain transactions to realize potential tax efficiencies in support of our expected global business expansion. These transactions are meant to align the global economic ownership of our intellectual property rights with our current and future business operations. We are uncertain as to whether the tax efficiencies sought by this alignment will materialize and may choose to unwind these transactions in the future.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition, or results of operations. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Significant disruptions of information technology systems or breaches of data security could materially adversely affect our business, results of operations and financial condition.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. Breaches and other inappropriate access can be difficult to detect and any delay in identifying them could increase their harm. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. In addition, our work from home policy implemented in response to the COVID-19 pandemic could increase our cyber security risk, create data accessibility concerns, and make us more susceptible to communication disruptions. U.S. and international authorities have been warning businesses of increased cybersecurity threats from actors seeking to exploit the COVID-19 pandemic. Any such breaches of security and inappropriate access could disrupt our operations, harm our reputation or otherwise have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical study data from completed or ongoing or planned clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Moreover, if a computer security breach affects our systems, corrupts our data or results in the unauthorized disclosure or release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, supervisory bodies, credit reporting agencies, the media or individuals pursuant to various federal, state and foreign data protection, privacy and security laws, regulations and guidelines, if applicable. For example, these may include the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) as amended by the Health Information Technology for Clinical Health Act of 2009, and its implementing rules and regulations, U.S. state breach notification laws and the EU General Data Protection Regulation (EU) 2016/679 (“GDPR”). We would also be exposed to a risk of loss, enforcement measures, penalties, fines, indemnification claims or litigation and potential civil or criminal liability, which could materially adversely affect our business, results of operations and financial condition. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Changes in and failures to comply with U.S. and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and financial performance.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, retention, and security of personal data, such as information that we collect about patients and healthcare providers in connection with clinical trials in the U.S. and abroad. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, affect our or our vendors’ ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the U.S., HIPAA imposes, among other things, certain standards and obligations on covered entities including certain healthcare providers, health plans and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain, or transmit individually identifiable health information for or on behalf of a covered entity relating to the privacy, security, transmission and breach reporting of individually identifiable health information. Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. We may become subject to new privacy or cybersecurity regulations. Such laws and regulations could affect our ability to process personal data (in particular, our ability to use certain data for purposes such as risk or fraud avoidance, marketing or advertising), our ability to control our costs by using certain vendors or service providers, or impact our ability to offer certain services in certain jurisdictions. For example, the California Consumer Privacy Act (“CCPA”) became effective on January 1, 2020. The CCPA establishes a privacy framework for covered businesses, including an expansive definition of personal information and data privacy rights for California residents. The CCPA includes a framework with potentially severe statutory damages and private rights of action. The CCPA requires covered companies to provide new disclosures to California consumers (as that word is broadly defined in the CCPA), provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. As we expand our operations, the CCPA will likely impact our business activities and may increase our compliance costs and potential liability. If we fail to comply with the CCPA, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Other states are beginning to pass similar laws, and some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. In the event that we are subject to HIPAA, the CCPA or other U.S. privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. Many countries in these regions have established or are in the process of establishing privacy and data security legal frameworks with which we, our customers, or our vendors must comply. For example, the EU has adopted the GDPR, which went into effect in May 2018 and introduces strict requirements for processing the personal information of EU subjects, including clinical trial data. The GDPR is likely to increase compliance burdens on us, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and process information about them. The processing of sensitive personal data, such as physical health condition, may impose heightened compliance burdens under the GDPR and is a topic of active interest among foreign regulators. In addition, the GDPR provides for more robust regulatory enforcement and fines of up to €20 million or 4 percent of the annual global revenue of the noncompliant company, whichever is greater. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s695CE5926AEE5FADCE4C16CE1EA4E34D"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Intellectual Property</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If Teoxane fails to obtain and maintain patent, licensing arrangements or other protection for the proprietary intellectual property that we have exclusive distribution rights to, we could lose our rights related to the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, which would have a material adverse effect on our potential to generate revenue, our business prospects, and our results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If Teoxane fails to obtain and maintain patent, licensing arrangements or other protection for the proprietary intellectual property that we have exclusive distribution rights to, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. The intellectual property underlying the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to the Teoxane Agreement, including:</span></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-indent:0px;"><span style="padding-bottom:16px;font-family:inherit;font-size:10pt;padding-right:48px;">•</span><span style="font-family:inherit;font-size:10pt;">the scope of rights granted under the Teoxane Agreement and other interpretation-related issues;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent to which our technology and processes infringe on intellectual property of Teoxane that is not subject to the Teoxane Agreement;</span></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-indent:0px;"><span style="padding-bottom:16px;font-family:inherit;font-size:10pt;padding-right:48px;">•</span><span style="font-family:inherit;font-size:10pt;">the sublicensing of patent and other rights under our collaborative development relationships; and</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ownership of inventions and know-how resulting from the development of intellectual property under the Teoxane Agreement.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected products or product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If our efforts to protect our intellectual property related to DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> or any future product candidates, including DaxibotulinumtoxinA Topical and biosimilar, are not adequate, we may not be able to compete effectively.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, DaxibotulinumtoxinA Topical, biosimilar, and our development programs. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thereby eroding our competitive position.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law in ways affecting the scope or validity of issued patents. The patent applications that we own or license may fail to result in issued patents in the U.S. or foreign countries. Competitors in the field of cosmetics, pharmaceuticals, and botulinum toxin have created a substantial amount of prior art, including scientific publications, patents and patent applications. Our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope of such issued patents or any other issued patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be opposed by any person within nine months from the publication of their grant. Our European Patent EP 2 661 276 for “Topical composition comprising botulinum toxin and a dye” was opposed in the European Patent Office by Allergan plc on May 2, 2018, and although this patent is not material to our business, we continue to take appropriate measures to defend the patent. On May 10, 2019 our European Patent No. EP 2 490 986 B1 for “Methods and Systems For Purifying Non-Complexed Botulinum Neurotoxin” was opposed. We are vigorously defending this patent in the European Patent Office. We were informed in May 2019 that our patent application NC2018/0005351 pending in Colombia for “Injectable Botulinum Toxin Formulations And Methods of Use Thereof Having Long Duration of Therapeutic Effect” was opposed. We have responded to this pre-grant opposition. Furthermore, even if our patents and applications are unchallenged, they may not adequately protect our intellectual property or prevent others from designing around our claims.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> In addition, the patent laws of the U.S. provide procedures for third parties to challenge the validity of issued patents. Patents issued from applications filed after March 15, 2013 may be challenged by third parties using the post-grant review procedure which allows challenges for a number of reasons, including prior art, sufficiency of disclosure, and subject matter eligibility. Under the inter partes review procedure, any third party may challenge the validity of any issued U.S. Patent in the U.S. Patent and Trademark Office (“USPTO”) on the basis of prior art patents or printed publications. Because of a lower evidentiary standard necessary to invalidate a patent claim in USPTO proceedings as compared to the evidentiary standard relied on in U.S. federal court, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates is challenged, then it could threaten our ability to commercialize DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar or any future product candidates, and could threaten our ability to prevent competitive products from being marketed. Further, if we encounter delays in our clinical trials, the period of time during which we could market DaxibotulinumtoxinA for Injection, or any future product candidates under patent protection would be reduced. The results of our REALISE 1 Phase 3 clinical trial may be relevant to our patent strategy for our DaxibotulinumtoxinA Topical program.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since patent applications in the U.S. and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications. Furthermore, for applications filed before March 16, 2013, or patents issuing from such applications, an interference proceeding can be provoked by a third party, or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications and patents. As of March 16, 2013, the U.S. transitioned to a “first-to-file” system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. The change to “first-to-file” from “first-to-invent” is one of the changes to the patent laws of the United States resulting from the Leahy-Smith America Invents Act signed into law on September 16, 2011. Among some of the other changes to the patent laws are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. Moreover, any actions we may bring to enforce our intellectual property against our competitors could provoke them to bring counterclaims against us, and some of our competitors have substantially greater intellectual property portfolios and financial resources than we have.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also rely on trade secret protection and confidentiality agreements to protect proprietary know-how that may not be patentable, processes for which patents may be difficult to obtain or enforce and any other elements of our product development and manufacturing processes that involve proprietary know-how, information or technology that is not covered by patents.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In an effort to protect our trade secrets and other confidential information, we require our employees, consultants, collaborators and advisers to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements, however, may not provide us with adequate protection against improper use or disclosure of confidential information, and these agreements may be breached. Adequate remedies may not exist in the event of unauthorized use or disclosure of our confidential information. A breach of confidentiality could significantly affect our competitive position. In addition, in some situations, these agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, collaborators or advisers have previous employment or consulting relationships. To the extent that our employees, consultants or contractors use any intellectual property owned by others in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. Also, others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets and other confidential information.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If we infringe or are alleged to infringe intellectual property rights of third parties, our business could be harmed.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our research, development and commercialization activities may infringe or otherwise violate or be claimed to infringe or otherwise violate patents owned or controlled by other parties. Competitors in the field of cosmetics, pharmaceuticals and botulinum toxin have developed large portfolios of patents and patent applications in fields relating to our business. For example, there are patents held by third parties that relate to the treatment with botulinum toxin-based products for indications we are currently developing. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us. These third parties could bring claims against us that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of patent infringement claims, or to avoid potential claims, we may choose or be required to seek licenses from third parties. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product based on our current or future indications, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry. In addition to infringement claims against us, we may become a party to other patent litigation and other proceedings, including interference, derivation or post-grant proceedings declared or granted by the USPTO and similar proceedings in foreign countries, regarding intellectual property rights with respect to our current or future products. The cost to us of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Patent litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and time-consuming.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Competitors may infringe upon our intellectual property, including our patents or the patents of our licensors. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interference, derivation, inter partes review, post-grant review or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to our patents or patent applications or those of our licensors or collaborators. Litigation or USPTO proceedings brought by us may fail or may be invoked against us by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management. We may not be able, either alone or with our licensors or collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the U.S.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. and in some cases may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws.</span></div><div><a id="s6C09FE24F4B806CAA26416CE1ED34EC1"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Government Regulation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our business and products are subject to extensive government regulation.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the U.S., principally by the FDA, the U.S. Drug Enforcement Administration, the CDC, and foreign regulatory authorities. Failure to comply with all applicable regulatory requirements, including those promulgated under FDCA, the Public Health Service Act, and Controlled Substances Act, may subject us to operating restrictions and criminal prosecution, monetary penalties and other disciplinary actions, including, sanctions, warning letters, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, or exclusion from future participation in the Medicare and Medicaid programs.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After our other products receive regulatory approval, we, and our direct and indirect suppliers, will remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections may result in the implementation of Risk Evaluation and Mitigation Strategies programs, completion of government mandated clinical trials, and government enforcement action relating to labeling, advertising, marketing and promotion, as well as regulations governing manufacturing controls noted above.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">The regulatory approval process is highly uncertain and we or any collaboration partner may not obtain regulatory approval for the commercialization of DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> or any future product candidates.*</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries, which regulations differ from country to country. Neither we nor any collaboration partner are permitted to market DaxibotulinumtoxinA for Injection or any future product candidates in the U.S. until we receive approval of a BLA from the FDA. Even though filed with the FDA, our BLA may receive a Complete Response Letter identifying deficiencies that must be addressed, rather than an approval. Obtaining regulatory approval of a BLA can be a lengthy, expensive and uncertain process. Similarly, Teoxane must do the same with its PMAs to the FDA for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, failure to comply with FDA and other applicable U.S. and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions or other actions, including:</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">warning letters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">civil and criminal penalties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">injunctions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">withdrawal of approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">product seizure or detention;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">product recalls;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">total or partial suspension of production; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refusal to approve pending BLAs or supplements to approved BLAs.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prior to obtaining approval to commercialize a product candidate in the U.S. or abroad, we or our collaborators must demonstrate with substantial evidence from well controlled clinical trials, and to the satisfaction of the FDA or other foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical and clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA or other regulatory authorities denying approval of a product candidate for any or all targeted indications.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Regulatory approval of a BLA or BLA supplement is not guaranteed, and the approval process is expensive and may take several years. The FDA also has substantial discretion in the approval process. Despite the time and expense expended, failure can occur at any stage, and we could encounter problems that cause us to abandon or repeat clinical trials, or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for FDA approval varies depending on the product candidate, the disease or the condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA can delay, limit or deny approval of a product candidate for many reasons, including the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a product candidate may not be deemed safe, effective, or of required quality;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FDA officials may not find the data from preclinical studies and clinical trials sufficient;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA might not approve our third-party manufacturers’ processes or facilities; or</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA may change its approval policies or adopt new regulations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain approval, our business and results of operations will be materially and adversely harmed.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The COVID-19 pandemic has affected the business of the FDA and may affect the business of the European Medicines Agency (“EMA”) or other health authorities. In March 2020, the FDA announced the postponement of most foreign inspections due to the global impact of COVID-19. If a prolonged government shutdown or other disruption to the normal functioning of government agencies occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business or prospects. For instance, interruption or delays in the operations of the FDA or other applicable local or foreign regulatory agencies caused by the COVID-19 pandemic may cause delays in meetings related to planned or completed clinical trials and may affect the review and approval timelines for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, RHA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidates, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">including the PDUFA target action date for DaxibotulinumtoxinA for Injection in the treatment of glabellar lines. In addition, the COVID-19 pandemic has generally diverted healthcare resources away from the conduct of clinical trials and may cause delays or difficulties in clinical site initiation and site inspection, including difficulties in recruiting clinical site investigators and clinical site staff. Further, delays in the operations of the FDA or other applicable local or foreign regulatory agencies may result in delays or difficulties in obtaining required inspections of the facilities where we or third parties with whom we contract manufacture any of our product candidates, or the raw materials used in the manufacture of our product candidates, which may affect the approval timeline for our product candidates, including DaxibotulinumtoxinA for Injection in the treatment of glabellar lines. For instance, b</span><span style="font-family:inherit;font-size:10pt;color:#212529;">efore approving BLA, the FDA can inspect the facilities at which we plan to manufacture </span><span style="font-family:inherit;font-size:10pt;">DaxibotulinumtoxinA for Injection and the </span><span style="font-family:inherit;font-size:10pt;color:#212529;">FDA will not approve the BLA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> are Class III medical devices that require PMA approval before they may be commercialized in the U.S. Although Teoxane has received PMA for RHA® 2, RHA® 3 and RHA® 4 dermal fillers, we and Teoxane will be subject to ongoing and pervasive regulatory requirements governing, among other things, the manufacture, marketing, advertising, medical device reporting, sale, promotion, registration, and listing of these devices. For example, periodic reports must be submitted to the FDA as a condition of PMA approval. These reports include safety and effectiveness information about the device after its approval. Failure to submit such reports, or failure to submit the reports in a timely manner, could result in enforcement action by the FDA. Following its review of the periodic reports, the FDA might ask for additional information or initiate further investigation. Any failure to comply with the conditions of approval could result in the withdrawal of PMA approval and the inability to continue to market the device. The medical device regulations to which we are subject are complex and have become more stringent over time, and we have no history of operating as a distributor of Class III medical devices. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory authorities, including recalls, Dear Doctor letters and negative publicity which would negatively affect our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Even if we receive regulatory approval for DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> or any future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, may limit or delay regulatory approval and may subject us to penalties if we fail to comply with applicable regulatory requirements.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Once regulatory approval has been granted, DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or any approved product will be subject to continual regulatory review by the FDA and/or non-U.S. regulatory authorities. Additionally, any product candidates, if approved, will be subject to extensive and ongoing regulatory requirements, including labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any regulatory approvals that we or our collaborators receive for DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or any future product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the applicable regulatory agency approves DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or any future product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCPs for any clinical trials that we conduct post-approval. The </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> are currently subject to such extensive and ongoing regulatory requirements, reports, registration and continued compliance. Later discovery of previously unknown problems with DaxibotulinumtoxinA for Injection, the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> or any future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fines, warning letters or holds on clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">refusal by the FDA to approve pending applications or supplements to approved applications submitted by us or our strategic collaborators, or suspension or revocation of product license approvals;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">product seizure or detention, or refusal to permit the import or export of products; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">injunctions or the imposition of civil or criminal penalties.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or other countries. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If we fail to obtain regulatory approvals in foreign jurisdictions for DaxibotulinumtoxinA for Injection, or any future product candidates including DaxibotulinumtoxinA Topical or biosimilar, we will be unable to market our products outside of the U.S.*</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to regulations in the U.S., we will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval procedures vary among countries and can involve additional clinical testing, or the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive the necessary approvals to commercialize our products in geographies outside of the U.S.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, interruption or delays in the operations of applicable foreign regulatory agencies caused by the COVID-19 pandemic may affect the review and approval timelines of such agencies for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, biosimilar, RHA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> 1 or any future hyaluronic acid filler products developed pursuant to the Teoxane Agreement or any future product candidates.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">The </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">, and, if approved, DaxibotulinumtoxinA for Injection or any other products, may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so, we could be subject to sanctions that would materially harm our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As we commercialize the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">, and if we are successful in commercializing DaxibotulinumtoxinA for Injection, or any other products including DaxibotulinumtoxinA Topical or biosimilar, the FDA and foreign regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">We may in the future be subject to various U.S. federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">While we do not expect that DaxibotulinumtoxinA for Injection, if approved for the treatment of glabellar lines, or the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> will subject us to all of the various U.S. federal and state laws intended to prevent healthcare fraud and abuse, we may be subject to, or in the future become subject to, such laws for treatment of other indications. The federal anti-kickback statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal healthcare programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “ACA”) to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act (“FCA”). Many states have similar laws that apply to their state healthcare programs as well as private payors.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal false claims and civil monetary penalties laws, including the FCA impose liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal healthcare program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HIPAA imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HIPAA also imposes, among other things, certain standards and obligations on covered entities including certain healthcare providers, health plans and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain, or transmit individually identifiable health information for or on behalf of a covered entity relating to the privacy, security, transmission and breach reporting of individually identifiable health information.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal Physician Payments Sunshine Act, and its implementing regulations, require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to Centers for Medicare & Medicaid Services information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Beginning in 2022, covered manufacturers will also be required to report annually regarding payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives and report ownership or investment interests held by such healthcare professionals and their immediate family members.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also be subject to analogous state laws and regulations, including: state anti-kickback and false claims laws, state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources, state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities, and state and local laws that require the registration of our pharmaceutical sales representatives.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">77</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">State and federal authorities have aggressively targeted pharmaceutical manufacturers for alleged violations of these anti-fraud statutes for a range of activities, such as those based on improper research or consulting contracts with physicians and other healthcare professionals, certain marketing arrangements that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. Companies targeted in such prosecutions have paid substantial fines in the hundreds of millions of dollars or more, have been forced to implement extensive corrective action plans, and have often become subject to consent decrees severely restricting the manner in which they conduct business. Further, defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. If we become the target of such an investigation or prosecution based on our activities such as contractual relationships with providers or institutions, or our marketing and promotional practices, we could be subject to significant civil, criminal, and administrative sanctions, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, imprisonment, additional reporting requirements, and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Also, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Legislative or regulatory healthcare reforms in the U.S. may make it more difficult and costly for us to obtain regulatory clearance or approval of DaxibotulinumtoxinA for Injection, topical, or any future product candidates and to produce, market, and distribute the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> and, if clearance or approval is obtained, DaxibotulinumtoxinA for Injection and our other products.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. For example, the ACA was passed in March 2010, and substantially changed the way healthcare is financed by both governmental and private insurers, and continues to significantly impact the U.S. biotechnology industry. There remain judicial and Congressional challenges to certain aspects of the ACA, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA’s individual mandate to carry health insurance. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. It is unclear how this decision, future decisions, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, there have been several recent U.S. congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement methodologies for drug products. At the federal level, the Trump administration’s budget proposal for fiscal year 2020 contained further drug price control measures that could be enacted during the budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic drugs for low-income patients. Further, the Trump administration released a “Blueprint” to lower drug prices and reduce out </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. The Department of Health and Human Services has solicited feedback on some of these measures and, at the same, has implemented others under its existing authority. While some of these and other measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of, or affect the price that we may charge for, DaxibotulinumtoxinA for Injection, or any future product candidates including DaxibotulinumtoxinA Topical or biosimilar. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs on our commercialization efforts for the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could require, among other things:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes to manufacturing methods;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">recall, replacement, or discontinuance of one or more of our products; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">additional recordkeeping.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div><a id="s35947C94B352CE765DA616CE1F0276B5"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to the Ownership of Our Common Stock</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">The trading price of our common stock is volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. The stock markets in general and the markets for pharmaceutical biopharmaceutical and biotechnology stocks in particular have experienced extreme volatility that may have been for reasons that are related or unrelated to the operating performance of the issuer. The market price for our common stock may be influenced by many factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">regulatory or legal developments in the U.S. and foreign countries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our success or lack of success in commercializing the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">results from or delays in clinical trials of our product candidates, including our ongoing ASPEN Phase 3 clinical program in cervical dystonia and our Phase 2 programs in plantar fasciitis, adult upper limb spasticity, forehead lines, and lateral canthal lines all with DaxibotulinumtoxinA for Injection;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements of regulatory approval or disapproval of DaxibotulinumtoxinA for Injection, the RHA® dermal fillers or any future product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FDA or other U.S. or foreign regulatory actions or guidance affecting us or our industry;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">introductions and announcements of new products by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in the structure of healthcare payment systems;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, joint ventures or capital commitments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts’ reports or recommendations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">quarterly variations in our results of operations or those of our future competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">sales of substantial amounts of our stock by insiders and large stockholders, or the expectation that such sales might occur;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">general economic, industry and market conditions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">additions or departures of key personnel;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">intellectual property, product liability or other litigation against us;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expiration or termination of our potential relationships with customers and strategic partners;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the occurrence of trade wars or barriers, or the perception that trade wars or barriers will occur; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any buying or selling of shares of our common stock or other hedging transactions in our common stock in connection with the 2027 Notes or the capped call transactions;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">widespread public health crises such as the COVID-19 pandemic; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">other factors described in this “Risk Factors” section.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In addition, in the past, stockholders have initiated class actions against pharmaceutical companies, including us, following periods of volatility in their stock prices. Such litigation instituted against us could cause us to incur substantial costs and divert management’s attention and resources.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts may cease to publish research on our company at any time in their discretion. A lack of research coverage may adversely affect the liquidity and market price of our common stock. We will not have any control of the equity research analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company, or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of our common stock to drop significantly, even if our business is doing well.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. In March 2018, we entered into the 2018 At-the-Market Agreement (“2018 ATM Agreement”). Under the 2018 ATM Agreement, we may offer and sell common stock having aggregate proceeds of up to </span><span style="font-family:inherit;font-size:10pt;">$125 million</span><span style="font-family:inherit;font-size:10pt;"> from time to time through Cantor Fitzgerald as our sales agent. No sales of our common stock have been sold under the 2018 ATM Agreement as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. In January 2019, we completed the 2019 follow-on public offering, pursuant to which we issued </span><span style="font-family:inherit;font-size:10pt;">6,764,705</span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at a public offering price of </span><span style="font-family:inherit;font-size:10pt;">$17.00</span><span style="font-family:inherit;font-size:10pt;"> per share, including the exercise of the underwriters’ over-allotment option to purchase </span><span style="font-family:inherit;font-size:10pt;">882,352</span><span style="font-family:inherit;font-size:10pt;"> additional shares of common stock, for aggregate net proceeds of </span><span style="font-family:inherit;font-size:10pt;">$107.6 million</span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts, commissions and other offering expenses. During December 2019 and January 2020, we completed a follow-on public offering of an aggregate of </span><span style="font-family:inherit;font-size:10pt;">7,475,000</span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at a public offering price of </span><span style="font-family:inherit;font-size:10pt;">$17.00</span><span style="font-family:inherit;font-size:10pt;"> per share, including the exercise of the underwriters’ over-allotment option to purchase </span><span style="font-family:inherit;font-size:10pt;">975,000</span><span style="font-family:inherit;font-size:10pt;"> additional shares of common stock, for aggregate net proceeds of </span><span style="font-family:inherit;font-size:10pt;">$119.2 million</span><span style="font-family:inherit;font-size:10pt;">, after deducting underwriting discounts, commissions and other offering expenses.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. Any sales of securities by stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Provisions in our corporate charter documents and under Delaware law could discourage takeover attempts and lead to management entrenchment, and the market price of our common stock may be lower as a result.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain provisions in our amended and restated certificate of incorporation and amended and restated bylaws may make it difficult for a third party to acquire, or attempt to acquire, control of our company, even if a change in control was considered favorable by you and other stockholders. For example, our board of directors has the authority to issue up to 5,000,000 shares of preferred stock. Our board of directors can fix the price, rights, preferences, privileges, and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction. As a result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our charter documents also contain other provisions that could have an anti-takeover effect, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">only one of our three classes of directors will be elected each year;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">no cumulative voting in the election of directors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability of our board of directors to issues shares of preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the exclusive right of our board of directors to elect a director to fill a vacancy or newly created directorship;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">stockholders will not be permitted to take actions by written consent;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">stockholders cannot call a special meeting of stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">stockholders must give advance notice to nominate directors or submit proposals for consideration at stockholder meetings;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ability of our board of directors, by a majority vote, to amend the bylaws; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the requirement for the affirmative vote of at least 66 2/3 percent or more of the outstanding common stock to amend many of the provisions described above.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law (the “DGCL”), which regulates corporate acquisitions. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that certain investors are willing to pay for our stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our amended and restated certificate of incorporation also provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, as permitted by Section 145 of the DGCL, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We will indemnify our directors and officers for serving us in those capacities, or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gains.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any existing or future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:0px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Conversion of the </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> may dilute the ownership interest of our stockholders or may otherwise depress the price of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The conversion of some or all of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> may dilute the ownership interests of our stockholders. Upon conversion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, we have the option to pay or deliver, as the case may be, cash, shares of our common stock, or a combination of cash and shares of our common stock. If we elect to settle our conversion obligation in shares of our common stock or a combination of cash and shares of our common stock, any sales in the public market of our common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> may encourage short selling by market participants because the conversion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> could be used to satisfy short positions, or anticipated conversion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> into shares of our common stock could depress the price of our common stock.</span></div><div><a id="s69E8B960283E81AF9C3A16CE1F2168C4"></a></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Sales of Unregistered Securities </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">January 10, 2020</span><span style="font-family:inherit;font-size:10pt;">, we issued </span><span style="font-family:inherit;font-size:10pt;">2,500,000</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock to Teoxane in consideration of their granting exclusive distribution rights to us pursuant to the Teoxane Agreement. The transaction was exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2020, a warrant to purchase 34,113 shares of common stock held by one holder was net exercised for 11,134 shares of common stock (the “Warrant Net Exercise Shares”). The issuance of the Warrant Net Exercise Shares to the holder of the warrant was made by us pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended, contained in Section 3(a)(9) thereunder.</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Issuer Purchases of Equity Securities</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have not and do not currently intend to retire or repurchase any of our shares other than providing our employees with the option to withhold shares to satisfy tax withholding amounts due from employees upon the vesting of restricted stock awards in connection with our 2014 EIP and 2014 IN.</span></div><div><a id="sC7D8D3321BA6F63EDE7F16CE1F50EDDD"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><a id="s122343E4B71DFD05E2E416CE1F6F47E8"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div><a id="s8EED0C078312CBFCC17C16CE1F9E5AE5"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 5. OTHER INFORMATION</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">83</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s81E07E2E773A17E0BF0216CE1FCD32BA"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:bold;text-decoration:none;">ITEM 6. EXHIBITS</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following exhibits are included herein or incorporated herein by reference:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Incorporated by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">File No.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filling Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Filed Herewith</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1479290/000119312514045629/d674914dex31.htm"><span style="font-family:inherit;font-size:9pt;">Amended and Restated Certificate of Incorporation</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-36297</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">February 11, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1479290/000119312513488614/d513724dex34.htm"><span style="font-family:inherit;font-size:9pt;">Amended and Restated Bylaws</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-193154</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">December 31, 2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1479290/000119312514033118/d513724dex44.htm"><span style="font-family:inherit;font-size:9pt;">Form of Common Stock Certificate</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">S-1/A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">333-193154</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">February 3, 2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1479290/000119312520038556/d889444dex41.htm"><span style="font-family:inherit;font-size:9pt;">Indenture, dated as of February 14, 2020, by and between Revance Therapeutics, Inc. and U.S. Bank National Association, as Trustee</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-36297</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">February 14, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1479290/000119312520038556/d889444dex41.htm"><span style="font-family:inherit;font-size:9pt;">Form of Global Note, representing Revance Therapeutics, Inc.’s 1.75% Convertible Senior Notes due 2027 (included as Exhibit A to the Indenture filed as Exhibit 4.2)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-36297</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">February 14, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.1*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1479290/000147929020000042/fy1910-kex1027director.htm"><span style="font-family:inherit;font-size:9pt;">Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-36297 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.27</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">February 26, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.2*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1479290/000147929020000042/fy1910-kex1028mgtbonus.htm"><span style="font-family:inherit;font-size:9pt;">Revance Therapeutics, Inc. 2020 Management Bonus Plan</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-36297 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.28</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">February 26, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.3*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1479290/000147929020000042/fy1910-kex1041executiv.htm"><span style="font-family:inherit;font-size:9pt;">Separation Agreement effective January 8, 2020 by and between Revance Therapeutics, Inc. and Caryn G. McDowell</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-36297 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.41</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">February 26, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.4*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1479290/000147929020000042/fy1910-kex1042revancex.htm"><span style="font-family:inherit;font-size:9pt;">Executive Employment Agreement dated February 17, 2020 by and between Revance Therapeutics, Inc. and Dwight Moxie</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-36297 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.42</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">February 26, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.5+</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1479290/000147929020000042/fy1910-kexhibit1043teo.htm"><span style="font-family:inherit;font-size:9pt;">Exclusive Distribution Agreement, dated January 10, 2020, by and between Revance Therapeutics, Inc. and Teoxane SA</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">001-36297 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10.43</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">February 26, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">31.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="rvnc-q120exhibit311.htm"><span style="font-family:inherit;font-size:9pt;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) promulgated under the Exchange Act</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">31.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="rvnc-q120exhibit312.htm"><span style="font-family:inherit;font-size:9pt;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) promulgated under the Exchange Act</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32.1†</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="rvnc-q120exhibit321.htm"><span style="font-family:inherit;font-size:9pt;">Certification of the Principal Executive Officer pursuant to18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">32.2†</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="rvnc-q120exhibit322.htm"><span style="font-family:inherit;font-size:9pt;">Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.SCH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Schema Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.DEF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibits 101)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">X</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Indicates a management contract or compensatory plan or arrangement.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">+ </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Portions of this exhibit (indicated by asterisks) have been omitted as the registrant has determined that (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm to the registrant if publicly disclosed.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">† </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, and shall not be deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Exchange Act. Such certifications shall not be deemed incorporated by reference into any filing of Revance Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">85</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><hr style="page-break-after:always"></hr><div><a id="s328F12C490B21E66EA5E16CE11751B67"></a></div><div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:54%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">REVANCE THERAPEUTICS, INC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: May 7, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Mark J. Foley</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Mark J. Foley</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(Duly Authorized Principal Executive Officer)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Tobin C. Schilke</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Tobin C. Schilke</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Financial Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(Duly Authorized Principal Financial Officer and Principal Accounting Officer)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div> </div></body> </html> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.1 <SEQUENCE>2 <FILENAME>rvnc-q120exhibit311.htm <DESCRIPTION>EXHIBIT 31.1 <TEXT> <!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <html> <head> <!-- Document created using Wdesk 1 --> <!-- Copyright 2020 Workiva --> <title>Exhibit</title> </head> <body><div style="font-family:Times New Roman;font-size:10pt;"> <div><a name="s3D02CD92A7EB55A671DB16CE29DA3621"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Mark J. Foley, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Form 10-Q of Revance Therapeutics, Inc.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:41px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">May 7, 2020</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark J. Foley</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mark J. Foley</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(Duly Authorized Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.2 <SEQUENCE>3 <FILENAME>rvnc-q120exhibit312.htm <DESCRIPTION>EXHIBIT 31.2 <TEXT> <!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <html> <head> <!-- Document created using Wdesk 1 --> <!-- Copyright 2020 Workiva --> <title>Exhibit</title> </head> <body><div style="font-family:Times New Roman;font-size:10pt;"> <div><a name="s5CC0A9E071C572FE319016CE2A85681E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Tobin C. Schilke, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Form 10-Q of Revance Therapeutics, Inc.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">May 7, 2020</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Tobin C. Schilke</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tobin C. Schilke</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(Duly Authorized Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-32.1 <SEQUENCE>4 <FILENAME>rvnc-q120exhibit321.htm <DESCRIPTION>EXHIBIT 32.1 <TEXT> <!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <html> <head> <!-- Document created using Wdesk 1 --> <!-- Copyright 2020 Workiva --> <title>Exhibit</title> </head> <body><div style="font-family:Times New Roman;font-size:10pt;"> <div><a name="s0FD57708BB17C5CAA68516CE2B31C6DA"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Mark J. Foley, Chief Executive Officer of Revance Therapeutics, Inc. (the “Company”), hereby certifies that, to the best of his knowledge: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s Quarterly Report on Form 10-Q for the period ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;">, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: </font><font style="font-family:inherit;font-size:10pt;">May 7, 2020</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">I</font><font style="font-family:inherit;font-size:7pt;font-weight:bold;">N</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> W</font><font style="font-family:inherit;font-size:7pt;font-weight:bold;">ITNESS</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> W</font><font style="font-family:inherit;font-size:7pt;font-weight:bold;">HEREOF</font><font style="font-family:inherit;font-size:10pt;">, the undersigned has set his hands hereto as of the 7</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;"> day of May, 2020. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Mark J. Foley</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Mark J. Foley</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(Duly Authorized Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Revance Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-32.2 <SEQUENCE>5 <FILENAME>rvnc-q120exhibit322.htm <DESCRIPTION>EXHIBIT 32.2 <TEXT> <!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"> <html> <head> <!-- Document created using Wdesk 1 --> <!-- Copyright 2020 Workiva --> <title>Exhibit</title> </head> <body><div style="font-family:Times New Roman;font-size:10pt;"> <div><a name="s354520A5301CD07A074116CE2BCDBC87"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.2 </font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Tobin C. Schilke, Chief Financial Officer of Revance Therapeutics, Inc. (the “Company”), hereby certifies that, to the best of his knowledge: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s Quarterly Report on Form 10-Q for the period ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2020</font><font style="font-family:inherit;font-size:10pt;">, to which this Certification is attached as Exhibit 32.2 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:1px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: </font><font style="font-family:inherit;font-size:10pt;">May 7, 2020</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">I</font><font style="font-family:inherit;font-size:7pt;font-weight:bold;">N</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> W</font><font style="font-family:inherit;font-size:7pt;font-weight:bold;">ITNESS</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> W</font><font style="font-family:inherit;font-size:7pt;font-weight:bold;">HEREOF</font><font style="font-family:inherit;font-size:10pt;">, the undersigned has set his hands hereto as of the 7</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:10pt;"> day of May, 2020. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Tobin C. Schilke</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Tobin C. Schilke</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(Duly Authorized Principal Financial Officer and Principal Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Revance Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.SCH <SEQUENCE>6 <FILENAME>rvnc-20200331.xsd <DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!--XBRL Document Created with Wdesk from Workiva--> <!-- --> <xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.revance.com/20200331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:rvnc="http://www.revance.com/20200331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema"> <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" /> <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" /> <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" /> <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" /> <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" /> <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" /> <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" /> <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" /> <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" /> <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" /> <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" /> <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" /> <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" /> <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" /> <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" /> <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" /> <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" /> <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" /> <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" /> <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" /> <xsd:annotation> <xsd:appinfo> <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" /> <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" /> <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" /> <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rvnc-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" /> <link:roleType id="CashEquivalentsAndShortTermInvestments" roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestments"> <link:definition>2103100 - Disclosure - Cash Equivalents and Short-Term Investments</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CashEquivalentsAndShortTermInvestmentsDetail" roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail"> <link:definition>2403402 - Disclosure - Cash Equivalents and Short-Term Investments (Detail)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CashEquivalentsAndShortTermInvestmentsTables" roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsTables"> <link:definition>2303301 - Disclosure - Cash Equivalents and Short-Term Investments (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.revance.com/role/CommitmentsAndContingencies"> <link:definition>2110100 - Disclosure - Commitments and Contingencies</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"> <link:definition>2410401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CompanyAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies"> <link:definition>2101100 - Disclosure - The Company and Summary of Significant Accounting Policies</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"> <link:definition>2401402 - Disclosure - The Company and Summary of Significant Accounting Policies- Additional Information (Detail)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies"> <link:definition>2201201 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited"> <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"> <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" roleURI="http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited"> <link:definition>1002000 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"> <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited"> <link:definition>1003000 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical"> <link:definition>1003001 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="ConvertibleSeniorNotes" roleURI="http://www.revance.com/role/ConvertibleSeniorNotes"> <link:definition>2107100 - Disclosure - Convertible Senior Notes</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="ConvertibleSeniorNotesCappedCallTransactionsDetails" roleURI="http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails"> <link:definition>2407405 - Disclosure - Convertible Senior Notes - Capped Call Transactions (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" roleURI="http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails"> <link:definition>2407404 - Disclosure - Convertible Senior Notes - Carrying Amount of Liability Component (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="ConvertibleSeniorNotesDetails" roleURI="http://www.revance.com/role/ConvertibleSeniorNotesDetails"> <link:definition>2407402 - Disclosure - Convertible Senior Notes (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="ConvertibleSeniorNotesInterestExpenseDetails" roleURI="http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails"> <link:definition>2407403 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="ConvertibleSeniorNotesTables" roleURI="http://www.revance.com/role/ConvertibleSeniorNotesTables"> <link:definition>2307301 - Disclosure - Convertible Senior Notes (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="CoverPage" roleURI="http://www.revance.com/role/CoverPage"> <link:definition>0001000 - Document - Cover Page</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="DerivativeLiability" roleURI="http://www.revance.com/role/DerivativeLiability"> <link:definition>2105100 - Disclosure - Derivative Liability</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="DerivativeLiabilityAdditionalInformationDetail" roleURI="http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail"> <link:definition>2405401 - Disclosure - Derivative Liability - Additional Information (Detail)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="FairValueMeasurements" roleURI="http://www.revance.com/role/FairValueMeasurements"> <link:definition>2109100 - Disclosure - Fair Value Measurements</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" roleURI="http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail"> <link:definition>2409402 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" roleURI="http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail"> <link:definition>2409403 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.revance.com/role/FairValueMeasurementsTables"> <link:definition>2309301 - Disclosure - Fair Value Measurements (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="FillerDistributionAgreement" roleURI="http://www.revance.com/role/FillerDistributionAgreement"> <link:definition>2104100 - Disclosure - Filler Distribution Agreement</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="FillerDistributionAgreementDistributionsRightsDetails" roleURI="http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails"> <link:definition>2404403 - Disclosure - Filler Distribution Agreement - Distributions Rights (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="FillerDistributionAgreementNarrativeDetails" roleURI="http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails"> <link:definition>2404402 - Disclosure - Filler Distribution Agreement - Narrative (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="FillerDistributionAgreementTables" roleURI="http://www.revance.com/role/FillerDistributionAgreementTables"> <link:definition>2304301 - Disclosure - Filler Distribution Agreement (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="Leases" roleURI="http://www.revance.com/role/Leases"> <link:definition>2106100 - Disclosure - Leases</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="LeasesLeasesDetails" roleURI="http://www.revance.com/role/LeasesLeasesDetails"> <link:definition>2406402 - Disclosure - Leases Leases (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="LeasesLeasesOperatingLeaseCostsDetails" roleURI="http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails"> <link:definition>2406403 - Disclosure - Leases Leases - Operating Lease Costs (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" roleURI="http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails"> <link:definition>2406404 - Disclosure - Leases Leases - Operating Lease Liability Maturities (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="LeasesLeasesOperatingLeaseLiabilityMaturitiesDetailsCalc2" roleURI="http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetailsCalc2"> <link:definition>2406404 - Disclosure - Leases Leases - Operating Lease Liability Maturities (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="LeasesLeasesSupplementalCashFlowInformationDetails" roleURI="http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails"> <link:definition>2406406 - Disclosure - Leases Leases - Supplemental Cash Flow Information (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="LeasesLeasesTables" roleURI="http://www.revance.com/role/LeasesLeasesTables"> <link:definition>2306301 - Disclosure - Leases Leases (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="Revenue" roleURI="http://www.revance.com/role/Revenue"> <link:definition>2102100 - Disclosure - Revenue</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="RevenueDetails" roleURI="http://www.revance.com/role/RevenueDetails"> <link:definition>2402401 - Disclosure - Revenue (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="StockholdersEquityAndStockBasedCompensation" roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensation"> <link:definition>2108100 - Disclosure - Stockholders' Equity and Stock-Based Compensation</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails"> <link:definition>2408403 - Disclosure - Stockholders' Equity and Stock-Based Compensation - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails"> <link:definition>2408402 - Disclosure - Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Additional Information (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails"> <link:definition>2408404 - Disclosure - Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Schedule of Stock-based Compensation Expense (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType id="StockholdersEquityAndStockBasedCompensationTables" roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationTables"> <link:definition>2308301 - Disclosure - Stockholders' Equity and Stock-Based Compensation (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> </xsd:appinfo> </xsd:annotation> <xsd:element id="rvnc_AccruedMilestoneObligations" name="AccruedMilestoneObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" /> <xsd:element id="rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions" name="AdjustmentToAdditionalPaidInCapitalCappedCallTransactions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_AttheMarketOfferingMember" name="AttheMarketOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_BioSentinelInc.Member" name="BioSentinelInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_BotulinumToxinResearchAssociatesInc.Member" name="BotulinumToxinResearchAssociatesInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments" name="CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" /> <xsd:element id="rvnc_CappedCallsPremiumPercentageOverSalePrice" name="CappedCallsPremiumPercentageOverSalePrice" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_CappedCallsPriceCap" name="CappedCallsPriceCap" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" /> <xsd:element id="rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum" name="CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_CollaborativeAgreementContractualPeriod" name="CollaborativeAgreementContractualPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_CollaborativeAgreementExtendedContractualPeriod" name="CollaborativeAgreementExtendedContractualPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_ContingentLicensingRoyaltyRevenue" name="ContingentLicensingRoyaltyRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" /> <xsd:element abstract="true" id="rvnc_DebtConversionTermsOneMember" name="DebtConversionTermsOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_DebtConversionTermsTwoMember" name="DebtConversionTermsTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_DebtInstrumentConvertibleTermsOfConversionAxis" name="DebtInstrumentConvertibleTermsOfConversionAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_DebtInstrumentConvertibleTermsOfConversionDomain" name="DebtInstrumentConvertibleTermsOfConversionDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" name="DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_DebtIssuanceCostsGrossEquityComponent" name="DebtIssuanceCostsGrossEquityComponent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" /> <xsd:element id="rvnc_DebtIssuanceCostsGrossLiabilityComponent" name="DebtIssuanceCostsGrossLiabilityComponent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" /> <xsd:element abstract="true" id="rvnc_DerivativeLiabilitySettlementMember" name="DerivativeLiabilitySettlementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_DevelopmentServicesMember" name="DevelopmentServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_ESPPPurchasesMember" name="ESPPPurchasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_EquityComponentOfConvertibleDebtTransactionCost" name="EquityComponentOfConvertibleDebtTransactionCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" /> <xsd:element id="rvnc_FairValueMeasurementInput" name="FairValueMeasurementInput" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_FairValueMeasurementInputDuration" name="FairValueMeasurementInputDuration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_FollowOnOfferingMember" name="FollowOnOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_ForeignWithholdingTaxAmount" name="ForeignWithholdingTaxAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" /> <xsd:element id="rvnc_GainLossonDerivativeInstrumentsContractNetPretax" name="GainLossonDerivativeInstrumentsContractNetPretax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" /> <xsd:element id="rvnc_IncreaseDecreaseinOperatingLeaseLiabilities" name="IncreaseDecreaseinOperatingLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" /> <xsd:element id="rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets" name="IncreaseDecreaseinOperatingLeaseRightofUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" /> <xsd:element id="rvnc_IndemnificationLiabilityRecordedduringPeriod" name="IndemnificationLiabilityRecordedduringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" /> <xsd:element id="rvnc_LesseeSupplementalCashFlowInformationTableTextBlock" name="LesseeSupplementalCashFlowInformationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_ListLaboratoriesMember" name="ListLaboratoriesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_MedicisPharmaceuticalCorporationMember" name="MedicisPharmaceuticalCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_MylanIrelandLimitedMember" name="MylanIrelandLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" name="NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" /> <xsd:element id="rvnc_NoncashDeferredOfferingCosts" name="NoncashDeferredOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" /> <xsd:element id="rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount" name="ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" /> <xsd:element id="rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue" name="RevenueRecognitionMilestoneMethodMaximumRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" /> <xsd:element id="rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum" name="SaleofStockIssuanceCostsCommissionPercentageMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_SettlementAndTerminationLineItems" name="SettlementAndTerminationLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" name="ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum" name="StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" /> <xsd:element id="rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants" name="StockIssuedDuringPeriodSharesExerciseofWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased" name="StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased" name="StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_TeoxaneAgreementMember" name="TeoxaneAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_TwentyTwentySevenNotesMember" name="TwentyTwentySevenNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" name="TwoThousandAndFourteenEquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_TwoThousandAndFourteenInducementPlanMember" name="TwoThousandAndFourteenInducementPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element abstract="true" id="rvnc_ValeantPharmaceuticalsInternationalInc.Member" name="ValeantPharmaceuticalsInternationalInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" /> <xsd:element id="rvnc_WorkingCapitalSurplus" name="WorkingCapitalSurplus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" /> </xsd:schema> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.CAL <SEQUENCE>7 <FILENAME>rvnc-20200331_cal.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!--XBRL Document Created with Wdesk from Workiva--> <!-- --> <link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"> <link:roleRef roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestments" xlink:href="rvnc-20200331.xsd#CashEquivalentsAndShortTermInvestments" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" xlink:href="rvnc-20200331.xsd#CashEquivalentsAndShortTermInvestmentsDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:href="rvnc-20200331.xsd#CashEquivalentsAndShortTermInvestmentsTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CommitmentsAndContingencies" xlink:href="rvnc-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="rvnc-20200331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="rvnc-20200331.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="rvnc-20200331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rvnc-20200331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotes" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotes" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesCappedCallTransactionsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesTables" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CoverPage" xlink:href="rvnc-20200331.xsd#CoverPage" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/DerivativeLiability" xlink:href="rvnc-20200331.xsd#DerivativeLiability" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" xlink:href="rvnc-20200331.xsd#DerivativeLiabilityAdditionalInformationDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurements" xlink:href="rvnc-20200331.xsd#FairValueMeasurements" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" xlink:href="rvnc-20200331.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" xlink:href="rvnc-20200331.xsd#FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurementsTables" xlink:href="rvnc-20200331.xsd#FairValueMeasurementsTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreement" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreement" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreementDistributionsRightsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreementNarrativeDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreementTables" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreementTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/Leases" xlink:href="rvnc-20200331.xsd#Leases" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesOperatingLeaseCostsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetailsCalc2" xlink:href="rvnc-20200331.xsd#LeasesLeasesOperatingLeaseLiabilityMaturitiesDetailsCalc2" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesSupplementalCashFlowInformationDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesTables" xlink:href="rvnc-20200331.xsd#LeasesLeasesTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/Revenue" xlink:href="rvnc-20200331.xsd#Revenue" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/RevenueDetails" xlink:href="rvnc-20200331.xsd#RevenueDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensation" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensation" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationTables" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationTables" xlink:type="simple" /> <link:calculationLink xlink:role="http://www.revance.com/role/CashEquivalentsAndShortTermInvestments" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" /> <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" /> </link:calculationLink> <link:calculationLink xlink:role="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/CommitmentsAndContingencies" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_e3a9f6af-c6ea-b2aa-5261-e372c3b13e26" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_e3a9f6af-c6ea-b2aa-5261-e372c3b13e26" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" /> <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_293ecac9-0396-b0f6-2701-a4671048537d" xlink:type="locator" /> <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_293ecac9-0396-b0f6-2701-a4671048537d" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" /> <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" /> <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_c2051fc9-6e3c-3055-fde4-401ea0dbd57b" xlink:type="locator" /> <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_c2051fc9-6e3c-3055-fde4-401ea0dbd57b" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="loc_us-gaap_SeniorLongTermNotes_ad947d1a-1b7e-edb4-f141-360afe26c702" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_SeniorLongTermNotes_ad947d1a-1b7e-edb4-f141-360afe26c702" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" /> <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9a00ddef-ccc2-f99c-735a-66b1e1849bbf" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9a00ddef-ccc2-f99c-735a-66b1e1849bbf" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" /> <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" /> </link:calculationLink> <link:calculationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_bb3ca310-54c5-4e0d-b64d-c788b99f29c6" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_bb3ca310-54c5-4e0d-b64d-c788b99f29c6" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_bb3ca310-54c5-4e0d-b64d-c788b99f29c6" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="locator" /> <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_Revenues_425ada39-f194-a279-47ac-dd09cf899fb1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_6cb44edd-e583-5e13-0d25-26cd54dcda09" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_bb3ca310-54c5-4e0d-b64d-c788b99f29c6" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_6cb44edd-e583-5e13-0d25-26cd54dcda09" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" /> <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_bb3ca310-54c5-4e0d-b64d-c788b99f29c6" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_GainLossonDerivativeInstrumentsContractNetPretax" xlink:label="loc_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_61205692-38ba-41c0-2861-ebfdae91056d" xlink:type="locator" /> <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_bb3ca310-54c5-4e0d-b64d-c788b99f29c6" xlink:to="loc_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_61205692-38ba-41c0-2861-ebfdae91056d" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" /> <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_bb3ca310-54c5-4e0d-b64d-c788b99f29c6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" /> <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="arc" /> </link:calculationLink> <link:calculationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ef5710e3-3727-237d-7e98-9d98fe0017fc" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c839a0d8-dfea-e1a5-fc91-ef95e7aed9cb" xlink:type="locator" /> <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c839a0d8-dfea-e1a5-fc91-ef95e7aed9cb" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" /> <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94f5ae99-7bd8-4f8c-5311-9522abc2f1bd" xlink:type="locator" /> <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94f5ae99-7bd8-4f8c-5311-9522abc2f1bd" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" /> <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" /> <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" /> <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets" xlink:label="loc_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_baaa80ad-7bc5-52de-b217-ebfdae549a4c" xlink:type="locator" /> <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_baaa80ad-7bc5-52de-b217-ebfdae549a4c" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_596f4189-155d-4012-cbaf-764843162122" xlink:type="locator" /> <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_596f4189-155d-4012-cbaf-764843162122" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="locator" /> <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_98295987-9a25-45fa-2afd-dec7faffd47b" xlink:type="locator" /> <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_98295987-9a25-45fa-2afd-dec7faffd47b" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="locator" /> <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_IncreaseDecreaseinOperatingLeaseLiabilities" xlink:label="loc_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_2c630997-ad30-8e8c-2d54-ebfdae9b59ef" xlink:type="locator" /> <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_2c630997-ad30-8e8c-2d54-ebfdae9b59ef" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_64589f54-c78b-3b4d-2741-1fc26cfb953a" xlink:type="locator" /> <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_64589f54-c78b-3b4d-2741-1fc26cfb953a" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" /> <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="locator" /> <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_36fa2e8f-8278-9ee7-fcfb-31ef0fe41d05" xlink:type="locator" /> <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_36fa2e8f-8278-9ee7-fcfb-31ef0fe41d05" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_0ccd9808-af25-d5c0-92fa-163b4b743159" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_0ccd9808-af25-d5c0-92fa-163b4b743159" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount" xlink:label="loc_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_3dbed2f7-94b2-f32d-8179-ebfdae6e0f14" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_3dbed2f7-94b2-f32d-8179-ebfdae6e0f14" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_5555695e-df0b-7c90-2b32-778881453620" xlink:type="locator" /> <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_5555695e-df0b-7c90-2b32-778881453620" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d03b640f-8d2c-4108-a1c4-1354103a7ee2" xlink:type="locator" /> <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d03b640f-8d2c-4108-a1c4-1354103a7ee2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="locator" /> <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5df585f7-cbd5-fdda-5710-23eacb1392b0" xlink:type="locator" /> <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5df585f7-cbd5-fdda-5710-23eacb1392b0" xlink:type="arc" /> </link:calculationLink> <link:calculationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotes" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b5390da0-4b10-f083-5d88-d4657fa5b028" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b5390da0-4b10-f083-5d88-d4657fa5b028" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b203031c-861c-8c5e-65f5-f1b72d84dfd1" xlink:type="locator" /> <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b203031c-861c-8c5e-65f5-f1b72d84dfd1" xlink:type="arc" /> </link:calculationLink> <link:calculationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesDetails" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8707b686-ab67-5afd-96da-fedb3cce1b93" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8707b686-ab67-5afd-96da-fedb3cce1b93" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_a4567c23-eef7-473f-21b3-15ac8f57524e" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_a4567c23-eef7-473f-21b3-15ac8f57524e" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_149d6655-b7f8-5049-ef74-296db479f8f9" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_149d6655-b7f8-5049-ef74-296db479f8f9" xlink:type="arc" /> </link:calculationLink> <link:calculationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesTables" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/CoverPage" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/DerivativeLiability" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/FairValueMeasurements" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/FairValueMeasurementsTables" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/FillerDistributionAgreement" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/FillerDistributionAgreementTables" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/Leases" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/LeasesLeasesDetails" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="arc" /> </link:calculationLink> <link:calculationLink xlink:role="http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" /> <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" /> <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" /> <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" /> <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" /> </link:calculationLink> <link:calculationLink xlink:role="http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetailsCalc2" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30010AE5ADDC1FCEB0C09DEC93050541_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_30010AE5ADDC1FCEB0C09DEC93050541_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" /> <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30010AE5ADDC1FCEB0C09DEC93050541_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_30010AE5ADDC1FCEB0C09DEC93050541_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_30010AE5ADDC1FCEB0C09DEC93050541_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" /> <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_30010AE5ADDC1FCEB0C09DEC93050541_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_30010AE5ADDC1FCEB0C09DEC93050541_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" /> </link:calculationLink> <link:calculationLink xlink:role="http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/LeasesLeasesTables" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/Revenue" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/RevenueDetails" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensation" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended" /> <link:calculationLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationTables" xlink:type="extended" /> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.DEF <SEQUENCE>8 <FILENAME>rvnc-20200331_def.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!--XBRL Document Created with Wdesk from Workiva--> <!-- --> <link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"> <link:roleRef roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestments" xlink:href="rvnc-20200331.xsd#CashEquivalentsAndShortTermInvestments" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" xlink:href="rvnc-20200331.xsd#CashEquivalentsAndShortTermInvestmentsDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:href="rvnc-20200331.xsd#CashEquivalentsAndShortTermInvestmentsTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CommitmentsAndContingencies" xlink:href="rvnc-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="rvnc-20200331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="rvnc-20200331.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="rvnc-20200331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rvnc-20200331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotes" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotes" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesCappedCallTransactionsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesTables" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CoverPage" xlink:href="rvnc-20200331.xsd#CoverPage" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/DerivativeLiability" xlink:href="rvnc-20200331.xsd#DerivativeLiability" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" xlink:href="rvnc-20200331.xsd#DerivativeLiabilityAdditionalInformationDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurements" xlink:href="rvnc-20200331.xsd#FairValueMeasurements" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" xlink:href="rvnc-20200331.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" xlink:href="rvnc-20200331.xsd#FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurementsTables" xlink:href="rvnc-20200331.xsd#FairValueMeasurementsTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreement" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreement" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreementDistributionsRightsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreementNarrativeDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreementTables" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreementTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/Leases" xlink:href="rvnc-20200331.xsd#Leases" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesOperatingLeaseCostsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesSupplementalCashFlowInformationDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesTables" xlink:href="rvnc-20200331.xsd#LeasesLeasesTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/Revenue" xlink:href="rvnc-20200331.xsd#Revenue" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/RevenueDetails" xlink:href="rvnc-20200331.xsd#RevenueDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensation" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensation" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationTables" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationTables" xlink:type="simple" /> <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" /> <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" /> <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" /> <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" /> <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" /> <link:definitionLink xlink:role="http://www.revance.com/role/CashEquivalentsAndShortTermInvestments" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E3142312802C2BCBA8C99DEC9361931E" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E3142312802C2BCBA8C99DEC9361931E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E3142312802C2BCBA8C99DEC9361931E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E3142312802C2BCBA8C99DEC9361931E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_92296FC73EFC1EC2109A9DEC9362DBC7" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_92296FC73EFC1EC2109A9DEC9362DBC7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0EBF0935F0EF68A2B65B9DEC9363841C" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0EBF0935F0EF68A2B65B9DEC9363841C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_519CCF9D3A6107DE053D9DEC9363FDAF" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_519CCF9D3A6107DE053D9DEC9363FDAF" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_41AB881B95ED50E644F19DEC9363C3BA" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:to="loc_us-gaap_CommercialPaperMember_41AB881B95ED50E644F19DEC9363C3BA" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_BB004BAB7F3A166F45349DEC93636C2C" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_BB004BAB7F3A166F45349DEC93636C2C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_AC4DAAE150DDB5B102DB9DEC93644C9B" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_AC4DAAE150DDB5B102DB9DEC93644C9B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_60326EDD381050C6DABE9DEC9364382A_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_AC4DAAE150DDB5B102DB9DEC93644C9B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_60326EDD381050C6DABE9DEC9364382A_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_60326EDD381050C6DABE9DEC9364382A" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_AC4DAAE150DDB5B102DB9DEC93644C9B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_60326EDD381050C6DABE9DEC9364382A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_6B5FFB480494EC55D4A99DEC9364EA32" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_60326EDD381050C6DABE9DEC9364382A" xlink:to="loc_us-gaap_CashEquivalentsMember_6B5FFB480494EC55D4A99DEC9364EA32" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_CC575373C47DFBF1802A9DEC9365FF38" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_60326EDD381050C6DABE9DEC9364382A" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_CC575373C47DFBF1802A9DEC9365FF38" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5FA638AAFD1E242CBD99DEC93669924" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5FA638AAFD1E242CBD99DEC93669924" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C93BF647C71F9BBD5E779DEC9366A08F" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C93BF647C71F9BBD5E779DEC9366A08F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1D0C3EE72D78E9DF1B0D9DEC93662557" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1D0C3EE72D78E9DF1B0D9DEC93662557" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE4E61FEFA8BB60AE4869DEC9367F016" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE4E61FEFA8BB60AE4869DEC9367F016" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_57CBA01D4F2ACD4CF5039DEC93678499" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_57CBA01D4F2ACD4CF5039DEC93678499" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/CommitmentsAndContingencies" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:to="loc_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_BotulinumToxinResearchAssociatesInc.Member" xlink:label="loc_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058" xlink:to="loc_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6D28920673E28FE1EA249DEC92DE2A1A" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6D28920673E28FE1EA249DEC92DE2A1A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5726A9C3F5C13299710C9DEC92DE8B94" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5726A9C3F5C13299710C9DEC92DE8B94" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5726A9C3F5C13299710C9DEC92DE8B94" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5726A9C3F5C13299710C9DEC92DE8B94" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TeoxaneAgreementMember" xlink:label="loc_rvnc_TeoxaneAgreementMember_30784FEB0E25C7D9E2239EC6483E451F" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:to="loc_rvnc_TeoxaneAgreementMember_30784FEB0E25C7D9E2239EC6483E451F" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ListLaboratoriesMember" xlink:label="loc_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:to="loc_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_BotulinumToxinResearchAssociatesInc.Member" xlink:label="loc_rvnc_BotulinumToxinResearchAssociatesInc.Member_A9EF8E68BC4F5B63B7599DEC92E06A57" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:to="loc_rvnc_BotulinumToxinResearchAssociatesInc.Member_A9EF8E68BC4F5B63B7599DEC92E06A57" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_BioSentinelInc.Member" xlink:label="loc_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:to="loc_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditRiskContractMember" xlink:label="loc_us-gaap_CreditRiskContractMember_4CD8D4C50650CC7EA1329DEC92E26844" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7" xlink:to="loc_us-gaap_CreditRiskContractMember_4CD8D4C50650CC7EA1329DEC92E26844" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CollaborativeAgreementContractualPeriod" xlink:label="loc_rvnc_CollaborativeAgreementContractualPeriod_3FE8BFAE207653540F829EC647BAB5C3" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="loc_rvnc_CollaborativeAgreementContractualPeriod_3FE8BFAE207653540F829EC647BAB5C3" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CollaborativeAgreementExtendedContractualPeriod" xlink:label="loc_rvnc_CollaborativeAgreementExtendedContractualPeriod_C8162A68A95A05959A519ECF5641F330" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="loc_rvnc_CollaborativeAgreementExtendedContractualPeriod_C8162A68A95A05959A519ECF5641F330" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AccruedMilestoneObligations" xlink:label="loc_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="loc_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_1D2C99A2508101273B579DEC92E4287F" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_1D2C99A2508101273B579DEC92E4287F" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_IndemnificationLiabilityRecordedduringPeriod" xlink:label="loc_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="loc_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A" xlink:to="loc_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_003D98FA4ECE750DCD18E627CC7872C3" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_003D98FA4ECE750DCD18E627CC7872C3" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_003D98FA4ECE750DCD18E627CC7872C3" xlink:to="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_003D98FA4ECE750DCD18E627CC7872C3" xlink:to="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2978E893C86C5AC8949CE627CC783BD8" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:to="loc_us-gaap_CommonStockMember_2978E893C86C5AC8949CE627CC783BD8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_365CCAB69FB894E50598E627CC797642" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_365CCAB69FB894E50598E627CC797642" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72D9F60C37B1C0E60B6BE627CC79F4FE" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72D9F60C37B1C0E60B6BE627CC79F4FE" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_920314E4C2DC0DFAA564E627CC796CB4" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:to="loc_us-gaap_RetainedEarningsMember_920314E4C2DC0DFAA564E627CC796CB4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9216B93F16A280A0C7B7E627CC7A4636" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9216B93F16A280A0C7B7E627CC7A4636" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_243066B1F132E3120DF2E627CC7A15B4" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockholdersEquity_243066B1F132E3120DF2E627CC7A15B4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_4C4C546D4C8D64708649E627CC7AD160" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_4C4C546D4C8D64708649E627CC7AD160" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1312279B31E9C72D0D21E627CC7AF081" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1312279B31E9C72D0D21E627CC7AF081" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased" xlink:label="loc_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased" xlink:label="loc_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB" xlink:type="locator" /> <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07430BC45C0FC2C2B226E627CC7BF486" xlink:type="locator" /> <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07430BC45C0FC2C2B226E627CC7BF486" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9B3588110AA3B6A02FFFE627CC7B2010" xlink:type="locator" /> <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9B3588110AA3B6A02FFFE627CC7B2010" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B79CD62D2A0CFD8886E0E627CC7B9C87" xlink:type="locator" /> <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B79CD62D2A0CFD8886E0E627CC7B9C87" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_09C031797D466857960EE627CC7BD90D" xlink:type="locator" /> <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_09C031797D466857960EE627CC7BD90D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9FB87F2D789C29E1D0E3E627CC7B1CC4" xlink:type="locator" /> <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9FB87F2D789C29E1D0E3E627CC7B1CC4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D56C37DB5EE1449AA9AAE627CC7CFDF2" xlink:type="locator" /> <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D56C37DB5EE1449AA9AAE627CC7CFDF2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0EED978D7EEFDCF2AEDDE627CC7CF874" xlink:type="locator" /> <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0EED978D7EEFDCF2AEDDE627CC7CF874" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions" xlink:label="loc_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336" xlink:type="locator" /> <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5B36F14325539D762D93E627CC7CE052" xlink:type="locator" /> <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5B36F14325539D762D93E627CC7CE052" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D08E5C14ACCDDCCEBD97E627CC7C4646" xlink:type="locator" /> <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D08E5C14ACCDDCCEBD97E627CC7C4646" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_45934276991D6E8F5693E627CC7CE771" xlink:type="locator" /> <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_NetIncomeLoss_45934276991D6E8F5693E627CC7CE771" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_715681E27B7ED30878B6A002E31BEBED" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_666409343C618E8304B6A002E30C1ED9" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_715681E27B7ED30878B6A002E31BEBED" xlink:to="loc_us-gaap_StatementTable_666409343C618E8304B6A002E30C1ED9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_39B42D882C105426D744A002FF2EF609" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_666409343C618E8304B6A002E30C1ED9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_39B42D882C105426D744A002FF2EF609" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F2CDCE00B7156D1A4DEA002FF2F6A2B_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_39B42D882C105426D744A002FF2EF609" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F2CDCE00B7156D1A4DEA002FF2F6A2B_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F2CDCE00B7156D1A4DEA002FF2F6A2B" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_39B42D882C105426D744A002FF2EF609" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F2CDCE00B7156D1A4DEA002FF2F6A2B" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_FollowOnOfferingMember" xlink:label="loc_rvnc_FollowOnOfferingMember_C88D4B90F41EF540333DA004FE2A6701" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F2CDCE00B7156D1A4DEA002FF2F6A2B" xlink:to="loc_rvnc_FollowOnOfferingMember_C88D4B90F41EF540333DA004FE2A6701" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_CD9A1A116E9912EDBA3C9FDB3EF871AA" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715681E27B7ED30878B6A002E31BEBED" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_CD9A1A116E9912EDBA3C9FDB3EF871AA" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_EquityComponentOfConvertibleDebtTransactionCost" xlink:label="loc_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_715681E27B7ED30878B6A002E31BEBED" xlink:to="loc_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotes" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="loc_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_94DDFA75577A02D5FBB7ECDE9A109781" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745" xlink:to="loc_us-gaap_ConvertibleDebtMember_94DDFA75577A02D5FBB7ECDE9A109781" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:to="loc_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwentyTwentySevenNotesMember" xlink:label="loc_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1" xlink:to="loc_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_57A5F3E463CCA9B2FBDFECD68129164B" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_57A5F3E463CCA9B2FBDFECD68129164B" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CappedCallsPriceCap" xlink:label="loc_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="loc_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CappedCallsPremiumPercentageOverSalePrice" xlink:label="loc_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="loc_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_2C583238236D8498EFF6ECDE99F1E73E" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_2C583238236D8498EFF6ECDE99F1E73E" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments" xlink:label="loc_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="loc_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E3F2B642869A033DB9CCEC729782BC56" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_B43B03BC8D2C2466A46CEC72978024DC" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E3F2B642869A033DB9CCEC729782BC56" xlink:to="loc_us-gaap_DebtInstrumentTable_B43B03BC8D2C2466A46CEC72978024DC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6CC8702DE6514B0E63A0EC72978166DC" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_B43B03BC8D2C2466A46CEC72978024DC" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6CC8702DE6514B0E63A0EC72978166DC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_C9BB4FDFFE2ED6548552EC729781B52B_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6CC8702DE6514B0E63A0EC72978166DC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_C9BB4FDFFE2ED6548552EC729781B52B_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_C9BB4FDFFE2ED6548552EC729781B52B" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6CC8702DE6514B0E63A0EC72978166DC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_C9BB4FDFFE2ED6548552EC729781B52B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_4AA63C1230CE81F935C2EC7297815EA2" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_C9BB4FDFFE2ED6548552EC729781B52B" xlink:to="loc_us-gaap_ConvertibleDebtMember_4AA63C1230CE81F935C2EC7297815EA2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_98014F1B0EA32BA1D57BEC729782E51B" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_B43B03BC8D2C2466A46CEC72978024DC" xlink:to="loc_us-gaap_DebtInstrumentAxis_98014F1B0EA32BA1D57BEC729782E51B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5FD0A0D6F479A1B57452EC72978202A7_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_98014F1B0EA32BA1D57BEC729782E51B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5FD0A0D6F479A1B57452EC72978202A7_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5FD0A0D6F479A1B57452EC72978202A7" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_98014F1B0EA32BA1D57BEC729782E51B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5FD0A0D6F479A1B57452EC72978202A7" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwentyTwentySevenNotesMember" xlink:label="loc_rvnc_TwentyTwentySevenNotesMember_A579A35C9D1FCF4B9DDAEC729782196F" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5FD0A0D6F479A1B57452EC72978202A7" xlink:to="loc_rvnc_TwentyTwentySevenNotesMember_A579A35C9D1FCF4B9DDAEC729782196F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9E363010A2C36778A40EEC7297837B18" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E3F2B642869A033DB9CCEC729782BC56" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9E363010A2C36778A40EEC7297837B18" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_C3B271DC3208963E058EEC729788C954" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E3F2B642869A033DB9CCEC729782BC56" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_C3B271DC3208963E058EEC729788C954" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_AB13292A6890F9C8BB6CEC729788CE47" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E3F2B642869A033DB9CCEC729782BC56" xlink:to="loc_us-gaap_LongTermDebt_AB13292A6890F9C8BB6CEC729788CE47" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1F099385161E5F5D5DF3EC729BE8469E" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentTable_1F099385161E5F5D5DF3EC729BE8469E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_B7D994C6C169AE19E0AEEC729BE9C217" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1F099385161E5F5D5DF3EC729BE8469E" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_B7D994C6C169AE19E0AEEC729BE9C217" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0B517DFDA109778D9EE3EC729BE953A1_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_B7D994C6C169AE19E0AEEC729BE9C217" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0B517DFDA109778D9EE3EC729BE953A1_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0B517DFDA109778D9EE3EC729BE953A1" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_B7D994C6C169AE19E0AEEC729BE9C217" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0B517DFDA109778D9EE3EC729BE953A1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_45A6B9A7767726565F77EC729BE9E46C" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0B517DFDA109778D9EE3EC729BE953A1" xlink:to="loc_us-gaap_ConvertibleDebtMember_45A6B9A7767726565F77EC729BE9E46C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8A1EA9DED1CBA3064424EC729BE92FF4" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1F099385161E5F5D5DF3EC729BE8469E" xlink:to="loc_us-gaap_DebtInstrumentAxis_8A1EA9DED1CBA3064424EC729BE92FF4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E60145930BE4BA6F14C4EC729BEAB9D7_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8A1EA9DED1CBA3064424EC729BE92FF4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E60145930BE4BA6F14C4EC729BEAB9D7_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E60145930BE4BA6F14C4EC729BEAB9D7" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8A1EA9DED1CBA3064424EC729BE92FF4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E60145930BE4BA6F14C4EC729BEAB9D7" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwentyTwentySevenNotesMember" xlink:label="loc_rvnc_TwentyTwentySevenNotesMember_319501202EF7B94DC78FEC729BEADA9F" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E60145930BE4BA6F14C4EC729BEAB9D7" xlink:to="loc_rvnc_TwentyTwentySevenNotesMember_319501202EF7B94DC78FEC729BEADA9F" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:label="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1F099385161E5F5D5DF3EC729BE8469E" xlink:to="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:label="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:to="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464_default" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:label="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:to="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtConversionTermsOneMember" xlink:label="loc_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:to="loc_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtConversionTermsTwoMember" xlink:label="loc_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:to="loc_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_D1BD64FCD0C7A4577FC2EC729BEB4999" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_D1BD64FCD0C7A4577FC2EC729BEB4999" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D92ACF9F03A0B6756AB3EC729BEBA55E" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D92ACF9F03A0B6756AB3EC729BEBA55E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_12BCB4D59C3AAFE9616BEC729BECEDE7" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_12BCB4D59C3AAFE9616BEC729BECEDE7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4660E9109556DCA01BC2EC729BEC0C61" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4660E9109556DCA01BC2EC729BEC0C61" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_E87E6424EC0281D07DBDEC729BECD4AB" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_E87E6424EC0281D07DBDEC729BECD4AB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_047CED478E58CE15A56AEC729BEC27C0" xlink:type="locator" /> <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_047CED478E58CE15A56AEC729BEC27C0" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" xlink:label="loc_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2" xlink:type="locator" /> <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_D4671F1331E0645A3DD2EC729BECB058" xlink:type="locator" /> <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_D4671F1331E0645A3DD2EC729BECB058" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_AC8AA3700EF2B21CDC5BEC729BED6BA2" xlink:type="locator" /> <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_AC8AA3700EF2B21CDC5BEC729BED6BA2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_0DAB0BA5CBA9F174EA0BEC729BED609E" xlink:type="locator" /> <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_0DAB0BA5CBA9F174EA0BEC729BED609E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6E250EA51497470C6B6CEC729BED14A6" xlink:type="locator" /> <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_LongTermDebt_6E250EA51497470C6B6CEC729BED14A6" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7D000BFC656926C92032EC729BED17D5" xlink:type="locator" /> <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7D000BFC656926C92032EC729BED17D5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7B42CFBAFF6F3521EB9EEC729BED8EF8" xlink:type="locator" /> <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7B42CFBAFF6F3521EB9EEC729BED8EF8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_8EDBC817323A362B460FEC729BEDAE65" xlink:type="locator" /> <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_8EDBC817323A362B460FEC729BEDAE65" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtIssuanceCostsGrossLiabilityComponent" xlink:label="loc_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C" xlink:type="locator" /> <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtIssuanceCostsGrossEquityComponent" xlink:label="loc_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB" xlink:type="locator" /> <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D02A873908BFE1703E5FEC7299F9B351" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_DebtInstrumentTable_D02A873908BFE1703E5FEC7299F9B351" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3051EC4895A1B0C23FC8EC7299F94E6F" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D02A873908BFE1703E5FEC7299F9B351" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3051EC4895A1B0C23FC8EC7299F94E6F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7729217DF1A2718330E6EC7299FA9999_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3051EC4895A1B0C23FC8EC7299F94E6F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7729217DF1A2718330E6EC7299FA9999_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7729217DF1A2718330E6EC7299FA9999" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3051EC4895A1B0C23FC8EC7299F94E6F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7729217DF1A2718330E6EC7299FA9999" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_62A6A8977529380104EFEC7299FA6FC8" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7729217DF1A2718330E6EC7299FA9999" xlink:to="loc_us-gaap_ConvertibleDebtMember_62A6A8977529380104EFEC7299FA6FC8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BA3958DFDC583354714BEC7299FB9EB0" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_D02A873908BFE1703E5FEC7299F9B351" xlink:to="loc_us-gaap_DebtInstrumentAxis_BA3958DFDC583354714BEC7299FB9EB0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5F0C24F5EE033AF13BC4EC7299FBC33F_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_BA3958DFDC583354714BEC7299FB9EB0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5F0C24F5EE033AF13BC4EC7299FBC33F_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5F0C24F5EE033AF13BC4EC7299FBC33F" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_BA3958DFDC583354714BEC7299FB9EB0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5F0C24F5EE033AF13BC4EC7299FBC33F" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwentyTwentySevenNotesMember" xlink:label="loc_rvnc_TwentyTwentySevenNotesMember_A54745BE885D967E4A59EC7299FB145A" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5F0C24F5EE033AF13BC4EC7299FBC33F" xlink:to="loc_rvnc_TwentyTwentySevenNotesMember_A54745BE885D967E4A59EC7299FB145A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_05DE047FC3987177A5C5EC7299FCC741" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_05DE047FC3987177A5C5EC7299FCC741" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_A6EF01FF4179FB73AC18EC7299FC8D4C" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_A6EF01FF4179FB73AC18EC7299FC8D4C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_C3D2921EBB7B4F0EB4A3EC7299FC7B78" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_C3D2921EBB7B4F0EB4A3EC7299FC7B78" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_DE47FD3A0E81FD7EAC80EC7299FD5BE3" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_InterestExpenseDebt_DE47FD3A0E81FD7EAC80EC7299FD5BE3" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4C88DE011E705DA55661EC7299FD652B" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4C88DE011E705DA55661EC7299FD652B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_D3C8E0496F2E1011F291EC7299FD9F71" xlink:type="locator" /> <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_D3C8E0496F2E1011F291EC7299FD9F71" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_8452B8F9AC256D80F714EC7299FD69E6" xlink:type="locator" /> <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_8452B8F9AC256D80F714EC7299FD69E6" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_165597B931FC4A65A353EC7299FDACC0" xlink:type="locator" /> <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_165597B931FC4A65A353EC7299FDACC0" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesTables" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/CoverPage" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/DerivativeLiability" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" xlink:type="extended"> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_SettlementAndTerminationLineItems" xlink:label="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_A27C08B2F3A3197383689F89F72AD96F" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_A27C08B2F3A3197383689F89F72AD96F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputEntityCreditRiskMember" xlink:label="loc_us-gaap_MeasurementInputEntityCreditRiskMember_97F9310E75BB8FBEB39E9F89F72A896B" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:to="loc_us-gaap_MeasurementInputEntityCreditRiskMember_97F9310E75BB8FBEB39E9F89F72A896B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D047D0C4BF2C3ADA59A59F89F72A9352" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D047D0C4BF2C3ADA59A59F89F72A9352" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2B1144C5F8459BD7B6CE9F89F72AE98B" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2B1144C5F8459BD7B6CE9F89F72AE98B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CDDF33A1C638CECFB3459F89F72ACD14_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2B1144C5F8459BD7B6CE9F89F72AE98B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CDDF33A1C638CECFB3459F89F72ACD14_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CDDF33A1C638CECFB3459F89F72ACD14" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2B1144C5F8459BD7B6CE9F89F72AE98B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CDDF33A1C638CECFB3459F89F72ACD14" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_MedicisPharmaceuticalCorporationMember" xlink:label="loc_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CDDF33A1C638CECFB3459F89F72ACD14" xlink:to="loc_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ValeantPharmaceuticalsInternationalInc.Member" xlink:label="loc_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CDDF33A1C638CECFB3459F89F72ACD14" xlink:to="loc_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_76871C27A72C9010F0C19F89F72AA3B1" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_76871C27A72C9010F0C19F89F72AA3B1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F1F7B603930F9DAB40EB9F89F72AE086_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76871C27A72C9010F0C19F89F72AA3B1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F1F7B603930F9DAB40EB9F89F72AE086_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F1F7B603930F9DAB40EB9F89F72AE086" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76871C27A72C9010F0C19F89F72AA3B1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F1F7B603930F9DAB40EB9F89F72AE086" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditRiskContractMember" xlink:label="loc_us-gaap_CreditRiskContractMember_D0F9EEC2CA73B4048A469F89F72A1BBC" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F1F7B603930F9DAB40EB9F89F72AE086" xlink:to="loc_us-gaap_CreditRiskContractMember_D0F9EEC2CA73B4048A469F89F72A1BBC" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AccruedMilestoneObligations" xlink:label="loc_rvnc_AccruedMilestoneObligations_C236A8E44585A0C72DCC9F89F732E9A8" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:to="loc_rvnc_AccruedMilestoneObligations_C236A8E44585A0C72DCC9F89F732E9A8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9A00FB9030404A05D4C19F89F732CB43" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9A00FB9030404A05D4C19F89F732CB43" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_FairValueMeasurementInputDuration" xlink:label="loc_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:to="loc_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_FairValueMeasurementInput" xlink:label="loc_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:to="loc_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/FairValueMeasurements" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2269856FC0B71A6867799DEC933D38C7" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2269856FC0B71A6867799DEC933D38C7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3C65A4A0E786571E1C409DEC933E8183" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3C65A4A0E786571E1C409DEC933E8183" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F8380070E0FD7D1F9EE59DEC933F17C9" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_F8380070E0FD7D1F9EE59DEC933F17C9" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_510609F4C5ED5295408B9DEC933FB918" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_510609F4C5ED5295408B9DEC933FB918" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8488E3DCB15FA1124EFB9DEC9340C9D7" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8488E3DCB15FA1124EFB9DEC9340C9D7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A5A64EC5E77A0177BE769DEC93409A5B" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_A5A64EC5E77A0177BE769DEC93409A5B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C5A7BEF46EC399FBFB799DEC93409FEA" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C5A7BEF46EC399FBFB799DEC93409FEA" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_83774B85BB65290FF9179DEC93400DC8" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_us-gaap_CommercialPaperMember_83774B85BB65290FF9179DEC93400DC8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaturityOvernightMember" xlink:label="loc_us-gaap_MaturityOvernightMember_1F5D833A0C70B46C7E049EAE67CDA361" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_us-gaap_MaturityOvernightMember_1F5D833A0C70B46C7E049EAE67CDA361" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DerivativeLiabilitySettlementMember" xlink:label="loc_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA" xlink:type="locator" /> <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_FAC0DB65B1320CC8D1C39DEC9342AC64" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_FAC0DB65B1320CC8D1C39DEC9342AC64" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6897DD9DAB4E105A33779DEC9342B146" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_6897DD9DAB4E105A33779DEC9342B146" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E0C0543F9D372185C7749DEC932EF37E" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E0C0543F9D372185C7749DEC932EF37E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E916F2916694B34F72DC9DEC932FD645_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E0C0543F9D372185C7749DEC932EF37E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E916F2916694B34F72DC9DEC932FD645_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E916F2916694B34F72DC9DEC932FD645" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E0C0543F9D372185C7749DEC932EF37E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E916F2916694B34F72DC9DEC932FD645" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DerivativeLiabilitySettlementMember" xlink:label="loc_rvnc_DerivativeLiabilitySettlementMember_EE52B60D413F7F9865799DEC932F1064" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E916F2916694B34F72DC9DEC932FD645" xlink:to="loc_rvnc_DerivativeLiabilitySettlementMember_EE52B60D413F7F9865799DEC932F1064" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_EF5E25B60721053A0E009EC07FCB26A5" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_EF5E25B60721053A0E009EC07FCB26A5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11DE20D9E8AA5BEF2C3E9DEC9330AEBD" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11DE20D9E8AA5BEF2C3E9DEC9330AEBD" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39F4153666A35CAC59039DEC93315C61" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39F4153666A35CAC59039DEC93315C61" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/FairValueMeasurementsTables" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/FillerDistributionAgreement" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_3F5A8B213AFAAD44ACABE627CC003D99" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB" xlink:to="loc_us-gaap_DistributionRightsMember_3F5A8B213AFAAD44ACABE627CC003D99" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72CD544DAB8F5EAB162DE627CC0109D1" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72CD544DAB8F5EAB162DE627CC0109D1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_B5B9DFA89B83CFDFA322E627CC01B8FE" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_B5B9DFA89B83CFDFA322E627CC01B8FE" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E9E99663015106B2DC7DE627CC01A4C7" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E9E99663015106B2DC7DE627CC01A4C7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14F2406A24511E09B1A4E627CC01706A" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14F2406A24511E09B1A4E627CC01706A" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TeoxaneAgreementMember" xlink:label="loc_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389" xlink:to="loc_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_879C5BA9C63D6C9D3A30E627CC0C39FF" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_879C5BA9C63D6C9D3A30E627CC0C39FF" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CollaborativeAgreementContractualPeriod" xlink:label="loc_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="loc_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CollaborativeAgreementExtendedContractualPeriod" xlink:label="loc_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="loc_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_C0002C2ED95E51D6A01AE6343A48989B" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_C0002C2ED95E51D6A01AE6343A48989B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_06FD5430C9AD1166B10CE6308F53F98E" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_06FD5430C9AD1166B10CE6308F53F98E" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/FillerDistributionAgreementTables" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/Leases" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/LeasesLeasesDetails" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/LeasesLeasesTables" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/Revenue" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/RevenueDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:to="loc_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:to="loc_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:to="loc_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DevelopmentServicesMember" xlink:label="loc_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E" xlink:to="loc_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_2935C9AF814213F6685D9FDB3E6ADDA1" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:to="loc_srt_CounterpartyNameAxis_2935C9AF814213F6685D9FDB3E6ADDA1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3EAB4C8152568B2E622B9FDB3E6AF0BF_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2935C9AF814213F6685D9FDB3E6ADDA1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3EAB4C8152568B2E622B9FDB3E6AF0BF_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3EAB4C8152568B2E622B9FDB3E6AF0BF" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2935C9AF814213F6685D9FDB3E6ADDA1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3EAB4C8152568B2E622B9FDB3E6AF0BF" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_MylanIrelandLimitedMember" xlink:label="loc_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3EAB4C8152568B2E622B9FDB3E6AF0BF" xlink:to="loc_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" xlink:label="loc_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3EAB4C8152568B2E622B9FDB3E6AF0BF" xlink:to="loc_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0ED3A0318DCCFC94FE4A9FDB3E703050" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0ED3A0318DCCFC94FE4A9FDB3E703050" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ContingentLicensingRoyaltyRevenue" xlink:label="loc_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue" xlink:label="loc_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_E1B9503A4C6E93E5197F9FDB3E713BD8" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_E1B9503A4C6E93E5197F9FDB3E713BD8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E35692E9FBADD07875CC9FDB3E716D87" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_Revenues_E35692E9FBADD07875CC9FDB3E716D87" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A5380E3A8AE0D73F563D9FDB3E7266DC" xlink:type="locator" /> <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A5380E3A8AE0D73F563D9FDB3E7266DC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1458225BEBDD392F07179FDB3E72B0CB" xlink:type="locator" /> <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1458225BEBDD392F07179FDB3E72B0CB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_1D16B695F9847B81F4FF9FDB3E72654C" xlink:type="locator" /> <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_1D16B695F9847B81F4FF9FDB3E72654C" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ForeignWithholdingTaxAmount" xlink:label="loc_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F" xlink:type="locator" /> <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_B69C1FD602684AE3CC149FDB3E722BE6" xlink:type="locator" /> <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_B69C1FD602684AE3CC149FDB3E722BE6" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensation" xlink:type="extended" /> <link:definitionLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_FAEB6FCA4CD412119DCCE637EB3867F2" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_FAEB6FCA4CD412119DCCE637EB3867F2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A98AD3B09C69DCDD01E7E627CAD83D4B" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:to="loc_us-gaap_EmployeeStockOptionMember_A98AD3B09C69DCDD01E7E627CAD83D4B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_BC43D4CAF6A942EB59FBE627CAD83247" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:to="loc_us-gaap_RestrictedStockMember_BC43D4CAF6A942EB59FBE627CAD83247" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ESPPPurchasesMember" xlink:label="loc_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:to="loc_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_EAF165B9AE2488F9043BE627CAD94BB3" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:to="loc_us-gaap_WarrantMember_EAF165B9AE2488F9043BE627CAD94BB3" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47A2F282714200CA0887E627CAD9F5DA" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47A2F282714200CA0887E627CAD9F5DA" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="loc_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:to="loc_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:to="loc_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_C11DA27059BCA75C0E60E6554FC7CF7E" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB" xlink:to="loc_srt_WeightedAverageMember_C11DA27059BCA75C0E60E6554FC7CF7E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="loc_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_AA128E8704EDA2F32302E6554FC8EE96" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:to="loc_us-gaap_StockCompensationPlanMember_AA128E8704EDA2F32302E6554FC8EE96" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_B2B3490435753A0C3CF7E6554FC8B68A" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:to="loc_us-gaap_RestrictedStockMember_B2B3490435753A0C3CF7E6554FC8B68A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_2AC9936081859FF981F7E6554FC80A49" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:to="loc_us-gaap_PerformanceSharesMember_2AC9936081859FF981F7E6554FC80A49" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_74EBEF4C0EB79BF0C85BE6554FC99106" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_74EBEF4C0EB79BF0C85BE6554FC99106" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_D9C162777CDB3B3FD22DE6554FC93183" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:to="loc_us-gaap_EmployeeStockMember_D9C162777CDB3B3FD22DE6554FC93183" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:to="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:to="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E515BB01D38BCF5A099CE6554FCABF58" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:to="loc_us-gaap_CommonStockMember_E515BB01D38BCF5A099CE6554FCABF58" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8C96A6AA4CD214BFF8A3E6554FCAB113" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:to="loc_us-gaap_WarrantMember_8C96A6AA4CD214BFF8A3E6554FCAB113" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_FollowOnOfferingMember" xlink:label="loc_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:to="loc_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_9FEF8C1220B8A7E958DAE6554FCBB9B6" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:to="loc_us-gaap_OverAllotmentOptionMember_9FEF8C1220B8A7E958DAE6554FCBB9B6" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AttheMarketOfferingMember" xlink:label="loc_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:to="loc_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="loc_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:to="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:to="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:label="loc_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:to="loc_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwoThousandAndFourteenInducementPlanMember" xlink:label="loc_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:to="loc_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="loc_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:to="loc_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_FF7E55DFC678E59987A4E6554FCD0305" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_FF7E55DFC678E59987A4E6554FCD0305" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D1D74FAE638C438B4001E6554FCD065C" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D1D74FAE638C438B4001E6554FCD065C" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D" xlink:type="locator" /> <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7531457E13AE97BDF19FE6554FCD9743" xlink:type="locator" /> <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7531457E13AE97BDF19FE6554FCD9743" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A17EF1C162B75C69FA55E6554FCE599A" xlink:type="locator" /> <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A17EF1C162B75C69FA55E6554FCE599A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4B12BFF62C25C96017AE6554FCEBAB5" xlink:type="locator" /> <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4B12BFF62C25C96017AE6554FCEBAB5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1F94521EAF057ED35D7E6554FCE3264" xlink:type="locator" /> <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1F94521EAF057ED35D7E6554FCE3264" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_0104608ACA0F08B2CEABE6554FCE8E6C" xlink:type="locator" /> <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_SharePrice_0104608ACA0F08B2CEABE6554FCE8E6C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C22CEBDE07FBA2342459E6554FCEEFBA" xlink:type="locator" /> <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C22CEBDE07FBA2342459E6554FCEEFBA" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum" xlink:label="loc_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192" xlink:type="locator" /> <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum" xlink:label="loc_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6" xlink:type="locator" /> <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D_default" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D_default" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6E6798CFB76DC5B74FE49F83F6D3ADF1" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6E6798CFB76DC5B74FE49F83F6D3ADF1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_65497392562DDFAE81D09F83F6D4408A" xlink:type="locator" /> <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_65497392562DDFAE81D09F83F6D4408A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3CECF961A2DDA3938C529F83F6D4DF16" xlink:type="locator" /> <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3CECF961A2DDA3938C529F83F6D4DF16" xlink:type="arc" /> </link:definitionLink> <link:definitionLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationTables" xlink:type="extended" /> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.LAB <SEQUENCE>9 <FILENAME>rvnc-20200331_lab.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!--XBRL Document Created with Wdesk from Workiva--> <!-- --> <link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" /> <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"> <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B629740EE655299D32FB9DEC936E84FF_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B629740EE655299D32FB9DEC936E84FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B629740EE655299D32FB9DEC936E84FF" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B629740EE655299D32FB9DEC936E84FF" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B629740EE655299D32FB9DEC936E84FF" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_719AF9B731C57A32B8129DEC936FE82F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_719AF9B731C57A32B8129DEC936FE82F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label> <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_719AF9B731C57A32B8129DEC936FE82F_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_719AF9B731C57A32B8129DEC936FE82F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_719AF9B731C57A32B8129DEC936FE82F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_719AF9B731C57A32B8129DEC936FE82F" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_719AF9B731C57A32B8129DEC936FE82F" xlink:type="arc" /> <link:label id="lab_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02_label_en-US" xlink:label="lab_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="lab_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:type="arc" /> <link:label id="lab_dei_DocumentType_9E84199FEBC09D8028A7E627CCAA3F72_terseLabel_en-US" xlink:label="lab_dei_DocumentType_9E84199FEBC09D8028A7E627CCAA3F72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label> <link:label id="lab_dei_DocumentType_9E84199FEBC09D8028A7E627CCAA3F72_label_en-US" xlink:label="lab_dei_DocumentType_9E84199FEBC09D8028A7E627CCAA3F72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9E84199FEBC09D8028A7E627CCAA3F72" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_9E84199FEBC09D8028A7E627CCAA3F72" xlink:to="lab_dei_DocumentType_9E84199FEBC09D8028A7E627CCAA3F72" xlink:type="arc" /> <link:label id="lab_dei_DocumentQuarterlyReport_7197F885E1EBD9EBD661E627CCAA01E0_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_7197F885E1EBD9EBD661E627CCAA01E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label> <link:label id="lab_dei_DocumentQuarterlyReport_7197F885E1EBD9EBD661E627CCAA01E0_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_7197F885E1EBD9EBD661E627CCAA01E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_7197F885E1EBD9EBD661E627CCAA01E0" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_7197F885E1EBD9EBD661E627CCAA01E0" xlink:to="lab_dei_DocumentQuarterlyReport_7197F885E1EBD9EBD661E627CCAA01E0" xlink:type="arc" /> <link:label id="lab_dei_DocumentPeriodEndDate_3097DECA04A092AC2B00E627CCABB47D_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_3097DECA04A092AC2B00E627CCABB47D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label> <link:label id="lab_dei_DocumentPeriodEndDate_3097DECA04A092AC2B00E627CCABB47D_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_3097DECA04A092AC2B00E627CCABB47D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_3097DECA04A092AC2B00E627CCABB47D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_3097DECA04A092AC2B00E627CCABB47D" xlink:to="lab_dei_DocumentPeriodEndDate_3097DECA04A092AC2B00E627CCABB47D" xlink:type="arc" /> <link:label id="lab_dei_DocumentTransitionReport_0A73E0F544D15BFB7CE8E627CCABAD33_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_0A73E0F544D15BFB7CE8E627CCABAD33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label> <link:label id="lab_dei_DocumentTransitionReport_0A73E0F544D15BFB7CE8E627CCABAD33_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_0A73E0F544D15BFB7CE8E627CCABAD33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_0A73E0F544D15BFB7CE8E627CCABAD33" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_0A73E0F544D15BFB7CE8E627CCABAD33" xlink:to="lab_dei_DocumentTransitionReport_0A73E0F544D15BFB7CE8E627CCABAD33" xlink:type="arc" /> <link:label id="lab_dei_EntityFileNumber_2E8157D42E9B00B0E196E627CCABF317_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_2E8157D42E9B00B0E196E627CCABF317" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label> <link:label id="lab_dei_EntityFileNumber_2E8157D42E9B00B0E196E627CCABF317_label_en-US" xlink:label="lab_dei_EntityFileNumber_2E8157D42E9B00B0E196E627CCABF317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_2E8157D42E9B00B0E196E627CCABF317" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_2E8157D42E9B00B0E196E627CCABF317" xlink:to="lab_dei_EntityFileNumber_2E8157D42E9B00B0E196E627CCABF317" xlink:type="arc" /> <link:label id="lab_dei_EntityRegistrantName_AD90E93662B3B8B3D948E627CCAB8877_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_AD90E93662B3B8B3D948E627CCAB8877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label> <link:label id="lab_dei_EntityRegistrantName_AD90E93662B3B8B3D948E627CCAB8877_label_en-US" xlink:label="lab_dei_EntityRegistrantName_AD90E93662B3B8B3D948E627CCAB8877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_AD90E93662B3B8B3D948E627CCAB8877" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_AD90E93662B3B8B3D948E627CCAB8877" xlink:to="lab_dei_EntityRegistrantName_AD90E93662B3B8B3D948E627CCAB8877" xlink:type="arc" /> <link:label id="lab_dei_EntityIncorporationStateCountryCode_C59E4927861F77F3EC63E627CCABCF02_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_C59E4927861F77F3EC63E627CCABCF02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label> <link:label id="lab_dei_EntityIncorporationStateCountryCode_C59E4927861F77F3EC63E627CCABCF02_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_C59E4927861F77F3EC63E627CCABCF02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_C59E4927861F77F3EC63E627CCABCF02" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_C59E4927861F77F3EC63E627CCABCF02" xlink:to="lab_dei_EntityIncorporationStateCountryCode_C59E4927861F77F3EC63E627CCABCF02" xlink:type="arc" /> <link:label id="lab_dei_EntityTaxIdentificationNumber_F05479F89295D8BC74A1E627CCABD462_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_F05479F89295D8BC74A1E627CCABD462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label> <link:label id="lab_dei_EntityTaxIdentificationNumber_F05479F89295D8BC74A1E627CCABD462_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_F05479F89295D8BC74A1E627CCABD462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_F05479F89295D8BC74A1E627CCABD462" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_F05479F89295D8BC74A1E627CCABD462" xlink:to="lab_dei_EntityTaxIdentificationNumber_F05479F89295D8BC74A1E627CCABD462" xlink:type="arc" /> <link:label id="lab_dei_EntityAddressAddressLine1_4B835299CA80D903E34FE627CCAC92CA_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_4B835299CA80D903E34FE627CCAC92CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label> <link:label id="lab_dei_EntityAddressAddressLine1_4B835299CA80D903E34FE627CCAC92CA_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_4B835299CA80D903E34FE627CCAC92CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_4B835299CA80D903E34FE627CCAC92CA" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_4B835299CA80D903E34FE627CCAC92CA" xlink:to="lab_dei_EntityAddressAddressLine1_4B835299CA80D903E34FE627CCAC92CA" xlink:type="arc" /> <link:label id="lab_dei_EntityAddressCityOrTown_F0D6178491D2C323A1FEE627CCAC1792_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_F0D6178491D2C323A1FEE627CCAC1792" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label> <link:label id="lab_dei_EntityAddressCityOrTown_F0D6178491D2C323A1FEE627CCAC1792_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_F0D6178491D2C323A1FEE627CCAC1792" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_F0D6178491D2C323A1FEE627CCAC1792" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_F0D6178491D2C323A1FEE627CCAC1792" xlink:to="lab_dei_EntityAddressCityOrTown_F0D6178491D2C323A1FEE627CCAC1792" xlink:type="arc" /> <link:label id="lab_dei_EntityAddressStateOrProvince_731878E01DCCAC5EF164E627CCAC4F65_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_731878E01DCCAC5EF164E627CCAC4F65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label> <link:label id="lab_dei_EntityAddressStateOrProvince_731878E01DCCAC5EF164E627CCAC4F65_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_731878E01DCCAC5EF164E627CCAC4F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_731878E01DCCAC5EF164E627CCAC4F65" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_731878E01DCCAC5EF164E627CCAC4F65" xlink:to="lab_dei_EntityAddressStateOrProvince_731878E01DCCAC5EF164E627CCAC4F65" xlink:type="arc" /> <link:label id="lab_dei_EntityAddressPostalZipCode_41BF0422C648872BEB48E627CCAC567B_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_41BF0422C648872BEB48E627CCAC567B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label> <link:label id="lab_dei_EntityAddressPostalZipCode_41BF0422C648872BEB48E627CCAC567B_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_41BF0422C648872BEB48E627CCAC567B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_41BF0422C648872BEB48E627CCAC567B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_41BF0422C648872BEB48E627CCAC567B" xlink:to="lab_dei_EntityAddressPostalZipCode_41BF0422C648872BEB48E627CCAC567B" xlink:type="arc" /> <link:label id="lab_dei_CityAreaCode_5C9F8761EAB6F8D51718E627CCACB1E5_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_5C9F8761EAB6F8D51718E627CCACB1E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label> <link:label id="lab_dei_CityAreaCode_5C9F8761EAB6F8D51718E627CCACB1E5_label_en-US" xlink:label="lab_dei_CityAreaCode_5C9F8761EAB6F8D51718E627CCACB1E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_5C9F8761EAB6F8D51718E627CCACB1E5" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_5C9F8761EAB6F8D51718E627CCACB1E5" xlink:to="lab_dei_CityAreaCode_5C9F8761EAB6F8D51718E627CCACB1E5" xlink:type="arc" /> <link:label id="lab_dei_LocalPhoneNumber_AE142CA140768C284C7BE627CCACD408_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_AE142CA140768C284C7BE627CCACD408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label> <link:label id="lab_dei_LocalPhoneNumber_AE142CA140768C284C7BE627CCACD408_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_AE142CA140768C284C7BE627CCACD408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_AE142CA140768C284C7BE627CCACD408" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_AE142CA140768C284C7BE627CCACD408" xlink:to="lab_dei_LocalPhoneNumber_AE142CA140768C284C7BE627CCACD408" xlink:type="arc" /> <link:label id="lab_dei_Security12bTitle_F243A8D08BFDFD548160E627CCADE67E_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_F243A8D08BFDFD548160E627CCADE67E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label> <link:label id="lab_dei_Security12bTitle_F243A8D08BFDFD548160E627CCADE67E_label_en-US" xlink:label="lab_dei_Security12bTitle_F243A8D08BFDFD548160E627CCADE67E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_F243A8D08BFDFD548160E627CCADE67E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_F243A8D08BFDFD548160E627CCADE67E" xlink:to="lab_dei_Security12bTitle_F243A8D08BFDFD548160E627CCADE67E" xlink:type="arc" /> <link:label id="lab_dei_TradingSymbol_33D365ECAD051E19E82AE627CCAD3B20_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_33D365ECAD051E19E82AE627CCAD3B20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label> <link:label id="lab_dei_TradingSymbol_33D365ECAD051E19E82AE627CCAD3B20_label_en-US" xlink:label="lab_dei_TradingSymbol_33D365ECAD051E19E82AE627CCAD3B20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_33D365ECAD051E19E82AE627CCAD3B20" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_33D365ECAD051E19E82AE627CCAD3B20" xlink:to="lab_dei_TradingSymbol_33D365ECAD051E19E82AE627CCAD3B20" xlink:type="arc" /> <link:label id="lab_dei_SecurityExchangeName_7D9FEDA272F5DCD41F77E627CCAD4B7E_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_7D9FEDA272F5DCD41F77E627CCAD4B7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label> <link:label id="lab_dei_SecurityExchangeName_7D9FEDA272F5DCD41F77E627CCAD4B7E_label_en-US" xlink:label="lab_dei_SecurityExchangeName_7D9FEDA272F5DCD41F77E627CCAD4B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_7D9FEDA272F5DCD41F77E627CCAD4B7E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_7D9FEDA272F5DCD41F77E627CCAD4B7E" xlink:to="lab_dei_SecurityExchangeName_7D9FEDA272F5DCD41F77E627CCAD4B7E" xlink:type="arc" /> <link:label id="lab_dei_EntityCurrentReportingStatus_369B9033E7E46A18A0A6E627CCAD3AC5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_369B9033E7E46A18A0A6E627CCAD3AC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label> <link:label id="lab_dei_EntityCurrentReportingStatus_369B9033E7E46A18A0A6E627CCAD3AC5_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_369B9033E7E46A18A0A6E627CCAD3AC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_369B9033E7E46A18A0A6E627CCAD3AC5" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_369B9033E7E46A18A0A6E627CCAD3AC5" xlink:to="lab_dei_EntityCurrentReportingStatus_369B9033E7E46A18A0A6E627CCAD3AC5" xlink:type="arc" /> <link:label id="lab_dei_EntityInteractiveDataCurrent_B1AAE053FC54FE0C5D85E627CCAD1C8E_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_B1AAE053FC54FE0C5D85E627CCAD1C8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label> <link:label id="lab_dei_EntityInteractiveDataCurrent_B1AAE053FC54FE0C5D85E627CCAD1C8E_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_B1AAE053FC54FE0C5D85E627CCAD1C8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_B1AAE053FC54FE0C5D85E627CCAD1C8E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_B1AAE053FC54FE0C5D85E627CCAD1C8E" xlink:to="lab_dei_EntityInteractiveDataCurrent_B1AAE053FC54FE0C5D85E627CCAD1C8E" xlink:type="arc" /> <link:label id="lab_dei_EntityFilerCategory_43CFBF1C4233F89B502FE627CCADCF00_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_43CFBF1C4233F89B502FE627CCADCF00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label> <link:label id="lab_dei_EntityFilerCategory_43CFBF1C4233F89B502FE627CCADCF00_label_en-US" xlink:label="lab_dei_EntityFilerCategory_43CFBF1C4233F89B502FE627CCADCF00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_43CFBF1C4233F89B502FE627CCADCF00" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_43CFBF1C4233F89B502FE627CCADCF00" xlink:to="lab_dei_EntityFilerCategory_43CFBF1C4233F89B502FE627CCADCF00" xlink:type="arc" /> <link:label id="lab_dei_EntitySmallBusiness_59E64C5B167D4BE08171E627CCAD8FE1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_59E64C5B167D4BE08171E627CCAD8FE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label> <link:label id="lab_dei_EntitySmallBusiness_59E64C5B167D4BE08171E627CCAD8FE1_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_59E64C5B167D4BE08171E627CCAD8FE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_59E64C5B167D4BE08171E627CCAD8FE1" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_59E64C5B167D4BE08171E627CCAD8FE1" xlink:to="lab_dei_EntitySmallBusiness_59E64C5B167D4BE08171E627CCAD8FE1" xlink:type="arc" /> <link:label id="lab_dei_EntityEmergingGrowthCompany_4D860FC3974B60B2E102E627CCAEEB0F_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_4D860FC3974B60B2E102E627CCAEEB0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth</link:label> <link:label id="lab_dei_EntityEmergingGrowthCompany_4D860FC3974B60B2E102E627CCAEEB0F_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_4D860FC3974B60B2E102E627CCAEEB0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_4D860FC3974B60B2E102E627CCAEEB0F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_4D860FC3974B60B2E102E627CCAEEB0F" xlink:to="lab_dei_EntityEmergingGrowthCompany_4D860FC3974B60B2E102E627CCAEEB0F" xlink:type="arc" /> <link:label id="lab_dei_EntityShellCompany_126D95E9D9458BA6BF4CE627CCAE2523_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_126D95E9D9458BA6BF4CE627CCAE2523" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label> <link:label id="lab_dei_EntityShellCompany_126D95E9D9458BA6BF4CE627CCAE2523_label_en-US" xlink:label="lab_dei_EntityShellCompany_126D95E9D9458BA6BF4CE627CCAE2523" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_126D95E9D9458BA6BF4CE627CCAE2523" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_126D95E9D9458BA6BF4CE627CCAE2523" xlink:to="lab_dei_EntityShellCompany_126D95E9D9458BA6BF4CE627CCAE2523" xlink:type="arc" /> <link:label id="lab_dei_EntityCommonStockSharesOutstanding_616EB2C9B955F6F21BF5E627CCAE9AD1_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_616EB2C9B955F6F21BF5E627CCAE9AD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label> <link:label id="lab_dei_EntityCommonStockSharesOutstanding_616EB2C9B955F6F21BF5E627CCAE9AD1_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_616EB2C9B955F6F21BF5E627CCAE9AD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_616EB2C9B955F6F21BF5E627CCAE9AD1" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_616EB2C9B955F6F21BF5E627CCAE9AD1" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_616EB2C9B955F6F21BF5E627CCAE9AD1" xlink:type="arc" /> <link:label id="lab_dei_EntityCentralIndexKey_B20C8A69E98BDB27111EE627CCAEC358_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_B20C8A69E98BDB27111EE627CCAEC358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label> <link:label id="lab_dei_EntityCentralIndexKey_B20C8A69E98BDB27111EE627CCAEC358_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_B20C8A69E98BDB27111EE627CCAEC358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_B20C8A69E98BDB27111EE627CCAEC358" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_B20C8A69E98BDB27111EE627CCAEC358" xlink:to="lab_dei_EntityCentralIndexKey_B20C8A69E98BDB27111EE627CCAEC358" xlink:type="arc" /> <link:label id="lab_dei_CurrentFiscalYearEndDate_FED177B6F0A95DC2F737E627CCAEDA85_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_FED177B6F0A95DC2F737E627CCAEDA85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label> <link:label id="lab_dei_CurrentFiscalYearEndDate_FED177B6F0A95DC2F737E627CCAEDA85_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_FED177B6F0A95DC2F737E627CCAEDA85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FED177B6F0A95DC2F737E627CCAEDA85" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_FED177B6F0A95DC2F737E627CCAEDA85" xlink:to="lab_dei_CurrentFiscalYearEndDate_FED177B6F0A95DC2F737E627CCAEDA85" xlink:type="arc" /> <link:label id="lab_dei_DocumentFiscalYearFocus_48B874E42ECABC467841E627CCAF40D6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_48B874E42ECABC467841E627CCAF40D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label> <link:label id="lab_dei_DocumentFiscalYearFocus_48B874E42ECABC467841E627CCAF40D6_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_48B874E42ECABC467841E627CCAF40D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_48B874E42ECABC467841E627CCAF40D6" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_48B874E42ECABC467841E627CCAF40D6" xlink:to="lab_dei_DocumentFiscalYearFocus_48B874E42ECABC467841E627CCAF40D6" xlink:type="arc" /> <link:label id="lab_dei_DocumentFiscalPeriodFocus_7A81073322120D8995DCE627CCAFEE51_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_7A81073322120D8995DCE627CCAFEE51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label> <link:label id="lab_dei_DocumentFiscalPeriodFocus_7A81073322120D8995DCE627CCAFEE51_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_7A81073322120D8995DCE627CCAFEE51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7A81073322120D8995DCE627CCAFEE51" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_7A81073322120D8995DCE627CCAFEE51" xlink:to="lab_dei_DocumentFiscalPeriodFocus_7A81073322120D8995DCE627CCAFEE51" xlink:type="arc" /> <link:label id="lab_dei_AmendmentFlag_82487A141CF70E178788E627CCAFCF67_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_82487A141CF70E178788E627CCAFCF67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label> <link:label id="lab_dei_AmendmentFlag_82487A141CF70E178788E627CCAFCF67_label_en-US" xlink:label="lab_dei_AmendmentFlag_82487A141CF70E178788E627CCAFCF67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_82487A141CF70E178788E627CCAFCF67" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_82487A141CF70E178788E627CCAFCF67" xlink:to="lab_dei_AmendmentFlag_82487A141CF70E178788E627CCAFCF67" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtDisclosureAbstract_2C97CB8B0C69F7269EF9ECD68126BE6F_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_2C97CB8B0C69F7269EF9ECD68126BE6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2C97CB8B0C69F7269EF9ECD68126BE6F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2C97CB8B0C69F7269EF9ECD68126BE6F" xlink:to="lab_us-gaap_DebtDisclosureAbstract_2C97CB8B0C69F7269EF9ECD68126BE6F" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label> <link:label id="lab_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:to="lab_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:type="arc" /> <link:label id="lab_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label> <link:label id="lab_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:type="arc" /> <link:label id="lab_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label> <link:label id="lab_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745" xlink:type="arc" /> <link:label id="lab_us-gaap_ConvertibleDebtMember_94DDFA75577A02D5FBB7ECDE9A109781_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_94DDFA75577A02D5FBB7ECDE9A109781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label> <link:label id="lab_us-gaap_ConvertibleDebtMember_94DDFA75577A02D5FBB7ECDE9A109781_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_94DDFA75577A02D5FBB7ECDE9A109781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_94DDFA75577A02D5FBB7ECDE9A109781" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_94DDFA75577A02D5FBB7ECDE9A109781" xlink:to="lab_us-gaap_ConvertibleDebtMember_94DDFA75577A02D5FBB7ECDE9A109781" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label> <link:label id="lab_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:to="lab_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label> <link:label id="lab_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1" xlink:type="arc" /> <link:label id="lab_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901_verboseLabel_en-US" xlink:label="lab_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2027 Notes</link:label> <link:label id="lab_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901_label_en-US" xlink:label="lab_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty Twenty Seven Notes [Member]</link:label> <link:label id="lab_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901_documentation_en-US" xlink:label="lab_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty Twenty Seven Notes [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwentyTwentySevenNotesMember" xlink:label="loc_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901" xlink:to="lab_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label> <link:label id="lab_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="lab_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:type="arc" /> <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_57A5F3E463CCA9B2FBDFECD68129164B_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_57A5F3E463CCA9B2FBDFECD68129164B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment of capped call transactions</link:label> <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_57A5F3E463CCA9B2FBDFECD68129164B_label_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_57A5F3E463CCA9B2FBDFECD68129164B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Derivative Instrument, Financing Activities</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_57A5F3E463CCA9B2FBDFECD68129164B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_57A5F3E463CCA9B2FBDFECD68129164B" xlink:to="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_57A5F3E463CCA9B2FBDFECD68129164B" xlink:type="arc" /> <link:label id="lab_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8_terseLabel_en-US" xlink:label="lab_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price cap (in dollars per share)</link:label> <link:label id="lab_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8_label_en-US" xlink:label="lab_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capped Calls, Price Cap</link:label> <link:label id="lab_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8_documentation_en-US" xlink:label="lab_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capped Calls, Price Cap</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CappedCallsPriceCap" xlink:label="loc_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8" xlink:to="lab_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8" xlink:type="arc" /> <link:label id="lab_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F_terseLabel_en-US" xlink:label="lab_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium percentage over sale price</link:label> <link:label id="lab_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F_label_en-US" xlink:label="lab_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capped Calls, Premium Percentage Over Sale Price</link:label> <link:label id="lab_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F_documentation_en-US" xlink:label="lab_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capped Calls, Premium Percentage Over Sale Price</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CappedCallsPremiumPercentageOverSalePrice" xlink:label="loc_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F" xlink:to="lab_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2C583238236D8498EFF6ECDE99F1E73E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2C583238236D8498EFF6ECDE99F1E73E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (in dollars per share)</link:label> <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2C583238236D8498EFF6ECDE99F1E73E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2C583238236D8498EFF6ECDE99F1E73E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_2C583238236D8498EFF6ECDE99F1E73E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_2C583238236D8498EFF6ECDE99F1E73E" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2C583238236D8498EFF6ECDE99F1E73E" xlink:type="arc" /> <link:label id="lab_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF_terseLabel_en-US" xlink:label="lab_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares subject to anti-dilution adjustments (in shares)</link:label> <link:label id="lab_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF_label_en-US" xlink:label="lab_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capped Calls, Number Of Shares Subject To Anti-dilution Adjustments</link:label> <link:label id="lab_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF_documentation_en-US" xlink:label="lab_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capped Calls, Number Of Shares Subject To Anti-dilution Adjustments</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments" xlink:label="loc_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF" xlink:to="lab_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF" xlink:type="arc" /> <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92B3D4ECE9AB77C40D0E9DEC92EC03E2_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92B3D4ECE9AB77C40D0E9DEC92EC03E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92B3D4ECE9AB77C40D0E9DEC92EC03E2" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92B3D4ECE9AB77C40D0E9DEC92EC03E2" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92B3D4ECE9AB77C40D0E9DEC92EC03E2" xlink:type="arc" /> <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85031F0FF2D9A2AB9ED99DEC92ECC04A_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85031F0FF2D9A2AB9ED99DEC92ECC04A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label> <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85031F0FF2D9A2AB9ED99DEC92ECC04A_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85031F0FF2D9A2AB9ED99DEC92ECC04A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85031F0FF2D9A2AB9ED99DEC92ECC04A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85031F0FF2D9A2AB9ED99DEC92ECC04A" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85031F0FF2D9A2AB9ED99DEC92ECC04A" xlink:type="arc" /> <link:label id="lab_us-gaap_EquityAbstract_3998C6836E7FD34FD7739DEC92CC1CD9_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_3998C6836E7FD34FD7739DEC92CC1CD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_3998C6836E7FD34FD7739DEC92CC1CD9" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_3998C6836E7FD34FD7739DEC92CC1CD9" xlink:to="lab_us-gaap_EquityAbstract_3998C6836E7FD34FD7739DEC92CC1CD9" xlink:type="arc" /> <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_D4087CBA1990FE4277869DEC92CD3A84_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_D4087CBA1990FE4277869DEC92CD3A84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity and Stock-Based Compensation</link:label> <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_D4087CBA1990FE4277869DEC92CD3A84_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_D4087CBA1990FE4277869DEC92CD3A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_D4087CBA1990FE4277869DEC92CD3A84" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_D4087CBA1990FE4277869DEC92CD3A84" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_D4087CBA1990FE4277869DEC92CD3A84" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_FE435D939F03E8DA210E9DEC933C7725_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_FE435D939F03E8DA210E9DEC933C7725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_FE435D939F03E8DA210E9DEC933C7725" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FE435D939F03E8DA210E9DEC933C7725" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_FE435D939F03E8DA210E9DEC933C7725" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label> <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label> <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label> <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2269856FC0B71A6867799DEC933D38C7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_2269856FC0B71A6867799DEC933D38C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label> <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_2269856FC0B71A6867799DEC933D38C7_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_2269856FC0B71A6867799DEC933D38C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2269856FC0B71A6867799DEC933D38C7" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_2269856FC0B71A6867799DEC933D38C7" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_2269856FC0B71A6867799DEC933D38C7" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label> <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label> <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3C65A4A0E786571E1C409DEC933E8183_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_3C65A4A0E786571E1C409DEC933E8183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label> <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3C65A4A0E786571E1C409DEC933E8183_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_3C65A4A0E786571E1C409DEC933E8183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3C65A4A0E786571E1C409DEC933E8183" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_3C65A4A0E786571E1C409DEC933E8183" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_3C65A4A0E786571E1C409DEC933E8183" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueInputsLevel2Member_F8380070E0FD7D1F9EE59DEC933F17C9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_F8380070E0FD7D1F9EE59DEC933F17C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label> <link:label id="lab_us-gaap_FairValueInputsLevel2Member_F8380070E0FD7D1F9EE59DEC933F17C9_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_F8380070E0FD7D1F9EE59DEC933F17C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F8380070E0FD7D1F9EE59DEC933F17C9" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_F8380070E0FD7D1F9EE59DEC933F17C9" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_F8380070E0FD7D1F9EE59DEC933F17C9" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueInputsLevel3Member_510609F4C5ED5295408B9DEC933FB918_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_510609F4C5ED5295408B9DEC933FB918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label> <link:label id="lab_us-gaap_FairValueInputsLevel3Member_510609F4C5ED5295408B9DEC933FB918_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_510609F4C5ED5295408B9DEC933FB918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_510609F4C5ED5295408B9DEC933FB918" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_510609F4C5ED5295408B9DEC933FB918" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_510609F4C5ED5295408B9DEC933FB918" xlink:type="arc" /> <link:label id="lab_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label> <link:label id="lab_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:to="lab_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:type="arc" /> <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label> <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:type="arc" /> <link:label id="lab_us-gaap_MoneyMarketFundsMember_8488E3DCB15FA1124EFB9DEC9340C9D7_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_8488E3DCB15FA1124EFB9DEC9340C9D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label> <link:label id="lab_us-gaap_MoneyMarketFundsMember_8488E3DCB15FA1124EFB9DEC9340C9D7_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_8488E3DCB15FA1124EFB9DEC9340C9D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8488E3DCB15FA1124EFB9DEC9340C9D7" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_8488E3DCB15FA1124EFB9DEC9340C9D7" xlink:to="lab_us-gaap_MoneyMarketFundsMember_8488E3DCB15FA1124EFB9DEC9340C9D7" xlink:type="arc" /> <link:label id="lab_us-gaap_USTreasurySecuritiesMember_A5A64EC5E77A0177BE769DEC93409A5B_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_A5A64EC5E77A0177BE769DEC93409A5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. treasury securities</link:label> <link:label id="lab_us-gaap_USTreasurySecuritiesMember_A5A64EC5E77A0177BE769DEC93409A5B_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_A5A64EC5E77A0177BE769DEC93409A5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A5A64EC5E77A0177BE769DEC93409A5B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_A5A64EC5E77A0177BE769DEC93409A5B" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_A5A64EC5E77A0177BE769DEC93409A5B" xlink:type="arc" /> <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C5A7BEF46EC399FBFB799DEC93409FEA_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C5A7BEF46EC399FBFB799DEC93409FEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government agency obligations</link:label> <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C5A7BEF46EC399FBFB799DEC93409FEA_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C5A7BEF46EC399FBFB799DEC93409FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C5A7BEF46EC399FBFB799DEC93409FEA" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C5A7BEF46EC399FBFB799DEC93409FEA" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C5A7BEF46EC399FBFB799DEC93409FEA" xlink:type="arc" /> <link:label id="lab_us-gaap_CommercialPaperMember_83774B85BB65290FF9179DEC93400DC8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_83774B85BB65290FF9179DEC93400DC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label> <link:label id="lab_us-gaap_CommercialPaperMember_83774B85BB65290FF9179DEC93400DC8_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_83774B85BB65290FF9179DEC93400DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_83774B85BB65290FF9179DEC93400DC8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_83774B85BB65290FF9179DEC93400DC8" xlink:to="lab_us-gaap_CommercialPaperMember_83774B85BB65290FF9179DEC93400DC8" xlink:type="arc" /> <link:label id="lab_us-gaap_MaturityOvernightMember_1F5D833A0C70B46C7E049EAE67CDA361_terseLabel_en-US" xlink:label="lab_us-gaap_MaturityOvernightMember_1F5D833A0C70B46C7E049EAE67CDA361" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight repurchase agreements</link:label> <link:label id="lab_us-gaap_MaturityOvernightMember_1F5D833A0C70B46C7E049EAE67CDA361_label_en-US" xlink:label="lab_us-gaap_MaturityOvernightMember_1F5D833A0C70B46C7E049EAE67CDA361" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity Overnight [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaturityOvernightMember" xlink:label="loc_us-gaap_MaturityOvernightMember_1F5D833A0C70B46C7E049EAE67CDA361" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturityOvernightMember_1F5D833A0C70B46C7E049EAE67CDA361" xlink:to="lab_us-gaap_MaturityOvernightMember_1F5D833A0C70B46C7E049EAE67CDA361" xlink:type="arc" /> <link:label id="lab_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA_terseLabel_en-US" xlink:label="lab_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label> <link:label id="lab_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA_label_en-US" xlink:label="lab_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability Settlement [Member]</link:label> <link:label id="lab_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA_documentation_en-US" xlink:label="lab_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Liability Settlement [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DerivativeLiabilitySettlementMember" xlink:label="loc_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA" xlink:to="lab_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</link:label> <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_FAC0DB65B1320CC8D1C39DEC9342AC64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_FAC0DB65B1320CC8D1C39DEC9342AC64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label> <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_FAC0DB65B1320CC8D1C39DEC9342AC64_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_FAC0DB65B1320CC8D1C39DEC9342AC64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_FAC0DB65B1320CC8D1C39DEC9342AC64" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_FAC0DB65B1320CC8D1C39DEC9342AC64" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_FAC0DB65B1320CC8D1C39DEC9342AC64" xlink:type="arc" /> <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_6897DD9DAB4E105A33779DEC9342B146_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_6897DD9DAB4E105A33779DEC9342B146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total liabilities measured at fair value</link:label> <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_6897DD9DAB4E105A33779DEC9342B146_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_6897DD9DAB4E105A33779DEC9342B146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6897DD9DAB4E105A33779DEC9342B146" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6897DD9DAB4E105A33779DEC9342B146" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_6897DD9DAB4E105A33779DEC9342B146" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label> <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:type="arc" /> <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label> <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:type="arc" /> <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label> <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:type="arc" /> <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_FAEB6FCA4CD412119DCCE637EB3867F2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_FAEB6FCA4CD412119DCCE637EB3867F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label> <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_FAEB6FCA4CD412119DCCE637EB3867F2_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_FAEB6FCA4CD412119DCCE637EB3867F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_FAEB6FCA4CD412119DCCE637EB3867F2" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_FAEB6FCA4CD412119DCCE637EB3867F2" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_FAEB6FCA4CD412119DCCE637EB3867F2" xlink:type="arc" /> <link:label id="lab_us-gaap_EmployeeStockOptionMember_A98AD3B09C69DCDD01E7E627CAD83D4B_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_A98AD3B09C69DCDD01E7E627CAD83D4B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outstanding common stock options</link:label> <link:label id="lab_us-gaap_EmployeeStockOptionMember_A98AD3B09C69DCDD01E7E627CAD83D4B_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_A98AD3B09C69DCDD01E7E627CAD83D4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A98AD3B09C69DCDD01E7E627CAD83D4B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_A98AD3B09C69DCDD01E7E627CAD83D4B" xlink:to="lab_us-gaap_EmployeeStockOptionMember_A98AD3B09C69DCDD01E7E627CAD83D4B" xlink:type="arc" /> <link:label id="lab_us-gaap_RestrictedStockMember_BC43D4CAF6A942EB59FBE627CAD83247_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_BC43D4CAF6A942EB59FBE627CAD83247" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested restricted stock awards and performance stock awards</link:label> <link:label id="lab_us-gaap_RestrictedStockMember_BC43D4CAF6A942EB59FBE627CAD83247_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_BC43D4CAF6A942EB59FBE627CAD83247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_BC43D4CAF6A942EB59FBE627CAD83247" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_BC43D4CAF6A942EB59FBE627CAD83247" xlink:to="lab_us-gaap_RestrictedStockMember_BC43D4CAF6A942EB59FBE627CAD83247" xlink:type="arc" /> <link:label id="lab_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969_terseLabel_en-US" xlink:label="lab_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock expected to be purchased on June 30 under the 2014 ESPP</link:label> <link:label id="lab_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969_label_en-US" xlink:label="lab_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ESPP Purchases [Member]</link:label> <link:label id="lab_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969_documentation_en-US" xlink:label="lab_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ESPP Purchases [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ESPPPurchasesMember" xlink:label="loc_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969" xlink:to="lab_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969" xlink:type="arc" /> <link:label id="lab_us-gaap_WarrantMember_EAF165B9AE2488F9043BE627CAD94BB3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_EAF165B9AE2488F9043BE627CAD94BB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding common stock warrants</link:label> <link:label id="lab_us-gaap_WarrantMember_EAF165B9AE2488F9043BE627CAD94BB3_label_en-US" xlink:label="lab_us-gaap_WarrantMember_EAF165B9AE2488F9043BE627CAD94BB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_EAF165B9AE2488F9043BE627CAD94BB3" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_EAF165B9AE2488F9043BE627CAD94BB3" xlink:to="lab_us-gaap_WarrantMember_EAF165B9AE2488F9043BE627CAD94BB3" xlink:type="arc" /> <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label> <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5" xlink:type="arc" /> <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47A2F282714200CA0887E627CAD9F5DA_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47A2F282714200CA0887E627CAD9F5DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)</link:label> <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47A2F282714200CA0887E627CAD9F5DA_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47A2F282714200CA0887E627CAD9F5DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47A2F282714200CA0887E627CAD9F5DA" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47A2F282714200CA0887E627CAD9F5DA" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47A2F282714200CA0887E627CAD9F5DA" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label> <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:type="arc" /> <link:label id="lab_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label> <link:label id="lab_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555_label_en-US" xlink:label="lab_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:to="lab_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:type="arc" /> <link:label id="lab_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB_terseLabel_en-US" xlink:label="lab_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label> <link:label id="lab_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB_label_en-US" xlink:label="lab_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB" xlink:to="lab_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB" xlink:type="arc" /> <link:label id="lab_srt_WeightedAverageMember_C11DA27059BCA75C0E60E6554FC7CF7E_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember_C11DA27059BCA75C0E60E6554FC7CF7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label> <link:label id="lab_srt_WeightedAverageMember_C11DA27059BCA75C0E60E6554FC7CF7E_label_en-US" xlink:label="lab_srt_WeightedAverageMember_C11DA27059BCA75C0E60E6554FC7CF7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_C11DA27059BCA75C0E60E6554FC7CF7E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember_C11DA27059BCA75C0E60E6554FC7CF7E" xlink:to="lab_srt_WeightedAverageMember_C11DA27059BCA75C0E60E6554FC7CF7E" xlink:type="arc" /> <link:label id="lab_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label> <link:label id="lab_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:to="lab_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:type="arc" /> <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label> <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:type="arc" /> <link:label id="lab_us-gaap_StockCompensationPlanMember_AA128E8704EDA2F32302E6554FC8EE96_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_AA128E8704EDA2F32302E6554FC8EE96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement</link:label> <link:label id="lab_us-gaap_StockCompensationPlanMember_AA128E8704EDA2F32302E6554FC8EE96_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_AA128E8704EDA2F32302E6554FC8EE96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_AA128E8704EDA2F32302E6554FC8EE96" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember_AA128E8704EDA2F32302E6554FC8EE96" xlink:to="lab_us-gaap_StockCompensationPlanMember_AA128E8704EDA2F32302E6554FC8EE96" xlink:type="arc" /> <link:label id="lab_us-gaap_RestrictedStockMember_B2B3490435753A0C3CF7E6554FC8B68A_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_B2B3490435753A0C3CF7E6554FC8B68A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_B2B3490435753A0C3CF7E6554FC8B68A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_B2B3490435753A0C3CF7E6554FC8B68A" xlink:to="lab_us-gaap_RestrictedStockMember_B2B3490435753A0C3CF7E6554FC8B68A" xlink:type="arc" /> <link:label id="lab_us-gaap_PerformanceSharesMember_2AC9936081859FF981F7E6554FC80A49_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_2AC9936081859FF981F7E6554FC80A49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance-based Common Stock</link:label> <link:label id="lab_us-gaap_PerformanceSharesMember_2AC9936081859FF981F7E6554FC80A49_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_2AC9936081859FF981F7E6554FC80A49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_2AC9936081859FF981F7E6554FC80A49" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_2AC9936081859FF981F7E6554FC80A49" xlink:to="lab_us-gaap_PerformanceSharesMember_2AC9936081859FF981F7E6554FC80A49" xlink:type="arc" /> <link:label id="lab_us-gaap_EmployeeStockOptionMember_74EBEF4C0EB79BF0C85BE6554FC99106_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_74EBEF4C0EB79BF0C85BE6554FC99106" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_74EBEF4C0EB79BF0C85BE6554FC99106" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_74EBEF4C0EB79BF0C85BE6554FC99106" xlink:to="lab_us-gaap_EmployeeStockOptionMember_74EBEF4C0EB79BF0C85BE6554FC99106" xlink:type="arc" /> <link:label id="lab_us-gaap_EmployeeStockMember_D9C162777CDB3B3FD22DE6554FC93183_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_D9C162777CDB3B3FD22DE6554FC93183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label> <link:label id="lab_us-gaap_EmployeeStockMember_D9C162777CDB3B3FD22DE6554FC93183_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_D9C162777CDB3B3FD22DE6554FC93183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_D9C162777CDB3B3FD22DE6554FC93183" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_D9C162777CDB3B3FD22DE6554FC93183" xlink:to="lab_us-gaap_EmployeeStockMember_D9C162777CDB3B3FD22DE6554FC93183" xlink:type="arc" /> <link:label id="lab_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label> <link:label id="lab_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:type="arc" /> <link:label id="lab_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label> <link:label id="lab_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:to="lab_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:type="arc" /> <link:label id="lab_us-gaap_CommonStockMember_E515BB01D38BCF5A099CE6554FCABF58_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_E515BB01D38BCF5A099CE6554FCABF58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label> <link:label id="lab_us-gaap_CommonStockMember_E515BB01D38BCF5A099CE6554FCABF58_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_E515BB01D38BCF5A099CE6554FCABF58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E515BB01D38BCF5A099CE6554FCABF58" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_E515BB01D38BCF5A099CE6554FCABF58" xlink:to="lab_us-gaap_CommonStockMember_E515BB01D38BCF5A099CE6554FCABF58" xlink:type="arc" /> <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label> <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:type="arc" /> <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label> <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:type="arc" /> <link:label id="lab_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7_terseLabel_en-US" xlink:label="lab_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Follow On Offering</link:label> <link:label id="lab_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7_label_en-US" xlink:label="lab_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Follow On Offering [Member]</link:label> <link:label id="lab_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7_documentation_en-US" xlink:label="lab_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Follow On Offering [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_FollowOnOfferingMember" xlink:label="loc_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7" xlink:to="lab_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7" xlink:type="arc" /> <link:label id="lab_us-gaap_OverAllotmentOptionMember_9FEF8C1220B8A7E958DAE6554FCBB9B6_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_9FEF8C1220B8A7E958DAE6554FCBB9B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label> <link:label id="lab_us-gaap_OverAllotmentOptionMember_9FEF8C1220B8A7E958DAE6554FCBB9B6_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_9FEF8C1220B8A7E958DAE6554FCBB9B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_9FEF8C1220B8A7E958DAE6554FCBB9B6" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_9FEF8C1220B8A7E958DAE6554FCBB9B6" xlink:to="lab_us-gaap_OverAllotmentOptionMember_9FEF8C1220B8A7E958DAE6554FCBB9B6" xlink:type="arc" /> <link:label id="lab_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC_terseLabel_en-US" xlink:label="lab_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At the Market Offering</link:label> <link:label id="lab_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC_label_en-US" xlink:label="lab_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At the Market Offering [Member]</link:label> <link:label id="lab_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC_documentation_en-US" xlink:label="lab_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At the Market Offering [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AttheMarketOfferingMember" xlink:label="loc_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC" xlink:to="lab_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC" xlink:type="arc" /> <link:label id="lab_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label> <link:label id="lab_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:to="lab_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:type="arc" /> <link:label id="lab_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label> <link:label id="lab_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:to="lab_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:type="arc" /> <link:label id="lab_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C_terseLabel_en-US" xlink:label="lab_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Equity Incentive Plan</link:label> <link:label id="lab_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C_label_en-US" xlink:label="lab_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Fourteen Equity Incentive Plan [Member]</link:label> <link:label id="lab_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C_documentation_en-US" xlink:label="lab_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Fourteen Equity Incentive Plan [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:label="loc_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C" xlink:to="lab_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C" xlink:type="arc" /> <link:label id="lab_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892_terseLabel_en-US" xlink:label="lab_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Inducement Plan</link:label> <link:label id="lab_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892_label_en-US" xlink:label="lab_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Fourteen Inducement Plan [Member]</link:label> <link:label id="lab_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892_documentation_en-US" xlink:label="lab_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Fourteen Inducement Plan [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwoThousandAndFourteenInducementPlanMember" xlink:label="loc_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892" xlink:to="lab_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892" xlink:type="arc" /> <link:label id="lab_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26_terseLabel_en-US" xlink:label="lab_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label> <link:label id="lab_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26_label_en-US" xlink:label="lab_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label> <link:label id="lab_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26_documentation_en-US" xlink:label="lab_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="loc_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26" xlink:to="lab_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26" xlink:type="arc" /> <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label> <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:type="arc" /> <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_FF7E55DFC678E59987A4E6554FCD0305_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_FF7E55DFC678E59987A4E6554FCD0305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for purchase under common stock warrants (in shares)</link:label> <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_FF7E55DFC678E59987A4E6554FCD0305_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_FF7E55DFC678E59987A4E6554FCD0305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_FF7E55DFC678E59987A4E6554FCD0305" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_FF7E55DFC678E59987A4E6554FCD0305" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_FF7E55DFC678E59987A4E6554FCD0305" xlink:type="arc" /> <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D1D74FAE638C438B4001E6554FCD065C_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D1D74FAE638C438B4001E6554FCD065C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price per share (in USD per share)</link:label> <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D1D74FAE638C438B4001E6554FCD065C_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D1D74FAE638C438B4001E6554FCD065C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D1D74FAE638C438B4001E6554FCD065C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D1D74FAE638C438B4001E6554FCD065C" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D1D74FAE638C438B4001E6554FCD065C" xlink:type="arc" /> <link:label id="lab_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D_terseLabel_en-US" xlink:label="lab_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon exercise of warrant (shares)</link:label> <link:label id="lab_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D_label_en-US" xlink:label="lab_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Warrants</link:label> <link:label id="lab_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D_documentation_en-US" xlink:label="lab_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Warrants</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D" xlink:to="lab_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D" xlink:type="arc" /> <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7531457E13AE97BDF19FE6554FCD9743_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7531457E13AE97BDF19FE6554FCD9743" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, capital shares reserved for future issuance (in shares)</link:label> <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7531457E13AE97BDF19FE6554FCD9743_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7531457E13AE97BDF19FE6554FCD9743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7531457E13AE97BDF19FE6554FCD9743" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7531457E13AE97BDF19FE6554FCD9743" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7531457E13AE97BDF19FE6554FCD9743" xlink:type="arc" /> <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A17EF1C162B75C69FA55E6554FCE599A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A17EF1C162B75C69FA55E6554FCE599A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares underlying stock options granted (in shares)</link:label> <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A17EF1C162B75C69FA55E6554FCE599A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A17EF1C162B75C69FA55E6554FCE599A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A17EF1C162B75C69FA55E6554FCE599A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A17EF1C162B75C69FA55E6554FCE599A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A17EF1C162B75C69FA55E6554FCE599A" xlink:type="arc" /> <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4B12BFF62C25C96017AE6554FCEBAB5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4B12BFF62C25C96017AE6554FCEBAB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares granted under restricted stock awards (shares)</link:label> <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4B12BFF62C25C96017AE6554FCEBAB5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4B12BFF62C25C96017AE6554FCEBAB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4B12BFF62C25C96017AE6554FCEBAB5" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4B12BFF62C25C96017AE6554FCEBAB5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4B12BFF62C25C96017AE6554FCEBAB5" xlink:type="arc" /> <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1F94521EAF057ED35D7E6554FCE3264_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1F94521EAF057ED35D7E6554FCE3264" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period, shares, new issues (in shares)</link:label> <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1F94521EAF057ED35D7E6554FCE3264_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1F94521EAF057ED35D7E6554FCE3264" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1F94521EAF057ED35D7E6554FCE3264" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1F94521EAF057ED35D7E6554FCE3264" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1F94521EAF057ED35D7E6554FCE3264" xlink:type="arc" /> <link:label id="lab_us-gaap_SharePrice_0104608ACA0F08B2CEABE6554FCE8E6C_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_0104608ACA0F08B2CEABE6554FCE8E6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollar per share)</link:label> <link:label id="lab_us-gaap_SharePrice_0104608ACA0F08B2CEABE6554FCE8E6C_label_en-US" xlink:label="lab_us-gaap_SharePrice_0104608ACA0F08B2CEABE6554FCE8E6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_0104608ACA0F08B2CEABE6554FCE8E6C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_0104608ACA0F08B2CEABE6554FCE8E6C" xlink:to="lab_us-gaap_SharePrice_0104608ACA0F08B2CEABE6554FCE8E6C" xlink:type="arc" /> <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C22CEBDE07FBA2342459E6554FCEEFBA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C22CEBDE07FBA2342459E6554FCEEFBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label> <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C22CEBDE07FBA2342459E6554FCEEFBA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C22CEBDE07FBA2342459E6554FCEEFBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C22CEBDE07FBA2342459E6554FCEEFBA" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C22CEBDE07FBA2342459E6554FCEEFBA" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_C22CEBDE07FBA2342459E6554FCEEFBA" xlink:type="arc" /> <link:label id="lab_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192_terseLabel_en-US" xlink:label="lab_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance sales agreement, authorized offering price, maximum</link:label> <link:label id="lab_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192_label_en-US" xlink:label="lab_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Sales Agreement, Authorized Offering Price, Maximum</link:label> <link:label id="lab_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192_documentation_en-US" xlink:label="lab_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Sales Agreement, Authorized Offering Price, Maximum</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum" xlink:label="loc_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192" xlink:to="lab_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192" xlink:type="arc" /> <link:label id="lab_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6_terseLabel_en-US" xlink:label="lab_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission, percentage, maximum</link:label> <link:label id="lab_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6_label_en-US" xlink:label="lab_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Issuance Costs, Commission, Percentage, Maximum</link:label> <link:label id="lab_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6_documentation_en-US" xlink:label="lab_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Issuance Costs, Commission, Percentage, Maximum</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum" xlink:label="loc_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6" xlink:to="lab_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label> <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:type="arc" /> <link:label id="lab_rvnc_DerivativeLiabilitySettlementMember_EE52B60D413F7F9865799DEC932F1064_verboseLabel_en-US" xlink:label="lab_rvnc_DerivativeLiabilitySettlementMember_EE52B60D413F7F9865799DEC932F1064" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DerivativeLiabilitySettlementMember" xlink:label="loc_rvnc_DerivativeLiabilitySettlementMember_EE52B60D413F7F9865799DEC932F1064" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_DerivativeLiabilitySettlementMember_EE52B60D413F7F9865799DEC932F1064" xlink:to="lab_rvnc_DerivativeLiabilitySettlementMember_EE52B60D413F7F9865799DEC932F1064" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label> <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:type="arc" /> <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_EF5E25B60721053A0E009EC07FCB26A5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_EF5E25B60721053A0E009EC07FCB26A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt, fair value disclosures</link:label> <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_EF5E25B60721053A0E009EC07FCB26A5_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_EF5E25B60721053A0E009EC07FCB26A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_EF5E25B60721053A0E009EC07FCB26A5" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures_EF5E25B60721053A0E009EC07FCB26A5" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures_EF5E25B60721053A0E009EC07FCB26A5" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label> <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11DE20D9E8AA5BEF2C3E9DEC9330AEBD_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11DE20D9E8AA5BEF2C3E9DEC9330AEBD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value as of December 31, 2019</link:label> <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11DE20D9E8AA5BEF2C3E9DEC9330AEBD_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11DE20D9E8AA5BEF2C3E9DEC9330AEBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11DE20D9E8AA5BEF2C3E9DEC9330AEBD" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11DE20D9E8AA5BEF2C3E9DEC9330AEBD" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11DE20D9E8AA5BEF2C3E9DEC9330AEBD" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39F4153666A35CAC59039DEC93315C61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39F4153666A35CAC59039DEC93315C61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label> <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39F4153666A35CAC59039DEC93315C61_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39F4153666A35CAC59039DEC93315C61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39F4153666A35CAC59039DEC93315C61" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39F4153666A35CAC59039DEC93315C61" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39F4153666A35CAC59039DEC93315C61" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B022A31C8B3A3505AA3C9DEC93315AD4_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B022A31C8B3A3505AA3C9DEC93315AD4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value as of March 31, 2020</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B022A31C8B3A3505AA3C9DEC93315AD4" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B022A31C8B3A3505AA3C9DEC93315AD4" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B022A31C8B3A3505AA3C9DEC93315AD4" xlink:type="arc" /> <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5D9062C634DF1D72D09DE627CC0A80A7_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5D9062C634DF1D72D09DE627CC0A80A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5D9062C634DF1D72D09DE627CC0A80A7" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5D9062C634DF1D72D09DE627CC0A80A7" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5D9062C634DF1D72D09DE627CC0A80A7" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label> <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:type="arc" /> <link:label id="lab_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label> <link:label id="lab_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:to="lab_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:type="arc" /> <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label> <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389" xlink:type="arc" /> <link:label id="lab_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C_terseLabel_en-US" xlink:label="lab_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Teoxane Agreement</link:label> <link:label id="lab_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C_label_en-US" xlink:label="lab_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Teoxane Agreement [Member]</link:label> <link:label id="lab_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C_documentation_en-US" xlink:label="lab_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Teoxane Agreement [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TeoxaneAgreementMember" xlink:label="loc_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C" xlink:to="lab_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C" xlink:type="arc" /> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:type="arc" /> <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_879C5BA9C63D6C9D3A30E627CC0C39FF_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_879C5BA9C63D6C9D3A30E627CC0C39FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period, purchase of assets (in shares)</link:label> <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_879C5BA9C63D6C9D3A30E627CC0C39FF_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_879C5BA9C63D6C9D3A30E627CC0C39FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_879C5BA9C63D6C9D3A30E627CC0C39FF" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_879C5BA9C63D6C9D3A30E627CC0C39FF" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_879C5BA9C63D6C9D3A30E627CC0C39FF" xlink:type="arc" /> <link:label id="lab_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227_terseLabel_en-US" xlink:label="lab_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, contractual period</link:label> <link:label id="lab_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227_label_en-US" xlink:label="lab_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Contractual Period</link:label> <link:label id="lab_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227_documentation_en-US" xlink:label="lab_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Contractual Period</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CollaborativeAgreementContractualPeriod" xlink:label="loc_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227" xlink:to="lab_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227" xlink:type="arc" /> <link:label id="lab_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D_terseLabel_en-US" xlink:label="lab_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, extended contractual period</link:label> <link:label id="lab_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D_label_en-US" xlink:label="lab_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Extended Contractual Period</link:label> <link:label id="lab_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D_documentation_en-US" xlink:label="lab_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Extended Contractual Period</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CollaborativeAgreementExtendedContractualPeriod" xlink:label="loc_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D" xlink:to="lab_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_C0002C2ED95E51D6A01AE6343A48989B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_C0002C2ED95E51D6A01AE6343A48989B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of assets acquired</link:label> <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_C0002C2ED95E51D6A01AE6343A48989B_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired_C0002C2ED95E51D6A01AE6343A48989B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Assets Acquired</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_C0002C2ED95E51D6A01AE6343A48989B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired_C0002C2ED95E51D6A01AE6343A48989B" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired_C0002C2ED95E51D6A01AE6343A48989B" xlink:type="arc" /> <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_06FD5430C9AD1166B10CE6308F53F98E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_06FD5430C9AD1166B10CE6308F53F98E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash in-process research and development</link:label> <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_06FD5430C9AD1166B10CE6308F53F98E_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_06FD5430C9AD1166B10CE6308F53F98E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_06FD5430C9AD1166B10CE6308F53F98E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_06FD5430C9AD1166B10CE6308F53F98E" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_06FD5430C9AD1166B10CE6308F53F98E" xlink:type="arc" /> <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_793C541CDDAAE4B1B06CE627CC7708C8_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_793C541CDDAAE4B1B06CE627CC7708C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_793C541CDDAAE4B1B06CE627CC7708C8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_793C541CDDAAE4B1B06CE627CC7708C8" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_793C541CDDAAE4B1B06CE627CC7708C8" xlink:type="arc" /> <link:label id="lab_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label> <link:label id="lab_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1_label_en-US" xlink:label="lab_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:to="lab_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:type="arc" /> <link:label id="lab_us-gaap_CommonStockMember_2978E893C86C5AC8949CE627CC783BD8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_2978E893C86C5AC8949CE627CC783BD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2978E893C86C5AC8949CE627CC783BD8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_2978E893C86C5AC8949CE627CC783BD8" xlink:to="lab_us-gaap_CommonStockMember_2978E893C86C5AC8949CE627CC783BD8" xlink:type="arc" /> <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_365CCAB69FB894E50598E627CC797642_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_365CCAB69FB894E50598E627CC797642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label> <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_365CCAB69FB894E50598E627CC797642_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_365CCAB69FB894E50598E627CC797642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_365CCAB69FB894E50598E627CC797642" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_365CCAB69FB894E50598E627CC797642" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_365CCAB69FB894E50598E627CC797642" xlink:type="arc" /> <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72D9F60C37B1C0E60B6BE627CC79F4FE_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72D9F60C37B1C0E60B6BE627CC79F4FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Accumulated Comprehensive Gain (Loss)</link:label> <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72D9F60C37B1C0E60B6BE627CC79F4FE_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72D9F60C37B1C0E60B6BE627CC79F4FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72D9F60C37B1C0E60B6BE627CC79F4FE" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72D9F60C37B1C0E60B6BE627CC79F4FE" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72D9F60C37B1C0E60B6BE627CC79F4FE" xlink:type="arc" /> <link:label id="lab_us-gaap_RetainedEarningsMember_920314E4C2DC0DFAA564E627CC796CB4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_920314E4C2DC0DFAA564E627CC796CB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label> <link:label id="lab_us-gaap_RetainedEarningsMember_920314E4C2DC0DFAA564E627CC796CB4_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_920314E4C2DC0DFAA564E627CC796CB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_920314E4C2DC0DFAA564E627CC796CB4" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_920314E4C2DC0DFAA564E627CC796CB4" xlink:to="lab_us-gaap_RetainedEarningsMember_920314E4C2DC0DFAA564E627CC796CB4" xlink:type="arc" /> <link:label id="lab_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label> <link:label id="lab_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A" xlink:to="lab_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A" xlink:type="arc" /> <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label> <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:type="arc" /> <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9216B93F16A280A0C7B7E627CC7A4636_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_9216B93F16A280A0C7B7E627CC7A4636" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (in shares)</link:label> <link:label id="lab_us-gaap_CommonStockSharesOutstanding_9216B93F16A280A0C7B7E627CC7A4636_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_9216B93F16A280A0C7B7E627CC7A4636" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9216B93F16A280A0C7B7E627CC7A4636" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_9216B93F16A280A0C7B7E627CC7A4636" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_9216B93F16A280A0C7B7E627CC7A4636" xlink:type="arc" /> <link:label id="lab_us-gaap_StockholdersEquity_243066B1F132E3120DF2E627CC7A15B4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_243066B1F132E3120DF2E627CC7A15B4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label> <link:label id="lab_us-gaap_StockholdersEquity_243066B1F132E3120DF2E627CC7A15B4_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_243066B1F132E3120DF2E627CC7A15B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_243066B1F132E3120DF2E627CC7A15B4" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_243066B1F132E3120DF2E627CC7A15B4" xlink:to="lab_us-gaap_StockholdersEquity_243066B1F132E3120DF2E627CC7A15B4" xlink:type="arc" /> <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_4C4C546D4C8D64708649E627CC7AD160_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_4C4C546D4C8D64708649E627CC7AD160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the Teoxane Agreement (in shares)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_4C4C546D4C8D64708649E627CC7AD160" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_4C4C546D4C8D64708649E627CC7AD160" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_4C4C546D4C8D64708649E627CC7AD160" xlink:type="arc" /> <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1312279B31E9C72D0D21E627CC7AF081_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1312279B31E9C72D0D21E627CC7AF081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the Teoxane Agreement</link:label> <link:label id="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1312279B31E9C72D0D21E627CC7AF081_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1312279B31E9C72D0D21E627CC7AF081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1312279B31E9C72D0D21E627CC7AF081" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1312279B31E9C72D0D21E627CC7AF081" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1312279B31E9C72D0D21E627CC7AF081" xlink:type="arc" /> <link:label id="lab_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88_terseLabel_en-US" xlink:label="lab_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)</link:label> <link:label id="lab_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88_label_en-US" xlink:label="lab_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Restricted Stock Award, Net of Shares Repurchased</link:label> <link:label id="lab_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88_documentation_en-US" xlink:label="lab_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Restricted Stock Award, Net of Shares Repurchased</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased" xlink:label="loc_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88" xlink:to="lab_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88" xlink:type="arc" /> <link:label id="lab_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB_terseLabel_en-US" xlink:label="lab_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of restricted stock awards and performance stock awards, net of cancellation</link:label> <link:label id="lab_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB_label_en-US" xlink:label="lab_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Restricted Stock Award, Net Of Shares Repurchased</link:label> <link:label id="lab_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB_documentation_en-US" xlink:label="lab_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Restricted Stock Award, Net of Shares Repurchased</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased" xlink:label="loc_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB" xlink:to="lab_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB" xlink:type="arc" /> <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07430BC45C0FC2C2B226E627CC7BF486_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07430BC45C0FC2C2B226E627CC7BF486" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with offerings (in shares)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07430BC45C0FC2C2B226E627CC7BF486" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07430BC45C0FC2C2B226E627CC7BF486" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07430BC45C0FC2C2B226E627CC7BF486" xlink:type="arc" /> <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9B3588110AA3B6A02FFFE627CC7B2010_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9B3588110AA3B6A02FFFE627CC7B2010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with offerings</link:label> <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9B3588110AA3B6A02FFFE627CC7B2010_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9B3588110AA3B6A02FFFE627CC7B2010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9B3588110AA3B6A02FFFE627CC7B2010" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9B3588110AA3B6A02FFFE627CC7B2010" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9B3588110AA3B6A02FFFE627CC7B2010" xlink:type="arc" /> <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B79CD62D2A0CFD8886E0E627CC7B9C87_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B79CD62D2A0CFD8886E0E627CC7B9C87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options and warrants (in shares)</link:label> <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B79CD62D2A0CFD8886E0E627CC7B9C87_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B79CD62D2A0CFD8886E0E627CC7B9C87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B79CD62D2A0CFD8886E0E627CC7B9C87" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B79CD62D2A0CFD8886E0E627CC7B9C87" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B79CD62D2A0CFD8886E0E627CC7B9C87" xlink:type="arc" /> <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_09C031797D466857960EE627CC7BD90D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_09C031797D466857960EE627CC7BD90D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net settlement of restricted stock awards for employee taxes (in shares)</link:label> <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_09C031797D466857960EE627CC7BD90D_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_09C031797D466857960EE627CC7BD90D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_09C031797D466857960EE627CC7BD90D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_09C031797D466857960EE627CC7BD90D" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_09C031797D466857960EE627CC7BD90D" xlink:type="arc" /> <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9FB87F2D789C29E1D0E3E627CC7B1CC4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9FB87F2D789C29E1D0E3E627CC7B1CC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options and warrants</link:label> <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9FB87F2D789C29E1D0E3E627CC7B1CC4_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9FB87F2D789C29E1D0E3E627CC7B1CC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9FB87F2D789C29E1D0E3E627CC7B1CC4" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9FB87F2D789C29E1D0E3E627CC7B1CC4" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9FB87F2D789C29E1D0E3E627CC7B1CC4" xlink:type="arc" /> <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D56C37DB5EE1449AA9AAE627CC7CFDF2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D56C37DB5EE1449AA9AAE627CC7CFDF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of convertible senior notes, net of transaction costs of $3,583</link:label> <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D56C37DB5EE1449AA9AAE627CC7CFDF2_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D56C37DB5EE1449AA9AAE627CC7CFDF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D56C37DB5EE1449AA9AAE627CC7CFDF2" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D56C37DB5EE1449AA9AAE627CC7CFDF2" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D56C37DB5EE1449AA9AAE627CC7CFDF2" xlink:type="arc" /> <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0EED978D7EEFDCF2AEDDE627CC7CF874_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0EED978D7EEFDCF2AEDDE627CC7CF874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label> <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0EED978D7EEFDCF2AEDDE627CC7CF874_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0EED978D7EEFDCF2AEDDE627CC7CF874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0EED978D7EEFDCF2AEDDE627CC7CF874" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0EED978D7EEFDCF2AEDDE627CC7CF874" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0EED978D7EEFDCF2AEDDE627CC7CF874" xlink:type="arc" /> <link:label id="lab_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336_negatedTerseLabel_en-US" xlink:label="lab_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capped call transactions</link:label> <link:label id="lab_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336_label_en-US" xlink:label="lab_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To Additional Paid In Capital, Capped Call Transactions</link:label> <link:label id="lab_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336_documentation_en-US" xlink:label="lab_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustment To Additional Paid In Capital, Capped Call Transactions</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions" xlink:label="loc_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336" xlink:to="lab_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336" xlink:type="arc" /> <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5B36F14325539D762D93E627CC7CE052_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5B36F14325539D762D93E627CC7CE052" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net settlement of restricted stock awards for employee taxes</link:label> <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5B36F14325539D762D93E627CC7CE052_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5B36F14325539D762D93E627CC7CE052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5B36F14325539D762D93E627CC7CE052" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5B36F14325539D762D93E627CC7CE052" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5B36F14325539D762D93E627CC7CE052" xlink:type="arc" /> <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D08E5C14ACCDDCCEBD97E627CC7C4646_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D08E5C14ACCDDCCEBD97E627CC7C4646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain and adjustment on securities included in net loss</link:label> <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D08E5C14ACCDDCCEBD97E627CC7C4646_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D08E5C14ACCDDCCEBD97E627CC7C4646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D08E5C14ACCDDCCEBD97E627CC7C4646" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D08E5C14ACCDDCCEBD97E627CC7C4646" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D08E5C14ACCDDCCEBD97E627CC7C4646" xlink:type="arc" /> <link:label id="lab_us-gaap_NetIncomeLoss_45934276991D6E8F5693E627CC7CE771_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_45934276991D6E8F5693E627CC7CE771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label> <link:label id="lab_us-gaap_NetIncomeLoss_45934276991D6E8F5693E627CC7CE771_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_45934276991D6E8F5693E627CC7CE771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_45934276991D6E8F5693E627CC7CE771" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_45934276991D6E8F5693E627CC7CE771" xlink:to="lab_us-gaap_NetIncomeLoss_45934276991D6E8F5693E627CC7CE771" xlink:type="arc" /> <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1F4D564D5F2E79809782E627CC7DF05B_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1F4D564D5F2E79809782E627CC7DF05B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (in shares)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1F4D564D5F2E79809782E627CC7DF05B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_1F4D564D5F2E79809782E627CC7DF05B" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1F4D564D5F2E79809782E627CC7DF05B" xlink:type="arc" /> <link:label id="lab_us-gaap_StockholdersEquity_735A56EDF6293F6002F4E627CC7D9E0D_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_735A56EDF6293F6002F4E627CC7D9E0D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_735A56EDF6293F6002F4E627CC7D9E0D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_735A56EDF6293F6002F4E627CC7D9E0D" xlink:to="lab_us-gaap_StockholdersEquity_735A56EDF6293F6002F4E627CC7D9E0D" xlink:type="arc" /> <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869" xlink:type="arc" /> <link:label id="lab_us-gaap_NumberOfOperatingSegments_50C88530B428338C1369BA9003EC37BC_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_50C88530B428338C1369BA9003EC37BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label> <link:label id="lab_us-gaap_NumberOfOperatingSegments_50C88530B428338C1369BA9003EC37BC_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_50C88530B428338C1369BA9003EC37BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_50C88530B428338C1369BA9003EC37BC" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_50C88530B428338C1369BA9003EC37BC" xlink:to="lab_us-gaap_NumberOfOperatingSegments_50C88530B428338C1369BA9003EC37BC" xlink:type="arc" /> <link:label id="lab_us-gaap_NetIncomeLoss_911C19F4D4162A4146A3BA5FF6B948C5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_911C19F4D4162A4146A3BA5FF6B948C5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_911C19F4D4162A4146A3BA5FF6B948C5" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_911C19F4D4162A4146A3BA5FF6B948C5" xlink:to="lab_us-gaap_NetIncomeLoss_911C19F4D4162A4146A3BA5FF6B948C5" xlink:type="arc" /> <link:label id="lab_rvnc_WorkingCapitalSurplus_AD432C4B6F534CEF8148BA5FF6B9F421_terseLabel_en-US" xlink:label="lab_rvnc_WorkingCapitalSurplus_AD432C4B6F534CEF8148BA5FF6B9F421" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital surplus</link:label> <link:label id="lab_rvnc_WorkingCapitalSurplus_AD432C4B6F534CEF8148BA5FF6B9F421_label_en-US" xlink:label="lab_rvnc_WorkingCapitalSurplus_AD432C4B6F534CEF8148BA5FF6B9F421" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital Surplus</link:label> <link:label id="lab_rvnc_WorkingCapitalSurplus_AD432C4B6F534CEF8148BA5FF6B9F421_documentation_en-US" xlink:label="lab_rvnc_WorkingCapitalSurplus_AD432C4B6F534CEF8148BA5FF6B9F421" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Working Capital Surplus</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_WorkingCapitalSurplus" xlink:label="loc_rvnc_WorkingCapitalSurplus_AD432C4B6F534CEF8148BA5FF6B9F421" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_WorkingCapitalSurplus_AD432C4B6F534CEF8148BA5FF6B9F421" xlink:to="lab_rvnc_WorkingCapitalSurplus_AD432C4B6F534CEF8148BA5FF6B9F421" xlink:type="arc" /> <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_881D640E2F4F27379E88BA5FF6B9C32F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_881D640E2F4F27379E88BA5FF6B9C32F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label> <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_881D640E2F4F27379E88BA5FF6B9C32F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_881D640E2F4F27379E88BA5FF6B9C32F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_881D640E2F4F27379E88BA5FF6B9C32F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_881D640E2F4F27379E88BA5FF6B9C32F" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_881D640E2F4F27379E88BA5FF6B9C32F" xlink:type="arc" /> <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_F6E24786A52500531960BA5FF6B9B601_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_F6E24786A52500531960BA5FF6B9B601" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label> <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_F6E24786A52500531960BA5FF6B9B601_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_F6E24786A52500531960BA5FF6B9B601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_F6E24786A52500531960BA5FF6B9B601" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_F6E24786A52500531960BA5FF6B9B601" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_F6E24786A52500531960BA5FF6B9B601" xlink:type="arc" /> <link:label id="lab_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum_E04CA7D5858EB3A14A54BA5FF6B90BFF_terseLabel_en-US" xlink:label="lab_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum_E04CA7D5858EB3A14A54BA5FF6B90BFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, and investments, expected funding term for operating plan (in months)</link:label> <link:label id="lab_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum_E04CA7D5858EB3A14A54BA5FF6B90BFF_label_en-US" xlink:label="lab_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum_E04CA7D5858EB3A14A54BA5FF6B90BFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, and Investments, Operating Plan Funding Term, Minimum</link:label> <link:label id="lab_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum_E04CA7D5858EB3A14A54BA5FF6B90BFF_documentation_en-US" xlink:label="lab_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum_E04CA7D5858EB3A14A54BA5FF6B90BFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, and Investments, Operating Plan Funding Term, Minimum</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum" xlink:label="loc_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum_E04CA7D5858EB3A14A54BA5FF6B90BFF" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum_E04CA7D5858EB3A14A54BA5FF6B90BFF" xlink:to="lab_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum_E04CA7D5858EB3A14A54BA5FF6B90BFF" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_56CA1A51FCF4D787769E16CE0F1B53E9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_56CA1A51FCF4D787769E16CE0F1B53E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of Financial Instruments</link:label> <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_56CA1A51FCF4D787769E16CE0F1B53E9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_56CA1A51FCF4D787769E16CE0F1B53E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_56CA1A51FCF4D787769E16CE0F1B53E9" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_56CA1A51FCF4D787769E16CE0F1B53E9" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_56CA1A51FCF4D787769E16CE0F1B53E9" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7FECE2DAA355CCC0754E16CE0F1B04E4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7FECE2DAA355CCC0754E16CE0F1B04E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Changes in Fair Value of Financial Instruments</link:label> <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7FECE2DAA355CCC0754E16CE0F1B04E4_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7FECE2DAA355CCC0754E16CE0F1B04E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7FECE2DAA355CCC0754E16CE0F1B04E4" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7FECE2DAA355CCC0754E16CE0F1B04E4" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7FECE2DAA355CCC0754E16CE0F1B04E4" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_9E363010A2C36778A40EEC7297837B18_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_9E363010A2C36778A40EEC7297837B18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027 Notes</link:label> <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_9E363010A2C36778A40EEC7297837B18_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_9E363010A2C36778A40EEC7297837B18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9E363010A2C36778A40EEC7297837B18" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_9E363010A2C36778A40EEC7297837B18" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_9E363010A2C36778A40EEC7297837B18" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_C3B271DC3208963E058EEC729788C954_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_C3B271DC3208963E058EEC729788C954" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Unamortized debt discount and debt issuance costs</link:label> <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_C3B271DC3208963E058EEC729788C954_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_C3B271DC3208963E058EEC729788C954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_C3B271DC3208963E058EEC729788C954" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_C3B271DC3208963E058EEC729788C954" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_C3B271DC3208963E058EEC729788C954" xlink:type="arc" /> <link:label id="lab_us-gaap_LongTermDebt_AB13292A6890F9C8BB6CEC729788CE47_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_AB13292A6890F9C8BB6CEC729788CE47" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Carrying amount of 2027 Notes</link:label> <link:label id="lab_us-gaap_LongTermDebt_AB13292A6890F9C8BB6CEC729788CE47_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_AB13292A6890F9C8BB6CEC729788CE47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_AB13292A6890F9C8BB6CEC729788CE47" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_AB13292A6890F9C8BB6CEC729788CE47" xlink:to="lab_us-gaap_LongTermDebt_AB13292A6890F9C8BB6CEC729788CE47" xlink:type="arc" /> <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_CC0B048C437FE84CB5AAE627CC9ABE68_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_CC0B048C437FE84CB5AAE627CC9ABE68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_CC0B048C437FE84CB5AAE627CC9ABE68" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CC0B048C437FE84CB5AAE627CC9ABE68" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_CC0B048C437FE84CB5AAE627CC9ABE68" xlink:type="arc" /> <link:label id="lab_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label> <link:label id="lab_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:to="lab_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:type="arc" /> <link:label id="lab_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT ASSETS</link:label> <link:label id="lab_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE" xlink:to="lab_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE" xlink:type="arc" /> <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69AF35044FD158D9B3D9E627CC9B2455_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69AF35044FD158D9B3D9E627CC9B2455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label> <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69AF35044FD158D9B3D9E627CC9B2455_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69AF35044FD158D9B3D9E627CC9B2455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69AF35044FD158D9B3D9E627CC9B2455" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69AF35044FD158D9B3D9E627CC9B2455" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_69AF35044FD158D9B3D9E627CC9B2455" xlink:type="arc" /> <link:label id="lab_us-gaap_ShortTermInvestments_C5CD119409F86F80CF62E627CC9BFB33_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_C5CD119409F86F80CF62E627CC9BFB33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label> <link:label id="lab_us-gaap_ShortTermInvestments_C5CD119409F86F80CF62E627CC9BFB33_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_C5CD119409F86F80CF62E627CC9BFB33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_C5CD119409F86F80CF62E627CC9BFB33" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_C5CD119409F86F80CF62E627CC9BFB33" xlink:to="lab_us-gaap_ShortTermInvestments_C5CD119409F86F80CF62E627CC9BFB33" xlink:type="arc" /> <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76A29D3A8BEF9E972CDEE627CC9C7CD1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76A29D3A8BEF9E972CDEE627CC9C7CD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label> <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76A29D3A8BEF9E972CDEE627CC9C7CD1_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76A29D3A8BEF9E972CDEE627CC9C7CD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76A29D3A8BEF9E972CDEE627CC9C7CD1" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76A29D3A8BEF9E972CDEE627CC9C7CD1" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76A29D3A8BEF9E972CDEE627CC9C7CD1" xlink:type="arc" /> <link:label id="lab_us-gaap_AssetsCurrent_95CAF33356F88F17C6E9E627CC9C1669_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_95CAF33356F88F17C6E9E627CC9C1669" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label> <link:label id="lab_us-gaap_AssetsCurrent_95CAF33356F88F17C6E9E627CC9C1669_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_95CAF33356F88F17C6E9E627CC9C1669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_95CAF33356F88F17C6E9E627CC9C1669" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_95CAF33356F88F17C6E9E627CC9C1669" xlink:to="lab_us-gaap_AssetsCurrent_95CAF33356F88F17C6E9E627CC9C1669" xlink:type="arc" /> <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_F46ECE9622C4B8986C36E627CC9CAE7F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_F46ECE9622C4B8986C36E627CC9CAE7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label> <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_F46ECE9622C4B8986C36E627CC9CAE7F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_F46ECE9622C4B8986C36E627CC9CAE7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_F46ECE9622C4B8986C36E627CC9CAE7F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_F46ECE9622C4B8986C36E627CC9CAE7F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_F46ECE9622C4B8986C36E627CC9CAE7F" xlink:type="arc" /> <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_1BA88FFC24A15494109CE627CC9CAC41_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet_1BA88FFC24A15494109CE627CC9CAC41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label> <link:label id="lab_us-gaap_OtherIntangibleAssetsNet_1BA88FFC24A15494109CE627CC9CAC41_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsNet_1BA88FFC24A15494109CE627CC9CAC41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets, Net</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_1BA88FFC24A15494109CE627CC9CAC41" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsNet_1BA88FFC24A15494109CE627CC9CAC41" xlink:to="lab_us-gaap_OtherIntangibleAssetsNet_1BA88FFC24A15494109CE627CC9CAC41" xlink:type="arc" /> <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_BF9426193E8D606D8C35E627CC9C75DC_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_BF9426193E8D606D8C35E627CC9C75DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right of use assets</link:label> <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_BF9426193E8D606D8C35E627CC9C75DC_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_BF9426193E8D606D8C35E627CC9C75DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_BF9426193E8D606D8C35E627CC9C75DC" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_BF9426193E8D606D8C35E627CC9C75DC" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_BF9426193E8D606D8C35E627CC9C75DC" xlink:type="arc" /> <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9B3CE728160A9D95ABC3E627CC9C25F2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9B3CE728160A9D95ABC3E627CC9C25F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label> <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9B3CE728160A9D95ABC3E627CC9C25F2_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9B3CE728160A9D95ABC3E627CC9C25F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9B3CE728160A9D95ABC3E627CC9C25F2" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9B3CE728160A9D95ABC3E627CC9C25F2" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9B3CE728160A9D95ABC3E627CC9C25F2" xlink:type="arc" /> <link:label id="lab_us-gaap_OtherAssetsNoncurrent_B4C17F13F1C1E3503064E627CC9DC4B8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_B4C17F13F1C1E3503064E627CC9DC4B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label> <link:label id="lab_us-gaap_OtherAssetsNoncurrent_B4C17F13F1C1E3503064E627CC9DC4B8_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_B4C17F13F1C1E3503064E627CC9DC4B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_B4C17F13F1C1E3503064E627CC9DC4B8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_B4C17F13F1C1E3503064E627CC9DC4B8" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_B4C17F13F1C1E3503064E627CC9DC4B8" xlink:type="arc" /> <link:label id="lab_us-gaap_Assets_AAD5FC272A05609CFDD2E627CC9D021E_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_AAD5FC272A05609CFDD2E627CC9D021E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL ASSETS</link:label> <link:label id="lab_us-gaap_Assets_AAD5FC272A05609CFDD2E627CC9D021E_label_en-US" xlink:label="lab_us-gaap_Assets_AAD5FC272A05609CFDD2E627CC9D021E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_AAD5FC272A05609CFDD2E627CC9D021E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_AAD5FC272A05609CFDD2E627CC9D021E" xlink:to="lab_us-gaap_Assets_AAD5FC272A05609CFDD2E627CC9D021E" xlink:type="arc" /> <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS’ EQUITY</link:label> <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:type="arc" /> <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CURRENT LIABILITIES</link:label> <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:type="arc" /> <link:label id="lab_us-gaap_AccountsPayableCurrent_140D37B511C896EDAEC2E627CC9D46DE_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_140D37B511C896EDAEC2E627CC9D46DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label> <link:label id="lab_us-gaap_AccountsPayableCurrent_140D37B511C896EDAEC2E627CC9D46DE_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_140D37B511C896EDAEC2E627CC9D46DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_140D37B511C896EDAEC2E627CC9D46DE" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_140D37B511C896EDAEC2E627CC9D46DE" xlink:to="lab_us-gaap_AccountsPayableCurrent_140D37B511C896EDAEC2E627CC9D46DE" xlink:type="arc" /> <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9FF4CAE9EDEDDF20B131E627CC9EF4D7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_9FF4CAE9EDEDDF20B131E627CC9EF4D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and other current liabilities</link:label> <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_9FF4CAE9EDEDDF20B131E627CC9EF4D7_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_9FF4CAE9EDEDDF20B131E627CC9EF4D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9FF4CAE9EDEDDF20B131E627CC9EF4D7" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_9FF4CAE9EDEDDF20B131E627CC9EF4D7" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_9FF4CAE9EDEDDF20B131E627CC9EF4D7" xlink:type="arc" /> <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_F4722FB9A4CA375EAC94E627CC9E394A_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_F4722FB9A4CA375EAC94E627CC9E394A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, current portion</link:label> <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_F4722FB9A4CA375EAC94E627CC9E394A_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_F4722FB9A4CA375EAC94E627CC9E394A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_F4722FB9A4CA375EAC94E627CC9E394A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_F4722FB9A4CA375EAC94E627CC9E394A" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_F4722FB9A4CA375EAC94E627CC9E394A" xlink:type="arc" /> <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5F4E89756D466BE30A83E627CC9E154C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_5F4E89756D466BE30A83E627CC9E154C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current portion</link:label> <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5F4E89756D466BE30A83E627CC9E154C_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_5F4E89756D466BE30A83E627CC9E154C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5F4E89756D466BE30A83E627CC9E154C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_5F4E89756D466BE30A83E627CC9E154C" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_5F4E89756D466BE30A83E627CC9E154C" xlink:type="arc" /> <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_D3B2E376DB85131DFA4FE627CC9EA8F9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_D3B2E376DB85131DFA4FE627CC9EA8F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label> <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_D3B2E376DB85131DFA4FE627CC9EA8F9_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_D3B2E376DB85131DFA4FE627CC9EA8F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_D3B2E376DB85131DFA4FE627CC9EA8F9" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_D3B2E376DB85131DFA4FE627CC9EA8F9" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_D3B2E376DB85131DFA4FE627CC9EA8F9" xlink:type="arc" /> <link:label id="lab_us-gaap_LiabilitiesCurrent_CCB7AEE952A5E881E537E627CC9E6B0F_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_CCB7AEE952A5E881E537E627CC9E6B0F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label> <link:label id="lab_us-gaap_LiabilitiesCurrent_CCB7AEE952A5E881E537E627CC9E6B0F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_CCB7AEE952A5E881E537E627CC9E6B0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_CCB7AEE952A5E881E537E627CC9E6B0F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_CCB7AEE952A5E881E537E627CC9E6B0F" xlink:to="lab_us-gaap_LiabilitiesCurrent_CCB7AEE952A5E881E537E627CC9E6B0F" xlink:type="arc" /> <link:label id="lab_us-gaap_SeniorLongTermNotes_BA67841876EA67985F99E627CC9FBC23_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLongTermNotes_BA67841876EA67985F99E627CC9FBC23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes</link:label> <link:label id="lab_us-gaap_SeniorLongTermNotes_BA67841876EA67985F99E627CC9FBC23_label_en-US" xlink:label="lab_us-gaap_SeniorLongTermNotes_BA67841876EA67985F99E627CC9FBC23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes, Noncurrent</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="loc_us-gaap_SeniorLongTermNotes_BA67841876EA67985F99E627CC9FBC23" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLongTermNotes_BA67841876EA67985F99E627CC9FBC23" xlink:to="lab_us-gaap_SeniorLongTermNotes_BA67841876EA67985F99E627CC9FBC23" xlink:type="arc" /> <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_B1294E1D06822D319730E627CC9F2C18_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_B1294E1D06822D319730E627CC9F2C18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label> <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_B1294E1D06822D319730E627CC9F2C18_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_B1294E1D06822D319730E627CC9F2C18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_B1294E1D06822D319730E627CC9F2C18" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_B1294E1D06822D319730E627CC9F2C18" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_B1294E1D06822D319730E627CC9F2C18" xlink:type="arc" /> <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_06B3D11611B96A9F130DE627CC9F8D9B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_06B3D11611B96A9F130DE627CC9F8D9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label> <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_06B3D11611B96A9F130DE627CC9F8D9B_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_06B3D11611B96A9F130DE627CC9F8D9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06B3D11611B96A9F130DE627CC9F8D9B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06B3D11611B96A9F130DE627CC9F8D9B" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_06B3D11611B96A9F130DE627CC9F8D9B" xlink:type="arc" /> <link:label id="lab_us-gaap_Liabilities_8517A5B8783FF2198BAFE627CC9F2BDB_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_8517A5B8783FF2198BAFE627CC9F2BDB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES</link:label> <link:label id="lab_us-gaap_Liabilities_8517A5B8783FF2198BAFE627CC9F2BDB_label_en-US" xlink:label="lab_us-gaap_Liabilities_8517A5B8783FF2198BAFE627CC9F2BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_8517A5B8783FF2198BAFE627CC9F2BDB" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_8517A5B8783FF2198BAFE627CC9F2BDB" xlink:to="lab_us-gaap_Liabilities_8517A5B8783FF2198BAFE627CC9F2BDB" xlink:type="arc" /> <link:label id="lab_us-gaap_CommitmentsAndContingencies_4546792C41CC4AB8AAEBE627CC9FE704_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_4546792C41CC4AB8AAEBE627CC9FE704" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 10)</link:label> <link:label id="lab_us-gaap_CommitmentsAndContingencies_4546792C41CC4AB8AAEBE627CC9FE704_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_4546792C41CC4AB8AAEBE627CC9FE704" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4546792C41CC4AB8AAEBE627CC9FE704" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_4546792C41CC4AB8AAEBE627CC9FE704" xlink:to="lab_us-gaap_CommitmentsAndContingencies_4546792C41CC4AB8AAEBE627CC9FE704" xlink:type="arc" /> <link:label id="lab_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS’ EQUITY</link:label> <link:label id="lab_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:to="lab_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:type="arc" /> <link:label id="lab_us-gaap_PreferredStockValue_25617A38E251ECFEC7E8E627CCA0FE5A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_25617A38E251ECFEC7E8E627CCA0FE5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2020 and December 31, 2019</link:label> <link:label id="lab_us-gaap_PreferredStockValue_25617A38E251ECFEC7E8E627CCA0FE5A_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_25617A38E251ECFEC7E8E627CCA0FE5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_25617A38E251ECFEC7E8E627CCA0FE5A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_25617A38E251ECFEC7E8E627CCA0FE5A" xlink:to="lab_us-gaap_PreferredStockValue_25617A38E251ECFEC7E8E627CCA0FE5A" xlink:type="arc" /> <link:label id="lab_us-gaap_CommonStockValue_ACA6D1A355E2991771CAE627CCA0B812_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_ACA6D1A355E2991771CAE627CCA0B812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.001 per share — 95,000,000 shares authorized both as of March 31, 2020 and December 31, 2019; 57,026,154 and 52,374,735 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</link:label> <link:label id="lab_us-gaap_CommonStockValue_ACA6D1A355E2991771CAE627CCA0B812_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_ACA6D1A355E2991771CAE627CCA0B812" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ACA6D1A355E2991771CAE627CCA0B812" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_ACA6D1A355E2991771CAE627CCA0B812" xlink:to="lab_us-gaap_CommonStockValue_ACA6D1A355E2991771CAE627CCA0B812" xlink:type="arc" /> <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_E74356FE9B01AFE75251E627CCA082DF_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_E74356FE9B01AFE75251E627CCA082DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label> <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_E74356FE9B01AFE75251E627CCA082DF_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_E74356FE9B01AFE75251E627CCA082DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_E74356FE9B01AFE75251E627CCA082DF" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_E74356FE9B01AFE75251E627CCA082DF" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_E74356FE9B01AFE75251E627CCA082DF" xlink:type="arc" /> <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE4F8F1FCB3368618ACFE627CCA0D79A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE4F8F1FCB3368618ACFE627CCA0D79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label> <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE4F8F1FCB3368618ACFE627CCA0D79A_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE4F8F1FCB3368618ACFE627CCA0D79A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE4F8F1FCB3368618ACFE627CCA0D79A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE4F8F1FCB3368618ACFE627CCA0D79A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE4F8F1FCB3368618ACFE627CCA0D79A" xlink:type="arc" /> <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_89771E95F513C8ADA4B6E627CCA058F8_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_89771E95F513C8ADA4B6E627CCA058F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89771E95F513C8ADA4B6E627CCA058F8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89771E95F513C8ADA4B6E627CCA058F8" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_89771E95F513C8ADA4B6E627CCA058F8" xlink:type="arc" /> <link:label id="lab_us-gaap_StockholdersEquity_ED88E6F98BEA79B96404E627CCA03E62_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_ED88E6F98BEA79B96404E627CCA03E62" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL STOCKHOLDERS’ EQUITY</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_ED88E6F98BEA79B96404E627CCA03E62" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_ED88E6F98BEA79B96404E627CCA03E62" xlink:to="lab_us-gaap_StockholdersEquity_ED88E6F98BEA79B96404E627CCA03E62" xlink:type="arc" /> <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_52F2E9EA5A3CDEF4EFACE627CCA1C749_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_52F2E9EA5A3CDEF4EFACE627CCA1C749" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY</link:label> <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_52F2E9EA5A3CDEF4EFACE627CCA1C749_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_52F2E9EA5A3CDEF4EFACE627CCA1C749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_52F2E9EA5A3CDEF4EFACE627CCA1C749" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_52F2E9EA5A3CDEF4EFACE627CCA1C749" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_52F2E9EA5A3CDEF4EFACE627CCA1C749" xlink:type="arc" /> <link:label id="lab_us-gaap_LeasesAbstract_D3DE3F22ABD5F13416C39DEC931D1DC8_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_D3DE3F22ABD5F13416C39DEC931D1DC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_D3DE3F22ABD5F13416C39DEC931D1DC8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_D3DE3F22ABD5F13416C39DEC931D1DC8" xlink:to="lab_us-gaap_LeasesAbstract_D3DE3F22ABD5F13416C39DEC931D1DC8" xlink:type="arc" /> <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A80A4F1F1490867B3A3F9DEC931E937C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A80A4F1F1490867B3A3F9DEC931E937C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label> <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A80A4F1F1490867B3A3F9DEC931E937C_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A80A4F1F1490867B3A3F9DEC931E937C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A80A4F1F1490867B3A3F9DEC931E937C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A80A4F1F1490867B3A3F9DEC931E937C" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A80A4F1F1490867B3A3F9DEC931E937C" xlink:type="arc" /> <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_5DFC672ACF46C89673F29DEC931E5A38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_5DFC672ACF46C89673F29DEC931E5A38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extended term of lease</link:label> <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_5DFC672ACF46C89673F29DEC931E5A38_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_5DFC672ACF46C89673F29DEC931E5A38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5DFC672ACF46C89673F29DEC931E5A38" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5DFC672ACF46C89673F29DEC931E5A38" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_5DFC672ACF46C89673F29DEC931E5A38" xlink:type="arc" /> <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0CFA625EA110F004E812E627CB2F0CB4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_0CFA625EA110F004E812E627CB2F0CB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label> <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0CFA625EA110F004E812E627CB2F0CB4_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_0CFA625EA110F004E812E627CB2F0CB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0CFA625EA110F004E812E627CB2F0CB4" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_0CFA625EA110F004E812E627CB2F0CB4" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_0CFA625EA110F004E812E627CB2F0CB4" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label> <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:type="arc" /> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:type="arc" /> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB" xlink:type="arc" /> <link:label id="lab_us-gaap_DistributionRightsMember_3F5A8B213AFAAD44ACABE627CC003D99_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_3F5A8B213AFAAD44ACABE627CC003D99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution Rights</link:label> <link:label id="lab_us-gaap_DistributionRightsMember_3F5A8B213AFAAD44ACABE627CC003D99_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_3F5A8B213AFAAD44ACABE627CC003D99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_3F5A8B213AFAAD44ACABE627CC003D99" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember_3F5A8B213AFAAD44ACABE627CC003D99" xlink:to="lab_us-gaap_DistributionRightsMember_3F5A8B213AFAAD44ACABE627CC003D99" xlink:type="arc" /> <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label> <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:type="arc" /> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72CD544DAB8F5EAB162DE627CC0109D1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72CD544DAB8F5EAB162DE627CC0109D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72CD544DAB8F5EAB162DE627CC0109D1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72CD544DAB8F5EAB162DE627CC0109D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72CD544DAB8F5EAB162DE627CC0109D1" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72CD544DAB8F5EAB162DE627CC0109D1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72CD544DAB8F5EAB162DE627CC0109D1" xlink:type="arc" /> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_B5B9DFA89B83CFDFA322E627CC01B8FE_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_B5B9DFA89B83CFDFA322E627CC01B8FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Carrying Amount</link:label> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_B5B9DFA89B83CFDFA322E627CC01B8FE_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_B5B9DFA89B83CFDFA322E627CC01B8FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_B5B9DFA89B83CFDFA322E627CC01B8FE" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_B5B9DFA89B83CFDFA322E627CC01B8FE" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_B5B9DFA89B83CFDFA322E627CC01B8FE" xlink:type="arc" /> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E9E99663015106B2DC7DE627CC01A4C7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E9E99663015106B2DC7DE627CC01A4C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label> <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E9E99663015106B2DC7DE627CC01A4C7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E9E99663015106B2DC7DE627CC01A4C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E9E99663015106B2DC7DE627CC01A4C7" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E9E99663015106B2DC7DE627CC01A4C7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E9E99663015106B2DC7DE627CC01A4C7" xlink:type="arc" /> <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_14F2406A24511E09B1A4E627CC01706A_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_14F2406A24511E09B1A4E627CC01706A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label> <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_14F2406A24511E09B1A4E627CC01706A_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_14F2406A24511E09B1A4E627CC01706A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14F2406A24511E09B1A4E627CC01706A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14F2406A24511E09B1A4E627CC01706A" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_14F2406A24511E09B1A4E627CC01706A" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_306469CEE9EB39D85DA69F83877AE933_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_306469CEE9EB39D85DA69F83877AE933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share</link:label> <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_306469CEE9EB39D85DA69F83877AE933_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_306469CEE9EB39D85DA69F83877AE933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_306469CEE9EB39D85DA69F83877AE933" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_306469CEE9EB39D85DA69F83877AE933" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_306469CEE9EB39D85DA69F83877AE933" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_41FC95BCB4C893D2377C9F8387785918_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_41FC95BCB4C893D2377C9F8387785918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label> <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_41FC95BCB4C893D2377C9F8387785918_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_41FC95BCB4C893D2377C9F8387785918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_41FC95BCB4C893D2377C9F8387785918" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_41FC95BCB4C893D2377C9F8387785918" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_41FC95BCB4C893D2377C9F8387785918" xlink:type="arc" /> <link:label id="lab_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label> <link:label id="lab_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:to="lab_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:type="arc" /> <link:label id="lab_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label> <link:label id="lab_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:to="lab_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:type="arc" /> <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label> <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058" xlink:type="arc" /> <link:label id="lab_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC_terseLabel_en-US" xlink:label="lab_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Botulinum Toxin Research Associates, Inc.</link:label> <link:label id="lab_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC_label_en-US" xlink:label="lab_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Botulinum Toxin Research Associates, Inc. [Member]</link:label> <link:label id="lab_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC_documentation_en-US" xlink:label="lab_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Botulinum Toxin Research Associates, Inc. [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_BotulinumToxinResearchAssociatesInc.Member" xlink:label="loc_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC" xlink:to="lab_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC" xlink:type="arc" /> <link:label id="lab_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label> <link:label id="lab_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:type="arc" /> <link:label id="lab_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label> <link:label id="lab_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E" xlink:type="arc" /> <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_6D28920673E28FE1EA249DEC92DE2A1A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_6D28920673E28FE1EA249DEC92DE2A1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Liabilities</link:label> <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_6D28920673E28FE1EA249DEC92DE2A1A_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_6D28920673E28FE1EA249DEC92DE2A1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6D28920673E28FE1EA249DEC92DE2A1A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_6D28920673E28FE1EA249DEC92DE2A1A" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_6D28920673E28FE1EA249DEC92DE2A1A" xlink:type="arc" /> <link:label id="lab_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6_terseLabel_en-US" xlink:label="lab_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">List Laboratories</link:label> <link:label id="lab_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6_label_en-US" xlink:label="lab_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">List Laboratories [Member]</link:label> <link:label id="lab_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6_documentation_en-US" xlink:label="lab_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">List Laboratories [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ListLaboratoriesMember" xlink:label="loc_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6" xlink:to="lab_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6" xlink:type="arc" /> <link:label id="lab_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411_terseLabel_en-US" xlink:label="lab_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BioSentinel, Inc.</link:label> <link:label id="lab_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411_label_en-US" xlink:label="lab_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BioSentinel, Inc. [Member]</link:label> <link:label id="lab_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411_documentation_en-US" xlink:label="lab_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BioSentinel, Inc. [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_BioSentinelInc.Member" xlink:label="loc_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411" xlink:to="lab_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411" xlink:type="arc" /> <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label> <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:type="arc" /> <link:label id="lab_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label> <link:label id="lab_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7" xlink:type="arc" /> <link:label id="lab_us-gaap_CreditRiskContractMember_4CD8D4C50650CC7EA1329DEC92E26844_terseLabel_en-US" xlink:label="lab_us-gaap_CreditRiskContractMember_4CD8D4C50650CC7EA1329DEC92E26844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Approval Payment Derivative</link:label> <link:label id="lab_us-gaap_CreditRiskContractMember_4CD8D4C50650CC7EA1329DEC92E26844_label_en-US" xlink:label="lab_us-gaap_CreditRiskContractMember_4CD8D4C50650CC7EA1329DEC92E26844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Risk Contract [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditRiskContractMember" xlink:label="loc_us-gaap_CreditRiskContractMember_4CD8D4C50650CC7EA1329DEC92E26844" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditRiskContractMember_4CD8D4C50650CC7EA1329DEC92E26844" xlink:to="lab_us-gaap_CreditRiskContractMember_4CD8D4C50650CC7EA1329DEC92E26844" xlink:type="arc" /> <link:label id="lab_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label> <link:label id="lab_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="lab_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:type="arc" /> <link:label id="lab_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2_verboseLabel_en-US" xlink:label="lab_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued milestone obligations</link:label> <link:label id="lab_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2_label_en-US" xlink:label="lab_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Milestone Obligations</link:label> <link:label id="lab_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2_documentation_en-US" xlink:label="lab_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Milestone Obligations</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AccruedMilestoneObligations" xlink:label="loc_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2" xlink:to="lab_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2" xlink:type="arc" /> <link:label id="lab_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968_terseLabel_en-US" xlink:label="lab_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification liability recorded during the period</link:label> <link:label id="lab_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968_label_en-US" xlink:label="lab_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indemnification Liability Recorded during Period</link:label> <link:label id="lab_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968_documentation_en-US" xlink:label="lab_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indemnification Liability Recorded during Period</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_IndemnificationLiabilityRecordedduringPeriod" xlink:label="loc_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968" xlink:to="lab_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968" xlink:type="arc" /> <link:label id="lab_us-gaap_OperatingLeaseCost_4AB1C5BAABBCC3E6E8889DEC9317837C_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_4AB1C5BAABBCC3E6E8889DEC9317837C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label> <link:label id="lab_us-gaap_OperatingLeaseCost_4AB1C5BAABBCC3E6E8889DEC9317837C_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_4AB1C5BAABBCC3E6E8889DEC9317837C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_4AB1C5BAABBCC3E6E8889DEC9317837C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_4AB1C5BAABBCC3E6E8889DEC9317837C" xlink:to="lab_us-gaap_OperatingLeaseCost_4AB1C5BAABBCC3E6E8889DEC9317837C" xlink:type="arc" /> <link:label id="lab_us-gaap_VariableLeaseCost_D0A2ED92BE17693C08DD9DEC93178F8E_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_D0A2ED92BE17693C08DD9DEC93178F8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label> <link:label id="lab_us-gaap_VariableLeaseCost_D0A2ED92BE17693C08DD9DEC93178F8E_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_D0A2ED92BE17693C08DD9DEC93178F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_D0A2ED92BE17693C08DD9DEC93178F8E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_D0A2ED92BE17693C08DD9DEC93178F8E" xlink:to="lab_us-gaap_VariableLeaseCost_D0A2ED92BE17693C08DD9DEC93178F8E" xlink:type="arc" /> <link:label id="lab_us-gaap_LeaseCost_0EB99FE8A0B6153F6B009DEC93187A60_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_0EB99FE8A0B6153F6B009DEC93187A60" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease costs</link:label> <link:label id="lab_us-gaap_LeaseCost_0EB99FE8A0B6153F6B009DEC93187A60_label_en-US" xlink:label="lab_us-gaap_LeaseCost_0EB99FE8A0B6153F6B009DEC93187A60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_0EB99FE8A0B6153F6B009DEC93187A60" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_0EB99FE8A0B6153F6B009DEC93187A60" xlink:to="lab_us-gaap_LeaseCost_0EB99FE8A0B6153F6B009DEC93187A60" xlink:type="arc" /> <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_18FA47F11EF6CAFA47AA9FDB3E7D808A_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_18FA47F11EF6CAFA47AA9FDB3E7D808A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label> <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_18FA47F11EF6CAFA47AA9FDB3E7D808A_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_18FA47F11EF6CAFA47AA9FDB3E7D808A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_18FA47F11EF6CAFA47AA9FDB3E7D808A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_18FA47F11EF6CAFA47AA9FDB3E7D808A" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_18FA47F11EF6CAFA47AA9FDB3E7D808A" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label> <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:type="arc" /> <link:label id="lab_us-gaap_RepurchaseAgreementsMember_BB004BAB7F3A166F45349DEC93636C2C_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_BB004BAB7F3A166F45349DEC93636C2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Overnight repurchase agreements</link:label> <link:label id="lab_us-gaap_RepurchaseAgreementsMember_BB004BAB7F3A166F45349DEC93636C2C_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_BB004BAB7F3A166F45349DEC93636C2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_BB004BAB7F3A166F45349DEC93636C2C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_BB004BAB7F3A166F45349DEC93636C2C" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_BB004BAB7F3A166F45349DEC93636C2C" xlink:type="arc" /> <link:label id="lab_us-gaap_CashEquivalentsMember_6B5FFB480494EC55D4A99DEC9364EA32_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember_6B5FFB480494EC55D4A99DEC9364EA32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label> <link:label id="lab_us-gaap_CashEquivalentsMember_6B5FFB480494EC55D4A99DEC9364EA32_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember_6B5FFB480494EC55D4A99DEC9364EA32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_6B5FFB480494EC55D4A99DEC9364EA32" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember_6B5FFB480494EC55D4A99DEC9364EA32" xlink:to="lab_us-gaap_CashEquivalentsMember_6B5FFB480494EC55D4A99DEC9364EA32" xlink:type="arc" /> <link:label id="lab_us-gaap_OtherCurrentAssetsMember_CC575373C47DFBF1802A9DEC9365FF38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_CC575373C47DFBF1802A9DEC9365FF38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label> <link:label id="lab_us-gaap_OtherCurrentAssetsMember_CC575373C47DFBF1802A9DEC9365FF38_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_CC575373C47DFBF1802A9DEC9365FF38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_CC575373C47DFBF1802A9DEC9365FF38" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_CC575373C47DFBF1802A9DEC9365FF38" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_CC575373C47DFBF1802A9DEC9365FF38" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label> <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:type="arc" /> <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5FA638AAFD1E242CBD99DEC93669924_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5FA638AAFD1E242CBD99DEC93669924" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label> <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5FA638AAFD1E242CBD99DEC93669924_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5FA638AAFD1E242CBD99DEC93669924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5FA638AAFD1E242CBD99DEC93669924" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5FA638AAFD1E242CBD99DEC93669924" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5FA638AAFD1E242CBD99DEC93669924" xlink:type="arc" /> <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C93BF647C71F9BBD5E779DEC9366A08F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C93BF647C71F9BBD5E779DEC9366A08F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains</link:label> <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C93BF647C71F9BBD5E779DEC9366A08F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C93BF647C71F9BBD5E779DEC9366A08F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C93BF647C71F9BBD5E779DEC9366A08F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C93BF647C71F9BBD5E779DEC9366A08F" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C93BF647C71F9BBD5E779DEC9366A08F" xlink:type="arc" /> <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1D0C3EE72D78E9DF1B0D9DEC93662557_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1D0C3EE72D78E9DF1B0D9DEC93662557" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Losses</link:label> <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1D0C3EE72D78E9DF1B0D9DEC93662557_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1D0C3EE72D78E9DF1B0D9DEC93662557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1D0C3EE72D78E9DF1B0D9DEC93662557" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1D0C3EE72D78E9DF1B0D9DEC93662557" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1D0C3EE72D78E9DF1B0D9DEC93662557" xlink:type="arc" /> <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE4E61FEFA8BB60AE4869DEC9367F016_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE4E61FEFA8BB60AE4869DEC9367F016" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label> <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE4E61FEFA8BB60AE4869DEC9367F016_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE4E61FEFA8BB60AE4869DEC9367F016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE4E61FEFA8BB60AE4869DEC9367F016" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE4E61FEFA8BB60AE4869DEC9367F016" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE4E61FEFA8BB60AE4869DEC9367F016" xlink:type="arc" /> <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_57CBA01D4F2ACD4CF5039DEC93678499_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_57CBA01D4F2ACD4CF5039DEC93678499" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporary impairments on available-for-sale securities</link:label> <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_57CBA01D4F2ACD4CF5039DEC93678499_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_57CBA01D4F2ACD4CF5039DEC93678499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_57CBA01D4F2ACD4CF5039DEC93678499" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_57CBA01D4F2ACD4CF5039DEC93678499" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_57CBA01D4F2ACD4CF5039DEC93678499" xlink:type="arc" /> <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_98955F57299A38F20D279E93E6C18440_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_98955F57299A38F20D279E93E6C18440" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label> <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_98955F57299A38F20D279E93E6C18440_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_98955F57299A38F20D279E93E6C18440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_98955F57299A38F20D279E93E6C18440" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_98955F57299A38F20D279E93E6C18440" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_98955F57299A38F20D279E93E6C18440" xlink:type="arc" /> <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:type="arc" /> <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label> <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B" xlink:type="arc" /> <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label> <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:type="arc" /> <link:label id="lab_us-gaap_ShareBasedCompensation_1A72B97E6485C54BBAD1E655517E67AB_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_1A72B97E6485C54BBAD1E655517E67AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label> <link:label id="lab_us-gaap_ShareBasedCompensation_1A72B97E6485C54BBAD1E655517E67AB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_1A72B97E6485C54BBAD1E655517E67AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1A72B97E6485C54BBAD1E655517E67AB" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_1A72B97E6485C54BBAD1E655517E67AB" xlink:to="lab_us-gaap_ShareBasedCompensation_1A72B97E6485C54BBAD1E655517E67AB" xlink:type="arc" /> <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C61E4BF1F663618EC765E655517FF807_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C61E4BF1F663618EC765E655517FF807" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label> <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C61E4BF1F663618EC765E655517FF807_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C61E4BF1F663618EC765E655517FF807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C61E4BF1F663618EC765E655517FF807" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C61E4BF1F663618EC765E655517FF807" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C61E4BF1F663618EC765E655517FF807" xlink:type="arc" /> <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_FF32E903C3049D59F519E655517F3B90_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_FF32E903C3049D59F519E655517F3B90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label> <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_FF32E903C3049D59F519E655517F3B90_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_FF32E903C3049D59F519E655517F3B90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_FF32E903C3049D59F519E655517F3B90" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_FF32E903C3049D59F519E655517F3B90" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_FF32E903C3049D59F519E655517F3B90" xlink:type="arc" /> <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_C27D1C74C3FA1D53EF8EE655517F9ED7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_C27D1C74C3FA1D53EF8EE655517F9ED7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of discount on investments</link:label> <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_C27D1C74C3FA1D53EF8EE655517F9ED7_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_C27D1C74C3FA1D53EF8EE655517F9ED7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_C27D1C74C3FA1D53EF8EE655517F9ED7" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_C27D1C74C3FA1D53EF8EE655517F9ED7" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_C27D1C74C3FA1D53EF8EE655517F9ED7" xlink:type="arc" /> <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_3D987BF96674C336AD4CE655518024A3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_3D987BF96674C336AD4CE655518024A3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other non-cash operating activities</link:label> <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_3D987BF96674C336AD4CE655518024A3_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_3D987BF96674C336AD4CE655518024A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3D987BF96674C336AD4CE655518024A3" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_3D987BF96674C336AD4CE655518024A3" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_3D987BF96674C336AD4CE655518024A3" xlink:type="arc" /> <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label> <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:type="arc" /> <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_C8F98F88172B1C887EB0E65551807CDF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_C8F98F88172B1C887EB0E65551807CDF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label> <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_C8F98F88172B1C887EB0E65551807CDF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_C8F98F88172B1C887EB0E65551807CDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_C8F98F88172B1C887EB0E65551807CDF" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_C8F98F88172B1C887EB0E65551807CDF" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_C8F98F88172B1C887EB0E65551807CDF" xlink:type="arc" /> <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_16EEEA909454DF002F95E6555181F150_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_16EEEA909454DF002F95E6555181F150" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label> <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_16EEEA909454DF002F95E6555181F150_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_16EEEA909454DF002F95E6555181F150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_16EEEA909454DF002F95E6555181F150" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_16EEEA909454DF002F95E6555181F150" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_16EEEA909454DF002F95E6555181F150" xlink:type="arc" /> <link:label id="lab_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_E92E43F32C10F7E2EA2EE65551815FB5_negatedLabel_en-US" xlink:label="lab_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_E92E43F32C10F7E2EA2EE65551815FB5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease right of use assets</link:label> <link:label id="lab_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_E92E43F32C10F7E2EA2EE65551815FB5_label_en-US" xlink:label="lab_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_E92E43F32C10F7E2EA2EE65551815FB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Right of Use Assets</link:label> <link:label id="lab_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_E92E43F32C10F7E2EA2EE65551815FB5_documentation_en-US" xlink:label="lab_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_E92E43F32C10F7E2EA2EE65551815FB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Right of Use Assets</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets" xlink:label="loc_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_E92E43F32C10F7E2EA2EE65551815FB5" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_E92E43F32C10F7E2EA2EE65551815FB5" xlink:to="lab_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_E92E43F32C10F7E2EA2EE65551815FB5" xlink:type="arc" /> <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9D12320F4339ABB950C4E65551814F83_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9D12320F4339ABB950C4E65551814F83" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label> <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9D12320F4339ABB950C4E65551814F83_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9D12320F4339ABB950C4E65551814F83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9D12320F4339ABB950C4E65551814F83" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9D12320F4339ABB950C4E65551814F83" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9D12320F4339ABB950C4E65551814F83" xlink:type="arc" /> <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3EF99EDF81C75CF015BEE65551829A2D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3EF99EDF81C75CF015BEE65551829A2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label> <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3EF99EDF81C75CF015BEE65551829A2D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3EF99EDF81C75CF015BEE65551829A2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3EF99EDF81C75CF015BEE65551829A2D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3EF99EDF81C75CF015BEE65551829A2D" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3EF99EDF81C75CF015BEE65551829A2D" xlink:type="arc" /> <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3EF7F2DA8DA54B6C4698E65551822000_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3EF7F2DA8DA54B6C4698E65551822000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and other liabilities</link:label> <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3EF7F2DA8DA54B6C4698E65551822000_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3EF7F2DA8DA54B6C4698E65551822000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3EF7F2DA8DA54B6C4698E65551822000" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3EF7F2DA8DA54B6C4698E65551822000" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3EF7F2DA8DA54B6C4698E65551822000" xlink:type="arc" /> <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_68DA206B19599E56C314E6555182C798_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_68DA206B19599E56C314E6555182C798" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label> <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_68DA206B19599E56C314E6555182C798_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_68DA206B19599E56C314E6555182C798" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_68DA206B19599E56C314E6555182C798" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_68DA206B19599E56C314E6555182C798" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_68DA206B19599E56C314E6555182C798" xlink:type="arc" /> <link:label id="lab_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_B576DC0302C5B2B485E3E65551831462_terseLabel_en-US" xlink:label="lab_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_B576DC0302C5B2B485E3E65551831462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label> <link:label id="lab_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_B576DC0302C5B2B485E3E65551831462_label_en-US" xlink:label="lab_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_B576DC0302C5B2B485E3E65551831462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label> <link:label id="lab_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_B576DC0302C5B2B485E3E65551831462_documentation_en-US" xlink:label="lab_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_B576DC0302C5B2B485E3E65551831462" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liabilities</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_IncreaseDecreaseinOperatingLeaseLiabilities" xlink:label="loc_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_B576DC0302C5B2B485E3E65551831462" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_B576DC0302C5B2B485E3E65551831462" xlink:to="lab_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_B576DC0302C5B2B485E3E65551831462" xlink:type="arc" /> <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7AB68B2139ECDDF9CE07E65551832493_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7AB68B2139ECDDF9CE07E65551832493" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label> <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7AB68B2139ECDDF9CE07E65551832493_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7AB68B2139ECDDF9CE07E65551832493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7AB68B2139ECDDF9CE07E65551832493" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7AB68B2139ECDDF9CE07E65551832493" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7AB68B2139ECDDF9CE07E65551832493" xlink:type="arc" /> <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label> <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:type="arc" /> <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_39118BF06BB92F82FD22E65551837DEF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_39118BF06BB92F82FD22E65551837DEF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label> <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_39118BF06BB92F82FD22E65551837DEF_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_39118BF06BB92F82FD22E65551837DEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_39118BF06BB92F82FD22E65551837DEF" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_39118BF06BB92F82FD22E65551837DEF" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_39118BF06BB92F82FD22E65551837DEF" xlink:type="arc" /> <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_CBE4F36CF607ACC35766E65551848996_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_CBE4F36CF607ACC35766E65551848996" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label> <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_CBE4F36CF607ACC35766E65551848996_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_CBE4F36CF607ACC35766E65551848996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_CBE4F36CF607ACC35766E65551848996" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_CBE4F36CF607ACC35766E65551848996" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_CBE4F36CF607ACC35766E65551848996" xlink:type="arc" /> <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_AE08D0B3864204671BD1E65551845B35_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_AE08D0B3864204671BD1E65551845B35" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets</link:label> <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_AE08D0B3864204671BD1E65551845B35_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_AE08D0B3864204671BD1E65551845B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_AE08D0B3864204671BD1E65551845B35" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_AE08D0B3864204671BD1E65551845B35" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_AE08D0B3864204671BD1E65551845B35" xlink:type="arc" /> <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_84B561C1F9C1391BF03EE65551842F7D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_84B561C1F9C1391BF03EE65551842F7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investments</link:label> <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_84B561C1F9C1391BF03EE65551842F7D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_84B561C1F9C1391BF03EE65551842F7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_84B561C1F9C1391BF03EE65551842F7D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_84B561C1F9C1391BF03EE65551842F7D" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_84B561C1F9C1391BF03EE65551842F7D" xlink:type="arc" /> <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_956647F65ED722B4A9C6E6555184C4D5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_956647F65ED722B4A9C6E6555184C4D5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label> <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_956647F65ED722B4A9C6E6555184C4D5_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_956647F65ED722B4A9C6E6555184C4D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_956647F65ED722B4A9C6E6555184C4D5" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_956647F65ED722B4A9C6E6555184C4D5" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_956647F65ED722B4A9C6E6555184C4D5" xlink:type="arc" /> <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock in connection with offerings, net of commissions and discount</link:label> <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:type="arc" /> <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_1B6C8BEA085A49537FEEE6555185E819_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_1B6C8BEA085A49537FEEE6555185E819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible senior notes</link:label> <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_1B6C8BEA085A49537FEEE6555185E819_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_1B6C8BEA085A49537FEEE6555185E819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_1B6C8BEA085A49537FEEE6555185E819" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_1B6C8BEA085A49537FEEE6555185E819" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_1B6C8BEA085A49537FEEE6555185E819" xlink:type="arc" /> <link:label id="lab_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_637F7F45729A4B2A6FACE6555185736F_terseLabel_en-US" xlink:label="lab_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_637F7F45729A4B2A6FACE6555185736F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock in connection with offerings, net of commissions and discount</link:label> <link:label id="lab_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_637F7F45729A4B2A6FACE6555185736F_label_en-US" xlink:label="lab_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_637F7F45729A4B2A6FACE6555185736F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Follow-On Offering, Net of Commissions and Discount</link:label> <link:label id="lab_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_637F7F45729A4B2A6FACE6555185736F_documentation_en-US" xlink:label="lab_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_637F7F45729A4B2A6FACE6555185736F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance of Follow-On Offering, Net of Commissions and Discount</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount" xlink:label="loc_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_637F7F45729A4B2A6FACE6555185736F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_637F7F45729A4B2A6FACE6555185736F" xlink:to="lab_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_637F7F45729A4B2A6FACE6555185736F" xlink:type="arc" /> <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6AEA2C47D3EEA2D58A7FE655518A2469_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_6AEA2C47D3EEA2D58A7FE655518A2469" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options and common stock warrants</link:label> <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6AEA2C47D3EEA2D58A7FE655518A2469_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_6AEA2C47D3EEA2D58A7FE655518A2469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6AEA2C47D3EEA2D58A7FE655518A2469" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_6AEA2C47D3EEA2D58A7FE655518A2469" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_6AEA2C47D3EEA2D58A7FE655518A2469" xlink:type="arc" /> <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_E186D5F8995BECD356EEE655518BD15C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_E186D5F8995BECD356EEE655518BD15C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of capped call transactions</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_E186D5F8995BECD356EEE655518BD15C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_E186D5F8995BECD356EEE655518BD15C" xlink:to="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_E186D5F8995BECD356EEE655518BD15C" xlink:type="arc" /> <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_523E2D623F13F47B4B6BE655518B9371_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_523E2D623F13F47B4B6BE655518B9371" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of convertible senior notes transaction costs</link:label> <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_523E2D623F13F47B4B6BE655518B9371_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_523E2D623F13F47B4B6BE655518B9371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_523E2D623F13F47B4B6BE655518B9371" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_523E2D623F13F47B4B6BE655518B9371" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_523E2D623F13F47B4B6BE655518B9371" xlink:type="arc" /> <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6049F59C249F7E778108E655518BB255_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6049F59C249F7E778108E655518BB255" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net settlement of restricted stock awards for employee taxes</link:label> <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6049F59C249F7E778108E655518BB255_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6049F59C249F7E778108E655518BB255" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6049F59C249F7E778108E655518BB255" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6049F59C249F7E778108E655518BB255" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6049F59C249F7E778108E655518BB255" xlink:type="arc" /> <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_6B1924B8BB7B3052BE89E655518BEFC0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_6B1924B8BB7B3052BE89E655518BEFC0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of offering costs</link:label> <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_6B1924B8BB7B3052BE89E655518BEFC0_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_6B1924B8BB7B3052BE89E655518BEFC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6B1924B8BB7B3052BE89E655518BEFC0" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_6B1924B8BB7B3052BE89E655518BEFC0" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_6B1924B8BB7B3052BE89E655518BEFC0" xlink:type="arc" /> <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_05065A5F94B0401F4B05E655518C174A_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_05065A5F94B0401F4B05E655518C174A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label> <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_05065A5F94B0401F4B05E655518C174A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_05065A5F94B0401F4B05E655518C174A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05065A5F94B0401F4B05E655518C174A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05065A5F94B0401F4B05E655518C174A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_05065A5F94B0401F4B05E655518C174A" xlink:type="arc" /> <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15B698164E180E5B8E63E669042A22E5_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15B698164E180E5B8E63E669042A22E5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</link:label> <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15B698164E180E5B8E63E669042A22E5_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15B698164E180E5B8E63E669042A22E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15B698164E180E5B8E63E669042A22E5" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15B698164E180E5B8E63E669042A22E5" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15B698164E180E5B8E63E669042A22E5" xlink:type="arc" /> <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65538ACA715AD83E80F4E655518C61AC_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65538ACA715AD83E80F4E655518C61AC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period</link:label> <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65538ACA715AD83E80F4E655518C61AC_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65538ACA715AD83E80F4E655518C61AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65538ACA715AD83E80F4E655518C61AC" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65538ACA715AD83E80F4E655518C61AC" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65538ACA715AD83E80F4E655518C61AC" xlink:type="arc" /> <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A9FF48A6647E074DA775E655518CAE08_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A9FF48A6647E074DA775E655518CAE08" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A9FF48A6647E074DA775E655518CAE08" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A9FF48A6647E074DA775E655518CAE08" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A9FF48A6647E074DA775E655518CAE08" xlink:type="arc" /> <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:</link:label> <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F" xlink:type="arc" /> <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2271C5B6D251DA93B229E655518C435A_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2271C5B6D251DA93B229E655518C435A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the Teoxane Agreement</link:label> <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2271C5B6D251DA93B229E655518C435A_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2271C5B6D251DA93B229E655518C435A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2271C5B6D251DA93B229E655518C435A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2271C5B6D251DA93B229E655518C435A" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2271C5B6D251DA93B229E655518C435A" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_BC7DC54628B816E8F28BE655518D6028_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_BC7DC54628B816E8F28BE655518D6028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued transaction costs on convertible senior notes</link:label> <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_BC7DC54628B816E8F28BE655518D6028_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_BC7DC54628B816E8F28BE655518D6028" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_BC7DC54628B816E8F28BE655518D6028" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_BC7DC54628B816E8F28BE655518D6028" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_BC7DC54628B816E8F28BE655518D6028" xlink:type="arc" /> <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_35F790CB1B09E21AA4DAE655518D642A_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_35F790CB1B09E21AA4DAE655518D642A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment purchases included in accounts payable and accruals</link:label> <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_35F790CB1B09E21AA4DAE655518D642A_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_35F790CB1B09E21AA4DAE655518D642A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_35F790CB1B09E21AA4DAE655518D642A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_35F790CB1B09E21AA4DAE655518D642A" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_35F790CB1B09E21AA4DAE655518D642A" xlink:type="arc" /> <link:label id="lab_rvnc_NoncashDeferredOfferingCosts_FEDC77D21281B24FE0FBE655518D696B_terseLabel_en-US" xlink:label="lab_rvnc_NoncashDeferredOfferingCosts_FEDC77D21281B24FE0FBE655518D696B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued offering costs</link:label> <link:label id="lab_rvnc_NoncashDeferredOfferingCosts_FEDC77D21281B24FE0FBE655518D696B_label_en-US" xlink:label="lab_rvnc_NoncashDeferredOfferingCosts_FEDC77D21281B24FE0FBE655518D696B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Deferred Offering Costs</link:label> <link:label id="lab_rvnc_NoncashDeferredOfferingCosts_FEDC77D21281B24FE0FBE655518D696B_documentation_en-US" xlink:label="lab_rvnc_NoncashDeferredOfferingCosts_FEDC77D21281B24FE0FBE655518D696B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Deferred Offering Costs</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_NoncashDeferredOfferingCosts" xlink:label="loc_rvnc_NoncashDeferredOfferingCosts_FEDC77D21281B24FE0FBE655518D696B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_NoncashDeferredOfferingCosts_FEDC77D21281B24FE0FBE655518D696B" xlink:to="lab_rvnc_NoncashDeferredOfferingCosts_FEDC77D21281B24FE0FBE655518D696B" xlink:type="arc" /> <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_CDD63868ABE92405AB8BE627CC1653D0_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_CDD63868ABE92405AB8BE627CC1653D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Filler Distribution Agreement</link:label> <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_CDD63868ABE92405AB8BE627CC1653D0_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_CDD63868ABE92405AB8BE627CC1653D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_CDD63868ABE92405AB8BE627CC1653D0" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_CDD63868ABE92405AB8BE627CC1653D0" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_CDD63868ABE92405AB8BE627CC1653D0" xlink:type="arc" /> <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_91D70CE104FD7F546A64E627CBF687EF_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_91D70CE104FD7F546A64E627CBF687EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents and Short-Term Investments</link:label> <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_91D70CE104FD7F546A64E627CBF687EF_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_91D70CE104FD7F546A64E627CBF687EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_91D70CE104FD7F546A64E627CBF687EF" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_91D70CE104FD7F546A64E627CBF687EF" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_91D70CE104FD7F546A64E627CBF687EF" xlink:type="arc" /> <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_05DE047FC3987177A5C5EC7299FCC741_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization_05DE047FC3987177A5C5EC7299FCC741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label> <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_05DE047FC3987177A5C5EC7299FCC741_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization_05DE047FC3987177A5C5EC7299FCC741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_05DE047FC3987177A5C5EC7299FCC741" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization_05DE047FC3987177A5C5EC7299FCC741" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization_05DE047FC3987177A5C5EC7299FCC741" xlink:type="arc" /> <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_A6EF01FF4179FB73AC18EC7299FC8D4C_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_A6EF01FF4179FB73AC18EC7299FC8D4C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount</link:label> <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_A6EF01FF4179FB73AC18EC7299FC8D4C_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_A6EF01FF4179FB73AC18EC7299FC8D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_A6EF01FF4179FB73AC18EC7299FC8D4C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_A6EF01FF4179FB73AC18EC7299FC8D4C" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_A6EF01FF4179FB73AC18EC7299FC8D4C" xlink:type="arc" /> <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_C3D2921EBB7B4F0EB4A3EC7299FC7B78_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_C3D2921EBB7B4F0EB4A3EC7299FC7B78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label> <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_C3D2921EBB7B4F0EB4A3EC7299FC7B78_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_C3D2921EBB7B4F0EB4A3EC7299FC7B78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_C3D2921EBB7B4F0EB4A3EC7299FC7B78" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_C3D2921EBB7B4F0EB4A3EC7299FC7B78" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_C3D2921EBB7B4F0EB4A3EC7299FC7B78" xlink:type="arc" /> <link:label id="lab_us-gaap_InterestExpenseDebt_DE47FD3A0E81FD7EAC80EC7299FD5BE3_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_DE47FD3A0E81FD7EAC80EC7299FD5BE3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total interest expense</link:label> <link:label id="lab_us-gaap_InterestExpenseDebt_DE47FD3A0E81FD7EAC80EC7299FD5BE3_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_DE47FD3A0E81FD7EAC80EC7299FD5BE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_DE47FD3A0E81FD7EAC80EC7299FD5BE3" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_DE47FD3A0E81FD7EAC80EC7299FD5BE3" xlink:to="lab_us-gaap_InterestExpenseDebt_DE47FD3A0E81FD7EAC80EC7299FD5BE3" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4C88DE011E705DA55661EC7299FD652B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4C88DE011E705DA55661EC7299FD652B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective percentage</link:label> <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4C88DE011E705DA55661EC7299FD652B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4C88DE011E705DA55661EC7299FD652B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4C88DE011E705DA55661EC7299FD652B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4C88DE011E705DA55661EC7299FD652B" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4C88DE011E705DA55661EC7299FD652B" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_D3C8E0496F2E1011F291EC7299FD9F71_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_D3C8E0496F2E1011F291EC7299FD9F71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unamortized discount</link:label> <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_D3C8E0496F2E1011F291EC7299FD9F71_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_D3C8E0496F2E1011F291EC7299FD9F71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_D3C8E0496F2E1011F291EC7299FD9F71" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_D3C8E0496F2E1011F291EC7299FD9F71" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_D3C8E0496F2E1011F291EC7299FD9F71" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_8452B8F9AC256D80F714EC7299FD69E6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_8452B8F9AC256D80F714EC7299FD69E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining discount amortization period</link:label> <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_8452B8F9AC256D80F714EC7299FD69E6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_8452B8F9AC256D80F714EC7299FD69E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_8452B8F9AC256D80F714EC7299FD69E6" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_8452B8F9AC256D80F714EC7299FD69E6" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_8452B8F9AC256D80F714EC7299FD69E6" xlink:type="arc" /> <link:label id="lab_us-gaap_DeferredFinanceCostsNet_165597B931FC4A65A353EC7299FDACC0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_165597B931FC4A65A353EC7299FDACC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, net</link:label> <link:label id="lab_us-gaap_DeferredFinanceCostsNet_165597B931FC4A65A353EC7299FDACC0_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_165597B931FC4A65A353EC7299FDACC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_165597B931FC4A65A353EC7299FDACC0" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_165597B931FC4A65A353EC7299FDACC0" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_165597B931FC4A65A353EC7299FDACC0" xlink:type="arc" /> <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_29D10DE79534F46A2DB716CE0F1B5F77_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_29D10DE79534F46A2DB716CE0F1B5F77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, par value (in dollars per share)</link:label> <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_29D10DE79534F46A2DB716CE0F1B5F77_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_29D10DE79534F46A2DB716CE0F1B5F77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29D10DE79534F46A2DB716CE0F1B5F77" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29D10DE79534F46A2DB716CE0F1B5F77" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_29D10DE79534F46A2DB716CE0F1B5F77" xlink:type="arc" /> <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1C395032A01E2AB9432816CE0F1B2733_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1C395032A01E2AB9432816CE0F1B2733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock authorized (shares)</link:label> <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1C395032A01E2AB9432816CE0F1B2733_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1C395032A01E2AB9432816CE0F1B2733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1C395032A01E2AB9432816CE0F1B2733" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_1C395032A01E2AB9432816CE0F1B2733" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_1C395032A01E2AB9432816CE0F1B2733" xlink:type="arc" /> <link:label id="lab_us-gaap_PreferredStockSharesIssued_9B2235E416B530E6AC2F16CE0F1BB6D0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_9B2235E416B530E6AC2F16CE0F1BB6D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock issued (shares)</link:label> <link:label id="lab_us-gaap_PreferredStockSharesIssued_9B2235E416B530E6AC2F16CE0F1BB6D0_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_9B2235E416B530E6AC2F16CE0F1BB6D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9B2235E416B530E6AC2F16CE0F1BB6D0" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_9B2235E416B530E6AC2F16CE0F1BB6D0" xlink:to="lab_us-gaap_PreferredStockSharesIssued_9B2235E416B530E6AC2F16CE0F1BB6D0" xlink:type="arc" /> <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_BEBC744DA182312D6ED016CE0F1B3C3A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_BEBC744DA182312D6ED016CE0F1B3C3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock outstanding (shares)</link:label> <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_BEBC744DA182312D6ED016CE0F1B3C3A_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_BEBC744DA182312D6ED016CE0F1B3C3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_BEBC744DA182312D6ED016CE0F1B3C3A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_BEBC744DA182312D6ED016CE0F1B3C3A" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_BEBC744DA182312D6ED016CE0F1B3C3A" xlink:type="arc" /> <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0EFD7F55E9EB78FDBDFB16CE0F1BB76C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0EFD7F55E9EB78FDBDFB16CE0F1BB76C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollar per share)</link:label> <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0EFD7F55E9EB78FDBDFB16CE0F1BB76C_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0EFD7F55E9EB78FDBDFB16CE0F1BB76C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0EFD7F55E9EB78FDBDFB16CE0F1BB76C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_0EFD7F55E9EB78FDBDFB16CE0F1BB76C" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0EFD7F55E9EB78FDBDFB16CE0F1BB76C" xlink:type="arc" /> <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5F6367A9689CF4350B3D16CE0F1BCAE0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_5F6367A9689CF4350B3D16CE0F1BCAE0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label> <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5F6367A9689CF4350B3D16CE0F1BCAE0_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_5F6367A9689CF4350B3D16CE0F1BCAE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5F6367A9689CF4350B3D16CE0F1BCAE0" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_5F6367A9689CF4350B3D16CE0F1BCAE0" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_5F6367A9689CF4350B3D16CE0F1BCAE0" xlink:type="arc" /> <link:label id="lab_us-gaap_CommonStockSharesIssued_2D64DA6AD02196CBC1A116CE0F1BDEF7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_2D64DA6AD02196CBC1A116CE0F1BDEF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label> <link:label id="lab_us-gaap_CommonStockSharesIssued_2D64DA6AD02196CBC1A116CE0F1BDEF7_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_2D64DA6AD02196CBC1A116CE0F1BDEF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2D64DA6AD02196CBC1A116CE0F1BDEF7" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_2D64DA6AD02196CBC1A116CE0F1BDEF7" xlink:to="lab_us-gaap_CommonStockSharesIssued_2D64DA6AD02196CBC1A116CE0F1BDEF7" xlink:type="arc" /> <link:label id="lab_us-gaap_CommonStockSharesOutstanding_DEDFC2F66B2FB065E58816CE0F1B3D24_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_DEDFC2F66B2FB065E58816CE0F1B3D24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_DEDFC2F66B2FB065E58816CE0F1B3D24" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_DEDFC2F66B2FB065E58816CE0F1B3D24" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_DEDFC2F66B2FB065E58816CE0F1B3D24" xlink:type="arc" /> <link:label id="lab_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="lab_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:type="arc" /> <link:label id="lab_us-gaap_Revenues_A2BB27AE9EEF470050819D3E475BC147_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_A2BB27AE9EEF470050819D3E475BC147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label> <link:label id="lab_us-gaap_Revenues_A2BB27AE9EEF470050819D3E475BC147_label_en-US" xlink:label="lab_us-gaap_Revenues_A2BB27AE9EEF470050819D3E475BC147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A2BB27AE9EEF470050819D3E475BC147" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_A2BB27AE9EEF470050819D3E475BC147" xlink:to="lab_us-gaap_Revenues_A2BB27AE9EEF470050819D3E475BC147" xlink:type="arc" /> <link:label id="lab_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label> <link:label id="lab_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520" xlink:to="lab_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520" xlink:type="arc" /> <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_76187FD817AA8F548AA69D3E475C91F0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_76187FD817AA8F548AA69D3E475C91F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label> <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_76187FD817AA8F548AA69D3E475C91F0_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_76187FD817AA8F548AA69D3E475C91F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_76187FD817AA8F548AA69D3E475C91F0" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_76187FD817AA8F548AA69D3E475C91F0" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_76187FD817AA8F548AA69D3E475C91F0" xlink:type="arc" /> <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ACC6024A73F141EBF8D19D3E475CA77E_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ACC6024A73F141EBF8D19D3E475CA77E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label> <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ACC6024A73F141EBF8D19D3E475CA77E_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ACC6024A73F141EBF8D19D3E475CA77E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ACC6024A73F141EBF8D19D3E475CA77E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ACC6024A73F141EBF8D19D3E475CA77E" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ACC6024A73F141EBF8D19D3E475CA77E" xlink:type="arc" /> <link:label id="lab_us-gaap_OperatingExpenses_6CE1132747E8B08082A79D3E475CE4C0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_6CE1132747E8B08082A79D3E475CE4C0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label> <link:label id="lab_us-gaap_OperatingExpenses_6CE1132747E8B08082A79D3E475CE4C0_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_6CE1132747E8B08082A79D3E475CE4C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_6CE1132747E8B08082A79D3E475CE4C0" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_6CE1132747E8B08082A79D3E475CE4C0" xlink:to="lab_us-gaap_OperatingExpenses_6CE1132747E8B08082A79D3E475CE4C0" xlink:type="arc" /> <link:label id="lab_us-gaap_OperatingIncomeLoss_74B98D66E3C8C947B10F9D3E475D92E9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_74B98D66E3C8C947B10F9D3E475D92E9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label> <link:label id="lab_us-gaap_OperatingIncomeLoss_74B98D66E3C8C947B10F9D3E475D92E9_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_74B98D66E3C8C947B10F9D3E475D92E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_74B98D66E3C8C947B10F9D3E475D92E9" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_74B98D66E3C8C947B10F9D3E475D92E9" xlink:to="lab_us-gaap_OperatingIncomeLoss_74B98D66E3C8C947B10F9D3E475D92E9" xlink:type="arc" /> <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_B856B537404C1A10B87D9D3E475DDFC6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating_B856B537404C1A10B87D9D3E475DDFC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label> <link:label id="lab_us-gaap_InvestmentIncomeNonoperating_B856B537404C1A10B87D9D3E475DDFC6_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating_B856B537404C1A10B87D9D3E475DDFC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Nonoperating</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_B856B537404C1A10B87D9D3E475DDFC6" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating_B856B537404C1A10B87D9D3E475DDFC6" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating_B856B537404C1A10B87D9D3E475DDFC6" xlink:type="arc" /> <link:label id="lab_us-gaap_InterestExpense_9EC83A2822B78B0A2AEE9D3E475D45E8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_9EC83A2822B78B0A2AEE9D3E475D45E8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label> <link:label id="lab_us-gaap_InterestExpense_9EC83A2822B78B0A2AEE9D3E475D45E8_label_en-US" xlink:label="lab_us-gaap_InterestExpense_9EC83A2822B78B0A2AEE9D3E475D45E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_9EC83A2822B78B0A2AEE9D3E475D45E8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_9EC83A2822B78B0A2AEE9D3E475D45E8" xlink:to="lab_us-gaap_InterestExpense_9EC83A2822B78B0A2AEE9D3E475D45E8" xlink:type="arc" /> <link:label id="lab_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_7DC1C2EE5458C88634889D3E475E5FD3_terseLabel_en-US" xlink:label="lab_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_7DC1C2EE5458C88634889D3E475E5FD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of derivative liability</link:label> <link:label id="lab_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_7DC1C2EE5458C88634889D3E475E5FD3_label_en-US" xlink:label="lab_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_7DC1C2EE5458C88634889D3E475E5FD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Contract, Net, Pretax</link:label> <link:label id="lab_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_7DC1C2EE5458C88634889D3E475E5FD3_documentation_en-US" xlink:label="lab_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_7DC1C2EE5458C88634889D3E475E5FD3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Contract, Net, Pretax</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_GainLossonDerivativeInstrumentsContractNetPretax" xlink:label="loc_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_7DC1C2EE5458C88634889D3E475E5FD3" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_7DC1C2EE5458C88634889D3E475E5FD3" xlink:to="lab_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_7DC1C2EE5458C88634889D3E475E5FD3" xlink:type="arc" /> <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7EBF90141BDAAB76A8379D3E475ED39F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_7EBF90141BDAAB76A8379D3E475ED39F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label> <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7EBF90141BDAAB76A8379D3E475ED39F_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_7EBF90141BDAAB76A8379D3E475ED39F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7EBF90141BDAAB76A8379D3E475ED39F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7EBF90141BDAAB76A8379D3E475ED39F" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_7EBF90141BDAAB76A8379D3E475ED39F" xlink:type="arc" /> <link:label id="lab_us-gaap_IncomeLossAttributableToParent_D69041F0479C52EA781D9D4ABC0E18AB_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent_D69041F0479C52EA781D9D4ABC0E18AB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label> <link:label id="lab_us-gaap_IncomeLossAttributableToParent_D69041F0479C52EA781D9D4ABC0E18AB_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent_D69041F0479C52EA781D9D4ABC0E18AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_D69041F0479C52EA781D9D4ABC0E18AB" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_D69041F0479C52EA781D9D4ABC0E18AB" xlink:to="lab_us-gaap_IncomeLossAttributableToParent_D69041F0479C52EA781D9D4ABC0E18AB" xlink:type="arc" /> <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8FF04FA9BE66111B407B9D494A84D9FA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_8FF04FA9BE66111B407B9D494A84D9FA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label> <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8FF04FA9BE66111B407B9D494A84D9FA_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_8FF04FA9BE66111B407B9D494A84D9FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8FF04FA9BE66111B407B9D494A84D9FA" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8FF04FA9BE66111B407B9D494A84D9FA" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_8FF04FA9BE66111B407B9D494A84D9FA" xlink:type="arc" /> <link:label id="lab_us-gaap_NetIncomeLoss_9B904880A46591A5CB5C9D3E475EFB26_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_9B904880A46591A5CB5C9D3E475EFB26" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9B904880A46591A5CB5C9D3E475EFB26" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_9B904880A46591A5CB5C9D3E475EFB26" xlink:to="lab_us-gaap_NetIncomeLoss_9B904880A46591A5CB5C9D3E475EFB26" xlink:type="arc" /> <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_88927E41F92412D363EF9D3E475E0B25_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_88927E41F92412D363EF9D3E475E0B25" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain and adjustment on securities included in net loss</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_88927E41F92412D363EF9D3E475E0B25" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_88927E41F92412D363EF9D3E475E0B25" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_88927E41F92412D363EF9D3E475E0B25" xlink:type="arc" /> <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9A43D18429C7944711C49D3E475E5DAD_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_9A43D18429C7944711C49D3E475E5DAD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label> <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_9A43D18429C7944711C49D3E475E5DAD_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_9A43D18429C7944711C49D3E475E5DAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9A43D18429C7944711C49D3E475E5DAD" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9A43D18429C7944711C49D3E475E5DAD" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_9A43D18429C7944711C49D3E475E5DAD" xlink:type="arc" /> <link:label id="lab_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_018EA70A7DAACB90C24E9D3E475F7E2D_verboseLabel_en-US" xlink:label="lab_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_018EA70A7DAACB90C24E9D3E475F7E2D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss</link:label> <link:label id="lab_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_018EA70A7DAACB90C24E9D3E475F7E2D_label_en-US" xlink:label="lab_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_018EA70A7DAACB90C24E9D3E475F7E2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income Loss Available To Common Stockholders, Basic And Diluted</link:label> <link:label id="lab_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_018EA70A7DAACB90C24E9D3E475F7E2D_documentation_en-US" xlink:label="lab_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_018EA70A7DAACB90C24E9D3E475F7E2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Income Loss Available To Common Stockholders, Basic And Diluted</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="loc_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_018EA70A7DAACB90C24E9D3E475F7E2D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_018EA70A7DAACB90C24E9D3E475F7E2D" xlink:to="lab_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_018EA70A7DAACB90C24E9D3E475F7E2D" xlink:type="arc" /> <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_33508CF652775FC0A1E69D3E475FCFCB_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_33508CF652775FC0A1E69D3E475FCFCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss (in dollar per share)</link:label> <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_33508CF652775FC0A1E69D3E475FCFCB_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_33508CF652775FC0A1E69D3E475FCFCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_33508CF652775FC0A1E69D3E475FCFCB" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_33508CF652775FC0A1E69D3E475FCFCB" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_33508CF652775FC0A1E69D3E475FCFCB" xlink:type="arc" /> <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_28A21E1C2DB75DD066459D3E475F9A16_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_28A21E1C2DB75DD066459D3E475F9A16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted weighted-average number of shares used in computing net loss per share (in shares)</link:label> <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_28A21E1C2DB75DD066459D3E475F9A16_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_28A21E1C2DB75DD066459D3E475F9A16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_28A21E1C2DB75DD066459D3E475F9A16" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_28A21E1C2DB75DD066459D3E475F9A16" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_28A21E1C2DB75DD066459D3E475F9A16" xlink:type="arc" /> <link:label id="lab_us-gaap_LeaseCostTableTextBlock_385C29ADF81186B2EFD316CE0ECCA387_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_385C29ADF81186B2EFD316CE0ECCA387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Costs</link:label> <link:label id="lab_us-gaap_LeaseCostTableTextBlock_385C29ADF81186B2EFD316CE0ECCA387_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_385C29ADF81186B2EFD316CE0ECCA387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_385C29ADF81186B2EFD316CE0ECCA387" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_385C29ADF81186B2EFD316CE0ECCA387" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_385C29ADF81186B2EFD316CE0ECCA387" xlink:type="arc" /> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2E80021757059AF0E35316CE0ECC7C09_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2E80021757059AF0E35316CE0ECC7C09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Liability Maturities</link:label> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2E80021757059AF0E35316CE0ECC7C09_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2E80021757059AF0E35316CE0ECC7C09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2E80021757059AF0E35316CE0ECC7C09" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2E80021757059AF0E35316CE0ECC7C09" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2E80021757059AF0E35316CE0ECC7C09" xlink:type="arc" /> <link:label id="lab_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock_43FF1ECEE8CDB7F3E90116CE0ECC625A_terseLabel_en-US" xlink:label="lab_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock_43FF1ECEE8CDB7F3E90116CE0ECC625A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information</link:label> <link:label id="lab_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock_43FF1ECEE8CDB7F3E90116CE0ECC625A_label_en-US" xlink:label="lab_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock_43FF1ECEE8CDB7F3E90116CE0ECC625A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Supplemental Cash Flow Information [Table Text Block]</link:label> <link:label id="lab_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock_43FF1ECEE8CDB7F3E90116CE0ECC625A_documentation_en-US" xlink:label="lab_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock_43FF1ECEE8CDB7F3E90116CE0ECC625A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Supplemental Cash Flow Information [Table Text Block]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_LesseeSupplementalCashFlowInformationTableTextBlock" xlink:label="loc_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock_43FF1ECEE8CDB7F3E90116CE0ECC625A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock_43FF1ECEE8CDB7F3E90116CE0ECC625A" xlink:to="lab_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock_43FF1ECEE8CDB7F3E90116CE0ECC625A" xlink:type="arc" /> <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_14D1F6E2F811B19DC19E9DEC932854C8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_14D1F6E2F811B19DC19E9DEC932854C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label> <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_14D1F6E2F811B19DC19E9DEC932854C8_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_14D1F6E2F811B19DC19E9DEC932854C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_14D1F6E2F811B19DC19E9DEC932854C8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_14D1F6E2F811B19DC19E9DEC932854C8" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_14D1F6E2F811B19DC19E9DEC932854C8" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label> <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:type="arc" /> <link:label id="lab_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label> <link:label id="lab_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:to="lab_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:type="arc" /> <link:label id="lab_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label> <link:label id="lab_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E" xlink:to="lab_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E" xlink:type="arc" /> <link:label id="lab_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4_terseLabel_en-US" xlink:label="lab_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Services</link:label> <link:label id="lab_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4_label_en-US" xlink:label="lab_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Services [Member]</link:label> <link:label id="lab_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4_documentation_en-US" xlink:label="lab_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Services [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DevelopmentServicesMember" xlink:label="loc_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4" xlink:to="lab_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4" xlink:type="arc" /> <link:label id="lab_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A_terseLabel_en-US" xlink:label="lab_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mylan</link:label> <link:label id="lab_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A_label_en-US" xlink:label="lab_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mylan Ireland Limited [Member]</link:label> <link:label id="lab_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A_documentation_en-US" xlink:label="lab_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mylan Ireland Limited [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_MylanIrelandLimitedMember" xlink:label="loc_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A" xlink:to="lab_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A" xlink:type="arc" /> <link:label id="lab_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61_terseLabel_en-US" xlink:label="lab_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.</link:label> <link:label id="lab_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61_label_en-US" xlink:label="lab_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. [Member]</link:label> <link:label id="lab_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61_documentation_en-US" xlink:label="lab_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" xlink:label="loc_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61" xlink:to="lab_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61" xlink:type="arc" /> <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label> <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:type="arc" /> <link:label id="lab_us-gaap_ContractWithCustomerLiability_0ED3A0318DCCFC94FE4A9FDB3E703050_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_0ED3A0318DCCFC94FE4A9FDB3E703050" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable upfront payment</link:label> <link:label id="lab_us-gaap_ContractWithCustomerLiability_0ED3A0318DCCFC94FE4A9FDB3E703050_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_0ED3A0318DCCFC94FE4A9FDB3E703050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0ED3A0318DCCFC94FE4A9FDB3E703050" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_0ED3A0318DCCFC94FE4A9FDB3E703050" xlink:to="lab_us-gaap_ContractWithCustomerLiability_0ED3A0318DCCFC94FE4A9FDB3E703050" xlink:type="arc" /> <link:label id="lab_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD_terseLabel_en-US" xlink:label="lab_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent payments</link:label> <link:label id="lab_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD_label_en-US" xlink:label="lab_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Licensing Royalty Revenue</link:label> <link:label id="lab_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD_documentation_en-US" xlink:label="lab_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Licensing Royalty Revenue</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ContingentLicensingRoyaltyRevenue" xlink:label="loc_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD" xlink:to="lab_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD" xlink:type="arc" /> <link:label id="lab_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2_terseLabel_en-US" xlink:label="lab_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue maximum for receipt of tiered milestone payments</link:label> <link:label id="lab_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2_label_en-US" xlink:label="lab_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Maximum Revenue</link:label> <link:label id="lab_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2_documentation_en-US" xlink:label="lab_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Maximum Revenue</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue" xlink:label="loc_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2" xlink:to="lab_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2" xlink:type="arc" /> <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_E1B9503A4C6E93E5197F9FDB3E713BD8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_E1B9503A4C6E93E5197F9FDB3E713BD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation</link:label> <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_E1B9503A4C6E93E5197F9FDB3E713BD8_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_E1B9503A4C6E93E5197F9FDB3E713BD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_E1B9503A4C6E93E5197F9FDB3E713BD8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_E1B9503A4C6E93E5197F9FDB3E713BD8" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_E1B9503A4C6E93E5197F9FDB3E713BD8" xlink:type="arc" /> <link:label id="lab_us-gaap_Revenues_E35692E9FBADD07875CC9FDB3E716D87_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_E35692E9FBADD07875CC9FDB3E716D87" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E35692E9FBADD07875CC9FDB3E716D87" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_E35692E9FBADD07875CC9FDB3E716D87" xlink:to="lab_us-gaap_Revenues_E35692E9FBADD07875CC9FDB3E716D87" xlink:type="arc" /> <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1458225BEBDD392F07179FDB3E72B0CB_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1458225BEBDD392F07179FDB3E72B0CB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1458225BEBDD392F07179FDB3E72B0CB" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1458225BEBDD392F07179FDB3E72B0CB" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_1458225BEBDD392F07179FDB3E72B0CB" xlink:type="arc" /> <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_1D16B695F9847B81F4FF9FDB3E72654C_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross_1D16B695F9847B81F4FF9FDB3E72654C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, asset, before allowance for credit loss</link:label> <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_1D16B695F9847B81F4FF9FDB3E72654C_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross_1D16B695F9847B81F4FF9FDB3E72654C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, before Allowance for Credit Loss</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_1D16B695F9847B81F4FF9FDB3E72654C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetGross_1D16B695F9847B81F4FF9FDB3E72654C" xlink:to="lab_us-gaap_ContractWithCustomerAssetGross_1D16B695F9847B81F4FF9FDB3E72654C" xlink:type="arc" /> <link:label id="lab_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F_terseLabel_en-US" xlink:label="lab_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign withholding tax, amount</link:label> <link:label id="lab_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F_label_en-US" xlink:label="lab_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Withholding Tax, Amount</link:label> <link:label id="lab_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F_documentation_en-US" xlink:label="lab_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Withholding Tax, Amount</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ForeignWithholdingTaxAmount" xlink:label="loc_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F" xlink:to="lab_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F" xlink:type="arc" /> <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_B69C1FD602684AE3CC149FDB3E722BE6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_B69C1FD602684AE3CC149FDB3E722BE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, revenue recognized</link:label> <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_B69C1FD602684AE3CC149FDB3E722BE6_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_B69C1FD602684AE3CC149FDB3E722BE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_B69C1FD602684AE3CC149FDB3E722BE6" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_B69C1FD602684AE3CC149FDB3E722BE6" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_B69C1FD602684AE3CC149FDB3E722BE6" xlink:type="arc" /> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_FB2C42E70CB9D1222F899DEC930C5D76_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_FB2C42E70CB9D1222F899DEC930C5D76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 remaining nine months</link:label> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_FB2C42E70CB9D1222F899DEC930C5D76_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_FB2C42E70CB9D1222F899DEC930C5D76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_FB2C42E70CB9D1222F899DEC930C5D76" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_FB2C42E70CB9D1222F899DEC930C5D76" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_FB2C42E70CB9D1222F899DEC930C5D76" xlink:type="arc" /> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E07CA789A6BE491319289DEC930D7D4F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E07CA789A6BE491319289DEC930D7D4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E07CA789A6BE491319289DEC930D7D4F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E07CA789A6BE491319289DEC930D7D4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E07CA789A6BE491319289DEC930D7D4F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E07CA789A6BE491319289DEC930D7D4F" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E07CA789A6BE491319289DEC930D7D4F" xlink:type="arc" /> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8CDF5D8BDE6CAABF60929DEC930DC5C4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8CDF5D8BDE6CAABF60929DEC930DC5C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8CDF5D8BDE6CAABF60929DEC930DC5C4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8CDF5D8BDE6CAABF60929DEC930DC5C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8CDF5D8BDE6CAABF60929DEC930DC5C4" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8CDF5D8BDE6CAABF60929DEC930DC5C4" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8CDF5D8BDE6CAABF60929DEC930DC5C4" xlink:type="arc" /> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_605369CD044CC54A94A09DEC930D76E1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_605369CD044CC54A94A09DEC930D76E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_605369CD044CC54A94A09DEC930D76E1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_605369CD044CC54A94A09DEC930D76E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_605369CD044CC54A94A09DEC930D76E1" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_605369CD044CC54A94A09DEC930D76E1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_605369CD044CC54A94A09DEC930D76E1" xlink:type="arc" /> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_CD397245C1D8D2F2CFE09DEC930ED9B1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_CD397245C1D8D2F2CFE09DEC930ED9B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_CD397245C1D8D2F2CFE09DEC930ED9B1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_CD397245C1D8D2F2CFE09DEC930ED9B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_CD397245C1D8D2F2CFE09DEC930ED9B1" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_CD397245C1D8D2F2CFE09DEC930ED9B1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_CD397245C1D8D2F2CFE09DEC930ED9B1" xlink:type="arc" /> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_A5BBA1592916FE75867D9DEC930E3E30_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_A5BBA1592916FE75867D9DEC930E3E30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 and thereafter</link:label> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_A5BBA1592916FE75867D9DEC930E3E30_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_A5BBA1592916FE75867D9DEC930E3E30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_A5BBA1592916FE75867D9DEC930E3E30" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_A5BBA1592916FE75867D9DEC930E3E30" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_A5BBA1592916FE75867D9DEC930E3E30" xlink:type="arc" /> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08DF9D41CD7262EF22569DEC930E9078_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08DF9D41CD7262EF22569DEC930E9078" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease payments</link:label> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08DF9D41CD7262EF22569DEC930E9078_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08DF9D41CD7262EF22569DEC930E9078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08DF9D41CD7262EF22569DEC930E9078" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08DF9D41CD7262EF22569DEC930E9078" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08DF9D41CD7262EF22569DEC930E9078" xlink:type="arc" /> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_FFFF80FFEACFEDB1B0DD9DEC930EC045_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_FFFF80FFEACFEDB1B0DD9DEC930EC045" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest (1)</link:label> <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_FFFF80FFEACFEDB1B0DD9DEC930EC045_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_FFFF80FFEACFEDB1B0DD9DEC930EC045" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_FFFF80FFEACFEDB1B0DD9DEC930EC045" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_FFFF80FFEACFEDB1B0DD9DEC930EC045" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_FFFF80FFEACFEDB1B0DD9DEC930EC045" xlink:type="arc" /> <link:label id="lab_us-gaap_OperatingLeaseLiability_08C184CA4F9BCB0DEE4F9DEC930F4862_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_08C184CA4F9BCB0DEE4F9DEC930F4862" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease payments</link:label> <link:label id="lab_us-gaap_OperatingLeaseLiability_08C184CA4F9BCB0DEE4F9DEC930F4862_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_08C184CA4F9BCB0DEE4F9DEC930F4862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_08C184CA4F9BCB0DEE4F9DEC930F4862" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_08C184CA4F9BCB0DEE4F9DEC930F4862" xlink:to="lab_us-gaap_OperatingLeaseLiability_08C184CA4F9BCB0DEE4F9DEC930F4862" xlink:type="arc" /> <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_45F47207B2B7E028D1489DEC930FE3A1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_45F47207B2B7E028D1489DEC930FE3A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate (percent)</link:label> <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_45F47207B2B7E028D1489DEC930FE3A1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_45F47207B2B7E028D1489DEC930FE3A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_45F47207B2B7E028D1489DEC930FE3A1" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_45F47207B2B7E028D1489DEC930FE3A1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_45F47207B2B7E028D1489DEC930FE3A1" xlink:type="arc" /> <link:label id="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD_terseLabel_en-US" xlink:label="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Terms Of Conversion [Axis]</link:label> <link:label id="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD_label_en-US" xlink:label="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Terms Of Conversion [Axis]</link:label> <link:label id="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD_documentation_en-US" xlink:label="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Terms Of Conversion [Axis]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:label="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:to="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:type="arc" /> <link:label id="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464_terseLabel_en-US" xlink:label="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Terms Of Conversion [Domain]</link:label> <link:label id="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464_label_en-US" xlink:label="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Terms Of Conversion [Domain]</link:label> <link:label id="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464_documentation_en-US" xlink:label="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Debt Instrument Convertible Terms Of Conversion [Axis]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:label="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:to="lab_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:type="arc" /> <link:label id="lab_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989_terseLabel_en-US" xlink:label="lab_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One</link:label> <link:label id="lab_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989_label_en-US" xlink:label="lab_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One [Member]</link:label> <link:label id="lab_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989_documentation_en-US" xlink:label="lab_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms One [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtConversionTermsOneMember" xlink:label="loc_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989" xlink:to="lab_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989" xlink:type="arc" /> <link:label id="lab_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D_terseLabel_en-US" xlink:label="lab_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two</link:label> <link:label id="lab_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D_label_en-US" xlink:label="lab_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two [Member]</link:label> <link:label id="lab_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D_documentation_en-US" xlink:label="lab_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion Terms Two [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtConversionTermsTwoMember" xlink:label="loc_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D" xlink:to="lab_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_D1BD64FCD0C7A4577FC2EC729BEB4999_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_D1BD64FCD0C7A4577FC2EC729BEB4999" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label> <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_D1BD64FCD0C7A4577FC2EC729BEB4999_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_D1BD64FCD0C7A4577FC2EC729BEB4999" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_D1BD64FCD0C7A4577FC2EC729BEB4999" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_D1BD64FCD0C7A4577FC2EC729BEB4999" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_D1BD64FCD0C7A4577FC2EC729BEB4999" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_D92ACF9F03A0B6756AB3EC729BEBA55E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_D92ACF9F03A0B6756AB3EC729BEBA55E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated percentage</link:label> <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_D92ACF9F03A0B6756AB3EC729BEBA55E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_D92ACF9F03A0B6756AB3EC729BEBA55E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D92ACF9F03A0B6756AB3EC729BEBA55E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D92ACF9F03A0B6756AB3EC729BEBA55E" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_D92ACF9F03A0B6756AB3EC729BEBA55E" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4660E9109556DCA01BC2EC729BEC0C61_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4660E9109556DCA01BC2EC729BEC0C61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold trading days</link:label> <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4660E9109556DCA01BC2EC729BEC0C61_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4660E9109556DCA01BC2EC729BEC0C61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4660E9109556DCA01BC2EC729BEC0C61" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4660E9109556DCA01BC2EC729BEC0C61" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4660E9109556DCA01BC2EC729BEC0C61" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_E87E6424EC0281D07DBDEC729BECD4AB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_E87E6424EC0281D07DBDEC729BECD4AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold consecutive trading days</link:label> <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_E87E6424EC0281D07DBDEC729BECD4AB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_E87E6424EC0281D07DBDEC729BECD4AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_E87E6424EC0281D07DBDEC729BECD4AB" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_E87E6424EC0281D07DBDEC729BECD4AB" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_E87E6424EC0281D07DBDEC729BECD4AB" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_047CED478E58CE15A56AEC729BEC27C0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_047CED478E58CE15A56AEC729BEC27C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of stock price trigger</link:label> <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_047CED478E58CE15A56AEC729BEC27C0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_047CED478E58CE15A56AEC729BEC27C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_047CED478E58CE15A56AEC729BEC27C0" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_047CED478E58CE15A56AEC729BEC27C0" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_047CED478E58CE15A56AEC729BEC27C0" xlink:type="arc" /> <link:label id="lab_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2_terseLabel_en-US" xlink:label="lab_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold percentage of stock trading price</link:label> <link:label id="lab_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2_label_en-US" xlink:label="lab_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage Of Stock Trading Price</link:label> <link:label id="lab_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2_documentation_en-US" xlink:label="lab_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage Of Stock Trading Price</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" xlink:label="loc_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2" xlink:to="lab_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_D4671F1331E0645A3DD2EC729BECB058_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_D4671F1331E0645A3DD2EC729BECB058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio</link:label> <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_D4671F1331E0645A3DD2EC729BECB058_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_D4671F1331E0645A3DD2EC729BECB058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_D4671F1331E0645A3DD2EC729BECB058" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_D4671F1331E0645A3DD2EC729BECB058" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_D4671F1331E0645A3DD2EC729BECB058" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_0DAB0BA5CBA9F174EA0BEC729BED609E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_0DAB0BA5CBA9F174EA0BEC729BED609E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption price, percentage</link:label> <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_0DAB0BA5CBA9F174EA0BEC729BED609E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_0DAB0BA5CBA9F174EA0BEC729BED609E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_0DAB0BA5CBA9F174EA0BEC729BED609E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_0DAB0BA5CBA9F174EA0BEC729BED609E" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_0DAB0BA5CBA9F174EA0BEC729BED609E" xlink:type="arc" /> <link:label id="lab_us-gaap_LongTermDebt_6E250EA51497470C6B6CEC729BED14A6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_6E250EA51497470C6B6CEC729BED14A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6E250EA51497470C6B6CEC729BED14A6" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_6E250EA51497470C6B6CEC729BED14A6" xlink:to="lab_us-gaap_LongTermDebt_6E250EA51497470C6B6CEC729BED14A6" xlink:type="arc" /> <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7B42CFBAFF6F3521EB9EEC729BED8EF8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7B42CFBAFF6F3521EB9EEC729BED8EF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount of equity component</link:label> <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7B42CFBAFF6F3521EB9EEC729BED8EF8_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7B42CFBAFF6F3521EB9EEC729BED8EF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7B42CFBAFF6F3521EB9EEC729BED8EF8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7B42CFBAFF6F3521EB9EEC729BED8EF8" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7B42CFBAFF6F3521EB9EEC729BED8EF8" xlink:type="arc" /> <link:label id="lab_us-gaap_DeferredFinanceCostsGross_8EDBC817323A362B460FEC729BEDAE65_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_8EDBC817323A362B460FEC729BEDAE65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label> <link:label id="lab_us-gaap_DeferredFinanceCostsGross_8EDBC817323A362B460FEC729BEDAE65_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_8EDBC817323A362B460FEC729BEDAE65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_8EDBC817323A362B460FEC729BEDAE65" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross_8EDBC817323A362B460FEC729BEDAE65" xlink:to="lab_us-gaap_DeferredFinanceCostsGross_8EDBC817323A362B460FEC729BEDAE65" xlink:type="arc" /> <link:label id="lab_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C_terseLabel_en-US" xlink:label="lab_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, liability component</link:label> <link:label id="lab_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C_label_en-US" xlink:label="lab_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross, Liability Component</link:label> <link:label id="lab_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C_documentation_en-US" xlink:label="lab_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross, Liability Component</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtIssuanceCostsGrossLiabilityComponent" xlink:label="loc_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C" xlink:to="lab_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C" xlink:type="arc" /> <link:label id="lab_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB_terseLabel_en-US" xlink:label="lab_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, equity component</link:label> <link:label id="lab_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB_label_en-US" xlink:label="lab_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross, Equity Component</link:label> <link:label id="lab_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB_documentation_en-US" xlink:label="lab_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross, Equity Component</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtIssuanceCostsGrossEquityComponent" xlink:label="loc_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB" xlink:to="lab_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB" xlink:type="arc" /> <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_293168C83D7FBD2FCF05EADD66E33CEB_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_293168C83D7FBD2FCF05EADD66E33CEB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label> <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_293168C83D7FBD2FCF05EADD66E33CEB_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_293168C83D7FBD2FCF05EADD66E33CEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_293168C83D7FBD2FCF05EADD66E33CEB" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_293168C83D7FBD2FCF05EADD66E33CEB" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_293168C83D7FBD2FCF05EADD66E33CEB" xlink:type="arc" /> <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_65550955CA8C4BF74584EADD66E4DEDA_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_65550955CA8C4BF74584EADD66E4DEDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label> <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_65550955CA8C4BF74584EADD66E4DEDA_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_65550955CA8C4BF74584EADD66E4DEDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_65550955CA8C4BF74584EADD66E4DEDA" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_65550955CA8C4BF74584EADD66E4DEDA" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_65550955CA8C4BF74584EADD66E4DEDA" xlink:type="arc" /> <link:label id="lab_us-gaap_UseOfEstimates_A1AD86D33B28CA49CAEAEADD66E4243E_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_A1AD86D33B28CA49CAEAEADD66E4243E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label> <link:label id="lab_us-gaap_UseOfEstimates_A1AD86D33B28CA49CAEAEADD66E4243E_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_A1AD86D33B28CA49CAEAEADD66E4243E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_A1AD86D33B28CA49CAEAEADD66E4243E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_A1AD86D33B28CA49CAEAEADD66E4243E" xlink:to="lab_us-gaap_UseOfEstimates_A1AD86D33B28CA49CAEAEADD66E4243E" xlink:type="arc" /> <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_032DA88FE5D63867C7C6EADD66E4EB5E_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_032DA88FE5D63867C7C6EADD66E4EB5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label> <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_032DA88FE5D63867C7C6EADD66E4EB5E_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_032DA88FE5D63867C7C6EADD66E4EB5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_032DA88FE5D63867C7C6EADD66E4EB5E" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_032DA88FE5D63867C7C6EADD66E4EB5E" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_032DA88FE5D63867C7C6EADD66E4EB5E" xlink:type="arc" /> <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_291327D3D9E4C5DEEA46EADD66E42F5D_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_291327D3D9E4C5DEEA46EADD66E42F5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Pronouncements</link:label> <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_291327D3D9E4C5DEEA46EADD66E42F5D_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_291327D3D9E4C5DEEA46EADD66E42F5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_291327D3D9E4C5DEEA46EADD66E42F5D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_291327D3D9E4C5DEEA46EADD66E42F5D" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_291327D3D9E4C5DEEA46EADD66E42F5D" xlink:type="arc" /> <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8EDDAAFAD60CE80C171016CE0F4ADB71_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8EDDAAFAD60CE80C171016CE0F4ADB71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company and Summary of Significant Accounting Policies</link:label> <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8EDDAAFAD60CE80C171016CE0F4ADB71_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8EDDAAFAD60CE80C171016CE0F4ADB71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8EDDAAFAD60CE80C171016CE0F4ADB71" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8EDDAAFAD60CE80C171016CE0F4ADB71" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8EDDAAFAD60CE80C171016CE0F4ADB71" xlink:type="arc" /> <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_7E278B37C88F6C5A4A05BA17F428247F_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_7E278B37C88F6C5A4A05BA17F428247F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label> <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_7E278B37C88F6C5A4A05BA17F428247F_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_7E278B37C88F6C5A4A05BA17F428247F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_7E278B37C88F6C5A4A05BA17F428247F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_7E278B37C88F6C5A4A05BA17F428247F" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_7E278B37C88F6C5A4A05BA17F428247F" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ECFCEBC0D404C0E267BDE627CC14E455_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ECFCEBC0D404C0E267BDE627CC14E455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label> <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ECFCEBC0D404C0E267BDE627CC14E455_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ECFCEBC0D404C0E267BDE627CC14E455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ECFCEBC0D404C0E267BDE627CC14E455" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ECFCEBC0D404C0E267BDE627CC14E455" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ECFCEBC0D404C0E267BDE627CC14E455" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label> <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:type="arc" /> <link:label id="lab_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label> <link:label id="lab_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:type="arc" /> <link:label id="lab_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label> <link:label id="lab_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:type="arc" /> <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_A27C08B2F3A3197383689F89F72AD96F_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_A27C08B2F3A3197383689F89F72AD96F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term</link:label> <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_A27C08B2F3A3197383689F89F72AD96F_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_A27C08B2F3A3197383689F89F72AD96F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_A27C08B2F3A3197383689F89F72AD96F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_A27C08B2F3A3197383689F89F72AD96F" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_A27C08B2F3A3197383689F89F72AD96F" xlink:type="arc" /> <link:label id="lab_us-gaap_MeasurementInputEntityCreditRiskMember_97F9310E75BB8FBEB39E9F89F72A896B_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputEntityCreditRiskMember_97F9310E75BB8FBEB39E9F89F72A896B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Entity Credit Risk</link:label> <link:label id="lab_us-gaap_MeasurementInputEntityCreditRiskMember_97F9310E75BB8FBEB39E9F89F72A896B_label_en-US" xlink:label="lab_us-gaap_MeasurementInputEntityCreditRiskMember_97F9310E75BB8FBEB39E9F89F72A896B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Entity Credit Risk [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputEntityCreditRiskMember" xlink:label="loc_us-gaap_MeasurementInputEntityCreditRiskMember_97F9310E75BB8FBEB39E9F89F72A896B" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputEntityCreditRiskMember_97F9310E75BB8FBEB39E9F89F72A896B" xlink:to="lab_us-gaap_MeasurementInputEntityCreditRiskMember_97F9310E75BB8FBEB39E9F89F72A896B" xlink:type="arc" /> <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_D047D0C4BF2C3ADA59A59F89F72A9352_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_D047D0C4BF2C3ADA59A59F89F72A9352" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate</link:label> <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_D047D0C4BF2C3ADA59A59F89F72A9352_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_D047D0C4BF2C3ADA59A59F89F72A9352" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D047D0C4BF2C3ADA59A59F89F72A9352" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D047D0C4BF2C3ADA59A59F89F72A9352" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_D047D0C4BF2C3ADA59A59F89F72A9352" xlink:type="arc" /> <link:label id="lab_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D_terseLabel_en-US" xlink:label="lab_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medicis Pharmaceutical Corporation</link:label> <link:label id="lab_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D_label_en-US" xlink:label="lab_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medicis Pharmaceutical Corporation [Member]</link:label> <link:label id="lab_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D_documentation_en-US" xlink:label="lab_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicis Pharmaceutical Corporation [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_MedicisPharmaceuticalCorporationMember" xlink:label="loc_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D" xlink:to="lab_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D" xlink:type="arc" /> <link:label id="lab_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF_terseLabel_en-US" xlink:label="lab_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valeant Pharmaceuticals International, Inc.</link:label> <link:label id="lab_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF_label_en-US" xlink:label="lab_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valeant Pharmaceuticals International, Inc. [Member]</link:label> <link:label id="lab_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF_documentation_en-US" xlink:label="lab_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valeant Pharmaceuticals International, Inc. [Member]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ValeantPharmaceuticalsInternationalInc.Member" xlink:label="loc_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF" xlink:to="lab_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF" xlink:type="arc" /> <link:label id="lab_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F_terseLabel_en-US" xlink:label="lab_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement And Termination [Line Items]</link:label> <link:label id="lab_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F_label_en-US" xlink:label="lab_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement And Termination [Line Items]</link:label> <link:label id="lab_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F_documentation_en-US" xlink:label="lab_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Settlement And Termination [Line Items]</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_SettlementAndTerminationLineItems" xlink:label="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:to="lab_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:type="arc" /> <link:label id="lab_rvnc_AccruedMilestoneObligations_C236A8E44585A0C72DCC9F89F732E9A8_terseLabel_en-US" xlink:label="lab_rvnc_AccruedMilestoneObligations_C236A8E44585A0C72DCC9F89F732E9A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrecurring milestone payment</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AccruedMilestoneObligations" xlink:label="loc_rvnc_AccruedMilestoneObligations_C236A8E44585A0C72DCC9F89F732E9A8" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_AccruedMilestoneObligations_C236A8E44585A0C72DCC9F89F732E9A8" xlink:to="lab_rvnc_AccruedMilestoneObligations_C236A8E44585A0C72DCC9F89F732E9A8" xlink:type="arc" /> <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9A00FB9030404A05D4C19F89F732CB43_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9A00FB9030404A05D4C19F89F732CB43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of derivative</link:label> <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9A00FB9030404A05D4C19F89F732CB43_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9A00FB9030404A05D4C19F89F732CB43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9A00FB9030404A05D4C19F89F732CB43" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9A00FB9030404A05D4C19F89F732CB43" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9A00FB9030404A05D4C19F89F732CB43" xlink:type="arc" /> <link:label id="lab_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D_terseLabel_en-US" xlink:label="lab_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, measurement input, duration</link:label> <link:label id="lab_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D_label_en-US" xlink:label="lab_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Input, Duration</link:label> <link:label id="lab_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D_documentation_en-US" xlink:label="lab_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Input, Duration</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_FairValueMeasurementInputDuration" xlink:label="loc_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D" xlink:to="lab_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D" xlink:type="arc" /> <link:label id="lab_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D_terseLabel_en-US" xlink:label="lab_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value, measurement input (percent)</link:label> <link:label id="lab_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D_label_en-US" xlink:label="lab_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Input</link:label> <link:label id="lab_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D_documentation_en-US" xlink:label="lab_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Input</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_FairValueMeasurementInput" xlink:label="loc_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D" xlink:to="lab_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D" xlink:type="arc" /> <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_CD9A1A116E9912EDBA3C9FDB3EF871AA_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_CD9A1A116E9912EDBA3C9FDB3EF871AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of stock issuance costs</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_CD9A1A116E9912EDBA3C9FDB3EF871AA" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_CD9A1A116E9912EDBA3C9FDB3EF871AA" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_CD9A1A116E9912EDBA3C9FDB3EF871AA" xlink:type="arc" /> <link:label id="lab_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3_terseLabel_en-US" xlink:label="lab_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of convertible debt, transaction cost</link:label> <link:label id="lab_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3_label_en-US" xlink:label="lab_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component Of Convertible Debt, Transaction Cost</link:label> <link:label id="lab_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3_documentation_en-US" xlink:label="lab_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Component Of Convertible Debt, Transaction Cost</link:label> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_EquityComponentOfConvertibleDebtTransactionCost" xlink:label="loc_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3" xlink:to="lab_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3" xlink:type="arc" /> <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label> <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:type="arc" /> <link:label id="lab_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label> <link:label id="lab_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:type="arc" /> <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label> <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:type="arc" /> <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6E6798CFB76DC5B74FE49F83F6D3ADF1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6E6798CFB76DC5B74FE49F83F6D3ADF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label> <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6E6798CFB76DC5B74FE49F83F6D3ADF1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6E6798CFB76DC5B74FE49F83F6D3ADF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6E6798CFB76DC5B74FE49F83F6D3ADF1" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6E6798CFB76DC5B74FE49F83F6D3ADF1" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6E6798CFB76DC5B74FE49F83F6D3ADF1" xlink:type="arc" /> <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_65497392562DDFAE81D09F83F6D4408A_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_65497392562DDFAE81D09F83F6D4408A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative</link:label> <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_65497392562DDFAE81D09F83F6D4408A_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_65497392562DDFAE81D09F83F6D4408A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_65497392562DDFAE81D09F83F6D4408A" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_65497392562DDFAE81D09F83F6D4408A" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_65497392562DDFAE81D09F83F6D4408A" xlink:type="arc" /> <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label> <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06" xlink:type="arc" /> <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3CECF961A2DDA3938C529F83F6D4DF16_positiveLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_3CECF961A2DDA3938C529F83F6D4DF16" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:type="resource" xml:lang="en-US">Total stock based compensation expense</link:label> <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3CECF961A2DDA3938C529F83F6D4DF16_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_3CECF961A2DDA3938C529F83F6D4DF16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3CECF961A2DDA3938C529F83F6D4DF16" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_3CECF961A2DDA3938C529F83F6D4DF16" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_3CECF961A2DDA3938C529F83F6D4DF16" xlink:type="arc" /> <link:label id="lab_us-gaap_LongTermDebtTextBlock_8DA51200DAB1181AC47EBA163DA59652_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock_8DA51200DAB1181AC47EBA163DA59652" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes</link:label> <link:label id="lab_us-gaap_LongTermDebtTextBlock_8DA51200DAB1181AC47EBA163DA59652_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock_8DA51200DAB1181AC47EBA163DA59652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt [Text Block]</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_8DA51200DAB1181AC47EBA163DA59652" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock_8DA51200DAB1181AC47EBA163DA59652" xlink:to="lab_us-gaap_LongTermDebtTextBlock_8DA51200DAB1181AC47EBA163DA59652" xlink:type="arc" /> <link:label id="lab_us-gaap_OperatingLeasePayments_1260019F2EA7F21A93C49DEC92F1A167_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_1260019F2EA7F21A93C49DEC92F1A167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</link:label> <link:label id="lab_us-gaap_OperatingLeasePayments_1260019F2EA7F21A93C49DEC92F1A167_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_1260019F2EA7F21A93C49DEC92F1A167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1260019F2EA7F21A93C49DEC92F1A167" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_1260019F2EA7F21A93C49DEC92F1A167" xlink:to="lab_us-gaap_OperatingLeasePayments_1260019F2EA7F21A93C49DEC92F1A167" xlink:type="arc" /> <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A2A3A8BDBB382269654A9DEC92F1C7C9_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A2A3A8BDBB382269654A9DEC92F1C7C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for operating lease liabilities</link:label> <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A2A3A8BDBB382269654A9DEC92F1C7C9_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A2A3A8BDBB382269654A9DEC92F1C7C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A2A3A8BDBB382269654A9DEC92F1C7C9" xlink:type="locator" /> <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A2A3A8BDBB382269654A9DEC92F1C7C9" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A2A3A8BDBB382269654A9DEC92F1C7C9" xlink:type="arc" /> </link:labelLink> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.PRE <SEQUENCE>10 <FILENAME>rvnc-20200331_pre.xml <DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT <TEXT> <XBRL> <?xml version="1.0" encoding="US-ASCII"?> <!--XBRL Document Created with Wdesk from Workiva--> <!-- --> <link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"> <link:roleRef roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestments" xlink:href="rvnc-20200331.xsd#CashEquivalentsAndShortTermInvestments" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" xlink:href="rvnc-20200331.xsd#CashEquivalentsAndShortTermInvestmentsDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:href="rvnc-20200331.xsd#CashEquivalentsAndShortTermInvestmentsTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CommitmentsAndContingencies" xlink:href="rvnc-20200331.xsd#CommitmentsAndContingencies" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="rvnc-20200331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:href="rvnc-20200331.xsd#CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="rvnc-20200331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="rvnc-20200331.xsd#CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="rvnc-20200331.xsd#CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotes" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotes" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesCappedCallTransactionsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/ConvertibleSeniorNotesTables" xlink:href="rvnc-20200331.xsd#ConvertibleSeniorNotesTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/CoverPage" xlink:href="rvnc-20200331.xsd#CoverPage" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/DerivativeLiability" xlink:href="rvnc-20200331.xsd#DerivativeLiability" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" xlink:href="rvnc-20200331.xsd#DerivativeLiabilityAdditionalInformationDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurements" xlink:href="rvnc-20200331.xsd#FairValueMeasurements" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" xlink:href="rvnc-20200331.xsd#FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" xlink:href="rvnc-20200331.xsd#FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FairValueMeasurementsTables" xlink:href="rvnc-20200331.xsd#FairValueMeasurementsTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreement" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreement" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreementDistributionsRightsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreementNarrativeDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/FillerDistributionAgreementTables" xlink:href="rvnc-20200331.xsd#FillerDistributionAgreementTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/Leases" xlink:href="rvnc-20200331.xsd#Leases" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesOperatingLeaseCostsDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails" xlink:href="rvnc-20200331.xsd#LeasesLeasesSupplementalCashFlowInformationDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/LeasesLeasesTables" xlink:href="rvnc-20200331.xsd#LeasesLeasesTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/Revenue" xlink:href="rvnc-20200331.xsd#Revenue" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/RevenueDetails" xlink:href="rvnc-20200331.xsd#RevenueDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensation" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensation" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" xlink:type="simple" /> <link:roleRef roleURI="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationTables" xlink:href="rvnc-20200331.xsd#StockholdersEquityAndStockBasedCompensationTables" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" /> <link:presentationLink xlink:role="http://www.revance.com/role/CashEquivalentsAndShortTermInvestments" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_60F58E85D6C5A22848B1E627CBF63B5A" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_91D70CE104FD7F546A64E627CBF687EF" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_60F58E85D6C5A22848B1E627CBF63B5A" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_91D70CE104FD7F546A64E627CBF687EF" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35564E140A1DF6BF0BEA9DEC93612FAA" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_35564E140A1DF6BF0BEA9DEC93612FAA" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E3142312802C2BCBA8C99DEC9361931E" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E3142312802C2BCBA8C99DEC9361931E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E3142312802C2BCBA8C99DEC9361931E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_92296FC73EFC1EC2109A9DEC9362DBC7" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:to="loc_us-gaap_MoneyMarketFundsMember_92296FC73EFC1EC2109A9DEC9362DBC7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0EBF0935F0EF68A2B65B9DEC9363841C" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0EBF0935F0EF68A2B65B9DEC9363841C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_519CCF9D3A6107DE053D9DEC9363FDAF" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_519CCF9D3A6107DE053D9DEC9363FDAF" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_41AB881B95ED50E644F19DEC9363C3BA" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:to="loc_us-gaap_CommercialPaperMember_41AB881B95ED50E644F19DEC9363C3BA" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_BB004BAB7F3A166F45349DEC93636C2C" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ECB33B18E65208877E6E9DEC9362EEC0" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_BB004BAB7F3A166F45349DEC93636C2C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_AC4DAAE150DDB5B102DB9DEC93644C9B" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_AC4DAAE150DDB5B102DB9DEC93644C9B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_60326EDD381050C6DABE9DEC9364382A" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_AC4DAAE150DDB5B102DB9DEC93644C9B" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_60326EDD381050C6DABE9DEC9364382A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_6B5FFB480494EC55D4A99DEC9364EA32" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_60326EDD381050C6DABE9DEC9364382A" xlink:to="loc_us-gaap_CashEquivalentsMember_6B5FFB480494EC55D4A99DEC9364EA32" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_CC575373C47DFBF1802A9DEC9365FF38" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_60326EDD381050C6DABE9DEC9364382A" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_CC575373C47DFBF1802A9DEC9365FF38" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_C824C9F0F09CB608E11D9DEC9361F337" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5FA638AAFD1E242CBD99DEC93669924" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C5FA638AAFD1E242CBD99DEC93669924" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C93BF647C71F9BBD5E779DEC9366A08F" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_C93BF647C71F9BBD5E779DEC9366A08F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1D0C3EE72D78E9DF1B0D9DEC93662557" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1D0C3EE72D78E9DF1B0D9DEC93662557" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE4E61FEFA8BB60AE4869DEC9367F016" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_BE4E61FEFA8BB60AE4869DEC9367F016" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_57CBA01D4F2ACD4CF5039DEC93678499" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_72AAAC94BFB6BFF0AF609DEC93654185" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_57CBA01D4F2ACD4CF5039DEC93678499" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsTables" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B629740EE655299D32FB9DEC936E84FF" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_719AF9B731C57A32B8129DEC936FE82F" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B629740EE655299D32FB9DEC936E84FF" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_719AF9B731C57A32B8129DEC936FE82F" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CommitmentsAndContingencies" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92B3D4ECE9AB77C40D0E9DEC92EC03E2" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85031F0FF2D9A2AB9ED99DEC92ECC04A" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_92B3D4ECE9AB77C40D0E9DEC92EC03E2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_85031F0FF2D9A2AB9ED99DEC92ECC04A" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7F0A5ED3A3F8319E3AB29DEC92DA59A2" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7F0A5ED3A3F8319E3AB29DEC92DA59A2" xlink:to="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:to="loc_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4F0309FF9B4477C9F0319DEC92DC833B" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_BotulinumToxinResearchAssociatesInc.Member" xlink:label="loc_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1F203265E8D0D41D01669DEC92DC4058" xlink:to="loc_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_D18F73015F475A87CCF99DEC92DDEC24" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_6D28920673E28FE1EA249DEC92DE2A1A" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_77EF02C6E345B9C9B23F9DEC92DD2A6E" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_6D28920673E28FE1EA249DEC92DE2A1A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5726A9C3F5C13299710C9DEC92DE8B94" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5726A9C3F5C13299710C9DEC92DE8B94" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5726A9C3F5C13299710C9DEC92DE8B94" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TeoxaneAgreementMember" xlink:label="loc_rvnc_TeoxaneAgreementMember_30784FEB0E25C7D9E2239EC6483E451F" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:to="loc_rvnc_TeoxaneAgreementMember_30784FEB0E25C7D9E2239EC6483E451F" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ListLaboratoriesMember" xlink:label="loc_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:to="loc_rvnc_ListLaboratoriesMember_3E8723F1A97BC693EF749DEC92E064D6" xlink:type="arc" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:to="loc_rvnc_BotulinumToxinResearchAssociatesInc.Member_C7A96E5390D7BE1F99489DEC92DC6FEC" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_BioSentinelInc.Member" xlink:label="loc_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9C5D4A9C6C703B955A9A9DEC92DE8C67" xlink:to="loc_rvnc_BioSentinelInc.Member_1A0BE3D81FCF13329F4B9DEC92E1E411" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_639B940F9AC72BEAA1D29DEC92E18BBF" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditRiskContractMember" xlink:label="loc_us-gaap_CreditRiskContractMember_4CD8D4C50650CC7EA1329DEC92E26844" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_BDAA4460AD069E1549289DEC92E219E7" xlink:to="loc_us-gaap_CreditRiskContractMember_4CD8D4C50650CC7EA1329DEC92E26844" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_AB275ED40B67409C3D8F9DEC92DAA753" xlink:to="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CollaborativeAgreementContractualPeriod" xlink:label="loc_rvnc_CollaborativeAgreementContractualPeriod_3FE8BFAE207653540F829EC647BAB5C3" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="loc_rvnc_CollaborativeAgreementContractualPeriod_3FE8BFAE207653540F829EC647BAB5C3" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CollaborativeAgreementExtendedContractualPeriod" xlink:label="loc_rvnc_CollaborativeAgreementExtendedContractualPeriod_C8162A68A95A05959A519ECF5641F330" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="loc_rvnc_CollaborativeAgreementExtendedContractualPeriod_C8162A68A95A05959A519ECF5641F330" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AccruedMilestoneObligations" xlink:label="loc_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="loc_rvnc_AccruedMilestoneObligations_9055B1723C36005579179DEC92E401D2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_1D2C99A2508101273B579DEC92E4287F" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_1D2C99A2508101273B579DEC92E4287F" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_IndemnificationLiabilityRecordedduringPeriod" xlink:label="loc_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E60FA43AC138DC991F0C9DEC92E2CCE4" xlink:to="loc_rvnc_IndemnificationLiabilityRecordedduringPeriod_BAE3F03F7D861AA8CD2C9DEC92E42968" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AC9DBFA4C8734C05383216CE0F4AABD6" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8EDDAAFAD60CE80C171016CE0F4ADB71" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AC9DBFA4C8734C05383216CE0F4AABD6" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8EDDAAFAD60CE80C171016CE0F4ADB71" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_50C88530B428338C1369BA9003EC37BC" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869" xlink:to="loc_us-gaap_NumberOfOperatingSegments_50C88530B428338C1369BA9003EC37BC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_911C19F4D4162A4146A3BA5FF6B948C5" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869" xlink:to="loc_us-gaap_NetIncomeLoss_911C19F4D4162A4146A3BA5FF6B948C5" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_WorkingCapitalSurplus" xlink:label="loc_rvnc_WorkingCapitalSurplus_AD432C4B6F534CEF8148BA5FF6B9F421" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869" xlink:to="loc_rvnc_WorkingCapitalSurplus_AD432C4B6F534CEF8148BA5FF6B9F421" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_881D640E2F4F27379E88BA5FF6B9C32F" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_881D640E2F4F27379E88BA5FF6B9C32F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_F6E24786A52500531960BA5FF6B9B601" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_F6E24786A52500531960BA5FF6B9B601" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum" xlink:label="loc_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum_E04CA7D5858EB3A14A54BA5FF6B90BFF" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6220B222A297C3DE33CFBA5FF6B84869" xlink:to="loc_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum_E04CA7D5858EB3A14A54BA5FF6B90BFF" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_223A59D5C28A3FCF7615EADD66E34249" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_293168C83D7FBD2FCF05EADD66E33CEB" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_223A59D5C28A3FCF7615EADD66E34249" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_293168C83D7FBD2FCF05EADD66E33CEB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_65550955CA8C4BF74584EADD66E4DEDA" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_223A59D5C28A3FCF7615EADD66E34249" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_65550955CA8C4BF74584EADD66E4DEDA" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_A1AD86D33B28CA49CAEAEADD66E4243E" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_223A59D5C28A3FCF7615EADD66E34249" xlink:to="loc_us-gaap_UseOfEstimates_A1AD86D33B28CA49CAEAEADD66E4243E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_032DA88FE5D63867C7C6EADD66E4EB5E" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_223A59D5C28A3FCF7615EADD66E34249" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_032DA88FE5D63867C7C6EADD66E4EB5E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_291327D3D9E4C5DEEA46EADD66E42F5D" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_223A59D5C28A3FCF7615EADD66E34249" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_291327D3D9E4C5DEEA46EADD66E42F5D" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_CC0B048C437FE84CB5AAE627CC9ABE68" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CC0B048C437FE84CB5AAE627CC9ABE68" xlink:to="loc_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69AF35044FD158D9B3D9E627CC9B2455" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_69AF35044FD158D9B3D9E627CC9B2455" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_C5CD119409F86F80CF62E627CC9BFB33" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE" xlink:to="loc_us-gaap_ShortTermInvestments_C5CD119409F86F80CF62E627CC9BFB33" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76A29D3A8BEF9E972CDEE627CC9C7CD1" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_76A29D3A8BEF9E972CDEE627CC9C7CD1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_95CAF33356F88F17C6E9E627CC9C1669" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5426D1AD8E358848C33AE627CC9B2CCE" xlink:to="loc_us-gaap_AssetsCurrent_95CAF33356F88F17C6E9E627CC9C1669" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_F46ECE9622C4B8986C36E627CC9CAE7F" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_F46ECE9622C4B8986C36E627CC9CAE7F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsNet" xlink:label="loc_us-gaap_OtherIntangibleAssetsNet_1BA88FFC24A15494109CE627CC9CAC41" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:to="loc_us-gaap_OtherIntangibleAssetsNet_1BA88FFC24A15494109CE627CC9CAC41" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_BF9426193E8D606D8C35E627CC9C75DC" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_BF9426193E8D606D8C35E627CC9C75DC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9B3CE728160A9D95ABC3E627CC9C25F2" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_9B3CE728160A9D95ABC3E627CC9C25F2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_B4C17F13F1C1E3503064E627CC9DC4B8" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_B4C17F13F1C1E3503064E627CC9DC4B8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_AAD5FC272A05609CFDD2E627CC9D021E" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3921C9479F01F4E4D4C2E627CC9B262A" xlink:to="loc_us-gaap_Assets_AAD5FC272A05609CFDD2E627CC9D021E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_CC0B048C437FE84CB5AAE627CC9ABE68" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_140D37B511C896EDAEC2E627CC9D46DE" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:to="loc_us-gaap_AccountsPayableCurrent_140D37B511C896EDAEC2E627CC9D46DE" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9FF4CAE9EDEDDF20B131E627CC9EF4D7" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9FF4CAE9EDEDDF20B131E627CC9EF4D7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_F4722FB9A4CA375EAC94E627CC9E394A" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_F4722FB9A4CA375EAC94E627CC9E394A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5F4E89756D466BE30A83E627CC9E154C" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5F4E89756D466BE30A83E627CC9E154C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_D3B2E376DB85131DFA4FE627CC9EA8F9" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_D3B2E376DB85131DFA4FE627CC9EA8F9" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_CCB7AEE952A5E881E537E627CC9E6B0F" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ECF5B8196315A16CDB71E627CC9DD0B6" xlink:to="loc_us-gaap_LiabilitiesCurrent_CCB7AEE952A5E881E537E627CC9E6B0F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorLongTermNotes" xlink:label="loc_us-gaap_SeniorLongTermNotes_BA67841876EA67985F99E627CC9FBC23" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:to="loc_us-gaap_SeniorLongTermNotes_BA67841876EA67985F99E627CC9FBC23" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_B1294E1D06822D319730E627CC9F2C18" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_B1294E1D06822D319730E627CC9F2C18" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06B3D11611B96A9F130DE627CC9F8D9B" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_06B3D11611B96A9F130DE627CC9F8D9B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_8517A5B8783FF2198BAFE627CC9F2BDB" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:to="loc_us-gaap_Liabilities_8517A5B8783FF2198BAFE627CC9F2BDB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4546792C41CC4AB8AAEBE627CC9FE704" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4546792C41CC4AB8AAEBE627CC9FE704" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:to="loc_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_25617A38E251ECFEC7E8E627CCA0FE5A" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:to="loc_us-gaap_PreferredStockValue_25617A38E251ECFEC7E8E627CCA0FE5A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_ACA6D1A355E2991771CAE627CCA0B812" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:to="loc_us-gaap_CommonStockValue_ACA6D1A355E2991771CAE627CCA0B812" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_E74356FE9B01AFE75251E627CCA082DF" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_E74356FE9B01AFE75251E627CCA082DF" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE4F8F1FCB3368618ACFE627CCA0D79A" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CE4F8F1FCB3368618ACFE627CCA0D79A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89771E95F513C8ADA4B6E627CCA058F8" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_89771E95F513C8ADA4B6E627CCA058F8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_ED88E6F98BEA79B96404E627CCA03E62" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_BAFF292CAE90F7C2A030E627CC9F703A" xlink:to="loc_us-gaap_StockholdersEquity_ED88E6F98BEA79B96404E627CCA03E62" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_52F2E9EA5A3CDEF4EFACE627CCA1C749" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2658B18034B8A1BFB459E627CC9DB418" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_52F2E9EA5A3CDEF4EFACE627CCA1C749" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_D530BC9C3F7DDE665B0816CE0F1BD228" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29D10DE79534F46A2DB716CE0F1B5F77" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D530BC9C3F7DDE665B0816CE0F1BD228" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29D10DE79534F46A2DB716CE0F1B5F77" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1C395032A01E2AB9432816CE0F1B2733" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D530BC9C3F7DDE665B0816CE0F1BD228" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1C395032A01E2AB9432816CE0F1B2733" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9B2235E416B530E6AC2F16CE0F1BB6D0" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D530BC9C3F7DDE665B0816CE0F1BD228" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9B2235E416B530E6AC2F16CE0F1BB6D0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_BEBC744DA182312D6ED016CE0F1B3C3A" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D530BC9C3F7DDE665B0816CE0F1BD228" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_BEBC744DA182312D6ED016CE0F1B3C3A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0EFD7F55E9EB78FDBDFB16CE0F1BB76C" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D530BC9C3F7DDE665B0816CE0F1BD228" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0EFD7F55E9EB78FDBDFB16CE0F1BB76C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5F6367A9689CF4350B3D16CE0F1BCAE0" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D530BC9C3F7DDE665B0816CE0F1BD228" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5F6367A9689CF4350B3D16CE0F1BCAE0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2D64DA6AD02196CBC1A116CE0F1BDEF7" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D530BC9C3F7DDE665B0816CE0F1BD228" xlink:to="loc_us-gaap_CommonStockSharesIssued_2D64DA6AD02196CBC1A116CE0F1BDEF7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_DEDFC2F66B2FB065E58816CE0F1B3D24" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_D530BC9C3F7DDE665B0816CE0F1BD228" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_DEDFC2F66B2FB065E58816CE0F1B3D24" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A2BB27AE9EEF470050819D3E475BC147" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_Revenues_A2BB27AE9EEF470050819D3E475BC147" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_76187FD817AA8F548AA69D3E475C91F0" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_76187FD817AA8F548AA69D3E475C91F0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ACC6024A73F141EBF8D19D3E475CA77E" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ACC6024A73F141EBF8D19D3E475CA77E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_6CE1132747E8B08082A79D3E475CE4C0" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2E8E18538D9292BDF0169D3E475C6520" xlink:to="loc_us-gaap_OperatingExpenses_6CE1132747E8B08082A79D3E475CE4C0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_74B98D66E3C8C947B10F9D3E475D92E9" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_OperatingIncomeLoss_74B98D66E3C8C947B10F9D3E475D92E9" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_B856B537404C1A10B87D9D3E475DDFC6" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_B856B537404C1A10B87D9D3E475DDFC6" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_9EC83A2822B78B0A2AEE9D3E475D45E8" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_InterestExpense_9EC83A2822B78B0A2AEE9D3E475D45E8" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_GainLossonDerivativeInstrumentsContractNetPretax" xlink:label="loc_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_7DC1C2EE5458C88634889D3E475E5FD3" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_rvnc_GainLossonDerivativeInstrumentsContractNetPretax_7DC1C2EE5458C88634889D3E475E5FD3" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7EBF90141BDAAB76A8379D3E475ED39F" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7EBF90141BDAAB76A8379D3E475ED39F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_D69041F0479C52EA781D9D4ABC0E18AB" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_D69041F0479C52EA781D9D4ABC0E18AB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8FF04FA9BE66111B407B9D494A84D9FA" xlink:type="locator" /> <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8FF04FA9BE66111B407B9D494A84D9FA" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9B904880A46591A5CB5C9D3E475EFB26" xlink:type="locator" /> <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_NetIncomeLoss_9B904880A46591A5CB5C9D3E475EFB26" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_88927E41F92412D363EF9D3E475E0B25" xlink:type="locator" /> <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_88927E41F92412D363EF9D3E475E0B25" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9A43D18429C7944711C49D3E475E5DAD" xlink:type="locator" /> <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9A43D18429C7944711C49D3E475E5DAD" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted" xlink:label="loc_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_018EA70A7DAACB90C24E9D3E475F7E2D" xlink:type="locator" /> <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted_018EA70A7DAACB90C24E9D3E475F7E2D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_33508CF652775FC0A1E69D3E475FCFCB" xlink:type="locator" /> <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_33508CF652775FC0A1E69D3E475FCFCB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_28A21E1C2DB75DD066459D3E475F9A16" xlink:type="locator" /> <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D99ECA344BAE0844E2089D3E475B07D6" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_28A21E1C2DB75DD066459D3E475F9A16" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2B2E69B237F7B6D0FE17E655517D9C62" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B" xlink:to="loc_us-gaap_NetIncomeLoss_2B2E69B237F7B6D0FE17E655517D9C62" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_F99E5AAC6B9EA22C54EAE655517EDE7B" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_F99E5AAC6B9EA22C54EAE655517EDE7B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1A72B97E6485C54BBAD1E655517E67AB" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:to="loc_us-gaap_ShareBasedCompensation_1A72B97E6485C54BBAD1E655517E67AB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C61E4BF1F663618EC765E655517FF807" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_C61E4BF1F663618EC765E655517FF807" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_FF32E903C3049D59F519E655517F3B90" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_FF32E903C3049D59F519E655517F3B90" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_C27D1C74C3FA1D53EF8EE655517F9ED7" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_C27D1C74C3FA1D53EF8EE655517F9ED7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_3D987BF96674C336AD4CE655518024A3" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_51A49B022E809FF23759E655517E22EF" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_3D987BF96674C336AD4CE655518024A3" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_C8F98F88172B1C887EB0E65551807CDF" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_C8F98F88172B1C887EB0E65551807CDF" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_16EEEA909454DF002F95E6555181F150" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_16EEEA909454DF002F95E6555181F150" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets" xlink:label="loc_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_E92E43F32C10F7E2EA2EE65551815FB5" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:to="loc_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets_E92E43F32C10F7E2EA2EE65551815FB5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9D12320F4339ABB950C4E65551814F83" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_9D12320F4339ABB950C4E65551814F83" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3EF99EDF81C75CF015BEE65551829A2D" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3EF99EDF81C75CF015BEE65551829A2D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3EF7F2DA8DA54B6C4698E65551822000" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_3EF7F2DA8DA54B6C4698E65551822000" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_68DA206B19599E56C314E6555182C798" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_68DA206B19599E56C314E6555182C798" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_IncreaseDecreaseinOperatingLeaseLiabilities" xlink:label="loc_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_B576DC0302C5B2B485E3E65551831462" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EEA78972BDF61BA36745E6555180D2F0" xlink:to="loc_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities_B576DC0302C5B2B485E3E65551831462" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7AB68B2139ECDDF9CE07E65551832493" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_2974BC707E431213A758E655517DFD4B" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7AB68B2139ECDDF9CE07E65551832493" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_39118BF06BB92F82FD22E65551837DEF" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_39118BF06BB92F82FD22E65551837DEF" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_CBE4F36CF607ACC35766E65551848996" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_CBE4F36CF607ACC35766E65551848996" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_AE08D0B3864204671BD1E65551845B35" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_AE08D0B3864204671BD1E65551845B35" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_84B561C1F9C1391BF03EE65551842F7D" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_84B561C1F9C1391BF03EE65551842F7D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_956647F65ED722B4A9C6E6555184C4D5" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_A35BB84C2DD1B7A14424E6555183BB48" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_956647F65ED722B4A9C6E6555184C4D5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_1B6C8BEA085A49537FEEE6555185E819" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_1B6C8BEA085A49537FEEE6555185E819" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount" xlink:label="loc_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_637F7F45729A4B2A6FACE6555185736F" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:to="loc_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount_637F7F45729A4B2A6FACE6555185736F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6AEA2C47D3EEA2D58A7FE655518A2469" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6AEA2C47D3EEA2D58A7FE655518A2469" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_E186D5F8995BECD356EEE655518BD15C" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_E186D5F8995BECD356EEE655518BD15C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_523E2D623F13F47B4B6BE655518B9371" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_523E2D623F13F47B4B6BE655518B9371" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6049F59C249F7E778108E655518BB255" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6049F59C249F7E778108E655518BB255" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6B1924B8BB7B3052BE89E655518BEFC0" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6B1924B8BB7B3052BE89E655518BEFC0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05065A5F94B0401F4B05E655518C174A" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_B460910A4C72CAF142E3E6555185B736" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_05065A5F94B0401F4B05E655518C174A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15B698164E180E5B8E63E669042A22E5" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_15B698164E180E5B8E63E669042A22E5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65538ACA715AD83E80F4E655518C61AC" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_65538ACA715AD83E80F4E655518C61AC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A9FF48A6647E074DA775E655518CAE08" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A9FF48A6647E074DA775E655518CAE08" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_F5FFC28696DE26733567E655517D9576" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2271C5B6D251DA93B229E655518C435A" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_2271C5B6D251DA93B229E655518C435A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_BC7DC54628B816E8F28BE655518D6028" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_BC7DC54628B816E8F28BE655518D6028" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_35F790CB1B09E21AA4DAE655518D642A" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_35F790CB1B09E21AA4DAE655518D642A" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_NoncashDeferredOfferingCosts" xlink:label="loc_rvnc_NoncashDeferredOfferingCosts_FEDC77D21281B24FE0FBE655518D696B" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6CE1A4DA711FEFC503D9E655518C756F" xlink:to="loc_rvnc_NoncashDeferredOfferingCosts_FEDC77D21281B24FE0FBE655518D696B" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_793C541CDDAAE4B1B06CE627CC7708C8" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_793C541CDDAAE4B1B06CE627CC7708C8" xlink:to="loc_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_003D98FA4ECE750DCD18E627CC7872C3" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_003D98FA4ECE750DCD18E627CC7872C3" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_003D98FA4ECE750DCD18E627CC7872C3" xlink:to="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_2978E893C86C5AC8949CE627CC783BD8" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:to="loc_us-gaap_CommonStockMember_2978E893C86C5AC8949CE627CC783BD8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_365CCAB69FB894E50598E627CC797642" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_365CCAB69FB894E50598E627CC797642" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72D9F60C37B1C0E60B6BE627CC79F4FE" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_72D9F60C37B1C0E60B6BE627CC79F4FE" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_920314E4C2DC0DFAA564E627CC796CB4" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_CAB16ABF2ACCD995EAF3E627CC781F61" xlink:to="loc_us-gaap_RetainedEarningsMember_920314E4C2DC0DFAA564E627CC796CB4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3AF45E57FB9FE7CB26ECE627CC7781D1" xlink:to="loc_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EA1D88BD7576E238D38CE627CC799F0A" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9216B93F16A280A0C7B7E627CC7A4636" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9216B93F16A280A0C7B7E627CC7A4636" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_243066B1F132E3120DF2E627CC7A15B4" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockholdersEquity_243066B1F132E3120DF2E627CC7A15B4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_4C4C546D4C8D64708649E627CC7AD160" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_4C4C546D4C8D64708649E627CC7AD160" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1312279B31E9C72D0D21E627CC7AF081" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_1312279B31E9C72D0D21E627CC7AF081" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased" xlink:label="loc_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased_99DD2D853B9EE1E71F28E627CC7A9B88" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased" xlink:label="loc_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased_0F790E46DEFD9B15BC62E627CC7A65DB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07430BC45C0FC2C2B226E627CC7BF486" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_07430BC45C0FC2C2B226E627CC7BF486" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9B3588110AA3B6A02FFFE627CC7B2010" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9B3588110AA3B6A02FFFE627CC7B2010" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B79CD62D2A0CFD8886E0E627CC7B9C87" xlink:type="locator" /> <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_B79CD62D2A0CFD8886E0E627CC7B9C87" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_09C031797D466857960EE627CC7BD90D" xlink:type="locator" /> <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_09C031797D466857960EE627CC7BD90D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9FB87F2D789C29E1D0E3E627CC7B1CC4" xlink:type="locator" /> <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9FB87F2D789C29E1D0E3E627CC7B1CC4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D56C37DB5EE1449AA9AAE627CC7CFDF2" xlink:type="locator" /> <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_D56C37DB5EE1449AA9AAE627CC7CFDF2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0EED978D7EEFDCF2AEDDE627CC7CF874" xlink:type="locator" /> <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0EED978D7EEFDCF2AEDDE627CC7CF874" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions" xlink:label="loc_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336" xlink:type="locator" /> <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions_3B5F85160CE9095F6103E627CC7CC336" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5B36F14325539D762D93E627CC7CE052" xlink:type="locator" /> <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_5B36F14325539D762D93E627CC7CE052" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D08E5C14ACCDDCCEBD97E627CC7C4646" xlink:type="locator" /> <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_D08E5C14ACCDDCCEBD97E627CC7C4646" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_45934276991D6E8F5693E627CC7CE771" xlink:type="locator" /> <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_NetIncomeLoss_45934276991D6E8F5693E627CC7CE771" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1F4D564D5F2E79809782E627CC7DF05B" xlink:type="locator" /> <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1F4D564D5F2E79809782E627CC7DF05B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_735A56EDF6293F6002F4E627CC7D9E0D" xlink:type="locator" /> <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_146DBCD2047E961E5D7FE627CC799B8D" xlink:to="loc_us-gaap_StockholdersEquity_735A56EDF6293F6002F4E627CC7D9E0D" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_FC2E99AF601C695447049FDB3EF72710" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_666409343C618E8304B6A002E30C1ED9" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_FC2E99AF601C695447049FDB3EF72710" xlink:to="loc_us-gaap_StatementTable_666409343C618E8304B6A002E30C1ED9" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_39B42D882C105426D744A002FF2EF609" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_666409343C618E8304B6A002E30C1ED9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_39B42D882C105426D744A002FF2EF609" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F2CDCE00B7156D1A4DEA002FF2F6A2B" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_39B42D882C105426D744A002FF2EF609" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F2CDCE00B7156D1A4DEA002FF2F6A2B" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_FollowOnOfferingMember" xlink:label="loc_rvnc_FollowOnOfferingMember_C88D4B90F41EF540333DA004FE2A6701" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4F2CDCE00B7156D1A4DEA002FF2F6A2B" xlink:to="loc_rvnc_FollowOnOfferingMember_C88D4B90F41EF540333DA004FE2A6701" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_715681E27B7ED30878B6A002E31BEBED" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_666409343C618E8304B6A002E30C1ED9" xlink:to="loc_us-gaap_StatementLineItems_715681E27B7ED30878B6A002E31BEBED" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_CD9A1A116E9912EDBA3C9FDB3EF871AA" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715681E27B7ED30878B6A002E31BEBED" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_CD9A1A116E9912EDBA3C9FDB3EF871AA" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_EquityComponentOfConvertibleDebtTransactionCost" xlink:label="loc_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_715681E27B7ED30878B6A002E31BEBED" xlink:to="loc_rvnc_EquityComponentOfConvertibleDebtTransactionCost_F2D94CE21BFB846292989FDB3EF80EA3" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotes" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_C0186E9E880496C0CDA1BA15598E0D0E" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_8DA51200DAB1181AC47EBA163DA59652" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_C0186E9E880496C0CDA1BA15598E0D0E" xlink:to="loc_us-gaap_LongTermDebtTextBlock_8DA51200DAB1181AC47EBA163DA59652" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2C97CB8B0C69F7269EF9ECD68126BE6F" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2C97CB8B0C69F7269EF9ECD68126BE6F" xlink:to="loc_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_184B3DD23669F2106EEEECDE99F12531" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_94DDFA75577A02D5FBB7ECDE9A109781" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_B63A272E93721D57D5B0ECDE9A01E745" xlink:to="loc_us-gaap_ConvertibleDebtMember_94DDFA75577A02D5FBB7ECDE9A109781" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:to="loc_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_15D0BE2C869225F7E9F7ECD68127283F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwentyTwentySevenNotesMember" xlink:label="loc_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3E9530323A43AC28DB72ECD6812750D1" xlink:to="loc_rvnc_TwentyTwentySevenNotesMember_5DD89AFC91F542DC83FCECD681283901" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7D4C98A5D65DE7F28001ECD681265317" xlink:to="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_57A5F3E463CCA9B2FBDFECD68129164B" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_57A5F3E463CCA9B2FBDFECD68129164B" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CappedCallsPriceCap" xlink:label="loc_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="loc_rvnc_CappedCallsPriceCap_6C6130137210B15CABBAECD6812A6EA8" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CappedCallsPremiumPercentageOverSalePrice" xlink:label="loc_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="loc_rvnc_CappedCallsPremiumPercentageOverSalePrice_DABF6DC8D12BADAA7D9BECD6812AAE6F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_2C583238236D8498EFF6ECDE99F1E73E" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_2C583238236D8498EFF6ECDE99F1E73E" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments" xlink:label="loc_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_770E66DBC8CDB7C9C291ECD681296108" xlink:to="loc_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments_F7B28F708716486466BDECDD9B2685FF" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F38ADC865532D11FCF76EC7297804D6C" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_B43B03BC8D2C2466A46CEC72978024DC" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F38ADC865532D11FCF76EC7297804D6C" xlink:to="loc_us-gaap_DebtInstrumentTable_B43B03BC8D2C2466A46CEC72978024DC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6CC8702DE6514B0E63A0EC72978166DC" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B43B03BC8D2C2466A46CEC72978024DC" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6CC8702DE6514B0E63A0EC72978166DC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_C9BB4FDFFE2ED6548552EC729781B52B" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6CC8702DE6514B0E63A0EC72978166DC" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_C9BB4FDFFE2ED6548552EC729781B52B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_4AA63C1230CE81F935C2EC7297815EA2" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_C9BB4FDFFE2ED6548552EC729781B52B" xlink:to="loc_us-gaap_ConvertibleDebtMember_4AA63C1230CE81F935C2EC7297815EA2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_98014F1B0EA32BA1D57BEC729782E51B" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B43B03BC8D2C2466A46CEC72978024DC" xlink:to="loc_us-gaap_DebtInstrumentAxis_98014F1B0EA32BA1D57BEC729782E51B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5FD0A0D6F479A1B57452EC72978202A7" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_98014F1B0EA32BA1D57BEC729782E51B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5FD0A0D6F479A1B57452EC72978202A7" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwentyTwentySevenNotesMember" xlink:label="loc_rvnc_TwentyTwentySevenNotesMember_A579A35C9D1FCF4B9DDAEC729782196F" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5FD0A0D6F479A1B57452EC72978202A7" xlink:to="loc_rvnc_TwentyTwentySevenNotesMember_A579A35C9D1FCF4B9DDAEC729782196F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_E3F2B642869A033DB9CCEC729782BC56" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_B43B03BC8D2C2466A46CEC72978024DC" xlink:to="loc_us-gaap_DebtInstrumentLineItems_E3F2B642869A033DB9CCEC729782BC56" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9E363010A2C36778A40EEC7297837B18" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E3F2B642869A033DB9CCEC729782BC56" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9E363010A2C36778A40EEC7297837B18" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_C3B271DC3208963E058EEC729788C954" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E3F2B642869A033DB9CCEC729782BC56" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_C3B271DC3208963E058EEC729788C954" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_AB13292A6890F9C8BB6CEC729788CE47" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_E3F2B642869A033DB9CCEC729782BC56" xlink:to="loc_us-gaap_LongTermDebt_AB13292A6890F9C8BB6CEC729788CE47" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A9D599288E11393EFA98EC729BE80B56" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1F099385161E5F5D5DF3EC729BE8469E" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A9D599288E11393EFA98EC729BE80B56" xlink:to="loc_us-gaap_DebtInstrumentTable_1F099385161E5F5D5DF3EC729BE8469E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_B7D994C6C169AE19E0AEEC729BE9C217" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1F099385161E5F5D5DF3EC729BE8469E" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_B7D994C6C169AE19E0AEEC729BE9C217" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0B517DFDA109778D9EE3EC729BE953A1" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_B7D994C6C169AE19E0AEEC729BE9C217" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0B517DFDA109778D9EE3EC729BE953A1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_45A6B9A7767726565F77EC729BE9E46C" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0B517DFDA109778D9EE3EC729BE953A1" xlink:to="loc_us-gaap_ConvertibleDebtMember_45A6B9A7767726565F77EC729BE9E46C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8A1EA9DED1CBA3064424EC729BE92FF4" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1F099385161E5F5D5DF3EC729BE8469E" xlink:to="loc_us-gaap_DebtInstrumentAxis_8A1EA9DED1CBA3064424EC729BE92FF4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_E60145930BE4BA6F14C4EC729BEAB9D7" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8A1EA9DED1CBA3064424EC729BE92FF4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_E60145930BE4BA6F14C4EC729BEAB9D7" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwentyTwentySevenNotesMember" xlink:label="loc_rvnc_TwentyTwentySevenNotesMember_319501202EF7B94DC78FEC729BEADA9F" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_E60145930BE4BA6F14C4EC729BEAB9D7" xlink:to="loc_rvnc_TwentyTwentySevenNotesMember_319501202EF7B94DC78FEC729BEADA9F" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtInstrumentConvertibleTermsOfConversionAxis" xlink:label="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1F099385161E5F5D5DF3EC729BE8469E" xlink:to="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtInstrumentConvertibleTermsOfConversionDomain" xlink:label="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_4F44347FB29109B3955AEC729BEA4FDD" xlink:to="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtConversionTermsOneMember" xlink:label="loc_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:to="loc_rvnc_DebtConversionTermsOneMember_720EDEA5EF1623162255EC729BEB4989" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtConversionTermsTwoMember" xlink:label="loc_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rvnc_DebtInstrumentConvertibleTermsOfConversionDomain_6BA98C39AA4712E79726EC729BEA4464" xlink:to="loc_rvnc_DebtConversionTermsTwoMember_0D9AC908BD276D32DC7DEC729BEBB07D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1F099385161E5F5D5DF3EC729BE8469E" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_D1BD64FCD0C7A4577FC2EC729BEB4999" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_D1BD64FCD0C7A4577FC2EC729BEB4999" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D92ACF9F03A0B6756AB3EC729BEBA55E" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_D92ACF9F03A0B6756AB3EC729BEBA55E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_12BCB4D59C3AAFE9616BEC729BECEDE7" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_12BCB4D59C3AAFE9616BEC729BECEDE7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4660E9109556DCA01BC2EC729BEC0C61" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_4660E9109556DCA01BC2EC729BEC0C61" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_E87E6424EC0281D07DBDEC729BECD4AB" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_E87E6424EC0281D07DBDEC729BECD4AB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_047CED478E58CE15A56AEC729BEC27C0" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_047CED478E58CE15A56AEC729BEC27C0" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice" xlink:label="loc_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice_28F2E65E185C42C3DC88EC729BECEAA2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_D4671F1331E0645A3DD2EC729BECB058" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_D4671F1331E0645A3DD2EC729BECB058" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_AC8AA3700EF2B21CDC5BEC729BED6BA2" xlink:type="locator" /> <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_AC8AA3700EF2B21CDC5BEC729BED6BA2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_0DAB0BA5CBA9F174EA0BEC729BED609E" xlink:type="locator" /> <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_0DAB0BA5CBA9F174EA0BEC729BED609E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6E250EA51497470C6B6CEC729BED14A6" xlink:type="locator" /> <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_LongTermDebt_6E250EA51497470C6B6CEC729BED14A6" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7D000BFC656926C92032EC729BED17D5" xlink:type="locator" /> <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_7D000BFC656926C92032EC729BED17D5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7B42CFBAFF6F3521EB9EEC729BED8EF8" xlink:type="locator" /> <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_7B42CFBAFF6F3521EB9EEC729BED8EF8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_8EDBC817323A362B460FEC729BEDAE65" xlink:type="locator" /> <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_8EDBC817323A362B460FEC729BEDAE65" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtIssuanceCostsGrossLiabilityComponent" xlink:label="loc_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C" xlink:type="locator" /> <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_rvnc_DebtIssuanceCostsGrossLiabilityComponent_9D100B77FAE0396641DAEC729BED696C" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DebtIssuanceCostsGrossEquityComponent" xlink:label="loc_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB" xlink:type="locator" /> <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7EC5032B5B4CC243F811EC729BEB308E" xlink:to="loc_rvnc_DebtIssuanceCostsGrossEquityComponent_FD27284AE5F34D15FEAEEC729BEEA7BB" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F89BF1EBA3B99E2B0E38EC7299F9456A" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_D02A873908BFE1703E5FEC7299F9B351" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F89BF1EBA3B99E2B0E38EC7299F9456A" xlink:to="loc_us-gaap_DebtInstrumentTable_D02A873908BFE1703E5FEC7299F9B351" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3051EC4895A1B0C23FC8EC7299F94E6F" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D02A873908BFE1703E5FEC7299F9B351" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3051EC4895A1B0C23FC8EC7299F94E6F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7729217DF1A2718330E6EC7299FA9999" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3051EC4895A1B0C23FC8EC7299F94E6F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7729217DF1A2718330E6EC7299FA9999" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_62A6A8977529380104EFEC7299FA6FC8" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7729217DF1A2718330E6EC7299FA9999" xlink:to="loc_us-gaap_ConvertibleDebtMember_62A6A8977529380104EFEC7299FA6FC8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_BA3958DFDC583354714BEC7299FB9EB0" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D02A873908BFE1703E5FEC7299F9B351" xlink:to="loc_us-gaap_DebtInstrumentAxis_BA3958DFDC583354714BEC7299FB9EB0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5F0C24F5EE033AF13BC4EC7299FBC33F" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_BA3958DFDC583354714BEC7299FB9EB0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5F0C24F5EE033AF13BC4EC7299FBC33F" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwentyTwentySevenNotesMember" xlink:label="loc_rvnc_TwentyTwentySevenNotesMember_A54745BE885D967E4A59EC7299FB145A" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5F0C24F5EE033AF13BC4EC7299FBC33F" xlink:to="loc_rvnc_TwentyTwentySevenNotesMember_A54745BE885D967E4A59EC7299FB145A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_D02A873908BFE1703E5FEC7299F9B351" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_05DE047FC3987177A5C5EC7299FCC741" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_05DE047FC3987177A5C5EC7299FCC741" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_A6EF01FF4179FB73AC18EC7299FC8D4C" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_A6EF01FF4179FB73AC18EC7299FC8D4C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_C3D2921EBB7B4F0EB4A3EC7299FC7B78" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_C3D2921EBB7B4F0EB4A3EC7299FC7B78" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_DE47FD3A0E81FD7EAC80EC7299FD5BE3" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_InterestExpenseDebt_DE47FD3A0E81FD7EAC80EC7299FD5BE3" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4C88DE011E705DA55661EC7299FD652B" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_4C88DE011E705DA55661EC7299FD652B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_D3C8E0496F2E1011F291EC7299FD9F71" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_D3C8E0496F2E1011F291EC7299FD9F71" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_8452B8F9AC256D80F714EC7299FD69E6" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_8452B8F9AC256D80F714EC7299FD69E6" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_165597B931FC4A65A353EC7299FDACC0" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3FB7033DDF1DEE38B5A8EC7299FC1033" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_165597B931FC4A65A353EC7299FDACC0" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/ConvertibleSeniorNotesTables" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5AF25A37670FEF99333FBA15599E00AB" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_7E278B37C88F6C5A4A05BA17F428247F" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5AF25A37670FEF99333FBA15599E00AB" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_7E278B37C88F6C5A4A05BA17F428247F" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/CoverPage" xlink:type="extended"> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:type="locator" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9E84199FEBC09D8028A7E627CCAA3F72" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_DocumentType_9E84199FEBC09D8028A7E627CCAA3F72" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_7197F885E1EBD9EBD661E627CCAA01E0" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_DocumentQuarterlyReport_7197F885E1EBD9EBD661E627CCAA01E0" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_3097DECA04A092AC2B00E627CCABB47D" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_DocumentPeriodEndDate_3097DECA04A092AC2B00E627CCABB47D" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_0A73E0F544D15BFB7CE8E627CCABAD33" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_DocumentTransitionReport_0A73E0F544D15BFB7CE8E627CCABAD33" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_2E8157D42E9B00B0E196E627CCABF317" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityFileNumber_2E8157D42E9B00B0E196E627CCABF317" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_AD90E93662B3B8B3D948E627CCAB8877" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityRegistrantName_AD90E93662B3B8B3D948E627CCAB8877" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_C59E4927861F77F3EC63E627CCABCF02" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityIncorporationStateCountryCode_C59E4927861F77F3EC63E627CCABCF02" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_F05479F89295D8BC74A1E627CCABD462" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityTaxIdentificationNumber_F05479F89295D8BC74A1E627CCABD462" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_4B835299CA80D903E34FE627CCAC92CA" xlink:type="locator" /> <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityAddressAddressLine1_4B835299CA80D903E34FE627CCAC92CA" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_F0D6178491D2C323A1FEE627CCAC1792" xlink:type="locator" /> <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityAddressCityOrTown_F0D6178491D2C323A1FEE627CCAC1792" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_731878E01DCCAC5EF164E627CCAC4F65" xlink:type="locator" /> <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityAddressStateOrProvince_731878E01DCCAC5EF164E627CCAC4F65" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_41BF0422C648872BEB48E627CCAC567B" xlink:type="locator" /> <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityAddressPostalZipCode_41BF0422C648872BEB48E627CCAC567B" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_5C9F8761EAB6F8D51718E627CCACB1E5" xlink:type="locator" /> <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_CityAreaCode_5C9F8761EAB6F8D51718E627CCACB1E5" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_AE142CA140768C284C7BE627CCACD408" xlink:type="locator" /> <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_LocalPhoneNumber_AE142CA140768C284C7BE627CCACD408" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_F243A8D08BFDFD548160E627CCADE67E" xlink:type="locator" /> <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_Security12bTitle_F243A8D08BFDFD548160E627CCADE67E" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_33D365ECAD051E19E82AE627CCAD3B20" xlink:type="locator" /> <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_TradingSymbol_33D365ECAD051E19E82AE627CCAD3B20" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_7D9FEDA272F5DCD41F77E627CCAD4B7E" xlink:type="locator" /> <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_SecurityExchangeName_7D9FEDA272F5DCD41F77E627CCAD4B7E" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_369B9033E7E46A18A0A6E627CCAD3AC5" xlink:type="locator" /> <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityCurrentReportingStatus_369B9033E7E46A18A0A6E627CCAD3AC5" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_B1AAE053FC54FE0C5D85E627CCAD1C8E" xlink:type="locator" /> <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityInteractiveDataCurrent_B1AAE053FC54FE0C5D85E627CCAD1C8E" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_43CFBF1C4233F89B502FE627CCADCF00" xlink:type="locator" /> <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityFilerCategory_43CFBF1C4233F89B502FE627CCADCF00" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_59E64C5B167D4BE08171E627CCAD8FE1" xlink:type="locator" /> <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntitySmallBusiness_59E64C5B167D4BE08171E627CCAD8FE1" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_4D860FC3974B60B2E102E627CCAEEB0F" xlink:type="locator" /> <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityEmergingGrowthCompany_4D860FC3974B60B2E102E627CCAEEB0F" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_126D95E9D9458BA6BF4CE627CCAE2523" xlink:type="locator" /> <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityShellCompany_126D95E9D9458BA6BF4CE627CCAE2523" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_616EB2C9B955F6F21BF5E627CCAE9AD1" xlink:type="locator" /> <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_616EB2C9B955F6F21BF5E627CCAE9AD1" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_B20C8A69E98BDB27111EE627CCAEC358" xlink:type="locator" /> <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_EntityCentralIndexKey_B20C8A69E98BDB27111EE627CCAEC358" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FED177B6F0A95DC2F737E627CCAEDA85" xlink:type="locator" /> <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_CurrentFiscalYearEndDate_FED177B6F0A95DC2F737E627CCAEDA85" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_48B874E42ECABC467841E627CCAF40D6" xlink:type="locator" /> <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_DocumentFiscalYearFocus_48B874E42ECABC467841E627CCAF40D6" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7A81073322120D8995DCE627CCAFEE51" xlink:type="locator" /> <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7A81073322120D8995DCE627CCAFEE51" xlink:type="arc" /> <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_82487A141CF70E178788E627CCAFCF67" xlink:type="locator" /> <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_FB7E9E62B0A55E90C509E627CCAAEF02" xlink:to="loc_dei_AmendmentFlag_82487A141CF70E178788E627CCAFCF67" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/DerivativeLiability" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1EE0636B518AD3E907BF9E93E6C0D76D" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_98955F57299A38F20D279E93E6C18440" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1EE0636B518AD3E907BF9E93E6C0D76D" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_98955F57299A38F20D279E93E6C18440" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C13891CEE5D68227A00F9F89F72AE0EC" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C13891CEE5D68227A00F9F89F72AE0EC" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_C4948C33F62D0AE769A19F89F72A310B" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_A27C08B2F3A3197383689F89F72AD96F" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_A27C08B2F3A3197383689F89F72AD96F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputEntityCreditRiskMember" xlink:label="loc_us-gaap_MeasurementInputEntityCreditRiskMember_97F9310E75BB8FBEB39E9F89F72A896B" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:to="loc_us-gaap_MeasurementInputEntityCreditRiskMember_97F9310E75BB8FBEB39E9F89F72A896B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D047D0C4BF2C3ADA59A59F89F72A9352" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_87D316BC8319FCFAC5A29F89F72A5FDE" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_D047D0C4BF2C3ADA59A59F89F72A9352" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2B1144C5F8459BD7B6CE9F89F72AE98B" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2B1144C5F8459BD7B6CE9F89F72AE98B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CDDF33A1C638CECFB3459F89F72ACD14" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2B1144C5F8459BD7B6CE9F89F72AE98B" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CDDF33A1C638CECFB3459F89F72ACD14" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_MedicisPharmaceuticalCorporationMember" xlink:label="loc_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CDDF33A1C638CECFB3459F89F72ACD14" xlink:to="loc_rvnc_MedicisPharmaceuticalCorporationMember_DC88C1152EB701E160EB9F89F72AF74D" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ValeantPharmaceuticalsInternationalInc.Member" xlink:label="loc_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CDDF33A1C638CECFB3459F89F72ACD14" xlink:to="loc_rvnc_ValeantPharmaceuticalsInternationalInc.Member_68FFDD77300910B999A99F89F72AD7CF" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_76871C27A72C9010F0C19F89F72AA3B1" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_76871C27A72C9010F0C19F89F72AA3B1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F1F7B603930F9DAB40EB9F89F72AE086" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_76871C27A72C9010F0C19F89F72AA3B1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F1F7B603930F9DAB40EB9F89F72AE086" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditRiskContractMember" xlink:label="loc_us-gaap_CreditRiskContractMember_D0F9EEC2CA73B4048A469F89F72A1BBC" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F1F7B603930F9DAB40EB9F89F72AE086" xlink:to="loc_us-gaap_CreditRiskContractMember_D0F9EEC2CA73B4048A469F89F72A1BBC" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_SettlementAndTerminationLineItems" xlink:label="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_17B4D4771E326553A4709F89F72A7C27" xlink:to="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AccruedMilestoneObligations" xlink:label="loc_rvnc_AccruedMilestoneObligations_C236A8E44585A0C72DCC9F89F732E9A8" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:to="loc_rvnc_AccruedMilestoneObligations_C236A8E44585A0C72DCC9F89F732E9A8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9A00FB9030404A05D4C19F89F732CB43" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_9A00FB9030404A05D4C19F89F732CB43" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_FairValueMeasurementInputDuration" xlink:label="loc_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:to="loc_rvnc_FairValueMeasurementInputDuration_BD08F681704482DE5D479F89F732575D" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_FairValueMeasurementInput" xlink:label="loc_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rvnc_SettlementAndTerminationLineItems_6175107C0DE6B31EBCE09F89F72AB02F" xlink:to="loc_rvnc_FairValueMeasurementInput_EEEC8731482524FE19A69F89F7326E7D" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/FairValueMeasurements" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_27203A6C6FB0447358A5E627CB2E4D92" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0CFA625EA110F004E812E627CB2F0CB4" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_27203A6C6FB0447358A5E627CB2E4D92" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_0CFA625EA110F004E812E627CB2F0CB4" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_FE435D939F03E8DA210E9DEC933C7725" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FE435D939F03E8DA210E9DEC933C7725" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0FA25087E4A3DE4F78939DEC933CA2C2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_2269856FC0B71A6867799DEC933D38C7" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_28FF24927FD76E7B21F49DEC933DA667" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_2269856FC0B71A6867799DEC933D38C7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1E2A25CFA08E7947EB609DEC933EE1D2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3C65A4A0E786571E1C409DEC933E8183" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3C65A4A0E786571E1C409DEC933E8183" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F8380070E0FD7D1F9EE59DEC933F17C9" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_F8380070E0FD7D1F9EE59DEC933F17C9" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_510609F4C5ED5295408B9DEC933FB918" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1F55182F7AAA4F6FF4839DEC933ED1A4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_510609F4C5ED5295408B9DEC933FB918" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D46ED63586B9928136BE9DEC933F6B83" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8488E3DCB15FA1124EFB9DEC9340C9D7" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8488E3DCB15FA1124EFB9DEC9340C9D7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A5A64EC5E77A0177BE769DEC93409A5B" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_A5A64EC5E77A0177BE769DEC93409A5B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C5A7BEF46EC399FBFB799DEC93409FEA" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_C5A7BEF46EC399FBFB799DEC93409FEA" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_83774B85BB65290FF9179DEC93400DC8" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_us-gaap_CommercialPaperMember_83774B85BB65290FF9179DEC93400DC8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaturityOvernightMember" xlink:label="loc_us-gaap_MaturityOvernightMember_1F5D833A0C70B46C7E049EAE67CDA361" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_us-gaap_MaturityOvernightMember_1F5D833A0C70B46C7E049EAE67CDA361" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DerivativeLiabilitySettlementMember" xlink:label="loc_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7931F79D85AB1F812B9B9DEC933F11FA" xlink:to="loc_rvnc_DerivativeLiabilitySettlementMember_6F2B4249829A9837AFD29DEC93410CDA" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78AA37D11635B037B5419DEC933CEE3D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_FAC0DB65B1320CC8D1C39DEC9342AC64" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_FAC0DB65B1320CC8D1C39DEC9342AC64" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6897DD9DAB4E105A33779DEC9342B146" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C63FF3FDAC452AAEB70D9DEC9341F72B" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_6897DD9DAB4E105A33779DEC9342B146" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DB6AB96433D337308DB99DEC932EF5F0" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DB6AB96433D337308DB99DEC932EF5F0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_E0C0543F9D372185C7749DEC932EF37E" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_E0C0543F9D372185C7749DEC932EF37E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E916F2916694B34F72DC9DEC932FD645" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_E0C0543F9D372185C7749DEC932EF37E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E916F2916694B34F72DC9DEC932FD645" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DerivativeLiabilitySettlementMember" xlink:label="loc_rvnc_DerivativeLiabilitySettlementMember_EE52B60D413F7F9865799DEC932F1064" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_E916F2916694B34F72DC9DEC932FD645" xlink:to="loc_rvnc_DerivativeLiabilitySettlementMember_EE52B60D413F7F9865799DEC932F1064" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_3F9A104A09DCFA1315789DEC932EC09B" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_EF5E25B60721053A0E009EC07FCB26A5" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_EF5E25B60721053A0E009EC07FCB26A5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_A574804FEAA40A186A6E9DEC932FA428" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11DE20D9E8AA5BEF2C3E9DEC9330AEBD" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11DE20D9E8AA5BEF2C3E9DEC9330AEBD" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39F4153666A35CAC59039DEC93315C61" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_39F4153666A35CAC59039DEC93315C61" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B022A31C8B3A3505AA3C9DEC93315AD4" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_B73A014B5CBEF310C3C69DEC9330458D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B022A31C8B3A3505AA3C9DEC93315AD4" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/FairValueMeasurementsTables" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_817E87B34C9A646DF73216CE0F1B1776" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_56CA1A51FCF4D787769E16CE0F1B53E9" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_817E87B34C9A646DF73216CE0F1B1776" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_56CA1A51FCF4D787769E16CE0F1B53E9" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7FECE2DAA355CCC0754E16CE0F1B04E4" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_817E87B34C9A646DF73216CE0F1B1776" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7FECE2DAA355CCC0754E16CE0F1B04E4" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/FillerDistributionAgreement" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_035B1346EA0F2FA621D9E627CC16CD73" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_CDD63868ABE92405AB8BE627CC1653D0" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_035B1346EA0F2FA621D9E627CC16CD73" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_CDD63868ABE92405AB8BE627CC1653D0" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45D429F1DB38DA135805E627CBFF1D0C" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_45D429F1DB38DA135805E627CBFF1D0C" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5701A6D447868F82031BE627CC00FD0B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_3F5A8B213AFAAD44ACABE627CC003D99" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7239A0BD08B336799048E627CC0005DB" xlink:to="loc_us-gaap_DistributionRightsMember_3F5A8B213AFAAD44ACABE627CC003D99" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_B72B6A62D3F1A795172BE627CBFFE2A7" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72CD544DAB8F5EAB162DE627CC0109D1" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_72CD544DAB8F5EAB162DE627CC0109D1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_B5B9DFA89B83CFDFA322E627CC01B8FE" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_B5B9DFA89B83CFDFA322E627CC01B8FE" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E9E99663015106B2DC7DE627CC01A4C7" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_E9E99663015106B2DC7DE627CC01A4C7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14F2406A24511E09B1A4E627CC01706A" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_6C9E82E3602725502DD0E627CC004637" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_14F2406A24511E09B1A4E627CC01706A" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5D9062C634DF1D72D09DE627CC0A80A7" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5D9062C634DF1D72D09DE627CC0A80A7" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A92FF6A67C9BFE019E18E627CC0A5268" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TeoxaneAgreementMember" xlink:label="loc_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9066CC10BBBC5020F43AE627CC0B9389" xlink:to="loc_rvnc_TeoxaneAgreementMember_37D873D50EDED17F558FE627CC0B690C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6987E7C49AA94C74E2E0E627CC0A97A5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_879C5BA9C63D6C9D3A30E627CC0C39FF" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_879C5BA9C63D6C9D3A30E627CC0C39FF" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CollaborativeAgreementContractualPeriod" xlink:label="loc_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="loc_rvnc_CollaborativeAgreementContractualPeriod_007B359FAD56314044BDE627CC0C5227" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_CollaborativeAgreementExtendedContractualPeriod" xlink:label="loc_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="loc_rvnc_CollaborativeAgreementExtendedContractualPeriod_7191ED92D7F9BDAC4702E627CC0B773D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_C0002C2ED95E51D6A01AE6343A48989B" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_C0002C2ED95E51D6A01AE6343A48989B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_06FD5430C9AD1166B10CE6308F53F98E" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1AE0FBCBC529F57CB174E627CC0BC4B8" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_06FD5430C9AD1166B10CE6308F53F98E" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/FillerDistributionAgreementTables" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7D55949DF5FDBC3DF6CCE627CC14C472" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ECFCEBC0D404C0E267BDE627CC14E455" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7D55949DF5FDBC3DF6CCE627CC14C472" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ECFCEBC0D404C0E267BDE627CC14E455" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/Leases" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_6A986D1E89B743EF59329DEC9328E590" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_14D1F6E2F811B19DC19E9DEC932854C8" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6A986D1E89B743EF59329DEC9328E590" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_14D1F6E2F811B19DC19E9DEC932854C8" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/LeasesLeasesDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_D3DE3F22ABD5F13416C39DEC931D1DC8" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A80A4F1F1490867B3A3F9DEC931E937C" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3DE3F22ABD5F13416C39DEC931D1DC8" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A80A4F1F1490867B3A3F9DEC931E937C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5DFC672ACF46C89673F29DEC931E5A38" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_D3DE3F22ABD5F13416C39DEC931D1DC8" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5DFC672ACF46C89673F29DEC931E5A38" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_9DECC7766564EE8F58549DEC93168959" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_4AB1C5BAABBCC3E6E8889DEC9317837C" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9DECC7766564EE8F58549DEC93168959" xlink:to="loc_us-gaap_OperatingLeaseCost_4AB1C5BAABBCC3E6E8889DEC9317837C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_D0A2ED92BE17693C08DD9DEC93178F8E" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9DECC7766564EE8F58549DEC93168959" xlink:to="loc_us-gaap_VariableLeaseCost_D0A2ED92BE17693C08DD9DEC93178F8E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_0EB99FE8A0B6153F6B009DEC93187A60" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9DECC7766564EE8F58549DEC93168959" xlink:to="loc_us-gaap_LeaseCost_0EB99FE8A0B6153F6B009DEC93187A60" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_CB8F14A34A23D8E0373F9DEC930C45F5" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_FB2C42E70CB9D1222F899DEC930C5D76" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CB8F14A34A23D8E0373F9DEC930C45F5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_FB2C42E70CB9D1222F899DEC930C5D76" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E07CA789A6BE491319289DEC930D7D4F" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CB8F14A34A23D8E0373F9DEC930C45F5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_E07CA789A6BE491319289DEC930D7D4F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8CDF5D8BDE6CAABF60929DEC930DC5C4" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CB8F14A34A23D8E0373F9DEC930C45F5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_8CDF5D8BDE6CAABF60929DEC930DC5C4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_605369CD044CC54A94A09DEC930D76E1" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CB8F14A34A23D8E0373F9DEC930C45F5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_605369CD044CC54A94A09DEC930D76E1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_CD397245C1D8D2F2CFE09DEC930ED9B1" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CB8F14A34A23D8E0373F9DEC930C45F5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_CD397245C1D8D2F2CFE09DEC930ED9B1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_A5BBA1592916FE75867D9DEC930E3E30" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CB8F14A34A23D8E0373F9DEC930C45F5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_A5BBA1592916FE75867D9DEC930E3E30" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08DF9D41CD7262EF22569DEC930E9078" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CB8F14A34A23D8E0373F9DEC930C45F5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_08DF9D41CD7262EF22569DEC930E9078" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_FFFF80FFEACFEDB1B0DD9DEC930EC045" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CB8F14A34A23D8E0373F9DEC930C45F5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_FFFF80FFEACFEDB1B0DD9DEC930EC045" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_08C184CA4F9BCB0DEE4F9DEC930F4862" xlink:type="locator" /> <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CB8F14A34A23D8E0373F9DEC930C45F5" xlink:to="loc_us-gaap_OperatingLeaseLiability_08C184CA4F9BCB0DEE4F9DEC930F4862" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_45F47207B2B7E028D1489DEC930FE3A1" xlink:type="locator" /> <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CB8F14A34A23D8E0373F9DEC930C45F5" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_45F47207B2B7E028D1489DEC930FE3A1" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_27F367C30518FE1AA4BC9DEC92F0CB77" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1260019F2EA7F21A93C49DEC92F1A167" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27F367C30518FE1AA4BC9DEC92F0CB77" xlink:to="loc_us-gaap_OperatingLeasePayments_1260019F2EA7F21A93C49DEC92F1A167" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A2A3A8BDBB382269654A9DEC92F1C7C9" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_27F367C30518FE1AA4BC9DEC92F0CB77" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_A2A3A8BDBB382269654A9DEC92F1C7C9" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/LeasesLeasesTables" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_CCF2CFCF9D01670131DA16CE0ECCA59B" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_385C29ADF81186B2EFD316CE0ECCA387" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CCF2CFCF9D01670131DA16CE0ECCA59B" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_385C29ADF81186B2EFD316CE0ECCA387" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2E80021757059AF0E35316CE0ECC7C09" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CCF2CFCF9D01670131DA16CE0ECCA59B" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_2E80021757059AF0E35316CE0ECC7C09" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_LesseeSupplementalCashFlowInformationTableTextBlock" xlink:label="loc_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock_43FF1ECEE8CDB7F3E90116CE0ECC625A" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_CCF2CFCF9D01670131DA16CE0ECCA59B" xlink:to="loc_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock_43FF1ECEE8CDB7F3E90116CE0ECC625A" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/Revenue" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AA5357F394F86DC152B79FDB3E7DB397" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_18FA47F11EF6CAFA47AA9FDB3E7D808A" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AA5357F394F86DC152B79FDB3E7DB397" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_18FA47F11EF6CAFA47AA9FDB3E7D808A" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/RevenueDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86EAC0424ED0CF735EB99FDB3E681861" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_86EAC0424ED0CF735EB99FDB3E681861" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:to="loc_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_E8686FD15973D390BEBD9FDB3E690CB1" xlink:to="loc_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_DevelopmentServicesMember" xlink:label="loc_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F6A6CB29F4F1D0B485079FDB3E69515E" xlink:to="loc_rvnc_DevelopmentServicesMember_F7B101E32F046C4BF4D79FDB3E6AF0D4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_2935C9AF814213F6685D9FDB3E6ADDA1" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:to="loc_srt_CounterpartyNameAxis_2935C9AF814213F6685D9FDB3E6ADDA1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3EAB4C8152568B2E622B9FDB3E6AF0BF" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2935C9AF814213F6685D9FDB3E6ADDA1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3EAB4C8152568B2E622B9FDB3E6AF0BF" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_MylanIrelandLimitedMember" xlink:label="loc_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3EAB4C8152568B2E622B9FDB3E6AF0BF" xlink:to="loc_rvnc_MylanIrelandLimitedMember_D40AFB3C20EFFE2D0B779FDB3E70E57A" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" xlink:label="loc_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3EAB4C8152568B2E622B9FDB3E6AF0BF" xlink:to="loc_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member_08D6A9D2361168DF70BD9FDB3E70BD61" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_C9678E5BFF5B5599B09B9FDB3E690EF2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0ED3A0318DCCFC94FE4A9FDB3E703050" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0ED3A0318DCCFC94FE4A9FDB3E703050" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ContingentLicensingRoyaltyRevenue" xlink:label="loc_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_rvnc_ContingentLicensingRoyaltyRevenue_FD08FBF01C443F7FE6749FDB3E713AAD" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue" xlink:label="loc_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue_3B0F7E5A08AF5AECDD009FDB3E719ED2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_E1B9503A4C6E93E5197F9FDB3E713BD8" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_E1B9503A4C6E93E5197F9FDB3E713BD8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E35692E9FBADD07875CC9FDB3E716D87" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_Revenues_E35692E9FBADD07875CC9FDB3E716D87" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A5380E3A8AE0D73F563D9FDB3E7266DC" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_A5380E3A8AE0D73F563D9FDB3E7266DC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1458225BEBDD392F07179FDB3E72B0CB" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_1458225BEBDD392F07179FDB3E72B0CB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetGross" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_1D16B695F9847B81F4FF9FDB3E72654C" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_1D16B695F9847B81F4FF9FDB3E72654C" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ForeignWithholdingTaxAmount" xlink:label="loc_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F" xlink:type="locator" /> <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_rvnc_ForeignWithholdingTaxAmount_3A67890C41DE98A319A39FDB3E72179F" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_B69C1FD602684AE3CC149FDB3E722BE6" xlink:type="locator" /> <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7F0D8354BC4125BAF4EF9FDB3E70D3FA" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_B69C1FD602684AE3CC149FDB3E722BE6" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensation" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_3998C6836E7FD34FD7739DEC92CC1CD9" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_D4087CBA1990FE4277869DEC92CD3A84" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3998C6836E7FD34FD7739DEC92CC1CD9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_D4087CBA1990FE4277869DEC92CD3A84" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_928ED4D4826B6D31DDDBE627CAD77028" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_928ED4D4826B6D31DDDBE627CAD77028" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_AD81B2C9240021B6C3E2E627CAD8B327" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_FAEB6FCA4CD412119DCCE637EB3867F2" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_FAEB6FCA4CD412119DCCE637EB3867F2" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_A98AD3B09C69DCDD01E7E627CAD83D4B" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:to="loc_us-gaap_EmployeeStockOptionMember_A98AD3B09C69DCDD01E7E627CAD83D4B" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_BC43D4CAF6A942EB59FBE627CAD83247" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:to="loc_us-gaap_RestrictedStockMember_BC43D4CAF6A942EB59FBE627CAD83247" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_ESPPPurchasesMember" xlink:label="loc_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:to="loc_rvnc_ESPPPurchasesMember_2517E7B3B322ABA77FB9E627CAD96969" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_EAF165B9AE2488F9043BE627CAD94BB3" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50A170AE8FA625C3D639E627CAD85606" xlink:to="loc_us-gaap_WarrantMember_EAF165B9AE2488F9043BE627CAD94BB3" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F4F98D5ABBD890947478E627CAD7BB9E" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47A2F282714200CA0887E627CAD9F5DA" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0AE48983CA8B17398E3EE627CAD9B0F5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_47A2F282714200CA0887E627CAD9F5DA" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4431A17D34C32316EABAE6554FC16CD4" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4431A17D34C32316EABAE6554FC16CD4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="loc_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_64F7576F9E50D5BBAEADE6554FC1E555" xlink:to="loc_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_C11DA27059BCA75C0E60E6554FC7CF7E" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_D34E073D47F0CFA95BD8E6554FC235BB" xlink:to="loc_srt_WeightedAverageMember_C11DA27059BCA75C0E60E6554FC7CF7E" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="loc_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9434ACA6C1D0DE000E72E6554FC8FBF6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_AA128E8704EDA2F32302E6554FC8EE96" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:to="loc_us-gaap_StockCompensationPlanMember_AA128E8704EDA2F32302E6554FC8EE96" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_B2B3490435753A0C3CF7E6554FC8B68A" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:to="loc_us-gaap_RestrictedStockMember_B2B3490435753A0C3CF7E6554FC8B68A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_2AC9936081859FF981F7E6554FC80A49" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:to="loc_us-gaap_PerformanceSharesMember_2AC9936081859FF981F7E6554FC80A49" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_74EBEF4C0EB79BF0C85BE6554FC99106" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_74EBEF4C0EB79BF0C85BE6554FC99106" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_D9C162777CDB3B3FD22DE6554FC93183" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_244FA7B252C86B638E53E6554FC893C7" xlink:to="loc_us-gaap_EmployeeStockMember_D9C162777CDB3B3FD22DE6554FC93183" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_C8DB430807FF7F0C4C6EE6554FC93AC0" xlink:to="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E515BB01D38BCF5A099CE6554FCABF58" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:to="loc_us-gaap_CommonStockMember_E515BB01D38BCF5A099CE6554FCABF58" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8C96A6AA4CD214BFF8A3E6554FCAB113" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0485574ED390E3FE48D6E6554FC958E4" xlink:to="loc_us-gaap_WarrantMember_8C96A6AA4CD214BFF8A3E6554FCAB113" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9B6482EDDD37E5994C7FE6554FCA9545" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_FollowOnOfferingMember" xlink:label="loc_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:to="loc_rvnc_FollowOnOfferingMember_DEC19383BC0D26078976E6554FCB58E7" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_9FEF8C1220B8A7E958DAE6554FCBB9B6" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:to="loc_us-gaap_OverAllotmentOptionMember_9FEF8C1220B8A7E958DAE6554FCBB9B6" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_AttheMarketOfferingMember" xlink:label="loc_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_B5FCF392D6BB709537EAE6554FCACC04" xlink:to="loc_rvnc_AttheMarketOfferingMember_AC8B7409CCF92ABB4220E6554FCB51CC" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="loc_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_C9FBE3B4A010C42DD670E6554FCBC5C8" xlink:to="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:label="loc_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:to="loc_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember_0B7DF139F66ED15B9F54E6554FCC2F9C" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwoThousandAndFourteenInducementPlanMember" xlink:label="loc_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:to="loc_rvnc_TwoThousandAndFourteenInducementPlanMember_9661493D8A55AA6E0992E6554FCC3892" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:label="loc_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0FA55F94CB9BB5C854F0E6554FCC8A37" xlink:to="loc_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_3314BD6EF150779822F2E6554FCC3A26" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_532D0A8E7E02AA5A6008E6554FC14888" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_FF7E55DFC678E59987A4E6554FCD0305" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_FF7E55DFC678E59987A4E6554FCD0305" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D1D74FAE638C438B4001E6554FCD065C" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_D1D74FAE638C438B4001E6554FCD065C" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D" xlink:type="locator" /> <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants_2A9019E93FFCDCFBCB1BE6554FCD2E0D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7531457E13AE97BDF19FE6554FCD9743" xlink:type="locator" /> <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7531457E13AE97BDF19FE6554FCD9743" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A17EF1C162B75C69FA55E6554FCE599A" xlink:type="locator" /> <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_A17EF1C162B75C69FA55E6554FCE599A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4B12BFF62C25C96017AE6554FCEBAB5" xlink:type="locator" /> <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_C4B12BFF62C25C96017AE6554FCEBAB5" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1F94521EAF057ED35D7E6554FCE3264" xlink:type="locator" /> <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D1F94521EAF057ED35D7E6554FCE3264" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_0104608ACA0F08B2CEABE6554FCE8E6C" xlink:type="locator" /> <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_SharePrice_0104608ACA0F08B2CEABE6554FCE8E6C" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C22CEBDE07FBA2342459E6554FCEEFBA" xlink:type="locator" /> <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_C22CEBDE07FBA2342459E6554FCEEFBA" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum" xlink:label="loc_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192" xlink:type="locator" /> <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum_9B2A12966058D153131BE6554FCFE192" xlink:type="arc" /> <link:loc xlink:href="rvnc-20200331.xsd#rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum" xlink:label="loc_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6" xlink:type="locator" /> <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CFE099306481E995857FE6554FCCDF90" xlink:to="loc_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum_B90FE2374CFA4F9495A0E65889DF4AF6" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_232783ED84503F94319F9F83F6CF15E8" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_232783ED84503F94319F9F83F6CF15E8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38533CC6F1357EF3D55E9F83F6D33F22" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6E6798CFB76DC5B74FE49F83F6D3ADF1" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6E6798CFB76DC5B74FE49F83F6D3ADF1" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_65497392562DDFAE81D09F83F6D4408A" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2983C1D42FB07B59AD739F83F6D3337D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_65497392562DDFAE81D09F83F6D4408A" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9C1E7D208D0FAB66ADC09F83F6D24A83" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3CECF961A2DDA3938C529F83F6D4DF16" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_332186E55D4F170C10B99F83F6D48A06" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3CECF961A2DDA3938C529F83F6D4DF16" xlink:type="arc" /> </link:presentationLink> <link:presentationLink xlink:role="http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationTables" xlink:type="extended"> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D98351322CE940CDB4569F838772F6D1" xlink:type="locator" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_306469CEE9EB39D85DA69F83877AE933" xlink:type="locator" /> <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D98351322CE940CDB4569F838772F6D1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_306469CEE9EB39D85DA69F83877AE933" xlink:type="arc" /> <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_41FC95BCB4C893D2377C9F8387785918" xlink:type="locator" /> <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D98351322CE940CDB4569F838772F6D1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_41FC95BCB4C893D2377C9F8387785918" xlink:type="arc" /> </link:presentationLink> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>11 <FILENAME>R27.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809612880"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short-Term Investments (Detail) - USD ($)<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Dec. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td> <td class="nump">$ 509,109,000<span></span> </td> <td class="nump">$ 282,683,000<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td> <td class="nump">524,000<span></span> </td> <td class="nump">8,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td> <td class="text"> <span></span> </td> <td class="num">(5,000)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td> <td class="nump">509,633,000<span></span> </td> <td class="nump">282,686,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary impairments on available-for-sale securities</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td> <td class="nump">285,012,000<span></span> </td> <td class="nump">163,731,000<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Short-term investments</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td> <td class="nump">224,621,000<span></span> </td> <td class="nump">118,955,000<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td> <td class="nump">179,031,000<span></span> </td> <td class="nump">136,258,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td> <td class="nump">179,031,000<span></span> </td> <td class="nump">136,258,000<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td> <td class="nump">30,124,000<span></span> </td> <td class="nump">48,349,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td> <td class="nump">182,000<span></span> </td> <td class="nump">6,000<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td> <td class="nump">30,306,000<span></span> </td> <td class="nump">48,355,000<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agency obligations</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td> <td class="nump">159,634,000<span></span> </td> <td class="nump">5,993,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td> <td class="nump">342,000<span></span> </td> <td class="nump">2,000<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td> <td class="text"> <span></span> </td> <td class="num">(5,000)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td> <td class="nump">159,976,000<span></span> </td> <td class="nump">5,990,000<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td> <td class="nump">140,320,000<span></span> </td> <td class="nump">77,082,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td> <td class="nump">140,320,000<span></span> </td> <td class="nump">77,082,000<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight repurchase agreements</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td> <td class="nump">0<span></span> </td> <td class="nump">15,001,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 15,001,000<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_RepurchaseAgreementsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_RepurchaseAgreementsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>12 <FILENAME>R23.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789578320"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Stock-Based Compensation (Tables)<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible senior notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,878,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,305,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,372,676</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards and performance stock awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799,982</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>768,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock expected to be purchased on June 30 under the 2014 ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,861</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was allocated as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,442</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,080</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,544</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,159</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>13 <FILENAME>R42.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811819104"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Dec. 31, 2019</div></th> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 184,613<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">136,258<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. treasury securities</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">48,355<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. government agency obligations</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Commercial paper</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Overnight repurchase agreements</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">98,073<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money market funds</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. treasury securities</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government agency obligations</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">5,990<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">77,082<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Overnight repurchase agreements</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">15,001<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money market funds</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. treasury securities</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. government agency obligations</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Commercial paper</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Overnight repurchase agreements</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">$ 509,633<span></span> </td> <td class="nump">282,686<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td> <td class="nump">3,042<span></span> </td> <td class="nump">2,952<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Money market funds</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">179,031<span></span> </td> <td class="nump">136,258<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. treasury securities</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">30,306<span></span> </td> <td class="nump">48,355<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | U.S. government agency obligations</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">159,976<span></span> </td> <td class="nump">5,990<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Commercial paper</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">140,320<span></span> </td> <td class="nump">77,082<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Overnight repurchase agreements</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="text"> <span></span> </td> <td class="nump">15,001<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Derivative liability</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td> <td class="nump">3,042<span></span> </td> <td class="nump">2,952<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">209,337<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Money market funds</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">179,031<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | U.S. treasury securities</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">30,306<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | U.S. government agency obligations</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Commercial paper</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 1 | Derivative liability</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">300,296<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Money market funds</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | U.S. treasury securities</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | U.S. government agency obligations</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">159,976<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Commercial paper</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">140,320<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 2 | Derivative liability</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td> <td class="nump">3,042<span></span> </td> <td class="nump">2,952<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Money market funds</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | U.S. treasury securities</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | U.S. government agency obligations</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Commercial paper</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total assets measured at fair value</a></td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level 3 | Derivative liability</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured at fair value</a></td> <td class="nump">$ 3,042<span></span> </td> <td class="nump">$ 2,952<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MaturityOvernightMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MaturityOvernightMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rvnc_DerivativeLiabilitySettlementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rvnc_DerivativeLiabilitySettlementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>14 <FILENAME>Show.js <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>15 <FILENAME>rvncq12010-q_htm.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <XML> <?xml version="1.0" encoding="utf-8"?> <xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rvnc="http://www.revance.com/20200331" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"> <link:schemaRef xlink:href="rvnc-20200331.xsd" xlink:type="simple"/> <context id="FD2020Q1YTD"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="I2020Q2Apr24"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> </entity> <period> <instant>2020-04-24</instant> </period> </context> <context id="FI2019Q4"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2020Q1"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FD2019Q1QTD"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-03-31</instant> </period> </context> <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-03-31</instant> </period> </context> <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2018-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2019Q1"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> </entity> <period> <instant>2019-03-31</instant> </period> </context> <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2018-12-31</instant> </period> </context> <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-03-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2018-12-31</instant> </period> </context> <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2018-12-31</instant> </period> </context> <context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-03-31</instant> </period> </context> <context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FD2019Q1QTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvnc:FollowOnOfferingMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FD2020Q1QTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvnc:FollowOnOfferingMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FI2018Q4"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> </entity> <period> <instant>2018-12-31</instant> </period> </context> <context id="I2019Q1Jan31_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-01-31</instant> </period> </context> <context id="FD2019Q1YTD_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rvnc:DevelopmentServicesMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FI2020Q1_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rvnc:DevelopmentServicesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="D2019Q1Jan_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-01-31</endDate> </period> </context> <context id="I2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:MylanIrelandLimitedMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2018-02-28</instant> </period> </context> <context id="FI2020Q1_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:MylanIrelandLimitedMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2019Q4_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rvnc:DevelopmentServicesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FD2020Q1YTD_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2020Q1YTD_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rvnc:DevelopmentServicesMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="D2020Q1Mar31_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-03-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="D2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:MylanIrelandLimitedMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2018-02-28</startDate> <endDate>2018-02-28</endDate> </period> </context> <context id="FD2019Q1YTD_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rvnc:ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FD2019Q4YTD"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-12-31</endDate> </period> </context> <context id="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:TeoxaneAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-01-31</endDate> </period> </context> <context id="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:TeoxaneAgreementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-12-31</endDate> </period> </context> <context id="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputEntityCreditRiskMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputEntityCreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputEntityCreditRiskMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputEntityCreditRiskMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-12-31</endDate> </period> </context> <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-12-31</endDate> </period> </context> <context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_ValeantPharmaceuticalsInternationalInc.Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:ValeantPharmaceuticalsInternationalInc.Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:MedicisPharmaceuticalCorporationMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-02-14</instant> </period> </context> <context id="FD2020Q1YTD_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsOneMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="rvnc:DebtInstrumentConvertibleTermsOfConversionAxis">rvnc:DebtConversionTermsOneMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-02-14</startDate> <endDate>2020-02-14</endDate> </period> </context> <context id="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-02-14</startDate> <endDate>2020-02-14</endDate> </period> </context> <context id="D2020Q1Feb14"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> </entity> <period> <startDate>2020-02-14</startDate> <endDate>2020-02-14</endDate> </period> </context> <context id="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsTwoMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">rvnc:TwentyTwentySevenNotesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="rvnc:DebtInstrumentConvertibleTermsOfConversionAxis">rvnc:DebtConversionTermsTwoMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-02-14</startDate> <endDate>2020-02-14</endDate> </period> </context> <context id="I2020Q1Feb14"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> </entity> <period> <instant>2020-02-14</instant> </period> </context> <context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_rvnc_ESPPPurchasesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rvnc:ESPPPurchasesMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_rvnc_ESPPPurchasesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">rvnc:ESPPPurchasesMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenInducementPlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenInducementPlanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="I2020Q1Jan1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-01-01</instant> </period> </context> <context id="FI2020Q1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenInducementPlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenInducementPlanMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="I2020Q1Jan1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-01-01</instant> </period> </context> <context id="FD2020Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_AttheMarketOfferingMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvnc:AttheMarketOfferingMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="I2020Q1Jan31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-01-31</instant> </period> </context> <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="D2019Q4Dec-31_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvnc:FollowOnOfferingMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-12-01</startDate> <endDate>2019-12-31</endDate> </period> </context> <context id="D2020Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-01-31</endDate> </period> </context> <context id="FI2019Q4_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">rvnc:FollowOnOfferingMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="D2020Q1Feb29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-02-01</startDate> <endDate>2020-02-29</endDate> </period> </context> <context id="FI2020Q1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rvnc:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2019Q4_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="I2020Q1Feb29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-02-29</instant> </period> </context> <context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2019-01-01</startDate> <endDate>2019-03-31</endDate> </period> </context> <context id="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FD2020Q1YTD_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FI2020Q1_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MaturityOvernightMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rvnc:DerivativeLiabilitySettlementMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2019-12-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_TypeOfArrangementAxis_rvnc_BioSentinelInc.Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:BioSentinelInc.Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FD2020Q1YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2020-01-01</startDate> <endDate>2020-03-31</endDate> </period> </context> <context id="FI2020Q1_us-gaap_TypeOfArrangementAxis_rvnc_BotulinumToxinResearchAssociatesInc.Member"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:BotulinumToxinResearchAssociatesInc.Member</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <context id="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_ListLaboratoriesMember"> <entity> <identifier scheme="http://www.sec.gov/CIK">0001479290</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CreditRiskContractMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">rvnc:ListLaboratoriesMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2020-03-31</instant> </period> </context> <unit id="day"> <measure>rvnc:day</measure> </unit> <unit id="shares"> <measure>shares</measure> </unit> <unit id="usdPerShare"> <divide> <unitNumerator> <measure>iso4217:USD</measure> </unitNumerator> <unitDenominator> <measure>shares</measure> </unitDenominator> </divide> </unit> <unit id="usd"> <measure>iso4217:USD</measure> </unit> <unit id="number"> <measure>pure</measure> </unit> <unit id="segment"> <measure>rvnc:segment</measure> </unit> <dei:AmendmentFlag contextRef="FD2020Q1YTD" id="Fact-A53417FA44C8C6B5686B16CE0BB38847-wk-Fact-A53417FA44C8C6B5686B16CE0BB38847">false</dei:AmendmentFlag> <dei:CurrentFiscalYearEndDate contextRef="FD2020Q1YTD" id="Fact-08316D5F92A1DFA463359FDD235CF4A4-wk-Fact-08316D5F92A1DFA463359FDD235CF4A4">--12-31</dei:CurrentFiscalYearEndDate> <dei:DocumentFiscalPeriodFocus contextRef="FD2020Q1YTD" id="Fact-1B640A2E9A2BDF4008FD9D33A166C8E3-wk-Fact-1B640A2E9A2BDF4008FD9D33A166C8E3">Q1</dei:DocumentFiscalPeriodFocus> <dei:DocumentFiscalYearFocus contextRef="FD2020Q1YTD" id="Fact-1CB60E9EA0FEA7A49D1D9FDD235C3BFF-wk-Fact-1CB60E9EA0FEA7A49D1D9FDD235C3BFF">2020</dei:DocumentFiscalYearFocus> <dei:EntityCentralIndexKey contextRef="FD2020Q1YTD" id="Fact-97505126AF2BC14F947E16CE0BB3B5C0-wk-Fact-97505126AF2BC14F947E16CE0BB3B5C0">0001479290</dei:EntityCentralIndexKey> <rvnc:CollaborativeAgreementExtendedContractualPeriod contextRef="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" id="Fact-28574750F5613F3F2DDD9ECF56B2F2BF-wk-Fact-28574750F5613F3F2DDD9ECF56B2F2BF">P2Y</rvnc:CollaborativeAgreementExtendedContractualPeriod> <rvnc:CollaborativeAgreementExtendedContractualPeriod contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" id="Fact-4A47EE6E6F640052A910BA75277227CD-wk-Fact-4A47EE6E6F640052A910BA75277227CD">P2Y</rvnc:CollaborativeAgreementExtendedContractualPeriod> <rvnc:EquityComponentOfConvertibleDebtTransactionCost contextRef="FD2020Q1YTD" decimals="-3" id="Fact-D904FB26257B0C90019E9DEE12F69B44-wk-Fact-D904FB26257B0C90019E9DEE12F69B44" unitRef="usd">3583000</rvnc:EquityComponentOfConvertibleDebtTransactionCost> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2019Q4" decimals="INF" id="Fact-8A739AACD4617482682016CE0BF16726-wk-Fact-8A739AACD4617482682016CE0BF16726" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2020Q1" decimals="INF" id="Fact-CD074FF215803999F8E016CE0BF1E9DE-wk-Fact-CD074FF215803999F8E016CE0BF1E9DE" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:CommonStockSharesAuthorized contextRef="FI2019Q4" decimals="INF" id="Fact-DF453F91963E45CA2F0F16CE0BF1C945-wk-Fact-DF453F91963E45CA2F0F16CE0BF1C945" unitRef="shares">95000000</us-gaap:CommonStockSharesAuthorized> <us-gaap:CommonStockSharesAuthorized contextRef="FI2020Q1" decimals="INF" id="Fact-655A4109DE3243A2D5FE16CE0BF1A1ED-wk-Fact-655A4109DE3243A2D5FE16CE0BF1A1ED" unitRef="shares">95000000</us-gaap:CommonStockSharesAuthorized> <us-gaap:CommonStockSharesIssued contextRef="FI2019Q4" decimals="INF" id="Fact-1E10309A8B1B19FCEFDD16CE0C01C953-wk-Fact-1E10309A8B1B19FCEFDD16CE0C01C953" unitRef="shares">52374735</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockSharesIssued contextRef="FI2020Q1" decimals="INF" id="Fact-6D3DFB8AFDBCC479673516CE0BF19E21-wk-Fact-6D3DFB8AFDBCC479673516CE0BF19E21" unitRef="shares">57026154</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q4" decimals="INF" id="Fact-2F93161C58991DB241E616CE0BF10B60-wk-Fact-2F93161C58991DB241E616CE0BF10B60" unitRef="shares">52374735</us-gaap:CommonStockSharesOutstanding> <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="FD2019Q1YTD_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" decimals="INF" id="Fact-5107A64AA961D0D3BBD49E5C3EF49299-wk-Fact-5107A64AA961D0D3BBD49E5C3EF49299" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized> <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-FD4B6FB295556D96C368BA2C8F436F92-wk-Fact-FD4B6FB295556D96C368BA2C8F436F92" unitRef="number">0.0308804</us-gaap:DebtInstrumentConvertibleConversionRatio1> <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale contextRef="FD2019Q4YTD" decimals="INF" id="Fact-18948D1B1026E7BDA5A416CE0DB6E260-wk-Fact-18948D1B1026E7BDA5A416CE0DB6E260" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale> <us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2019Q1QTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember" decimals="-3" id="Fact-E18BFAFA18947CAE6C689DD0A2B03E69-wk-Fact-E18BFAFA18947CAE6C689DD0A2B03E69" unitRef="usd">521000</us-gaap:PaymentsOfStockIssuanceCosts> <us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2020Q1QTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember" decimals="-3" id="Fact-5896F6541618082022439DD0A2C0D026-wk-Fact-5896F6541618082022439DD0A2C0D026" unitRef="usd">44000</us-gaap:PaymentsOfStockIssuanceCosts> <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2019Q4" decimals="INF" id="Fact-C06BA8AFB9A30F8297F316CE0BF14DAC-wk-Fact-C06BA8AFB9A30F8297F316CE0BF14DAC" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare> <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2020Q1" decimals="INF" id="Fact-E1072FD22819E7636A3516CE0BF1AA8B-wk-Fact-E1072FD22819E7636A3516CE0BF1AA8B" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare> <us-gaap:PreferredStockSharesAuthorized contextRef="FI2019Q4" decimals="INF" id="Fact-F08D0DCC0D81FDB193AA16CE0BF1D3E9-wk-Fact-F08D0DCC0D81FDB193AA16CE0BF1D3E9" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized> <us-gaap:PreferredStockSharesAuthorized contextRef="FI2020Q1" decimals="INF" id="Fact-9CD3A459603F4CAEF70316CE0BF1C4B6-wk-Fact-9CD3A459603F4CAEF70316CE0BF1C4B6" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized> <us-gaap:PreferredStockSharesIssued contextRef="FI2019Q4" decimals="INF" id="Fact-76B39EEBE573DF9DADF916CE0BF149C6-wk-Fact-76B39EEBE573DF9DADF916CE0BF149C6" unitRef="shares">0</us-gaap:PreferredStockSharesIssued> <us-gaap:PreferredStockSharesIssued contextRef="FI2020Q1" decimals="INF" id="Fact-A982CDBC0914CD08510816CE0BF1E131-wk-Fact-A982CDBC0914CD08510816CE0BF1E131" unitRef="shares">0</us-gaap:PreferredStockSharesIssued> <us-gaap:PreferredStockSharesOutstanding contextRef="FI2019Q4" decimals="INF" id="Fact-DF98AA929C41ED8B010216CE0BF133C6-wk-Fact-DF98AA929C41ED8B010216CE0BF133C6" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding> <us-gaap:PreferredStockSharesOutstanding contextRef="FI2020Q1" decimals="INF" id="Fact-7F523DC3C19478143D0516CE0BF1F84A-wk-Fact-7F523DC3C19478143D0516CE0BF1F84A" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding> <dei:DocumentType contextRef="FD2020Q1YTD" id="d12615397e582-wk-Fact-0CB8BE635CEC952959A216CE0B938AEB">10-Q</dei:DocumentType> <dei:DocumentQuarterlyReport contextRef="FD2020Q1YTD" id="d12615397e642-wk-Fact-DD065EDC568892E1983F16CE0B93F88A">true</dei:DocumentQuarterlyReport> <dei:DocumentPeriodEndDate contextRef="FD2020Q1YTD" id="d12615397e659-wk-Fact-E16F28BDF23C54B4B6029FDFA838E2B2">2020-03-31</dei:DocumentPeriodEndDate> <dei:DocumentTransitionReport contextRef="FD2020Q1YTD" id="d12615397e692-wk-Fact-C8F943EA2B64D53BA3F216CE0BB3466B">false</dei:DocumentTransitionReport> <dei:EntityFileNumber contextRef="FD2020Q1YTD" id="d12615397e723-wk-Fact-5029470F944CC0E4C86016CE0B936A68">001-36297</dei:EntityFileNumber> <dei:EntityRegistrantName contextRef="FD2020Q1YTD" id="d12615397e757-wk-Fact-2395072A736FEF6BB37E16CE0BA3E83F">Revance Therapeutics, Inc.</dei:EntityRegistrantName> <dei:EntityIncorporationStateCountryCode contextRef="FD2020Q1YTD" id="d12615397e819-wk-Fact-0B8B372C23E2A9A0B3CB16CE0BA399A4">DE</dei:EntityIncorporationStateCountryCode> <dei:EntityTaxIdentificationNumber contextRef="FD2020Q1YTD" id="d12615397e824-wk-Fact-7BF7CA93936BD23F865016CE0BA3744C">77-0551645</dei:EntityTaxIdentificationNumber> <dei:EntityAddressAddressLine1 contextRef="FD2020Q1YTD" id="d12615397e854-wk-Fact-8309C7B0EBFC78457E6216CE0B930B3F">7555 Gateway Boulevard</dei:EntityAddressAddressLine1> <dei:EntityAddressCityOrTown contextRef="FD2020Q1YTD" id="d12615397e859-wk-Fact-B215CA117D9971671C4316CE0B9374E1">Newark</dei:EntityAddressCityOrTown> <dei:EntityAddressStateOrProvince contextRef="FD2020Q1YTD" id="d12615397e864-wk-Fact-579FBCB824E448E2E1A216CE0B930FDC">CA</dei:EntityAddressStateOrProvince> <dei:EntityAddressPostalZipCode contextRef="FD2020Q1YTD" id="d12615397e869-wk-Fact-0828A197264F13BD2D1316CE0B931242">94560</dei:EntityAddressPostalZipCode> <dei:CityAreaCode contextRef="FD2020Q1YTD" id="d12615397e883-wk-Fact-2F8B6A48EAA0E50795B316CE0B936903">510</dei:CityAreaCode> <dei:LocalPhoneNumber contextRef="FD2020Q1YTD" id="d12615397e888-wk-Fact-E93F324BDCC44D37079416CE0B93D091">742-3400</dei:LocalPhoneNumber> <dei:Security12bTitle contextRef="FD2020Q1YTD" id="d12615397e941-wk-Fact-E3BDD2CE77BB8634132816CE0BB3B564">Common Stock, par value $0.001 per share</dei:Security12bTitle> <dei:TradingSymbol contextRef="FD2020Q1YTD" id="d12615397e946-wk-Fact-82CAE3D4C954F042C16016CE0BB3B71E">RVNC</dei:TradingSymbol> <dei:SecurityExchangeName contextRef="FD2020Q1YTD" id="d12615397e951-wk-Fact-2B4708775AF59480B29E16CE0BB3CA47">NASDAQ</dei:SecurityExchangeName> <dei:EntityCurrentReportingStatus contextRef="FD2020Q1YTD" id="d12615397e956-wk-Fact-85956DFCE3583B41D52016CE0B9362D3">Yes</dei:EntityCurrentReportingStatus> <dei:EntityInteractiveDataCurrent contextRef="FD2020Q1YTD" id="d12615397e969-wk-Fact-7EB9F960391E6F1BA3E716CE0B93A70D">Yes</dei:EntityInteractiveDataCurrent> <dei:EntityFilerCategory contextRef="FD2020Q1YTD" id="d12615397e1008-wk-Fact-62A6A37C2BDB836380DDE64CBBFF2BA6">Accelerated Filer</dei:EntityFilerCategory> <dei:EntityEmergingGrowthCompany contextRef="FD2020Q1YTD" id="d12615397e1023-wk-Fact-75AD781A0DA6055D439516CE0BA359E8">false</dei:EntityEmergingGrowthCompany> <dei:EntitySmallBusiness contextRef="FD2020Q1YTD" id="d12615397e1044-wk-Fact-EABFC43E6E66F0C5F9CA16CE0BA31DA4">true</dei:EntitySmallBusiness> <dei:EntityShellCompany contextRef="FD2020Q1YTD" id="d12615397e1064-wk-Fact-ADA6C4F55671C9D8781F16CE0B936007">false</dei:EntityShellCompany> <dei:EntityCommonStockSharesOutstanding contextRef="I2020Q2Apr24" decimals="INF" id="d12615397e1078-wk-Fact-146E47BAB0EC0CBDD8A540B0ECF1A5EA" unitRef="shares">57052046</dei:EntityCommonStockSharesOutstanding> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2020Q1" decimals="-3" id="d12621436e712-wk-Fact-F0BFBD873E5A635AA49B9D2B33EAC25C" unitRef="usd">286649000</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2019Q4" decimals="-3" id="d12621436e731-wk-Fact-03395A28B48998BFBDDF9D2B36E6C6D6" unitRef="usd">171160000</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:ShortTermInvestments contextRef="FI2020Q1" decimals="-3" id="d12621436e746-wk-Fact-8C004DAC08A497D128769D2B36C13B66" unitRef="usd">224621000</us-gaap:ShortTermInvestments> <us-gaap:ShortTermInvestments contextRef="FI2019Q4" decimals="-3" id="d12621436e765-wk-Fact-E707AFBED65FADCCA3299D2B36C1339B" unitRef="usd">118955000</us-gaap:ShortTermInvestments> <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e785-wk-Fact-87718DF2B0B8CC92D3FD9D2B36D72016" unitRef="usd">7171000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent> <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e804-wk-Fact-E6F41393145D2FA941829D2B33E46CF9" unitRef="usd">6487000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent> <us-gaap:AssetsCurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e824-wk-Fact-2D209DD505F5058E44EC9D2B365CC54A" unitRef="usd">518441000</us-gaap:AssetsCurrent> <us-gaap:AssetsCurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e843-wk-Fact-6EE0CD3BAB5A35580C299D2B35C9A551" unitRef="usd">296602000</us-gaap:AssetsCurrent> <us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2020Q1" decimals="-3" id="d12621436e863-wk-Fact-8FC74F339FA59B9DB0609D2B340D13E3" unitRef="usd">13967000</us-gaap:PropertyPlantAndEquipmentNet> <us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q4" decimals="-3" id="d12621436e882-wk-Fact-DDD476F9DFAD7A91FAF69D2B36F66AB8" unitRef="usd">14755000</us-gaap:PropertyPlantAndEquipmentNet> <us-gaap:OtherIntangibleAssetsNet contextRef="FI2020Q1" decimals="-3" id="d12621436e902-wk-Fact-8CF38F2A2EB9F02E1FB29D3FB6622310" unitRef="usd">32334000</us-gaap:OtherIntangibleAssetsNet> <us-gaap:OtherIntangibleAssetsNet contextRef="FI2019Q4" decimals="-3" id="d12621436e921-wk-Fact-0A337136D9E3A114EE5D9D3FB6BB9F7A" unitRef="usd">0</us-gaap:OtherIntangibleAssetsNet> <us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2020Q1" decimals="-3" id="d12621436e941-wk-Fact-EC282D7D56FD98CC252E9D2B33FA311B" unitRef="usd">25961000</us-gaap:OperatingLeaseRightOfUseAsset> <us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q4" decimals="-3" id="d12621436e960-wk-Fact-C8374AFF91F031E4A46F9D3F0C04C690" unitRef="usd">26531000</us-gaap:OperatingLeaseRightOfUseAsset> <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e981-wk-Fact-10F7EDB6B5A4E9C5C0499D3EC48D29C3" unitRef="usd">730000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent> <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e1000-wk-Fact-84360100EB83F168D4AD9D3EC494D15C" unitRef="usd">730000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent> <us-gaap:OtherAssetsNoncurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e1020-wk-Fact-B7DD73222DD5B4DEA9119D2B3419A9E6" unitRef="usd">1494000</us-gaap:OtherAssetsNoncurrent> <us-gaap:OtherAssetsNoncurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e1039-wk-Fact-09DD457133C11F0977C09D2B36E676D0" unitRef="usd">1669000</us-gaap:OtherAssetsNoncurrent> <us-gaap:Assets contextRef="FI2020Q1" decimals="-3" id="d12621436e1064-wk-Fact-3915A2EF17097CE0DAD89D2B34678C6B" unitRef="usd">592927000</us-gaap:Assets> <us-gaap:Assets contextRef="FI2019Q4" decimals="-3" id="d12621436e1083-wk-Fact-118CE045B5DE2DAFDF0E9D2B3438E014" unitRef="usd">340287000</us-gaap:Assets> <us-gaap:AccountsPayableCurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e1185-wk-Fact-5E15E75B7EB2F41FEDF19D2B342881C1" unitRef="usd">8709000</us-gaap:AccountsPayableCurrent> <us-gaap:AccountsPayableCurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e1204-wk-Fact-51149614F0FDAB5D3FF09D2B34288473" unitRef="usd">8010000</us-gaap:AccountsPayableCurrent> <us-gaap:AccruedLiabilitiesCurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e1219-wk-Fact-85DE8FDA1017FF99DB159D2B36F64BD2" unitRef="usd">16178000</us-gaap:AccruedLiabilitiesCurrent> <us-gaap:AccruedLiabilitiesCurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e1238-wk-Fact-264EC5A453E68C6B5C509D2B33FF8C22" unitRef="usd">18636000</us-gaap:AccruedLiabilitiesCurrent> <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e1258-wk-Fact-188C14911E79D442EA2A9D2B340A8568" unitRef="usd">10079000</us-gaap:ContractWithCustomerLiabilityCurrent> <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e1277-wk-Fact-8FF315723A0CA7256BA49D2B36E687D1" unitRef="usd">7911000</us-gaap:ContractWithCustomerLiabilityCurrent> <us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e1297-wk-Fact-FC2815627D633CDDBF009D2B36B10B6D" unitRef="usd">3627000</us-gaap:OperatingLeaseLiabilityCurrent> <us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e1316-wk-Fact-09CC574222CD91219CCD9D40952BB5D8" unitRef="usd">3470000</us-gaap:OperatingLeaseLiabilityCurrent> <us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e1336-wk-Fact-55B1CA30FFD6A2F2949A9D2B3500E8C0" unitRef="usd">3042000</us-gaap:DerivativeLiabilitiesCurrent> <us-gaap:DerivativeLiabilitiesCurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e1355-wk-Fact-4DCAB9419E976BC6EC8B9D2B33F40B7A" unitRef="usd">2952000</us-gaap:DerivativeLiabilitiesCurrent> <us-gaap:LiabilitiesCurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e1375-wk-Fact-C17490A4AD7CF1735E3A9D2B352F8A0B" unitRef="usd">41635000</us-gaap:LiabilitiesCurrent> <us-gaap:LiabilitiesCurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e1394-wk-Fact-4EA4D4422A402876079F9D2B366CFF33" unitRef="usd">40979000</us-gaap:LiabilitiesCurrent> <us-gaap:SeniorLongTermNotes contextRef="FI2020Q1" decimals="-3" id="d12621436e1415-wk-Fact-309679D6B7186C527E1E9D4077E63E88" unitRef="usd">171305000</us-gaap:SeniorLongTermNotes> <us-gaap:SeniorLongTermNotes contextRef="FI2019Q4" decimals="-3" id="d12621436e1434-wk-Fact-B806F8789FB5B580511D9D4077E68B58" unitRef="usd">0</us-gaap:SeniorLongTermNotes> <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e1454-wk-Fact-CA71EB9B90B2A39C8D519D2B3428BE51" unitRef="usd">46722000</us-gaap:ContractWithCustomerLiabilityNoncurrent> <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e1473-wk-Fact-30E4C02C05AC370F5B4D9D2B36D7C75E" unitRef="usd">47948000</us-gaap:ContractWithCustomerLiabilityNoncurrent> <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2020Q1" decimals="-3" id="d12621436e1493-wk-Fact-77F4EC7CB1AA611F169C9D2B34CB18C6" unitRef="usd">24890000</us-gaap:OperatingLeaseLiabilityNoncurrent> <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q4" decimals="-3" id="d12621436e1512-wk-Fact-71AB17EE2B9510AF898D9D4022B7EED5" unitRef="usd">25870000</us-gaap:OperatingLeaseLiabilityNoncurrent> <us-gaap:Liabilities contextRef="FI2020Q1" decimals="-3" id="d12621436e1532-wk-Fact-130538A3FA052B4C5DAF9D2B365CED3C" unitRef="usd">284552000</us-gaap:Liabilities> <us-gaap:Liabilities contextRef="FI2019Q4" decimals="-3" id="d12621436e1551-wk-Fact-C688EC2AC964411833E19D2B36D75E78" unitRef="usd">114797000</us-gaap:Liabilities> <us-gaap:CommitmentsAndContingencies contextRef="FI2020Q1" id="d12621436e1571-wk-Fact-1626B4ACE72837D170CC16CE0BD2516A" unitRef="usd" xsi:nil="true"/> <us-gaap:CommitmentsAndContingencies contextRef="FI2019Q4" id="d12621436e1590-wk-Fact-E07023E26173C77918F316CE0BD2BE8E" unitRef="usd" xsi:nil="true"/> <us-gaap:PreferredStockValue contextRef="FI2020Q1" decimals="-3" id="d12621436e1651-wk-Fact-5C2FD04C8409BD5CD5F99D2B36D0DBE8" unitRef="usd">0</us-gaap:PreferredStockValue> <us-gaap:PreferredStockValue contextRef="FI2019Q4" decimals="-3" id="d12621436e1670-wk-Fact-608B6CD177CC44AE837A9D2B3565C3AD" unitRef="usd">0</us-gaap:PreferredStockValue> <us-gaap:CommonStockValue contextRef="FI2020Q1" decimals="-3" id="d12621436e1690-wk-Fact-33D606C37B12919053659D2B3419FB18" unitRef="usd">57000</us-gaap:CommonStockValue> <us-gaap:CommonStockValue contextRef="FI2019Q4" decimals="-3" id="d12621436e1709-wk-Fact-D42F11B6D99BF3273C879D2B349C76CB" unitRef="usd">52000</us-gaap:CommonStockValue> <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2020Q1" decimals="-3" id="d12621436e1729-wk-Fact-F657BF73F33C2B51FA609D2B365C1FEA" unitRef="usd">1213931000</us-gaap:AdditionalPaidInCapitalCommonStock> <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2019Q4" decimals="-3" id="d12621436e1748-wk-Fact-1C3926188E68593D22CD9D2B36C152D4" unitRef="usd">1069639000</us-gaap:AdditionalPaidInCapitalCommonStock> <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2020Q1" decimals="-3" id="d12621436e1768-wk-Fact-FE327EE41F215EC583889D2B340D6823" unitRef="usd">524000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax> <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q4" decimals="-3" id="d12621436e1787-wk-Fact-B4C7433FD8EFE5AB645A9D2B33EE6B19" unitRef="usd">3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2020Q1" decimals="-3" id="d12621436e1807-wk-Fact-BCFBD491579B3B8373929D2B3405D82D" unitRef="usd">-906137000</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q4" decimals="-3" id="d12621436e1827-wk-Fact-F9D453BC9CAB518148E19D2B35F81B70" unitRef="usd">-844204000</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:StockholdersEquity contextRef="FI2020Q1" decimals="-3" id="d12621436e1849-wk-Fact-03146407C6278DA3AC389D2B33CFFF9F" unitRef="usd">308375000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="FI2019Q4" decimals="-3" id="d12621436e1868-wk-Fact-AE894A6E1BEAAF3C3DA59D2B3419611C" unitRef="usd">225490000</us-gaap:StockholdersEquity> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2020Q1" decimals="-3" id="d12621436e1893-wk-Fact-14D27C8CD13183E9A7109D2B35948EE2" unitRef="usd">592927000</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2019Q4" decimals="-3" id="d12621436e1912-wk-Fact-700D877007C1E4F96D469D2B362D5816" unitRef="usd">340287000</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:Revenues contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e629-wk-Fact-BF4267F6A30305BC40319D2B5F1EF05F" unitRef="usd">58000</us-gaap:Revenues> <us-gaap:Revenues contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e648-wk-Fact-B98B3B37B25769E22CBB9D2B5D64B2A8" unitRef="usd">278000</us-gaap:Revenues> <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e704-wk-Fact-EE29D8B1BD64FC3996679D2B5DDD2560" unitRef="usd">39794000</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e723-wk-Fact-40254D156FFEECD4E0669D2B5DF72CCC" unitRef="usd">23995000</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e743-wk-Fact-85A0E04DAB3A295CCF519D2B5D4C0969" unitRef="usd">21224000</us-gaap:SellingGeneralAndAdministrativeExpense> <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e762-wk-Fact-0F40F1356DEA7ED438969D2B5E82470A" unitRef="usd">12910000</us-gaap:SellingGeneralAndAdministrativeExpense> <us-gaap:OperatingExpenses contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e782-wk-Fact-E06FBEEAA4421CADD0BE9D2B5E98FDFB" unitRef="usd">61018000</us-gaap:OperatingExpenses> <us-gaap:OperatingExpenses contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e801-wk-Fact-3C7D17648A424A988AF39D2B5EA9F4B1" unitRef="usd">36905000</us-gaap:OperatingExpenses> <us-gaap:OperatingIncomeLoss contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e821-wk-Fact-4A778B6E00077BDAD7879D2B5F294512" unitRef="usd">-60960000</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e841-wk-Fact-575870A31ACD2DF5F3109D2B5DA30186" unitRef="usd">-36627000</us-gaap:OperatingIncomeLoss> <us-gaap:InvestmentIncomeNonoperating contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e862-wk-Fact-624FE0EDC18DA1031C389D2B5F232BCE" unitRef="usd">1491000</us-gaap:InvestmentIncomeNonoperating> <us-gaap:InvestmentIncomeNonoperating contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e881-wk-Fact-20CCEA0FA6D9D4DB30099D2B5EA43259" unitRef="usd">1570000</us-gaap:InvestmentIncomeNonoperating> <us-gaap:InterestExpense contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e901-wk-Fact-AB01D538A5914CE6E1309D2B5F0AB7EE" unitRef="usd">2148000</us-gaap:InterestExpense> <us-gaap:InterestExpense contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e921-wk-Fact-526C4B7F0279B99EB1629D2B5E76DFF2" unitRef="usd">0</us-gaap:InterestExpense> <rvnc:GainLossonDerivativeInstrumentsContractNetPretax contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e941-wk-Fact-F3643A11132DF7FB3A3A9D2B5D2FC532" unitRef="usd">-90000</rvnc:GainLossonDerivativeInstrumentsContractNetPretax> <rvnc:GainLossonDerivativeInstrumentsContractNetPretax contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e961-wk-Fact-AF0428AC684B0CA7E3E19D2B5E9ECF40" unitRef="usd">-92000</rvnc:GainLossonDerivativeInstrumentsContractNetPretax> <us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e983-wk-Fact-E54E3FD7518251E668089D2B5DB8D2DC" unitRef="usd">-126000</us-gaap:OtherNonoperatingIncomeExpense> <us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e1003-wk-Fact-40E174470D6A3AC5FC769D2B5F157A14" unitRef="usd">-155000</us-gaap:OtherNonoperatingIncomeExpense> <us-gaap:IncomeLossAttributableToParent contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e1024-wk-Fact-0056394CBAD212A742E59D2B5E7CD264" unitRef="usd">-61833000</us-gaap:IncomeLossAttributableToParent> <us-gaap:IncomeLossAttributableToParent contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e1044-wk-Fact-95C8A11864076B86AEB39D2B5E8C7263" unitRef="usd">-35304000</us-gaap:IncomeLossAttributableToParent> <us-gaap:IncomeTaxExpenseBenefit contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e1065-wk-Fact-7E68F15A42AE4CF082DA9D49454F576B" unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit> <us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e1085-wk-Fact-16C28965C031E0FBC1E89D494575B27B" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit> <us-gaap:NetIncomeLoss contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e1105-wk-Fact-BA1FF15B4CA0DDA458E59D498527475E" unitRef="usd">-61933000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e1125-wk-Fact-35172A14585C522013BE9D49851DE52E" unitRef="usd">-35304000</us-gaap:NetIncomeLoss> <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e1146-wk-Fact-51CF807C0D4E9437C4899D2B5D7F01D8" unitRef="usd">521000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax> <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e1165-wk-Fact-EC44B8822CCFFEDD73069D2B5E3934BF" unitRef="usd">78000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax> <us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e1190-wk-Fact-06C4DC4E1DE75E49F0D19D2B5F10AE7E" unitRef="usd">-61412000</us-gaap:ComprehensiveIncomeNetOfTax> <us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e1210-wk-Fact-F2881B65C6C78A14574A9D2B5F05E091" unitRef="usd">-35226000</us-gaap:ComprehensiveIncomeNetOfTax> <rvnc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="FD2020Q1YTD" decimals="-3" id="d12617460e1231-wk-Fact-CA84447418828AC9EE8B9D2B5E87760B" unitRef="usd">-61933000</rvnc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted> <rvnc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted contextRef="FD2019Q1QTD" decimals="-3" id="d12617460e1251-wk-Fact-E6974548A83F8A77AD879D2B5E48DC80" unitRef="usd">-35304000</rvnc:NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted> <us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2020Q1YTD" decimals="2" id="d12617460e1272-wk-Fact-77FADF0F687D2F1A9F1A9D2B5F1AB050" unitRef="usdPerShare">-1.15</us-gaap:EarningsPerShareBasicAndDiluted> <us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q1QTD" decimals="2" id="d12617460e1292-wk-Fact-14507C35D0DB80F6F08A9D2B5E2AFC0C" unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareBasicAndDiluted> <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2020Q1YTD" decimals="0" id="d12617460e1308-wk-Fact-1F368849E82927FE05C29D2B5E92DCFB" unitRef="shares">53868036</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted> <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q1QTD" decimals="0" id="d12617460e1327-wk-Fact-E34105B5A73060CB08159D2B5E0B22A1" unitRef="shares">41598919</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted> <us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e900-wk-Fact-819C488F63892D235CED9D2BAFC918D8" unitRef="shares">52374735</us-gaap:CommonStockSharesOutstanding> <us-gaap:StockholdersEquity contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="d12632072e914-wk-Fact-00CD0AC75AA83751A4A19D2BB0C764A1" unitRef="usd">52000</us-gaap:StockholdersEquity> <us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e933-wk-Fact-B6683177EDCAEC3145B69D2BB108236F" unitRef="shares">36975203</us-gaap:CommonStockSharesOutstanding> <us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="d12632072e948-wk-Fact-19EEA4D2DC1B2DAAD3539D2BB1FE052F" unitRef="usd">37000</us-gaap:StockholdersEquity> <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e968-wk-Fact-7E3F31BB57ECAAB441C89D8838A5A3C4" unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets> <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="d12632072e982-wk-Fact-F9E76A4B79840E0F3A669D886B183A19" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets> <rvnc:StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e1036-wk-Fact-49906911C7D7579A99029D5997D8DE8C" unitRef="shares">1197054</rvnc:StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased> <rvnc:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="d12632072e1050-wk-Fact-52CBB5A01C4B40B374BE9D59E1AB111E" unitRef="usd">1000</rvnc:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased> <rvnc:StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e1069-wk-Fact-4BD40254436BD41414049D59ADEE8F07" unitRef="shares">323026</rvnc:StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased> <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e1104-wk-Fact-AE52ED6B5C60E4BC486C9D5B18C74BEA" unitRef="shares">975000</us-gaap:StockIssuedDuringPeriodSharesNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="d12632072e1118-wk-Fact-C359DE8DF444E95885F99D5B68EDC2E4" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e1137-wk-Fact-327AAC536E076D096B279D5B33B581B7" unitRef="shares">6764705</us-gaap:StockIssuedDuringPeriodSharesNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="d12632072e1152-wk-Fact-81CA9E04B4135BBA0DA89D5B7B091EE3" unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e1172-wk-Fact-99FE77E900F6A44793D49D5C98EFD6DA" unitRef="shares">52352</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised> <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e1205-wk-Fact-1612B4B52B988478F3709D2BB0E308DC" unitRef="shares">2824</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised> <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e1240-wk-Fact-D89EDB46F80448C5597E9D2BAFA52626" unitRef="shares">72987</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation> <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e1274-wk-Fact-D3EE3F165F3F8CCB26969D2BB12C5125" unitRef="shares">61100</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation> <us-gaap:CommonStockSharesOutstanding contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e1311-wk-Fact-38B77879F60727C890129D5D60612506" unitRef="shares">57026154</us-gaap:CommonStockSharesOutstanding> <us-gaap:StockholdersEquity contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="d12632072e1325-wk-Fact-F2EB1B14E09E6EA448FF9D5D64D66E65" unitRef="usd">57000</us-gaap:StockholdersEquity> <us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12632072e1344-wk-Fact-DE386FE13D851E6AD8EA9D5D69B42B8F" unitRef="shares">44004658</us-gaap:CommonStockSharesOutstanding> <us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="d12632072e1359-wk-Fact-99C8A42A34F8446546779D5D6E9DED79" unitRef="usd">44000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1465-wk-Fact-FF161EA58A16ABBBA7989D5DF626C72D" unitRef="usd">1069639000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1499-wk-Fact-669F69D9004BA69157269D5DFE970D8E" unitRef="usd">830368000</us-gaap:StockholdersEquity> <us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1533-wk-Fact-83411B6EA935B31DFD2D9D9EB3226A55" unitRef="usd">43397000</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets> <rvnc:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1601-wk-Fact-2EC08157E1F34FB2E2429D6523C15E9C" unitRef="usd">-1000</rvnc:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1670-wk-Fact-1C09AEDD2585619EE1D39D2BB0858214" unitRef="usd">15536000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1704-wk-Fact-67BF1BA337255183F8619D2BAFEA014F" unitRef="usd">107572000</us-gaap:StockIssuedDuringPeriodValueNewIssues> <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1738-wk-Fact-04BA1278ED0A372284C29D82A15DDD28" unitRef="usd">572000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised> <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1772-wk-Fact-5CF6D73C1D44EA7BA5BD9D8241E0D5CC" unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised> <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1806-wk-Fact-2590D96076B1D1059BC09D9C70E303F9" unitRef="usd">108510000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1874-wk-Fact-3F88020CCEE2D30200619D8167555CB7" unitRef="usd">6544000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1908-wk-Fact-816323F84A6EDD406CDE9D2BB21BCE87" unitRef="usd">4159000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue> <rvnc:AdjustmentToAdditionalPaidInCapitalCappedCallTransactions contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e1942-wk-Fact-3F1D3388467FFFF34F309D2BAF868AA8" unitRef="usd">28865000</rvnc:AdjustmentToAdditionalPaidInCapitalCappedCallTransactions> <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e2011-wk-Fact-14CBD78598BB57EFE1C59D80DCA0E0B0" unitRef="usd">1401000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation> <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e2046-wk-Fact-1220E1F1C7B6D40983B99D2BB0486136" unitRef="usd">1049000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation> <us-gaap:StockholdersEquity contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e2082-wk-Fact-BF700E18BDF89A18F5B29D2BB026F234" unitRef="usd">1213931000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="d12632072e2116-wk-Fact-619C7DDC250B9097A72C9D2BB258AC1B" unitRef="usd">941068000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="d12632072e2222-wk-Fact-C97500730B161A6BE6679D2BB06759C0" unitRef="usd">3000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="d12632072e2256-wk-Fact-B1D729612F256359CBF99D2BB0A2EE74" unitRef="usd">-8000</us-gaap:StockholdersEquity> <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="d12632072e2291-wk-Fact-60FF3B2A341AEF4C23729D7FC57A4A5B" unitRef="usd">521000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax> <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="d12632072e2325-wk-Fact-2ABEB46FAC958FD186499D7FCCF76B74" unitRef="usd">78000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax> <us-gaap:StockholdersEquity contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="d12632072e2359-wk-Fact-8F9CFAD9E347D394D7689D2BAF60FB72" unitRef="usd">524000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="d12632072e2393-wk-Fact-A1594776776493CB3C149D2BB14E3294" unitRef="usd">70000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="d12632072e2499-wk-Fact-4DD963712F30DA7E81EB9D2BB19D3662" unitRef="usd">-844204000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="d12632072e2534-wk-Fact-3D9F12E28EC4FF3650E29D2BB1BC3358" unitRef="usd">-684775000</us-gaap:StockholdersEquity> <us-gaap:NetIncomeLoss contextRef="FD2020Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="d12632072e2569-wk-Fact-26BE0C98A5F797A7C50C9D7F6EE58782" unitRef="usd">-61933000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="d12632072e2604-wk-Fact-A008AAB8FE0A1F65BDF69D7F75EB1465" unitRef="usd">-35304000</us-gaap:NetIncomeLoss> <us-gaap:StockholdersEquity contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="d12632072e2639-wk-Fact-B5F1E994D276143C32CA9D2BB0094B44" unitRef="usd">-906137000</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="d12632072e2674-wk-Fact-064A0067FEB101B407EC9D2BB17A8511" unitRef="usd">-720079000</us-gaap:StockholdersEquity> <us-gaap:CommonStockSharesOutstanding contextRef="FI2020Q1" decimals="INF" id="d12632072e2695-wk-Fact-8E7D441A11370C62FB5A16CE0BF1355D" unitRef="shares">57026154</us-gaap:CommonStockSharesOutstanding> <us-gaap:StockholdersEquity contextRef="FI2020Q1" decimals="-3" id="d12632072e2714-wk-Fact-03146407C6278DA3AC389D2B33CFFF9F" unitRef="usd">308375000</us-gaap:StockholdersEquity> <us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q1" decimals="INF" id="d12632072e2728-wk-Fact-97DA84E2548A84F96AF59D7EB8CAF2CF" unitRef="shares">44004658</us-gaap:CommonStockSharesOutstanding> <us-gaap:StockholdersEquity contextRef="FI2019Q1" decimals="-3" id="d12632072e2748-wk-Fact-FF74B35BBC8BADA38B919D7EBABEBF0F" unitRef="usd">221103000</us-gaap:StockholdersEquity> <us-gaap:NetIncomeLoss contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e667-wk-Fact-BA1FF15B4CA0DDA458E59D498527475E" unitRef="usd">-61933000</us-gaap:NetIncomeLoss> <us-gaap:NetIncomeLoss contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e687-wk-Fact-35172A14585C522013BE9D49851DE52E" unitRef="usd">-35304000</us-gaap:NetIncomeLoss> <us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e744-wk-Fact-FB69C1D3CB63DCDD18649DFF8FAFCC14" unitRef="usd">11184000</us-gaap:ResearchAndDevelopmentInProcess> <us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e763-wk-Fact-C8F71AADC9C5100F030E9DFF8FAF0087" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess> <us-gaap:ShareBasedCompensation contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e783-wk-Fact-1247425740E361E1AD1E9DFDB3C4BB02" unitRef="usd">6544000</us-gaap:ShareBasedCompensation> <us-gaap:ShareBasedCompensation contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e802-wk-Fact-001FBFFAFB70666038F89DFDB40990E2" unitRef="usd">4159000</us-gaap:ShareBasedCompensation> <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e822-wk-Fact-49FFCE3E3264DCB1B7C99DFEDE224C62" unitRef="usd">1505000</us-gaap:AmortizationOfFinancingCostsAndDiscounts> <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e841-wk-Fact-9D795B8A3A616A92585B9DFEDE22C635" unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts> <us-gaap:DepreciationDepletionAndAmortization contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e861-wk-Fact-3B30301072618322BBD99DFD0B0E4A24" unitRef="usd">739000</us-gaap:DepreciationDepletionAndAmortization> <us-gaap:DepreciationDepletionAndAmortization contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e880-wk-Fact-DEAF29C8252EE6CB45E79DFD0ACE0907" unitRef="usd">628000</us-gaap:DepreciationDepletionAndAmortization> <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e900-wk-Fact-FF0630A6E9116BE72D3B9D2C55E6D12F" unitRef="usd">513000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments> <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e920-wk-Fact-2784E7DA9DF6591C47E89D2C56068253" unitRef="usd">649000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments> <us-gaap:OtherNoncashIncomeExpense contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e941-wk-Fact-342617EE8905DDE0F2849D2C537DFC07" unitRef="usd">-371000</us-gaap:OtherNoncashIncomeExpense> <us-gaap:OtherNoncashIncomeExpense contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e960-wk-Fact-0C9D7650CE5F328ACC059D2C53786D2D" unitRef="usd">-88000</us-gaap:OtherNoncashIncomeExpense> <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1022-wk-Fact-6E2099CF8F0E0CE2C3019D2C5325F207" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable> <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1041-wk-Fact-837DFFAD3BA66B4B6C8B9D2C54550E0A" unitRef="usd">-27000000</us-gaap:IncreaseDecreaseInAccountsReceivable> <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1061-wk-Fact-FABC3AB954F1555C53519D2C531D1941" unitRef="usd">467000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets> <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1081-wk-Fact-39A4EC1C884C2EFBD3FE9D2C5369013A" unitRef="usd">1018000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets> <rvnc:IncreaseDecreaseinOperatingLeaseRightofUseAssets contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1102-wk-Fact-174DF8453F017C00F41E9D2C543998B1" unitRef="usd">-570000</rvnc:IncreaseDecreaseinOperatingLeaseRightofUseAssets> <rvnc:IncreaseDecreaseinOperatingLeaseRightofUseAssets contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1121-wk-Fact-BF278E303F52C4EC802D9D2C54A35AC5" unitRef="usd">3440000</rvnc:IncreaseDecreaseinOperatingLeaseRightofUseAssets> <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1142-wk-Fact-1570CE961E738E47D8339D2C555DAC96" unitRef="usd">-175000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets> <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1161-wk-Fact-E0E2EEA14339B05463899D2C55823170" unitRef="usd">-101000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets> <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1181-wk-Fact-35F70206B6197415127E9D2C5349E9BF" unitRef="usd">789000</us-gaap:IncreaseDecreaseInAccountsPayable> <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1200-wk-Fact-A30D2532045675A533899D2C53AC9A4C" unitRef="usd">-3736000</us-gaap:IncreaseDecreaseInAccountsPayable> <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1221-wk-Fact-4240FCF86EFF7B2149E19D2C539CFA34" unitRef="usd">-2373000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities> <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1241-wk-Fact-BC5BA473BCB2A4C73D769D2C539C2EAC" unitRef="usd">-2298000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities> <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1262-wk-Fact-8C1532DD49772E73B49D9D2C537D086F" unitRef="usd">942000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability> <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1281-wk-Fact-C61386A9C48EAFF31F969D2C552E8B4A" unitRef="usd">-278000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability> <rvnc:IncreaseDecreaseinOperatingLeaseLiabilities contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1302-wk-Fact-B7623A92458D614324C59D2C551196FD" unitRef="usd">-822000</rvnc:IncreaseDecreaseinOperatingLeaseLiabilities> <rvnc:IncreaseDecreaseinOperatingLeaseLiabilities contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1322-wk-Fact-A0046BF9ABCCB4D532069D2C533ADC0E" unitRef="usd">3333000</rvnc:IncreaseDecreaseinOperatingLeaseLiabilities> <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1342-wk-Fact-7BE5A87584B17EC5B5BD9D2C564BD13E" unitRef="usd">-43289000</us-gaap:NetCashProvidedByUsedInOperatingActivities> <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1362-wk-Fact-E60F2E10E0166C3BECFA9D2C54E84BF3" unitRef="usd">-11414000</us-gaap:NetCashProvidedByUsedInOperatingActivities> <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1425-wk-Fact-B5F279E745F78C44E2809D2C55C1CD61" unitRef="usd">159412000</us-gaap:PaymentsToAcquireShortTermInvestments> <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1445-wk-Fact-74D2F20F9999780BFCBA9D2C533A24B8" unitRef="usd">127357000</us-gaap:PaymentsToAcquireShortTermInvestments> <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1466-wk-Fact-757E0EF790E31D396FAF9D2C56347CE4" unitRef="usd">539000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment> <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1486-wk-Fact-96D07C9963A8D39FAD9F9D2C53552000" unitRef="usd">1084000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment> <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1507-wk-Fact-3A1B0226533A0264D07A9E03AD88083B" unitRef="usd">118000</us-gaap:PaymentsToAcquireIntangibleAssets> <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1527-wk-Fact-2B07AF43E61F098C9D099E03AC206615" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets> <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1547-wk-Fact-55490928DF47FDA98B059D2C5362C59E" unitRef="usd">54500000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments> <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1566-wk-Fact-B2CF6EB7F4499FBF71299D2C53BCE26E" unitRef="usd">25000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments> <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1586-wk-Fact-C51E6823204E10B4BB919D2C532A7FC9" unitRef="usd">-105569000</us-gaap:NetCashProvidedByUsedInInvestingActivities> <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1606-wk-Fact-62719852320B910D2A319D2C539C348A" unitRef="usd">-103441000</us-gaap:NetCashProvidedByUsedInInvestingActivities> <us-gaap:ProceedsFromConvertibleDebt contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1668-wk-Fact-0F9BFF570C5C8C4D5DBA9E071C0C8464" unitRef="usd">287500000</us-gaap:ProceedsFromConvertibleDebt> <us-gaap:ProceedsFromConvertibleDebt contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1687-wk-Fact-D07491695423D50C2FDE9E071C3D8B6C" unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt> <rvnc:ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1707-wk-Fact-84A9847AD26A05E452419E04CD49C3BB" unitRef="usd">15581000</rvnc:ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount> <rvnc:ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1726-wk-Fact-6A9B75189FBBD4CA8B079E04CD4978DD" unitRef="usd">108100000</rvnc:ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount> <us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1746-wk-Fact-34E7CCDE114691E14C319D2C53ACF570" unitRef="usd">572000</us-gaap:ProceedsFromStockOptionsExercised> <us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1765-wk-Fact-6D8C9AAB096A85C2CBA99D2C538DA8B3" unitRef="usd">18000</us-gaap:ProceedsFromStockOptionsExercised> <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1785-wk-Fact-745AE0BF7884156D53509E07EDC8AF72" unitRef="usd">28865000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities> <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1805-wk-Fact-A89F160079C1E3D130C59E07EDCF89D8" unitRef="usd">0</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities> <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1825-wk-Fact-8DAACCB91C85E935C94A9E08DA1BC749" unitRef="usd">8703000</us-gaap:PaymentsOfDebtIssuanceCosts> <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1845-wk-Fact-062384438CFB96A63FCA9E08DA21383F" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts> <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1866-wk-Fact-A723554B268E05562C3C9E053E0940D8" unitRef="usd">1401000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation> <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1886-wk-Fact-4306D317BF23E25EBFA79E053E6A3FA4" unitRef="usd">1049000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation> <us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1907-wk-Fact-F02B15D6ECC22AFCD3D89E0598409B37" unitRef="usd">337000</us-gaap:PaymentsOfStockIssuanceCosts> <us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1927-wk-Fact-BF141A2072AB0A1D3E8A9E059849DA4D" unitRef="usd">201000</us-gaap:PaymentsOfStockIssuanceCosts> <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1948-wk-Fact-D9B4001402FB28E945F59D2C55A13D18" unitRef="usd">264347000</us-gaap:NetCashProvidedByUsedInFinancingActivities> <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e1967-wk-Fact-A09BE4FE2F1AEC27FBF49D2C540A6547" unitRef="usd">106868000</us-gaap:NetCashProvidedByUsedInFinancingActivities> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e1987-wk-Fact-AE28771CC74C74E110029D2C53EAA896" unitRef="usd">115489000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e2006-wk-Fact-CF0D88A88373C02CEF9A9D2C5474B82F" unitRef="usd">-7987000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2019Q4" decimals="-3" id="d12621112e2027-wk-Fact-550B619F1133681193EC9D2C564B91C4" unitRef="usd">171890000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="-3" id="d12621112e2046-wk-Fact-6CF2B65BE87F716702369D2C54C91913" unitRef="usd">73986000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2020Q1" decimals="-3" id="d12621112e2071-wk-Fact-FFB1D2C78FFE15CF67F09D2C53713CE4" unitRef="usd">287379000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2019Q1" decimals="-3" id="d12621112e2090-wk-Fact-28AFF7248E8DC3F9C9FE9D2C530C7226" unitRef="usd">65999000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e2151-wk-Fact-E312EDFE4F85BA4651829E101A1165AB" unitRef="usd">43400000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1> <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e2170-wk-Fact-1AE289961BBB76CF97C19E101A1800D6" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1> <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e2190-wk-Fact-7C8E711B7C835C6E6DCB9E0DE717D11D" unitRef="usd">487000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction> <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e2209-wk-Fact-A5B0271DBD69CFCE66189E0DE72F0E0B" unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction> <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e2229-wk-Fact-EB56F84DC0CF679932469E0CC175BD7A" unitRef="usd">247000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1> <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1 contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e2248-wk-Fact-3DCC0246EDDD57137BAF9E0CC175F8D6" unitRef="usd">1108000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1> <rvnc:NoncashDeferredOfferingCosts contextRef="FD2020Q1YTD" decimals="-3" id="d12621112e2268-wk-Fact-4449FC3A57D93B915BD39E0D2565FCBF" unitRef="usd">0</rvnc:NoncashDeferredOfferingCosts> <rvnc:NoncashDeferredOfferingCosts contextRef="FD2019Q1QTD" decimals="-3" id="d12621112e2287-wk-Fact-C91B5BC0D8148484DC889E0D251FB033" unitRef="usd">320000</rvnc:NoncashDeferredOfferingCosts> <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2020Q1YTD" id="TextSelection-C298E355549DB8DDAB7116CE0CFB98F3-0-wk-Fact-E8318E4B1671FE32E81216CE0D0AE048">The Company and Summary of Significant Accounting Policies<div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">The Company</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revance Therapeutics, Inc is a biotechnology company, developing new innovations in neuromodulators for aesthetic and therapeutic indications. Our lead product candidate, DaxibotulinumtoxinA for Injection, combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. We have successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines. In </span><span style="font-family:inherit;font-size:10pt;">November 2019</span><span style="font-family:inherit;font-size:10pt;">, we submitted the Biologics License Application (“BLA”) to the United States (the “U.S.”) Food and Drug Administration (the “FDA”) for DaxibotulinumtoxinA for Injection in the treatment of moderate to severe glabellar (frown) lines. The FDA accepted the BLA on </span><span style="font-family:inherit;font-size:10pt;">February 5, 2020</span><span style="font-family:inherit;font-size:10pt;">, and the Prescription Drug User Fee Act (“PDUFA”) target action date is </span><span style="font-family:inherit;font-size:10pt;">November 25, 2020</span><span style="font-family:inherit;font-size:10pt;">. We are also evaluating DaxibotulinumtoxinA for Injection in upper facial lines - glabellar lines, forehead lines and crow’s feet combined -- as well as in three therapeutic indications -- cervical dystonia, adult upper limb spasticity and plantar fasciitis. Beyond DaxibotulinumtoxinA for Injection, we have begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. In </span><span style="font-family:inherit;font-size:10pt;">January 2020</span><span style="font-family:inherit;font-size:10pt;">, we entered into an exclusive distribution agreement (the “Teoxane Agreement”) with Teoxane SA (“Teoxane”), pursuant to which Teoxane granted us with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid® (RHA®) dermal fillers. We are dedicated to making a difference by transforming patient experiences.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since inception, we have devoted substantially all of our efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, the biosimilar to BOTOX®, and preparing the commercial launch of Teoxane’s line of Resilient Hyaluronic Acid® dermal fillers. We have incurred losses and negative cash flows from operations. We have not generated product revenue to date, and will continue to incur significant research and development and other expenses related to our ongoing operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had a net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$61.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had a working capital surplus of </span><span style="font-family:inherit;font-size:10pt;"><span>$476.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;"><span>$906.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. In recent years, we have funded our operations primarily through a combination of issuance and sale of common stock and issuance of convertible senior notes. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had capital resources of </span><span style="font-family:inherit;font-size:10pt;"><span>$511.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> consisting of cash, cash equivalents, and short-term investments. We believe that our existing capital resources will fund the operating plan through at least the next </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> months following the issuance of this Form 10-Q, and may identify additional capital resources to fund our operations.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated balance sheets for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which was filed with the Securities and Exchange Commission (“SEC”), on </span><span style="font-family:inherit;font-size:10pt;">February 26, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. We operate in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> segment.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Principles of Consolidation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include our accounts and our wholly-owned subsidiaries. All intercompany transactions have been eliminated.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, revenue recognition, deferred revenue classification, accruals including clinical trial costs, stock-based compensation, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration of asset acquisitions, and accounting for income taxes. We base these estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances. The worldwide continued spread of COVID-19 has caused a global slowdown of economic activity which has decreased demand for a broad variety of goods and services, including from our potential customers, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. We are unable to predict the future effect resulting from the COVID-19 pandemic on, for instance, paused clinical trials and revised product launch timing. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intangible Assets</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets acquired in asset acquisition are stated at cost, less accumulated amortization on the condensed consolidated balance sheets, and are amortized on a ratable basis over their useful life. Assets acquired as part of an asset acquisition that are considered to be in-process research and development are immediately expensed unless there is an alternative future use in other research and development projects.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">. The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. We adopted ASU 2018-15 on January 1, 2020 on a prospective basis.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.</span></div></us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock> <us-gaap:NetIncomeLoss contextRef="FD2020Q1YTD" decimals="-5" id="d12621867e550-wk-Fact-BD9BA33525A31E6315269E43D9A21533" unitRef="usd">-61900000</us-gaap:NetIncomeLoss> <rvnc:WorkingCapitalSurplus contextRef="FI2020Q1" decimals="-5" id="d12621867e558-wk-Fact-FE89EF67283137E8FCC59E4406B97DC6" unitRef="usd">476800000</rvnc:WorkingCapitalSurplus> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2020Q1" decimals="-5" id="d12621867e562-wk-Fact-4A1A01DEDE27C4BEB81D9E442713B91C" unitRef="usd">-906100000</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="FI2020Q1" decimals="-5" id="d12621867e571-wk-Fact-FC8BE53F87E73911CBC29E449030FB43" unitRef="usd">511300000</us-gaap:CashCashEquivalentsAndShortTermInvestments> <rvnc:CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum contextRef="FD2020Q1YTD" id="d12621867e575-wk-Fact-FCB6907041EAAFB34D5B9E44B5F3BEF1">P12M</rvnc:CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum> <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2020Q1YTD" id="TextSelection-505A28BB26367AA2FC5516CE0CFB69B5-0-wk-Fact-930468E0F461FB10F87516CE0D0A87A5"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated balance sheets for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which was filed with the Securities and Exchange Commission (“SEC”), on </span><span style="font-family:inherit;font-size:10pt;">February 26, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. We operate in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> segment.</span></div></us-gaap:BasisOfAccountingPolicyPolicyTextBlock> <us-gaap:NumberOfOperatingSegments contextRef="FD2020Q1YTD" decimals="INF" id="d12621867e611-wk-Fact-93A3E1F412D50F927257BA900572F212" unitRef="segment">1</us-gaap:NumberOfOperatingSegments> <us-gaap:ConsolidationPolicyTextBlock contextRef="FD2020Q1YTD" id="TextSelection-B52B571B2F718C993FDA16CE0CFBFD7A-0-wk-Fact-64D1160B755AF36CAF7816CE0D0A7C44"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Principles of Consolidation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include our accounts and our wholly-owned subsidiaries. All intercompany transactions have been eliminated.</span></div></us-gaap:ConsolidationPolicyTextBlock> <us-gaap:UseOfEstimates contextRef="FD2020Q1YTD" id="TextSelection-A0CD9C376DCF4DC758B616CE0CFB738E-0-wk-Fact-D50947ACBBE8F11583F716CE0D0A74B4"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, revenue recognition, deferred revenue classification, accruals including clinical trial costs, stock-based compensation, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration of asset acquisitions, and accounting for income taxes. We base these estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances. The worldwide continued spread of COVID-19 has caused a global slowdown of economic activity which has decreased demand for a broad variety of goods and services, including from our potential customers, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. We are unable to predict the future effect resulting from the COVID-19 pandemic on, for instance, paused clinical trials and revised product launch timing. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.</span></div></us-gaap:UseOfEstimates> <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="FD2020Q1YTD" id="TextSelection-66C1497223B77462043D9E3E8A04BE94-0-wk-Fact-B225DAFAD587D2AC63369E40A8DAA46C"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intangible Assets</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets acquired in asset acquisition are stated at cost, less accumulated amortization on the condensed consolidated balance sheets, and are amortized on a ratable basis over their useful life. Assets acquired as part of an asset acquisition that are considered to be in-process research and development are immediately expensed unless there is an alternative future use in other research and development projects.</span></div></us-gaap:IntangibleAssetsFiniteLivedPolicy> <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2020Q1YTD" id="TextSelection-7F461FF31C464DCE93D316CE0D0AA8D8-0-wk-Fact-850C8E88B088EBFF15B816CE0D0A1810"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">. The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. We adopted ASU 2018-15 on January 1, 2020 on a prospective basis.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.</span></div></us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock> <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2020Q1YTD" id="TextSelection-3047348B0A28FDA0BCDC16CE0D0A5177-0-wk-Fact-7B7BBD5C829620D2BD1916CE0D58622B">Revenue<span style="font-family:inherit;font-size:10pt;font-weight:bold;">    </span><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Mylan Collaboration and License Agreement</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">    </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Agreement Terms</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into a collaboration agreement with Mylan Ireland Limited, a wholly-owned indirect subsidiary of Mylan N.V. (“Mylan”) in February 2018 (the “Mylan Collaboration”), pursuant to which we agreed to collaborate with Mylan exclusively, on a world-wide basis (excluding Japan), to develop, manufacture, and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®. In August 2019, the Mylan Collaboration was amended to, among other things, revise the period of time for Mylan to decide whether to continue the development and commercialization of the biosimilar beyond the initial development plan (the “Continuation Decision”) to be on or before the later of (i) April 30, 2020 or (ii) 30 calendar days from the date that we provide Mylan with certain deliverables. On May 1, 2020, we announced that we are continuing discussions with Mylan regarding whether or not Mylan plans to move forward with the biosimilar program.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Mylan Collaboration, Mylan has paid us an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:10pt;"> in non-refundable upfront fees, and the agreement provides for additional contingent payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate, upon the achievement of specified clinical and regulatory (i.e., a biosimilar biological pathway) milestones and of specified, tiered sales milestones of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$225 million</span></span><span style="font-family:inherit;font-size:10pt;">. The payments do not represent a financing component for the transfer of goods or services. The contingent payments would be payable after the Continuation Decision and upon meeting certain milestones. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. We estimated the transaction price for the Mylan Collaboration using the most likely amount method. In order to determine the transaction price, we evaluated all of the payments to be received during the duration of the contract, which included milestones and consideration payable by Mylan. Other than the upfront payment, all other milestones and consideration we may earn under the Mylan Collaboration are subject to uncertainties related to development achievements, Mylan’s rights to terminate the agreement, and estimated effort for cost-sharing payments. Components of such estimated effort for cost-sharing payments include both internal and external costs. Consequently, the transaction price does not include any milestones and considerations that, if included, could result in a probable significant reversal of revenue when related uncertainties become resolved. Sales-based milestones and royalties are not included in the transaction price until the sales occur because the underlying value relates to the license and the license is the predominant feature in the Mylan Collaboration. We re-evaluate the transaction price at each reporting period.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to the unfulfilled performance obligations is </span><span style="font-family:inherit;font-size:10pt;"><span>$106.8 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue and estimate deferred revenue based on the cost of services incurred over the total estimated cost of services to be provided for the development period. For revenue recognition purposes, the development period is estimated to extend through </span><span style="font-family:inherit;font-size:10pt;">2024</span><span style="font-family:inherit;font-size:10pt;">. It is possible that this period will change and is assessed at each reporting date.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized revenue related to development services of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we estimated short-term deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively; and long-term deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$18.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fosun License Agreement </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Agreement Terms</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">December 2018</span><span style="font-family:inherit;font-size:10pt;">, we entered into a license agreement (the “Fosun License Agreement”) with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”), whereby we have granted Fosun the exclusive rights to develop and commercialize our proprietary DaxibotulinumtoxinA for Injection in mainland China, Hong Kong and Macau (the “Fosun Territory”) and certain sublicense rights.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Fosun License Agreement, in </span><span style="font-family:inherit;font-size:10pt;">January 2019</span><span style="font-family:inherit;font-size:10pt;"> we received a non-refundable upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of foreign withholding tax of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. We are also eligible to receive (i) additional contingent payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$230.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of specified milestones based on (a) the submission and approval of biologics license applications (“BLAs”) for certain aesthetic and therapeutic indications and (b) first calendar year net sales, and (ii) tiered royalty payments in low double digit to high teen percentages on annual net sales. The royalty percentages are subject to reduction in the event that (i) we do not have any valid and unexpired patent claims that cover the product in the Fosun Territory, (ii) biosimilars of the product are sold in the Fosun Territory or (iii) Fosun needs to pay compensation to third parties to either avoid patent infringement or market the product in the Fosun Territory. In </span><span style="font-family:inherit;font-size:10pt;">March 2020</span><span style="font-family:inherit;font-size:10pt;">, we received from Fosun a milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, before foreign withholding tax of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, for the acceptance of the BLA submission to the FDA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimated the transaction price for the Fosun License Agreement using the most likely amount method. We evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered. We will re-evaluate the transaction price at each reporting period and upon a change in circumstances. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to unfulfilled performance obligation is </span><span style="font-family:inherit;font-size:10pt;"><span>$31.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> revenue has been recognized from the Fosun License Agreement for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Substantially all payments received to date were included in long-term deferred revenue as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div></us-gaap:CollaborativeArrangementDisclosureTextBlock> <us-gaap:ContractWithCustomerLiability contextRef="I2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember" decimals="-6" id="d12614521e530-wk-Fact-99E1FC9BC965D91FC5AB9E5649A133B2" unitRef="usd">30000000</us-gaap:ContractWithCustomerLiability> <rvnc:ContingentLicensingRoyaltyRevenue contextRef="I2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember" decimals="INF" id="d12614521e534-wk-Fact-63343EFA6DFAD637E8AD9E5674F3B5A2" unitRef="usd">100000000</rvnc:ContingentLicensingRoyaltyRevenue> <rvnc:RevenueRecognitionMilestoneMethodMaximumRevenue contextRef="D2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember" decimals="INF" id="d12614521e538-wk-Fact-327FB26BBED14B1E15549E56A041864C" unitRef="usd">225000000</rvnc:RevenueRecognitionMilestoneMethodMaximumRevenue> <us-gaap:RevenueRemainingPerformanceObligation contextRef="FI2020Q1_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember" decimals="-5" id="d12614521e556-wk-Fact-42410B1C4A4BA2954A749E5707CD7CCE" unitRef="usd">106800000</us-gaap:RevenueRemainingPerformanceObligation> <us-gaap:Revenues contextRef="FD2020Q1YTD_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" decimals="-5" id="d12614521e578-wk-Fact-6D828E08D1BE8E3B4E8C9E5766999BA3" unitRef="usd">100000</us-gaap:Revenues> <us-gaap:Revenues contextRef="FD2019Q1YTD_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" decimals="-5" id="d12614521e582-wk-Fact-E28C1E5136900260ECAC9E5774C15F6B" unitRef="usd">300000</us-gaap:Revenues> <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="FI2020Q1_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" decimals="-5" id="d12614521e595-wk-Fact-6B056765F8066E6CEFA89E57AB42B5DB" unitRef="usd">10100000</us-gaap:ContractWithCustomerLiabilityCurrent> <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="FI2019Q4_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" decimals="-5" id="d12614521e599-wk-Fact-1D6B0DAE2D0C963959F69E57AA08437D" unitRef="usd">7900000</us-gaap:ContractWithCustomerLiabilityCurrent> <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="FI2020Q1_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" decimals="-5" id="d12614521e603-wk-Fact-A1E2C4AC85D049D320D59E57CF543FA0" unitRef="usd">15700000</us-gaap:ContractWithCustomerLiabilityNoncurrent> <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="FI2019Q4_srt_ProductOrServiceAxis_rvnc_DevelopmentServicesMember" decimals="-5" id="d12614521e607-wk-Fact-4CBF9F24FC39579489C69E57CE29C1AA" unitRef="usd">18000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent> <us-gaap:ContractWithCustomerAssetGross contextRef="I2019Q1Jan31_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" decimals="-5" id="d12614521e632-wk-Fact-73E17E0CE6933B029D4E9E589EAF1EAF" unitRef="usd">30000000.0</us-gaap:ContractWithCustomerAssetGross> <rvnc:ForeignWithholdingTaxAmount contextRef="D2019Q1Jan_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" decimals="-5" id="d12614521e636-wk-Fact-5A1424060256C3DFF77D9E58F7152DF0" unitRef="usd">3000000.0</rvnc:ForeignWithholdingTaxAmount> <rvnc:ContingentLicensingRoyaltyRevenue contextRef="I2019Q1Jan31_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" decimals="-5" id="d12614521e640-wk-Fact-1A8D5070A3D63FA75CCF9E592FAB5F56" unitRef="usd">230500000</rvnc:ContingentLicensingRoyaltyRevenue> <us-gaap:ContractWithCustomerAssetGross contextRef="FI2020Q1_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" decimals="-5" id="d12614521e649-wk-Fact-94C7169D6B95E75129309E59DC4023AE" unitRef="usd">1000000.0</us-gaap:ContractWithCustomerAssetGross> <rvnc:ForeignWithholdingTaxAmount contextRef="D2020Q1Mar31_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" decimals="-5" id="d12614521e653-wk-Fact-9F0DD46BF769F09186EB9E5A394A55F1" unitRef="usd">100000</rvnc:ForeignWithholdingTaxAmount> <us-gaap:RevenueRemainingPerformanceObligation contextRef="FI2020Q1" decimals="-5" id="d12614521e667-wk-Fact-B7AA8AF59A61402640979E5B17569CBC" unitRef="usd">31000000.0</us-gaap:RevenueRemainingPerformanceObligation> <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="FD2020Q1YTD_srt_CounterpartyNameAxis_rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member" decimals="INF" id="d12614521e673-wk-Fact-D812FF950FD9037E09C316CE0D58CF61" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized> <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="FD2020Q1YTD" id="TextSelection-22A4B373D1FB4888805216CE0D7851A5-0-wk-Fact-D806EA252BC9E0B8196916CE0D78417B">Cash Equivalents and Short-Term Investments<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our cash equivalents and short-term investments consist of money market funds, U.S. treasury securities, U.S. government agency obligations, commercial paper, and overnight repurchase agreements which are classified as available-for-sale securities.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of amortized cost, unrealized gains and losses, and fair value of our cash equivalents and short-term investments: </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in thousands</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,349</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,634</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Classified as:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>285,012</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224,621</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> other-than-temporary impairments on our available-for-sale securities and the contractual maturities of the available-for-sale securities are less than one-year.</span></div></us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock> <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="FD2020Q1YTD" id="TextSelection-EAD93BF74717DB7B608016CE0D78E0FA-0-wk-Fact-AD32E28F2A4ADE9C9B0F16CE0D78090F"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of amortized cost, unrealized gains and losses, and fair value of our cash equivalents and short-term investments: </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in thousands</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,349</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,634</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Classified as:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>285,012</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224,621</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12623856e1009-wk-Fact-FFB31A55EA10CDE179C69D30CD4B5B9F" unitRef="usd">179031000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12623856e1028-wk-Fact-FD430ABFE92FADD7A9719D30CDAF49C8" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12623856e1047-wk-Fact-DD365295C87A8795377E9D30CB1025C2" unitRef="usd">179031000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12623856e1067-wk-Fact-3932BB558B4070C6E1069D30CBC9031A" unitRef="usd">136258000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12623856e1086-wk-Fact-0F663FC0F244AA8142349D30CD79D798" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12623856e1106-wk-Fact-250EF027CB9912B10D4C9D30CD4B48F5" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12623856e1125-wk-Fact-54F9F0B3D7F36C750F009D30CC3D978C" unitRef="usd">136258000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12623856e1140-wk-Fact-03CA9651B8ECE6BD29B19D30CA74F25E" unitRef="usd">30124000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12623856e1159-wk-Fact-4EA91C5FC5FDC6B2B1B79D30CC1E1EAA" unitRef="usd">182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12623856e1178-wk-Fact-F1078035D5D0223C443C9D30CC9289ED" unitRef="usd">30306000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12623856e1198-wk-Fact-EF784C52EAF02D67A5EA9D30CD4BF645" unitRef="usd">48349000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12623856e1217-wk-Fact-90302ACF4C35CAC011759D30CCB18B64" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12623856e1236-wk-Fact-4C94B2BAF862D410AEF19D30CDAF9EF6" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12623856e1256-wk-Fact-0A3436B45647749A81499D30CD8947B1" unitRef="usd">48355000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12623856e1276-wk-Fact-6F715F8533553B3AADAA9D30CD3AE713" unitRef="usd">159634000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12623856e1295-wk-Fact-879D06353CAE073629FA9D30CD6AEA92" unitRef="usd">342000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12623856e1314-wk-Fact-899CCF1AA6CADF7906089D30C9ED30B2" unitRef="usd">159976000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12623856e1334-wk-Fact-EA18974E3B97E71E7C1C9D30CCB1B91B" unitRef="usd">5993000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12623856e1353-wk-Fact-DD4156458377701D7C9A9D30CD79179D" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12623856e1372-wk-Fact-CAAA7C63C4EE96F4630F9D30CD792947" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12623856e1393-wk-Fact-3FCA806ED77454B8C3C99D30CDDE8001" unitRef="usd">5990000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12623856e1413-wk-Fact-EC435AC05356F7D549CC9D30CD89F579" unitRef="usd">140320000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12623856e1432-wk-Fact-4E73A6F63CCD43B9A0DF9D30CDAF81B1" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12623856e1451-wk-Fact-C81D91659EDCF91B9E1B9D30CD8987F5" unitRef="usd">140320000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12623856e1471-wk-Fact-738B5276F80871782E419D30CD99978E" unitRef="usd">77082000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12623856e1490-wk-Fact-6CD35A362B548F0AB71E9D30CBE8A323" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12623856e1509-wk-Fact-0176C9FA0BA9EA38A12A9D30CA4800CC" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12623856e1529-wk-Fact-4E810B8019B5126551DF9D30CDBF430C" unitRef="usd">77082000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" decimals="-3" id="d12623856e1549-wk-Fact-9179FC695248AC2561A19D30CDA90241" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" decimals="-3" id="d12623856e1568-wk-Fact-08B016E0C7565DD89F249D30CB94B719" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" decimals="-3" id="d12623856e1587-wk-Fact-3F9F723AD4EF61E4330B9D30CB4968A5" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" decimals="-3" id="d12623856e1607-wk-Fact-C7CAE9143205EB1A40E39D30CD3D1A0C" unitRef="usd">15001000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" decimals="-3" id="d12623856e1626-wk-Fact-53AD56CF7E944F7649FC9D30CD5AD968" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" decimals="-3" id="d12623856e1645-wk-Fact-EB20E90A961F89894D219D30CA924A82" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_RepurchaseAgreementsMember" decimals="-3" id="d12623856e1665-wk-Fact-0001BC41D6882527B4B79D30CA1C8BAD" unitRef="usd">15001000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2020Q1" decimals="-3" id="d12623856e1690-wk-Fact-447F3A920DD607886B409D30CCB1A464" unitRef="usd">509109000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2020Q1" decimals="-3" id="d12623856e1709-wk-Fact-0183717938DD5382242A9D30CCC0DFD1" unitRef="usd">524000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2020Q1" decimals="-3" id="d12623856e1728-wk-Fact-9312ED530FEEC6AD559D9D30CDCE112D" unitRef="usd">509633000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q4" decimals="-3" id="d12623856e1748-wk-Fact-33086F7A2CC576592D159D30CCC0322C" unitRef="usd">282683000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q4" decimals="-3" id="d12623856e1767-wk-Fact-308D857D5B258F9D44039D30CDBF8021" unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax> <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q4" decimals="-3" id="d12623856e1787-wk-Fact-FC97D6DAD82AF266E6289D30CC6C0DAB" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q4" decimals="-3" id="d12623856e1807-wk-Fact-326E9D25EE9237B3C03B9D30CD5A7E0C" unitRef="usd">282686000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" decimals="-3" id="d12623856e2154-wk-Fact-82671B996D089C9BD16E9D30CAC17CB6" unitRef="usd">285012000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_CashEquivalentsMember" decimals="-3" id="d12623856e2235-wk-Fact-008954EC1DB1335B913A9D30CD3D4758" unitRef="usd">163731000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2020Q1_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember" decimals="-3" id="d12623856e2290-wk-Fact-F723E23343663F8B48EB9D30CD9907B1" unitRef="usd">224621000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember" decimals="-3" id="d12623856e2371-wk-Fact-0F36F04FBC808E0B463C9D30CDBF6634" unitRef="usd">118955000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2020Q1" decimals="-3" id="d12623856e2436-wk-Fact-9312ED530FEEC6AD559D9D30CDCE112D" unitRef="usd">509633000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q4" decimals="-3" id="d12623856e2517-wk-Fact-326E9D25EE9237B3C03B9D30CD5A7E0C" unitRef="usd">282686000</us-gaap:AvailableForSaleSecuritiesDebtSecurities> <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale contextRef="FD2020Q1YTD" decimals="INF" id="d12623856e2548-wk-Fact-E8EACEF8AFD2F1B3626816CE0D785A65" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale> <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="FD2020Q1YTD" id="TextSelection-6052ADBFACB5707F72639FEE1B9C0D65-0-wk-Fact-EBDE311A0A60695AC98C9FF146E35ACB"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, we entered into an exclusive distribution agreement (the “Teoxane Agreement”) with Teoxane SA (“Teoxane”), pursuant to which Teoxane granted us with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid® (“RHA®”) dermal fillers in exchange for </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock and certain other commitments by us. The Teoxane Agreement includes rights to i) RHA® 2, RHA® 3 and RHA® 4 which have been approved by the FDA for the correction of moderate to severe dynamic facial wrinkles and folds, including RHA® 2, RHA® 3 and RHA® 4 in the currently approved indications, ii) RHA® 1, which is currently in clinical trials for the treatment of perioral rhytids , and iii) future hyaluronic acid filler advancements and products by Teoxane (collectively the “</span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">”) in the U.S. and U.S. territories and possessions. The Teoxane Agreement will be effective for a term of </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> upon product launch and may be extended for a two-year period upon the mutual agreement of the parties. We are required to meet certain minimum purchase obligations and certain minimum expenditure requirements, which are discussed in </span><a href="#s432F768E2BFB1A06A47A16CE0E304583" style="font-family:inherit;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Note 10</span></a><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If Teoxane pursues regulatory approval for RHA® dermal fillers for certain new indications or filler technologies, including innovations with respect to existing products in the U.S., we will be subject to certain specified cost-sharing arrangements for third party expenses incurred in achieving regulatory approval for such products. We will also have a right of first negotiation with respect to any cosmeceutical products that Teoxane wishes to distribute in the U.S, and Teoxane will have a right of first negotiation in connection with the distribution of DaxibotulinumtoxinA for Injection for aesthetic use, outside the U.S. and U.S. territories where Teoxane has an affiliate. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Teoxane Agreement is accounted for as an asset acquisition for the distribution rights of various approved and unapproved products and indications. The aggregate purchase consideration for the distribution rights is </span><span style="font-family:inherit;font-size:10pt;"><span>$43.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, consisting of the fair value of the </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares transferred to Teoxane and transaction costs. The purchase consideration is allocated to the underlying groups of approved and unapproved products based on their relative fair values, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$11.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> is allocated to certain unapproved products and future innovations, or in-process research and development assets, and is recognized as research and development expense on the condensed consolidated statements of operations and comprehensive loss. The remaining purchase consideration is allocated to the currently approved products and indications, and is recognized as an intangible asset on the condensed consolidated balance sheets. The intangible asset will be amortized over approximately </span><span style="font-family:inherit;font-size:10pt;"><span>4</span></span><span style="font-family:inherit;font-size:10pt;"> years commencing upon the first delivery of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> products from Teoxane. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarized the distribution rights:</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Initial Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution rights to approved products and indications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:IntangibleAssetsDisclosureTextBlock> <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" decimals="INF" id="d12615753e514-wk-Fact-B032CD16EFBCDE9244219E658E198858" unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets> <rvnc:CollaborativeAgreementContractualPeriod contextRef="FD2020Q1YTD_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" id="d12615753e522-wk-Fact-78A21240FB2EF83546569FF22C5D0437">P10Y</rvnc:CollaborativeAgreementContractualPeriod> <us-gaap:FairValueOfAssetsAcquired contextRef="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" decimals="-5" id="d12615753e537-wk-Fact-343DECDAD40A7C6A21FDE6343A734581" unitRef="usd">43500000</us-gaap:FairValueOfAssetsAcquired> <us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" decimals="INF" id="d12615753e541-wk-Fact-B032CD16EFBCDE9244219E658E198858" unitRef="shares">2500000</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets> <us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2020Q1YTD" decimals="-5" id="d12615753e545-wk-Fact-F855C0214C7681DFAB0FE63050E7F37D" unitRef="usd">11200000</us-gaap:ResearchAndDevelopmentInProcess> <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" id="d12615753e549-wk-Fact-5B212957A92B24563871C3EA30898EFC">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife> <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="FD2020Q1YTD" id="TextSelection-24CE1801B0E9033C4831BA7837866DF3-0-wk-Fact-6D386B417D63DB0E205BBA78D50F08BC"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarized the distribution rights:</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Initial Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution rights to approved products and indications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock> <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-3" id="d12615753e718-wk-Fact-ACB6702638F0C7994848E62E1D5FC220" unitRef="usd">32334000</us-gaap:FiniteLivedIntangibleAssetsGross> <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-3" id="d12615753e737-wk-Fact-D4BF49E05573B7D002D0E62E1D03BC75" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization> <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2020Q1_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-3" id="d12615753e756-wk-Fact-B980316ACCA2C4FD0580E62E1D08A987" unitRef="usd">32334000</us-gaap:IntangibleAssetsNetExcludingGoodwill> <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="FD2020Q1YTD" id="TextSelection-DBB7AE9B3B5BB192D6629E96C94D1407-0-wk-Fact-3660FD0AD501CD8DB01E9E96ECB667B2">Derivative Liability<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2012, we entered into a settlement agreement in which we are obligated to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon achieving regulatory approval for DaxibotulinumtoxinA for Injection or DaxibotulinumtoxinA Topical. We determined that such payment was a derivative instrument that requires fair value accounting as a liability and periodic fair value remeasurements until settled. The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the derivative liability was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span>0.7 years</span></span><span style="font-family:inherit;font-size:10pt;"> based on an expected BLA approval in 2020, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>0.2%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>7.5%</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the derivative liability was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span>0.9 years</span></span><span style="font-family:inherit;font-size:10pt;"> based on an expected BLA approval in 2020, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.6%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>7.5%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock> <rvnc:AccruedMilestoneObligations contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_ValeantPharmaceuticalsInternationalInc.Member" decimals="-5" id="d12624158e522-wk-Fact-090E38245355008D64549E9792716AFF" unitRef="usd">4000000.0</rvnc:AccruedMilestoneObligations> <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" decimals="-5" id="d12624158e533-wk-Fact-E7CA653557F6B1486C1F9E97D3A21ED5" unitRef="usd">3000000.0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue> <rvnc:FairValueMeasurementInputDuration contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" id="d12624158e537-wk-Fact-4777EACBEA7472881A1C9E9849590818">P0Y8M12D</rvnc:FairValueMeasurementInputDuration> <rvnc:FairValueMeasurementInput contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" decimals="3" id="d12624158e541-wk-Fact-6EE1F7A3AE3F6E8E93949E982A34735E" unitRef="number">0.002</rvnc:FairValueMeasurementInput> <rvnc:FairValueMeasurementInput contextRef="FD2020Q1YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputEntityCreditRiskMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" decimals="3" id="d12624158e545-wk-Fact-12C3D16241CB34166DF89E9876FF250C" unitRef="number">0.075</rvnc:FairValueMeasurementInput> <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" decimals="-5" id="d12624158e554-wk-Fact-0B3405EC7B57EDA11A5A9E989A2B438E" unitRef="usd">3000000.0</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue> <rvnc:FairValueMeasurementInputDuration contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" id="d12624158e558-wk-Fact-E2027A98E09CAD8F6D299E98BBB29F5F">P0Y10M24D</rvnc:FairValueMeasurementInputDuration> <rvnc:FairValueMeasurementInput contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" decimals="3" id="d12624158e562-wk-Fact-23240068438ECD436E4F9E98DC86BBB5" unitRef="number">0.016</rvnc:FairValueMeasurementInput> <rvnc:FairValueMeasurementInput contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputEntityCreditRiskMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember" decimals="3" id="d12624158e566-wk-Fact-B30A08C89656696916C19E98FCF972BD" unitRef="number">0.075</rvnc:FairValueMeasurementInput> <us-gaap:LesseeOperatingLeasesTextBlock contextRef="FD2020Q1YTD" id="TextSelection-54BF64622D00411197BD16CE0E1A6FC0-0-wk-Fact-9CD3E937AF03654ACE6216CE0E1DCD47">Leases<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have non-cancelable operating leases for facilities for research, manufacturing, and administrative functions, and equipment operating leases. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the weighted average remaining lease term is </span><span style="font-family:inherit;font-size:10pt;"><span>6.8 years</span></span><span style="font-family:inherit;font-size:10pt;">. The monthly payments for the facility lease escalate over the facility lease term with the exception of a decrease in payments at the beginning of </span><span style="font-family:inherit;font-size:10pt;">2022</span><span style="font-family:inherit;font-size:10pt;">. We have options to extend the facility operating leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>14.0 years</span></span><span style="font-family:inherit;font-size:10pt;">. Our lease contracts do not contain termination options, residual value guarantees or restrictive covenants. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating lease costs are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, maturities of the Company’s operating lease liabilities are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 remaining nine months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,057</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,557</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,979</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,462</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of operating lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,517</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Our lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of </span><span style="font-family:inherit;font-size:8pt;"><span>12.0%</span></span><span style="font-family:inherit;font-size:8pt;">, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to the operating leases was as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:LesseeOperatingLeasesTextBlock> <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="FI2020Q1" id="d12628723e521-wk-Fact-DE284517372B320E72569E9BD4EDF3CC">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1> <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="FI2020Q1" id="d12628723e529-wk-Fact-75C7BDF5B93E00E0C23D9E9BF8CA4C04">P14Y</us-gaap:LesseeOperatingLeaseRenewalTerm> <us-gaap:LeaseCostTableTextBlock contextRef="FD2020Q1YTD" id="TextSelection-1E961174C9F6342BC47616CE0E1A5C12-0-wk-Fact-73DE5DB974D89088AFAD16CE0E1DC92C"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating lease costs are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.</span></div></us-gaap:LeaseCostTableTextBlock> <us-gaap:OperatingLeaseCost contextRef="FD2020Q1YTD" decimals="-3" id="d12628723e649-wk-Fact-23299672053195705A3B9D3180737FCF" unitRef="usd">1425000</us-gaap:OperatingLeaseCost> <us-gaap:OperatingLeaseCost contextRef="FD2019Q1QTD" decimals="-3" id="d12628723e668-wk-Fact-512CFAC19744E643217F9E9B2FEF99FC" unitRef="usd">1343000</us-gaap:OperatingLeaseCost> <us-gaap:VariableLeaseCost contextRef="FD2020Q1YTD" decimals="-3" id="d12628723e685-wk-Fact-9E5394E019F3046DE0399D318093B095" unitRef="usd">77000</us-gaap:VariableLeaseCost> <us-gaap:VariableLeaseCost contextRef="FD2019Q1QTD" decimals="-3" id="d12628723e704-wk-Fact-FE02A81E6B511386D1599E9B316B2121" unitRef="usd">290000</us-gaap:VariableLeaseCost> <us-gaap:LeaseCost contextRef="FD2020Q1YTD" decimals="-3" id="d12628723e729-wk-Fact-422A34712A518B8ECB859D31803EB564" unitRef="usd">1502000</us-gaap:LeaseCost> <us-gaap:LeaseCost contextRef="FD2019Q1QTD" decimals="-3" id="d12628723e748-wk-Fact-EB3217D241219E39E42F9E9B32C24186" unitRef="usd">1633000</us-gaap:LeaseCost> <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="FD2020Q1YTD" id="TextSelection-48668C1DA0985CBE1F8416CE0E196C78-0-wk-Fact-E48CD374D4FCAB4A7E3A16CE0E1EDE47"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, maturities of the Company’s operating lease liabilities are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 remaining nine months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,057</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,557</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,979</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,462</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of operating lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,517</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Our lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of </span><span style="font-family:inherit;font-size:8pt;"><span>12.0%</span></span><span style="font-family:inherit;font-size:8pt;">, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates. </span></div></td></tr></table></us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="FI2020Q1" decimals="-3" id="d12628723e820-wk-Fact-D32A358D6DB835AEF0AE9D318669F354" unitRef="usd">5057000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="FI2020Q1" decimals="-3" id="d12628723e835-wk-Fact-B504E5622E380FF7E2DF9D31868B41A5" unitRef="usd">6942000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="FI2020Q1" decimals="-3" id="d12628723e855-wk-Fact-8FA5371A4CA2A94266AB9D318734F97E" unitRef="usd">5464000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="FI2020Q1" decimals="-3" id="d12628723e875-wk-Fact-228F8F67A22CA4AE5ADA9D3186BDA90C" unitRef="usd">5557000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="FI2020Q1" decimals="-3" id="d12628723e895-wk-Fact-5E0DB9B5B6E6418A86AD9D31873A59BB" unitRef="usd">5733000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="FI2020Q1" decimals="-3" id="d12628723e915-wk-Fact-D8494842D1DA9AA7873C9D3187129DE0" unitRef="usd">12226000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive> <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="FI2020Q1" decimals="-3" id="d12628723e935-wk-Fact-E5DCA83B7CE43869A2A79D318606C912" unitRef="usd">40979000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue> <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="FI2020Q1" decimals="-3" id="d12628723e957-wk-Fact-E3D199DA0528E07151829D31863FA9B0" unitRef="usd">12462000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount> <us-gaap:OperatingLeaseLiability contextRef="FI2020Q1" decimals="-3" id="d12628723e983-wk-Fact-DE6085B67AC6543639279D3186E8BA11" unitRef="usd">28517000</us-gaap:OperatingLeaseLiability> <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="FI2020Q1" decimals="3" id="d12628723e996-wk-Fact-293A8C95C7B0647F0E3B9E9F8EEA6F9D" unitRef="number">0.120</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent> <rvnc:LesseeSupplementalCashFlowInformationTableTextBlock contextRef="FD2020Q1YTD" id="TextSelection-73354E9BDC2F05107A6716CE0E198E13-0-wk-Fact-E68EB0C234B78133D34216CE0E1D9465"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to the operating leases was as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></rvnc:LesseeSupplementalCashFlowInformationTableTextBlock> <us-gaap:OperatingLeasePayments contextRef="FD2020Q1YTD" decimals="-3" id="d12628723e1119-wk-Fact-1C7591458A98BC8A667B9D318B437982" unitRef="usd">1677000</us-gaap:OperatingLeasePayments> <us-gaap:OperatingLeasePayments contextRef="FD2019Q1QTD" decimals="-3" id="d12628723e1138-wk-Fact-CF56CEF32AF221C1790B9E9E55AD0A22" unitRef="usd">1450000</us-gaap:OperatingLeasePayments> <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2020Q1YTD" decimals="-3" id="d12628723e1158-wk-Fact-969EDEAA2E15E5A9547B9D318B4AD8F8" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability> <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2019Q1QTD" decimals="-3" id="d12628723e1177-wk-Fact-04188F6EE348A2C80AD69E9E57F58E88" unitRef="usd">3890000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability> <us-gaap:LongTermDebtTextBlock contextRef="FD2020Q1YTD" id="TextSelection-38233C4932C9AD308CDCBA14EA194951-0-wk-Fact-DBCCBDB2F3D9F7B5AA07BA163DCB335F">Convertible Senior Notes<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">February 14, 2020</span><span style="font-family:inherit;font-size:10pt;">, we issued convertible senior notes that are due in 2027 (the “</span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">”) with an aggregate principal balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$287.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, pursuant to an indenture, dated </span><span style="font-family:inherit;font-size:10pt;">February 14, 2020</span><span style="font-family:inherit;font-size:10pt;">, between Revance and U.S. Bank National Association, as trustee (the “Indenture”). The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> are senior unsecured obligations and bear interest at a rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> per year, payable semiannually in arrears on </span><span style="font-family:inherit;font-size:10pt;">February 15</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August 15</span><span style="font-family:inherit;font-size:10pt;"> of each year, beginning on </span><span style="font-family:inherit;font-size:10pt;">August 15, 2020</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> will mature on </span><span style="font-family:inherit;font-size:10pt;">February 15, 2027</span><span style="font-family:inherit;font-size:10pt;">, unless earlier converted, redeemed or repurchased. In connection with issuing the 2027 Notes, we received </span><span style="font-family:inherit;font-size:10pt;"><span>$278.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net proceeds, after deducting the initial purchasers’ discount, commissions, and other issuance costs. A portion of the net proceeds from the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> were used to purchase the capped call transactions described below and the remainder will be used to fund expenses associated with commercial launch activities for both the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and, if approved, DaxibotulinumtoxinA for Injection for glabellar lines, research and development, and other corporate activities.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> may be converted at any time by the holders prior to the close of business on the business day immediately preceding </span><span style="font-family:inherit;font-size:10pt;">November 15, 2026</span><span style="font-family:inherit;font-size:10pt;"> only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending on </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> (and only during such fiscal quarter), if the last reported sale price of our common stock for at least </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during a period of </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day; (2) during the </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> business day period after any </span><span style="font-family:inherit;font-size:10pt;"><span>ten</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> for each trading day of the measurement period was less than </span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after </span><span style="font-family:inherit;font-size:10pt;">November 15, 2026</span><span style="font-family:inherit;font-size:10pt;"> until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> at any time, regardless of the foregoing circumstances. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The conversion rate will initially be </span><span style="font-family:inherit;font-size:10pt;">30.8804</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock per </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$32.38</span></span><span style="font-family:inherit;font-size:10pt;"> per share of our common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or if we deliver a notice of redemption, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> in connection with such a corporate event or notice of redemption, as the case may be.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not redeem the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> prior to </span><span style="font-family:inherit;font-size:10pt;">February 20, 2024</span><span style="font-family:inherit;font-size:10pt;">. We may redeem for cash all or any portion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, at our option, on or after </span><span style="font-family:inherit;font-size:10pt;">February 20, 2024</span><span style="font-family:inherit;font-size:10pt;"> if the last reported sale price of our common stock has been at least </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price then in effect for at least </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during any </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#212529;">If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their 2027 Notes at a fundamental change repurchase price equal to </span><span style="font-family:inherit;font-size:10pt;color:#212529;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;color:#212529;"> of the principal amount of the 2027 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accounting for the issuance of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, we separated the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> into liability and equity components. The carrying amount of the liability component was </span><span style="font-family:inherit;font-size:10pt;"><span>$175.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was calculated by using a discount rate of </span><span style="font-family:inherit;font-size:10pt;"><span>9.5%</span></span><span style="font-family:inherit;font-size:10pt;">, which was estimated to be our borrowing rate on the issuance date for a similar debt instrument without the conversion feature. The carrying amount of the equity component was </span><span style="font-family:inherit;font-size:10pt;"><span>$112.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, which represents the conversion option, and was determined by deducting the fair value of the liability component from the par value of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. The equity component of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> is included in additional paid-in capital in the condensed consolidated balance sheets and will not be subsequently remeasured as long as it continues to meet the conditions for equity classification. The difference between the principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> and the liability component (the “debt discount”) is amortized to interest expense in the condensed consolidated statements of operations and comprehensive loss using the effective interest method over the term of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total transaction costs for the issuance of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$9.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, consisting of initial purchasers’ discount, commissions, and other issuance costs. We allocated the total transaction costs proportionally to the liability and equity components. The transaction costs attributed to the liability component were </span><span style="font-family:inherit;font-size:10pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, which were recorded as debt issuance costs (presented as contra debt in our condensed consolidated balance sheets) and are amortized to interest expense in the condensed consolidated statements of operations and comprehensive loss over the term of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. The transaction costs attributed to the equity component were </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, which were included in additional paid-in capital.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense relating to the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> in the condensed consolidated statements of operations and comprehensive loss are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>643</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,461</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate on the liability component of the </span><span style="font-family:inherit;font-size:8pt;">2027 Notes</span><span style="font-family:inherit;font-size:8pt;"> was </span><span style="font-family:inherit;font-size:8pt;"><span>9.5%</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, which remained unchanged from the issuance date. As of </span><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, the unamortized debt discount was </span><span style="font-family:inherit;font-size:8pt;"><span>$110.6 million</span></span><span style="font-family:inherit;font-size:8pt;">, and will be amortized over </span><span style="font-family:inherit;font-size:8pt;"><span>6.9</span></span><span style="font-family:inherit;font-size:8pt;"> years.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, the unamortized debt issuance cost for the </span><span style="font-family:inherit;font-size:8pt;">2027 Notes</span><span style="font-family:inherit;font-size:8pt;"> was </span><span style="font-family:inherit;font-size:8pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:8pt;"> on the condensed consolidated balance sheets.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the convertible senior notes on the condensed consolidated balance sheets represented the carrying amount of the liability component of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, net of unamortized debt discounts and debt issuance costs, which are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Unamortized debt discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(116,195</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying amount of 2027 Notes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Capped Call Transactions</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Concurrently with the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, we entered into capped call transactions with one of the initial purchasers and another financial institution (the “option counterparties”) and used </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$28.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the net proceeds from the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce the potential dilutive effect upon conversion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">and/or offset any cash payments we are required to make in excess of the principal amount of converted </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, as the case may be, with such reduction and/or offset subject to a price cap of </span><span style="font-family:inherit;font-size:10pt;"><span>$48.88</span></span><span style="font-family:inherit;font-size:10pt;"> of our common stock per share, which represents a premium of </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> over the last reported sale price of our common stock on </span><span style="font-family:inherit;font-size:10pt;">February 10, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;color:#212529;">The cap</span><span style="font-family:inherit;font-size:10pt;">ped calls have an initial strike price of </span><span style="font-family:inherit;font-size:10pt;"><span>$32.38</span></span><span style="font-family:inherit;font-size:10pt;"> per share, subject to certain adjustments, which corresponds to the conversion option strike </span><span style="font-family:inherit;font-size:10pt;color:#212529;">price</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. The capped call transactions cover, subject to anti-dilution adjustments, approximately </span><span style="font-family:inherit;font-size:10pt;color:#212529;"><span>8.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The capped call transactions are separate transactions that we entered into with the option counterparties and are not part of the terms of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. As the capped call transactions meet certain accounting criteria, the premium paid of </span><span style="font-family:inherit;font-size:10pt;"><span>$28.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as a reduction in additional paid-in capital in the condensed consolidated balance sheets, and will not be remeasured to fair value as long as the accounting criteria continue to be met. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had not purchased any shares under the capped call transactions.</span></div></us-gaap:LongTermDebtTextBlock> <us-gaap:DebtInstrumentFaceAmount contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e526-wk-Fact-2054F579CB22BEBF9DEBBA2E353B2C99" unitRef="usd">287500000</us-gaap:DebtInstrumentFaceAmount> <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e539-wk-Fact-8F338D68EF70E8540CD3BA199F1A0735" unitRef="number">0.0175</us-gaap:DebtInstrumentInterestRateStatedPercentage> <us-gaap:ProceedsFromConvertibleDebt contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="d12624780e564-wk-Fact-5874B2D3225AB3C5DD53BA1CDD621E3F" unitRef="usd">278300000</us-gaap:ProceedsFromConvertibleDebt> <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsOneMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e591-wk-Fact-2C64C0184720EB7E8861BA1E43DDE6B2" unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays> <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsOneMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e595-wk-Fact-D79E08C85224E98E7EC6BA213713522A" unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1> <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsOneMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e600-wk-Fact-5A77DA62CBDDA53DE74CBA226AB1875E" unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger> <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsTwoMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e604-wk-Fact-67FBB74F8E4F72935C10BA2685A31A95" unitRef="day">5</us-gaap:DebtInstrumentConvertibleThresholdTradingDays> <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsTwoMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e608-wk-Fact-A077975A1532668858DABA26E1499306" unitRef="day">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1> <rvnc:DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice contextRef="D2020Q1Feb14_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis_rvnc_DebtConversionTermsTwoMember_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="2" id="d12624780e620-wk-Fact-8BDEFFB725303FD87FE3BA293F042DE2" unitRef="number">0.98</rvnc:DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice> <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e652-wk-Fact-8846D8BE2A4051205A11BA2F117D0D95" unitRef="usdPerShare">32.38</us-gaap:DebtInstrumentConvertibleConversionPrice1> <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e679-wk-Fact-E6B630CD28FD151F71D3BA35D214B991" unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger> <us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e684-wk-Fact-E61631C51C63E544CFE4BA3655D29793" unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays> <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e688-wk-Fact-8FB0375FFABD94C2E2ADBA36C204325C" unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1> <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e692-wk-Fact-E5E552B40AC6F2FDD390BA33D961F9E3" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage> <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="D2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e707-wk-Fact-E5E552B40AC6F2FDD390BA33D961F9E3" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage> <us-gaap:LongTermDebt contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="d12624780e722-wk-Fact-D4ED2390DB618BC7AA5CBA63C8FEB8A8" unitRef="usd">175400000</us-gaap:LongTermDebt> <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="3" id="d12624780e726-wk-Fact-236A96A9710F5739AB33BA39170F6439" unitRef="number">0.095</us-gaap:DebtInstrumentInterestRateEffectivePercentage> <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="d12624780e730-wk-Fact-6E4A101E63A3B20CC465BA3BDA3C2668" unitRef="usd">112100000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent> <us-gaap:DeferredFinanceCostsGross contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="d12624780e758-wk-Fact-913E03E419E2FC98A573BA5097810FB9" unitRef="usd">9200000</us-gaap:DeferredFinanceCostsGross> <rvnc:DebtIssuanceCostsGrossLiabilityComponent contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="d12624780e762-wk-Fact-F94A22E67B0EFF7E65FFBA52F68C9EBB" unitRef="usd">5600000</rvnc:DebtIssuanceCostsGrossLiabilityComponent> <rvnc:DebtIssuanceCostsGrossEquityComponent contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="d12624780e770-wk-Fact-32E6B43476522BF263A1BA51AAC0D3F2" unitRef="usd">3600000</rvnc:DebtIssuanceCostsGrossEquityComponent> <us-gaap:ConvertibleDebtTableTextBlock contextRef="FD2020Q1YTD" id="TextSelection-10CD32D4A1C413D096C8BA16A631B3AA-0-wk-Fact-C1A84FE2D9DC7BB4BDDDBA17F4347944"><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense relating to the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> in the condensed consolidated statements of operations and comprehensive loss are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>643</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,461</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate on the liability component of the </span><span style="font-family:inherit;font-size:8pt;">2027 Notes</span><span style="font-family:inherit;font-size:8pt;"> was </span><span style="font-family:inherit;font-size:8pt;"><span>9.5%</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, which remained unchanged from the issuance date. As of </span><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, the unamortized debt discount was </span><span style="font-family:inherit;font-size:8pt;"><span>$110.6 million</span></span><span style="font-family:inherit;font-size:8pt;">, and will be amortized over </span><span style="font-family:inherit;font-size:8pt;"><span>6.9</span></span><span style="font-family:inherit;font-size:8pt;"> years.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, the unamortized debt issuance cost for the </span><span style="font-family:inherit;font-size:8pt;">2027 Notes</span><span style="font-family:inherit;font-size:8pt;"> was </span><span style="font-family:inherit;font-size:8pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:8pt;"> on the condensed consolidated balance sheets.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the convertible senior notes on the condensed consolidated balance sheets represented the carrying amount of the liability component of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, net of unamortized debt discounts and debt issuance costs, which are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Unamortized debt discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(116,195</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying amount of 2027 Notes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:ConvertibleDebtTableTextBlock> <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="FD2020Q1YTD" decimals="-3" id="d12624780e849-wk-Fact-DAB602D4D1F77F95AF72BA44984E86B9" unitRef="usd">643000</us-gaap:InterestExpenseDebtExcludingAmortization> <us-gaap:AmortizationOfDebtDiscountPremium contextRef="FD2020Q1YTD" decimals="-3" id="d12624780e866-wk-Fact-D206663CC30C7AF3157ABA44FC826F77" unitRef="usd">1461000</us-gaap:AmortizationOfDebtDiscountPremium> <us-gaap:AmortizationOfFinancingCosts contextRef="FD2020Q1YTD" decimals="-3" id="d12624780e888-wk-Fact-911D64836C8A8561F60ABA458C3F6254" unitRef="usd">44000</us-gaap:AmortizationOfFinancingCosts> <us-gaap:InterestExpenseDebt contextRef="FD2020Q1YTD" decimals="-3" id="d12624780e913-wk-Fact-EF7AA1571712A04C9989BA45CF7EDBDE" unitRef="usd">2148000</us-gaap:InterestExpenseDebt> <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="3" id="d12624780e930-wk-Fact-236A96A9710F5739AB33BA39170F6439" unitRef="number">0.095</us-gaap:DebtInstrumentInterestRateEffectivePercentage> <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="d12624780e942-wk-Fact-60370442A8C4F59693D1BA488AC9264E" unitRef="usd">110600000</us-gaap:DebtInstrumentUnamortizedDiscount> <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 contextRef="FD2020Q1YTD_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" id="d12624780e947-wk-Fact-DDC7240B5D3521B00E69BA49009E98A9">P6Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1> <us-gaap:DeferredFinanceCostsNet contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="d12624780e967-wk-Fact-17D3A37D2214E1581CDBBA4BA929ACAB" unitRef="usd">5600000</us-gaap:DeferredFinanceCostsNet> <us-gaap:DebtInstrumentCarryingAmount contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="d12624780e1028-wk-Fact-F94308A32E3FCD2549E0BA6148789613" unitRef="usd">287500000</us-gaap:DebtInstrumentCarryingAmount> <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="d12624780e1043-wk-Fact-B2DC4EB3720FD0690E9CBA620FB231C1" unitRef="usd">116195000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet> <us-gaap:LongTermDebt contextRef="FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="d12624780e1069-wk-Fact-4285CA903F9441B93208BA625E108F4B" unitRef="usd">171305000</us-gaap:LongTermDebt> <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities contextRef="D2020Q1Feb14" decimals="-5" id="d12624780e1087-wk-Fact-8E4D51A7214DF2E94587BA67585A391B" unitRef="usd">28900000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities> <rvnc:CappedCallsPriceCap contextRef="I2020Q1Feb14" decimals="2" id="d12624780e1106-wk-Fact-03DBB637D9965989A451BA68437135CA" unitRef="usdPerShare">48.88</rvnc:CappedCallsPriceCap> <rvnc:CappedCallsPremiumPercentageOverSalePrice contextRef="D2020Q1Feb14" decimals="INF" id="d12624780e1110-wk-Fact-5C849DCF1FD48E759B52BA6AF530FC91" unitRef="number">1</rvnc:CappedCallsPremiumPercentageOverSalePrice> <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="d12624780e1122-wk-Fact-8846D8BE2A4051205A11BA2F117D0D95" unitRef="usdPerShare">32.38</us-gaap:DebtInstrumentConvertibleConversionPrice1> <rvnc:CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments contextRef="FI2020Q1" decimals="-5" id="d12624780e1135-wk-Fact-6D10316BC8FD2479034EECDD9B8662A5" unitRef="shares">8900000</rvnc:CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments> <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities contextRef="D2020Q1Feb14" decimals="-5" id="d12624780e1146-wk-Fact-8E4D51A7214DF2E94587BA67585A391B" unitRef="usd">28900000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities> <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2020Q1YTD" id="TextSelection-0A1A73CDFF70B181F3DC16CE0E3F7D3F-0-wk-Fact-14AEC3B96CD306C2FB0A16CE0E5E13D0">Stockholders’ Equity and <span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</span><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock Warrants</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were outstanding at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.95</span></span><span style="font-family:inherit;font-size:10pt;"> per share, which expired in May 2020. In February 2020, warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were net exercised for </span><span style="font-family:inherit;font-size:10pt;"><span>11,134</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> common stock warrants were outstanding. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Equity Incentive Plan (the “2014 EIP”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2020, the number of shares of common stock reserved for issuance under the 2014 EIP increased by </span><span style="font-family:inherit;font-size:10pt;"><span>2,094,989</span></span><span style="font-family:inherit;font-size:10pt;"> shares. For the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>765,675</span></span><span style="font-family:inherit;font-size:10pt;"> stock options and </span><span style="font-family:inherit;font-size:10pt;"><span>1,261,225</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock awards, including </span><span style="font-family:inherit;font-size:10pt;"><span>215,000</span></span><span style="font-family:inherit;font-size:10pt;"> performance stock awards, were granted under the 2014 EIP. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>929,364</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 EIP.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Inducement Plan (the “2014 IN”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> stock options or restricted stock awards were granted under the 2014 IN. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>246,130</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 IN. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Employee Stock Purchase Plan (the “2014 ESPP”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2020, the number of shares of common stock reserved for issuance under the 2014 ESPP increased by </span><span style="font-family:inherit;font-size:10pt;"><span>300,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>1,704,005</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 ESPP.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Net Loss per Share</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, which includes the vested restricted stock awards. The diluted net loss per share is calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, underlying shares of convertible senior notes, outstanding stock options, outstanding common stock warrants, unvested restricted stock awards and performance stock awards, and shares of common stock expected to be purchased under 2014 ESPP are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible senior notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,878,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,305,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,372,676</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards and performance stock awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799,982</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>768,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock expected to be purchased on June 30 under the 2014 ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,861</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Follow-On Public Offering</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, we completed a follow-on public offering, pursuant to which we issued </span><span style="font-family:inherit;font-size:10pt;"><span>6,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$17.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$103.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, after underwriting discounts, commissions and other offering expenses. In January 2020, the underwriters exercised their over-allotment option to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>975,000</span></span><span style="font-family:inherit;font-size:10pt;"> additional shares of common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$17.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, after underwriting discounts, commissions and other offering expenses.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">At-The-Market Offering</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are party to a controlled equity offering sales agreement with Cantor Fitzgerald &amp; Co. (“Cantor Fitzgerald”) (the “2018 ATM Agreement”), under which we may offer and sell common stock having aggregate proceeds of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$125.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> through Cantor Fitzgerald as our sales agent. Under the 2018 ATM Agreement, sales of common stock through Cantor Fitzgerald will be made by means of ordinary brokers’ transactions on the Nasdaq or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by us and Cantor Fitzgerald. From time to time, Cantor Fitzgerald may sell the common stock based upon our instructions, and we will pay a commission to Cantor Fitzgerald of up to </span><span style="font-family:inherit;font-size:10pt;"><span>3.0%</span></span><span style="font-family:inherit;font-size:10pt;"> of the gross sales proceeds of any common stock sold through Cantor Fitzgerald. For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> common stock was sold under the 2018 ATM Agreement. </span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-based Compensation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was allocated as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,442</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,080</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,544</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,159</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:StockholdersEquityNoteDisclosureTextBlock> <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12625631e528-wk-Fact-A50FEF8FBF11EEF204B19EE19175B8D1" unitRef="shares">34113</us-gaap:ClassOfWarrantOrRightOutstanding> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2019Q4_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember" decimals="2" id="d12625631e532-wk-Fact-5BC2DF8C8AC3E4BFC0039EE1B9BE456C" unitRef="usdPerShare">14.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="I2020Q1Feb29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12625631e536-wk-Fact-B78506B6F2DBB90DFD469EE215D880A1" unitRef="shares">34113</us-gaap:ClassOfWarrantOrRightOutstanding> <rvnc:StockIssuedDuringPeriodSharesExerciseofWarrants contextRef="D2020Q1Feb29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12625631e540-wk-Fact-DB8031EBF501EEFBECC19EE37E83F005" unitRef="shares">11134</rvnc:StockIssuedDuringPeriodSharesExerciseofWarrants> <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="d12625631e549-wk-Fact-06B4B5E67431D8D2E1BA9EE3EE5CF570" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding> <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2020Q1Jan1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" decimals="INF" id="d12625631e559-wk-Fact-CED36268861999F29AD39EE97508C433" unitRef="shares">2094989</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_StockCompensationPlanMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" decimals="INF" id="d12625631e571-wk-Fact-B41AEE4EE9A5A87781709EE9DFDE5497" unitRef="shares">765675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" decimals="INF" id="d12625631e575-wk-Fact-FAADF015F35CB55C1C9C9EEA566EF951" unitRef="shares">1261225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" decimals="INF" id="d12625631e580-wk-Fact-30A15B7A692DAA369AEF9EEAAA30170A" unitRef="shares">215000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod> <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2020Q1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember" decimals="INF" id="d12625631e588-wk-Fact-33A9BED019B99AD197E29EEC798A521B" unitRef="shares">929364</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2020Q1YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenInducementPlanMember" decimals="INF" id="d12625631e606-wk-Fact-476D33932F260AD23C0F16CE0E5EA0F2" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2020Q1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenInducementPlanMember" decimals="INF" id="d12625631e614-wk-Fact-F23DD481B27255AB6C499F85639E0AFD" unitRef="shares">246130</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance> <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="I2020Q1Jan1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" decimals="INF" id="d12625631e625-wk-Fact-2CE766B17412C0265EAD9F85B602B099" unitRef="shares">300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance> <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2020Q1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" decimals="INF" id="d12625631e633-wk-Fact-9CA16AA4AF045672C9B59F85F9FF38BC" unitRef="shares">1704005</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance> <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2020Q1YTD" id="TextSelection-520D8B997FB4E39C7E5F16CE0E3F0897-0-wk-Fact-2646A453971AE01D937916CE0E5E5641"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible senior notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,878,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,305,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,372,676</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards and performance stock awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799,982</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>768,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock expected to be purchased on June 30 under the 2014 ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,861</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="0" id="d12625631e740-wk-Fact-B7FABFBC530F61C71C70E6376F987B45" unitRef="shares">8878938</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="0" id="d12625631e754-wk-Fact-E8280BF7EFCE3AA3CE29E63772A0AC49" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="d12625631e769-wk-Fact-A4388F7F30FB7968B87B9D3248ACB719" unitRef="shares">5305185</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="d12625631e783-wk-Fact-69536A5288B0BEFCB3139D32490438D0" unitRef="shares">4372676</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="0" id="d12625631e798-wk-Fact-59382BFA76B094F8F93A9D3248DB36A5" unitRef="shares">2799982</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockMember" decimals="0" id="d12625631e812-wk-Fact-560061AFA0BD1F2A30F49D324952BF04" unitRef="shares">768770</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_rvnc_ESPPPurchasesMember" decimals="0" id="d12625631e827-wk-Fact-0B9BF3179C6883D51ED89D3249334C5E" unitRef="shares">49861</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_rvnc_ESPPPurchasesMember" decimals="0" id="d12625631e841-wk-Fact-3377C948C49CD82013E59D32498A7703" unitRef="shares">35619</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="d12625631e856-wk-Fact-FFE77286625F57B3A0469F989603D9BD" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" decimals="0" id="d12625631e870-wk-Fact-51D264796CA5B60225D79F989A95927E" unitRef="shares">34113</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2019Q4Dec-31_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember" decimals="INF" id="d12625631e886-wk-Fact-BEBB392D7B74191563CC9EE68786700A" unitRef="shares">6500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues> <us-gaap:SharePrice contextRef="FI2019Q4_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember" decimals="INF" id="d12625631e890-wk-Fact-E0210BDE4DF7091248C59EE6B8FDF70C" unitRef="usdPerShare">17.00</us-gaap:SharePrice> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2019Q4Dec-31_us-gaap_SubsidiarySaleOfStockAxis_rvnc_FollowOnOfferingMember" decimals="-5" id="d12625631e894-wk-Fact-F3F4335AF51E610A531A9EE71D40C914" unitRef="usd">103600000</us-gaap:ProceedsFromIssuanceOfCommonStock> <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2020Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="d12625631e898-wk-Fact-54BDECF67E64E281A9DA9F8FCC10907A" unitRef="shares">975000</us-gaap:StockIssuedDuringPeriodSharesNewIssues> <us-gaap:SharePrice contextRef="I2020Q1Jan31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="d12625631e902-wk-Fact-58F4545A6A997DF94E329F9042E15990" unitRef="usdPerShare">17.00</us-gaap:SharePrice> <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2020Q1Jan_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="-5" id="d12625631e907-wk-Fact-5044724150299B3F98A29F901672E5E2" unitRef="usd">15600000</us-gaap:ProceedsFromIssuanceOfCommonStock> <rvnc:StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum contextRef="FD2020Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_AttheMarketOfferingMember" decimals="INF" id="d12625631e917-wk-Fact-063E2CD7059B76A90B46C3F996758BD1" unitRef="usd">125000000.0</rvnc:StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum> <rvnc:SaleofStockIssuanceCostsCommissionPercentageMaximum contextRef="FD2020Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_AttheMarketOfferingMember" decimals="INF" id="d12625631e921-wk-Fact-887D9F75662DE9EF5993E657A0C94792" unitRef="number">0.030</rvnc:SaleofStockIssuanceCostsCommissionPercentageMaximum> <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2020Q1YTD_us-gaap_SubsidiarySaleOfStockAxis_rvnc_AttheMarketOfferingMember" decimals="INF" id="d12625631e929-wk-Fact-23FA41FE14D609B7FF69C3F9EB10F888" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues> <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2020Q1YTD" id="TextSelection-775E5E9519BFD6242F029F8E2F86A75B-0-wk-Fact-D7B28D3FA3EA57D331A79F8E3B79F869"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was allocated as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,442</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,080</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,544</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,159</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="d12625631e1050-wk-Fact-A1856EB3F20418F217049F94C2BEA08A" unitRef="usd">2442000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="d12625631e1069-wk-Fact-9C5AD018D28AE0E5267D9F94C2A73E78" unitRef="usd">2079000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2020Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="d12625631e1084-wk-Fact-9FDF17C88F4D0E7BE70D9F94C387A713" unitRef="usd">4102000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="d12625631e1103-wk-Fact-C03E2BCA576BB86A38139F94C368F6DD" unitRef="usd">2080000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2020Q1YTD" decimals="-3" id="d12625631e1128-wk-Fact-BDBD159E793E6A64D5C09F94C35607A8" unitRef="usd">6544000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q1QTD" decimals="-3" id="d12625631e1147-wk-Fact-070C8EB699468EDC24759F94C4C5BE76" unitRef="usd">4159000</us-gaap:AllocatedShareBasedCompensationExpense> <us-gaap:FairValueDisclosuresTextBlock contextRef="FD2020Q1YTD" id="TextSelection-F06E84DBB60CD151613516CE0E15446F-0-wk-Fact-869A00B585092826E02E16CE0E173614">Fair Value Measurements<div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy:</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209,337</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>184,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For Level 1 investments, we use quoted prices in active markets for identical assets to determine the fair value. For Level 2 investments, we use quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trade of or quotes on the same or similar securities. We do not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the change in the fair value of our Level 3 financial instrument:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Liability </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment (</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Note 5</span><span style="font-family:inherit;font-size:10pt;">). Generally, increases or decreases in these unobservable inputs would result in a directionally similar impact to the fair value measurement of this derivative instrument. The significant unobservable inputs used in the fair value measurement of the product approval payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Note 7</span><span style="font-family:inherit;font-size:10pt;">) was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy. We carry </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> at face value less unamortized debt discount and issuance costs on our condensed consolidated balance sheets and present the fair value for disclosure purposes only. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$229.5 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div></us-gaap:FairValueDisclosuresTextBlock> <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2020Q1YTD" id="TextSelection-F3BF669FB8F1DA1F06BB16CE0E142470-0-wk-Fact-2A9D5197AF028F7AE02116CE0E1788DF"><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy:</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209,337</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>184,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12628440e811-wk-Fact-B3E55C352B95ECBC2A239D329E23573D" unitRef="usd">179031000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12628440e830-wk-Fact-1EA899450EED107C481C9D32A04332ED" unitRef="usd">179031000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12628440e849-wk-Fact-505F801FC838391995DE9D32A0752ADA" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12628440e869-wk-Fact-487B6E07B785B4C1BD9E9D329F7A80CF" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12628440e884-wk-Fact-FCD261DAAC73902343CA9D32A10D571A" unitRef="usd">30306000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12628440e903-wk-Fact-993F2CBBBFDCD36F79689D329EE615BC" unitRef="usd">30306000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12628440e922-wk-Fact-3D3D14F24C20E4B1C8A79D329D8F655F" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12628440e942-wk-Fact-10E3349F5DADE24F0CD39D329EB53FE4" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12628440e962-wk-Fact-65F27491F769023C26519EAA9B2D28FC" unitRef="usd">159976000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12628440e981-wk-Fact-C164791763B9567C77AA9EAAA66CE21F" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12628440e1000-wk-Fact-A2B073A34DD92422188B9EAAB6DAC4B3" unitRef="usd">159976000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12628440e1020-wk-Fact-37F5CEDCAFD483317F099EAAC745B1A4" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12628440e1040-wk-Fact-0D782BB2B1F572ACB9539D329DF20A0B" unitRef="usd">140320000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12628440e1059-wk-Fact-27CAA8ACFDA11C42B0C39D32A0DC00D0" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12628440e1078-wk-Fact-C9B2E72F8F75D1365A4B9D329FE2C7AF" unitRef="usd">140320000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12628440e1098-wk-Fact-5935556E56AD927C523B9D329D80A311" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e1123-wk-Fact-0365B2A0A701D3426EF49D329D8F8C18" unitRef="usd">509633000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e1142-wk-Fact-2E9A148167783C83B7109D329E543A3A" unitRef="usd">209337000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e1161-wk-Fact-3A921FC9039190B7DBF69D32A0A6FAAD" unitRef="usd">300296000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e1181-wk-Fact-457C4C4AAC87C11E8F8F9D329DA9B33C" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" decimals="-3" id="d12628440e1365-wk-Fact-53DE2763F48DB13283129D329E85A9C5" unitRef="usd">3042000</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" decimals="-3" id="d12628440e1384-wk-Fact-D0373815849059CA64B19D329F49E76B" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" decimals="-3" id="d12628440e1403-wk-Fact-0F6D7DD8520C7F5D7FA09D329F1700D9" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" decimals="-3" id="d12628440e1423-wk-Fact-60448ED4C812193ADD0B9D329DB049B4" unitRef="usd">3042000</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2020Q1_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e1444-wk-Fact-B36ACB1DE02CB04D8D5B9D329DA33C52" unitRef="usd">3042000</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e1463-wk-Fact-F4F6DFB0BD409FF798FF9D329FB1E88C" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e1482-wk-Fact-AB11131CFD5989B996C49D329D80B3B6" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2020Q1_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e1502-wk-Fact-BFEA14A8E225E6C20A3B9D32A01327D5" unitRef="usd">3042000</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12628440e1791-wk-Fact-F370D640CA319B7F23039EADCEDCDD71" unitRef="usd">136258000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12628440e1810-wk-Fact-21E8C58BE391C853FBAC9EADDE01BD3D" unitRef="usd">136258000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12628440e1829-wk-Fact-E924BFBD03E27C9058759EADEEA475D3" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="d12628440e1849-wk-Fact-C3BF21327F305DC4361F9EADFCCA0F1B" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12628440e1864-wk-Fact-CCA68120BE48A14A647C9EAE0577ACC4" unitRef="usd">48355000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12628440e1883-wk-Fact-05ED40C5F01C123B3E5B9EAE1346D60B" unitRef="usd">48355000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12628440e1902-wk-Fact-DDFC89B64C2459A24E549EAE1D337C5F" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="d12628440e1922-wk-Fact-115BBA0269070AA00DB19EAE2878D736" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12628440e1942-wk-Fact-FF90E7D27029AEEBC96D9EAE31B4B7CC" unitRef="usd">77082000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12628440e1961-wk-Fact-F1CBE27BDEFCA02FE7559EAE3FEF46C5" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12628440e1980-wk-Fact-B052CD909B34D425F5F29EAE4E16EE89" unitRef="usd">77082000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" decimals="-3" id="d12628440e2000-wk-Fact-BF9A89C5EB9518467CD49EAE5B026A09" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember" decimals="-3" id="d12628440e2020-wk-Fact-068BAAC169BA715761349EAE61DEDB12" unitRef="usd">15001000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember" decimals="-3" id="d12628440e2039-wk-Fact-745422467A091B9343029EAE6E910FC5" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember" decimals="-3" id="d12628440e2058-wk-Fact-A4B0FA2682E9E55695F99EAE7C375243" unitRef="usd">15001000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MaturityOvernightMember" decimals="-3" id="d12628440e2078-wk-Fact-A53DA0239946F65364BB9EAE8D4CFEA6" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12628440e2098-wk-Fact-C118DFE4F37E5758BF179EAE93BE2BB9" unitRef="usd">5990000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12628440e2117-wk-Fact-F018CE2E830B5FB00C5E9EAE9F044EC5" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12628440e2136-wk-Fact-3DE32DB64E84DF17E4069EAEACFAC50B" unitRef="usd">5990000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" decimals="-3" id="d12628440e2156-wk-Fact-F984492161CCC3BD55809EAEBB9EF585" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e2181-wk-Fact-BFA3ABB0821702A2D6D39EAEC4B9F44E" unitRef="usd">282686000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="d12628440e2200-wk-Fact-447035622EDD7C9181149EAED0D03E2C" unitRef="usd">184613000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="d12628440e2219-wk-Fact-52BD2E13F0A673314B189EAEDE5547F5" unitRef="usd">98073000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="d12628440e2239-wk-Fact-D708189AEA1CE9EA85DA9EAEF76845F2" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" decimals="-3" id="d12628440e2424-wk-Fact-A5981257C436066BC3D19EACB70B9204" unitRef="usd">2952000</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" decimals="-3" id="d12628440e2443-wk-Fact-3CB3385E0C86D4CB25639EACBEC60481" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" decimals="-3" id="d12628440e2462-wk-Fact-161766EAEB469701AAB29EACCB3578F0" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" decimals="-3" id="d12628440e2482-wk-Fact-84C5F412CA0636A901F69EACD9707963" unitRef="usd">2952000</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e2502-wk-Fact-55BDA79B9D0EA0C620A29EACE707526E" unitRef="usd">2952000</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e2521-wk-Fact-DF24E809729C38D8F8EF9EACEC0E0E3E" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e2540-wk-Fact-339D5FD43A4B04F6B78B9EACF6D5587E" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-3" id="d12628440e2560-wk-Fact-23CB5008B9C4461F7C589EACFFF5EED6" unitRef="usd">2952000</us-gaap:LiabilitiesFairValueDisclosure> <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2020Q1YTD" id="TextSelection-879DE68AA6A9BF9C888416CE0E15F6EC-0-wk-Fact-6A134F3CE4AF19CA801216CE0E164576"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the change in the fair value of our Level 3 financial instrument:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Liability </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" decimals="-3" id="d12628440e2632-wk-Fact-442C7D9D94EFF8D7A8039D32B23E7A08" unitRef="usd">2952000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2020Q1YTD_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" decimals="-3" id="d12628440e2647-wk-Fact-5516A20C33D502FB39679D32B2459111" unitRef="usd">90000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings> <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2020Q1_us-gaap_FinancialInstrumentAxis_rvnc_DerivativeLiabilitySettlementMember" decimals="-3" id="d12628440e2672-wk-Fact-231B73495CA6244BCA159D32B24B5820" unitRef="usd">3042000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue> <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="FI2020Q1" decimals="-5" id="d12628440e2717-wk-Fact-64F29F1577F423E2182D9EC0800D3C6C" unitRef="usd">229500000</us-gaap:ConvertibleDebtFairValueDisclosures> <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2020Q1YTD" id="TextSelection-79B8AFFAE68E9E8FC1EC16CE0E30CEBE-0-wk-Fact-486453D02CA93F39E79C16CE0E3054FB">Commitments and Contingencies<div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Teoxane Agreement </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are parties to the Teoxane Agreement (</span><a href="#s89e018506f474bc9b18873233c39430b" style="font-family:inherit;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Note 4</span></a><span style="font-family:inherit;font-size:10pt;">), which will be effective for a term of </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> upon product launch and may be extended for a two-year period upon the mutual agreement of the parties. We are required to meet certain minimum purchase obligations during each year of the term. We are also required to meet certain minimum expenditure requirements in connection with commercialization efforts. Either party may terminate the Teoxane Agreement in the event of the insolvency of, or a material breach by, the other party, including certain specified breaches that include the right for Teoxane to terminate the Teoxane Agreement for our failure to meet the minimum purchase requirements or commercialization expenditure during specified periods, or for our breach of the exclusivity obligations under the Teoxane Agreement.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Purchase Commitments</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are parties to a Technology Transfer, Validation and Commercial Fill/Finish Services Agreement with Ajinomoto Althea, Inc. dba Ajinomoto Bio-Pharma Services (“Althea”) (the “Althea Services Agreement”), under which Althea provides us a contract development and manufacturing organization, which allows us to have expanded capacity and a second source for drug product manufacturing in order to support a global launch of DaxibotulinumtoxinA for Injection. The initial term of the Althea Services Agreement expires in 2024, unless terminated sooner by either company and we have minimum purchase obligations based on our production forecasts. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Contingencies</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are obligated to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment to a developer of botulinum toxin, List Biological Laboratories, Inc. (“List Laboratories”), when a certain regulatory milestone is achieved. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the milestone had not been achieved. We are also obligated to pay royalties to List Laboratories on future sales of botulinum toxin products.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into an asset purchase agreement (the “BTRX Purchase Agreement”) with Botulinum Toxin Research Associates, Inc. (“BTRX”), under which we are obligated to pay up to </span><span style="font-family:inherit;font-size:10pt;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to BTRX upon the satisfaction of milestones relating to our product revenue, intellectual property, and clinical and regulatory events. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, a one-time intellectual property development milestone liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> has been recorded in accruals on our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into an agreement with BioSentinel, Inc. (“BioSentinel”), under which we in-license BioSentinel’s technology and expertise for research, development and manufacturing purposes. We are obligated to pay BioSentinel minimum quarterly use fees and a one-time milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> when regulatory approval is achieved. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the milestone has not been achieved.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Indemnification</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to our technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments we are obligated to pay under these indemnification agreements is not determinable because it involves claims that may be made against us in the future but have not been made. We have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> amounts associated with the indemnification agreements have been recorded.</span></div></us-gaap:CommitmentsAndContingenciesDisclosureTextBlock> <rvnc:CollaborativeAgreementContractualPeriod contextRef="D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember" id="d12629071e541-wk-Fact-E91EE9BB15B499C2F3469EC596E47DA3">P10Y</rvnc:CollaborativeAgreementContractualPeriod> <rvnc:AccruedMilestoneObligations contextRef="FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_ListLaboratoriesMember" decimals="-5" id="d12629071e557-wk-Fact-A08BD32ABB4F6FDD410116CE0E302F2C" unitRef="usd">2000000.0</rvnc:AccruedMilestoneObligations> <rvnc:AccruedMilestoneObligations contextRef="FI2020Q1_us-gaap_TypeOfArrangementAxis_rvnc_BotulinumToxinResearchAssociatesInc.Member" decimals="INF" id="d12629071e568-wk-Fact-E357AC907C94101B662E16CE0E305C0C" unitRef="usd">16000000.0</rvnc:AccruedMilestoneObligations> <us-gaap:FairValueOfAssetsAcquired contextRef="FD2020Q1YTD_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="d12629071e576-wk-Fact-586135969899C84F490E16CE0E30CFF5" unitRef="usd">1000000.0</us-gaap:FairValueOfAssetsAcquired> <rvnc:AccruedMilestoneObligations contextRef="FI2020Q1_us-gaap_TypeOfArrangementAxis_rvnc_BioSentinelInc.Member" decimals="-5" id="d12629071e583-wk-Fact-588E0FF0DEFC9EF88FE316CE0E305CC0" unitRef="usd">300000</rvnc:AccruedMilestoneObligations> <rvnc:IndemnificationLiabilityRecordedduringPeriod contextRef="FD2020Q1YTD" decimals="INF" id="d12629071e613-wk-Fact-C2DF14F796498883188916CE0E300687" unitRef="usd">0</rvnc:IndemnificationLiabilityRecordedduringPeriod> </xbrl> </XML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>16 <FILENAME>R7.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795844768"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th" colspan="2">3 Months Ended</th> </tr> <tr> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="num">$ (61,933)<span></span> </td> <td class="num">$ (35,304)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Non-cash in-process research and development</a></td> <td class="nump">11,184<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td> <td class="nump">6,544<span></span> </td> <td class="nump">4,159<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td> <td class="nump">1,505<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td> <td class="nump">739<span></span> </td> <td class="nump">628<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on investments</a></td> <td class="num">(513)<span></span> </td> <td class="num">(649)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash operating activities</a></td> <td class="nump">371<span></span> </td> <td class="nump">88<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td> <td class="nump">0<span></span> </td> <td class="nump">27,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td> <td class="num">(467)<span></span> </td> <td class="num">(1,018)<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets', window );">Operating lease right of use assets</a></td> <td class="nump">570<span></span> </td> <td class="num">(3,440)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td> <td class="nump">175<span></span> </td> <td class="nump">101<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td> <td class="nump">789<span></span> </td> <td class="num">(3,736)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accruals and other liabilities</a></td> <td class="num">(2,373)<span></span> </td> <td class="num">(2,298)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td> <td class="nump">942<span></span> </td> <td class="num">(278)<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td> <td class="num">(822)<span></span> </td> <td class="nump">3,333<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td> <td class="num">(43,289)<span></span> </td> <td class="num">(11,414)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td> <td class="num">(159,412)<span></span> </td> <td class="num">(127,357)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td> <td class="num">(539)<span></span> </td> <td class="num">(1,084)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td> <td class="num">(118)<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Proceeds from maturities of investments</a></td> <td class="nump">54,500<span></span> </td> <td class="nump">25,000<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">CASH FLOWS FROM FINANCING ACTIVITIES</a></td> <td class="num">(105,569)<span></span> </td> <td class="num">(103,441)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Proceeds from issuance of common stock in connection with offerings, net of commissions and discount</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible senior notes</a></td> <td class="nump">287,500<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount', window );">Proceeds from issuance of common stock in connection with offerings, net of commissions and discount</a></td> <td class="nump">15,581<span></span> </td> <td class="nump">108,100<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options and common stock warrants</a></td> <td class="nump">572<span></span> </td> <td class="nump">18<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities', window );">Payment of capped call transactions</a></td> <td class="num">(28,865)<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of convertible senior notes transaction costs</a></td> <td class="num">(8,703)<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net settlement of restricted stock awards for employee taxes</a></td> <td class="num">(1,401)<span></span> </td> <td class="num">(1,049)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td> <td class="num">(337)<span></span> </td> <td class="num">(201)<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td> <td class="nump">264,347<span></span> </td> <td class="nump">106,868<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH</a></td> <td class="nump">115,489<span></span> </td> <td class="num">(7,987)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period</a></td> <td class="nump">171,890<span></span> </td> <td class="nump">73,986<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period</a></td> <td class="nump">287,379<span></span> </td> <td class="nump">65,999<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Issuance of common stock in connection with the Teoxane Agreement</a></td> <td class="nump">43,400<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Accrued transaction costs on convertible senior notes</a></td> <td class="nump">487<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Property and equipment purchases included in accounts payable and accruals</a></td> <td class="nump">247<span></span> </td> <td class="nump">1,108<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_NoncashDeferredOfferingCosts', window );">Accrued offering costs</a></td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 320<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_IncreaseDecreaseinOperatingLeaseLiabilities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Liabilities</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_IncreaseDecreaseinOperatingLeaseLiabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Operating Lease Right of Use Assets</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_NoncashDeferredOfferingCosts"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Deferred Offering Costs</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_NoncashDeferredOfferingCosts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Follow-On Offering, Net of Commissions and Discount</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3505-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentFinancingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>17 <FILENAME>R3.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795866448"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Dec. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value (in dollars per share)</a></td> <td class="nump">$ 0.001<span></span> </td> <td class="nump">$ 0.001<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock authorized (shares)</a></td> <td class="nump">5,000,000<span></span> </td> <td class="nump">5,000,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock issued (shares)</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock outstanding (shares)</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollar per share)</a></td> <td class="nump">$ 0.001<span></span> </td> <td class="nump">$ 0.001<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td> <td class="nump">95,000,000<span></span> </td> <td class="nump">95,000,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td> <td class="nump">57,026,154<span></span> </td> <td class="nump">52,374,735<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td> <td class="nump">57,026,154<span></span> </td> <td class="nump">52,374,735<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>18 <FILENAME>R15.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792320528"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Stock-Based Compensation<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity and Stock-Based Compensation</a></td> <td class="text">Stockholders’ Equity and <span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-Based Compensation</span><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock Warrants</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were outstanding at an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.95</span></span><span style="font-family:inherit;font-size:10pt;"> per share, which expired in May 2020. In February 2020, warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock were net exercised for </span><span style="font-family:inherit;font-size:10pt;"><span>11,134</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> common stock warrants were outstanding. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Equity Incentive Plan (the “2014 EIP”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2020, the number of shares of common stock reserved for issuance under the 2014 EIP increased by </span><span style="font-family:inherit;font-size:10pt;"><span>2,094,989</span></span><span style="font-family:inherit;font-size:10pt;"> shares. For the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>765,675</span></span><span style="font-family:inherit;font-size:10pt;"> stock options and </span><span style="font-family:inherit;font-size:10pt;"><span>1,261,225</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock awards, including </span><span style="font-family:inherit;font-size:10pt;"><span>215,000</span></span><span style="font-family:inherit;font-size:10pt;"> performance stock awards, were granted under the 2014 EIP. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>929,364</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 EIP.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Inducement Plan (the “2014 IN”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> stock options or restricted stock awards were granted under the 2014 IN. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>246,130</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 IN. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">2014 Employee Stock Purchase Plan (the “2014 ESPP”)</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 1, 2020, the number of shares of common stock reserved for issuance under the 2014 ESPP increased by </span><span style="font-family:inherit;font-size:10pt;"><span>300,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>1,704,005</span></span><span style="font-family:inherit;font-size:10pt;"> shares were available for issuance under the 2014 ESPP.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Net Loss per Share</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period, which includes the vested restricted stock awards. The diluted net loss per share is calculated by giving effect to all potential dilutive common stock equivalents outstanding for the period. For purposes of this calculation, underlying shares of convertible senior notes, outstanding stock options, outstanding common stock warrants, unvested restricted stock awards and performance stock awards, and shares of common stock expected to be purchased under 2014 ESPP are considered common stock equivalents, which were excluded from the computation of diluted net loss per share because including them would have been antidilutive. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock equivalents that were excluded from the computation of diluted net loss per share are presented as below:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:73%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Convertible senior notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,878,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,305,185</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,372,676</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unvested restricted stock awards and performance stock awards</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,799,982</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>768,770</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares of common stock expected to be purchased on June 30 under the 2014 ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49,861</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding common stock warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34,113</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Follow-On Public Offering</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, we completed a follow-on public offering, pursuant to which we issued </span><span style="font-family:inherit;font-size:10pt;"><span>6,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$17.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$103.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, after underwriting discounts, commissions and other offering expenses. In January 2020, the underwriters exercised their over-allotment option to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>975,000</span></span><span style="font-family:inherit;font-size:10pt;"> additional shares of common stock at </span><span style="font-family:inherit;font-size:10pt;"><span>$17.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share for net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, after underwriting discounts, commissions and other offering expenses.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">At-The-Market Offering</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are party to a controlled equity offering sales agreement with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) (the “2018 ATM Agreement”), under which we may offer and sell common stock having aggregate proceeds of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$125.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> through Cantor Fitzgerald as our sales agent. Under the 2018 ATM Agreement, sales of common stock through Cantor Fitzgerald will be made by means of ordinary brokers’ transactions on the Nasdaq or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise agreed upon by us and Cantor Fitzgerald. From time to time, Cantor Fitzgerald may sell the common stock based upon our instructions, and we will pay a commission to Cantor Fitzgerald of up to </span><span style="font-family:inherit;font-size:10pt;"><span>3.0%</span></span><span style="font-family:inherit;font-size:10pt;"> of the gross sales proceeds of any common stock sold through Cantor Fitzgerald. For the three months ended </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> common stock was sold under the 2018 ATM Agreement. </span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Stock-based Compensation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was allocated as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,442</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,080</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,544</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,159</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&trid=2208762<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>19 <FILENAME>R11.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792583536"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Filler Distribution Agreement<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Filler Distribution Agreement</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, we entered into an exclusive distribution agreement (the “Teoxane Agreement”) with Teoxane SA (“Teoxane”), pursuant to which Teoxane granted us with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid® (“RHA®”) dermal fillers in exchange for </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock and certain other commitments by us. The Teoxane Agreement includes rights to i) RHA® 2, RHA® 3 and RHA® 4 which have been approved by the FDA for the correction of moderate to severe dynamic facial wrinkles and folds, including RHA® 2, RHA® 3 and RHA® 4 in the currently approved indications, ii) RHA® 1, which is currently in clinical trials for the treatment of perioral rhytids , and iii) future hyaluronic acid filler advancements and products by Teoxane (collectively the “</span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;">”) in the U.S. and U.S. territories and possessions. The Teoxane Agreement will be effective for a term of </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> upon product launch and may be extended for a two-year period upon the mutual agreement of the parties. We are required to meet certain minimum purchase obligations and certain minimum expenditure requirements, which are discussed in </span><a href="#s432F768E2BFB1A06A47A16CE0E304583" style="font-family:inherit;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Note 10</span></a><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If Teoxane pursues regulatory approval for RHA® dermal fillers for certain new indications or filler technologies, including innovations with respect to existing products in the U.S., we will be subject to certain specified cost-sharing arrangements for third party expenses incurred in achieving regulatory approval for such products. We will also have a right of first negotiation with respect to any cosmeceutical products that Teoxane wishes to distribute in the U.S, and Teoxane will have a right of first negotiation in connection with the distribution of DaxibotulinumtoxinA for Injection for aesthetic use, outside the U.S. and U.S. territories where Teoxane has an affiliate. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Teoxane Agreement is accounted for as an asset acquisition for the distribution rights of various approved and unapproved products and indications. The aggregate purchase consideration for the distribution rights is </span><span style="font-family:inherit;font-size:10pt;"><span>$43.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, consisting of the fair value of the </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares transferred to Teoxane and transaction costs. The purchase consideration is allocated to the underlying groups of approved and unapproved products based on their relative fair values, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$11.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> is allocated to certain unapproved products and future innovations, or in-process research and development assets, and is recognized as research and development expense on the condensed consolidated statements of operations and comprehensive loss. The remaining purchase consideration is allocated to the currently approved products and indications, and is recognized as an intangible asset on the condensed consolidated balance sheets. The intangible asset will be amortized over approximately </span><span style="font-family:inherit;font-size:10pt;"><span>4</span></span><span style="font-family:inherit;font-size:10pt;"> years commencing upon the first delivery of the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> products from Teoxane. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarized the distribution rights:</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Initial Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution rights to approved products and indications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&trid=2144416<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>20 <FILENAME>R19.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6593052224"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short-Term Investments (Tables)<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-sale Securities</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of amortized cost, unrealized gains and losses, and fair value of our cash equivalents and short-term investments: </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in thousands</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,349</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,634</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Classified as:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>285,012</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224,621</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&trid=2196928<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>21 <FILENAME>R32.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617314624"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases - Operating Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th" colspan="2">3 Months Ended</th> </tr> <tr> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td> <td class="nump">$ 1,425<span></span> </td> <td class="nump">$ 1,343<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td> <td class="nump">77<span></span> </td> <td class="nump">290<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease costs</a></td> <td class="nump">$ 1,502<span></span> </td> <td class="nump">$ 1,633<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeaseCost</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>22 <FILENAME>R36.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787555888"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Interest Expense (Details)<br> $ in Thousands</strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"> <div>Mar. 31, 2020 </div> <div>USD ($)</div> </th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td> <td class="nump">$ 643<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td> <td class="nump">1,461<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td> <td class="nump">44<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest expense</a></td> <td class="nump">$ 2,148<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2027 Notes</a></td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective percentage</a></td> <td class="nump">9.50%<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discount</a></td> <td class="nump">$ 110,600<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining discount amortization period</a></td> <td class="text">6 years 10 months 24 days<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td> <td class="nump">$ 5,600<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rvnc_TwentyTwentySevenNotesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rvnc_TwentyTwentySevenNotesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>23 <FILENAME>report.css <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>24 <FILENAME>R6.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796117072"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th" colspan="2">3 Months Ended</th> </tr> <tr> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td> <td class="nump">$ 337<span></span> </td> <td class="nump">$ 201<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_EquityComponentOfConvertibleDebtTransactionCost', window );">Equity component of convertible debt, transaction cost</a></td> <td class="nump">3,583<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rvnc_FollowOnOfferingMember', window );">Follow On Offering</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td> <td class="nump">$ 44<span></span> </td> <td class="nump">$ 521<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_EquityComponentOfConvertibleDebtTransactionCost"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Debt, Transaction Cost</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_EquityComponentOfConvertibleDebtTransactionCost</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rvnc_FollowOnOfferingMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rvnc_FollowOnOfferingMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>25 <FILENAME>R2.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809479952"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Dec. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td> <td class="nump">$ 286,649<span></span> </td> <td class="nump">$ 171,160<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td> <td class="nump">224,621<span></span> </td> <td class="nump">118,955<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td> <td class="nump">7,171<span></span> </td> <td class="nump">6,487<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td> <td class="nump">518,441<span></span> </td> <td class="nump">296,602<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td> <td class="nump">13,967<span></span> </td> <td class="nump">14,755<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIntangibleAssetsNet', window );">Intangible assets</a></td> <td class="nump">32,334<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td> <td class="nump">25,961<span></span> </td> <td class="nump">26,531<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td> <td class="nump">730<span></span> </td> <td class="nump">730<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td> <td class="nump">1,494<span></span> </td> <td class="nump">1,669<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td> <td class="nump">592,927<span></span> </td> <td class="nump">340,287<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td> <td class="nump">8,709<span></span> </td> <td class="nump">8,010<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accruals and other current liabilities</a></td> <td class="nump">16,178<span></span> </td> <td class="nump">18,636<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td> <td class="nump">10,079<span></span> </td> <td class="nump">7,911<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td> <td class="nump">3,627<span></span> </td> <td class="nump">3,470<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liability</a></td> <td class="nump">3,042<span></span> </td> <td class="nump">2,952<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Derivative liability</a></td> <td class="nump">41,635<span></span> </td> <td class="nump">40,979<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Convertible senior notes</a></td> <td class="nump">171,305<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td> <td class="nump">46,722<span></span> </td> <td class="nump">47,948<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td> <td class="nump">24,890<span></span> </td> <td class="nump">25,870<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td> <td class="nump">284,552<span></span> </td> <td class="nump">114,797<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 10)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS’ EQUITY</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, par value $0.001 per share — 5,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2020 and December 31, 2019</a></td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001 per share — 95,000,000 shares authorized both as of March 31, 2020 and December 31, 2019; 57,026,154 and 52,374,735 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively</a></td> <td class="nump">57<span></span> </td> <td class="nump">52<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td> <td class="nump">1,213,931<span></span> </td> <td class="nump">1,069,639<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td> <td class="nump">524<span></span> </td> <td class="nump">3<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td> <td class="num">(906,137)<span></span> </td> <td class="num">(844,204)<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS’ EQUITY</a></td> <td class="nump">308,375<span></span> </td> <td class="nump">225,490<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY</a></td> <td class="nump">$ 592,927<span></span> </td> <td class="nump">$ 340,287<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Assets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Liabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIntangibleAssetsNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherIntangibleAssetsNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PreferredStockValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>26 <FILENAME>R18.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792596224"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies (Policies)<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated balance sheets for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which was filed with the Securities and Exchange Commission (“SEC”), on </span><span style="font-family:inherit;font-size:10pt;">February 26, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. We operate in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> segment.</span></div><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Principles of Consolidation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include our accounts and our wholly-owned subsidiaries. All intercompany transactions have been eliminated.</span></div><span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, revenue recognition, deferred revenue classification, accruals including clinical trial costs, stock-based compensation, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration of asset acquisitions, and accounting for income taxes. We base these estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances. The worldwide continued spread of COVID-19 has caused a global slowdown of economic activity which has decreased demand for a broad variety of goods and services, including from our potential customers, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. We are unable to predict the future effect resulting from the COVID-19 pandemic on, for instance, paused clinical trials and revised product launch timing. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.</span></div><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intangible Assets</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets acquired in asset acquisition are stated at cost, less accumulated amortization on the condensed consolidated balance sheets, and are amortized on a ratable basis over their useful life. Assets acquired as part of an asset acquisition that are considered to be in-process research and development are immediately expensed unless there is an alternative future use in other research and development projects.</span></div><span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">. The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. We adopted ASU 2018-15 on January 1, 2020 on a prospective basis.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.</span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>27 <FILENAME>R14.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794442384"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Convertible Senior Notes</a></td> <td class="text">Convertible Senior Notes<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">February 14, 2020</span><span style="font-family:inherit;font-size:10pt;">, we issued convertible senior notes that are due in 2027 (the “</span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">”) with an aggregate principal balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$287.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, pursuant to an indenture, dated </span><span style="font-family:inherit;font-size:10pt;">February 14, 2020</span><span style="font-family:inherit;font-size:10pt;">, between Revance and U.S. Bank National Association, as trustee (the “Indenture”). The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> are senior unsecured obligations and bear interest at a rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.75%</span></span><span style="font-family:inherit;font-size:10pt;"> per year, payable semiannually in arrears on </span><span style="font-family:inherit;font-size:10pt;">February 15</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August 15</span><span style="font-family:inherit;font-size:10pt;"> of each year, beginning on </span><span style="font-family:inherit;font-size:10pt;">August 15, 2020</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> will mature on </span><span style="font-family:inherit;font-size:10pt;">February 15, 2027</span><span style="font-family:inherit;font-size:10pt;">, unless earlier converted, redeemed or repurchased. In connection with issuing the 2027 Notes, we received </span><span style="font-family:inherit;font-size:10pt;"><span>$278.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> in net proceeds, after deducting the initial purchasers’ discount, commissions, and other issuance costs. A portion of the net proceeds from the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> were used to purchase the capped call transactions described below and the remainder will be used to fund expenses associated with commercial launch activities for both the </span><span style="font-family:inherit;font-size:10pt;">RHA® dermal fillers</span><span style="font-family:inherit;font-size:10pt;"> and, if approved, DaxibotulinumtoxinA for Injection for glabellar lines, research and development, and other corporate activities.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> may be converted at any time by the holders prior to the close of business on the business day immediately preceding </span><span style="font-family:inherit;font-size:10pt;">November 15, 2026</span><span style="font-family:inherit;font-size:10pt;"> only under the following circumstances: (1) during any fiscal quarter commencing after the fiscal quarter ending on </span><span style="font-family:inherit;font-size:10pt;">June 30, 2020</span><span style="font-family:inherit;font-size:10pt;"> (and only during such fiscal quarter), if the last reported sale price of our common stock for at least </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during a period of </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day; (2) during the </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> business day period after any </span><span style="font-family:inherit;font-size:10pt;"><span>ten</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (the “measurement period”) in which the trading price (as defined in the Indenture) per </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> for each trading day of the measurement period was less than </span><span style="font-family:inherit;font-size:10pt;"><span>98%</span></span><span style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of our common stock and the conversion rate on each such trading day; (3) if we call any or all of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or (4) upon the occurrence of specified corporate events. On or after </span><span style="font-family:inherit;font-size:10pt;">November 15, 2026</span><span style="font-family:inherit;font-size:10pt;"> until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or any portion of their </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> at any time, regardless of the foregoing circumstances. Upon conversion, we will pay or deliver, as the case may be, cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The conversion rate will initially be </span><span style="font-family:inherit;font-size:10pt;">30.8804</span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock per </span><span style="font-family:inherit;font-size:10pt;">$1,000</span><span style="font-family:inherit;font-size:10pt;"> principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$32.38</span></span><span style="font-family:inherit;font-size:10pt;"> per share of our common stock). The conversion rate is subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, following certain corporate events that occur prior to the maturity date or if we deliver a notice of redemption, we will, in certain circumstances, increase the conversion rate for a holder who elects to convert its </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> in connection with such a corporate event or notice of redemption, as the case may be.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may not redeem the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> prior to </span><span style="font-family:inherit;font-size:10pt;">February 20, 2024</span><span style="font-family:inherit;font-size:10pt;">. We may redeem for cash all or any portion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, at our option, on or after </span><span style="font-family:inherit;font-size:10pt;">February 20, 2024</span><span style="font-family:inherit;font-size:10pt;"> if the last reported sale price of our common stock has been at least </span><span style="font-family:inherit;font-size:10pt;"><span>130%</span></span><span style="font-family:inherit;font-size:10pt;"> of the conversion price then in effect for at least </span><span style="font-family:inherit;font-size:10pt;"><span>20</span></span><span style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during any </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which we provide notice of redemption at a redemption price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> to be redeemed, plus any accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;color:#212529;">If we undergo a fundamental change (as defined in the Indenture), holders may require us to repurchase for cash all or any portion of their 2027 Notes at a fundamental change repurchase price equal to </span><span style="font-family:inherit;font-size:10pt;color:#212529;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;color:#212529;"> of the principal amount of the 2027 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accounting for the issuance of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, we separated the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> into liability and equity components. The carrying amount of the liability component was </span><span style="font-family:inherit;font-size:10pt;"><span>$175.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was calculated by using a discount rate of </span><span style="font-family:inherit;font-size:10pt;"><span>9.5%</span></span><span style="font-family:inherit;font-size:10pt;">, which was estimated to be our borrowing rate on the issuance date for a similar debt instrument without the conversion feature. The carrying amount of the equity component was </span><span style="font-family:inherit;font-size:10pt;"><span>$112.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, which represents the conversion option, and was determined by deducting the fair value of the liability component from the par value of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. The equity component of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> is included in additional paid-in capital in the condensed consolidated balance sheets and will not be subsequently remeasured as long as it continues to meet the conditions for equity classification. The difference between the principal amount of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> and the liability component (the “debt discount”) is amortized to interest expense in the condensed consolidated statements of operations and comprehensive loss using the effective interest method over the term of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total transaction costs for the issuance of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$9.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, consisting of initial purchasers’ discount, commissions, and other issuance costs. We allocated the total transaction costs proportionally to the liability and equity components. The transaction costs attributed to the liability component were </span><span style="font-family:inherit;font-size:10pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, which were recorded as debt issuance costs (presented as contra debt in our condensed consolidated balance sheets) and are amortized to interest expense in the condensed consolidated statements of operations and comprehensive loss over the term of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. The transaction costs attributed to the equity component were </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, which were included in additional paid-in capital.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense relating to the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> in the condensed consolidated statements of operations and comprehensive loss are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>643</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,461</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate on the liability component of the </span><span style="font-family:inherit;font-size:8pt;">2027 Notes</span><span style="font-family:inherit;font-size:8pt;"> was </span><span style="font-family:inherit;font-size:8pt;"><span>9.5%</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, which remained unchanged from the issuance date. As of </span><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, the unamortized debt discount was </span><span style="font-family:inherit;font-size:8pt;"><span>$110.6 million</span></span><span style="font-family:inherit;font-size:8pt;">, and will be amortized over </span><span style="font-family:inherit;font-size:8pt;"><span>6.9</span></span><span style="font-family:inherit;font-size:8pt;"> years.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, the unamortized debt issuance cost for the </span><span style="font-family:inherit;font-size:8pt;">2027 Notes</span><span style="font-family:inherit;font-size:8pt;"> was </span><span style="font-family:inherit;font-size:8pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:8pt;"> on the condensed consolidated balance sheets.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the convertible senior notes on the condensed consolidated balance sheets represented the carrying amount of the liability component of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, net of unamortized debt discounts and debt issuance costs, which are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Unamortized debt discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(116,195</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying amount of 2027 Notes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Capped Call Transactions</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Concurrently with the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, we entered into capped call transactions with one of the initial purchasers and another financial institution (the “option counterparties”) and used </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$28.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the net proceeds from the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce the potential dilutive effect upon conversion of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">and/or offset any cash payments we are required to make in excess of the principal amount of converted </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, as the case may be, with such reduction and/or offset subject to a price cap of </span><span style="font-family:inherit;font-size:10pt;"><span>$48.88</span></span><span style="font-family:inherit;font-size:10pt;"> of our common stock per share, which represents a premium of </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> over the last reported sale price of our common stock on </span><span style="font-family:inherit;font-size:10pt;">February 10, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;color:#212529;">The cap</span><span style="font-family:inherit;font-size:10pt;">ped calls have an initial strike price of </span><span style="font-family:inherit;font-size:10pt;"><span>$32.38</span></span><span style="font-family:inherit;font-size:10pt;"> per share, subject to certain adjustments, which corresponds to the conversion option strike </span><span style="font-family:inherit;font-size:10pt;color:#212529;">price</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. The capped call transactions cover, subject to anti-dilution adjustments, approximately </span><span style="font-family:inherit;font-size:10pt;color:#212529;"><span>8.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The capped call transactions are separate transactions that we entered into with the option counterparties and are not part of the terms of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">. As the capped call transactions meet certain accounting criteria, the premium paid of </span><span style="font-family:inherit;font-size:10pt;"><span>$28.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as a reduction in additional paid-in capital in the condensed consolidated balance sheets, and will not be remeasured to fair value as long as the accounting criteria continue to be met. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had not purchased any shares under the capped call transactions.</span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&trid=2208564<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>28 <FILENAME>R10.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799153024"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Short-Term Investments<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash Equivalents and Short-Term Investments</a></td> <td class="text">Cash Equivalents and Short-Term Investments<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our cash equivalents and short-term investments consist of money market funds, U.S. treasury securities, U.S. government agency obligations, commercial paper, and overnight repurchase agreements which are classified as available-for-sale securities.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table is a summary of amortized cost, unrealized gains and losses, and fair value of our cash equivalents and short-term investments: </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">in thousands</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,349</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,634</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,993</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,109</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,683</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Classified as:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>285,012</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short-term investments</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224,621</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118,955</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash equivalents and available-for-sale securities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> other-than-temporary impairments on our available-for-sale securities and the contractual maturities of the available-for-sale securities are less than one-year.</span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&trid=2176304<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>30 <FILENAME>R33.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6808527360"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases Leases - Operating Lease Liability Maturities (Details)<br> $ in Thousands</strong></div></th> <th class="th"> <div>Mar. 31, 2020 </div> <div>USD ($)</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 remaining nine months</a></td> <td class="nump">$ 5,057<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td> <td class="nump">6,942<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td> <td class="nump">5,464<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td> <td class="nump">5,557<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td> <td class="nump">5,733<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2025 and thereafter</a></td> <td class="nump">12,226<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td> <td class="nump">40,979<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest (1)</a></td> <td class="num">(12,462)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease payments</a></td> <td class="nump">$ 28,517<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate (percent)</a></td> <td class="nump">12.00%<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>31 <FILENAME>R37.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792556704"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Senior Notes - Carrying Amount of Liability Component (Details) - Convertible Debt - 2027 Notes - USD ($)<br> $ in Thousands</strong></div></th> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Feb. 14, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">2027 Notes</a></td> <td class="nump">$ 287,500<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and debt issuance costs</a></td> <td class="num">(116,195)<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount of 2027 Notes</a></td> <td class="nump">$ 171,305<span></span> </td> <td class="nump">$ 175,400<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LongTermDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rvnc_TwentyTwentySevenNotesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rvnc_TwentyTwentySevenNotesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>32 <FILENAME>R26.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797601024"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Details) - USD ($)<br></strong></div></th> <th class="th" colspan="1"></th> <th class="th" colspan="2">1 Months Ended</th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"><div>Feb. 28, 2018</div></th> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Jan. 31, 2019</div></th> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2019</div></th> <th class="th"><div>Dec. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 31,000,000.0<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 31,000,000.0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">58,000<span></span> </td> <td class="nump">$ 278,000<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td> <td class="text"> <span></span> </td> <td class="nump">10,079,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">10,079,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 7,911,000<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td> <td class="text"> <span></span> </td> <td class="nump">46,722,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">46,722,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">47,948,000<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rvnc_MylanIrelandLimitedMember', window );">Mylan</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Non-refundable upfront payment</a></td> <td class="nump">$ 30,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_ContingentLicensingRoyaltyRevenue', window );">Contingent payments</a></td> <td class="nump">100,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue', window );">Revenue maximum for receipt of tiered milestone payments</a></td> <td class="nump">$ 225,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td> <td class="text"> <span></span> </td> <td class="nump">106,800,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">106,800,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member', window );">Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_ContingentLicensingRoyaltyRevenue', window );">Contingent payments</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 230,500,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Contract with customer, asset, before allowance for credit loss</a></td> <td class="text"> <span></span> </td> <td class="nump">1,000,000.0<span></span> </td> <td class="nump">30,000,000.0<span></span> </td> <td class="nump">1,000,000.0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_ForeignWithholdingTaxAmount', window );">Foreign withholding tax, amount</a></td> <td class="text"> <span></span> </td> <td class="nump">100,000<span></span> </td> <td class="nump">$ 3,000,000.0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, liability, revenue recognized</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rvnc_DevelopmentServicesMember', window );">Development Services</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">100,000<span></span> </td> <td class="nump">$ 300,000<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current portion</a></td> <td class="text"> <span></span> </td> <td class="nump">10,100,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">10,100,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">7,900,000<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 15,700,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 15,700,000<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 18,000,000.0<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_ContingentLicensingRoyaltyRevenue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Licensing Royalty Revenue</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_ContingentLicensingRoyaltyRevenue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_ForeignWithholdingTaxAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Withholding Tax, Amount</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_ForeignWithholdingTaxAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Maximum Revenue</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Revenues</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rvnc_MylanIrelandLimitedMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">srt_CounterpartyNameAxis=rvnc_MylanIrelandLimitedMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">srt_CounterpartyNameAxis=rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rvnc_DevelopmentServicesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">srt_ProductOrServiceAxis=rvnc_DevelopmentServicesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>33 <FILENAME>R22.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792554448"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Tables)<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debt</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense relating to the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> in the condensed consolidated statements of operations and comprehensive loss are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contractual interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>643</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt discount </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,461</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The effective interest rate on the liability component of the </span><span style="font-family:inherit;font-size:8pt;">2027 Notes</span><span style="font-family:inherit;font-size:8pt;"> was </span><span style="font-family:inherit;font-size:8pt;"><span>9.5%</span></span><span style="font-family:inherit;font-size:8pt;"> for the </span><span style="font-family:inherit;font-size:8pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, which remained unchanged from the issuance date. As of </span><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, the unamortized debt discount was </span><span style="font-family:inherit;font-size:8pt;"><span>$110.6 million</span></span><span style="font-family:inherit;font-size:8pt;">, and will be amortized over </span><span style="font-family:inherit;font-size:8pt;"><span>6.9</span></span><span style="font-family:inherit;font-size:8pt;"> years.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup> </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">As of </span><span style="font-family:inherit;font-size:8pt;">March 31, 2020</span><span style="font-family:inherit;font-size:8pt;">, the unamortized debt issuance cost for the </span><span style="font-family:inherit;font-size:8pt;">2027 Notes</span><span style="font-family:inherit;font-size:8pt;"> was </span><span style="font-family:inherit;font-size:8pt;"><span>$5.6 million</span></span><span style="font-family:inherit;font-size:8pt;"> on the condensed consolidated balance sheets.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the convertible senior notes on the condensed consolidated balance sheets represented the carrying amount of the liability component of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;">, net of unamortized debt discounts and debt issuance costs, which are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>287,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: Unamortized debt discount and debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(116,195</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Carrying amount of 2027 Notes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>35 <FILENAME>R43.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792541776"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail)<br> $ in Thousands</strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"> <div>Mar. 31, 2020 </div> <div>USD ($)</div> </th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debt, fair value disclosures</a></td> <td class="nump">$ 229,500<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rvnc_DerivativeLiabilitySettlementMember', window );">Derivative Liability</a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2019</a></td> <td class="nump">2,952<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td> <td class="nump">90<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of March 31, 2020</a></td> <td class="nump">$ 3,042<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rvnc_DerivativeLiabilitySettlementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rvnc_DerivativeLiabilitySettlementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>36 <FILENAME>R8.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799153024"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">The Company and Summary of Significant Accounting Policies</a></td> <td class="text">The Company and Summary of Significant Accounting Policies<div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">The Company</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revance Therapeutics, Inc is a biotechnology company, developing new innovations in neuromodulators for aesthetic and therapeutic indications. Our lead product candidate, DaxibotulinumtoxinA for Injection, combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. We have successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines. In </span><span style="font-family:inherit;font-size:10pt;">November 2019</span><span style="font-family:inherit;font-size:10pt;">, we submitted the Biologics License Application (“BLA”) to the United States (the “U.S.”) Food and Drug Administration (the “FDA”) for DaxibotulinumtoxinA for Injection in the treatment of moderate to severe glabellar (frown) lines. The FDA accepted the BLA on </span><span style="font-family:inherit;font-size:10pt;">February 5, 2020</span><span style="font-family:inherit;font-size:10pt;">, and the Prescription Drug User Fee Act (“PDUFA”) target action date is </span><span style="font-family:inherit;font-size:10pt;">November 25, 2020</span><span style="font-family:inherit;font-size:10pt;">. We are also evaluating DaxibotulinumtoxinA for Injection in upper facial lines - glabellar lines, forehead lines and crow’s feet combined -- as well as in three therapeutic indications -- cervical dystonia, adult upper limb spasticity and plantar fasciitis. Beyond DaxibotulinumtoxinA for Injection, we have begun development of a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. In </span><span style="font-family:inherit;font-size:10pt;">January 2020</span><span style="font-family:inherit;font-size:10pt;">, we entered into an exclusive distribution agreement (the “Teoxane Agreement”) with Teoxane SA (“Teoxane”), pursuant to which Teoxane granted us with the exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid® (RHA®) dermal fillers. We are dedicated to making a difference by transforming patient experiences.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since inception, we have devoted substantially all of our efforts to identifying and developing product candidates for the aesthetic and therapeutic pharmaceutical markets, recruiting personnel, raising capital, conducting preclinical and clinical development of, and manufacturing development for DaxibotulinumtoxinA for Injection, DaxibotulinumtoxinA Topical, the biosimilar to BOTOX®, and preparing the commercial launch of Teoxane’s line of Resilient Hyaluronic Acid® dermal fillers. We have incurred losses and negative cash flows from operations. We have not generated product revenue to date, and will continue to incur significant research and development and other expenses related to our ongoing operations.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had a net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$61.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had a working capital surplus of </span><span style="font-family:inherit;font-size:10pt;"><span>$476.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and an accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;"><span>$906.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. In recent years, we have funded our operations primarily through a combination of issuance and sale of common stock and issuance of convertible senior notes. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had capital resources of </span><span style="font-family:inherit;font-size:10pt;"><span>$511.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> consisting of cash, cash equivalents, and short-term investments. We believe that our existing capital resources will fund the operating plan through at least the next </span><span style="font-family:inherit;font-size:10pt;"><span>12</span></span><span style="font-family:inherit;font-size:10pt;"> months following the issuance of this Form 10-Q, and may identify additional capital resources to fund our operations.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements are unaudited, and reflect all adjustments which are, in the opinion of management, of a normal recurring nature and necessary for a fair statement of the results for the interim periods presented. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated balance sheets for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. generally accepted accounting principles (“U.S. GAAP”). The interim results presented herein are not necessarily indicative of the results of operations that may be expected for the full fiscal year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, or any other future period. Our condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements contained in our Annual Report on Form 10-K for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, which was filed with the Securities and Exchange Commission (“SEC”), on </span><span style="font-family:inherit;font-size:10pt;">February 26, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries, and have been prepared in conformity with U.S. GAAP. We operate in </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> segment.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Principles of Consolidation</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our condensed consolidated financial statements include our accounts and our wholly-owned subsidiaries. All intercompany transactions have been eliminated.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, revenue recognition, deferred revenue classification, accruals including clinical trial costs, stock-based compensation, fair value of derivative liability, fair value of the liability component of the convertible senior notes, allocation of purchase consideration of asset acquisitions, and accounting for income taxes. We base these estimates on historical and anticipated results, trends and various other assumptions that we believe are reasonable under the circumstances. The worldwide continued spread of COVID-19 has caused a global slowdown of economic activity which has decreased demand for a broad variety of goods and services, including from our potential customers, while also disrupting sales channels and marketing activities for an unknown period of time until the disease is contained. We are unable to predict the future effect resulting from the COVID-19 pandemic on, for instance, paused clinical trials and revised product launch timing. As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change, as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intangible Assets</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets acquired in asset acquisition are stated at cost, less accumulated amortization on the condensed consolidated balance sheets, and are amortized on a ratable basis over their useful life. Assets acquired as part of an asset acquisition that are considered to be in-process research and development are immediately expensed unless there is an alternative future use in other research and development projects.</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40) Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;">. The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. We adopted ASU 2018-15 on January 1, 2020 on a prospective basis.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recent accounting pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations.</span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&trid=2197479<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>37 <FILENAME>R4.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809539040"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th" colspan="2">3 Months Ended</th> </tr> <tr> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td> <td class="nump">$ 58<span></span> </td> <td class="nump">$ 278<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td> <td class="nump">39,794<span></span> </td> <td class="nump">23,995<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td> <td class="nump">21,224<span></span> </td> <td class="nump">12,910<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td> <td class="nump">61,018<span></span> </td> <td class="nump">36,905<span></span> </td> </tr> <tr class="reu"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td> <td class="num">(60,960)<span></span> </td> <td class="num">(36,627)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td> <td class="nump">1,491<span></span> </td> <td class="nump">1,570<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td> <td class="num">(2,148)<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_GainLossonDerivativeInstrumentsContractNetPretax', window );">Changes in fair value of derivative liability</a></td> <td class="num">(90)<span></span> </td> <td class="num">(92)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td> <td class="num">(126)<span></span> </td> <td class="num">(155)<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss before income taxes</a></td> <td class="num">(61,833)<span></span> </td> <td class="num">(35,304)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td> <td class="num">(100)<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="num">(61,933)<span></span> </td> <td class="num">(35,304)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain and adjustment on securities included in net loss</a></td> <td class="nump">521<span></span> </td> <td class="nump">78<span></span> </td> </tr> <tr class="rou"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td> <td class="num">(61,412)<span></span> </td> <td class="num">(35,226)<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted', window );">Basic and diluted net loss</a></td> <td class="num">$ (61,933)<span></span> </td> <td class="num">$ (35,304)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss (in dollar per share)</a></td> <td class="num">$ (1.15)<span></span> </td> <td class="num">$ (0.85)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted-average number of shares used in computing net loss per share (in shares)</a></td> <td class="nump">53,868,036<span></span> </td> <td class="nump">41,598,919<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_GainLossonDerivativeInstrumentsContractNetPretax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Derivative Instruments, Contract, Net, Pretax</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_GainLossonDerivativeInstrumentsContractNetPretax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income Loss Available To Common Stockholders, Basic And Diluted</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InterestExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Revenues</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>38 <FILENAME>FilingSummary.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <XML> <?xml version='1.0' encoding='utf-8'?> <FilingSummary> <Version>3.20.1</Version> <ProcessingTime/> <ReportFormat>html</ReportFormat> <ContextCount>175</ContextCount> <ElementCount>310</ElementCount> <EntityCount>1</EntityCount> <FootnotesReported>false</FootnotesReported> <SegmentCount>56</SegmentCount> <ScenarioCount>0</ScenarioCount> <TuplesReported>false</TuplesReported> <UnitCount>6</UnitCount> <MyReports> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R1.htm</HtmlFileName> <LongName>0001000 - Document - Cover Page</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CoverPage</Role> <ShortName>Cover Page</ShortName> <MenuCategory>Cover</MenuCategory> <Position>1</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R2.htm</HtmlFileName> <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role> <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>2</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R3.htm</HtmlFileName> <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role> <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>3</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R4.htm</HtmlFileName> <LongName>1002000 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited</Role> <ShortName>Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>4</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R5.htm</HtmlFileName> <LongName>1003000 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited</Role> <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Condensed Consolidated Statements of Shareholders' Equity (Unaudited)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>5</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R6.htm</HtmlFileName> <LongName>1003001 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical</Role> <ShortName>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>6</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R7.htm</HtmlFileName> <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role> <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>7</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R8.htm</HtmlFileName> <LongName>2101100 - Disclosure - The Company and Summary of Significant Accounting Policies</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies</Role> <ShortName>The Company and Summary of Significant Accounting Policies</ShortName> <MenuCategory>Notes</MenuCategory> <Position>8</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R9.htm</HtmlFileName> <LongName>2102100 - Disclosure - Revenue</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/Revenue</Role> <ShortName>Revenue</ShortName> <MenuCategory>Notes</MenuCategory> <Position>9</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R10.htm</HtmlFileName> <LongName>2103100 - Disclosure - Cash Equivalents and Short-Term Investments</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CashEquivalentsAndShortTermInvestments</Role> <ShortName>Cash Equivalents and Short-Term Investments</ShortName> <MenuCategory>Notes</MenuCategory> <Position>10</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R11.htm</HtmlFileName> <LongName>2104100 - Disclosure - Filler Distribution Agreement</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/FillerDistributionAgreement</Role> <ShortName>Filler Distribution Agreement</ShortName> <MenuCategory>Notes</MenuCategory> <Position>11</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R12.htm</HtmlFileName> <LongName>2105100 - Disclosure - Derivative Liability</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/DerivativeLiability</Role> <ShortName>Derivative Liability</ShortName> <MenuCategory>Notes</MenuCategory> <Position>12</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R13.htm</HtmlFileName> <LongName>2106100 - Disclosure - Leases</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/Leases</Role> <ShortName>Leases</ShortName> <MenuCategory>Notes</MenuCategory> <Position>13</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R14.htm</HtmlFileName> <LongName>2107100 - Disclosure - Convertible Senior Notes</LongName> <ReportType>Notes</ReportType> <Role>http://www.revance.com/role/ConvertibleSeniorNotes</Role> <ShortName>Convertible Senior Notes</ShortName> <MenuCategory>Notes</MenuCategory> <Position>14</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R15.htm</HtmlFileName> <LongName>2108100 - Disclosure - Stockholders' Equity and Stock-Based Compensation</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/StockholdersEquityAndStockBasedCompensation</Role> <ShortName>Stockholders' Equity and Stock-Based Compensation</ShortName> <MenuCategory>Notes</MenuCategory> <Position>15</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R16.htm</HtmlFileName> <LongName>2109100 - Disclosure - Fair Value Measurements</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/FairValueMeasurements</Role> <ShortName>Fair Value Measurements</ShortName> <MenuCategory>Notes</MenuCategory> <Position>16</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R17.htm</HtmlFileName> <LongName>2110100 - Disclosure - Commitments and Contingencies</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CommitmentsAndContingencies</Role> <ShortName>Commitments and Contingencies</ShortName> <MenuCategory>Notes</MenuCategory> <Position>17</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R18.htm</HtmlFileName> <LongName>2201201 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies</Role> <ShortName>The Company and Summary of Significant Accounting Policies (Policies)</ShortName> <MenuCategory>Policies</MenuCategory> <ParentRole>http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies</ParentRole> <Position>18</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R19.htm</HtmlFileName> <LongName>2303301 - Disclosure - Cash Equivalents and Short-Term Investments (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsTables</Role> <ShortName>Cash Equivalents and Short-Term Investments (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://www.revance.com/role/CashEquivalentsAndShortTermInvestments</ParentRole> <Position>19</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R20.htm</HtmlFileName> <LongName>2304301 - Disclosure - Filler Distribution Agreement (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/FillerDistributionAgreementTables</Role> <ShortName>Filler Distribution Agreement (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://www.revance.com/role/FillerDistributionAgreement</ParentRole> <Position>20</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R21.htm</HtmlFileName> <LongName>2306301 - Disclosure - Leases Leases (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/LeasesLeasesTables</Role> <ShortName>Leases Leases (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <Position>21</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R22.htm</HtmlFileName> <LongName>2307301 - Disclosure - Convertible Senior Notes (Tables)</LongName> <ReportType>Notes</ReportType> <Role>http://www.revance.com/role/ConvertibleSeniorNotesTables</Role> <ShortName>Convertible Senior Notes (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://www.revance.com/role/ConvertibleSeniorNotes</ParentRole> <Position>22</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R23.htm</HtmlFileName> <LongName>2308301 - Disclosure - Stockholders' Equity and Stock-Based Compensation (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationTables</Role> <ShortName>Stockholders' Equity and Stock-Based Compensation (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://www.revance.com/role/StockholdersEquityAndStockBasedCompensation</ParentRole> <Position>23</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R24.htm</HtmlFileName> <LongName>2309301 - Disclosure - Fair Value Measurements (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/FairValueMeasurementsTables</Role> <ShortName>Fair Value Measurements (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://www.revance.com/role/FairValueMeasurements</ParentRole> <Position>24</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R25.htm</HtmlFileName> <LongName>2401402 - Disclosure - The Company and Summary of Significant Accounting Policies- Additional Information (Detail)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role> <ShortName>The Company and Summary of Significant Accounting Policies- Additional Information (Detail)</ShortName> <MenuCategory>Details</MenuCategory> <Position>25</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R26.htm</HtmlFileName> <LongName>2402401 - Disclosure - Revenue (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/RevenueDetails</Role> <ShortName>Revenue (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://www.revance.com/role/Revenue</ParentRole> <Position>26</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R27.htm</HtmlFileName> <LongName>2403402 - Disclosure - Cash Equivalents and Short-Term Investments (Detail)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail</Role> <ShortName>Cash Equivalents and Short-Term Investments (Detail)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsTables</ParentRole> <Position>27</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R28.htm</HtmlFileName> <LongName>2404402 - Disclosure - Filler Distribution Agreement - Narrative (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails</Role> <ShortName>Filler Distribution Agreement - Narrative (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>28</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R29.htm</HtmlFileName> <LongName>2404403 - Disclosure - Filler Distribution Agreement - Distributions Rights (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails</Role> <ShortName>Filler Distribution Agreement - Distributions Rights (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>29</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R30.htm</HtmlFileName> <LongName>2405401 - Disclosure - Derivative Liability - Additional Information (Detail)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail</Role> <ShortName>Derivative Liability - Additional Information (Detail)</ShortName> <MenuCategory>Details</MenuCategory> <Position>30</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R31.htm</HtmlFileName> <LongName>2406402 - Disclosure - Leases Leases (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/LeasesLeasesDetails</Role> <ShortName>Leases Leases (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://www.revance.com/role/LeasesLeasesTables</ParentRole> <Position>31</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R32.htm</HtmlFileName> <LongName>2406403 - Disclosure - Leases Leases - Operating Lease Costs (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails</Role> <ShortName>Leases Leases - Operating Lease Costs (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>32</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R33.htm</HtmlFileName> <LongName>2406404 - Disclosure - Leases Leases - Operating Lease Liability Maturities (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails</Role> <ShortName>Leases Leases - Operating Lease Liability Maturities (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>33</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R34.htm</HtmlFileName> <LongName>2406406 - Disclosure - Leases Leases - Supplemental Cash Flow Information (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails</Role> <ShortName>Leases Leases - Supplemental Cash Flow Information (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>34</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R35.htm</HtmlFileName> <LongName>2407402 - Disclosure - Convertible Senior Notes (Details)</LongName> <ReportType>Notes</ReportType> <Role>http://www.revance.com/role/ConvertibleSeniorNotesDetails</Role> <ShortName>Convertible Senior Notes (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://www.revance.com/role/ConvertibleSeniorNotesTables</ParentRole> <Position>35</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R36.htm</HtmlFileName> <LongName>2407403 - Disclosure - Convertible Senior Notes - Interest Expense (Details)</LongName> <ReportType>Notes</ReportType> <Role>http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails</Role> <ShortName>Convertible Senior Notes - Interest Expense (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>36</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R37.htm</HtmlFileName> <LongName>2407404 - Disclosure - Convertible Senior Notes - Carrying Amount of Liability Component (Details)</LongName> <ReportType>Notes</ReportType> <Role>http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails</Role> <ShortName>Convertible Senior Notes - Carrying Amount of Liability Component (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>37</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R38.htm</HtmlFileName> <LongName>2407405 - Disclosure - Convertible Senior Notes - Capped Call Transactions (Details)</LongName> <ReportType>Notes</ReportType> <Role>http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails</Role> <ShortName>Convertible Senior Notes - Capped Call Transactions (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>38</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R39.htm</HtmlFileName> <LongName>2408402 - Disclosure - Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Additional Information (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails</Role> <ShortName>Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Additional Information (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>39</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R40.htm</HtmlFileName> <LongName>2408403 - Disclosure - Stockholders' Equity and Stock-Based Compensation - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails</Role> <ShortName>Stockholders' Equity and Stock-Based Compensation - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>40</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R41.htm</HtmlFileName> <LongName>2408404 - Disclosure - Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Schedule of Stock-based Compensation Expense (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails</Role> <ShortName>Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Schedule of Stock-based Compensation Expense (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>41</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R42.htm</HtmlFileName> <LongName>2409402 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail</Role> <ShortName>Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail)</ShortName> <MenuCategory>Details</MenuCategory> <Position>42</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R43.htm</HtmlFileName> <LongName>2409403 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail</Role> <ShortName>Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail)</ShortName> <MenuCategory>Details</MenuCategory> <Position>43</Position> </Report> <Report instance="rvncq12010-q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R44.htm</HtmlFileName> <LongName>2410401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role> <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName> <MenuCategory>Details</MenuCategory> <Position>44</Position> </Report> <Report> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <LongName>All Reports</LongName> <ReportType>Book</ReportType> <ShortName>All Reports</ShortName> </Report> </MyReports> <InputFiles> <File doctype="10-Q" original="rvncq12010-q.htm">rvncq12010-q.htm</File> <File>rvnc-20200331.xsd</File> <File>rvnc-20200331_cal.xml</File> <File>rvnc-20200331_def.xml</File> <File>rvnc-20200331_lab.xml</File> <File>rvnc-20200331_pre.xml</File> <File>rvnc-q120exhibit311.htm</File> <File>rvnc-q120exhibit312.htm</File> <File>rvnc-q120exhibit321.htm</File> <File>rvnc-q120exhibit322.htm</File> </InputFiles> <SupplementalFiles/> <BaseTaxonomies> <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy> <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy> <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy> </BaseTaxonomies> <HasPresentationLinkbase>true</HasPresentationLinkbase> <HasCalculationLinkbase>true</HasCalculationLinkbase> </FilingSummary> </XML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>39 <FILENAME>R39.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810702512"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Additional Information (Details) - USD ($)<br></strong></div></th> <th class="th" colspan="3">1 Months Ended</th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"><div>Feb. 29, 2020</div></th> <th class="th"><div>Jan. 31, 2020</div></th> <th class="th"><div>Dec. 31, 2019</div></th> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2019</div></th> <th class="th"><div>Jan. 01, 2020</div></th> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">929,364<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">2,094,989<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenInducementPlanMember', window );">2014 Inducement Plan</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">246,130<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">300,000<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rvnc_FollowOnOfferingMember', window );">Follow On Offering</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues (in shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">6,500,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollar per share)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 17.00<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 103,600,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues (in shares)</a></td> <td class="text"> <span></span> </td> <td class="nump">975,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollar per share)</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 17.00<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 15,600,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=rvnc_AttheMarketOfferingMember', window );">At the Market Offering</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues (in shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum', window );">Stock issuance sales agreement, authorized offering price, maximum</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 125,000,000.0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum', window );">Commission, percentage, maximum</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">3.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Shares available for purchase under common stock warrants (in shares)</a></td> <td class="nump">34,113<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">34,113<span></span> </td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants', window );">Shares issued upon exercise of warrant (shares)</a></td> <td class="nump">11,134<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues (in shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">975,000<span></span> </td> <td class="nump">6,764,705<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Share-based Payment Arrangement | 2014 Equity Incentive Plan</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares underlying stock options granted (in shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">765,675<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | 2014 Equity Incentive Plan</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted under restricted stock awards (shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">1,261,225<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Common Stock | 2014 Equity Incentive Plan</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted under restricted stock awards (shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">215,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | 2014 Inducement Plan</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares underlying stock options granted (in shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock | 2014 Employee Stock Purchase Plan</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">1,704,005<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average | Outstanding common stock warrants</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in USD per share)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 14.95<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Issuance Costs, Commission, Percentage, Maximum</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Sales Agreement, Authorized Offering Price, Maximum</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise of Warrants</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenEquityIncentivePlanMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenEquityIncentivePlanMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenInducementPlanMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenInducementPlanMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PlanNameAxis=rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rvnc_FollowOnOfferingMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rvnc_FollowOnOfferingMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=rvnc_AttheMarketOfferingMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=rvnc_AttheMarketOfferingMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>40 <FILENAME>R31.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796039152"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases Leases (Details)<br></strong></div></th> <th class="th"><div>Mar. 31, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td> <td class="text">6 years 9 months 18 days<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extended term of lease</a></td> <td class="text">14 years<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>41 <FILENAME>R35.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810421920"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes (Details)<br></strong></div></th> <th class="th" colspan="1"></th> <th class="th" colspan="2">3 Months Ended</th> </tr> <tr> <th class="th"> <div>Feb. 14, 2020 </div> <div>USD ($) </div> <div>day </div> <div>$ / shares</div> </th> <th class="th"> <div>Mar. 31, 2020 </div> <div>USD ($)</div> </th> <th class="th"> <div>Mar. 31, 2019 </div> <div>USD ($)</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible senior notes</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 287,500,000<span></span> </td> <td class="nump">$ 0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2027 Notes</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td> <td class="nump">$ 287,500,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td> <td class="nump">1.75%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible senior notes</a></td> <td class="nump">$ 278,300,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td> <td class="nump">20<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td> <td class="nump">30<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td> <td class="nump">130.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td> <td class="nump">0.0308804<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td> <td class="nump">$ 32.38<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td> <td class="nump">100.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td> <td class="nump">$ 175,400,000<span></span> </td> <td class="nump">$ 171,305,000<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective percentage</a></td> <td class="text"> <span></span> </td> <td class="nump">9.50%<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying amount of equity component</a></td> <td class="nump">$ 112,100,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 9,200,000<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_DebtIssuanceCostsGrossLiabilityComponent', window );">Debt issuance costs, liability component</a></td> <td class="text"> <span></span> </td> <td class="nump">5,600,000<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_DebtIssuanceCostsGrossEquityComponent', window );">Debt issuance costs, equity component</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 3,600,000<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2027 Notes | Debt Conversion Terms One</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td> <td class="nump">20<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td> <td class="nump">30<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage of stock price trigger</a></td> <td class="nump">130.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2027 Notes | Debt Conversion Terms Two</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Threshold trading days | day</a></td> <td class="nump">5<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td> <td class="nump">10<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice', window );">Threshold percentage of stock trading price</a></td> <td class="nump">98.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Threshold Percentage Of Stock Trading Price</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_DebtIssuanceCostsGrossEquityComponent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Gross, Equity Component</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_DebtIssuanceCostsGrossEquityComponent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_DebtIssuanceCostsGrossLiabilityComponent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Gross, Liability Component</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_DebtIssuanceCostsGrossLiabilityComponent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:pureItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:integerItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:integerItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LongTermDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rvnc_TwentyTwentySevenNotesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rvnc_TwentyTwentySevenNotesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis=rvnc_DebtConversionTermsOneMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_DebtInstrumentConvertibleTermsOfConversionAxis=rvnc_DebtConversionTermsOneMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_DebtInstrumentConvertibleTermsOfConversionAxis=rvnc_DebtConversionTermsTwoMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_DebtInstrumentConvertibleTermsOfConversionAxis=rvnc_DebtConversionTermsTwoMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>JSON <SEQUENCE>42 <FILENAME>MetaLinks.json <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> { "instance": { "rvncq12010-q.htm": { "axisCustom": 1, "axisStandard": 19, "contextCount": 175, "dts": { "calculationLink": { "local": [ "rvnc-20200331_cal.xml" ] }, "definitionLink": { "local": [ "rvnc-20200331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "rvncq12010-q.htm" ] }, "labelLink": { "local": [ "rvnc-20200331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "rvnc-20200331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "rvnc-20200331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 390, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 20, "http://www.revance.com/20200331": 3, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 28 }, "keyCustom": 31, "keyStandard": 279, "memberCustom": 19, "memberStandard": 34, "nsprefix": "rvnc", "nsuri": "http://www.revance.com/20200331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.revance.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Cash Equivalents and Short-Term Investments", "role": "http://www.revance.com/role/CashEquivalentsAndShortTermInvestments", "shortName": "Cash Equivalents and Short-Term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Filler Distribution Agreement", "role": "http://www.revance.com/role/FillerDistributionAgreement", "shortName": "Filler Distribution Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Derivative Liability", "role": "http://www.revance.com/role/DerivativeLiability", "shortName": "Derivative Liability", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Leases", "role": "http://www.revance.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Convertible Senior Notes", "role": "http://www.revance.com/role/ConvertibleSeniorNotes", "shortName": "Convertible Senior Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Stockholders' Equity and Stock-Based Compensation", "role": "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensation", "shortName": "Stockholders' Equity and Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Fair Value Measurements", "role": "http://www.revance.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Commitments and Contingencies", "role": "http://www.revance.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - The Company and Summary of Significant Accounting Policies (Policies)", "role": "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "The Company and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Cash Equivalents and Short-Term Investments (Tables)", "role": "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsTables", "shortName": "Cash Equivalents and Short-Term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Filler Distribution Agreement (Tables)", "role": "http://www.revance.com/role/FillerDistributionAgreementTables", "shortName": "Filler Distribution Agreement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Leases Leases (Tables)", "role": "http://www.revance.com/role/LeasesLeasesTables", "shortName": "Leases Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Convertible Senior Notes (Tables)", "role": "http://www.revance.com/role/ConvertibleSeniorNotesTables", "shortName": "Convertible Senior Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Stockholders' Equity and Stock-Based Compensation (Tables)", "role": "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationTables", "shortName": "Stockholders' Equity and Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.revance.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - The Company and Summary of Significant Accounting Policies- Additional Information (Detail)", "role": "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "The Company and Summary of Significant Accounting Policies- Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Revenue (Details)", "role": "http://www.revance.com/role/RevenueDetails", "shortName": "Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "I2018Q1Feb28_srt_CounterpartyNameAxis_rvnc_MylanIrelandLimitedMember", "decimals": "-6", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Cash Equivalents and Short-Term Investments (Detail)", "role": "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail", "shortName": "Cash Equivalents and Short-Term Investments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentInProcess", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Filler Distribution Agreement - Narrative (Details)", "role": "http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails", "shortName": "Filler Distribution Agreement - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "D2020Q1Jan_us-gaap_TypeOfArrangementAxis_rvnc_TeoxaneAgreementMember", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Filler Distribution Agreement - Distributions Rights (Details)", "role": "http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails", "shortName": "Filler Distribution Agreement - Distributions Rights (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - Derivative Liability - Additional Information (Detail)", "role": "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail", "shortName": "Derivative Liability - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_CreditRiskContractMember_us-gaap_TypeOfArrangementAxis_rvnc_MedicisPharmaceuticalCorporationMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Leases Leases (Details)", "role": "http://www.revance.com/role/LeasesLeasesDetails", "shortName": "Leases Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406403 - Disclosure - Leases Leases - Operating Lease Costs (Details)", "role": "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails", "shortName": "Leases Leases - Operating Lease Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406404 - Disclosure - Leases Leases - Operating Lease Liability Maturities (Details)", "role": "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails", "shortName": "Leases Leases - Operating Lease Liability Maturities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "rvnc:LesseeSupplementalCashFlowInformationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406406 - Disclosure - Leases Leases - Supplemental Cash Flow Information (Details)", "role": "http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails", "shortName": "Leases Leases - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "rvnc:LesseeSupplementalCashFlowInformationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Convertible Senior Notes (Details)", "role": "http://www.revance.com/role/ConvertibleSeniorNotesDetails", "shortName": "Convertible Senior Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "I2020Q1Feb14_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Convertible Senior Notes - Interest Expense (Details)", "role": "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails", "shortName": "Convertible Senior Notes - Interest Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Convertible Senior Notes - Carrying Amount of Liability Component (Details)", "role": "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails", "shortName": "Convertible Senior Notes - Carrying Amount of Liability Component (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1_us-gaap_DebtInstrumentAxis_rvnc_TwentyTwentySevenNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "D2020Q1Feb14", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsForDerivativeInstrumentFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407405 - Disclosure - Convertible Senior Notes - Capped Call Transactions (Details)", "role": "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails", "shortName": "Convertible Senior Notes - Capped Call Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "D2020Q1Feb14", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsForDerivativeInstrumentFinancingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Additional Information (Details)", "role": "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails", "shortName": "Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1_us-gaap_PlanNameAxis_rvnc_TwoThousandAndFourteenEquityIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited)", "role": "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Stockholders' Equity and Stock-Based Compensation - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details)", "role": "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails", "shortName": "Stockholders' Equity and Stock-Based Compensation - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Schedule of Stock-based Compensation Expense (Details)", "role": "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails", "shortName": "Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Schedule of Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409402 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail)", "role": "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail", "shortName": "Fair Value Measurements - Schedule of Fair Value of Financial Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail)", "role": "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail", "shortName": "Fair Value Measurements - Summary of Changes in Fair Value of Financial Instruments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2020Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConvertibleDebtFairValueDisclosures", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "rvnc:IndemnificationLiabilityRecordedduringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410401 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "INF", "first": true, "lang": null, "name": "rvnc:IndemnificationLiabilityRecordedduringPeriod", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "role": "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Condensed Consolidated Statements of Shareholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003001 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical)", "role": "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical", "shortName": "Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Consolidated Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - The Company and Summary of Significant Accounting Policies", "role": "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies", "shortName": "The Company and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Revenue", "role": "http://www.revance.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "rvncq12010-q.htm", "contextRef": "FD2020Q1YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 56, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.revance.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "rvnc_AccruedMilestoneObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Milestone Obligations", "label": "Accrued Milestone Obligations", "terseLabel": "Nonrecurring milestone payment", "verboseLabel": "Accrued milestone obligations" } } }, "localname": "AccruedMilestoneObligations", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Adjustment To Additional Paid In Capital, Capped Call Transactions", "label": "Adjustment To Additional Paid In Capital, Capped Call Transactions", "negatedTerseLabel": "Capped call transactions" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalCappedCallTransactions", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_AttheMarketOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "At the Market Offering [Member]", "label": "At the Market Offering [Member]", "terseLabel": "At the Market Offering" } } }, "localname": "AttheMarketOfferingMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvnc_BioSentinelInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BioSentinel, Inc. [Member]", "label": "BioSentinel, Inc. [Member]", "terseLabel": "BioSentinel, Inc." } } }, "localname": "BioSentinelInc.Member", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_BotulinumToxinResearchAssociatesInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Botulinum Toxin Research Associates, Inc. [Member]", "label": "Botulinum Toxin Research Associates, Inc. [Member]", "terseLabel": "Botulinum Toxin Research Associates, Inc." } } }, "localname": "BotulinumToxinResearchAssociatesInc.Member", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capped Calls, Number Of Shares Subject To Anti-dilution Adjustments", "label": "Capped Calls, Number Of Shares Subject To Anti-dilution Adjustments", "terseLabel": "Number of shares subject to anti-dilution adjustments (in shares)" } } }, "localname": "CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails" ], "xbrltype": "sharesItemType" }, "rvnc_CappedCallsPremiumPercentageOverSalePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capped Calls, Premium Percentage Over Sale Price", "label": "Capped Calls, Premium Percentage Over Sale Price", "terseLabel": "Premium percentage over sale price" } } }, "localname": "CappedCallsPremiumPercentageOverSalePrice", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails" ], "xbrltype": "percentItemType" }, "rvnc_CappedCallsPriceCap": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capped Calls, Price Cap", "label": "Capped Calls, Price Cap", "terseLabel": "Price cap (in dollars per share)" } } }, "localname": "CappedCallsPriceCap", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails" ], "xbrltype": "perShareItemType" }, "rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash and Cash Equivalents, and Investments, Operating Plan Funding Term, Minimum", "label": "Cash and Cash Equivalents, and Investments, Operating Plan Funding Term, Minimum", "terseLabel": "Cash and cash equivalents, and investments, expected funding term for operating plan (in months)" } } }, "localname": "CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "rvnc_CollaborativeAgreementContractualPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Agreement, Contractual Period", "label": "Collaborative Agreement, Contractual Period", "terseLabel": "Collaborative agreement, contractual period" } } }, "localname": "CollaborativeAgreementContractualPeriod", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" ], "xbrltype": "durationItemType" }, "rvnc_CollaborativeAgreementExtendedContractualPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Agreement, Extended Contractual Period", "label": "Collaborative Agreement, Extended Contractual Period", "terseLabel": "Collaborative agreement, extended contractual period" } } }, "localname": "CollaborativeAgreementExtendedContractualPeriod", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" ], "xbrltype": "durationItemType" }, "rvnc_ContingentLicensingRoyaltyRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent Licensing Royalty Revenue", "label": "Contingent Licensing Royalty Revenue", "terseLabel": "Contingent payments" } } }, "localname": "ContingentLicensingRoyaltyRevenue", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_DebtConversionTermsOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Conversion Terms One [Member]", "label": "Debt Conversion Terms One [Member]", "terseLabel": "Debt Conversion Terms One" } } }, "localname": "DebtConversionTermsOneMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "rvnc_DebtConversionTermsTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Conversion Terms Two [Member]", "label": "Debt Conversion Terms Two [Member]", "terseLabel": "Debt Conversion Terms Two" } } }, "localname": "DebtConversionTermsTwoMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "rvnc_DebtInstrumentConvertibleTermsOfConversionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument Convertible Terms Of Conversion [Axis]", "label": "Debt Instrument Convertible Terms Of Conversion [Axis]", "terseLabel": "Debt Instrument Convertible Terms Of Conversion [Axis]" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionAxis", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "rvnc_DebtInstrumentConvertibleTermsOfConversionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Debt Instrument Convertible Terms Of Conversion [Axis]", "label": "Debt Instrument Convertible Terms Of Conversion [Domain]", "terseLabel": "Debt Instrument Convertible Terms Of Conversion [Domain]" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionDomain", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "rvnc_DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Convertible, Threshold Percentage Of Stock Trading Price", "label": "Debt Instrument, Convertible, Threshold Percentage Of Stock Trading Price", "terseLabel": "Threshold percentage of stock trading price" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockTradingPrice", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "percentItemType" }, "rvnc_DebtIssuanceCostsGrossEquityComponent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Issuance Costs, Gross, Equity Component", "label": "Debt Issuance Costs, Gross, Equity Component", "terseLabel": "Debt issuance costs, equity component" } } }, "localname": "DebtIssuanceCostsGrossEquityComponent", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_DebtIssuanceCostsGrossLiabilityComponent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Issuance Costs, Gross, Liability Component", "label": "Debt Issuance Costs, Gross, Liability Component", "terseLabel": "Debt issuance costs, liability component" } } }, "localname": "DebtIssuanceCostsGrossLiabilityComponent", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_DerivativeLiabilitySettlementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative Liability Settlement [Member]", "label": "Derivative Liability Settlement [Member]", "terseLabel": "Derivative liability", "verboseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilitySettlementMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail", "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "rvnc_DevelopmentServicesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Development Services [Member]", "label": "Development Services [Member]", "terseLabel": "Development Services" } } }, "localname": "DevelopmentServicesMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "rvnc_ESPPPurchasesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ESPP Purchases [Member]", "label": "ESPP Purchases [Member]", "terseLabel": "Shares of common stock expected to be purchased on June 30 under the 2014 ESPP" } } }, "localname": "ESPPPurchasesMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "rvnc_EquityComponentOfConvertibleDebtTransactionCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity Component Of Convertible Debt, Transaction Cost", "label": "Equity Component Of Convertible Debt, Transaction Cost", "terseLabel": "Equity component of convertible debt, transaction cost" } } }, "localname": "EquityComponentOfConvertibleDebtTransactionCost", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "rvnc_FairValueMeasurementInput": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value, Measurement Input", "label": "Fair Value, Measurement Input", "terseLabel": "Fair value, measurement input (percent)" } } }, "localname": "FairValueMeasurementInput", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "rvnc_FairValueMeasurementInputDuration": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value, Measurement Input, Duration", "label": "Fair Value, Measurement Input, Duration", "terseLabel": "Fair value, measurement input, duration" } } }, "localname": "FairValueMeasurementInputDuration", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "rvnc_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Follow On Offering [Member]", "label": "Follow On Offering [Member]", "terseLabel": "Follow On Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvnc_ForeignWithholdingTaxAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Foreign Withholding Tax, Amount", "label": "Foreign Withholding Tax, Amount", "terseLabel": "Foreign withholding tax, amount" } } }, "localname": "ForeignWithholdingTaxAmount", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_GainLossonDerivativeInstrumentsContractNetPretax": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Gain (Loss) on Derivative Instruments, Contract, Net, Pretax", "label": "Gain (Loss) on Derivative Instruments, Contract, Net, Pretax", "terseLabel": "Changes in fair value of derivative liability" } } }, "localname": "GainLossonDerivativeInstrumentsContractNetPretax", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_IncreaseDecreaseinOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Operating Lease Liabilities", "label": "Increase (Decrease) in Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseinOperatingLeaseLiabilities", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_IncreaseDecreaseinOperatingLeaseRightofUseAssets": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Operating Lease Right of Use Assets", "label": "Increase (Decrease) in Operating Lease Right of Use Assets", "negatedLabel": "Operating lease right of use assets" } } }, "localname": "IncreaseDecreaseinOperatingLeaseRightofUseAssets", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_IndemnificationLiabilityRecordedduringPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Indemnification Liability Recorded during Period", "label": "Indemnification Liability Recorded during Period", "terseLabel": "Indemnification liability recorded during the period" } } }, "localname": "IndemnificationLiabilityRecordedduringPeriod", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rvnc_LesseeSupplementalCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Supplemental Cash Flow Information [Table Text Block]", "label": "Lessee, Supplemental Cash Flow Information [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "LesseeSupplementalCashFlowInformationTableTextBlock", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/LeasesLeasesTables" ], "xbrltype": "textBlockItemType" }, "rvnc_ListLaboratoriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "List Laboratories [Member]", "label": "List Laboratories [Member]", "terseLabel": "List Laboratories" } } }, "localname": "ListLaboratoriesMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_MedicisPharmaceuticalCorporationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medicis Pharmaceutical Corporation [Member]", "label": "Medicis Pharmaceutical Corporation [Member]", "terseLabel": "Medicis Pharmaceutical Corporation" } } }, "localname": "MedicisPharmaceuticalCorporationMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_MylanIrelandLimitedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Mylan Ireland Limited [Member]", "label": "Mylan Ireland Limited [Member]", "terseLabel": "Mylan" } } }, "localname": "MylanIrelandLimitedMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "rvnc_NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net Income Loss Available To Common Stockholders, Basic And Diluted", "label": "Net Income Loss Available To Common Stockholders, Basic And Diluted", "verboseLabel": "Basic and diluted net loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_NoncashDeferredOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncash Deferred Offering Costs", "label": "Noncash Deferred Offering Costs", "terseLabel": "Accrued offering costs" } } }, "localname": "NoncashDeferredOfferingCosts", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds From Issuance of Follow-On Offering, Net of Commissions and Discount", "label": "Proceeds From Issuance of Follow-On Offering, Net of Commissions and Discount", "terseLabel": "Proceeds from issuance of common stock in connection with offerings, net of commissions and discount" } } }, "localname": "ProceedsFromIssuanceofFollowOnOfferingNetofCommissionsandDiscount", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_RevenueRecognitionMilestoneMethodMaximumRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Revenue Recognition, Milestone Method, Maximum Revenue", "label": "Revenue Recognition, Milestone Method, Maximum Revenue", "terseLabel": "Revenue maximum for receipt of tiered milestone payments" } } }, "localname": "RevenueRecognitionMilestoneMethodMaximumRevenue", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_SaleofStockIssuanceCostsCommissionPercentageMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of Stock, Issuance Costs, Commission, Percentage, Maximum", "label": "Sale of Stock, Issuance Costs, Commission, Percentage, Maximum", "terseLabel": "Commission, percentage, maximum" } } }, "localname": "SaleofStockIssuanceCostsCommissionPercentageMaximum", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "rvnc_SettlementAndTerminationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Settlement And Termination [Line Items]", "label": "Settlement And Termination [Line Items]", "terseLabel": "Settlement And Termination [Line Items]" } } }, "localname": "SettlementAndTerminationLineItems", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rvnc_ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. [Member]", "label": "Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. [Member]", "terseLabel": "Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd." } } }, "localname": "ShanghaiFosunPharmaceuticalIndustrialDevelopmentCo.Ltd.Member", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "rvnc_StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock Issuance Sales Agreement, Authorized Offering Price, Maximum", "label": "Stock Issuance Sales Agreement, Authorized Offering Price, Maximum", "terseLabel": "Stock issuance sales agreement, authorized offering price, maximum" } } }, "localname": "StockIssuanceSalesAgreementAuthorizedOfferingPriceMaximum", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "rvnc_StockIssuedDuringPeriodSharesExerciseofWarrants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period, Shares, Exercise of Warrants", "label": "Stock Issued During Period, Shares, Exercise of Warrants", "terseLabel": "Shares issued upon exercise of warrant (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesExerciseofWarrants", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period Shares Restricted Stock Award, Net of Shares Repurchased", "label": "Stock Issued During Period Shares Restricted Stock Award, Net of Shares Repurchased", "terseLabel": "Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Stock Issued During Period Value Restricted Stock Award, Net of Shares Repurchased", "label": "Stock Issued During Period Value Restricted Stock Award, Net Of Shares Repurchased", "terseLabel": "Issuance of restricted stock awards and performance stock awards, net of cancellation" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "rvnc_TeoxaneAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Teoxane Agreement [Member]", "label": "Teoxane Agreement [Member]", "terseLabel": "Teoxane Agreement" } } }, "localname": "TeoxaneAgreementMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "rvnc_TwentyTwentySevenNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Twenty Twenty Seven Notes [Member]", "label": "Twenty Twenty Seven Notes [Member]", "verboseLabel": "2027 Notes" } } }, "localname": "TwentyTwentySevenNotesMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails", "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails", "http://www.revance.com/role/ConvertibleSeniorNotesDetails", "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "rvnc_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]", "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]", "terseLabel": "2014 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvnc_TwoThousandAndFourteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand And Fourteen Equity Incentive Plan [Member]", "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]", "terseLabel": "2014 Equity Incentive Plan" } } }, "localname": "TwoThousandAndFourteenEquityIncentivePlanMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvnc_TwoThousandAndFourteenInducementPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand And Fourteen Inducement Plan [Member]", "label": "Two Thousand And Fourteen Inducement Plan [Member]", "terseLabel": "2014 Inducement Plan" } } }, "localname": "TwoThousandAndFourteenInducementPlanMember", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "rvnc_ValeantPharmaceuticalsInternationalInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Valeant Pharmaceuticals International, Inc. [Member]", "label": "Valeant Pharmaceuticals International, Inc. [Member]", "terseLabel": "Valeant Pharmaceuticals International, Inc." } } }, "localname": "ValeantPharmaceuticalsInternationalInc.Member", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rvnc_WorkingCapitalSurplus": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Working Capital Surplus", "label": "Working Capital Surplus", "terseLabel": "Working capital surplus" } } }, "localname": "WorkingCapitalSurplus", "nsuri": "http://www.revance.com/20200331", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r36", "r82" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r104", "r170", "r173", "r278", "r279" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r73" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Amortization of discount on investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accruals and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r39", "r40", "r41" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r38", "r41", "r42", "r199" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Other Accumulated Comprehensive Gain (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Acquired Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r15" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Net settlement of restricted stock awards for employee taxes" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r148" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt", "terseLabel": "Equity component of convertible senior notes, net of transaction costs of $3,583" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r177", "r179", "r190", "r191" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r179", "r186", "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "positiveLabel": "Total stock based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r55", "r72", "r225" ], "calculation": { "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "verboseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r51", "r72", "r227" ], "calculation": { "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r72", "r227" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail", "http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r102", "r255", "r271" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r2", "r3", "r34" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r110" ], "calculation": { "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r111" ], "calculation": { "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r108", "r118" ], "calculation": { "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r106", "r109", "r118" ], "calculation": { "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r180", "r187" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail", "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r203", "r207" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail", "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r22", "r74" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents, and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r69", "r74", "r78" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH \u2014 End of period", "periodStartLabel": "CASH, CASH EQUIVALENTS, AND RESTRICTED CASH \u2014 Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r69", "r223" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price per share (in USD per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [ "r85" ], "lang": { "en-US": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Shares available for purchase under common stock warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r194", "r195", "r197" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Revenue" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r31", "r135", "r263", "r276" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (Note 10)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r134", "r142" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r32" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollar per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r158" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending Balance (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $0.001 per share \u2014 95,000,000 shares authorized both as of March 31, 2020 and December 31, 2019; 57,026,154 and 52,374,735 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r44", "r46", "r47" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r79", "r198", "r200", "r201" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetGross": { "auth_ref": [ "r166", "r168", "r171" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, before Allowance for Credit Loss", "terseLabel": "Contract with customer, asset, before allowance for credit loss" } } }, "localname": "ContractWithCustomerAssetGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r166", "r167", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Non-refundable upfront payment" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r166", "r167", "r171" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "verboseLabel": "Deferred revenue, current portion" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r166", "r167", "r171" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "verboseLabel": "Deferred revenue, net of current portion" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r172" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with customer, liability, revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "Convertible debt, fair value disclosures" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r147" ], "lang": { "en-US": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails", "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails", "http://www.revance.com/role/ConvertibleSeniorNotesDetails", "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]", "terseLabel": "Convertible senior notes" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Convertible Debt" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditRiskContractMember": { "auth_ref": [ "r174", "r209" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the creditworthiness or the credit spread of an entity.", "label": "Credit Risk Contract [Member]", "terseLabel": "Product Approval Payment Derivative" } } }, "localname": "CreditRiskContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r9", "r11", "r12", "r256", "r257", "r269" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails", "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails", "http://www.revance.com/role/ConvertibleSeniorNotesDetails", "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r12", "r150", "r257", "r269" ], "calculation": { "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "2027 Notes" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r149" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "terseLabel": "Carrying amount of equity component" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price (in dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails", "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r29", "r159", "r160", "r162" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": { "auth_ref": [ "r153" ], "lang": { "en-US": { "role": { "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period", "terseLabel": "Remaining discount amortization period" } } }, "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.", "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Threshold percentage of stock price trigger" } } }, "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Threshold trading days" } } }, "localname": "DebtInstrumentConvertibleThresholdTradingDays", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r226", "r228" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r28", "r155", "r226" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective percentage" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails", "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r28" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails", "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails", "http://www.revance.com/role/ConvertibleSeniorNotesDetails", "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails", "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails", "http://www.revance.com/role/ConvertibleSeniorNotesDetails", "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price, percentage" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r30", "r83", "r159", "r161", "r162", "r163", "r225", "r226", "r228", "r268" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails", "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails", "http://www.revance.com/role/ConvertibleSeniorNotesDetails", "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r225", "r228" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r151", "r227" ], "calculation": { "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedTerseLabel": "Less: Unamortized debt discount and debt issuance costs" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r75", "r76", "r77" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "terseLabel": "Accrued transaction costs on convertible senior notes" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Available-for-sale Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsGross": { "auth_ref": [ "r227" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs" } } }, "localname": "DeferredFinanceCostsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r23", "r227" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r72", "r100" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r204", "r205", "r208", "r210" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Liability" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/DerivativeLiability" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "auth_ref": [ "r206" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "terseLabel": "Fair value of derivative" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability, Current", "terseLabel": "Derivative liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DistributionRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.", "label": "Distribution Rights [Member]", "terseLabel": "Distribution Rights" } } }, "localname": "DistributionRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic and diluted net loss (in dollar per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Outstanding common stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails", "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r158" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r218", "r221" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r218", "r221" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Changes in Fair Value of Financial Instruments" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r174", "r175", "r176", "r214", "r248" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r213", "r214", "r216", "r217", "r222" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r174", "r175", "r176", "r214", "r249" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r174", "r175", "r176", "r214", "r250" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r174", "r175", "r176", "r214", "r251" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r218", "r221" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "terseLabel": "Total assets measured at fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r219" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair value as of March 31, 2020", "periodStartLabel": "Fair value as of December 31, 2019" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r220", "r222" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfAssetsAcquired": { "auth_ref": [ "r75", "r76", "r77" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The fair value of assets acquired in noncash investing or financing activities.", "label": "Fair Value of Assets Acquired", "terseLabel": "Fair value of assets acquired" } } }, "localname": "FairValueOfAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r113", "r114", "r115", "r116", "r117", "r119", "r120", "r121", "r122" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail", "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-lived intangible asset, useful life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r129" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r125", "r126", "r129", "r130", "r253" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r129", "r253" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Initial Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r125", "r128" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeLossAttributableToParent": { "auth_ref": [ "r52" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Income (Loss) Attributable to Parent, before Tax", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r80", "r101", "r193" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedTerseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r71" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r71" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accruals and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r71" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Filler Distribution Agreement" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "auth_ref": [ "r79", "r128" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsFiniteLivedPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r124", "r127" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Net Carrying Amount" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r48", "r99", "r224", "r227", "r265" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r55", "r156" ], "calculation": { "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt", "totalLabel": "Total interest expense" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r57" ], "calculation": { "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual interest expense" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r54" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r112", "r254", "r266", "r280" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Cash Equivalents and Short-Term Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r239", "r241" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total operating lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Operating Lease Costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Operating Lease Liability Maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r240" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total operating lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r240" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "2025 and thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r240" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r240" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r240" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r240" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r240" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2020 remaining nine months" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r240" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less imputed interest (1)" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Extended term of lease" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r25" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r19", "r258", "r274" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Derivative liability" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r213" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Total liabilities measured at fair value" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r12", "r152", "r257", "r272" ], "calculation": { "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt", "totalLabel": "Carrying amount of 2027 Notes" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails", "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r157" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Convertible Senior Notes" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails", "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails", "http://www.revance.com/role/ConvertibleSeniorNotesDetails", "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r30", "r146" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails", "http://www.revance.com/role/ConvertibleSeniorNotesCarryingAmountOfLiabilityComponentDetails", "http://www.revance.com/role/ConvertibleSeniorNotesDetails", "http://www.revance.com/role/ConvertibleSeniorNotesInterestExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r143", "r144" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MaturityOvernightMember": { "auth_ref": [ "r86" ], "lang": { "en-US": { "role": { "documentation": "Maturity period of the day after the reporting date for repurchase agreements and similar transactions, for example, but not limited to, securities lending arrangements.", "label": "Maturity Overnight [Member]", "terseLabel": "Overnight repurchase agreements" } } }, "localname": "MaturityOvernightMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputEntityCreditRiskMember": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using risk of default, credit spread risk and downgrade risk.", "label": "Measurement Input, Entity Credit Risk [Member]", "terseLabel": "Measurement Input, Entity Credit Risk" } } }, "localname": "MeasurementInputEntityCreditRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Measurement Input, Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Measurement Input, Risk Free Interest Rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Proceeds from issuance of common stock in connection with offerings, net of commissions and discount" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69", "r70", "r73" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r43", "r45", "r50", "r73", "r89", "r264", "r277" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedTerseLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited", "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "auth_ref": [ "r75", "r76", "r77" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Issuance of common stock in connection with the Teoxane Agreement" } } }, "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": { "auth_ref": [ "r75", "r76", "r77" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.", "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)", "terseLabel": "Property and equipment purchases included in accounts payable and accruals" } } }, "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r233", "r241" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r230" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of operating lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r230" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r230" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r231", "r235" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r229" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r238", "r241" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate (percent)" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseLiabilityMaturitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r237", "r241" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r202" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "The Company and Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r23" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r37", "r39" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Unrealized gain and adjustment on securities included in net loss", "verboseLabel": "Unrealized gain and adjustment on securities included in net loss" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r203", "r211" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Short-term investments" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Other Intangible Assets, Net", "terseLabel": "Intangible assets" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r73" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other non-cash operating activities" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 5.0, "parentTag": "us-gaap_IncomeLossAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale", "terseLabel": "Other-than-temporary impairments on available-for-sale securities" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over-Allotment Option [Member]", "terseLabel": "Over-Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": { "auth_ref": [ "r65", "r68" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.", "label": "Payments for Derivative Instrument, Financing Activities", "negatedTerseLabel": "Payment of capped call transactions", "terseLabel": "Payment of capped call transactions" } } }, "localname": "PaymentsForDerivativeInstrumentFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.revance.com/role/ConvertibleSeniorNotesCappedCallTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r66" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Payment of convertible senior notes transaction costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r67" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedTerseLabel": "Payment of offering costs", "terseLabel": "Payments of stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r64" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Net settlement of restricted stock awards for employee taxes" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r60" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchase of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r60" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r61" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-term Investments", "negatedTerseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance-based Common Stock" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r180", "r187" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Convertible preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Convertible preferred stock authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Convertible preferred stock issued (shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r13" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Convertible preferred stock outstanding (shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r13" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Convertible preferred stock, par value $0.001 per share \u2014 5,000,000 shares authorized, and no shares issued and outstanding as of March 31, 2020 and December 31, 2019" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r2", "r20", "r21" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r63" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuance of convertible senior notes" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.revance.com/role/ConvertibleSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r62" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "auth_ref": [ "r59", "r61" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Maturities, Prepayments and Calls of Short-term Investments", "terseLabel": "Proceeds from maturities of investments" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r62", "r188" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of stock options and common stock warrants" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r6", "r7", "r132", "r275" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepurchaseAgreementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.", "label": "Repurchase Agreements [Member]", "terseLabel": "Overnight repurchase agreements" } } }, "localname": "RepurchaseAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r192", "r282" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Non-cash in-process research and development" } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r4", "r8", "r74", "r78", "r281" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock awards and performance stock awards", "verboseLabel": "Restricted Stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails", "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r16", "r164", "r273" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r169" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r49", "r97", "r98", "r103" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited", "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r236", "r241" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "auth_ref": [ "r125" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementDistributionsRightsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Summary of Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r179", "r185", "r189" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r179", "r185", "r189" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r213", "r214" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value of Financial Instruments" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r125", "r128" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r125", "r128" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/FillerDistributionAgreementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r81", "r243", "r244", "r245", "r246", "r247" ], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r180", "r187" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r53", "r123" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r58" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "General and Administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanScheduleOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorLongTermNotes": { "auth_ref": [ "r30" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.", "label": "Senior Notes, Noncurrent", "terseLabel": "Convertible senior notes" } } }, "localname": "SeniorLongTermNotes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r71" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares granted under restricted stock awards (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Shares underlying stock options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r178", "r181" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in dollar per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Net settlement of restricted stock awards for employee taxes (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r10", "r259", "r260", "r262", "r270" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r33", "r158" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r88" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "terseLabel": "Share-based Payment Arrangement" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r13", "r14", "r158", "r164" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock issued during period, shares, new issues (in shares)", "verboseLabel": "Issuance of common stock in connection with offerings (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Shares, Purchase of Assets", "terseLabel": "Issuance of common stock in connection with the Teoxane Agreement (in shares)", "verboseLabel": "Stock issued during period, purchase of assets (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited", "http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r13", "r14", "r158", "r164", "r182" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of common stock upon exercise of stock options and warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r13", "r14", "r158", "r164" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock in connection with offerings" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock Issued During Period, Value, Purchase of Assets", "terseLabel": "Issuance of common stock in connection with the Teoxane Agreement" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r33", "r158", "r164" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options and warrants" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r14", "r17", "r18", "r105" ], "calculation": { "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedCondensedConsolidatedStatementsOfShareholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity and Stock-Based Compensation" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfShareholdersEquityUnauditedConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail", "http://www.revance.com/role/FairValueMeasurementsSummaryOfChangesInFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.revance.com/role/DerivativeLiabilityAdditionalInformationDetail", "http://www.revance.com/role/FillerDistributionAgreementNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r174", "r261" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency obligations" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r174", "r176", "r261" ], "lang": { "en-US": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CashEquivalentsAndShortTermInvestmentsDetail", "http://www.revance.com/role/FairValueMeasurementsScheduleOfFairValueOfFinancialInstrumentsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r90", "r91", "r92", "r93", "r94", "r95", "r96" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CompanyAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r234", "r241" ], "calculation": { "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/LeasesLeasesOperatingLeaseCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Outstanding common stock warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationCommonStockEquivalentsExcludedFromCalculationOfEarningsPerShareDetails", "http://www.revance.com/role/StockholdersEquityAndStockBasedCompensationStockOptionPlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic and diluted weighted-average number of shares used in computing net loss per share (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.revance.com/role/CondensedConsolidatedStatementOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r131": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-02)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3A-03)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(5)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r212": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r254": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6)(a)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r283": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r284": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r285": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r286": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r287": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r288": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.20)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3505-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i)(4))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(m)(1)(i)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" } }, "version": "2.1" } </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>43 <FILENAME>R16.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792622112"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td> <td class="text">Fair Value Measurements<div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy:</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209,337</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>184,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For Level 1 investments, we use quoted prices in active markets for identical assets to determine the fair value. For Level 2 investments, we use quoted prices for similar assets sourced from certain third-party pricing services. The third-party pricing services generally utilize industry standard valuation models for which all significant inputs are observable, either directly or indirectly, to estimate the price or fair value of the securities. The primary input generally includes reported trade of or quotes on the same or similar securities. We do not make additional judgments or assumptions made to the pricing data sourced from the third-party pricing services. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the change in the fair value of our Level 3 financial instrument:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Liability </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor based primarily on the estimated timing of the payment and a credit risk adjustment (</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Note 5</span><span style="font-family:inherit;font-size:10pt;">). Generally, increases or decreases in these unobservable inputs would result in a directionally similar impact to the fair value measurement of this derivative instrument. The significant unobservable inputs used in the fair value measurement of the product approval payment derivative are the expected timing and probability of the payments at the valuation date and the credit risk adjustment.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">Note 7</span><span style="font-family:inherit;font-size:10pt;">) was determined on the basis of market prices observable for similar instruments and is considered Level 2 in the fair value hierarchy. We carry </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> at face value less unamortized debt discount and issuance costs on our condensed consolidated balance sheets and present the fair value for disclosure purposes only. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the </span><span style="font-family:inherit;font-size:10pt;">2027 Notes</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$229.5 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>44 <FILENAME>R12.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799159472"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Liability</a></td> <td class="text">Derivative Liability<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In 2012, we entered into a settlement agreement in which we are obligated to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon achieving regulatory approval for DaxibotulinumtoxinA for Injection or DaxibotulinumtoxinA Topical. We determined that such payment was a derivative instrument that requires fair value accounting as a liability and periodic fair value remeasurements until settled. The fair value of the derivative liability was determined by estimating the timing and probability of the related regulatory approval and multiplying the payment amount by this probability percentage and a discount factor. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the derivative liability was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span>0.7 years</span></span><span style="font-family:inherit;font-size:10pt;"> based on an expected BLA approval in 2020, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>0.2%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>7.5%</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the fair value of the derivative liability was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was measured using a term of </span><span style="font-family:inherit;font-size:10pt;"><span>0.9 years</span></span><span style="font-family:inherit;font-size:10pt;"> based on an expected BLA approval in 2020, a risk-free rate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.6%</span></span><span style="font-family:inherit;font-size:10pt;"> and a credit risk adjustment of </span><span style="font-family:inherit;font-size:10pt;"><span>7.5%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&trid=2229140<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>45 <FILENAME>R24.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636645312"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Instruments</a></td> <td class="text"><div style="line-height:120%;padding-bottom:0px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes, for assets and liabilities measured at fair value, the respective fair value and the classification by level of input within the fair value hierarchy:</span></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>179,031</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30,306</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159,976</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140,320</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>509,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209,337</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300,296</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,258</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. treasury securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48,355</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77,082</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Overnight repurchase agreements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15,001</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S. government agency obligations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,990</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282,686</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>184,613</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98,073</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative liability</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities measured at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of Financial Instruments</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the change in the fair value of our Level 3 financial instrument:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivative Liability </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,952</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Change in fair value</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value as of March 31, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,042</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>46 <FILENAME>R20.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6799037920"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Filler Distribution Agreement (Tables)<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarized the distribution rights:</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:50%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 31, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Initial Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution rights to approved products and indications</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>32,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>47 <FILENAME>R28.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787346544"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Filler Distribution Agreement - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th" colspan="1">1 Months Ended</th> <th class="th" colspan="2">3 Months Ended</th> </tr> <tr> <th class="th"><div>Jan. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Non-cash in-process research and development</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 11,184<span></span> </td> <td class="nump">$ 0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rvnc_TeoxaneAgreementMember', window );">Teoxane Agreement</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Stock issued during period, purchase of assets (in shares)</a></td> <td class="nump">2,500,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_CollaborativeAgreementContractualPeriod', window );">Collaborative agreement, contractual period</a></td> <td class="text">10 years<span></span> </td> <td class="text">10 years<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_CollaborativeAgreementExtendedContractualPeriod', window );">Collaborative agreement, extended contractual period</a></td> <td class="text">2 years<span></span> </td> <td class="text">2 years<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td> <td class="nump">$ 43,500<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_CollaborativeAgreementContractualPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Contractual Period</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_CollaborativeAgreementContractualPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_CollaborativeAgreementExtendedContractualPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Extended Contractual Period</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_CollaborativeAgreementExtendedContractualPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rvnc_TeoxaneAgreementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rvnc_TeoxaneAgreementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>48 <FILENAME>R41.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6808617744"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Stock-Based Compensation - Stock Option Plan Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th" colspan="2">3 Months Ended</th> </tr> <tr> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td> <td class="nump">$ 6,544<span></span> </td> <td class="nump">$ 4,159<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td> <td class="nump">2,442<span></span> </td> <td class="nump">2,079<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">General and Administrative</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock based compensation expense</a></td> <td class="nump">$ 4,102<span></span> </td> <td class="nump">$ 2,080<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>49 <FILENAME>R29.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6659572800"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Filler Distribution Agreement - Distributions Rights (Details) - Distribution Rights<br> $ in Thousands</strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"> <div>Mar. 31, 2020 </div> <div>USD ($)</div> </th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td> <td class="text">4 years<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Initial Carrying Amount</a></td> <td class="nump">$ 32,334<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td> <td class="nump">0<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td> <td class="nump">$ 32,334<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>50 <FILENAME>R25.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809396560"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Summary of Significant Accounting Policies- Additional Information (Detail)<br> $ in Thousands</strong></div></th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"> <div>Mar. 31, 2020 </div> <div>USD ($) </div> <div>segment</div> </th> <th class="th"> <div>Mar. 31, 2019 </div> <div>USD ($)</div> </th> <th class="th"> <div>Dec. 31, 2019 </div> <div>USD ($)</div> </th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | segment</a></td> <td class="nump">1<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="nump">$ 61,933<span></span> </td> <td class="nump">$ 35,304<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_WorkingCapitalSurplus', window );">Working capital surplus</a></td> <td class="nump">476,800<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td> <td class="nump">906,137<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 844,204<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td> <td class="nump">$ 511,300<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum', window );">Cash and cash equivalents, and investments, expected funding term for operating plan (in months)</a></td> <td class="text">12 months<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents, and Investments, Operating Plan Funding Term, Minimum</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_CashandCashEquivalentsandInvestmentsOperatingPlanFundingTermMinimum</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_WorkingCapitalSurplus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital Surplus</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_WorkingCapitalSurplus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:integerItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>51 <FILENAME>R21.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797231664"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases (Tables)<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Operating Lease Costs</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating lease costs are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.</span></div><span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating Lease Liability Maturities</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, maturities of the Company’s operating lease liabilities are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 remaining nine months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,057</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,557</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,979</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,462</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of operating lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,517</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Our lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of </span><span style="font-family:inherit;font-size:8pt;"><span>12.0%</span></span><span style="font-family:inherit;font-size:8pt;">, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates. </span></div></td></tr></table><span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock', window );">Supplemental Cash Flow Information</a></td> <td class="text"><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to the operating leases was as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_LesseeSupplementalCashFlowInformationTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Supplemental Cash Flow Information [Table Text Block]</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_LesseeSupplementalCashFlowInformationTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>52 <FILENAME>R40.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810727664"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity and Stock-Based Compensation - Common Stock Equivalents Excluded from the Calculation of Earnings per Share (Details) - shares<br></strong></div></th> <th class="th" colspan="2">3 Months Ended</th> </tr> <tr> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2019</div></th> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible senior notes</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)</a></td> <td class="nump">8,878,938<span></span> </td> <td class="nump">0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding common stock options</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)</a></td> <td class="nump">5,305,185<span></span> </td> <td class="nump">4,372,676<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock awards and performance stock awards</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)</a></td> <td class="nump">2,799,982<span></span> </td> <td class="nump">768,770<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rvnc_ESPPPurchasesMember', window );">Shares of common stock expected to be purchased on June 30 under the 2014 ESPP</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)</a></td> <td class="nump">49,861<span></span> </td> <td class="nump">35,619<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Outstanding common stock warrants</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from computation of diluted net income (loss) per share (in shares)</a></td> <td class="nump">0<span></span> </td> <td class="nump">34,113<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rvnc_ESPPPurchasesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=rvnc_ESPPPurchasesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>ZIP <SEQUENCE>53 <FILENAME>0001479290-20-000058-xbrl.zip <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 0001479290-20-000058-xbrl.zip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�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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EXCEL <SEQUENCE>54 <FILENAME>Financial_Report.xlsx <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 Financial_Report.xlsx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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>55 <FILENAME>R44.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798371200"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th> <th class="th" colspan="1">1 Months Ended</th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr> <th class="th"><div>Jan. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_IndemnificationLiabilityRecordedduringPeriod', window );">Indemnification liability recorded during the period</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rvnc_TeoxaneAgreementMember', window );">Teoxane Agreement</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_CollaborativeAgreementContractualPeriod', window );">Collaborative agreement, contractual period</a></td> <td class="text">10 years<span></span> </td> <td class="text">10 years<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_CollaborativeAgreementExtendedContractualPeriod', window );">Collaborative agreement, extended contractual period</a></td> <td class="text">2 years<span></span> </td> <td class="text">2 years<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td> <td class="nump">$ 43,500,000<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rvnc_ListLaboratoriesMember', window );">List Laboratories | Product Approval Payment Derivative</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_AccruedMilestoneObligations', window );">Accrued milestone obligations</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 2,000,000.0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rvnc_BotulinumToxinResearchAssociatesInc.Member', window );">Botulinum Toxin Research Associates, Inc.</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_AccruedMilestoneObligations', window );">Accrued milestone obligations</a></td> <td class="text"> <span></span> </td> <td class="nump">16,000,000.0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rvnc_BioSentinelInc.Member', window );">BioSentinel, Inc.</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_AccruedMilestoneObligations', window );">Accrued milestone obligations</a></td> <td class="text"> <span></span> </td> <td class="nump">300,000<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 1,000,000.0<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_AccruedMilestoneObligations"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Obligations</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_AccruedMilestoneObligations</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_CollaborativeAgreementContractualPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Contractual Period</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_CollaborativeAgreementContractualPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_CollaborativeAgreementExtendedContractualPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Extended Contractual Period</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_CollaborativeAgreementExtendedContractualPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_IndemnificationLiabilityRecordedduringPeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indemnification Liability Recorded during Period</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_IndemnificationLiabilityRecordedduringPeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rvnc_TeoxaneAgreementMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rvnc_TeoxaneAgreementMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rvnc_ListLaboratoriesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rvnc_ListLaboratoriesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CreditRiskContractMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CreditRiskContractMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rvnc_BotulinumToxinResearchAssociatesInc.Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rvnc_BotulinumToxinResearchAssociatesInc.Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rvnc_BioSentinelInc.Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rvnc_BioSentinelInc.Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>56 <FILENAME>R5.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797499584"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th"><div>Total</div></th> <th class="th"><div>Common Stock</div></th> <th class="th"><div>Additional Paid-In Capital</div></th> <th class="th"><div>Other Accumulated Comprehensive Gain (Loss)</div></th> <th class="th"><div>Accumulated Deficit</div></th> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td> <td class="text"> <span></span> </td> <td class="nump">36,975,203<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2018</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 37<span></span> </td> <td class="nump">$ 830,368<span></span> </td> <td class="num">$ (8)<span></span> </td> <td class="num">$ (684,775)<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased', window );">Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)</a></td> <td class="text"> <span></span> </td> <td class="nump">323,026<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with offerings (in shares)</a></td> <td class="text"> <span></span> </td> <td class="nump">6,764,705<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with offerings</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 7<span></span> </td> <td class="nump">107,572<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and warrants (in shares)</a></td> <td class="text"> <span></span> </td> <td class="nump">2,824<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net settlement of restricted stock awards for employee taxes (in shares)</a></td> <td class="text"> <span></span> </td> <td class="num">(61,100)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and warrants</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">18<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">4,159<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net settlement of restricted stock awards for employee taxes</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(1,049)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain and adjustment on securities included in net loss</a></td> <td class="nump">$ 78<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">78<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="num">$ (35,304)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(35,304)<span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2019</a></td> <td class="nump">44,004,658<span></span> </td> <td class="nump">44,004,658<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2019</a></td> <td class="nump">$ 221,103<span></span> </td> <td class="nump">$ 44<span></span> </td> <td class="nump">941,068<span></span> </td> <td class="nump">70<span></span> </td> <td class="num">(720,079)<span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td> <td class="nump">52,374,735<span></span> </td> <td class="nump">52,374,735<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td> <td class="nump">$ 225,490<span></span> </td> <td class="nump">$ 52<span></span> </td> <td class="nump">1,069,639<span></span> </td> <td class="nump">3<span></span> </td> <td class="num">(844,204)<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock in connection with the Teoxane Agreement (in shares)</a></td> <td class="text"> <span></span> </td> <td class="nump">2,500,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock in connection with the Teoxane Agreement</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 3<span></span> </td> <td class="nump">43,397<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased', window );">Issuance of restricted stock awards and performance stock awards, net of cancellation (in shares)</a></td> <td class="text"> <span></span> </td> <td class="nump">1,197,054<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased', window );">Issuance of restricted stock awards and performance stock awards, net of cancellation</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 1<span></span> </td> <td class="num">(1)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with offerings (in shares)</a></td> <td class="text"> <span></span> </td> <td class="nump">975,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with offerings</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 1<span></span> </td> <td class="nump">15,536<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and warrants (in shares)</a></td> <td class="text"> <span></span> </td> <td class="nump">52,352<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net settlement of restricted stock awards for employee taxes (in shares)</a></td> <td class="text"> <span></span> </td> <td class="num">(72,987)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options and warrants</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">572<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of convertible senior notes, net of transaction costs of $3,583</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">108,510<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">6,544<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions', window );">Capped call transactions</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(28,865)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net settlement of restricted stock awards for employee taxes</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(1,401)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain and adjustment on securities included in net loss</a></td> <td class="nump">521<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">521<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td> <td class="num">$ (61,933)<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(61,933)<span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2020</a></td> <td class="nump">57,026,154<span></span> </td> <td class="nump">57,026,154<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2020</a></td> <td class="nump">$ 308,375<span></span> </td> <td class="nump">$ 57<span></span> </td> <td class="nump">$ 1,213,931<span></span> </td> <td class="nump">$ 524<span></span> </td> <td class="num">$ (906,137)<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment To Additional Paid In Capital, Capped Call Transactions</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_AdjustmentToAdditionalPaidInCapitalCappedCallTransactions</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Restricted Stock Award, Net of Shares Repurchased</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_StockIssuedDuringPeriodSharesRestrictedStockAwardNetofSharesRepurchased</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Restricted Stock Award, Net of Shares Repurchased</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfSharesRepurchased</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>57 <FILENAME>R1.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6808528080"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Apr. 24, 2020</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td> <td class="text">10-Q<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td> <td class="text">true<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td> <td class="text">Mar. 31, 2020<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td> <td class="text">001-36297<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td> <td class="text">Revance Therapeutics, Inc.<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td> <td class="text">DE<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td> <td class="text">77-0551645<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td> <td class="text">7555 Gateway Boulevard<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td> <td class="text">Newark<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td> <td class="text">CA<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td> <td class="text">94560<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td> <td class="text">510<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td> <td class="text">742-3400<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td> <td class="text">Common Stock, par value $0.001 per share<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td> <td class="text">RVNC<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td> <td class="text">NASDAQ<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td> <td class="text">Yes<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td> <td class="text">Yes<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td> <td class="text">Accelerated Filer<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td> <td class="text">true<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td> <td class="text"> <span></span> </td> <td class="nump">57,052,046<span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td> <td class="text">0001479290<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td> <td class="text">--12-31<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td> <td class="text">2020<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td> <td class="text">Q1<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_AmendmentFlag</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CityAreaCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CoverAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gMonthDayItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:fiscalPeriodItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gYearItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:dateItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentTransitionReport</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentType</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:submissionTypeItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:stateOrProvinceItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:centralIndexKeyItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityFileNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:fileNumberItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityFilerCategory</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:filerCategoryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:edgarStateCountryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityRegistrantName</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityShellCompany</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntitySmallBusiness</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:employerIdItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_LocalPhoneNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_Security12bTitle</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:securityTitleItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_SecurityExchangeName</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:edgarExchangeCodeItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_TradingSymbol</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:tradingSymbolItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>58 <FILENAME>R9.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792583536"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Revenue</a></td> <td class="text">Revenue<span style="font-family:inherit;font-size:10pt;font-weight:bold;">    </span><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Mylan Collaboration and License Agreement</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">    </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Agreement Terms</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into a collaboration agreement with Mylan Ireland Limited, a wholly-owned indirect subsidiary of Mylan N.V. (“Mylan”) in February 2018 (the “Mylan Collaboration”), pursuant to which we agreed to collaborate with Mylan exclusively, on a world-wide basis (excluding Japan), to develop, manufacture, and commercialize a biosimilar to the branded biologic product (onabotulinumtoxinA) marketed as BOTOX®. In August 2019, the Mylan Collaboration was amended to, among other things, revise the period of time for Mylan to decide whether to continue the development and commercialization of the biosimilar beyond the initial development plan (the “Continuation Decision”) to be on or before the later of (i) April 30, 2020 or (ii) 30 calendar days from the date that we provide Mylan with certain deliverables. On May 1, 2020, we announced that we are continuing discussions with Mylan regarding whether or not Mylan plans to move forward with the biosimilar program.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Mylan Collaboration, Mylan has paid us an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>$30 million</span></span><span style="font-family:inherit;font-size:10pt;"> in non-refundable upfront fees, and the agreement provides for additional contingent payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate, upon the achievement of specified clinical and regulatory (i.e., a biosimilar biological pathway) milestones and of specified, tiered sales milestones of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$225 million</span></span><span style="font-family:inherit;font-size:10pt;">. The payments do not represent a financing component for the transfer of goods or services. The contingent payments would be payable after the Continuation Decision and upon meeting certain milestones. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC 606, transaction price is defined as the amount of consideration to which an entity expects to be entitled in exchange for promised goods or services to a customer. We estimated the transaction price for the Mylan Collaboration using the most likely amount method. In order to determine the transaction price, we evaluated all of the payments to be received during the duration of the contract, which included milestones and consideration payable by Mylan. Other than the upfront payment, all other milestones and consideration we may earn under the Mylan Collaboration are subject to uncertainties related to development achievements, Mylan’s rights to terminate the agreement, and estimated effort for cost-sharing payments. Components of such estimated effort for cost-sharing payments include both internal and external costs. Consequently, the transaction price does not include any milestones and considerations that, if included, could result in a probable significant reversal of revenue when related uncertainties become resolved. Sales-based milestones and royalties are not included in the transaction price until the sales occur because the underlying value relates to the license and the license is the predominant feature in the Mylan Collaboration. We re-evaluate the transaction price at each reporting period.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;"> </span><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to the unfulfilled performance obligations is </span><span style="font-family:inherit;font-size:10pt;"><span>$106.8 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recognize revenue and estimate deferred revenue based on the cost of services incurred over the total estimated cost of services to be provided for the development period. For revenue recognition purposes, the development period is estimated to extend through </span><span style="font-family:inherit;font-size:10pt;">2024</span><span style="font-family:inherit;font-size:10pt;">. It is possible that this period will change and is assessed at each reporting date.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recognized revenue related to development services of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we estimated short-term deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively; and long-term deferred revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$15.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$18.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fosun License Agreement </span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Agreement Terms</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In </span><span style="font-family:inherit;font-size:10pt;">December 2018</span><span style="font-family:inherit;font-size:10pt;">, we entered into a license agreement (the “Fosun License Agreement”) with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun”), whereby we have granted Fosun the exclusive rights to develop and commercialize our proprietary DaxibotulinumtoxinA for Injection in mainland China, Hong Kong and Macau (the “Fosun Territory”) and certain sublicense rights.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the Fosun License Agreement, in </span><span style="font-family:inherit;font-size:10pt;">January 2019</span><span style="font-family:inherit;font-size:10pt;"> we received a non-refundable upfront payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, net of foreign withholding tax of </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;"><span>$3.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. We are also eligible to receive (i) additional contingent payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$230.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> upon the achievement of specified milestones based on (a) the submission and approval of biologics license applications (“BLAs”) for certain aesthetic and therapeutic indications and (b) first calendar year net sales, and (ii) tiered royalty payments in low double digit to high teen percentages on annual net sales. The royalty percentages are subject to reduction in the event that (i) we do not have any valid and unexpired patent claims that cover the product in the Fosun Territory, (ii) biosimilars of the product are sold in the Fosun Territory or (iii) Fosun needs to pay compensation to third parties to either avoid patent infringement or market the product in the Fosun Territory. In </span><span style="font-family:inherit;font-size:10pt;">March 2020</span><span style="font-family:inherit;font-size:10pt;">, we received from Fosun a milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, before foreign withholding tax of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, for the acceptance of the BLA submission to the FDA for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar (frown) lines.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;text-decoration:none;">Revenue Recognition</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimated the transaction price for the Fosun License Agreement using the most likely amount method. We evaluated all of the variable payments to be received during the duration of the contract, which included payments from specified milestones, royalties, and estimated supplies to be delivered. We will re-evaluate the transaction price at each reporting period and upon a change in circumstances. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the transaction price allocated to unfulfilled performance obligation is </span><span style="font-family:inherit;font-size:10pt;"><span>$31.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>No</span></span><span style="font-family:inherit;font-size:10pt;"> revenue has been recognized from the Fosun License Agreement for the </span><span style="font-family:inherit;font-size:10pt;">three months ended March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. Substantially all payments received to date were included in long-term deferred revenue as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&trid=5833765<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>59 <FILENAME>R30.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809107872"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liability - Additional Information (Detail) - Product Approval Payment Derivative - USD ($)<br> $ in Millions</strong></div></th> <th class="th" colspan="1">3 Months Ended</th> <th class="th" colspan="1">12 Months Ended</th> </tr> <tr> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Dec. 31, 2019</div></th> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rvnc_MedicisPharmaceuticalCorporationMember', window );">Medicis Pharmaceutical Corporation</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_SettlementAndTerminationLineItems', window );"><strong>Settlement And Termination [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Fair value of derivative</a></td> <td class="nump">$ 3.0<span></span> </td> <td class="nump">$ 3.0<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=rvnc_ValeantPharmaceuticalsInternationalInc.Member', window );">Valeant Pharmaceuticals International, Inc.</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_SettlementAndTerminationLineItems', window );"><strong>Settlement And Termination [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_AccruedMilestoneObligations', window );">Nonrecurring milestone payment</a></td> <td class="nump">$ 4.0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term | Medicis Pharmaceutical Corporation</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_SettlementAndTerminationLineItems', window );"><strong>Settlement And Termination [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_FairValueMeasurementInputDuration', window );">Fair value, measurement input, duration</a></td> <td class="text">8 months 12 days<span></span> </td> <td class="text">10 months 24 days<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputEntityCreditRiskMember', window );">Measurement Input, Entity Credit Risk | Medicis Pharmaceutical Corporation</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_SettlementAndTerminationLineItems', window );"><strong>Settlement And Termination [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_FairValueMeasurementInput', window );">Fair value, measurement input (percent)</a></td> <td class="nump">7.50%<span></span> </td> <td class="nump">7.50%<span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate | Medicis Pharmaceutical Corporation</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_SettlementAndTerminationLineItems', window );"><strong>Settlement And Termination [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_FairValueMeasurementInput', window );">Fair value, measurement input (percent)</a></td> <td class="nump">0.20%<span></span> </td> <td class="nump">1.60%<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_AccruedMilestoneObligations"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Obligations</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_AccruedMilestoneObligations</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_FairValueMeasurementInput"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement Input</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_FairValueMeasurementInput</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_FairValueMeasurementInputDuration"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement Input, Duration</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_FairValueMeasurementInputDuration</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_SettlementAndTerminationLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement And Termination [Line Items]</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_SettlementAndTerminationLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rvnc_MedicisPharmaceuticalCorporationMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rvnc_MedicisPharmaceuticalCorporationMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CreditRiskContractMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CreditRiskContractMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=rvnc_ValeantPharmaceuticalsInternationalInc.Member"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=rvnc_ValeantPharmaceuticalsInternationalInc.Member</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputEntityCreditRiskMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputEntityCreditRiskMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>60 <FILENAME>R34.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789578896"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th> <th class="th" colspan="2">3 Months Ended</th> </tr> <tr> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td> <td class="nump">$ 1,677<span></span> </td> <td class="nump">$ 1,450<span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td> <td class="nump">$ 0<span></span> </td> <td class="nump">$ 3,890<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>61 <FILENAME>R38.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787566208"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes - Capped Call Transactions (Details) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th> <th class="th" colspan="1"></th> <th class="th" colspan="2">3 Months Ended</th> </tr> <tr> <th class="th"><div>Feb. 14, 2020</div></th> <th class="th"><div>Mar. 31, 2020</div></th> <th class="th"><div>Mar. 31, 2019</div></th> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities', window );">Payment of capped call transactions</a></td> <td class="nump">$ 28,900<span></span> </td> <td class="nump">$ 28,865<span></span> </td> <td class="nump">$ 0<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_CappedCallsPriceCap', window );">Price cap (in dollars per share)</a></td> <td class="nump">$ 48.88<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_CappedCallsPremiumPercentageOverSalePrice', window );">Premium percentage over sale price</a></td> <td class="nump">100.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments', window );">Number of shares subject to anti-dilution adjustments (in shares)</a></td> <td class="text"> <span></span> </td> <td class="nump">8.9<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 2027 Notes</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td> <td class="nump">$ 32.38<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capped Calls, Number Of Shares Subject To Anti-dilution Adjustments</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_CappedCallsNumberOfSharesSubjectToAntidilutionAdjustments</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_CappedCallsPremiumPercentageOverSalePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capped Calls, Premium Percentage Over Sale Price</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_CappedCallsPremiumPercentageOverSalePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rvnc_CappedCallsPriceCap"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capped Calls, Price Cap</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">rvnc_CappedCallsPriceCap</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>rvnc_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>num:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3505-108585<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentFinancingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=rvnc_TwentyTwentySevenNotesMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=rvnc_TwentyTwentySevenNotesMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>62 <FILENAME>R17.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792320528"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td> <td class="text">Commitments and Contingencies<div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Teoxane Agreement </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are parties to the Teoxane Agreement (</span><a href="#s89e018506f474bc9b18873233c39430b" style="font-family:inherit;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Note 4</span></a><span style="font-family:inherit;font-size:10pt;">), which will be effective for a term of </span><span style="font-family:inherit;font-size:10pt;"><span>ten years</span></span><span style="font-family:inherit;font-size:10pt;"> upon product launch and may be extended for a two-year period upon the mutual agreement of the parties. We are required to meet certain minimum purchase obligations during each year of the term. We are also required to meet certain minimum expenditure requirements in connection with commercialization efforts. Either party may terminate the Teoxane Agreement in the event of the insolvency of, or a material breach by, the other party, including certain specified breaches that include the right for Teoxane to terminate the Teoxane Agreement for our failure to meet the minimum purchase requirements or commercialization expenditure during specified periods, or for our breach of the exclusivity obligations under the Teoxane Agreement.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Purchase Commitments</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are parties to a Technology Transfer, Validation and Commercial Fill/Finish Services Agreement with Ajinomoto Althea, Inc. dba Ajinomoto Bio-Pharma Services (“Althea”) (the “Althea Services Agreement”), under which Althea provides us a contract development and manufacturing organization, which allows us to have expanded capacity and a second source for drug product manufacturing in order to support a global launch of DaxibotulinumtoxinA for Injection. The initial term of the Althea Services Agreement expires in 2024, unless terminated sooner by either company and we have minimum purchase obligations based on our production forecasts. </span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Contingencies</span></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are obligated to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment to a developer of botulinum toxin, List Biological Laboratories, Inc. (“List Laboratories”), when a certain regulatory milestone is achieved. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the milestone had not been achieved. We are also obligated to pay royalties to List Laboratories on future sales of botulinum toxin products.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into an asset purchase agreement (the “BTRX Purchase Agreement”) with Botulinum Toxin Research Associates, Inc. (“BTRX”), under which we are obligated to pay up to </span><span style="font-family:inherit;font-size:10pt;"><span>$16.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to BTRX upon the satisfaction of milestones relating to our product revenue, intellectual property, and clinical and regulatory events. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, a one-time intellectual property development milestone liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> has been recorded in accruals on our condensed consolidated balance sheets.</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We entered into an agreement with BioSentinel, Inc. (“BioSentinel”), under which we in-license BioSentinel’s technology and expertise for research, development and manufacturing purposes. We are obligated to pay BioSentinel minimum quarterly use fees and a one-time milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> when regulatory approval is achieved. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the milestone has not been achieved.</span></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Indemnification</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have standard indemnification agreements in the ordinary course of business. Under these indemnification agreements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to our technology. The term of these indemnification agreements is generally perpetual after the execution of the agreements. The maximum potential amount of future payments we are obligated to pay under these indemnification agreements is not determinable because it involves claims that may be made against us in the future but have not been made. We have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.</span></div><div style="line-height:120%;padding-bottom:12px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the </span><span style="font-family:inherit;font-size:10pt;">three months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> amounts associated with the indemnification agreements have been recorded.</span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&trid=2144648<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>63 <FILENAME>R13.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792607184"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th> <th class="th" colspan="1">3 Months Ended</th> </tr> <tr><th class="th"><div>Mar. 31, 2020</div></th></tr> <tr class="re"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td> <td class="text">Leases<div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have non-cancelable operating leases for facilities for research, manufacturing, and administrative functions, and equipment operating leases. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the weighted average remaining lease term is </span><span style="font-family:inherit;font-size:10pt;"><span>6.8 years</span></span><span style="font-family:inherit;font-size:10pt;">. The monthly payments for the facility lease escalate over the facility lease term with the exception of a decrease in payments at the beginning of </span><span style="font-family:inherit;font-size:10pt;">2022</span><span style="font-family:inherit;font-size:10pt;">. We have options to extend the facility operating leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>14.0 years</span></span><span style="font-family:inherit;font-size:10pt;">. Our lease contracts do not contain termination options, residual value guarantees or restrictive covenants. </span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The operating lease costs are summarized as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,343</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Variable lease cost </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,502</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Times_New_Roman;font-size:10pt;"><span>1,633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Variable lease cost includes management fees, common area maintenance, property taxes, and insurance, which are not included in the lease liabilities and are expensed as incurred.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, maturities of the Company’s operating lease liabilities are as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Year Ending December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 remaining nine months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,057</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,942</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,464</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,557</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,733</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 and thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,226</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40,979</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less imputed interest </span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12,462</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Present value of operating lease payments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,517</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:inherit;font-size:8pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Our lease contracts do not provide a readily determinable implicit rate. The imputed interest was based on a weighted average discount rate of </span><span style="font-family:inherit;font-size:8pt;"><span>12.0%</span></span><span style="font-family:inherit;font-size:8pt;">, which represents the estimated incremental borrowing based on the information available at the adoption or commencement dates. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to the operating leases was as follows:</span></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,450</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,890</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&trid=77888251<br></p></div> <a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>nonnum:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> </SEC-DOCUMENT>